disease	mesh_id	drug	phase	start_date	completion_date	nct_id
Multiple Myeloma	D009101	abemaciclib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	abemaciclib	Phase 2	2016	2019	NCT02693535;NCT03732703
Lymphoma, Non-Hodgkin	D008228	abemaciclib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	abemaciclib	Phase 2	2016	2016	NCT02693535
Lung Neoplasms	D008175	abemaciclib	Phase 1	2016	2016	NCT02779751
Lung Neoplasms	D008175	abemaciclib	Phase 2	2015	2020	NCT02450539;NCT02308020;NCT04010357;NCT04545710
Lung Neoplasms	D008175	abemaciclib	Phase 3	2014	2014	NCT02152631
Carcinoma, Non-Small-Cell Lung	D002289	abemaciclib	Phase 1	2014	2016	NCT02857270;NCT02779751;NCT02411591;NCT02079636
Carcinoma, Non-Small-Cell Lung	D002289	abemaciclib	Phase 2	2015	2019	NCT02450539;NCT02308020;NCT04165031
Urinary Bladder Neoplasms	D001749	abemaciclib	Phase 1	2019	2019	NCT03837821
Breast Neoplasms	D001943	abemaciclib	Phase 1	2014	2021	NCT04188548;NCT04316169;NCT04481113;NCT04483505;NCT02779751;NCT03099174;NCT04585724;NCT04514159;NCT03846583;NCT03616587;NCT02057133;NCT03878524;NCT04088032
Breast Neoplasms	D001943	abemaciclib	Phase 2	2014	2021	NCT04523857;NCT04352777;NCT04305834;NCT02747004;NCT04432454;NCT04256941;NCT03979508;NCT04603183;NCT04351230;NCT02308020;NCT03939897;NCT03130439;NCT03227328;NCT02831530;NCT03280563;NCT02675231;NCT03703466;NCT04614194;NCT04293393;NCT02102490;NCT04305236;NCT02441946;NCT03913234;NCT04227327
Breast Neoplasms	D001943	abemaciclib	Phase 3	2014	2021	NCT02763566;NCT03155997;NCT04565054;NCT04752332;NCT03425838;NCT02246621;NCT04158362;NCT02107703
Breast Neoplasms	D001943	abemaciclib	Phase 4	2019	2021	NCT04707196;NCT03988114;NCT04031885
Neoplasm, Residual	D018365	abemaciclib	Phase 2	2021	2021	NCT04523857
Carcinoma	D002277	abemaciclib	Phase 1	2019	2021	NCT04481113;NCT03905889;NCT04627064;NCT03878524
Carcinoma	D002277	abemaciclib	Phase 2	2019	2021	NCT04305834;NCT03781960;NCT03979508;NCT04351230;NCT03939897;NCT04616183;NCT04003896;NCT03531645;NCT03655444;NCT04469764
Neoplasm Metastasis	D009362	abemaciclib	Phase 1	2013	2017	NCT02688088;NCT02014129;NCT02919696;NCT02411591;NCT02117648
Neoplasm Metastasis	D009362	abemaciclib	Phase 2	2015	2015	NCT02308020
Neoplasm Metastasis	D009362	abemaciclib	Phase 4	2021	2021	NCT04707196
Head and Neck Neoplasms	D006258	abemaciclib	Phase 2	2017	2021	NCT03292250;NCT03938337;NCT04169074;NCT03356223;NCT03356587
Prostatic Neoplasms	D011471	abemaciclib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	abemaciclib	Phase 2	2018	2021	NCT03706365;NCT04408924;NCT04298983;NCT04751929;NCT04272645
Adenocarcinoma	D000230	abemaciclib	Phase 1	2019	2021	NCT04481113;NCT04049227;NCT03878524
Adenocarcinoma	D000230	abemaciclib	Phase 2	2017	2020	NCT03997448;NCT03643510;NCT04616183;NCT02981342
Endometrial Neoplasms	D016889	abemaciclib	Phase 1	2019	2019	NCT04188548
Endometrial Neoplasms	D016889	abemaciclib	Phase 2	2018	2020	NCT03675893;NCT03339843;NCT04469764;NCT04393285
Carcinoma, Hepatocellular	D006528	abemaciclib	Phase 2	2019	2019	NCT03781960
Mesothelioma	D008654	abemaciclib	Phase 1	2012	2012	NCT01655225
Mesothelioma	D008654	abemaciclib	Phase 2	2019	2019	NCT03654833
Neoplasms, Plasma Cell	D054219	abemaciclib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	abemaciclib	Phase 2	2019	2019	NCT03732703
Neurofibromatoses	D017253	abemaciclib	Phase 2	2021	2021	NCT04750928
Neurofibromatosis 1	D009456	abemaciclib	Phase 2	2021	2021	NCT04750928
Neurofibroma	D009455	abemaciclib	Phase 2	2021	2021	NCT04750928
Triple Negative Breast Neoplasms	D064726	abemaciclib	Phase 2	2020	2020	NCT03979508
Carcinoma in Situ	D002278	abemaciclib	Phase 2	2020	2020	NCT03979508
Carcinoma, Ductal	D044584	abemaciclib	Phase 2	2020	2020	NCT03979508
Carcinoma, Intraductal, Noninfiltrating	D002285	abemaciclib	Phase 2	2020	2020	NCT03979508
Carcinoma, Lobular	D018275	abemaciclib	Phase 2	2020	2020	NCT03979508
Breast Carcinoma In Situ	D000071960	abemaciclib	Phase 2	2020	2020	NCT03979508
Carcinoma, Ductal, Breast	D018270	abemaciclib	Phase 2	2020	2020	NCT03979508
Melanoma	D008545	abemaciclib	Phase 2	2015	2015	NCT02308020
Glioblastoma	D005909	abemaciclib	Phase 1	2019	2020	NCT04074785;NCT04391595
Glioblastoma	D005909	abemaciclib	Phase 2	2017	2020	NCT02981940;NCT02977780;NCT04118036
Brain Neoplasms	D001932	abemaciclib	Phase 1	2016	2019	NCT04074785;NCT02644460
Brain Neoplasms	D001932	abemaciclib	Phase 2	2017	2017	NCT03220646
Uterine Neoplasms	D014594	abemaciclib	Phase 2	2018	2018	NCT03643510
Retinoblastoma	D012175	abemaciclib	Phase 2	2017	2017	NCT03130439
Cholangiocarcinoma	D018281	abemaciclib	Phase 1	2016	2016	NCT02784795
Cholangiocarcinoma	D018281	abemaciclib	Phase 2	2018	2018	NCT03339843
Liposarcoma	D008080	abemaciclib	Phase 2	2016	2016	NCT02846987
Oligodendroglioma	D009837	abemaciclib	Phase 2	2019	2019	NCT03969706
Carcinoma, Endometrioid	D018269	abemaciclib	Phase 1	2019	2019	NCT04049227
Colorectal Neoplasms	D015179	abemaciclib	Phase 1	2016	2016	NCT02857270
Colorectal Neoplasms	D015179	abemaciclib	Phase 2	2019	2020	NCT04616183;NCT04165031
Rectal Neoplasms	D012004	abemaciclib	Phase 2	2020	2020	NCT04616183
Colonic Neoplasms	D003110	abemaciclib	Phase 2	2020	2020	NCT04616183
Thyroid Neoplasms	D013964	abemaciclib	Phase 2	2020	2020	NCT04552769
Thyroid Carcinoma, Anaplastic	D065646	abemaciclib	Phase 2	2020	2020	NCT04552769
Cystadenocarcinoma, Serous	D018284	abemaciclib	Phase 1	2021	2021	NCT04633239
Cystadenocarcinoma, Serous	D018284	abemaciclib	Phase 2	2019	2019	NCT03531645
Genital Neoplasms, Female	D005833	abemaciclib	Phase 2	2019	2019	NCT03531645
Neoplasms, Second Primary	D016609	abemaciclib	Phase 1	2017	2017	NCT02919696
Small Cell Lung Carcinoma	D055752	abemaciclib	Phase 2	2020	2020	NCT04010357
Sarcoma	D012509	abemaciclib	Phase 1	2016	2016	NCT02784795
Sarcoma	D012509	abemaciclib	Phase 2	2019	2019	NCT04040205
Osteosarcoma	D012516	abemaciclib	Phase 1	2016	2016	NCT02644460
Osteosarcoma	D012516	abemaciclib	Phase 2	2019	2019	NCT04040205
Chondrosarcoma	D002813	abemaciclib	Phase 2	2019	2019	NCT04040205
Carcinoma, Squamous Cell	D002294	abemaciclib	Phase 2	2017	2019	NCT03655444;NCT03356587
Squamous Cell Carcinoma of Head and Neck	D000077195	abemaciclib	Phase 2	2017	2019	NCT03655444;NCT03356587
Lymphoma, Mantle-Cell	D020522	abemaciclib	Phase 1	2016	2016	NCT02745769
Lymphoma, Mantle-Cell	D020522	abemaciclib	Phase 2	2013	2013	NCT01739309
Neuroendocrine Tumors	D018358	abemaciclib	Phase 2	2019	2019	NCT03891784
Carcinoid Tumor	D002276	abemaciclib	Phase 2	2019	2019	NCT03891784
Intestinal Neoplasms	D007414	abemaciclib	Phase 2	2019	2019	NCT03891784
Pancreatic Neoplasms	D010190	abemaciclib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	abemaciclib	Phase 2	2019	2019	NCT03891784
Stomach Neoplasms	D013274	abemaciclib	Phase 2	2019	2019	NCT03891784
Glioma	D005910	abemaciclib	Phase 1	2016	2020	NCT02644460;NCT04220892
Neuroblastoma	D009447	abemaciclib	Phase 1	2016	2016	NCT02644460
Rhabdomyosarcoma	D012208	abemaciclib	Phase 1	2016	2016	NCT02644460
Sarcoma, Ewing	D012512	abemaciclib	Phase 1	2016	2016	NCT02644460
Rhabdoid Tumor	D018335	abemaciclib	Phase 1	2016	2016	NCT02644460
Carcinoma, Renal Cell	D002292	abemaciclib	Phase 1	2019	2021	NCT03905889;NCT04627064
Lymphoma	D008223	abemaciclib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	abemaciclib	Phase 2	2013	2013	NCT01739309
Leukemia	D007938	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	abemaciclib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	abemaciclib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	abemaciclib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	abemaciclib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	abemaciclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	abemaciclib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	abemaciclib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	acalabrutinib	Phase 1	2014	2021	NCT02717624;NCT04462328;NCT04688151;NCT03527147;NCT02112526;NCT03219047
Lymphoma	D008223	acalabrutinib	Phase 2	2015	2022	NCT04765111;NCT02180711;NCT03162536;NCT04257578;NCT04566887;NCT04155710;NCT02213926;NCT04604067;NCT03932331;NCT04115631;NCT04002947;NCT04548648;NCT03571308;NCT03946878;NCT04646395;NCT03863184;NCT04189757;NCT04502394;NCT04783415;NCT02337829;NCT02362035;NCT04404088;NCT04189952;NCT03623373;NCT04169737;NCT03516617;NCT03788291;NCT04626791;NCT04402138;NCT04116437;NCT04484012;NCT04094142;NCT04546620;NCT03740529
Lymphoma	D008223	acalabrutinib	Phase 3	2016	2021	NCT04529772;NCT02972840;NCT04662255;NCT02735876;NCT04666038
Lymphoma, Mantle-Cell	D020522	acalabrutinib	Phase 1	2016	2020	NCT02717624;NCT04564040;NCT03219047
Lymphoma, Mantle-Cell	D020522	acalabrutinib	Phase 2	2015	2022	NCT04765111;NCT04716075;NCT03162536;NCT04566887;NCT02213926;NCT03932331;NCT04115631;NCT03946878;NCT03863184;NCT04189757;NCT04783415;NCT03623373;NCT04626791;NCT04402138;NCT04116437;NCT04484012;NCT03740529
Lymphoma, Mantle-Cell	D020522	acalabrutinib	Phase 3	2016	2021	NCT02972840;NCT04662255;NCT02735876
Leukemia, Lymphoid	D007945	acalabrutinib	Phase 1	2014	2014	NCT02296918;NCT02157324
Leukemia, Lymphoid	D007945	acalabrutinib	Phase 2	2014	2021	NCT04716075;NCT03162536;NCT04155710;NCT03685708;NCT03932331;NCT03580928;NCT02029443;NCT04502394;NCT03702231;NCT04657094;NCT02337829;NCT04189952;NCT04169737;NCT03516617;NCT03788291;NCT04016805;NCT03787264;NCT03328273;NCT04624633;NCT02717611;NCT04505254;NCT03740529
Leukemia, Lymphoid	D007945	acalabrutinib	Phase 3	2015	2021	NCT02477696;NCT04008706;NCT04075292;NCT04178798;NCT03836261;NCT02970318;NCT04666038
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	acalabrutinib	Phase 1	2014	2014	NCT02296918;NCT02157324
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	acalabrutinib	Phase 2	2014	2021	NCT04716075;NCT03162536;NCT04155710;NCT04660045;NCT03685708;NCT03932331;NCT04722172;NCT03580928;NCT02029443;NCT04502394;NCT03702231;NCT04657094;NCT02337829;NCT02362035;NCT04189952;NCT04169737;NCT03516617;NCT03788291;NCT04016805;NCT03787264;NCT04116437;NCT03328273;NCT04624633;NCT02717611;NCT04505254;NCT03740529
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	acalabrutinib	Phase 3	2015	2021	NCT02477696;NCT04008706;NCT02475681;NCT04075292;NCT04178798;NCT03836261;NCT02970318;NCT04666038
Pancreatic Neoplasms	D010190	acalabrutinib	Phase 2	2015	2015	NCT02362048;NCT02570711
Lymphoma, Non-Hodgkin	D008228	acalabrutinib	Phase 1	2018	2018	NCT03527147
Lymphoma, Non-Hodgkin	D008228	acalabrutinib	Phase 2	2015	2020	NCT02180711;NCT04257578;NCT04094142
Lymphoma, B-Cell	D016393	acalabrutinib	Phase 1	2014	2014	NCT02112526
Lymphoma, B-Cell	D016393	acalabrutinib	Phase 2	2015	2021	NCT02180711;NCT03162536;NCT04257578;NCT04604067;NCT04002947;NCT03571308;NCT04502394;NCT04189952;NCT04094142;NCT04546620;NCT03740529
Lymphoma, B-Cell	D016393	acalabrutinib	Phase 3	2020	2020	NCT04529772
Leukemia	D007938	acalabrutinib	Phase 1	2014	2014	NCT02296918;NCT02157324
Leukemia	D007938	acalabrutinib	Phase 2	2014	2021	NCT03162536;NCT04155710;NCT03013998;NCT03932331;NCT03580928;NCT02029443;NCT04477291;NCT04502394;NCT04657094;NCT02337829;NCT02362035;NCT04189952;NCT04169737;NCT03516617;NCT03788291;NCT04016805;NCT03328273;NCT04624633;NCT04505254;NCT03740529
Leukemia	D007938	acalabrutinib	Phase 3	2015	2021	NCT02477696;NCT04008706;NCT04075292;NCT04178798;NCT03836261;NCT02970318;NCT04666038
Lymphoma, Follicular	D008224	acalabrutinib	Phase 2	2017	2020	NCT03162536;NCT04404088
Lymphoma, B-Cell, Marginal Zone	D018442	acalabrutinib	Phase 2	2017	2021	NCT03162536;NCT04646395;NCT04189952;NCT03740529
Lymphoma, Large B-Cell, Diffuse	D016403	acalabrutinib	Phase 1	2014	2018	NCT03527147;NCT02112526
Lymphoma, Large B-Cell, Diffuse	D016403	acalabrutinib	Phase 2	2017	2021	NCT03162536;NCT04257578;NCT04604067;NCT04002947;NCT03571308;NCT03736616;NCT04502394;NCT04189952;NCT04546620
Lymphoma, Large B-Cell, Diffuse	D016403	acalabrutinib	Phase 3	2020	2020	NCT04529772
Hematologic Neoplasms	D019337	acalabrutinib	Phase 2	2015	2021	NCT03162536;NCT04630756;NCT02362035
Waldenstrom Macroglobulinemia	D008258	acalabrutinib	Phase 2	2014	2020	NCT03162536;NCT04624906;NCT02362035;NCT02180724;NCT04116437;NCT03740529
Leukemia, Myeloid	D007951	acalabrutinib	Phase 2	2016	2020	NCT03013998;NCT04477291
Leukemia, Myeloid, Acute	D015470	acalabrutinib	Phase 2	2016	2020	NCT03013998;NCT04477291
Leukemia, Prolymphocytic	D015463	acalabrutinib	Phase 1	2014	2014	NCT02296918
Leukemia, Prolymphocytic	D015463	acalabrutinib	Phase 2	2014	2014	NCT02029443
Carcinoma	D002277	acalabrutinib	Phase 2	2015	2015	NCT02448303;NCT02454179;NCT02351739
Carcinoma, Non-Small-Cell Lung	D002289	acalabrutinib	Phase 2	2015	2015	NCT02448303
Neoplasm Metastasis	D009362	acalabrutinib	Phase 1	2021	2021	NCT04462328
Multiple Myeloma	D009101	acalabrutinib	Phase 1	2015	2015	NCT02211014
Multiple Myeloma	D009101	acalabrutinib	Phase 2	2015	2015	NCT02362035;NCT02328014
Neoplasms, Plasma Cell	D054219	acalabrutinib	Phase 1	2015	2015	NCT02211014
Glioblastoma	D005909	acalabrutinib	Phase 2	2016	2016	NCT02586857
Ovarian Neoplasms	D010051	acalabrutinib	Phase 2	2015	2015	NCT02537444
Carcinoma, Ovarian Epithelial	D000077216	acalabrutinib	Phase 2	2015	2015	NCT02537444
Carcinoma, Squamous Cell	D002294	acalabrutinib	Phase 2	2015	2015	NCT02454179
Squamous Cell Carcinoma of Head and Neck	D000077195	acalabrutinib	Phase 2	2015	2015	NCT02454179
Carcinoma, Transitional Cell	D002295	acalabrutinib	Phase 2	2015	2015	NCT02351739
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 1	2009	2020	NCT03711422;NCT03827070;NCT02191891;NCT01288430;NCT01647711;NCT03054038;NCT01090011;NCT00993499;NCT04448379;NCT01999985;NCT02364609
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 2	2007	2021	NCT02716311;NCT02098954;NCT02369484;NCT03810872;NCT02595840;NCT02795156;NCT03574402;NCT02747953;NCT02488694;NCT03157089;NCT04148898;NCT03623750;NCT02470065;NCT02597946;NCT04470076;NCT01932229;NCT01542437;NCT03727724;NCT04497584;NCT01415011;NCT02906163;NCT01003899;NCT02183883;NCT00730925;NCT00525148;NCT03399669;NCT00711594;NCT01156545;NCT00796549;NCT02450656;NCT01746251
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 3	2008	2015	NCT02044380;NCT02438722;NCT01853826;NCT01523587;NCT01814553;NCT01121393;NCT00656136;NCT00949650;NCT01085136;NCT01953913
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 4	2014	2020	NCT04413201;NCT02695290;NCT02208843;NCT04356118;NCT02514174
Urinary Bladder Neoplasms	D001749	afatinib	Phase 2	2013	2015	NCT02122172;NCT02465060
Urethral Neoplasms	D014523	afatinib	Phase 2	2013	2013	NCT02122172
Ureteral Neoplasms	D014516	afatinib	Phase 2	2013	2013	NCT02122172
Multiple Myeloma	D009101	afatinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	afatinib	Phase 2	2015	2016	NCT02693535;NCT04439136;NCT02465060
Lymphoma, Non-Hodgkin	D008228	afatinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	afatinib	Phase 2	2016	2016	NCT02693535
Carcinoma, Squamous Cell	D002294	afatinib	Phase 1	2012	2018	NCT03652233;NCT01721525
Carcinoma, Squamous Cell	D002294	afatinib	Phase 2	2007	2020	NCT01732640;NCT01824823;NCT03088059;NCT03486509;NCT03157089;NCT01608022;NCT02979977;NCT00514943;NCT02541903;NCT03940976;NCT01538381;NCT02353936;NCT01415674;NCT03695510;NCT04533321
Carcinoma, Squamous Cell	D002294	afatinib	Phase 3	2011	2012	NCT01427478;NCT01345682
Carcinoma, Squamous Cell	D002294	afatinib	Phase 4	2018	2018	NCT04132102
Squamous Cell Carcinoma of Head and Neck	D000077195	afatinib	Phase 1	2013	2018	NCT03652233;NCT01783587
Squamous Cell Carcinoma of Head and Neck	D000077195	afatinib	Phase 2	2012	2019	NCT01732640;NCT01824823;NCT03088059;NCT01538381;NCT01415674;NCT03695510
Squamous Cell Carcinoma of Head and Neck	D000077195	afatinib	Phase 3	2011	2011	NCT01427478
Lung Neoplasms	D008175	afatinib	Phase 1	2011	2020	NCT03711422;NCT03827070;NCT01288430;NCT01836341;NCT04448379;NCT01999985;NCT02364609
Lung Neoplasms	D008175	afatinib	Phase 2	2008	2021	NCT02716311;NCT02629523;NCT02747953;NCT02488694;NCT03157089;NCT04148898;NCT02768337;NCT02625168;NCT02470065;NCT04470076;NCT01542437;NCT02271906;NCT04497584;NCT01480141;NCT01415011;NCT02906163;NCT02465060;NCT03399669;NCT00711594;NCT01156545;NCT01466660
Lung Neoplasms	D008175	afatinib	Phase 3	2015	2015	NCT02438722
Lung Neoplasms	D008175	afatinib	Phase 4	2020	2020	NCT04356118
Breast Neoplasms	D001943	afatinib	Phase 1	2009	2020	NCT00950742;NCT01649271;NCT03878524
Breast Neoplasms	D001943	afatinib	Phase 2	2006	2020	NCT01594177;NCT00826267;NCT02768337;NCT02511847;NCT01271725;NCT00431067;NCT01325428;NCT02465060;NCT01531764;NCT01441596;NCT02115048;NCT00425854;NCT00708214;NCT04158947
Breast Neoplasms	D001943	afatinib	Phase 3	2010	2010	NCT01125566
Stomach Neoplasms	D013274	afatinib	Phase 1	2012	2012	NCT01649271
Stomach Neoplasms	D013274	afatinib	Phase 2	2013	2016	NCT02501603;NCT01743365;NCT02465060
Carcinoma	D002277	afatinib	Phase 1	2011	2020	NCT02451553;NCT03652233;NCT01288430;NCT03878524
Carcinoma	D002277	afatinib	Phase 2	2007	2020	NCT01824823;NCT03088059;NCT02795156;NCT03486509;NCT03157089;NCT02491099;NCT01608022;NCT00514943;NCT02541903;NCT03940976;NCT04183712;NCT01538381;NCT02465060;NCT02353936;NCT01415674;NCT04533321
Carcinoma	D002277	afatinib	Phase 3	2011	2012	NCT01427478;NCT01523587;NCT01345682
Carcinoma	D002277	afatinib	Phase 4	2018	2018	NCT04132102
Neoplasm Metastasis	D009362	afatinib	Phase 1	2012	2018	NCT03711422;NCT01679405
Neoplasm Metastasis	D009362	afatinib	Phase 2	2011	2020	NCT04148898;NCT02142036;NCT03785249;NCT01441596;NCT04158947
Neoplasm Metastasis	D009362	afatinib	Phase 4	2020	2020	NCT04356118
Meningeal Neoplasms	D008577	afatinib	Phase 1	2018	2018	NCT03711422
Esophageal Neoplasms	D004938	afatinib	Phase 2	2014	2015	NCT02274012;NCT02465060;NCT02353936
Pancreatic Neoplasms	D010190	afatinib	Phase 1	2015	2020	NCT02451553;NCT02975141;NCT03878524
Pancreatic Neoplasms	D010190	afatinib	Phase 2	2015	2015	NCT02465060;NCT02450656
Carcinoma, Ductal	D044584	afatinib	Phase 1	2015	2015	NCT02451553
Head and Neck Neoplasms	D006258	afatinib	Phase 2	2007	2019	NCT02979977;NCT00514943;NCT03695510
Head and Neck Neoplasms	D006258	afatinib	Phase 3	2011	2014	NCT01856478;NCT02131155;NCT01345682;NCT01345669
Chordoma	D002817	afatinib	Phase 2	2018	2018	NCT03083678
Neoplasms, Second Primary	D016609	afatinib	Phase 2	2014	2020	NCT04148898;NCT02142036;NCT04158947
Neoplasms, Second Primary	D016609	afatinib	Phase 4	2020	2020	NCT04356118
Meningeal Carcinomatosis	D055756	afatinib	Phase 2	2019	2019	NCT04148898
Meningeal Carcinomatosis	D055756	afatinib	Phase 4	2020	2020	NCT04356118
Brain Neoplasms	D001932	afatinib	Phase 1	2016	2016	NCT02423525
Brain Neoplasms	D001932	afatinib	Phase 2	2015	2020	NCT02768337;NCT04158947
Rhabdomyosarcoma	D012208	afatinib	Phase 2	2015	2015	NCT02372006
Neuroectodermal Tumors	D017599	afatinib	Phase 2	2015	2015	NCT02372006
Neuroectodermal Tumors, Primitive	D018242	afatinib	Phase 2	2015	2015	NCT02372006
Colorectal Neoplasms	D015179	afatinib	Phase 2	2006	2015	NCT00801294;NCT01152437;NCT02465060;NCT01919879;NCT02450656
Cystadenocarcinoma, Serous	D018284	afatinib	Phase 2	2015	2015	NCT02491099
Esophageal Squamous Cell Carcinoma	D000077277	afatinib	Phase 2	2012	2019	NCT01608022;NCT03940976;NCT02353936
Neoplasms, Squamous Cell	D018307	afatinib	Phase 1	2012	2012	NCT01721525
Neoplasms, Squamous Cell	D018307	afatinib	Phase 2	2017	2017	NCT02979977
Glioma	D005910	afatinib	Phase 2	2008	2015	NCT00727506;NCT02465060
Triple Negative Breast Neoplasms	D064726	afatinib	Phase 2	2015	2015	NCT02511847
Adenocarcinoma	D000230	afatinib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	afatinib	Phase 2	2009	2020	NCT04201756;NCT02876081;NCT01003899;NCT01466660
Adenocarcinoma	D000230	afatinib	Phase 3	2009	2010	NCT01121393;NCT00949650
Adenocarcinoma of Lung	D000077192	afatinib	Phase 2	2009	2020	NCT04201756;NCT01003899;NCT01466660
Gallbladder Neoplasms	D005706	afatinib	Phase 2	2019	2019	NCT04183712
Small Cell Lung Carcinoma	D055752	afatinib	Phase 2	2017	2017	NCT02876081
Inflammatory Breast Neoplasms	D058922	afatinib	Phase 2	2011	2011	NCT01325428
Lymphoma	D008223	afatinib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	afatinib	Phase 2	2015	2015	NCT04439136;NCT02465060
Neoplasms, Plasma Cell	D054219	afatinib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	afatinib	Phase 2	2015	2015	NCT04439136;NCT02465060
Melanoma	D008545	afatinib	Phase 2	2015	2015	NCT02465060
Endometrial Neoplasms	D016889	afatinib	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	afatinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	afatinib	Phase 2	2015	2015	NCT02465060
Prostatic Neoplasms	D011471	afatinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	afatinib	Phase 2	2006	2015	NCT02465060;NCT00706628;NCT01320280
Rectal Neoplasms	D012004	afatinib	Phase 2	2015	2015	NCT02465060
Thyroid Neoplasms	D013964	afatinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	afatinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	afatinib	Phase 2	2015	2015	NCT02465060
Colonic Neoplasms	D003110	afatinib	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	afatinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Renal Cell	D002292	afatinib	Phase 2	2015	2015	NCT02465060
Kidney Neoplasms	D007680	afatinib	Phase 2	2015	2015	NCT02465060
Urologic Neoplasms	D014571	afatinib	Phase 2	2016	2016	NCT02780687
Glioblastoma	D005909	afatinib	Phase 1	2009	2009	NCT00977431
Gastrointestinal Neoplasms	D005770	afatinib	Phase 2	2015	2015	NCT02450656
Digestive System Neoplasms	D004067	afatinib	Phase 2	2015	2015	NCT02450656
Leukemia	D007938	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	afatinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	afatinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	afatinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	afatinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	afatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	afatinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	afatinib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	alectinib	Phase 1	2012	2012	NCT01634763
Lymphoma	D008223	alectinib	Phase 3	2016	2017	NCT02838420;NCT03194893
Lymphoma	D008223	alectinib	Phase 4	2020	2020	NCT04362072
Lung Neoplasms	D008175	alectinib	Phase 1	2014	2014	NCT02013219
Lung Neoplasms	D008175	alectinib	Phase 2	2013	2021	NCT04302025;NCT03944772;NCT04634110;NCT02706626;NCT04111705;NCT03202940;NCT03087448;NCT03131206;NCT03779191;NCT03737994;NCT03445000;NCT02450903;NCT01871805;NCT02521051
Lung Neoplasms	D008175	alectinib	Phase 3	2014	2017	NCT03178552;NCT02838420;NCT02075840;NCT02604342
Lung Neoplasms	D008175	alectinib	Phase 4	2020	2020	NCT04356118
Carcinoma, Non-Small-Cell Lung	D002289	alectinib	Phase 1	2014	2014	NCT02013219
Carcinoma, Non-Small-Cell Lung	D002289	alectinib	Phase 2	2013	2020	NCT02314481;NCT04302025;NCT03944772;NCT02706626;NCT03535740;NCT04111705;NCT03202940;NCT03087448;NCT03131206;NCT03445000;NCT02450903;NCT01801111;NCT01871805;NCT02521051;NCT03155009
Carcinoma, Non-Small-Cell Lung	D002289	alectinib	Phase 3	2014	2019	NCT03456076;NCT03178552;NCT02838420;NCT03596866;NCT02075840;NCT02604342
Carcinoma, Non-Small-Cell Lung	D002289	alectinib	Phase 4	2020	2020	NCT04356118
Neoplasms, Unknown Primary	D009382	alectinib	Phase 2	2018	2018	NCT03498521
Central Nervous System Neoplasms	D016543	alectinib	Phase 2	2021	2021	NCT04774718
Carcinoma	D002277	alectinib	Phase 2	2020	2020	NCT04644432
Carcinoma, Renal Cell	D002292	alectinib	Phase 2	2020	2020	NCT04644432
Kidney Neoplasms	D007680	alectinib	Phase 2	2020	2020	NCT04644432
Urogenital Neoplasms	D014565	alectinib	Phase 2	2020	2020	NCT04644432
Urologic Neoplasms	D014571	alectinib	Phase 2	2020	2020	NCT04644432
Neoplasm Metastasis	D009362	alectinib	Phase 2	2020	2021	NCT04634110;NCT04116541
Neoplasm Metastasis	D009362	alectinib	Phase 4	2020	2020	NCT04356118
Glioblastoma	D005909	alectinib	Phase 2	2018	2018	NCT03158389
Thyroid Neoplasms	D013964	alectinib	Phase 2	2017	2017	NCT03131206
Gastrointestinal Neoplasms	D005770	alectinib	Phase 2	2020	2020	NCT04591431
Neoplasms, Second Primary	D016609	alectinib	Phase 4	2020	2020	NCT04356118
Meningeal Carcinomatosis	D055756	alectinib	Phase 4	2020	2020	NCT04356118
Triple Negative Breast Neoplasms	D064726	alpelisib	Phase 1	2012	2012	NCT01623349
Triple Negative Breast Neoplasms	D064726	alpelisib	Phase 2	2020	2020	NCT04216472
Triple Negative Breast Neoplasms	D064726	alpelisib	Phase 3	2020	2020	NCT04251533
Breast Neoplasms	D001943	alpelisib	Phase 1	2010	2019	NCT02734615;NCT01623349;NCT03207529;NCT02058381;NCT04188548;NCT02167854;NCT02077933;NCT02038010;NCT01219699;NCT02088684;NCT02051751;NCT01791478;NCT01300962;NCT01870505
Breast Neoplasms	D001943	alpelisib	Phase 2	2013	2021	NCT02379247;NCT02506556;NCT01923168;NCT04300790;NCT04544189;NCT04215003;NCT03056755;NCT04524000;NCT04762979;NCT04216472;NCT03284957;NCT03386162;NCT01872260
Breast Neoplasms	D001943	alpelisib	Phase 3	2015	2020	NCT04251533;NCT04208178;NCT02437318;NCT03439046
Ovarian Neoplasms	D010051	alpelisib	Phase 1	2012	2012	NCT01623349
Ovarian Neoplasms	D010051	alpelisib	Phase 3	2021	2021	NCT04729387
Carcinoma, Ovarian Epithelial	D000077216	alpelisib	Phase 1	2012	2012	NCT01623349
Carcinoma, Ovarian Epithelial	D000077216	alpelisib	Phase 3	2021	2021	NCT04729387
Melanoma	D008545	alpelisib	Phase 1	2014	2014	NCT02273219
Uveal Neoplasms	D014604	alpelisib	Phase 1	2014	2014	NCT02273219
Head and Neck Neoplasms	D006258	alpelisib	Phase 1	2014	2014	NCT02051751
Head and Neck Neoplasms	D006258	alpelisib	Phase 2	2017	2017	NCT03292250
Carcinoma	D002277	alpelisib	Phase 1	2013	2019	NCT03207529;NCT01822613;NCT02537223
Carcinoma	D002277	alpelisib	Phase 2	2012	2020	NCT02145312;NCT02298595;NCT03601507;NCT01602315;NCT04216472
Carcinoma, Squamous Cell	D002294	alpelisib	Phase 1	2013	2015	NCT01822613;NCT02537223;NCT02282371
Carcinoma, Squamous Cell	D002294	alpelisib	Phase 2	2012	2018	NCT02145312;NCT02298595;NCT03601507;NCT01602315
Squamous Cell Carcinoma of Head and Neck	D000077195	alpelisib	Phase 1	2015	2015	NCT02537223
Squamous Cell Carcinoma of Head and Neck	D000077195	alpelisib	Phase 2	2012	2016	NCT02145312;NCT01602315
Endometrial Neoplasms	D016889	alpelisib	Phase 1	2019	2019	NCT04188548
Pancreatic Neoplasms	D010190	alpelisib	Phase 1	2014	2014	NCT02155088
Esophageal Squamous Cell Carcinoma	D000077277	alpelisib	Phase 1	2013	2013	NCT01822613
Oropharyngeal Neoplasms	D009959	alpelisib	Phase 2	2016	2016	NCT02298595
Neuroendocrine Tumors	D018358	alpelisib	Phase 1	2014	2014	NCT02077933
Carcinoma, Renal Cell	D002292	alpelisib	Phase 1	2014	2014	NCT02077933
Kidney Neoplasms	D007680	alpelisib	Phase 1	2014	2014	NCT02077933
Colorectal Neoplasms	D015179	alpelisib	Phase 2	2012	2021	NCT04753203;NCT01719380
Gastrointestinal Stromal Tumors	D046152	alpelisib	Phase 1	2013	2013	NCT01735968
Stomach Neoplasms	D013274	alpelisib	Phase 1	2012	2012	NCT01613950
Stomach Neoplasms	D013274	alpelisib	Phase 2	2020	2020	NCT04526470
Esophageal Neoplasms	D004938	alpelisib	Phase 1	2012	2012	NCT01613950
Rectal Neoplasms	D012004	alpelisib	Phase 1	2016	2016	NCT02550743
Meningioma	D008579	alpelisib	Phase 1	2019	2019	NCT03631953
Carcinoma, Ductal, Breast	D018270	alpelisib	Phase 1	2013	2013	NCT01791478
Lung Neoplasms	D008175	alpelisib	Phase 2	2015	2015	NCT02276027
Adenocarcinoma	D000230	alpelisib	Phase 2	2015	2015	NCT02276027
Adenocarcinoma of Lung	D000077192	alpelisib	Phase 2	2015	2015	NCT02276027
Prostatic Neoplasms	D011471	alpelisib	Phase 2	2016	2016	NCT02913131
Multiple Myeloma	D009101	alpelisib	Phase 1	2014	2014	NCT02144038
Neoplasms, Plasma Cell	D054219	alpelisib	Phase 1	2014	2014	NCT02144038
Neoplasms, Squamous Cell	D018307	alpelisib	Phase 1	2014	2014	NCT02282371
Head and Neck Neoplasms	D006258	amlexanox	Phase 2	2000	2000	NCT01083875
Colorectal Neoplasms	D015179	apatinib	Phase 2	2011	2020	NCT03344614;NCT03271255;NCT04067986;NCT03190616;NCT04715633;NCT04073615;NCT03193814;NCT03397199;NCT01531777;NCT03377842;NCT03132025;NCT02829385;NCT03403452;NCT03912857;NCT03210064;NCT04202978;NCT03412994
Colorectal Neoplasms	D015179	apatinib	Phase 3	2018	2018	NCT03365765
Adenocarcinoma	D000230	apatinib	Phase 1	2015	2018	NCT03244774;NCT02691871;NCT03071042
Adenocarcinoma	D000230	apatinib	Phase 2	2015	2021	NCT04006821;NCT04781686;NCT03349866;NCT03788174;NCT04459078;NCT03030937;NCT02704767;NCT03707639;NCT04121039;NCT03707028;NCT04190745;NCT04446091;NCT03116555;NCT04572542;NCT04609176;NCT03599778;NCT02493582;NCT03376737
Adenocarcinoma	D000230	apatinib	Phase 3	2017	2019	NCT03986385;NCT04208347;NCT03042611
Glioma	D005910	apatinib	Phase 2	2016	2020	NCT04253873;NCT02848794;NCT03741244;NCT03390062;NCT04588987
Breast Neoplasms	D001943	apatinib	Phase 1	2017	2019	NCT03075462;NCT03945604
Breast Neoplasms	D001943	apatinib	Phase 2	2010	2021	NCT03982485;NCT03243838;NCT03394287;NCT03805399;NCT03348098;NCT03735082;NCT03932526;NCT03086785;NCT03535961;NCT03457467;NCT04303741;NCT03775928;NCT02878057;NCT03254654;NCT01653561;NCT01176669;NCT03650738;NCT02768415;NCT04722718
Breast Neoplasms	D001943	apatinib	Phase 3	2017	2020	NCT03580395;NCT04335006;NCT04296370
Pancreatic Neoplasms	D010190	apatinib	Phase 2	2016	2021	NCT04723030;NCT03662035;NCT04101929;NCT02726854;NCT04415385;NCT02863367
Neoplasm Metastasis	D009362	apatinib	Phase 1	2017	2017	NCT03396211
Neoplasm Metastasis	D009362	apatinib	Phase 2	2017	2020	NCT03356600;NCT03742193;NCT04682249;NCT03913182;NCT04202978
Neoplasm Metastasis	D009362	apatinib	Phase 3	2016	2016	NCT02711007;NCT02702323
Neoplasms, Second Primary	D016609	apatinib	Phase 2	2017	2019	NCT03356600;NCT03913182
Neoplasms, Second Primary	D016609	apatinib	Phase 3	2016	2016	NCT02702323
Brain Neoplasms	D001932	apatinib	Phase 2	2017	2017	NCT03356600
Esophageal Neoplasms	D004938	apatinib	Phase 2	2015	2019	NCT03787251;NCT02683655;NCT03274011;NCT03649945;NCT02544737;NCT03170310;NCT03542422
Esophageal Neoplasms	D004938	apatinib	Phase 3	2017	2017	NCT03285906
Stomach Neoplasms	D013274	apatinib	Phase 1	2016	2017	NCT03026881;NCT03276156;NCT02711969
Stomach Neoplasms	D013274	apatinib	Phase 2	2015	2020	NCT04089657;NCT03030937;NCT03428425;NCT03878472;NCT02697838;NCT04345783;NCT02529878;NCT03472365;NCT03334591;NCT02942329;NCT03007446;NCT02596256;NCT02485015;NCT04195828;NCT02662959;NCT03229096;NCT03219593;NCT03192735;NCT03950141;NCT03154983;NCT04267549;NCT04572542;NCT04182724;NCT04286711;NCT04609176;NCT04338438;NCT03599778;NCT03258034;NCT03718624;NCT03144843;NCT03104283;NCT03954756;NCT02525237;NCT03271073;NCT04258644
Stomach Neoplasms	D013274	apatinib	Phase 3	2009	2020	NCT02537171;NCT02510469;NCT02409199;NCT03598348;NCT03355612;NCT03889626;NCT00970138;NCT02509806;NCT01512745;NCT04342910;NCT03813784;NCT03042611
Stomach Neoplasms	D013274	apatinib	Phase 4	2015	2016	NCT02426034;NCT02776527;NCT03384511
Osteosarcoma	D012516	apatinib	Phase 2	2017	2020	NCT04351308;NCT04044378;NCT03742193;NCT03539172;NCT03359018;NCT03163381
Osteosarcoma	D012516	apatinib	Phase 3	2016	2016	NCT02711007
Lung Neoplasms	D008175	apatinib	Phase 1	2016	2016	NCT03050411
Lung Neoplasms	D008175	apatinib	Phase 2	2010	2021	NCT03190239;NCT03547804;NCT03127319;NCT04133337;NCT03129256;NCT03461185;NCT03135977;NCT02974933;NCT04201990;NCT03417895;NCT03164694;NCT02540824;NCT01270386;NCT04425135;NCT03256721;NCT02733107;NCT02945852;NCT04128800;NCT02515435;NCT04683198;NCT03811054;NCT04749394;NCT04379739;NCT02995187;NCT03652857;NCT02980809;NCT03201146;NCT03389087;NCT04659785
Lung Neoplasms	D008175	apatinib	Phase 3	2011	2020	NCT02875457;NCT01287962;NCT04490421;NCT02702323;NCT04203485;NCT03651219;NCT02780778;NCT02332512
Lung Neoplasms	D008175	apatinib	Phase 4	2019	2019	NCT03792503
Carcinoma, Non-Small-Cell Lung	D002289	apatinib	Phase 1	2016	2016	NCT03050411
Carcinoma, Non-Small-Cell Lung	D002289	apatinib	Phase 2	2010	2021	NCT03190239;NCT03801200;NCT04670913;NCT03127319;NCT03083041;NCT04133337;NCT03129256;NCT03461185;NCT04506242;NCT02974933;NCT03267654;NCT02540824;NCT03416231;NCT01270386;NCT03256721;NCT02733107;NCT02515435;NCT03811054;NCT03758677;NCT03777124;NCT04749394;NCT04379739;NCT03652857;NCT03201146
Carcinoma, Non-Small-Cell Lung	D002289	apatinib	Phase 3	2011	2020	NCT01287962;NCT02824458;NCT04203485;NCT02780778;NCT02332512
Carcinoma, Non-Small-Cell Lung	D002289	apatinib	Phase 4	2019	2019	NCT03792503
Gastrointestinal Neoplasms	D005770	apatinib	Phase 2	2018	2018	NCT03271255
Gastrointestinal Neoplasms	D005770	apatinib	Phase 3	2019	2019	NCT03889626
Digestive System Neoplasms	D004067	apatinib	Phase 2	2018	2018	NCT03271255
Digestive System Neoplasms	D004067	apatinib	Phase 3	2019	2019	NCT03889626
Intestinal Neoplasms	D007414	apatinib	Phase 2	2018	2018	NCT03271255
Small Cell Lung Carcinoma	D055752	apatinib	Phase 2	2016	2021	NCT03547804;NCT03135977;NCT03417895;NCT02945852;NCT04128800;NCT04683198;NCT04453930;NCT02995187;NCT02980809;NCT03389087;NCT04659785;NCT03129698
Small Cell Lung Carcinoma	D055752	apatinib	Phase 3	2016	2020	NCT02875457;NCT03100955;NCT04490421;NCT03651219
Carcinoma, Squamous Cell	D002294	apatinib	Phase 1	2016	2020	NCT04393506;NCT02645864
Carcinoma, Squamous Cell	D002294	apatinib	Phase 2	2016	2020	NCT03603756;NCT03274011;NCT03193424;NCT02976896;NCT03424291;NCT03224221;NCT04666090;NCT03267121;NCT03096184;NCT03857763;NCT04440917;NCT03251417;NCT03320629;NCT03913182
Carcinoma, Squamous Cell	D002294	apatinib	Phase 4	2018	2018	NCT03725423
Esophageal Squamous Cell Carcinoma	D000077277	apatinib	Phase 1	2016	2016	NCT02645864
Esophageal Squamous Cell Carcinoma	D000077277	apatinib	Phase 2	2016	2020	NCT03603756;NCT03274011;NCT03193424;NCT02976896;NCT03224221;NCT04666090;NCT03857763;NCT03251417;NCT03320629;NCT03913182
Neoplasms, Squamous Cell	D018307	apatinib	Phase 2	2017	2018	NCT03603756;NCT03224221
Lymphoma	D008223	apatinib	Phase 2	2018	2020	NCT04476459;NCT03701022
Lymphoma	D008223	apatinib	Phase 4	2017	2018	NCT03631862;NCT03376958
Lymphoma, B-Cell	D016393	apatinib	Phase 2	2020	2020	NCT04476459
Lymphoma, B-Cell	D016393	apatinib	Phase 4	2017	2017	NCT03376958
Lymphoma, Large B-Cell, Diffuse	D016403	apatinib	Phase 2	2020	2020	NCT04476459
Lymphoma, Large B-Cell, Diffuse	D016403	apatinib	Phase 4	2017	2017	NCT03376958
Lymphoma, Large-Cell, Anaplastic	D017728	apatinib	Phase 2	2020	2020	NCT04476459
Carcinoma	D002277	apatinib	Phase 1	2016	2021	NCT04665362;NCT02645864;NCT04073784
Carcinoma	D002277	apatinib	Phase 2	2010	2021	NCT03520257;NCT03130270;NCT03511703;NCT04318730;NCT02727309;NCT04297202;NCT03193424;NCT02976896;NCT03424291;NCT04548271;NCT03092895;NCT03732105;NCT04191889;NCT02775370;NCT04014101;NCT03793725;NCT04188847;NCT01192971;NCT02942329;NCT04479527;NCT04411706;NCT04666090;NCT03267121;NCT03261791;NCT03709953;NCT03096184;NCT03046979;NCT03857763;NCT04156698;NCT02942693;NCT02874651;NCT03167385;NCT04535687;NCT04204577;NCT04586088;NCT02772029;NCT03612219;NCT04724226;NCT04547088;NCT04440917;NCT03251417;NCT03320629;NCT03913182;NCT03114085;NCT03213587;NCT03609489;NCT03427242;NCT03702491;NCT04350190;NCT03510416;NCT04701060;NCT02774200;NCT03839550
Carcinoma	D002277	apatinib	Phase 3	2009	2020	NCT04639180;NCT03355612;NCT00970138;NCT02329860
Carcinoma	D002277	apatinib	Phase 4	2018	2018	NCT03725423
Carcinoma, Hepatocellular	D006528	apatinib	Phase 1	2021	2021	NCT04665362
Carcinoma, Hepatocellular	D006528	apatinib	Phase 2	2010	2021	NCT03520257;NCT03511703;NCT04523662;NCT02727309;NCT04297202;NCT03732105;NCT04191889;NCT04014101;NCT03793725;NCT03463876;NCT01192971;NCT02942329;NCT04479527;NCT04411706;NCT04035876;NCT03261791;NCT03046979;NCT04204577;NCT02772029;NCT04724226;NCT03114085;NCT03510416;NCT04701060;NCT03839550
Carcinoma, Hepatocellular	D006528	apatinib	Phase 3	2014	2020	NCT04639180;NCT03274427;NCT02702323;NCT02329860;NCT03278444
Nasopharyngeal Carcinoma	D000077274	apatinib	Phase 1	2019	2019	NCT04073784
Nasopharyngeal Carcinoma	D000077274	apatinib	Phase 2	2016	2020	NCT03130270;NCT04548271;NCT03180476;NCT02874651;NCT04586088;NCT03612219;NCT04547088;NCT03213587;NCT04350190
Lymphoma, T-Cell	D016399	apatinib	Phase 2	2016	2018	NCT03701022;NCT02844881
Lymphoma, T-Cell	D016399	apatinib	Phase 4	2018	2018	NCT03631862
Lymphoma, T-Cell, Peripheral	D016411	apatinib	Phase 4	2018	2018	NCT03631862
Head and Neck Neoplasms	D006258	apatinib	Phase 2	2016	2018	NCT02943252;NCT02989259;NCT03654612
Thyroid Neoplasms	D013964	apatinib	Phase 2	2016	2020	NCT02731352;NCT04180007;NCT04612894;NCT03300765;NCT04560127;NCT03167385;NCT03199677
Thyroid Neoplasms	D013964	apatinib	Phase 3	2016	2016	NCT03048877
Mouth Neoplasms	D009062	apatinib	Phase 1	2020	2020	NCT04393506
Triple Negative Breast Neoplasms	D064726	apatinib	Phase 1	2017	2019	NCT03075462;NCT03945604
Triple Negative Breast Neoplasms	D064726	apatinib	Phase 2	2010	2019	NCT03243838;NCT03805399;NCT03348098;NCT03735082;NCT03932526;NCT03775928;NCT03254654;NCT01176669;NCT03650738
Triple Negative Breast Neoplasms	D064726	apatinib	Phase 3	2020	2020	NCT04335006
Uterine Cervical Neoplasms	D002583	apatinib	Phase 2	2018	2019	NCT03816553;NCT03546855;NCT04188847
Adenocarcinoma of Lung	D000077192	apatinib	Phase 1	2016	2016	NCT02691871
Adenocarcinoma of Lung	D000077192	apatinib	Phase 2	2015	2020	NCT04459078;NCT02704767;NCT02493582;NCT03376737
Melanoma	D008545	apatinib	Phase 2	2017	2020	NCT03422445;NCT04397770;NCT03955354;NCT04331093;NCT03986515;NCT03383237
Rhabdomyosarcoma	D012208	apatinib	Phase 2	2019	2019	NCT03868852
Liver Neoplasms	D008113	apatinib	Phase 2	2017	2020	NCT04523662;NCT03092895;NCT04204577
Liver Neoplasms	D008113	apatinib	Phase 3	2016	2016	NCT02702323
Ovarian Neoplasms	D010051	apatinib	Phase 1	2017	2017	NCT03075462
Ovarian Neoplasms	D010051	apatinib	Phase 2	2016	2020	NCT04590625;NCT04068974;NCT03587129;NCT03393507;NCT04348032;NCT02867956;NCT03298074;NCT04383977;NCT04517357;NCT03262545;NCT03942068;NCT03547375
Ovarian Neoplasms	D010051	apatinib	Phase 3	2019	2020	NCT04229615;NCT04000295
Ovarian Neoplasms	D010051	apatinib	Phase 4	2016	2016	NCT03384511
Carcinoma, Ovarian Epithelial	D000077216	apatinib	Phase 1	2017	2017	NCT03075462
Carcinoma, Ovarian Epithelial	D000077216	apatinib	Phase 2	2016	2020	NCT04590625;NCT04068974;NCT03587129;NCT03393507;NCT04348032;NCT02867956;NCT03298074;NCT04383977;NCT04517357;NCT03942068;NCT03547375
Carcinoma, Ovarian Epithelial	D000077216	apatinib	Phase 3	2019	2020	NCT04229615;NCT04000295
Thoracic Neoplasms	D013899	apatinib	Phase 2	2018	2019	NCT04133337;NCT03389256
Adrenocortical Carcinoma	D018268	apatinib	Phase 2	2020	2020	NCT04318730
Gestational Trophoblastic Disease	D031901	apatinib	Phase 2	2019	2019	NCT04047017
Squamous Cell Carcinoma of Head and Neck	D000077195	apatinib	Phase 2	2016	2020	NCT03424291;NCT03267121;NCT03096184;NCT04440917
Sarcoma	D012509	apatinib	Phase 1	2019	2019	NCT04074564
Sarcoma	D012509	apatinib	Phase 2	2017	2020	NCT03711279;NCT04126993;NCT03064243;NCT03539172;NCT04072042;NCT04012827;NCT04126811;NCT03121846;NCT04447274;NCT03104335;NCT03163381;NCT04239443
Fallopian Tube Neoplasms	D005185	apatinib	Phase 3	2020	2020	NCT04229615
Cholangiocarcinoma	D018281	apatinib	Phase 2	2017	2020	NCT03251443;NCT04642664;NCT04454905;NCT03521219
Carcinoma, Adenoid Cystic	D003528	apatinib	Phase 2	2016	2016	NCT02775370;NCT02942693
Neoplasms, Connective and Soft Tissue	D018204	apatinib	Phase 2	2018	2018	NCT03539172
Nasopharyngeal Neoplasms	D009303	apatinib	Phase 2	2016	2017	NCT03180476;NCT02874651
Colonic Neoplasms	D003110	apatinib	Phase 2	2021	2021	NCT04625803
Biliary Tract Neoplasms	D001661	apatinib	Phase 2	2017	2021	NCT04642664;NCT03144856;NCT03427242;NCT04720131
Carcinoma, Signet Ring Cell	D018279	apatinib	Phase 3	2017	2017	NCT03355612
Medulloblastoma	D008527	apatinib	Phase 2	2020	2020	NCT04501718
Adenocarcinoma, Mucinous	D002288	apatinib	Phase 2	2020	2020	NCT04446091
Cystadenocarcinoma	D003536	apatinib	Phase 2	2020	2020	NCT04446091
Carcinoma, Renal Cell	D002292	apatinib	Phase 2	2016	2020	NCT04535687;NCT02774200
Bile Duct Neoplasms	D001650	apatinib	Phase 2	2018	2018	NCT03609489
Gallbladder Neoplasms	D005706	apatinib	Phase 2	2018	2018	NCT03702491
Uterine Neoplasms	D014594	apatinib	Phase 2	2019	2019	NCT04239443
Gastrointestinal Stromal Tumors	D046152	avapritinib	Phase 1	2015	2015	NCT02508532
Gastrointestinal Stromal Tumors	D046152	avapritinib	Phase 2	2019	2019	NCT04254939
Gastrointestinal Stromal Tumors	D046152	avapritinib	Phase 3	2018	2018	NCT03465722
Mastocytosis	D008415	avapritinib	Phase 1	2016	2016	NCT02561988
Mastocytosis	D008415	avapritinib	Phase 2	2018	2019	NCT03580655;NCT03731260
Mastocytosis, Systemic	D034721	avapritinib	Phase 1	2016	2016	NCT02561988
Mastocytosis, Systemic	D034721	avapritinib	Phase 2	2018	2019	NCT03580655;NCT03731260
Leukemia, Mast-Cell	D007946	avapritinib	Phase 1	2016	2016	NCT02561988
Leukemia, Mast-Cell	D007946	avapritinib	Phase 2	2018	2018	NCT03580655
Hematologic Neoplasms	D019337	avapritinib	Phase 2	2018	2018	NCT03580655
Sarcoma	D012509	avapritinib	Phase 1	2016	2016	NCT03056599
Sarcoma	D012509	avapritinib	Phase 2	2021	2021	NCT04771520
Breast Neoplasms	D001943	avapritinib	Phase 2	2021	2021	NCT04771520
Lung Neoplasms	D008175	avapritinib	Phase 2	2021	2021	NCT04771520
Colorectal Neoplasms	D015179	avapritinib	Phase 2	2021	2021	NCT04771520
Melanoma	D008545	avapritinib	Phase 2	2021	2021	NCT04771520
Adenocarcinoma	D000230	avapritinib	Phase 2	2021	2021	NCT04771520
Esophageal Neoplasms	D004938	avapritinib	Phase 2	2021	2021	NCT04771520
Nervous System Neoplasms	D009423	avapritinib	Phase 2	2021	2021	NCT04771520
Central Nervous System Neoplasms	D016543	avapritinib	Phase 2	2021	2021	NCT04771520
Carcinoma	D002277	axitinib	Phase 1	2011	2020	NCT01441388;NCT04522323;NCT03289533;NCT02814461
Carcinoma	D002277	axitinib	Phase 2	2009	2020	NCT01441414;NCT04540705;NCT02667886;NCT01798446;NCT01806064;NCT01649180;NCT03494816;NCT01334112;NCT02788201;NCT04118855;NCT01273662;NCT03092856;NCT03438708;NCT04387500;NCT04698213;NCT03172754;NCT02639182;NCT01210495;NCT01558661;NCT04385654;NCT04337970;NCT02535533;NCT03990571;NCT03595124;NCT01352728;NCT02187302;NCT00835978;NCT02489695;NCT04370509;NCT02700568;NCT01727336;NCT03736330;NCT03592199;NCT01263769;NCT01483638
Carcinoma	D002277	axitinib	Phase 3	2016	2021	NCT02853331;NCT04510597;NCT04394975;NCT04764487
Carcinoma, Renal Cell	D002292	axitinib	Phase 1	2011	2020	NCT01441388;NCT04522323;NCT03086174;NCT01334073;NCT02133742;NCT02493751
Carcinoma, Renal Cell	D002292	axitinib	Phase 2	2006	2021	NCT01441414;NCT04540705;NCT03387514;NCT00282048;NCT02667886;NCT01798446;NCT02560012;NCT01806064;NCT01649180;NCT02579811;NCT03494816;NCT04118855;NCT03092856;NCT00569946;NCT03438708;NCT04387500;NCT04698213;NCT03172754;NCT01693822;NCT02639182;NCT04385654;NCT04337970;NCT02535533;NCT03595124;NCT03341845;NCT02187302;NCT00835978;NCT02489695;NCT04714697;NCT04370509;NCT02700568;NCT01727336;NCT03592199;NCT01263769
Carcinoma, Renal Cell	D002292	axitinib	Phase 3	2008	2021	NCT02853331;NCT04510597;NCT04394975;NCT01599754;NCT04764487;NCT02684006;NCT00678392;NCT00920816
Carcinoma, Non-Small-Cell Lung	D002289	axitinib	Phase 2	2005	2020	NCT00094094;NCT03386929;NCT03472560;NCT00735904;NCT00600821;NCT00768755;NCT00386555;NCT04459663
Lung Neoplasms	D008175	axitinib	Phase 2	2005	2020	NCT00094094;NCT03386929;NCT03472560;NCT00735904;NCT04459663
Kidney Neoplasms	D007680	axitinib	Phase 1	2017	2017	NCT03086174
Kidney Neoplasms	D007680	axitinib	Phase 2	2003	2020	NCT00076011;NCT00282048;NCT04698213;NCT03456401;NCT04385654;NCT04337970;NCT03736330;NCT02597322;NCT01263769
Kidney Neoplasms	D007680	axitinib	Phase 3	2008	2012	NCT01599754;NCT00678392;NCT00920816
Liver Neoplasms	D008113	axitinib	Phase 2	2020	2020	NCT04010071
Biliary Tract Neoplasms	D001661	axitinib	Phase 2	2020	2020	NCT04010071
Leukemia, Myeloid	D007951	axitinib	Phase 1	2017	2017	NCT02782403
Leukemia, Myeloid	D007951	axitinib	Phase 2	2003	2015	NCT02638428;NCT00071006
Melanoma	D008545	axitinib	Phase 1	2017	2017	NCT03086174
Melanoma	D008545	axitinib	Phase 2	2004	2021	NCT01321437;NCT03941795;NCT04688658;NCT04493203;NCT01533948;NCT04180995;NCT01174238;NCT00094107
Thyroid Neoplasms	D013964	axitinib	Phase 2	2004	2006	NCT00094055;NCT00176748;NCT00389441
Stomach Neoplasms	D013274	axitinib	Phase 1	2009	2009	NCT00842244
Leukemia	D007938	axitinib	Phase 1	2017	2017	NCT02782403
Leukemia	D007938	axitinib	Phase 2	2003	2003	NCT00071006
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	axitinib	Phase 1	2017	2017	NCT02782403
Blast Crisis	D001752	axitinib	Phase 1	2017	2017	NCT02782403
Leukemia, Myeloid, Accelerated Phase	D015465	axitinib	Phase 1	2017	2017	NCT02782403
Glioblastoma	D005909	axitinib	Phase 1	2011	2018	NCT01441388;NCT03275558
Glioblastoma	D005909	axitinib	Phase 2	2011	2017	NCT01562197;NCT03291314;NCT01508117
Carcinoma, Hepatocellular	D006528	axitinib	Phase 1	2011	2017	NCT01441388;NCT03289533;NCT02814461
Carcinoma, Hepatocellular	D006528	axitinib	Phase 2	2010	2011	NCT01334112;NCT01273662;NCT01210495;NCT01352728
Colorectal Neoplasms	D015179	axitinib	Phase 2	2006	2012	NCT04355156;NCT00460603;NCT01490866;NCT00615056;NCT01483638
Neuroendocrine Tumors	D018358	axitinib	Phase 3	2011	2011	NCT01744249
Urinary Bladder Neoplasms	D001749	axitinib	Phase 2	2017	2017	NCT02788201
Carcinoma, Transitional Cell	D002295	axitinib	Phase 2	2017	2017	NCT02788201
Carcinoid Tumor	D002276	axitinib	Phase 2	2011	2011	NCT01435122
Central Nervous System Neoplasms	D016543	axitinib	Phase 1	2014	2014	NCT02164838
Uveal Neoplasms	D014604	axitinib	Phase 2	2012	2012	NCT01533948
Multiple Myeloma	D009101	axitinib	Phase 2	2017	2017	NCT03297606
Lymphoma, Non-Hodgkin	D008228	axitinib	Phase 2	2017	2017	NCT03297606
Pheochromocytoma	D010673	axitinib	Phase 2	2013	2019	NCT01967576;NCT03839498
Paraganglioma	D010235	axitinib	Phase 2	2013	2019	NCT01967576;NCT03839498
Carotid Body Tumor	D002345	axitinib	Phase 2	2013	2019	NCT01967576;NCT03839498
Endometrial Neoplasms	D016889	axitinib	Phase 2	2016	2021	NCT04197219;NCT02912572
Pancreatic Neoplasms	D010190	axitinib	Phase 2	2005	2005	NCT00219557
Pancreatic Neoplasms	D010190	axitinib	Phase 3	2007	2007	NCT00471146
Gastrointestinal Stromal Tumors	D046152	axitinib	Phase 2	2019	2019	NCT04258956
Neurofibromatoses	D017253	axitinib	Phase 2	2014	2014	NCT02129647
Neurofibromatosis 1	D009456	axitinib	Phase 2	2014	2014	NCT02129647
Neurofibroma	D009455	axitinib	Phase 2	2014	2014	NCT02129647
Neurilemmoma	D009442	axitinib	Phase 2	2014	2014	NCT02129647
Neuroma, Acoustic	D009464	axitinib	Phase 2	2014	2014	NCT02129647
Neurofibromatosis 2	D016518	axitinib	Phase 2	2014	2014	NCT02129647
Carcinoma, Adenoid Cystic	D003528	axitinib	Phase 2	2012	2019	NCT01558661;NCT03990571;NCT02859012
Prostatic Neoplasms	D011471	axitinib	Phase 2	2011	2012	NCT01409200;NCT01385059
Adenocarcinoma	D000230	axitinib	Phase 2	2012	2012	NCT01409200
Adrenal Cortex Neoplasms	D000306	axitinib	Phase 2	2010	2010	NCT01255137
Adrenocortical Carcinoma	D018268	axitinib	Phase 2	2010	2010	NCT01255137
Sarcoma	D012509	axitinib	Phase 2	2010	2016	NCT02636725;NCT01140737
Sarcoma, Alveolar Soft Part	D018234	axitinib	Phase 2	2016	2016	NCT02636725
Salivary Gland Neoplasms	D012468	axitinib	Phase 2	2014	2014	NCT02857712
Carcinoma, Pancreatic Ductal	D021441	axitinib	Phase 3	2007	2007	NCT00471146
Solitary Fibrous Tumors	D054364	axitinib	Phase 2	2014	2014	NCT02261207
Neoplasms, Fibrous Tissue	D018218	axitinib	Phase 2	2014	2014	NCT02261207
Breast Neoplasms	D001943	axitinib	Phase 2	2004	2004	NCT00076024
Head and Neck Neoplasms	D006258	axitinib	Phase 2	2012	2016	NCT02762513;NCT01469546
Squamous Cell Carcinoma of Head and Neck	D000077195	axitinib	Phase 2	2012	2016	NCT02762513;NCT01469546
Leukemia, Myeloid, Acute	D015470	axitinib	Phase 2	2003	2003	NCT00071006
Preleukemia	D011289	axitinib	Phase 2	2003	2003	NCT00071006
Hemangiosarcoma	D006394	axitinib	Phase 2	2010	2010	NCT01140737
Mesothelioma	D008654	axitinib	Phase 2	2009	2009	NCT01211275
Carcinoma, Squamous Cell	D002294	axitinib	Phase 2	2012	2012	NCT01469546
Glioma	D005910	axitinib	Phase 1	2018	2018	NCT03275558
Gliosarcoma	D018316	axitinib	Phase 1	2018	2018	NCT03275558
Nasopharyngeal Carcinoma	D000077274	axitinib	Phase 2	2010	2010	NCT01249547
Skin Neoplasms	D012878	axitinib	Phase 2	2004	2004	NCT00094107
Lung Neoplasms	D008175	binimetinib	Phase 1	2013	2020	NCT02185690;NCT04005144;NCT02451865;NCT02964689;NCT01859026
Lung Neoplasms	D008175	binimetinib	Phase 2	2015	2021	NCT04735068;NCT04526782;NCT04292119;NCT03915951;NCT03170206;NCT02465060;NCT02276027
Carcinoma, Non-Small-Cell Lung	D002289	binimetinib	Phase 1	2013	2020	NCT03991819;NCT04005144;NCT02451865;NCT02964689;NCT01859026;NCT04543188
Carcinoma, Non-Small-Cell Lung	D002289	binimetinib	Phase 2	2019	2021	NCT04735068;NCT04526782;NCT03915951;NCT04585815
Melanoma	D008545	binimetinib	Phase 1	2017	2021	NCT04759846;NCT04741997;NCT03026517;NCT03864042;NCT03878719;NCT04543188
Melanoma	D008545	binimetinib	Phase 2	2011	2021	NCT04375527;NCT04511013;NCT02159066;NCT04221438;NCT04598009;NCT04074096;NCT01562899;NCT02631447;NCT01820364;NCT02902042;NCT03947385;NCT03911869;NCT01781572;NCT02263898;NCT03235245;NCT03563729;NCT01801358;NCT02465060;NCT04720768;NCT03898908;NCT02094872;NCT01320085;NCT04655157
Melanoma	D008545	binimetinib	Phase 3	2013	2021	NCT04657991;NCT01909453;NCT01763164
Skin Neoplasms	D012878	binimetinib	Phase 2	2015	2020	NCT04375527;NCT04511013;NCT04221438;NCT02465060
Breast Neoplasms	D001943	binimetinib	Phase 2	2015	2020	NCT04494958;NCT03106415;NCT03971409;NCT02465060
Triple Negative Breast Neoplasms	D064726	binimetinib	Phase 2	2017	2020	NCT04494958;NCT03106415;NCT03971409
Carcinoma	D002277	binimetinib	Phase 1	2015	2018	NCT02185690;NCT02105350
Carcinoma	D002277	binimetinib	Phase 2	2013	2021	NCT03981614;NCT04390243;NCT03971409;NCT04061980;NCT02465060;NCT01828034
Colorectal Neoplasms	D015179	binimetinib	Phase 1	2014	2018	NCT02613650;NCT02510001;NCT03374254
Colorectal Neoplasms	D015179	binimetinib	Phase 2	2013	2020	NCT03981614;NCT04044430;NCT03271047;NCT01927341;NCT02465060;NCT03475004;NCT03693170
Colorectal Neoplasms	D015179	binimetinib	Phase 3	2016	2020	NCT02928224;NCT03803553
Neuroendocrine Tumors	D018358	binimetinib	Phase 2	2019	2019	NCT03981614
Hematologic Neoplasms	D019337	binimetinib	Phase 2	2013	2013	NCT01885195
Glioma	D005910	binimetinib	Phase 2	2015	2016	NCT02285439;NCT02465060
Soft Tissue Neoplasms	D012983	binimetinib	Phase 2	2016	2016	NCT02285439
Brain Neoplasms	D001932	binimetinib	Phase 1	2020	2020	NCT04543188
Brain Neoplasms	D001932	binimetinib	Phase 2	2016	2019	NCT02285439;NCT03911869
Neurofibromatoses	D017253	binimetinib	Phase 2	2017	2017	NCT03231306
Neurofibromatosis 1	D009456	binimetinib	Phase 2	2017	2017	NCT03231306
Neurofibroma	D009455	binimetinib	Phase 2	2017	2017	NCT03231306
Neurofibroma, Plexiform	D018318	binimetinib	Phase 2	2017	2017	NCT03231306
Adenocarcinoma	D000230	binimetinib	Phase 2	2012	2020	NCT04044430;NCT01562899;NCT02276027
Rectal Neoplasms	D012004	binimetinib	Phase 1	2014	2014	NCT02041481
Rectal Neoplasms	D012004	binimetinib	Phase 2	2015	2020	NCT04044430;NCT02465060
Colonic Neoplasms	D003110	binimetinib	Phase 1	2014	2014	NCT02041481
Colonic Neoplasms	D003110	binimetinib	Phase 2	2015	2020	NCT04044430;NCT02465060
Pancreatic Neoplasms	D010190	binimetinib	Phase 1	2019	2019	NCT04132505
Pancreatic Neoplasms	D010190	binimetinib	Phase 2	2015	2021	NCT03637491;NCT04390243;NCT02465060
Leukemia	D007938	binimetinib	Phase 1	2014	2015	NCT02225574;NCT02049801
Leukemia	D007938	binimetinib	Phase 2	2014	2021	NCT02089230;NCT04322383
Leukemia, Myeloid	D007951	binimetinib	Phase 1	2014	2015	NCT02225574;NCT02049801
Leukemia, Myeloid	D007951	binimetinib	Phase 2	2014	2014	NCT02089230
Leukemia, Myeloid, Acute	D015470	binimetinib	Phase 1	2014	2014	NCT02049801
Leukemia, Myeloid, Acute	D015470	binimetinib	Phase 2	2014	2014	NCT02089230
Lymphoma	D008223	binimetinib	Phase 2	2015	2020	NCT04292119;NCT02465060;NCT04439344
Neoplasm Metastasis	D009362	binimetinib	Phase 2	2019	2019	NCT03911869;NCT03898908
Neoplasms, Second Primary	D016609	binimetinib	Phase 2	2019	2019	NCT03911869
Leukemia, Hairy Cell	D007943	binimetinib	Phase 2	2020	2021	NCT04322383;NCT04324112
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	binimetinib	Phase 1	2015	2015	NCT02225574
Thyroid Neoplasms	D013964	binimetinib	Phase 2	2015	2020	NCT04061980;NCT02465060
Gastrointestinal Stromal Tumors	D046152	binimetinib	Phase 1	2017	2017	NCT03158103
Gastrointestinal Stromal Tumors	D046152	binimetinib	Phase 2	2013	2013	NCT01991379
Fallopian Tube Neoplasms	D005185	binimetinib	Phase 1	2012	2012	NCT01649336
Fallopian Tube Neoplasms	D005185	binimetinib	Phase 3	2013	2013	NCT01849874
Carcinoma, Ovarian Epithelial	D000077216	binimetinib	Phase 1	2012	2012	NCT01649336
Carcinoma, Ovarian Epithelial	D000077216	binimetinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	binimetinib	Phase 3	2013	2013	NCT01849874
Biliary Tract Neoplasms	D001661	binimetinib	Phase 2	2016	2016	NCT02773459
Leukemia, Monocytic, Acute	D007948	binimetinib	Phase 1	2014	2014	NCT02049801
Leukemia, Myelomonocytic, Acute	D015479	binimetinib	Phase 1	2014	2014	NCT02049801
Leukemia, Erythroblastic, Acute	D004915	binimetinib	Phase 1	2014	2014	NCT02049801
Uveal Neoplasms	D014604	binimetinib	Phase 2	2013	2013	NCT01801358
Multiple Myeloma	D009101	binimetinib	Phase 2	2015	2016	NCT02465060;NCT04439344;NCT02834364
Neoplasms, Plasma Cell	D054219	binimetinib	Phase 2	2015	2016	NCT02465060;NCT04439344;NCT02834364
Endometrial Neoplasms	D016889	binimetinib	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	binimetinib	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	binimetinib	Phase 3	2013	2013	NCT01849874
Prostatic Neoplasms	D011471	binimetinib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	binimetinib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	binimetinib	Phase 2	2015	2015	NCT02465060
Urinary Bladder Neoplasms	D001749	binimetinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	binimetinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	binimetinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Renal Cell	D002292	binimetinib	Phase 2	2015	2015	NCT02465060
Kidney Neoplasms	D007680	binimetinib	Phase 2	2015	2015	NCT02465060
Glioblastoma	D005909	binimetinib	Phase 2	2019	2019	NCT03973918
Astrocytoma	D001254	binimetinib	Phase 2	2019	2019	NCT03973918
Gliosarcoma	D018316	binimetinib	Phase 2	2019	2019	NCT03973918
Adenocarcinoma of Lung	D000077192	binimetinib	Phase 2	2015	2015	NCT02276027
Leukemia	D007938	bosutinib	Phase 1	2017	2021	NCT02782403;NCT04655391
Leukemia	D007938	bosutinib	Phase 2	2006	2021	NCT00261846;NCT04578847;NCT03654768;NCT03128411;NCT02767063;NCT02906696;NCT04709731;NCT04258943;NCT03831776;NCT02445742;NCT02638467;NCT04006847;NCT02311998;NCT03610971;NCT00811070;NCT02810990;NCT04626024
Leukemia	D007938	bosutinib	Phase 3	2008	2019	NCT03746054;NCT00574873;NCT03106779;NCT02130557
Leukemia	D007938	bosutinib	Phase 4	2014	2014	NCT02228382
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	bosutinib	Phase 1	2008	2017	NCT02782403;NCT00759837;NCT01374139
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	bosutinib	Phase 2	2006	2021	NCT00261846;NCT04578847;NCT03205267;NCT03654768;NCT03128411;NCT02767063;NCT02906696;NCT04709731;NCT04258943;NCT03831776;NCT02638467;NCT04006847;NCT02311998;NCT03610971;NCT00811070;NCT02810990;NCT04626024
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	bosutinib	Phase 3	2008	2019	NCT03746054;NCT00574873;NCT03106779;NCT02130557
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	bosutinib	Phase 4	2014	2014	NCT02228382
Breast Neoplasms	D001943	bosutinib	Phase 1	2019	2019	NCT03854903
Breast Neoplasms	D001943	bosutinib	Phase 2	2006	2009	NCT00319254;NCT00959946;NCT00880009;NCT00793546
Neoplasm Metastasis	D009362	bosutinib	Phase 2	2006	2006	NCT00319254
Leukemia, Myeloid	D007951	bosutinib	Phase 1	2008	2021	NCT02782403;NCT00759837;NCT04655391
Leukemia, Myeloid	D007951	bosutinib	Phase 2	2007	2021	NCT04578847;NCT03205267;NCT03654768;NCT03128411;NCT02767063;NCT02906696;NCT04709731;NCT04258943;NCT03831776;NCT02445742;NCT04006847;NCT02311998;NCT03610971;NCT00811070;NCT02810990;NCT04626024
Leukemia, Myeloid	D007951	bosutinib	Phase 3	2014	2019	NCT03746054;NCT03106779;NCT02130557
Leukemia, Myeloid	D007951	bosutinib	Phase 4	2014	2014	NCT02228382
Leukemia, Myeloid, Chronic-Phase	D015466	bosutinib	Phase 2	2016	2021	NCT03205267;NCT03654768;NCT03128411;NCT02767063;NCT02906696;NCT04709731;NCT04258943;NCT03610971
Leukemia, Myeloid, Chronic-Phase	D015466	bosutinib	Phase 3	2014	2014	NCT02130557
Pancreatic Neoplasms	D010190	bosutinib	Phase 1	2010	2010	NCT01025570
Blast Crisis	D001752	bosutinib	Phase 1	2017	2017	NCT02782403
Blast Crisis	D001752	bosutinib	Phase 2	2015	2020	NCT04258943;NCT02311998
Leukemia, Myeloid, Accelerated Phase	D015465	bosutinib	Phase 1	2017	2017	NCT02782403
Leukemia, Myeloid, Accelerated Phase	D015465	bosutinib	Phase 2	2020	2020	NCT04258943
Uterine Cervical Neoplasms	D002583	bosutinib	Phase 1	2019	2019	NCT03023319
Mesothelioma	D008654	bosutinib	Phase 1	2019	2019	NCT03023319
Carcinoma, Non-Small-Cell Lung	D002289	bosutinib	Phase 1	2019	2019	NCT03023319
Thymoma	D013945	bosutinib	Phase 1	2019	2019	NCT03023319
Thymus Neoplasms	D013953	bosutinib	Phase 1	2019	2019	NCT03023319
Multiple Myeloma	D009101	bosutinib	Phase 2	2017	2017	NCT03297606
Lymphoma, Non-Hodgkin	D008228	bosutinib	Phase 2	2017	2017	NCT03297606
Glioblastoma	D005909	bosutinib	Phase 2	2009	2011	NCT01331291;NCT00959946
Cholangiocarcinoma	D018281	bosutinib	Phase 2	2009	2009	NCT00959946
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	bosutinib	Phase 2	2015	2015	NCT02311998
Leukemia, Lymphoid	D007945	bosutinib	Phase 2	2015	2015	NCT02311998
Leukemia, Myeloid, Acute	D015470	bosutinib	Phase 1	2021	2021	NCT04655391
Carcinoma, Non-Small-Cell Lung	D002289	brigatinib	Phase 1	2018	2020	NCT03707938;NCT04227028;NCT04005144
Carcinoma, Non-Small-Cell Lung	D002289	brigatinib	Phase 2	2011	2020	NCT04318938;NCT02094573;NCT01449461;NCT03410108;NCT02706626;NCT04074993;NCT03535740;NCT04111705;NCT03087448
Carcinoma, Non-Small-Cell Lung	D002289	brigatinib	Phase 3	2016	2019	NCT03596866;NCT02737501
Lymphoma	D008223	brigatinib	Phase 2	2011	2020	NCT03719898;NCT01449461;NCT04260009
Lymphoma, Non-Hodgkin	D008228	brigatinib	Phase 2	2018	2020	NCT03719898;NCT04260009
Lymphoma, Large-Cell, Anaplastic	D017728	brigatinib	Phase 2	2011	2020	NCT03719898;NCT01449461;NCT04260009
Carcinoma	D002277	brigatinib	Phase 1	2018	2020	NCT03707938;NCT04227028
Carcinoma	D002277	brigatinib	Phase 3	2016	2016	NCT02737501
Lung Neoplasms	D008175	brigatinib	Phase 1	2018	2020	NCT03707938;NCT04227028;NCT04005144
Lung Neoplasms	D008175	brigatinib	Phase 2	2017	2021	NCT04634110;NCT02706626;NCT04111705;NCT03087448;NCT03737994;NCT04223596
Lung Neoplasms	D008175	brigatinib	Phase 3	2016	2016	NCT02737501
Ependymoma	D004806	brigatinib	Phase 2	2020	2020	NCT04374305
Meningioma	D008579	brigatinib	Phase 2	2020	2020	NCT04374305
Neurofibromatoses	D017253	brigatinib	Phase 2	2020	2020	NCT04374305
Neurofibromatosis 1	D009456	brigatinib	Phase 2	2020	2020	NCT04374305
Neurofibroma	D009455	brigatinib	Phase 2	2020	2020	NCT04374305
Neurilemmoma	D009442	brigatinib	Phase 2	2020	2020	NCT04374305
Neuroma, Acoustic	D009464	brigatinib	Phase 2	2020	2020	NCT04374305
Neurofibromatosis 2	D016518	brigatinib	Phase 2	2020	2020	NCT04374305
Neoplasm Metastasis	D009362	brigatinib	Phase 2	2021	2021	NCT04634110
Neoplasms, Second Primary	D016609	brigatinib	Phase 2	2019	2019	NCT03868423
Gastrointestinal Neoplasms	D005770	brigatinib	Phase 2	2020	2020	NCT04591431
Melanoma	D008545	cabozantinib	Phase 1	2013	2020	NCT04514484;NCT01835184
Melanoma	D008545	cabozantinib	Phase 2	2013	2020	NCT04091750;NCT01835145;NCT03957551
Sarcoma	D012509	cabozantinib	Phase 1	2020	2020	NCT04514484;NCT04661852
Sarcoma	D012509	cabozantinib	Phase 2	2013	2021	NCT01755195;NCT04551430;NCT04200443;NCT02867592;NCT04220229;NCT01979393;NCT02243605
Lung Neoplasms	D008175	cabozantinib	Phase 1	2020	2020	NCT04173338;NCT04514484
Lung Neoplasms	D008175	cabozantinib	Phase 2	2007	2021	NCT02132598;NCT04151563;NCT00596648;NCT04131543;NCT03911193;NCT01639508;NCT01866410;NCT04310007
Carcinoma, Non-Small-Cell Lung	D002289	cabozantinib	Phase 1	2020	2020	NCT04173338;NCT04514484
Carcinoma, Non-Small-Cell Lung	D002289	cabozantinib	Phase 2	2007	2021	NCT02132598;NCT03468985;NCT04151563;NCT00596648;NCT02795156;NCT04131543;NCT01708954;NCT03911193;NCT01639508;NCT01866410;NCT04310007
Carcinoma, Non-Small-Cell Lung	D002289	cabozantinib	Phase 3	2020	2020	NCT04471428
Neoplasm Metastasis	D009362	cabozantinib	Phase 2	2012	2020	NCT02132598;NCT03967522;NCT01599793;NCT01834651;NCT04116541;NCT02260531
Neoplasms, Second Primary	D016609	cabozantinib	Phase 2	2015	2015	NCT02132598
Neoplasms, Second Primary	D016609	cabozantinib	Phase 3	2019	2019	NCT03793166
Carcinoma	D002277	cabozantinib	Phase 1	2012	2020	NCT02496208;NCT03299946;NCT03200587;NCT04514484;NCT02293980;NCT01709435;NCT03798626;NCT03878524
Carcinoma	D002277	cabozantinib	Phase 2	2012	2021	NCT04540705;NCT03824691;NCT03468985;NCT02036476;NCT03367741;NCT03149822;NCT03534804;NCT02795156;NCT04300140;NCT04454762;NCT04472767;NCT01658878;NCT03541902;NCT04316182;NCT03967522;NCT04066595;NCT03463681;NCT03899428;NCT04644432;NCT04079712;NCT03354884;NCT04497038;NCT03170960;NCT03586973;NCT01688999;NCT02867592;NCT03914300;NCT01835158;NCT01811212;NCT04511455;NCT03635892;NCT03634540;NCT04413123;NCT04071223;NCT04442581;NCT03370718;NCT04134390;NCT03612232;NCT03945773;NCT02761057;NCT03866382;NCT03339219;NCT04022343;NCT03943602;NCT02315430;NCT03468218;NCT01716715;NCT03428217;NCT01935934;NCT04767906;NCT04204850;NCT03685448;NCT04310007
Carcinoma	D002277	cabozantinib	Phase 3	2013	2021	NCT04586231;NCT04338269;NCT03729245;NCT03141177;NCT01865747;NCT03755791;NCT01908426;NCT03793166;NCT03937219
Carcinoma	D002277	cabozantinib	Phase 4	2019	2019	NCT03963206
Carcinoma, Renal Cell	D002292	cabozantinib	Phase 1	2010	2020	NCT02496208;NCT03200587;NCT04514484;NCT03138538;NCT01100619;NCT02293980;NCT03798626;NCT02071862
Carcinoma, Renal Cell	D002292	cabozantinib	Phase 2	2013	2021	NCT04540705;NCT03387514;NCT03149822;NCT04300140;NCT03541902;NCT03967522;NCT03463681;NCT04644432;NCT03354884;NCT03170960;NCT02867592;NCT01835158;NCT03635892;NCT03634540;NCT04413123;NCT04071223;NCT04134390;NCT03945773;NCT02761057;NCT03866382;NCT04322955;NCT03339219;NCT04022343;NCT02960906;NCT04714697;NCT03428217;NCT03685448
Carcinoma, Renal Cell	D002292	cabozantinib	Phase 3	2013	2021	NCT04586231;NCT04338269;NCT03729245;NCT03141177;NCT01865747;NCT03793166;NCT03937219
Urinary Bladder Neoplasms	D001749	cabozantinib	Phase 2	2012	2020	NCT03824691;NCT01688999;NCT03866382;NCT04289779
Hemangiosarcoma	D006394	cabozantinib	Phase 2	2020	2020	NCT04339738
Carcinoma, Merkel Cell	D015266	cabozantinib	Phase 2	2014	2014	NCT02036476
Skin Neoplasms	D012878	cabozantinib	Phase 1	2020	2020	NCT04514484
Skin Neoplasms	D012878	cabozantinib	Phase 2	2014	2014	NCT02036476
Endometrial Neoplasms	D016889	cabozantinib	Phase 2	2013	2018	NCT03367741;NCT03170960;NCT01935934
Prostatic Neoplasms	D011471	cabozantinib	Phase 1	2011	2021	NCT01347788;NCT04514484;NCT04477512;NCT01574937;NCT03878524
Prostatic Neoplasms	D011471	cabozantinib	Phase 2	2012	2021	NCT01703065;NCT01588821;NCT04631744;NCT01683994;NCT01630590;NCT01599793;NCT01428219;NCT01995058;NCT01834651;NCT03866382;NCT03964337
Prostatic Neoplasms	D011471	cabozantinib	Phase 3	2012	2020	NCT04446117;NCT01522443;NCT01605227
Uterine Cervical Neoplasms	D002583	cabozantinib	Phase 2	2020	2020	NCT04205799;NCT04230954
Breast Neoplasms	D001943	cabozantinib	Phase 1	2020	2020	NCT04514484;NCT03878524
Breast Neoplasms	D001943	cabozantinib	Phase 2	2011	2017	NCT01441947;NCT03316586;NCT01738438;NCT02260531
Mesothelioma	D008654	cabozantinib	Phase 1	2014	2020	NCT04173338;NCT02071862
Carcinoma, Transitional Cell	D002295	cabozantinib	Phase 1	2015	2020	NCT02496208;NCT04514484
Carcinoma, Transitional Cell	D002295	cabozantinib	Phase 2	2012	2019	NCT03534804;NCT01688999;NCT03866382
Thyroid Neoplasms	D013964	cabozantinib	Phase 1	2005	2020	NCT04514484;NCT01100619;NCT00215605;NCT01709435
Thyroid Neoplasms	D013964	cabozantinib	Phase 2	2013	2019	NCT03838692;NCT02041260;NCT03170960;NCT02867592;NCT03914300;NCT01838642;NCT01811212;NCT03630120;NCT03866382
Thyroid Neoplasms	D013964	cabozantinib	Phase 3	2008	2021	NCT03690388;NCT00704730;NCT04760288;NCT04211337
Thyroid Neoplasms	D013964	cabozantinib	Phase 4	2014	2014	NCT01896479
Carcinoma, Neuroendocrine	D018278	cabozantinib	Phase 1	2015	2020	NCT02496208;NCT04514484
Carcinoma, Neuroendocrine	D018278	cabozantinib	Phase 2	2017	2020	NCT03838692;NCT04524208;NCT04079712;NCT02867592;NCT03866382
Carcinoma, Neuroendocrine	D018278	cabozantinib	Phase 3	2020	2020	NCT04211337
Carcinoma, Neuroendocrine	D018278	cabozantinib	Phase 4	2014	2014	NCT01896479
Carcinoma, Hepatocellular	D006528	cabozantinib	Phase 1	2018	2020	NCT03299946;NCT04514484
Carcinoma, Hepatocellular	D006528	cabozantinib	Phase 2	2012	2021	NCT04454762;NCT04472767;NCT01658878;NCT04316182;NCT03899428;NCT03539822;NCT04497038;NCT03170960;NCT04588051;NCT03586973;NCT02867592;NCT04522908;NCT04511455;NCT04442581;NCT04767906;NCT04204850;NCT04435977
Carcinoma, Hepatocellular	D006528	cabozantinib	Phase 3	2013	2018	NCT03755791;NCT01908426
Carcinoma, Hepatocellular	D006528	cabozantinib	Phase 4	2019	2019	NCT03963206
Carcinosarcoma	D002296	cabozantinib	Phase 2	2013	2021	NCT04149275;NCT01935934
Mixed Tumor, Mullerian	D018200	cabozantinib	Phase 2	2021	2021	NCT04149275
Triple Negative Breast Neoplasms	D064726	cabozantinib	Phase 1	2014	2014	NCT02071862
Triple Negative Breast Neoplasms	D064726	cabozantinib	Phase 2	2017	2017	NCT03316586;NCT03170960
Carcinoma, Squamous Cell	D002294	cabozantinib	Phase 1	2015	2018	NCT02496208;NCT03667482
Carcinoma, Squamous Cell	D002294	cabozantinib	Phase 2	2018	2019	NCT03866382;NCT03943602;NCT03468218
Adenocarcinoma	D000230	cabozantinib	Phase 1	2015	2020	NCT02496208;NCT03878524
Adenocarcinoma	D000230	cabozantinib	Phase 2	2013	2020	NCT03539822;NCT04164979;NCT03866382;NCT02315430;NCT03213626;NCT01935934
Urethral Neoplasms	D014523	cabozantinib	Phase 1	2015	2015	NCT02496208
Urethral Neoplasms	D014523	cabozantinib	Phase 2	2012	2019	NCT01688999;NCT03866382
Carcinoma, Medullary	D018276	cabozantinib	Phase 1	2012	2020	NCT02496208;NCT04514484;NCT01709435
Carcinoma, Medullary	D018276	cabozantinib	Phase 2	2017	2019	NCT02867592;NCT04071223;NCT03866382
Penile Neoplasms	D010412	cabozantinib	Phase 1	2015	2015	NCT02496208
Penile Neoplasms	D010412	cabozantinib	Phase 2	2019	2019	NCT03866382
Ureteral Neoplasms	D014516	cabozantinib	Phase 1	2015	2015	NCT02496208
Pelvic Neoplasms	D010386	cabozantinib	Phase 1	2015	2015	NCT02496208
Kidney Neoplasms	D007680	cabozantinib	Phase 1	2014	2015	NCT02496208;NCT02293980
Kidney Neoplasms	D007680	cabozantinib	Phase 2	2012	2020	NCT04644432;NCT01688999;NCT01835158;NCT03634540;NCT04134390;NCT04322955;NCT02960906
Carcinoma, Small Cell	D018288	cabozantinib	Phase 1	2015	2020	NCT02496208;NCT04514484
Carcinoma, Small Cell	D018288	cabozantinib	Phase 2	2019	2020	NCT04079712;NCT03866382
Leukemia	D007938	cabozantinib	Phase 1	2013	2020	NCT01961765;NCT03878524
Leukemia, Myeloid	D007951	cabozantinib	Phase 1	2013	2020	NCT01961765;NCT03878524
Leukemia, Myeloid, Acute	D015470	cabozantinib	Phase 1	2013	2020	NCT01961765;NCT03878524
Urologic Neoplasms	D014571	cabozantinib	Phase 2	2018	2020	NCT03541902;NCT04644432
Salivary Gland Neoplasms	D012468	cabozantinib	Phase 2	2018	2018	NCT03729297
Uveal Neoplasms	D014604	cabozantinib	Phase 2	2013	2013	NCT01835145
Urogenital Neoplasms	D014565	cabozantinib	Phase 2	2020	2020	NCT04644432
Neuroendocrine Tumors	D018358	cabozantinib	Phase 2	2012	2020	NCT01466036;NCT04524208;NCT04079712;NCT04412629;NCT04400474;NCT04427787;NCT04197310
Neuroendocrine Tumors	D018358	cabozantinib	Phase 3	2018	2018	NCT03375320
Carcinoid Tumor	D002276	cabozantinib	Phase 2	2012	2019	NCT01466036;NCT04197310
Carcinoid Tumor	D002276	cabozantinib	Phase 3	2018	2018	NCT03375320
Neurofibromatoses	D017253	cabozantinib	Phase 2	2014	2014	NCT02101736
Neurofibromatosis 1	D009456	cabozantinib	Phase 2	2014	2014	NCT02101736
Neurofibroma	D009455	cabozantinib	Phase 2	2014	2014	NCT02101736
Neurofibroma, Plexiform	D018318	cabozantinib	Phase 2	2014	2014	NCT02101736
Cholangiocarcinoma	D018281	cabozantinib	Phase 2	2013	2013	NCT01954745
Bile Duct Neoplasms	D001650	cabozantinib	Phase 2	2013	2013	NCT01954745
Multiple Myeloma	D009101	cabozantinib	Phase 1	2012	2020	NCT01582295;NCT03878524
Multiple Myeloma	D009101	cabozantinib	Phase 2	2013	2018	NCT01866293;NCT03201250
Neoplasms, Plasma Cell	D054219	cabozantinib	Phase 1	2012	2020	NCT01582295;NCT03878524
Neoplasms, Plasma Cell	D054219	cabozantinib	Phase 2	2013	2018	NCT01866293;NCT03201250
Sarcoma, Kaposi	D012514	cabozantinib	Phase 1	2020	2020	NCT04514484
Ovarian Neoplasms	D010051	cabozantinib	Phase 1	2020	2020	NCT04514484
Carcinoma, Ovarian Epithelial	D000077216	cabozantinib	Phase 1	2020	2020	NCT04514484
Small Cell Lung Carcinoma	D055752	cabozantinib	Phase 1	2020	2020	NCT04514484
Leiomyosarcoma	D007890	cabozantinib	Phase 2	2020	2020	NCT04200443
Glioblastoma	D005909	cabozantinib	Phase 1	2009	2009	NCT00960492
Glioblastoma	D005909	cabozantinib	Phase 2	2008	2017	NCT01068782;NCT00704288;NCT02885324
Gliosarcoma	D018316	cabozantinib	Phase 1	2009	2009	NCT00960492
Thyroid Cancer, Papillary	D000077273	cabozantinib	Phase 1	2010	2010	NCT01100619
Thyroid Cancer, Papillary	D000077273	cabozantinib	Phase 2	2013	2019	NCT03914300;NCT01811212;NCT03630120
Adenocarcinoma, Follicular	D018263	cabozantinib	Phase 1	2010	2010	NCT01100619
Adenocarcinoma, Follicular	D018263	cabozantinib	Phase 2	2013	2019	NCT03914300;NCT01811212;NCT03630120
Gastrointestinal Stromal Tumors	D046152	cabozantinib	Phase 1	2014	2014	NCT02071862
Gastrointestinal Stromal Tumors	D046152	cabozantinib	Phase 2	2017	2017	NCT02216578
Carcinoma, Ductal	D044584	cabozantinib	Phase 2	2018	2018	NCT03354884
Adenoma, Islet Cell	D007516	cabozantinib	Phase 3	2018	2018	NCT03375320
Intestinal Neoplasms	D007414	cabozantinib	Phase 3	2018	2018	NCT03375320
Pancreatic Neoplasms	D010190	cabozantinib	Phase 1	2012	2020	NCT01663272;NCT03878524
Pancreatic Neoplasms	D010190	cabozantinib	Phase 3	2018	2018	NCT03375320
Stomach Neoplasms	D013274	cabozantinib	Phase 3	2018	2018	NCT03375320
Osteosarcoma	D012516	cabozantinib	Phase 1	2020	2020	NCT04661852
Osteosarcoma	D012516	cabozantinib	Phase 2	2014	2017	NCT02867592;NCT02243605
Sarcoma, Ewing	D012512	cabozantinib	Phase 1	2020	2020	NCT04661852
Sarcoma, Ewing	D012512	cabozantinib	Phase 2	2014	2017	NCT02867592;NCT02243605
Rhabdomyosarcoma	D012208	cabozantinib	Phase 2	2017	2017	NCT02867592
Wilms Tumor	D009396	cabozantinib	Phase 2	2017	2017	NCT02867592
Nervous System Neoplasms	D009423	cabozantinib	Phase 1	2012	2012	NCT01709435
Nervous System Neoplasms	D009423	cabozantinib	Phase 2	2017	2017	NCT02867592
Central Nervous System Neoplasms	D016543	cabozantinib	Phase 1	2012	2012	NCT01709435
Central Nervous System Neoplasms	D016543	cabozantinib	Phase 2	2017	2017	NCT02867592
Hepatoblastoma	D018197	cabozantinib	Phase 2	2017	2017	NCT02867592
Sarcoma, Alveolar Soft Part	D018234	cabozantinib	Phase 2	2017	2017	NCT02867592
Sarcoma, Clear Cell	D018227	cabozantinib	Phase 2	2017	2017	NCT02867592
Adrenocortical Carcinoma	D018268	cabozantinib	Phase 2	2017	2019	NCT02867592;NCT03370718;NCT03612232
Carcinoma, Papillary	D002291	cabozantinib	Phase 2	2013	2019	NCT03914300;NCT01811212
Neoplasms, Squamous Cell	D018307	cabozantinib	Phase 1	2018	2018	NCT03667482
Colorectal Neoplasms	D015179	cabozantinib	Phase 1	2014	2019	NCT02008383;NCT03798626
Colorectal Neoplasms	D015179	cabozantinib	Phase 2	2018	2018	NCT03542877
Astrocytoma	D001254	cabozantinib	Phase 2	2010	2017	NCT01068782;NCT02885324
Glioma	D005910	cabozantinib	Phase 2	2017	2017	NCT02885324
Brain Neoplasms	D001932	cabozantinib	Phase 2	2017	2017	NCT02885324
Adenocarcinoma, Clear Cell	D018262	cabozantinib	Phase 2	2013	2019	NCT03866382;NCT02315430;NCT01935934
Leydig Cell Tumor	D007984	cabozantinib	Phase 2	2019	2019	NCT03866382
Sertoli Cell Tumor	D012707	cabozantinib	Phase 2	2019	2019	NCT03866382
Squamous Cell Carcinoma of Head and Neck	D000077195	cabozantinib	Phase 2	2018	2018	NCT03468218
Pheochromocytoma	D010673	cabozantinib	Phase 2	2015	2020	NCT02302833;NCT04400474
Paraganglioma	D010235	cabozantinib	Phase 2	2015	2020	NCT02302833;NCT04400474
Carotid Body Tumor	D002345	cabozantinib	Phase 2	2015	2015	NCT02302833
Cystadenocarcinoma, Serous	D018284	cabozantinib	Phase 2	2013	2013	NCT01935934
Carcinoma, Endometrioid	D018269	cabozantinib	Phase 2	2013	2013	NCT01935934
Carcinoma, Adenosquamous	D018196	cabozantinib	Phase 2	2013	2013	NCT01935934
Thyroid Carcinoma, Anaplastic	D065646	cabozantinib	Phase 2	2020	2020	NCT04400474
Endocrine Gland Neoplasms	D004701	cabozantinib	Phase 2	2020	2020	NCT04400474
Lymphoma	D008223	cabozantinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	cabozantinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	cabozantinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	cabozantinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	cabozantinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	cabozantinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	cabozantinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	cabozantinib	Phase 1	2020	2020	NCT03878524
Gastrointestinal Neoplasms	D005770	cabozantinib	Phase 2	2019	2019	NCT04197310
Digestive System Neoplasms	D004067	cabozantinib	Phase 2	2019	2019	NCT04197310
Lung Neoplasms	D008175	ceritinib	Phase 1	2013	2018	NCT02292550;NCT02299505;NCT01772797;NCT03611738
Lung Neoplasms	D008175	ceritinib	Phase 2	2012	2021	NCT01964157;NCT02040870;NCT01685060;NCT02336451;NCT01685138;NCT04634110;NCT02706626;NCT04111705;NCT03087448;NCT03737994;NCT02450903;NCT02276027;NCT03399487
Lung Neoplasms	D008175	ceritinib	Phase 3	2013	2013	NCT01828099;NCT01828112
Lung Neoplasms	D008175	ceritinib	Phase 4	2020	2020	NCT04356118
Carcinoma, Non-Small-Cell Lung	D002289	ceritinib	Phase 1	2013	2018	NCT02292550;NCT02299505;NCT01772797;NCT02393625;NCT03611738
Carcinoma, Non-Small-Cell Lung	D002289	ceritinib	Phase 2	2012	2020	NCT01964157;NCT02040870;NCT01685060;NCT02336451;NCT01685138;NCT02706626;NCT03535740;NCT04111705;NCT03087448;NCT02450903;NCT03399487
Carcinoma, Non-Small-Cell Lung	D002289	ceritinib	Phase 3	2013	2013	NCT01828099;NCT01828112
Carcinoma, Non-Small-Cell Lung	D002289	ceritinib	Phase 4	2020	2020	NCT04356118
Lymphoma	D008223	ceritinib	Phase 1	2012	2013	NCT01742286;NCT01634763
Lymphoma	D008223	ceritinib	Phase 2	2016	2018	NCT02729961;NCT02465528
Lymphoma	D008223	ceritinib	Phase 4	2020	2020	NCT04362072
Sarcoma	D012509	ceritinib	Phase 3	2019	2019	NCT03784014
Melanoma	D008545	ceritinib	Phase 1	2018	2018	NCT03501368
Melanoma	D008545	ceritinib	Phase 2	2015	2021	NCT02645149;NCT02587650
Hematologic Neoplasms	D019337	ceritinib	Phase 2	2015	2015	NCT02343679
Neoplasm Metastasis	D009362	ceritinib	Phase 1	2016	2016	NCT02605746
Neoplasm Metastasis	D009362	ceritinib	Phase 2	2021	2021	NCT04634110
Neoplasm Metastasis	D009362	ceritinib	Phase 4	2020	2020	NCT04356118
Glioblastoma	D005909	ceritinib	Phase 1	2016	2016	NCT02605746
Glioblastoma	D005909	ceritinib	Phase 2	2016	2016	NCT02465528
Cholangiocarcinoma	D018281	ceritinib	Phase 2	2015	2015	NCT02374489;NCT02638909
Klatskin Tumor	D018285	ceritinib	Phase 2	2015	2015	NCT02374489
Lymphoma, Non-Hodgkin	D008228	ceritinib	Phase 2	2018	2018	NCT02729961
Lymphoma, Large-Cell, Anaplastic	D017728	ceritinib	Phase 2	2016	2018	NCT02729961;NCT02465528
Adenocarcinoma	D000230	ceritinib	Phase 2	2015	2015	NCT02513667;NCT02638909;NCT02276027
Adenocarcinoma of Lung	D000077192	ceritinib	Phase 2	2015	2015	NCT02513667;NCT02276027
Neuroblastoma	D009447	ceritinib	Phase 1	2016	2016	NCT02780128
Neuroblastoma	D009447	ceritinib	Phase 2	2015	2015	NCT02559778
Pancreatic Neoplasms	D010190	ceritinib	Phase 1	2015	2015	NCT02227940
Skin Neoplasms	D012878	ceritinib	Phase 2	2015	2015	NCT02587650
Thyroid Neoplasms	D013964	ceritinib	Phase 2	2015	2015	NCT02289144
Thyroid Carcinoma, Anaplastic	D065646	ceritinib	Phase 2	2015	2015	NCT02289144
Neoplasms, Second Primary	D016609	ceritinib	Phase 4	2020	2020	NCT04356118
Meningeal Carcinomatosis	D055756	ceritinib	Phase 4	2020	2020	NCT04356118
Colorectal Neoplasms	D015179	cetuximab	Phase 1	2003	2020	NCT02205398;NCT01380600;NCT03428958;NCT03319459;NCT03356158;NCT04449874;NCT03017807;NCT00478634;NCT00403052;NCT02573220;NCT00207155;NCT01787500;NCT00436072;NCT01184482;NCT00497497;NCT02124148;NCT00719199;NCT01420874;NCT02857270;NCT00671372;NCT00501410;NCT02630420;NCT01451632;NCT00925015;NCT00593060;NCT02110082;NCT02211443;NCT03290937;NCT03491709;NCT01791309;NCT00540943
Colorectal Neoplasms	D015179	cetuximab	Phase 2	1999	2021	NCT00910676;NCT04787341;NCT03693807;NCT02316496;NCT03135652;NCT00541112;NCT00862342;NCT00444678;NCT02063529;NCT00020917;NCT02291289;NCT00503685;NCT04561336;NCT04031872;NCT04668976;NCT01450319;NCT00215722;NCT03751176;NCT01801904;NCT04017650;NCT00614393;NCT01276379;NCT01079780;NCT04513951;NCT04241731;NCT00755534;NCT00842257;NCT00755118;NCT00055419;NCT01326000;NCT02216487;NCT00725400;NCT02164916;NCT03563157;NCT01832467;NCT00437268;NCT00522665;NCT04587128;NCT01522612;NCT04034459;NCT00005076;NCT00309179;NCT03164655;NCT02295930;NCT00954876;NCT01540344;NCT01225744;NCT00254137;NCT00227734;NCT01668498;NCT01384994;NCT00557102;NCT03169777;NCT00778830;NCT00803647;NCT01927341;NCT02953782;NCT02083653;NCT01413295;NCT01960023;NCT00290615;NCT00422773;NCT00594984;NCT01776307;NCT03405272;NCT00271011;NCT01032291;NCT01504477;NCT00551213;NCT00743678;NCT01075048;NCT02278133;NCT01836653;NCT03608046;NCT00466505;NCT02296203;NCT03874026;NCT04495621;NCT00852228;NCT01718808;NCT01640444;NCT01703390;NCT04515394;NCT03457896;NCT02508077;NCT00784667;NCT00479752;NCT04117945;NCT01152437;NCT03470350;NCT00286130;NCT00556413;NCT01281761;NCT02404935;NCT00544349;NCT04616183;NCT00362102;NCT00689624;NCT00598975;NCT04464967;NCT02965417;NCT00125034;NCT00537823;NCT00677924;NCT03567629;NCT03206073;NCT01086267;NCT04745130;NCT01387880;NCT02717923;NCT01409005;NCT00681876;NCT00251485;NCT00202787;NCT01322178;NCT00056030;NCT01892527;NCT00538291;NCT03366155;NCT01523639;NCT01919879;NCT01008475;NCT00637091;NCT01345526;NCT00766220;NCT00531115;NCT00766142;NCT00438737;NCT02713373;NCT01652482;NCT01925274;NCT01579357;NCT00361244;NCT01068132;NCT01442935;NCT03727763;NCT00559741;NCT00326495;NCT01867697;NCT00083720;NCT03174405;NCT00660582;NCT02117466;NCT00931840;NCT01394939;NCT00545545;NCT03693170;NCT04224415;NCT04160416;NCT00640081;NCT00251186;NCT01251536;NCT01703910;NCT01161316;NCT01190462;NCT00513266;NCT00044863;NCT01719380;NCT02515734;NCT04775862;NCT01252628;NCT01004159;NCT01673607;NCT02071069;NCT01858662;NCT00321100;NCT00577109;NCT03251612;NCT03186326;NCT01442649;NCT01051167;NCT03688230;NCT01060423;NCT02826837;NCT00439517;NCT03311750;NCT02292758;NCT00020930;NCT04165031;NCT04466254
Colorectal Neoplasms	D015179	cetuximab	Phase 3	2003	2021	NCT00061815;NCT04687631;NCT01878422;NCT04607421;NCT00640471;NCT00154102;NCT03206151;NCT01001377;NCT02928224;NCT00389870;NCT01910610;NCT01338558;NCT00063141;NCT01309126;NCT02978313;NCT04776655;NCT03391934;NCT01167725;NCT00975897;NCT01030042;NCT01895257;NCT00265850;NCT02942706;NCT00252564;NCT02934529;NCT00145314;NCT03362684;NCT04262635;NCT00182715;NCT04509635;NCT03717038;NCT00433927;NCT01741038;NCT01228734;NCT04525326;NCT02563002;NCT04008030;NCT02484833;NCT00079066;NCT03803553;NCT03231722;NCT00482222;NCT00208546;NCT03426371
Colorectal Neoplasms	D015179	cetuximab	Phase 4	2006	2011	NCT00327093;NCT01564810;NCT01315990
Head and Neck Neoplasms	D006258	cetuximab	Phase 1	2004	2021	NCT00820417;NCT01540682;NCT00906360;NCT01334177;NCT02555644;NCT01184482;NCT02817113;NCT01445405;NCT00397384;NCT01871311;NCT01637194;NCT00757549;NCT00291707;NCT00882583;NCT00622674;NCT01255800;NCT01451632;NCT02110082;NCT02391727;NCT00402545;NCT04722523;NCT01987375;NCT01935921;NCT02229656;NCT00629226;NCT04065555;NCT02627274
Head and Neck Neoplasms	D006258	cetuximab	Phase 2	1999	2020	NCT03844763;NCT03494322;NCT00462735;NCT01283334;NCT02573493;NCT03422536;NCT00927147;NCT00868491;NCT00665392;NCT02124707;NCT01620242;NCT00721513;NCT04474470;NCT01581970;NCT02633800;NCT03532737;NCT00468169;NCT00004865;NCT01262859;NCT01237483;NCT00939627;NCT03067610;NCT00646659;NCT00623558;NCT01816984;NCT01472653;NCT01040832;NCT01467115;NCT01979211;NCT00226239;NCT01256385;NCT01566435;NCT04282109;NCT01435252;NCT02979977;NCT00514943;NCT03134846;NCT01020864;NCT03769311;NCT02281955;NCT00319839;NCT01874860;NCT01412229;NCT00101348;NCT02630004;NCT03082534;NCT01081041;NCT01696955;NCT01437449;NCT02270814;NCT01316757;NCT01087970;NCT01057589;NCT00591149;NCT03727061;NCT00089297;NCT01744340;NCT00875849;NCT03691714;NCT01216020;NCT00881114;NCT00343083;NCT00714649;NCT02643550;NCT01009346;NCT00851877;NCT00570674;NCT01794845;NCT02422979;NCT03887442;NCT00005814;NCT00904345;NCT00409565;NCT00791141;NCT00301028;NCT01737450;NCT00660218;NCT01301248;NCT03356223;NCT00713219;NCT01588431;NCT00833261;NCT03051906;NCT00704639;NCT00703976;NCT01054625;NCT03713372;NCT00765011;NCT00738868;NCT00934518;NCT03077243
Head and Neck Neoplasms	D006258	cetuximab	Phase 3	1999	2019	NCT00716391;NCT00265941;NCT03769506;NCT00003809;NCT00004227;NCT02236936;NCT02252042;NCT02358031;NCT01884623;NCT00122460;NCT01969877;NCT00956007;NCT03258554;NCT02551159
Head and Neck Neoplasms	D006258	cetuximab	Phase 4	2011	2014	NCT02015650;NCT01553032
Carcinoma	D002277	cetuximab	Phase 1	2005	2021	NCT01380600;NCT03319459;NCT02764593;NCT00906360;NCT04361409;NCT01334177;NCT00104910;NCT03524326;NCT01552434;NCT02277197;NCT00397384;NCT04091867;NCT01198535;NCT02350712;NCT03498378;NCT02429089;NCT01360827;NCT02438995;NCT02938273;NCT02496663;NCT00903461;NCT01637194;NCT01716416;NCT01254617;NCT00207116;NCT01758731;NCT00402545;NCT04722523;NCT01935921;NCT02229656
Carcinoma	D002277	cetuximab	Phase 2	2002	2021	NCT00910676;NCT03387111;NCT04106362;NCT01218048;NCT01271439;NCT01332266;NCT01133665;NCT00508664;NCT02573493;NCT00084318;NCT03422536;NCT02014831;NCT00957853;NCT01245985;NCT01836029;NCT03953976;NCT03088059;NCT04229459;NCT00971932;NCT02124707;NCT03744208;NCT01884259;NCT01614938;NCT04017650;NCT02633800;NCT01230476;NCT02822482;NCT03389477;NCT04508829;NCT00240682;NCT01181401;NCT03944941;NCT01015664;NCT00499031;NCT01221753;NCT00725400;NCT01192087;NCT00939627;NCT01326559;NCT00142428;NCT00700440;NCT04508816;NCT01009203;NCT02718820;NCT03067610;NCT02624128;NCT01540344;NCT00933387;NCT03370276;NCT02255097;NCT02298595;NCT01816984;NCT01040832;NCT02054442;NCT01256385;NCT02812641;NCT01289522;NCT01025089;NCT03254927;NCT00292955;NCT00514943;NCT03169764;NCT01154920;NCT03817567;NCT02123381;NCT03769311;NCT00353717;NCT04285671;NCT02281955;NCT04428151;NCT00671437;NCT00101348;NCT00865098;NCT04375384;NCT03082534;NCT01760811;NCT03874741;NCT02753140;NCT01640444;NCT03365882;NCT03944252;NCT01104922;NCT01696955;NCT01488318;NCT04616183;NCT00362102;NCT02270814;NCT01316757;NCT00736944;NCT01830556;NCT03646461;NCT00591149;NCT03727061;NCT01602315;NCT03001570;NCT02507154;NCT01712919;NCT00096174;NCT00766142;NCT00570674;NCT01133678;NCT01794845;NCT02128906;NCT02369458;NCT01394939;NCT00082212;NCT00545545;NCT00617734;NCT00409565;NCT01109524;NCT03563170;NCT01417936;NCT02499120;NCT00044863;NCT01301248;NCT00894569;NCT04534855;NCT01252628;NCT01427205;NCT02143622;NCT00733889;NCT00636298;NCT01592721;NCT02599324;NCT01468896;NCT03109158;NCT02707588;NCT00934518;NCT03077243
Carcinoma	D002277	cetuximab	Phase 3	2008	2020	NCT01211938;NCT04590963;NCT03358472;NCT02347332;NCT02105636;NCT01855451;NCT03342352;NCT02236936;NCT01950689;NCT01810913;NCT00946712;NCT03717038;NCT02383966;NCT02563002;NCT03529279;NCT01012258;NCT01874171;NCT03258554;NCT01086826;NCT01177956;NCT02633176;NCT03349710
Carcinoma	D002277	cetuximab	Phase 4	2014	2014	NCT02015650
Lung Neoplasms	D008175	cetuximab	Phase 1	2005	2019	NCT00522886;NCT00397384;NCT03808701;NCT00288054;NCT00622674;NCT00207116;NCT01212627;NCT00569296
Lung Neoplasms	D008175	cetuximab	Phase 2	2000	2021	NCT00910676;NCT00828841;NCT02716311;NCT00112346;NCT00408499;NCT00081302;NCT00165334;NCT00124618;NCT00216203;NCT00492206;NCT00097214;NCT00034541;NCT00085501;NCT00986674;NCT01004731;NCT00315185;NCT00103207;NCT03717155;NCT00118183;NCT01102231;NCT00870870;NCT04285671;NCT00101348;NCT00998101;NCT04648189;NCT00343291;NCT00203931;NCT04464967;NCT01059188;NCT02845856;NCT00368992;NCT00193453;NCT00694603;NCT00117962;NCT00323869;NCT00330746;NCT00519831;NCT00097227;NCT01109524;NCT00673738;NCT00768131;NCT00063388;NCT00867009
Lung Neoplasms	D008175	cetuximab	Phase 3	2004	2015	NCT00533949;NCT00095199;NCT02438722;NCT00148798;NCT00112294;NCT00946712;NCT00820755
Carcinoma, Non-Small-Cell Lung	D002289	cetuximab	Phase 1	2005	2020	NCT00522886;NCT03319459;NCT04449874;NCT00397384;NCT03808701;NCT02496663;NCT02857270;NCT01090011;NCT00288054;NCT01451632;NCT00207116;NCT01212627;NCT00162318;NCT00569296
Carcinoma, Non-Small-Cell Lung	D002289	cetuximab	Phase 2	2000	2021	NCT00910676;NCT00828841;NCT02716311;NCT00112346;NCT00408499;NCT00081302;NCT00165334;NCT00406302;NCT00124618;NCT00216203;NCT00492206;NCT00097214;NCT00034541;NCT00874848;NCT00085501;NCT00986674;NCT01004731;NCT00315185;NCT03717155;NCT00118183;NCT01102231;NCT00870870;NCT03727724;NCT04285671;NCT00101348;NCT00998101;NCT00561054;NCT00343291;NCT00203931;NCT04464967;NCT00115518;NCT01059188;NCT02845856;NCT00368992;NCT00694603;NCT00117962;NCT00323869;NCT00330746;NCT00097227;NCT01109524;NCT00985855;NCT00673738;NCT00768131;NCT00063388;NCT00867009;NCT00842712;NCT04165031
Carcinoma, Non-Small-Cell Lung	D002289	cetuximab	Phase 3	2004	2015	NCT00533949;NCT00095199;NCT02438722;NCT00148798;NCT00112294;NCT00820755
Carcinoma, Squamous Cell	D002294	cetuximab	Phase 1	2007	2021	NCT02205398;NCT03319459;NCT02764593;NCT00906360;NCT04361409;NCT01334177;NCT01046266;NCT00736619;NCT03524326;NCT02277197;NCT01445405;NCT00397384;NCT04091867;NCT02350712;NCT03498378;NCT02429089;NCT01360827;NCT02438995;NCT02938273;NCT00903461;NCT01637194;NCT01716416;NCT03667482;NCT01254617;NCT01758731;NCT00402545;NCT04722523;NCT01935921;NCT02229656;NCT02282371
Carcinoma, Squamous Cell	D002294	cetuximab	Phase 2	2004	2021	NCT03387111;NCT04106362;NCT01218048;NCT00815295;NCT01332266;NCT01133665;NCT02573493;NCT00084318;NCT03422536;NCT02014831;NCT00957853;NCT01245985;NCT00815308;NCT01836029;NCT03953976;NCT03088059;NCT01577173;NCT02101034;NCT04229459;NCT00971932;NCT02124707;NCT03744208;NCT01884259;NCT02633800;NCT02822482;NCT03389477;NCT00165490;NCT00240682;NCT01181401;NCT03944941;NCT02057107;NCT01015664;NCT01221753;NCT00939627;NCT01009203;NCT03067610;NCT02624128;NCT00933387;NCT03024489;NCT03370276;NCT02255097;NCT00623558;NCT02298595;NCT01816984;NCT01040832;NCT02054442;NCT01979211;NCT01256385;NCT02812641;NCT03254927;NCT00968435;NCT04282109;NCT02979977;NCT00514943;NCT00661427;NCT03169764;NCT01154920;NCT03817567;NCT00705016;NCT02123381;NCT03769311;NCT01326923;NCT02281955;NCT02052960;NCT04428151;NCT01412229;NCT00671437;NCT00101348;NCT04375384;NCT03082534;NCT01760811;NCT03874741;NCT02753140;NCT01104922;NCT01488318;NCT02270814;NCT01316757;NCT04464967;NCT01830556;NCT03646461;NCT00591149;NCT01602315;NCT03691714;NCT02507154;NCT03126708;NCT00096174;NCT00343083;NCT02643550;NCT00570674;NCT01133678;NCT01794845;NCT02128906;NCT02369458;NCT00617734;NCT00409565;NCT01417936;NCT02499120;NCT00660218;NCT01864772;NCT01301248;NCT01252628;NCT01427205;NCT01588431;NCT02143622;NCT00251381;NCT03713372;NCT01592721;NCT01468896;NCT03109158;NCT02707588;NCT00934518;NCT03077243
Carcinoma, Squamous Cell	D002294	cetuximab	Phase 3	2004	2020	NCT03386838;NCT02741570;NCT04590963;NCT03358472;NCT02105636;NCT01855451;NCT03342352;NCT02236936;NCT02252042;NCT01950689;NCT01810913;NCT02383966;NCT02409186;NCT00122460;NCT01012258;NCT01874171;NCT03258554;NCT01086826;NCT01177956;NCT03349710
Carcinoma, Squamous Cell	D002294	cetuximab	Phase 4	2014	2014	NCT02015650
Oropharyngeal Neoplasms	D009959	cetuximab	Phase 1	2007	2011	NCT00906360;NCT01334177;NCT00397384;NCT01637194
Oropharyngeal Neoplasms	D009959	cetuximab	Phase 2	2005	2020	NCT04106362;NCT03422536;NCT01884259;NCT04508829;NCT00939627;NCT02298595;NCT01816984;NCT01435252;NCT02281955;NCT00101348;NCT03082534;NCT01316757;NCT01440270;NCT00251381;NCT03077243
Oropharyngeal Neoplasms	D009959	cetuximab	Phase 3	2011	2017	NCT01434394;NCT03258554
Squamous Cell Carcinoma of Head and Neck	D000077195	cetuximab	Phase 1	2007	2021	NCT02205398;NCT03319459;NCT02764593;NCT02124850;NCT04361409;NCT01046266;NCT00736619;NCT03524326;NCT02277197;NCT04091867;NCT02350712;NCT03498378;NCT02429089;NCT01360827;NCT02438995;NCT02938273;NCT00903461;NCT01716416;NCT01758731;NCT00402545;NCT04722523
Squamous Cell Carcinoma of Head and Neck	D000077195	cetuximab	Phase 2	2004	2021	NCT01218048;NCT01332266;NCT01283334;NCT02573493;NCT03422536;NCT00957853;NCT01245985;NCT01836029;NCT03953976;NCT03088059;NCT01577173;NCT02101034;NCT02216916;NCT00971932;NCT02124707;NCT03744208;NCT04474470;NCT01581970;NCT02822482;NCT03389477;NCT02057107;NCT01015664;NCT01221753;NCT02624128;NCT03370276;NCT02255097;NCT00623558;NCT01040832;NCT02054442;NCT01979211;NCT03254927;NCT00968435;NCT04282109;NCT03169764;NCT03134846;NCT01154920;NCT02052960;NCT04428151;NCT01412229;NCT00671437;NCT00865098;NCT04375384;NCT03082534;NCT03874741;NCT02753140;NCT04616196;NCT01104922;NCT01280318;NCT01696955;NCT03070366;NCT01488318;NCT02270814;NCT04464967;NCT00736944;NCT01830556;NCT03646461;NCT02268695;NCT01602315;NCT03691714;NCT02507154;NCT00096174;NCT00343083;NCT04278092;NCT02643550;NCT00570674;NCT01133678;NCT02369458;NCT01417936;NCT02499120;NCT01252628;NCT01427205;NCT01588431;NCT02143622;NCT01054625;NCT03713372;NCT01592721;NCT01468896;NCT03109158;NCT02707588
Squamous Cell Carcinoma of Head and Neck	D000077195	cetuximab	Phase 3	2004	2020	NCT03386838;NCT01931150;NCT02741570;NCT04590963;NCT03358472;NCT02347332;NCT02105636;NCT03342352;NCT01950689;NCT02383966;NCT00609284;NCT00122460;NCT00999700;NCT01012258;NCT03258554;NCT01086826;NCT02551159;NCT01177956;NCT03349710
Squamous Cell Carcinoma of Head and Neck	D000077195	cetuximab	Phase 4	2014	2014	NCT02015650
Pancreatic Neoplasms	D010190	cetuximab	Phase 1	2005	2011	NCT00467116;NCT00397384;NCT01420874;NCT00622674
Pancreatic Neoplasms	D010190	cetuximab	Phase 2	1999	2021	NCT00424827;NCT00536614;NCT00395252;NCT00225784;NCT00305877;NCT00338039;NCT01042028;NCT00408564;NCT00276744;NCT00101348;NCT01050426;NCT00871169;NCT00305760;NCT00091026;NCT04464967;NCT00042939;NCT00383149;NCT00326911;NCT00005591;NCT01077986;NCT00599833;NCT00923299
Pancreatic Neoplasms	D010190	cetuximab	Phase 3	2004	2004	NCT00075686
Neoplasm Metastasis	D009362	cetuximab	Phase 1	2005	2014	NCT02845999;NCT00835679;NCT02124148;NCT00207116
Neoplasm Metastasis	D009362	cetuximab	Phase 2	2002	2021	NCT03135652;NCT03493048;NCT00444678;NCT04189055;NCT01511146;NCT03164655;NCT00153998;NCT02142036;NCT01384994;NCT01289522;NCT00743678;NCT03323424;NCT01836653;NCT00852228;NCT00544349;NCT04464967;NCT01802645;NCT00125034;NCT00537823;NCT01322178;NCT00056030;NCT03009058;NCT03366155;NCT00438737;NCT00908024;NCT03785249;NCT00130689;NCT01442935;NCT01737450;NCT01703910;NCT00513266;NCT00044863;NCT01673607;NCT01923987
Neoplasm Metastasis	D009362	cetuximab	Phase 3	2007	2021	NCT04687631;NCT03031444;NCT04509635;NCT00433927;NCT04525326;NCT00482222
Neoplasm Metastasis	D009362	cetuximab	Phase 4	2006	2007	NCT00327093;NCT01564810;NCT00510627
Neoplasms, Second Primary	D016609	cetuximab	Phase 2	2008	2017	NCT03135652;NCT01511146;NCT02142036;NCT00743678;NCT01836653;NCT00852228;NCT01923987
Neoplasms, Second Primary	D016609	cetuximab	Phase 3	2016	2021	NCT04687631;NCT03031444;NCT04509635;NCT04525326
Neoplasms, Second Primary	D016609	cetuximab	Phase 4	2006	2006	NCT00327093
Liver Neoplasms	D008113	cetuximab	Phase 1	2007	2009	NCT00397384;NCT00835679
Liver Neoplasms	D008113	cetuximab	Phase 2	2004	2017	NCT03135652;NCT01511146;NCT00153998;NCT01384994;NCT00743678;NCT00852228;NCT00483405
Liver Neoplasms	D008113	cetuximab	Phase 3	2020	2021	NCT04687631;NCT04509635;NCT04525326
Liver Neoplasms	D008113	cetuximab	Phase 4	2006	2007	NCT01564810;NCT00510627
Neoplasms, Squamous Cell	D018307	cetuximab	Phase 1	2014	2018	NCT03667482;NCT02282371
Neoplasms, Squamous Cell	D018307	cetuximab	Phase 2	2007	2018	NCT00815295;NCT03666325;NCT03370276;NCT02979977;NCT00661427;NCT00705016;NCT01326923;NCT03126708;NCT01864772;NCT00934518
Neoplasms, Squamous Cell	D018307	cetuximab	Phase 3	2014	2014	NCT02252042
Cholangiocarcinoma	D018281	cetuximab	Phase 1	2007	2007	NCT00397384
Cholangiocarcinoma	D018281	cetuximab	Phase 2	2010	2020	NCT03693807;NCT04668976;NCT03768375;NCT01267344;NCT01247337;NCT02836847
Nasopharyngeal Carcinoma	D000077274	cetuximab	Phase 1	2007	2011	NCT00906360;NCT01334177;NCT00397384;NCT01637194
Nasopharyngeal Carcinoma	D000077274	cetuximab	Phase 2	2005	2020	NCT01271439;NCT01614938;NCT01230476;NCT00939627;NCT01326559;NCT00700440;NCT04508816;NCT01816984;NCT00101348;NCT03082534;NCT01316757;NCT02507154;NCT01712919;NCT04534855
Nasopharyngeal Carcinoma	D000077274	cetuximab	Phase 3	2015	2018	NCT03529279;NCT02633176
Laryngeal Neoplasms	D007822	cetuximab	Phase 1	2007	2014	NCT00906360;NCT01334177;NCT01445405;NCT00397384;NCT01637194;NCT02229656
Laryngeal Neoplasms	D007822	cetuximab	Phase 2	2005	2017	NCT00462735;NCT00169247;NCT01245985;NCT01884259;NCT00939627;NCT01816984;NCT00599131;NCT01435252;NCT00101348;NCT03082534;NCT00941135;NCT01316757;NCT01216020;NCT00765011
Laryngeal Neoplasms	D007822	cetuximab	Phase 3	2017	2017	NCT03258554
Pharyngeal Neoplasms	D010610	cetuximab	Phase 1	2008	2012	NCT01552434;NCT01445405
Pharyngeal Neoplasms	D010610	cetuximab	Phase 2	2007	2017	NCT00462735;NCT03067610;NCT01216020
Paranasal Sinus Neoplasms	D010255	cetuximab	Phase 1	2007	2011	NCT00906360;NCT01334177;NCT00397384;NCT01637194
Paranasal Sinus Neoplasms	D010255	cetuximab	Phase 2	2005	2013	NCT00462735;NCT00939627;NCT01816984;NCT00101348;NCT01316757
Nose Neoplasms	D009669	cetuximab	Phase 2	2007	2007	NCT00462735
Mesothelioma	D008654	cetuximab	Phase 2	2009	2009	NCT00996567
Stomach Neoplasms	D013274	cetuximab	Phase 1	2001	2018	NCT03319459;NCT00477880;NCT00397384
Stomach Neoplasms	D013274	cetuximab	Phase 2	2004	2021	NCT00398398;NCT01360086;NCT00275951;NCT00477711;NCT00397904;NCT00699881;NCT01611506;NCT00439608;NCT00384878;NCT04136600;NCT01388790;NCT01123811;NCT04464967;NCT00857246;NCT00130689
Stomach Neoplasms	D013274	cetuximab	Phase 3	2008	2008	NCT00678535
Colonic Neoplasms	D003110	cetuximab	Phase 1	2005	2020	NCT03774680;NCT01126450;NCT00494611;NCT01287130;NCT00134069;NCT01294826;NCT01217450;NCT00397384;NCT01198535;NCT00835679;NCT01637194;NCT01420874;NCT01254617
Colonic Neoplasms	D003110	cetuximab	Phase 2	2003	2021	NCT00336856;NCT01675999;NCT00845039;NCT00101348;NCT03365882;NCT04616183;NCT00193219;NCT01744340;NCT03446157;NCT00100841;NCT00551421;NCT00766220;NCT00077298;NCT03641976;NCT04775862;NCT01292356;NCT03524820
Colonic Neoplasms	D003110	cetuximab	Phase 3	2004	2010	NCT00647530;NCT00499369;NCT01167725;NCT00079274;NCT00265811
Rectal Neoplasms	D012004	cetuximab	Phase 1	2005	2020	NCT01126450;NCT00392470;NCT00134069;NCT01294826;NCT01217450;NCT00397384;NCT01198535;NCT00835679;NCT01254617;NCT04638036
Rectal Neoplasms	D012004	cetuximab	Phase 2	2003	2020	NCT00336856;NCT00541112;NCT00506844;NCT00689702;NCT04017650;NCT00964457;NCT00795301;NCT03391843;NCT00845039;NCT00383695;NCT00226941;NCT00101348;NCT03365882;NCT04616183;NCT00611858;NCT00100841;NCT00353457;NCT00551421;NCT00972881;NCT00077298;NCT00686166;NCT01609231;NCT00297128;NCT03022734;NCT01923987;NCT00527111
Rectal Neoplasms	D012004	cetuximab	Phase 3	2007	2020	NCT00499369;NCT04215731
Adenocarcinoma	D000230	cetuximab	Phase 1	2005	2011	NCT00104910;NCT01294826;NCT00397384;NCT01198535;NCT00835679
Adenocarcinoma	D000230	cetuximab	Phase 2	2004	2020	NCT01360086;NCT00395252;NCT00162110;NCT04554836;NCT00517829;NCT04017650;NCT00165490;NCT00716456;NCT00580073;NCT01123811;NCT03365882;NCT04117945;NCT04616183;NCT00100841;NCT00353457;NCT00551421;NCT00827671;NCT01703910;NCT02599324
Adenocarcinoma	D000230	cetuximab	Phase 3	2003	2010	NCT00077233;NCT01107639;NCT00946712
Esophageal Neoplasms	D004938	cetuximab	Phase 1	2007	2019	NCT04161560;NCT00397384
Esophageal Neoplasms	D004938	cetuximab	Phase 2	2004	2021	NCT01360086;NCT01787006;NCT00165490;NCT00397904;NCT00096031;NCT02636088;NCT00551759;NCT00439608;NCT00109850;NCT00425425;NCT00445861;NCT00544362;NCT01034189;NCT04464967;NCT00381706;NCT00130689;NCT00578201;NCT00735345;NCT00733889;NCT00636298
Esophageal Neoplasms	D004938	cetuximab	Phase 3	2008	2010	NCT00655876;NCT01107639;NCT00509561
Lymphoma	D008223	cetuximab	Phase 1	2020	2020	NCT03579888
Lymphoma	D008223	cetuximab	Phase 3	2000	2000	NCT00115700
Leukemia	D007938	cetuximab	Phase 1	2020	2020	NCT03579888
Leukemia	D007938	cetuximab	Phase 2	2014	2017	NCT03263208;NCT02028455
Lymphoma, Non-Hodgkin	D008228	cetuximab	Phase 1	2020	2020	NCT03579888
Leukemia, Lymphoid	D007945	cetuximab	Phase 1	2020	2020	NCT03579888
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	cetuximab	Phase 1	2020	2020	NCT03579888
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	cetuximab	Phase 2	2017	2017	NCT03263208
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	cetuximab	Phase 1	2020	2020	NCT03579888
Lymphoma, B-Cell	D016393	cetuximab	Phase 1	2020	2020	NCT03579888
Lymphoma, Mantle-Cell	D020522	cetuximab	Phase 1	2020	2020	NCT03579888
Lymphoma, Large B-Cell, Diffuse	D016403	cetuximab	Phase 1	2020	2020	NCT03579888
Biliary Tract Neoplasms	D001661	cetuximab	Phase 2	2006	2008	NCT00747097;NCT01216345;NCT00552149
Prostatic Neoplasms	D011471	cetuximab	Phase 2	2007	2008	NCT00448097;NCT00661492;NCT00728663
Skin Neoplasms	D012878	cetuximab	Phase 2	2018	2019	NCT03666325;NCT03944941
Breast Neoplasms	D001943	cetuximab	Phase 1	2006	2015	NCT01552434;NCT00367250;NCT02391727
Breast Neoplasms	D001943	cetuximab	Phase 2	2005	2021	NCT03692689;NCT00463788;NCT00633464;NCT00248287;NCT00232505;NCT00353717;NCT04464967;NCT00275041;NCT01097642;NCT00600249
Triple Negative Breast Neoplasms	D064726	cetuximab	Phase 1	2011	2011	NCT01451632
Triple Negative Breast Neoplasms	D064726	cetuximab	Phase 2	2008	2021	NCT03692689;NCT04464967;NCT01097642;NCT03761914
Glioblastoma	D005909	cetuximab	Phase 1	2009	2018	NCT03603379;NCT01238237
Glioblastoma	D005909	cetuximab	Phase 2	2006	2016	NCT02800486;NCT00463073;NCT02861898;NCT00311857;NCT01884740;NCT01044225
Carcinoma, Verrucous	D018289	cetuximab	Phase 1	2007	2011	NCT00906360;NCT01334177;NCT00397384;NCT01637194;NCT01254617
Carcinoma, Verrucous	D018289	cetuximab	Phase 2	2005	2013	NCT00939627;NCT01816984;NCT01256385;NCT00101348;NCT01316757
Salivary Gland Neoplasms	D012468	cetuximab	Phase 1	2007	2011	NCT00906360;NCT01334177;NCT00397384;NCT01637194;NCT01254617
Salivary Gland Neoplasms	D012468	cetuximab	Phase 2	2005	2013	NCT00984217;NCT00939627;NCT01816984;NCT01256385;NCT00101348;NCT01316757
Neoplasms, Unknown Primary	D009382	cetuximab	Phase 1	2007	2011	NCT00906360;NCT01334177;NCT00397384
Neoplasms, Unknown Primary	D009382	cetuximab	Phase 2	2005	2013	NCT00939627;NCT01816984;NCT00101348;NCT01316757;NCT00894569
Tongue Neoplasms	D014062	cetuximab	Phase 1	2007	2011	NCT00906360;NCT01334177;NCT00397384;NCT01637194
Tongue Neoplasms	D014062	cetuximab	Phase 2	2009	2013	NCT00939627;NCT01816984;NCT01316757
Esophageal Squamous Cell Carcinoma	D000077277	cetuximab	Phase 2	2004	2019	NCT00815308;NCT04229459;NCT00165490;NCT02812641;NCT03817567;NCT02123381;NCT03126708
Esophageal Squamous Cell Carcinoma	D000077277	cetuximab	Phase 3	2015	2015	NCT02409186
Adenoma	D000236	cetuximab	Phase 2	2011	2011	NCT00984217
Adenoma, Pleomorphic	D008949	cetuximab	Phase 2	2011	2011	NCT00984217
Syringoma	D018252	cetuximab	Phase 2	2011	2011	NCT00984217
Multiple Myeloma	D009101	cetuximab	Phase 2	2006	2012	NCT00368121;NCT01524978
Neoplasms, Plasma Cell	D054219	cetuximab	Phase 2	2006	2006	NCT00368121
Anus Neoplasms	D001005	cetuximab	Phase 1	2007	2012	NCT01621217;NCT00397384
Anus Neoplasms	D001005	cetuximab	Phase 2	2006	2018	NCT00324415;NCT03944252;NCT00316888;NCT03381352;NCT00955240
Papilloma	D010212	cetuximab	Phase 1	2007	2008	NCT00397384;NCT01637194
Papilloma	D010212	cetuximab	Phase 2	2005	2011	NCT01221753;NCT00101348
Precancerous Conditions	D011230	cetuximab	Phase 1	2001	2001	NCT00477880
Precancerous Conditions	D011230	cetuximab	Phase 2	2007	2010	NCT00524017;NCT01084083
Precancerous Conditions	D011230	cetuximab	Phase 3	2011	2011	NCT01302834
Carcinoma, Adenoid Cystic	D003528	cetuximab	Phase 1	2007	2008	NCT00397384;NCT01637194
Carcinoma, Adenoid Cystic	D003528	cetuximab	Phase 2	2005	2012	NCT01192087;NCT00101348
Carcinoma, Hepatocellular	D006528	cetuximab	Phase 2	2005	2018	NCT00142428;NCT03563170
Uterine Cervical Neoplasms	D002583	cetuximab	Phase 1	2005	2005	NCT00104910
Uterine Cervical Neoplasms	D002583	cetuximab	Phase 2	2004	2021	NCT00997009;NCT00957411;NCT00292955;NCT00518193;NCT00101192;NCT04464967
Carcinoma, Small Cell	D018288	cetuximab	Phase 1	2005	2005	NCT00104910
Small Cell Lung Carcinoma	D055752	cetuximab	Phase 1	2005	2005	NCT00104910
Small Cell Lung Carcinoma	D055752	cetuximab	Phase 2	2019	2019	NCT03761914
Carcinoma, Adenosquamous	D018196	cetuximab	Phase 1	2005	2005	NCT00104910
Carcinoma, Adenosquamous	D018196	cetuximab	Phase 2	2007	2007	NCT00570674
Brain Neoplasms	D001932	cetuximab	Phase 2	2009	2016	NCT02800486;NCT01012609;NCT02861898;NCT02855086
Astrocytoma	D001254	cetuximab	Phase 1	2009	2009	NCT01238237
Astrocytoma	D001254	cetuximab	Phase 2	2009	2016	NCT02800486;NCT01012609;NCT01884740
Mouth Neoplasms	D009062	cetuximab	Phase 1	2008	2011	NCT01445405;NCT01254617
Mouth Neoplasms	D009062	cetuximab	Phase 2	2009	2017	NCT03067610;NCT00933387;NCT03082534;NCT01216020;NCT01440270
Mouth Neoplasms	D009062	cetuximab	Phase 3	2011	2017	NCT01434394;NCT03258554
Lymphoma, Follicular	D008224	cetuximab	Phase 3	2000	2000	NCT00115700
Peritoneal Neoplasms	D010534	cetuximab	Phase 2	2003	2010	NCT01540344;NCT00766142;NCT00063401
Urologic Neoplasms	D014571	cetuximab	Phase 1	2012	2012	NCT01552434
Urologic Neoplasms	D014571	cetuximab	Phase 2	2006	2006	NCT00350025
Adenocarcinoma of Lung	D000077192	cetuximab	Phase 2	2005	2008	NCT00716456;NCT00118183;NCT00368992
Adenocarcinoma of Lung	D000077192	cetuximab	Phase 3	2009	2009	NCT00946712
Sarcoma	D012509	cetuximab	Phase 1	2005	2020	NCT01552434;NCT00622674;NCT03618381;NCT04483778
Sarcoma	D012509	cetuximab	Phase 2	2005	2021	NCT04464967;NCT00148109
Neurofibromatoses	D017253	cetuximab	Phase 1	2012	2012	NCT01552434
Lymphangioleiomyomatosis	D018192	cetuximab	Phase 1	2012	2012	NCT01552434
Thyroid Neoplasms	D013964	cetuximab	Phase 1	2012	2012	NCT01552434
Thoracic Neoplasms	D013899	cetuximab	Phase 1	2012	2012	NCT01552434
Genital Neoplasms, Female	D005833	cetuximab	Phase 1	2012	2012	NCT01552434
Neurofibromatosis 2	D016518	cetuximab	Phase 1	2012	2012	NCT01552434
Respiratory Tract Neoplasms	D012142	cetuximab	Phase 1	2012	2012	NCT01552434
Soft Tissue Neoplasms	D012983	cetuximab	Phase 1	2012	2012	NCT01552434
Endocrine Gland Neoplasms	D004701	cetuximab	Phase 1	2012	2012	NCT01552434
Genital Neoplasms, Male	D005834	cetuximab	Phase 1	2012	2012	NCT01552434
Neoplasms, Mesothelial	D018301	cetuximab	Phase 1	2012	2012	NCT01552434
Glioma	D005910	cetuximab	Phase 2	2006	2016	NCT00463073;NCT02855086;NCT01884740
Brain Stem Neoplasms	D020295	cetuximab	Phase 2	2009	2009	NCT01012609
Carcinoma, Basal Cell	D002280	cetuximab	Phase 1	2007	2008	NCT00397384;NCT01637194
Carcinoma, Basal Cell	D002280	cetuximab	Phase 2	2005	2005	NCT00101348
Gastrointestinal Stromal Tumors	D046152	cetuximab	Phase 1	2007	2007	NCT00397384
Carcinoid Tumor	D002276	cetuximab	Phase 1	2007	2007	NCT00397384
Gallbladder Neoplasms	D005706	cetuximab	Phase 1	2007	2007	NCT00397384
Gallbladder Neoplasms	D005706	cetuximab	Phase 2	2016	2016	NCT03768375;NCT02836847
Leiomyosarcoma	D007890	cetuximab	Phase 1	2007	2007	NCT00397384
Bile Duct Neoplasms	D001650	cetuximab	Phase 1	2007	2007	NCT00397384
Carcinoma, Mucoepidermoid	D018277	cetuximab	Phase 1	2007	2008	NCT00397384;NCT01637194
Carcinoma, Mucoepidermoid	D018277	cetuximab	Phase 2	2005	2005	NCT00101348
Esthesioneuroblastoma, Olfactory	D018304	cetuximab	Phase 1	2007	2008	NCT00397384;NCT01637194
Esthesioneuroblastoma, Olfactory	D018304	cetuximab	Phase 2	2005	2005	NCT00101348
Papilloma, Inverted	D018308	cetuximab	Phase 1	2007	2008	NCT00397384;NCT01637194
Papilloma, Inverted	D018308	cetuximab	Phase 2	2005	2005	NCT00101348
Malignant Carcinoid Syndrome	D008303	cetuximab	Phase 1	2007	2007	NCT00397384
Gastrointestinal Neoplasms	D005770	cetuximab	Phase 1	2007	2007	NCT00397384
Intestinal Neoplasms	D007414	cetuximab	Phase 1	2007	2007	NCT00397384
Thymoma	D013945	cetuximab	Phase 2	2009	2009	NCT01025089
Thymus Neoplasms	D013953	cetuximab	Phase 2	2009	2009	NCT01025089
Hypopharyngeal Neoplasms	D007012	cetuximab	Phase 2	2011	2011	NCT01435252
Adenocarcinoma, Mucinous	D002288	cetuximab	Phase 1	2009	2010	NCT01198535;NCT00835679
Adenocarcinoma, Mucinous	D002288	cetuximab	Phase 2	2004	2004	NCT00100841
Cystadenocarcinoma	D003536	cetuximab	Phase 1	2009	2010	NCT01198535;NCT00835679
Cystadenocarcinoma	D003536	cetuximab	Phase 2	2004	2004	NCT00100841
Carcinoma, Signet Ring Cell	D018279	cetuximab	Phase 1	2010	2010	NCT01198535
Pleural Effusion, Malignant	D016066	cetuximab	Phase 2	2005	2005	NCT00118183
Urinary Bladder Neoplasms	D001749	cetuximab	Phase 2	2008	2021	NCT00645593;NCT04464967
Myasthenia Gravis	D009157	cetuximab	Phase 3	2006	2006	NCT00294658
Carcinoma, Renal Cell	D002292	cetuximab	Phase 1	2005	2005	NCT00622674
Carcinoma, Renal Cell	D002292	cetuximab	Phase 2	2005	2015	NCT00101348;NCT02599324
Nasopharyngeal Neoplasms	D009303	cetuximab	Phase 2	2015	2017	NCT03082534;NCT02507154
Neoplastic Cells, Circulating	D009360	cetuximab	Phase 2	2012	2021	NCT04648189;NCT01640444
Endometrial Neoplasms	D016889	cetuximab	Phase 2	2006	2021	NCT00392769;NCT04464967
Ovarian Neoplasms	D010051	cetuximab	Phase 2	2004	2021	NCT04464967;NCT00082212
Adenocarcinoma, Bronchiolo-Alveolar	D002282	cetuximab	Phase 2	2006	2006	NCT00368992
Kidney Neoplasms	D007680	cetuximab	Phase 1	2005	2005	NCT00622674
Oligodendroglioma	D009837	cetuximab	Phase 2	2013	2013	NCT01884740
Chordoma	D002817	cetuximab	Phase 2	2018	2018	NCT03647423
Neuroblastoma	D009447	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Osteosarcoma	D012516	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Rhabdomyosarcoma	D012208	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Sarcoma, Ewing	D012512	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Wilms Tumor	D009396	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Retinoblastoma	D012175	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Sarcoma, Synovial	D013584	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Rhabdoid Tumor	D018335	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Hepatoblastoma	D018197	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Nerve Sheath Neoplasms	D018317	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Desmoplastic Small Round Cell Tumor	D058405	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Neurofibrosarcoma	D018319	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Sarcoma, Clear Cell	D018227	cetuximab	Phase 1	2019	2020	NCT03618381;NCT04483778
Fallopian Tube Neoplasms	D005185	cetuximab	Phase 2	2003	2003	NCT00063401
Lip Neoplasms	D008048	cetuximab	Phase 3	2017	2017	NCT03258554
Hematologic Neoplasms	D019337	cetuximab	Phase 1	2019	2019	NCT03783403
Leukemia, Myeloid	D007951	cetuximab	Phase 2	2019	2019	NCT03761914
Leukemia, Myeloid, Acute	D015470	cetuximab	Phase 2	2019	2019	NCT03761914
Multiple Myeloma	D009101	cobimetinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	cobimetinib	Phase 2	2016	2019	NCT02693535;NCT03312530;NCT03297606;NCT03732703
Lymphoma, Non-Hodgkin	D008228	cobimetinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	cobimetinib	Phase 2	2016	2017	NCT02693535;NCT03297606
Melanoma	D008545	cobimetinib	Phase 1	2011	2020	NCT04109456;NCT01843738;NCT02818023;NCT01876641;NCT03026517;NCT03543969;NCT03178851;NCT02721459;NCT01271803;NCT01656642
Melanoma	D008545	cobimetinib	Phase 2	2013	2020	NCT03625141;NCT02537600;NCT03514901;NCT02414750;NCT03101254;NCT02968303;NCT02303951;NCT01495988;NCT03224208;NCT04722575;NCT02583516;NCT03175432;NCT03430947;NCT01813214;NCT01959633;NCT03005639;NCT02036086;NCT02768207;NCT03554083;NCT02902029;NCT02230306
Melanoma	D008545	cobimetinib	Phase 3	2013	2017	NCT03273153;NCT02427893;NCT01689519;NCT02908672
Neoplasm Metastasis	D009362	cobimetinib	Phase 2	2015	2018	NCT03625141;NCT02537600;NCT03430947;NCT02230306
Lung Neoplasms	D008175	cobimetinib	Phase 2	2017	2020	NCT04302025;NCT03202940
Lung Neoplasms	D008175	cobimetinib	Phase 3	2017	2017	NCT03178552
Carcinoma, Non-Small-Cell Lung	D002289	cobimetinib	Phase 1	2015	2015	NCT02457793
Carcinoma, Non-Small-Cell Lung	D002289	cobimetinib	Phase 2	2017	2020	NCT04302025;NCT03600701;NCT03337698;NCT03202940
Carcinoma, Non-Small-Cell Lung	D002289	cobimetinib	Phase 3	2017	2017	NCT03178552
Neoplasms, Plasma Cell	D054219	cobimetinib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	cobimetinib	Phase 2	2017	2019	NCT03312530;NCT03732703
Colorectal Neoplasms	D015179	cobimetinib	Phase 1	2016	2016	NCT02876224
Colorectal Neoplasms	D015179	cobimetinib	Phase 2	2014	2018	NCT02291289;NCT03340558;NCT02060188
Leukemia	D007938	cobimetinib	Phase 1	2016	2020	NCT02670044;NCT03878524
Leukemia, Myeloid	D007951	cobimetinib	Phase 1	2016	2020	NCT02670044;NCT03878524
Leukemia, Myeloid, Acute	D015470	cobimetinib	Phase 1	2016	2020	NCT02670044;NCT03878524
Carcinoma	D002277	cobimetinib	Phase 1	2020	2020	NCT03878524
Carcinoma	D002277	cobimetinib	Phase 2	2017	2018	NCT03600701;NCT03181100;NCT03202316;NCT03108131
Neoplasms, Unknown Primary	D009382	cobimetinib	Phase 2	2018	2018	NCT03498521
Ovarian Neoplasms	D010051	cobimetinib	Phase 1	2019	2019	NCT03695380
Ovarian Neoplasms	D010051	cobimetinib	Phase 2	2018	2018	NCT03363867
Carcinoma, Ovarian Epithelial	D000077216	cobimetinib	Phase 1	2019	2019	NCT03695380
Carcinoma, Ovarian Epithelial	D000077216	cobimetinib	Phase 2	2018	2018	NCT03363867
Fallopian Tube Neoplasms	D005185	cobimetinib	Phase 2	2018	2018	NCT03363867
Adenocarcinoma	D000230	cobimetinib	Phase 1	2019	2020	NCT04005690;NCT03878524
Adenocarcinoma	D000230	cobimetinib	Phase 2	2011	2017	NCT03193190;NCT01506973;NCT03281369;NCT03108131
Adenocarcinoma	D000230	cobimetinib	Phase 3	2016	2016	NCT02788279
Pancreatic Neoplasms	D010190	cobimetinib	Phase 1	2019	2020	NCT04005690;NCT03878524
Sarcoma, Clear Cell	D018227	cobimetinib	Phase 2	2017	2017	NCT02968303
Cholangiocarcinoma	D018281	cobimetinib	Phase 2	2017	2017	NCT03201458
Breast Neoplasms	D001943	cobimetinib	Phase 1	2020	2020	NCT03878524
Breast Neoplasms	D001943	cobimetinib	Phase 2	2014	2018	NCT02322814;NCT03566485;NCT03395899
Triple Negative Breast Neoplasms	D064726	cobimetinib	Phase 2	2014	2014	NCT02322814
Leukemia, Myelomonocytic, Chronic	D015477	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	cobimetinib	Phase 2	2021	2021	NCT04409639
Leukemia, Myelomonocytic, Juvenile	D054429	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	cobimetinib	Phase 2	2021	2021	NCT04409639
Gastrointestinal Neoplasms	D005770	cobimetinib	Phase 2	2020	2020	NCT04214418;NCT04591431
Skin Neoplasms	D012878	cobimetinib	Phase 1	2016	2018	NCT03543969;NCT02721459
Skin Neoplasms	D012878	cobimetinib	Phase 2	2017	2018	NCT03175432;NCT03554083
Craniopharyngioma	D003397	cobimetinib	Phase 2	2017	2017	NCT03224767
Adamantinoma	D050398	cobimetinib	Phase 2	2017	2017	NCT03224767
Brain Neoplasms	D001932	cobimetinib	Phase 2	2015	2018	NCT03430947;NCT02230306
Sarcoma	D012509	cobimetinib	Phase 2	2020	2020	NCT04216953
Histiocytic Sarcoma	D054747	cobimetinib	Phase 2	2020	2020	NCT04079179
Histiocytic Disorders, Malignant	D015620	cobimetinib	Phase 2	2020	2020	NCT04079179
Thyroid Neoplasms	D013964	cobimetinib	Phase 2	2017	2017	NCT03181100
Thyroid Carcinoma, Anaplastic	D065646	cobimetinib	Phase 2	2017	2017	NCT03181100
Inflammatory Breast Neoplasms	D058922	cobimetinib	Phase 2	2017	2017	NCT03202316
Esophageal Neoplasms	D004938	cobimetinib	Phase 2	2017	2017	NCT03281369
Carcinoma, Squamous Cell	D002294	cobimetinib	Phase 2	2017	2017	NCT03108131
Lymphoma	D008223	cobimetinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	cobimetinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	cobimetinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	cobimetinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	cobimetinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	cobimetinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	cobimetinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	cobimetinib	Phase 1	2020	2020	NCT03878524
Mixed Tumor, Malignant	D018198	copanlisib	Phase 2	2018	2018	NCT03458728
Lymphoma	D008223	copanlisib	Phase 1	2014	2020	NCT03884998;NCT04156828;NCT03502733;NCT03498430;NCT02253420;NCT02155582;NCT03886649;NCT04431635;NCT04233697;NCT03878524
Lymphoma	D008223	copanlisib	Phase 2	2012	2021	NCT02391116;NCT03789240;NCT04155840;NCT04572763;NCT02455297;NCT04263584;NCT03581942;NCT03877055;NCT02342665;NCT03484819;NCT02535247;NCT02465060;NCT04433182;NCT03474744;NCT04750941;NCT01660451
Lymphoma	D008223	copanlisib	Phase 3	2015	2016	NCT02367040;NCT02626455;NCT02369016
Lymphoma, B-Cell	D016393	copanlisib	Phase 1	2019	2020	NCT04156828;NCT03886649
Lymphoma, B-Cell	D016393	copanlisib	Phase 2	2015	2021	NCT02391116;NCT04572763;NCT04263584;NCT03484819;NCT04433182
Lymphoma, B-Cell	D016393	copanlisib	Phase 3	2015	2015	NCT02367040
Lymphoma, Large B-Cell, Diffuse	D016403	copanlisib	Phase 1	2019	2020	NCT03884998;NCT04156828
Lymphoma, Large B-Cell, Diffuse	D016403	copanlisib	Phase 2	2015	2021	NCT02391116;NCT04572763;NCT04263584;NCT03484819;NCT04433182
Lymphoma, Follicular	D008224	copanlisib	Phase 1	2020	2020	NCT04156828
Lymphoma, Follicular	D008224	copanlisib	Phase 2	2019	2021	NCT03789240;NCT04750941
Carcinoma	D002277	copanlisib	Phase 1	2019	2020	NCT03586661;NCT03878524
Carcinoma	D002277	copanlisib	Phase 2	2015	2020	NCT02631590;NCT02822482;NCT03939897;NCT02728258;NCT04345913;NCT04108858;NCT02465060;NCT03735628;NCT03128619
Cholangiocarcinoma	D018281	copanlisib	Phase 2	2016	2016	NCT02631590
Urinary Bladder Neoplasms	D001749	copanlisib	Phase 2	2015	2016	NCT02631590;NCT02465060
Digestive System Neoplasms	D004067	copanlisib	Phase 2	2016	2016	NCT02631590
Gastrointestinal Neoplasms	D005770	copanlisib	Phase 2	2016	2016	NCT02631590
Leukemia	D007938	copanlisib	Phase 1	2019	2020	NCT03884998;NCT03878524
Leukemia	D007938	copanlisib	Phase 2	2020	2021	NCT04155840;NCT04685915
Leukemia, Lymphoid	D007945	copanlisib	Phase 1	2019	2020	NCT03884998;NCT03878524
Leukemia, Lymphoid	D007945	copanlisib	Phase 2	2020	2021	NCT04155840;NCT04685915
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	copanlisib	Phase 1	2019	2020	NCT03884998;NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	copanlisib	Phase 2	2020	2021	NCT04155840;NCT04685915
Breast Neoplasms	D001943	copanlisib	Phase 1	2016	2020	NCT04042051;NCT02705859;NCT03878524
Breast Neoplasms	D001943	copanlisib	Phase 2	2015	2020	NCT03803761;NCT03939897;NCT04345913;NCT03377101;NCT04108858;NCT02465060;NCT03128619
Lymphoma, Mantle-Cell	D020522	copanlisib	Phase 2	2015	2019	NCT02455297;NCT03877055
Carcinoma, Squamous Cell	D002294	copanlisib	Phase 2	2016	2016	NCT02822482
Squamous Cell Carcinoma of Head and Neck	D000077195	copanlisib	Phase 2	2016	2018	NCT02822482;NCT03735628
Lymphoma, Non-Hodgkin	D008228	copanlisib	Phase 1	2014	2020	NCT03884998;NCT03498430;NCT02253420;NCT02155582;NCT03886649;NCT03878524
Lymphoma, Non-Hodgkin	D008228	copanlisib	Phase 2	2012	2016	NCT02535247;NCT01660451
Lymphoma, Non-Hodgkin	D008228	copanlisib	Phase 3	2015	2016	NCT02367040;NCT02626455;NCT02369016
Waldenstrom Macroglobulinemia	D008258	copanlisib	Phase 1	2019	2019	NCT03884998
Thyroid Neoplasms	D013964	copanlisib	Phase 1	2020	2020	NCT04462471
Thyroid Neoplasms	D013964	copanlisib	Phase 2	2015	2015	NCT02465060
Thyroid Cancer, Papillary	D000077273	copanlisib	Phase 1	2020	2020	NCT04462471
Adenocarcinoma	D000230	copanlisib	Phase 1	2019	2020	NCT03586661;NCT03878524
Adenocarcinoma	D000230	copanlisib	Phase 2	2016	2016	NCT02728258
Cystadenocarcinoma, Serous	D018284	copanlisib	Phase 1	2019	2019	NCT03586661
Cystadenocarcinoma, Serous	D018284	copanlisib	Phase 2	2016	2016	NCT02728258
Carcinoma, Endometrioid	D018269	copanlisib	Phase 2	2016	2016	NCT02728258
Triple Negative Breast Neoplasms	D064726	copanlisib	Phase 2	2020	2020	NCT04345913
Lymphoma, T-Cell	D016399	copanlisib	Phase 1	2020	2020	NCT04233697
Lymphoma, T-Cell	D016399	copanlisib	Phase 2	2016	2018	NCT03052933;NCT02535247
Colonic Neoplasms	D003110	copanlisib	Phase 2	2015	2019	NCT03711058;NCT02465060
Lymphoma, T-Cell, Peripheral	D016411	copanlisib	Phase 1	2020	2020	NCT04233697
Lymphoma, T-Cell, Peripheral	D016411	copanlisib	Phase 2	2016	2016	NCT02535247
Melanoma	D008545	copanlisib	Phase 2	2015	2015	NCT02465060
Multiple Myeloma	D009101	copanlisib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	copanlisib	Phase 2	2015	2015	NCT02465060
Neoplasms, Plasma Cell	D054219	copanlisib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	copanlisib	Phase 2	2015	2015	NCT02465060
Glioma	D005910	copanlisib	Phase 2	2015	2015	NCT02465060
Lung Neoplasms	D008175	copanlisib	Phase 2	2015	2015	NCT02465060
Colorectal Neoplasms	D015179	copanlisib	Phase 2	2015	2015	NCT02465060
Endometrial Neoplasms	D016889	copanlisib	Phase 1	2019	2019	NCT03586661
Endometrial Neoplasms	D016889	copanlisib	Phase 2	2015	2021	NCT02465060;NCT04750941
Ovarian Neoplasms	D010051	copanlisib	Phase 1	2019	2019	NCT03586661
Ovarian Neoplasms	D010051	copanlisib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	copanlisib	Phase 1	2019	2019	NCT03586661
Carcinoma, Ovarian Epithelial	D000077216	copanlisib	Phase 2	2015	2015	NCT02465060
Prostatic Neoplasms	D011471	copanlisib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	copanlisib	Phase 2	2015	2020	NCT02465060;NCT04253262
Pancreatic Neoplasms	D010190	copanlisib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	copanlisib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	copanlisib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	copanlisib	Phase 2	2015	2015	NCT02465060
Rectal Neoplasms	D012004	copanlisib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	copanlisib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	copanlisib	Phase 2	2015	2018	NCT02465060;NCT03735628
Skin Neoplasms	D012878	copanlisib	Phase 2	2015	2015	NCT02465060
Carcinoma, Renal Cell	D002292	copanlisib	Phase 2	2015	2015	NCT02465060
Kidney Neoplasms	D007680	copanlisib	Phase 2	2015	2015	NCT02465060
Lymphoma, B-Cell, Marginal Zone	D018442	copanlisib	Phase 2	2019	2019	NCT03474744
Fallopian Tube Neoplasms	D005185	copanlisib	Phase 1	2019	2019	NCT03586661
Leukemia, Myeloid	D007951	copanlisib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	copanlisib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	copanlisib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	copanlisib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	copanlisib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	copanlisib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	copanlisib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	copanlisib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	copanlisib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	copanlisib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	copanlisib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	copanlisib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	copanlisib	Phase 1	2020	2020	NCT03878524
Carcinoma, Non-Small-Cell Lung	D002289	crizotinib	Phase 1	2006	2018	NCT00585195;NCT02277457;NCT02695550;NCT01441128;NCT01121575;NCT03607188;NCT01998126;NCT02511184
Carcinoma, Non-Small-Cell Lung	D002289	crizotinib	Phase 2	2010	2021	NCT02568267;NCT01964157;NCT02098954;NCT02584634;NCT04211922;NCT02040870;NCT03088930;NCT02094573;NCT01970865;NCT01752400;NCT01449461;NCT03574402;NCT03439215;NCT01685060;NCT01500824;NCT02336451;NCT01685138;NCT02499614;NCT04084717;NCT04641754;NCT02664935;NCT03909971;NCT00932451;NCT04111705;NCT03087448;NCT02314364;NCT03215693;NCT04193007;NCT01712217;NCT04621188;NCT04056572;NCT01945021;NCT01801111;NCT01822496;NCT01871805;NCT02574078;NCT03155009;NCT02134912;NCT03399487
Carcinoma, Non-Small-Cell Lung	D002289	crizotinib	Phase 3	2009	2021	NCT03052608;NCT02838420;NCT03596866;NCT04632758;NCT02075840;NCT00932893;NCT02201992;NCT01828112;NCT01639001;NCT04603807;NCT02767804;NCT02604342;NCT02737501;NCT04009317
Carcinoma, Non-Small-Cell Lung	D002289	crizotinib	Phase 4	2019	2020	NCT03672643;NCT04356118
Colorectal Neoplasms	D015179	crizotinib	Phase 1	2014	2014	NCT02510001
Colorectal Neoplasms	D015179	crizotinib	Phase 2	2015	2015	NCT02568267;NCT02465060
Melanoma	D008545	crizotinib	Phase 2	2015	2019	NCT02568267;NCT02223819;NCT03947385;NCT02465060
Pancreatic Neoplasms	D010190	crizotinib	Phase 2	2015	2015	NCT02568267;NCT02465060
Sarcoma	D012509	crizotinib	Phase 2	2012	2015	NCT02568267;NCT01524926
Ovarian Neoplasms	D010051	crizotinib	Phase 2	2015	2015	NCT02568267;NCT02465060
Brain Neoplasms	D001932	crizotinib	Phase 2	2015	2019	NCT02568267;NCT04193007
Thyroid Neoplasms	D013964	crizotinib	Phase 2	2015	2015	NCT02568267;NCT02465060
Neuroendocrine Tumors	D018358	crizotinib	Phase 2	2015	2015	NCT02568267
Cholangiocarcinoma	D018281	crizotinib	Phase 2	2015	2016	NCT02568267;NCT03768375;NCT02836847
Salivary Gland Neoplasms	D012468	crizotinib	Phase 2	2015	2015	NCT02568267
Head and Neck Neoplasms	D006258	crizotinib	Phase 2	2015	2015	NCT02568267
Thyroid Cancer, Papillary	D000077273	crizotinib	Phase 2	2015	2015	NCT02568267
Lymphoma, Large-Cell, Anaplastic	D017728	crizotinib	Phase 1	2006	2013	NCT00585195;NCT01606878
Lymphoma, Large-Cell, Anaplastic	D017728	crizotinib	Phase 2	2009	2015	NCT02568267;NCT01524926;NCT01449461;NCT01979536;NCT02419287;NCT00939770
Lymphoma, Large-Cell, Anaplastic	D017728	crizotinib	Phase 4	2015	2018	NCT02487316;NCT03707847
Multiple Myeloma	D009101	crizotinib	Phase 2	2015	2017	NCT02693535;NCT04439266;NCT03297606;NCT04439253;NCT02465060
Lymphoma, Non-Hodgkin	D008228	crizotinib	Phase 1	2013	2013	NCT01606878
Lymphoma, Non-Hodgkin	D008228	crizotinib	Phase 2	2009	2017	NCT02693535;NCT03297606;NCT01979536;NCT00939770
Lymphoma, Non-Hodgkin	D008228	crizotinib	Phase 4	2015	2015	NCT02487316
Lung Neoplasms	D008175	crizotinib	Phase 1	2006	2018	NCT01579994;NCT00585195;NCT02277457;NCT02695550;NCT01441128;NCT01121575;NCT03607188;NCT00965731;NCT01998126;NCT02511184
Lung Neoplasms	D008175	crizotinib	Phase 2	2012	2021	NCT01964157;NCT02584634;NCT04211922;NCT02040870;NCT03088930;NCT01970865;NCT01752400;NCT02183870;NCT01685060;NCT01500824;NCT02336451;NCT01685138;NCT04292119;NCT04634110;NCT04084717;NCT04641754;NCT02664935;NCT02465060;NCT04111705;NCT03087448;NCT02314364;NCT03215693;NCT01712217;NCT04621188;NCT03737994;NCT01945021;NCT01822496;NCT01871805;NCT02574078;NCT02134912;NCT03399487
Lung Neoplasms	D008175	crizotinib	Phase 3	2011	2019	NCT02838420;NCT04632758;NCT02075840;NCT02201992;NCT01828112;NCT01639001;NCT02767804;NCT02604342;NCT02737501;NCT01154140
Lung Neoplasms	D008175	crizotinib	Phase 4	2020	2020	NCT04356118
Leukemia, Myeloid	D007951	crizotinib	Phase 2	2015	2015	NCT02638428
Lymphoma	D008223	crizotinib	Phase 1	2011	2013	NCT01121588;NCT01606878
Lymphoma	D008223	crizotinib	Phase 2	2009	2020	NCT01449461;NCT04439266;NCT04292119;NCT04439253;NCT02465060;NCT01979536;NCT02419287;NCT00939770
Lymphoma	D008223	crizotinib	Phase 3	2016	2017	NCT02838420;NCT03194893
Lymphoma	D008223	crizotinib	Phase 4	2015	2018	NCT02487316;NCT03707847
Carcinoma, Renal Cell	D002292	crizotinib	Phase 1	2011	2011	NCT01441388
Carcinoma, Renal Cell	D002292	crizotinib	Phase 2	2012	2020	NCT01524926;NCT04644432;NCT02761057;NCT02465060
Rhabdomyosarcoma	D012208	crizotinib	Phase 2	2012	2012	NCT01524926
Sarcoma, Alveolar Soft Part	D018234	crizotinib	Phase 2	2012	2012	NCT01524926
Sarcoma, Clear Cell	D018227	crizotinib	Phase 2	2012	2012	NCT01524926
Rhabdomyosarcoma, Alveolar	D018232	crizotinib	Phase 2	2012	2012	NCT01524926
Neuroblastoma	D009447	crizotinib	Phase 1	2013	2017	NCT03107988;NCT01606878
Neuroblastoma	D009447	crizotinib	Phase 2	2009	2009	NCT00939770
Neuroblastoma	D009447	crizotinib	Phase 3	2018	2018	NCT03126916
Carcinoma	D002277	crizotinib	Phase 1	2011	2011	NCT01441388;NCT01441128
Carcinoma	D002277	crizotinib	Phase 2	2015	2020	NCT02788201;NCT04644432;NCT02761057;NCT02465060
Carcinoma	D002277	crizotinib	Phase 3	2014	2016	NCT02201992;NCT02737501
Glioblastoma	D005909	crizotinib	Phase 1	2011	2014	NCT01441388;NCT02270034
Carcinoma, Hepatocellular	D006528	crizotinib	Phase 1	2011	2011	NCT01441388
Carcinoma, Hepatocellular	D006528	crizotinib	Phase 2	2015	2015	NCT02465060
Uveal Neoplasms	D014604	crizotinib	Phase 2	2015	2015	NCT02223819
Endometrial Neoplasms	D016889	crizotinib	Phase 2	2015	2019	NCT04030429;NCT02465060
Neoplasms, Plasma Cell	D054219	crizotinib	Phase 2	2015	2015	NCT04439266;NCT04439253;NCT02465060
Urinary Bladder Neoplasms	D001749	crizotinib	Phase 2	2015	2017	NCT02788201;NCT02465060;NCT02612194
Carcinoma, Transitional Cell	D002295	crizotinib	Phase 2	2017	2017	NCT02788201
Kidney Neoplasms	D007680	crizotinib	Phase 2	2015	2020	NCT04644432;NCT02465060
Urogenital Neoplasms	D014565	crizotinib	Phase 2	2020	2020	NCT04644432
Urologic Neoplasms	D014571	crizotinib	Phase 2	2020	2020	NCT04644432
Adenocarcinoma	D000230	crizotinib	Phase 2	2014	2016	NCT02183870;NCT02946359;NCT02664935;NCT02435108
Prostatic Neoplasms	D011471	crizotinib	Phase 1	2014	2014	NCT02207504
Prostatic Neoplasms	D011471	crizotinib	Phase 2	2015	2015	NCT02465060
Neoplasm Metastasis	D009362	crizotinib	Phase 2	2014	2021	NCT02142036;NCT04634110;NCT04193007
Neoplasm Metastasis	D009362	crizotinib	Phase 4	2020	2020	NCT04356118
Neoplasms, Second Primary	D016609	crizotinib	Phase 2	2014	2019	NCT02142036;NCT04193007
Neoplasms, Second Primary	D016609	crizotinib	Phase 4	2020	2020	NCT04356118
Hematologic Neoplasms	D019337	crizotinib	Phase 2	2013	2013	NCT02034981
Adenocarcinoma of Lung	D000077192	crizotinib	Phase 2	2014	2016	NCT02946359;NCT02134912
Carcinoma, Squamous Cell	D002294	crizotinib	Phase 1	2011	2011	NCT01441128
Carcinoma, Squamous Cell	D002294	crizotinib	Phase 2	2015	2015	NCT02664935
Carcinoma, Large Cell	D018287	crizotinib	Phase 1	2011	2011	NCT01441128
Glioma	D005910	crizotinib	Phase 1	2012	2012	NCT01644773
Glioma	D005910	crizotinib	Phase 2	2015	2015	NCT02465060
Ganglioneuroblastoma	D018305	crizotinib	Phase 3	2018	2018	NCT03126916
Gallbladder Neoplasms	D005706	crizotinib	Phase 2	2016	2016	NCT03768375;NCT02836847
Breast Neoplasms	D001943	crizotinib	Phase 1	2014	2014	NCT02074878
Breast Neoplasms	D001943	crizotinib	Phase 2	2015	2019	NCT03620643;NCT02465060
Stomach Neoplasms	D013274	crizotinib	Phase 2	2015	2019	NCT03620643;NCT02465060
Carcinoma, Lobular	D018275	crizotinib	Phase 2	2019	2019	NCT03620643
Carcinoma, Ovarian Epithelial	D000077216	crizotinib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	crizotinib	Phase 2	2015	2015	NCT02465060
Rectal Neoplasms	D012004	crizotinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	crizotinib	Phase 2	2015	2015	NCT02465060
Colonic Neoplasms	D003110	crizotinib	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	crizotinib	Phase 2	2015	2015	NCT02465060
Ureteral Neoplasms	D014516	crizotinib	Phase 2	2016	2016	NCT02612194
Urethral Neoplasms	D014523	crizotinib	Phase 2	2016	2016	NCT02612194
Neurofibromatoses	D017253	crizotinib	Phase 2	2020	2020	NCT04283669
Neurofibromatosis 1	D009456	crizotinib	Phase 2	2020	2020	NCT04283669
Neurofibroma	D009455	crizotinib	Phase 2	2020	2020	NCT04283669
Neurilemmoma	D009442	crizotinib	Phase 2	2020	2020	NCT04283669
Neuroma, Acoustic	D009464	crizotinib	Phase 2	2020	2020	NCT04283669
Neurofibromatosis 2	D016518	crizotinib	Phase 2	2020	2020	NCT04283669
Meningeal Carcinomatosis	D055756	crizotinib	Phase 4	2020	2020	NCT04356118
Melanoma	D008545	dabrafenib	Phase 1	2013	2019	NCT02447939;NCT01767454;NCT02027961;NCT02915666;NCT02097225;NCT02357732;NCT03088176;NCT03026517;NCT03272464;NCT03332589;NCT01940809;NCT02382549;NCT02200562
Melanoma	D008545	dabrafenib	Phase 2	2010	2021	NCT01902173;NCT03149029;NCT02872259;NCT04310397;NCT02858921;NCT02625337;NCT02410863;NCT01266967;NCT01721603;NCT04527549;NCT01989585;NCT01928940;NCT02645149;NCT01978236;NCT02231775;NCT02083354;NCT02977052;NCT02257424;NCT01619774;NCT03754179;NCT02392871;NCT02314143;NCT03949153;NCT02968303;NCT02052193;NCT01972347;NCT03808441;NCT02130466;NCT03352947;NCT01519427;NCT03972046;NCT02296996;NCT02910700;NCT02110355;NCT01701037;NCT03563729;NCT04557956;NCT01726738;NCT03391050;NCT02465060;NCT02143050;NCT04059224;NCT01512251;NCT01153763;NCT02196181;NCT02039947;NCT03455764;NCT02974803;NCT01682213
Melanoma	D008545	dabrafenib	Phase 3	2010	2018	NCT01227889;NCT02967692;NCT02224781;NCT03551626;NCT01682083;NCT01584648;NCT01597908
Melanoma	D008545	dabrafenib	Phase 4	2017	2017	NCT03340506
Skin Neoplasms	D012878	dabrafenib	Phase 1	2013	2014	NCT02097225;NCT01940809
Skin Neoplasms	D012878	dabrafenib	Phase 2	2013	2021	NCT01902173;NCT04310397;NCT04527549;NCT01989585;NCT02231775;NCT02910700;NCT04557956;NCT02465060;NCT02196181
Skin Neoplasms	D012878	dabrafenib	Phase 3	2015	2015	NCT02224781
Thyroid Neoplasms	D013964	dabrafenib	Phase 1	2013	2020	NCT03975231;NCT01947023
Thyroid Neoplasms	D013964	dabrafenib	Phase 2	2012	2021	NCT04238624;NCT01723202;NCT04675710;NCT03244956;NCT04544111;NCT04739566;NCT04619316;NCT02465060;NCT04554680
Thyroid Carcinoma, Anaplastic	D065646	dabrafenib	Phase 1	2020	2020	NCT03975231
Thyroid Carcinoma, Anaplastic	D065646	dabrafenib	Phase 2	2020	2021	NCT04238624;NCT04675710;NCT04739566
Lung Neoplasms	D008175	dabrafenib	Phase 2	2011	2018	NCT02672358;NCT02465060;NCT01336634;NCT03543306
Lung Neoplasms	D008175	dabrafenib	Phase 4	2017	2017	NCT03340506
Carcinoma, Non-Small-Cell Lung	D002289	dabrafenib	Phase 2	2011	2020	NCT02672358;NCT04452877;NCT01336634
Carcinoma, Non-Small-Cell Lung	D002289	dabrafenib	Phase 4	2017	2017	NCT03340506
Glioma	D005910	dabrafenib	Phase 2	2015	2019	NCT02684058;NCT03919071;NCT02465060;NCT04201457
Glioma	D005910	dabrafenib	Phase 4	2017	2019	NCT03340506;NCT03975829
Ameloblastoma	D000564	dabrafenib	Phase 2	2017	2017	NCT02367859
Adamantinoma	D050398	dabrafenib	Phase 2	2017	2017	NCT02367859
Thyroid Cancer, Papillary	D000077273	dabrafenib	Phase 2	2012	2020	NCT01723202;NCT04544111
Adenocarcinoma, Follicular	D018263	dabrafenib	Phase 2	2012	2020	NCT01723202;NCT04544111
Neoplasm Metastasis	D009362	dabrafenib	Phase 1	2018	2018	NCT03332589
Neoplasm Metastasis	D009362	dabrafenib	Phase 2	2011	2019	NCT01266967;NCT01978236;NCT02142036;NCT03972046;NCT02039947;NCT02974803
Sarcoma	D012509	dabrafenib	Phase 3	2019	2019	NCT03784014
Carcinoma	D002277	dabrafenib	Phase 1	2013	2020	NCT03975231;NCT01947023;NCT03878524
Carcinoma	D002277	dabrafenib	Phase 2	2015	2021	NCT04675710;NCT04644432;NCT04739566;NCT02465060;NCT04554680
Multiple Myeloma	D009101	dabrafenib	Phase 1	2017	2020	NCT03091257;NCT03878524
Multiple Myeloma	D009101	dabrafenib	Phase 2	2015	2015	NCT04439292;NCT02465060
Neoplasms, Plasma Cell	D054219	dabrafenib	Phase 1	2017	2020	NCT03091257;NCT03878524
Neoplasms, Plasma Cell	D054219	dabrafenib	Phase 2	2015	2015	NCT04439292;NCT02465060
Glioblastoma	D005909	dabrafenib	Phase 2	2017	2019	NCT02684058;NCT03919071
Glioblastoma	D005909	dabrafenib	Phase 4	2019	2019	NCT03975829
Astrocytoma	D001254	dabrafenib	Phase 2	2017	2019	NCT02684058;NCT03919071
Astrocytoma	D001254	dabrafenib	Phase 4	2019	2019	NCT03975829
Oligodendroglioma	D009837	dabrafenib	Phase 2	2017	2017	NCT02684058
Oligodendroglioma	D009837	dabrafenib	Phase 4	2019	2019	NCT03975829
Ganglioglioma	D018303	dabrafenib	Phase 2	2017	2019	NCT02684058;NCT03919071
Ganglioglioma	D018303	dabrafenib	Phase 4	2019	2019	NCT03975829
Neurocytoma	D018306	dabrafenib	Phase 2	2017	2017	NCT02684058
Neurocytoma	D018306	dabrafenib	Phase 4	2019	2019	NCT03975829
Ganglioneuroma	D005729	dabrafenib	Phase 2	2017	2017	NCT02684058
Ganglioneuroma	D005729	dabrafenib	Phase 4	2019	2019	NCT03975829
Neurofibromatoses	D017253	dabrafenib	Phase 2	2015	2019	NCT02124772;NCT04201457
Neurofibromatoses	D017253	dabrafenib	Phase 4	2019	2019	NCT03975829
Neurofibromatosis 1	D009456	dabrafenib	Phase 2	2019	2019	NCT04201457
Neurofibromatosis 1	D009456	dabrafenib	Phase 4	2019	2019	NCT03975829
Colorectal Neoplasms	D015179	dabrafenib	Phase 1	2020	2020	NCT04294160
Colorectal Neoplasms	D015179	dabrafenib	Phase 2	2012	2018	NCT01750918;NCT03668431;NCT03428126;NCT02465060
Sarcoma, Clear Cell	D018227	dabrafenib	Phase 2	2017	2017	NCT02968303
Adenoma, Oxyphilic	D018249	dabrafenib	Phase 2	2020	2020	NCT04544111
Carcinoma, Renal Cell	D002292	dabrafenib	Phase 2	2015	2020	NCT04644432;NCT02465060
Kidney Neoplasms	D007680	dabrafenib	Phase 2	2015	2020	NCT04644432;NCT02465060
Urogenital Neoplasms	D014565	dabrafenib	Phase 2	2020	2020	NCT04644432
Urologic Neoplasms	D014571	dabrafenib	Phase 2	2020	2020	NCT04644432
Colonic Neoplasms	D003110	dabrafenib	Phase 2	2015	2018	NCT03428126;NCT02465060
Neoplasms, Second Primary	D016609	dabrafenib	Phase 1	2018	2018	NCT03332589
Neoplasms, Second Primary	D016609	dabrafenib	Phase 2	2014	2014	NCT02142036
Brain Neoplasms	D001932	dabrafenib	Phase 2	2013	2016	NCT01677741;NCT02974803
Neurofibroma	D009455	dabrafenib	Phase 2	2015	2019	NCT02124772;NCT04201457
Neurofibroma, Plexiform	D018318	dabrafenib	Phase 2	2015	2015	NCT02124772
Lymphoma	D008223	dabrafenib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	dabrafenib	Phase 2	2015	2015	NCT04439292;NCT02465060
Breast Neoplasms	D001943	dabrafenib	Phase 1	2020	2020	NCT03878524
Breast Neoplasms	D001943	dabrafenib	Phase 2	2015	2015	NCT02465060
Endometrial Neoplasms	D016889	dabrafenib	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	dabrafenib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	dabrafenib	Phase 2	2015	2015	NCT02465060
Prostatic Neoplasms	D011471	dabrafenib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	dabrafenib	Phase 2	2015	2015	NCT02465060
Pancreatic Neoplasms	D010190	dabrafenib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	dabrafenib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	dabrafenib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	dabrafenib	Phase 2	2015	2015	NCT02465060
Urinary Bladder Neoplasms	D001749	dabrafenib	Phase 2	2015	2015	NCT02465060
Rectal Neoplasms	D012004	dabrafenib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	dabrafenib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	dabrafenib	Phase 2	2015	2015	NCT02465060
Leukemia	D007938	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	dabrafenib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	dabrafenib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	dabrafenib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	dabrafenib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	dabrafenib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	dabrafenib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	dabrafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	dabrafenib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	dabrafenib	Phase 1	2020	2020	NCT03878524
Stomach Neoplasms	D013274	dacomitinib	Phase 2	2010	2010	NCT01152853
Head and Neck Neoplasms	D006258	dacomitinib	Phase 2	2008	2011	NCT00768664;NCT01449201
Neoplasms, Squamous Cell	D018307	dacomitinib	Phase 2	2008	2014	NCT00768664;NCT01449201;NCT02268747
Lung Neoplasms	D008175	dacomitinib	Phase 1	2010	2019	NCT03755102;NCT03810807;NCT01918761;NCT01441128;NCT01121575;NCT00971191
Lung Neoplasms	D008175	dacomitinib	Phase 2	2008	2020	NCT04027647;NCT04504071;NCT04339829;NCT01858389;NCT04675008;NCT00769067;NCT01465802
Lung Neoplasms	D008175	dacomitinib	Phase 3	2009	2011	NCT01000025;NCT01360554
Lung Neoplasms	D008175	dacomitinib	Phase 4	2020	2020	NCT04511533
Esophageal Neoplasms	D004938	dacomitinib	Phase 2	2015	2019	NCT03770988;NCT02353936
Carcinoma, Squamous Cell	D002294	dacomitinib	Phase 1	2011	2013	NCT01441128;NCT01737008
Carcinoma, Squamous Cell	D002294	dacomitinib	Phase 2	2011	2019	NCT03770988;NCT01728233;NCT01449201;NCT01608022;NCT02268747;NCT02353936
Triple Negative Breast Neoplasms	D064726	dacomitinib	Phase 1	2013	2013	NCT01920061
Carcinoma	D002277	dacomitinib	Phase 1	2011	2020	NCT01441128;NCT01737008;NCT03878524
Carcinoma	D002277	dacomitinib	Phase 2	2011	2015	NCT01728233;NCT01449201;NCT01608022;NCT02353936
Penile Neoplasms	D010412	dacomitinib	Phase 2	2013	2013	NCT01728233
Carcinoma, Non-Small-Cell Lung	D002289	dacomitinib	Phase 1	2010	2013	NCT01918761;NCT01441128;NCT01121575;NCT01034748;NCT00971191
Carcinoma, Non-Small-Cell Lung	D002289	dacomitinib	Phase 2	2008	2020	NCT00548093;NCT04027647;NCT04504071;NCT04339829;NCT01858389;NCT04675008;NCT00769067;NCT01465802;NCT00553254
Carcinoma, Non-Small-Cell Lung	D002289	dacomitinib	Phase 3	2009	2013	NCT01000025;NCT01360554;NCT01774721
Carcinoma, Non-Small-Cell Lung	D002289	dacomitinib	Phase 4	2020	2020	NCT04511533
Glioblastoma	D005909	dacomitinib	Phase 2	2010	2012	NCT01112527;NCT01520870
Squamous Cell Carcinoma of Head and Neck	D000077195	dacomitinib	Phase 1	2013	2013	NCT01737008
Squamous Cell Carcinoma of Head and Neck	D000077195	dacomitinib	Phase 2	2011	2011	NCT01449201
Colorectal Neoplasms	D015179	dacomitinib	Phase 2	2014	2014	NCT02039336
Esophageal Squamous Cell Carcinoma	D000077277	dacomitinib	Phase 2	2012	2015	NCT01608022;NCT02353936
Neoplasm Metastasis	D009362	dacomitinib	Phase 1	2008	2008	NCT00728390
Neoplasm Metastasis	D009362	dacomitinib	Phase 2	2014	2020	NCT04339829;NCT04675008;NCT02047747
Carcinoma, Large Cell	D018287	dacomitinib	Phase 1	2011	2011	NCT01441128
Brain Neoplasms	D001932	dacomitinib	Phase 2	2012	2020	NCT04339829;NCT01520870;NCT02047747
Mouth Neoplasms	D009062	dacomitinib	Phase 2	2010	2010	NCT01116843
Adenocarcinoma	D000230	dacomitinib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	dacomitinib	Phase 2	2009	2009	NCT00818441
Adenocarcinoma of Lung	D000077192	dacomitinib	Phase 2	2009	2009	NCT00818441
Lymphoma	D008223	dacomitinib	Phase 1	2020	2020	NCT03878524
Breast Neoplasms	D001943	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	dacomitinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	dacomitinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	dacomitinib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	dacomitinib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	dacomitinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	dacomitinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	dacomitinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	dacomitinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	dacomitinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	dacomitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	dacomitinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	dacomitinib	Phase 1	2020	2020	NCT03878524
Sarcoma	D012509	dasatinib	Phase 1	2012	2013	NCT01643278;NCT01916135
Sarcoma	D012509	dasatinib	Phase 2	2007	2008	NCT00464620;NCT00788125
Gastrointestinal Stromal Tumors	D046152	dasatinib	Phase 1	2012	2012	NCT01643278
Gastrointestinal Stromal Tumors	D046152	dasatinib	Phase 2	2007	2008	NCT00464620;NCT00568750
Gastrointestinal Stromal Tumors	D046152	dasatinib	Phase 3	2008	2008	NCT00688766
Carcinoma	D002277	dasatinib	Phase 1	2008	2020	NCT04164069;NCT01440998;NCT01660971;NCT00608361;NCT03878524
Carcinoma	D002277	dasatinib	Phase 2	2007	2017	NCT02059265;NCT00859937;NCT02788201;NCT00563290;NCT01488318;NCT00671788;NCT02465060;NCT00459108;NCT00507767
Cystadenocarcinoma	D003536	dasatinib	Phase 1	2009	2011	NCT01440998;NCT00835679
Cystadenocarcinoma	D003536	dasatinib	Phase 2	2014	2014	NCT02059265
Adenocarcinoma, Clear Cell	D018262	dasatinib	Phase 1	2011	2011	NCT01440998
Adenocarcinoma, Clear Cell	D018262	dasatinib	Phase 2	2014	2014	NCT02059265
Leukemia	D007938	dasatinib	Phase 1	2003	2020	NCT00316953;NCT00324077;NCT00732186;NCT00940524;NCT02680951;NCT00500006;NCT03560908;NCT00306202;NCT02081378;NCT00978731;NCT04603872;NCT03414450;NCT01077544;NCT00872976;NCT00103701;NCT03515200;NCT04580121;NCT00860535;NCT00345826;NCT01397734;NCT02047149;NCT02815059;NCT01751425;NCT03595917;NCT01460498;NCT02494882;NCT01643603;NCT00827138;NCT00892190;NCT00816283;NCT00064233;NCT01426334;NCT00608361;NCT02011945;NCT02819804;NCT02779283;NCT03878524
Leukemia	D007938	dasatinib	Phase 2	2001	2021	NCT01173679;NCT01667133;NCT00298987;NCT01310010;NCT04578847;NCT00866736;NCT01872442;NCT00101660;NCT01392170;NCT00777036;NCT01238211;NCT00391989;NCT02923986;NCT02143414;NCT03654768;NCT01218477;NCT00070499;NCT00982488;NCT00103844;NCT02767063;NCT03516279;NCT00895297;NCT00254423;NCT00364286;NCT00493181;NCT01606579;NCT03023046;NCT00438854;NCT01593254;NCT00829647;NCT01746836;NCT01804985;NCT00482703;NCT02113319;NCT02744768;NCT02689440;NCT01725204;NCT01207440;NCT01441882;NCT01030718;NCT01004497;NCT04006847;NCT01883219;NCT02709083;NCT00850382;NCT01342679;NCT00792948;NCT00337454;NCT01498445;NCT00563290;NCT01051115;NCT04747912;NCT01357655;NCT00852566;NCT00390793;NCT00101595;NCT00529763;NCT03610971;NCT01256398;NCT02420717;NCT01844765;NCT04216563;NCT01690065;NCT00949988;NCT02523976;NCT01802450;NCT00255346;NCT01916785;NCT01724879;NCT01620216;NCT00101816;NCT00036738;NCT02888990;NCT01460160;NCT01602952;NCT04126681;NCT01627132;NCT01887561;NCT03625388;NCT04329325;NCT00320190;NCT00112775;NCT04147533;NCT01850004;NCT01319981;NCT02043587;NCT04233346;NCT00101647;NCT04626024;NCT01876953
Leukemia	D007938	dasatinib	Phase 3	2005	2020	NCT03079505;NCT02883049;NCT02890784;NCT03117751;NCT02108951;NCT04375683;NCT00481247;NCT01460693;NCT03746054;NCT00123474;NCT00720109;NCT03564470;NCT02326311;NCT00549848;NCT02013648;NCT00362466;NCT03020030;NCT00123487;NCT03624530;NCT04530565;NCT00349518
Leukemia	D007938	dasatinib	Phase 4	2012	2019	NCT02690922;NCT02389920;NCT04155411;NCT03216070;NCT01660906;NCT01901666
Leukemia, Myeloid	D007951	dasatinib	Phase 1	2003	2020	NCT00316953;NCT00324077;NCT00732186;NCT02680951;NCT00500006;NCT02081378;NCT00978731;NCT03414450;NCT01077544;NCT00103701;NCT04580121;NCT00860535;NCT00345826;NCT01397734;NCT02047149;NCT01751425;NCT03595917;NCT01460498;NCT01643603;NCT00892190;NCT00816283;NCT00064233;NCT01426334;NCT02011945;NCT02779283;NCT03878524
Leukemia, Myeloid	D007951	dasatinib	Phase 2	2001	2020	NCT01667133;NCT00298987;NCT04578847;NCT00866736;NCT01872442;NCT00101660;NCT02638428;NCT01392170;NCT03205267;NCT01238211;NCT02923986;NCT03654768;NCT00070499;NCT00982488;NCT00103844;NCT02767063;NCT03516279;NCT00895297;NCT00254423;NCT00493181;NCT01606579;NCT01593254;NCT01746836;NCT01804985;NCT00482703;NCT02113319;NCT02689440;NCT01725204;NCT01207440;NCT01030718;NCT04006847;NCT02709083;NCT00850382;NCT01342679;NCT00337454;NCT01498445;NCT00852566;NCT00101595;NCT03610971;NCT01844765;NCT04216563;NCT01690065;NCT01802450;NCT00255346;NCT01916785;NCT01620216;NCT00101816;NCT00036738;NCT01602952;NCT04126681;NCT01627132;NCT01887561;NCT03625388;NCT00320190;NCT00112775;NCT04147533;NCT01850004;NCT04233346;NCT00101647;NCT04626024;NCT01876953
Leukemia, Myeloid	D007951	dasatinib	Phase 3	2005	2019	NCT03079505;NCT02890784;NCT02108951;NCT00481247;NCT01460693;NCT03746054;NCT00123474;NCT02013648;NCT00362466;NCT00123487
Leukemia, Myeloid	D007951	dasatinib	Phase 4	2012	2019	NCT04155411;NCT03216070;NCT01660906;NCT01901666
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	dasatinib	Phase 1	2003	2020	NCT00316953;NCT00324077;NCT00732186;NCT00500006;NCT02081378;NCT00978731;NCT03414450;NCT01077544;NCT00103701;NCT00860535;NCT00345826;NCT01397734;NCT02047149;NCT01751425;NCT03595917;NCT01460498;NCT00827138;NCT00816283;NCT00064233;NCT01426334;NCT02011945;NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	dasatinib	Phase 2	2001	2020	NCT01667133;NCT00298987;NCT04578847;NCT00866736;NCT01872442;NCT00101660;NCT01392170;NCT03205267;NCT03193281;NCT02268370;NCT02923986;NCT03654768;NCT00070499;NCT03573596;NCT00982488;NCT00103844;NCT02767063;NCT03516279;NCT00895297;NCT00254423;NCT00493181;NCT01606579;NCT01593254;NCT01746836;NCT01804985;NCT00482703;NCT02689440;NCT01725204;NCT01207440;NCT01030718;NCT04006847;NCT02709083;NCT01342679;NCT03906292;NCT00337454;NCT01498445;NCT00852566;NCT00390793;NCT00101595;NCT03610971;NCT01844765;NCT04216563;NCT01690065;NCT01802450;NCT01916785;NCT00101816;NCT00036738;NCT01602952;NCT04126681;NCT01627132;NCT01887561;NCT03625388;NCT00320190;NCT00112775;NCT04147533;NCT01850004;NCT04233346;NCT00101647;NCT04626024
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	dasatinib	Phase 3	2005	2019	NCT03079505;NCT02890784;NCT02108951;NCT00481247;NCT01460693;NCT03746054;NCT00123474;NCT02326311;NCT00362466;NCT00123487;NCT00349518
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	dasatinib	Phase 4	2012	2019	NCT02389920;NCT04155411;NCT03216070;NCT01660906;NCT01901666
Leukemia, Myeloid, Chronic-Phase	D015466	dasatinib	Phase 1	2003	2020	NCT00324077;NCT00103701;NCT00064233;NCT01426334;NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	dasatinib	Phase 2	2005	2019	NCT00777036;NCT03205267;NCT03654768;NCT02767063;NCT03516279;NCT00254423;NCT01593254;NCT01746836;NCT02689440;NCT01725204;NCT02709083;NCT03906292;NCT03610971;NCT01887561;NCT03625388;NCT00320190;NCT00112775;NCT01850004
Leukemia, Myeloid, Chronic-Phase	D015466	dasatinib	Phase 3	2005	2017	NCT03079505;NCT01460693;NCT00123474
Leukemia, Myeloid, Chronic-Phase	D015466	dasatinib	Phase 4	2012	2012	NCT01660906
Lung Neoplasms	D008175	dasatinib	Phase 1	2009	2013	NCT00787852;NCT01999985;NCT00779389
Lung Neoplasms	D008175	dasatinib	Phase 2	2006	2016	NCT00826449;NCT00787267;NCT01491633;NCT00470054;NCT00509041;NCT00564876;NCT00570401;NCT02465060;NCT00858403;NCT00459342;NCT02954523
Carcinoma, Non-Small-Cell Lung	D002289	dasatinib	Phase 1	2007	2013	NCT00787852;NCT00444015;NCT01999985
Carcinoma, Non-Small-Cell Lung	D002289	dasatinib	Phase 2	2007	2020	NCT00826449;NCT00787267;NCT00564876;NCT02750514;NCT01514864;NCT04284202;NCT00858403;NCT00459342;NCT02954523
Lymphoma	D008223	dasatinib	Phase 1	2008	2020	NCT04603872;NCT01643603;NCT00608361;NCT01609816;NCT03878524
Lymphoma	D008223	dasatinib	Phase 2	2006	2017	NCT01173679;NCT00364286;NCT03023046;NCT04439305;NCT00918463;NCT00788125;NCT02465060;NCT02043587;NCT00550615
Lymphoma	D008223	dasatinib	Phase 3	2017	2017	NCT03117751
Leukemia, Lymphoid	D007945	dasatinib	Phase 1	2006	2020	NCT00316953;NCT00940524;NCT02081378;NCT04603872;NCT03414450;NCT01077544;NCT00872976;NCT03515200;NCT00860535;NCT02815059;NCT03595917;NCT02494882;NCT01643603;NCT00816283;NCT00608361;NCT02819804;NCT02779283;NCT03878524
Leukemia, Lymphoid	D007945	dasatinib	Phase 2	2001	2021	NCT01173679;NCT01667133;NCT00298987;NCT01310010;NCT00391989;NCT02143414;NCT01361438;NCT00364286;NCT03023046;NCT00438854;NCT00829647;NCT02744768;NCT01207440;NCT01441882;NCT01030718;NCT01004497;NCT01883219;NCT00792948;NCT00563290;NCT01051115;NCT04747912;NCT00390793;NCT00101595;NCT01256398;NCT02420717;NCT00949988;NCT02523976;NCT01724879;NCT01620216;NCT00036738;NCT02888990;NCT01460160;NCT04329325;NCT01319981;NCT02043587
Leukemia, Lymphoid	D007945	dasatinib	Phase 3	2006	2020	NCT02883049;NCT03117751;NCT00720109;NCT00549848;NCT03020030;NCT04530565;NCT00349518
Leukemia, Lymphoid	D007945	dasatinib	Phase 4	2016	2016	NCT02690922
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	dasatinib	Phase 1	2008	2020	NCT00872976;NCT00608361;NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	dasatinib	Phase 2	2006	2011	NCT01173679;NCT00364286;NCT00438854;NCT00829647;NCT01441882;NCT00563290;NCT01051115;NCT00949988
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	dasatinib	Phase 1	2003	2020	NCT00316953;NCT00940524;NCT00500006;NCT02081378;NCT04603872;NCT03414450;NCT01077544;NCT00103701;NCT03515200;NCT00860535;NCT02815059;NCT03595917;NCT02494882;NCT00816283;NCT00608361;NCT02819804;NCT02779283;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	dasatinib	Phase 2	2001	2021	NCT01667133;NCT00298987;NCT01310010;NCT00391989;NCT02143414;NCT01361438;NCT03023046;NCT02744768;NCT01207440;NCT01030718;NCT01004497;NCT01883219;NCT00792948;NCT04747912;NCT00390793;NCT00101595;NCT01256398;NCT02420717;NCT02523976;NCT01724879;NCT01620216;NCT00036738;NCT02888990;NCT01460160;NCT04329325;NCT01319981;NCT02043587;NCT04233346
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	dasatinib	Phase 3	2005	2020	NCT02883049;NCT03117751;NCT04375683;NCT00720109;NCT03564470;NCT00549848;NCT03020030;NCT00123487;NCT03624530;NCT04530565;NCT00349518
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	dasatinib	Phase 4	2016	2016	NCT02690922
Rhabdomyosarcoma	D012208	dasatinib	Phase 2	2007	2017	NCT00464620;NCT03041701
Chondrosarcoma	D002813	dasatinib	Phase 2	2007	2007	NCT00464620
Chordoma	D002817	dasatinib	Phase 2	2007	2007	NCT00464620
Giant Cell Tumors	D005870	dasatinib	Phase 2	2007	2007	NCT00464620
Nerve Sheath Neoplasms	D018317	dasatinib	Phase 2	2007	2007	NCT00464620
Neurofibrosarcoma	D018319	dasatinib	Phase 2	2007	2007	NCT00464620
Hemangiopericytoma	D006393	dasatinib	Phase 2	2007	2007	NCT00464620
Bone Neoplasms	D001859	dasatinib	Phase 2	2007	2007	NCT00464620;NCT00566618
Giant Cell Tumor of Bone	D018212	dasatinib	Phase 2	2007	2007	NCT00464620
Sarcoma, Ewing	D012512	dasatinib	Phase 2	2007	2007	NCT00464620
Neuroectodermal Tumors, Primitive, Peripheral	D018241	dasatinib	Phase 2	2007	2007	NCT00464620
Sarcoma, Alveolar Soft Part	D018234	dasatinib	Phase 2	2007	2007	NCT00464620
Blast Crisis	D001752	dasatinib	Phase 1	2003	2020	NCT00316953;NCT03414450;NCT00103701;NCT00860535;NCT03595917;NCT00816283;NCT03878524
Blast Crisis	D001752	dasatinib	Phase 2	2004	2012	NCT01498445;NCT00390793;NCT00101595;NCT01690065;NCT00101816
Leukemia, Myeloid, Accelerated Phase	D015465	dasatinib	Phase 1	2006	2020	NCT00316953;NCT01426334;NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	dasatinib	Phase 2	2004	2004	NCT00101647
Leukemia, Myeloid, Accelerated Phase	D015465	dasatinib	Phase 3	2005	2005	NCT00123487
Breast Neoplasms	D001943	dasatinib	Phase 1	2007	2020	NCT00452673;NCT03878524
Breast Neoplasms	D001943	dasatinib	Phase 2	2006	2017	NCT00820170;NCT00566618;NCT01471106;NCT00817531;NCT01306942;NCT00767520;NCT02720185;NCT00696072;NCT00924352;NCT02465060;NCT00371345;NCT00754325;NCT00371254;NCT00780676;NCT00903006;NCT00546104;NCT00410813
Endometrial Neoplasms	D016889	dasatinib	Phase 1	2011	2012	NCT01482728;NCT01440998
Endometrial Neoplasms	D016889	dasatinib	Phase 2	2015	2015	NCT02465060
Neoplasm Metastasis	D009362	dasatinib	Phase 1	2009	2009	NCT00835679
Neoplasm Metastasis	D009362	dasatinib	Phase 2	2007	2014	NCT00566618;NCT02142036;NCT01703910
Neoplasms, Second Primary	D016609	dasatinib	Phase 2	2007	2014	NCT00566618;NCT02142036
Colorectal Neoplasms	D015179	dasatinib	Phase 1	2007	2019	NCT04164069;NCT00920868;NCT00501410
Colorectal Neoplasms	D015179	dasatinib	Phase 2	2012	2015	NCT02465060;NCT01703910
Polycythemia Vera	D011087	dasatinib	Phase 2	2005	2007	NCT00538980;NCT00255346
Glioblastoma	D005909	dasatinib	Phase 1	2008	2009	NCT00734864;NCT00895960;NCT00609999
Glioblastoma	D005909	dasatinib	Phase 2	2007	2009	NCT00869401;NCT00423735;NCT00892177;NCT00948389
Glioma	D005910	dasatinib	Phase 1	2009	2012	NCT00734864;NCT01644773;NCT00996723
Glioma	D005910	dasatinib	Phase 2	2014	2017	NCT02233049;NCT03352427;NCT02465060
Astrocytoma	D001254	dasatinib	Phase 1	2009	2009	NCT00734864
Gliosarcoma	D018316	dasatinib	Phase 1	2008	2009	NCT00734864;NCT00609999
Gliosarcoma	D018316	dasatinib	Phase 2	2007	2007	NCT00423735
Oligodendroglioma	D009837	dasatinib	Phase 1	2009	2009	NCT00734864
Leukemia, Myeloid, Acute	D015470	dasatinib	Phase 1	2011	2020	NCT02680951;NCT03560908;NCT04580121;NCT00892190;NCT02779283;NCT03878524
Leukemia, Myeloid, Acute	D015470	dasatinib	Phase 2	2005	2017	NCT01238211;NCT02923986;NCT01606579;NCT02113319;NCT00850382;NCT01690065;NCT00255346;NCT01620216;NCT01876953
Leukemia, Myeloid, Acute	D015470	dasatinib	Phase 3	2014	2014	NCT02013648
Salivary Gland Neoplasms	D012468	dasatinib	Phase 2	2007	2014	NCT00859937;NCT02558387;NCT00507767
Carcinoma, Adenoid Cystic	D003528	dasatinib	Phase 2	2009	2009	NCT00859937
Rhabdomyosarcoma, Alveolar	D018232	dasatinib	Phase 2	2017	2017	NCT03041701
Preleukemia	D011289	dasatinib	Phase 1	2011	2020	NCT01643603;NCT00892190;NCT03878524
Preleukemia	D011289	dasatinib	Phase 2	2005	2017	NCT02923986;NCT00255346
Multiple Myeloma	D009101	dasatinib	Phase 1	2008	2020	NCT04603872;NCT00560352;NCT00560391;NCT01643603;NCT01609816;NCT03878524
Multiple Myeloma	D009101	dasatinib	Phase 2	2007	2017	NCT04439305;NCT03297606;NCT00429949;NCT01116128;NCT02465060
Neoplasms, Plasma Cell	D054219	dasatinib	Phase 1	2008	2020	NCT04603872;NCT00560352;NCT00560391;NCT01609816;NCT03878524
Neoplasms, Plasma Cell	D054219	dasatinib	Phase 2	2007	2016	NCT04439305;NCT00429949;NCT01116128;NCT02465060
Lymphoma, Non-Hodgkin	D008228	dasatinib	Phase 1	2008	2020	NCT04603872;NCT01643603;NCT00608361;NCT01609816;NCT03878524
Lymphoma, Non-Hodgkin	D008228	dasatinib	Phase 2	2007	2017	NCT03023046;NCT03297606;NCT02043587;NCT00550615
Hematologic Neoplasms	D019337	dasatinib	Phase 1	2012	2020	NCT01643603;NCT03878524
Hematologic Neoplasms	D019337	dasatinib	Phase 4	2016	2016	NCT03844360
Small Cell Lung Carcinoma	D055752	dasatinib	Phase 2	2007	2007	NCT00470054
Pinealoma	D010871	dasatinib	Phase 2	2016	2016	NCT02596828
Nervous System Neoplasms	D009423	dasatinib	Phase 2	2008	2009	NCT00869401;NCT00788125
Central Nervous System Neoplasms	D016543	dasatinib	Phase 2	2008	2009	NCT00869401;NCT00788125
Mastocytosis	D008415	dasatinib	Phase 2	2005	2009	NCT00979160;NCT00255346
Mastocytosis, Systemic	D034721	dasatinib	Phase 2	2009	2009	NCT00979160
Prostatic Neoplasms	D011471	dasatinib	Phase 1	2013	2020	NCT01826838;NCT03878524
Prostatic Neoplasms	D011471	dasatinib	Phase 2	2007	2015	NCT01254864;NCT00385580;NCT00936975;NCT01685125;NCT02465060;NCT01260688;NCT00570700;NCT00860158;NCT01990196;NCT00918385;NCT00439270
Prostatic Neoplasms	D011471	dasatinib	Phase 3	2008	2008	NCT00744497
Melanoma	D008545	dasatinib	Phase 1	2013	2013	NCT01916135
Melanoma	D008545	dasatinib	Phase 2	2006	2015	NCT00436605;NCT02465060;NCT00597038;NCT00700882;NCT01876212;NCT01092728
Neoplasm, Residual	D018365	dasatinib	Phase 1	2012	2013	NCT01751425;NCT01460498
Neoplasm, Residual	D018365	dasatinib	Phase 2	2013	2018	NCT03516279;NCT01883219
Neoplasm, Residual	D018365	dasatinib	Phase 3	2018	2018	NCT03624530
Adenocarcinoma	D000230	dasatinib	Phase 1	2007	2020	NCT01440998;NCT00835679;NCT00598091;NCT03878524
Adenocarcinoma	D000230	dasatinib	Phase 2	2007	2012	NCT00474812;NCT01234935;NCT01652976;NCT01703910
Pancreatic Neoplasms	D010190	dasatinib	Phase 1	2012	2020	NCT01660971;NCT03878524
Pancreatic Neoplasms	D010190	dasatinib	Phase 2	2007	2015	NCT00474812;NCT01234935;NCT02465060;NCT01652976;NCT00544908;NCT01395017
Triple Negative Breast Neoplasms	D064726	dasatinib	Phase 2	2006	2017	NCT00817531;NCT02720185;NCT00371254
Neuroblastoma	D009447	dasatinib	Phase 2	2008	2015	NCT01467986;NCT00788125;NCT02559778
Urinary Bladder Neoplasms	D001749	dasatinib	Phase 2	2015	2017	NCT02788201;NCT02465060
Carcinoma, Transitional Cell	D002295	dasatinib	Phase 1	2011	2011	NCT01440998
Carcinoma, Transitional Cell	D002295	dasatinib	Phase 2	2017	2017	NCT02788201
Cystadenocarcinoma, Serous	D018284	dasatinib	Phase 1	2011	2011	NCT01440998
Carcinoma, Endometrioid	D018269	dasatinib	Phase 1	2011	2011	NCT01440998
Adenocarcinoma, Mucinous	D002288	dasatinib	Phase 1	2009	2011	NCT01440998;NCT00835679
Mesothelioma	D008654	dasatinib	Phase 1	2008	2008	NCT00652574
Mesothelioma	D008654	dasatinib	Phase 2	2007	2007	NCT00509041
Brain Neoplasms	D001932	dasatinib	Phase 1	2015	2015	NCT02389309
Brain Neoplasms	D001932	dasatinib	Phase 2	2007	2007	NCT00423735
Carcinoma, Acinar Cell	D018267	dasatinib	Phase 2	2011	2011	NCT01234935
Rectal Neoplasms	D012004	dasatinib	Phase 1	2009	2009	NCT00835679
Rectal Neoplasms	D012004	dasatinib	Phase 2	2007	2015	NCT00504153;NCT02465060
Colonic Neoplasms	D003110	dasatinib	Phase 1	2009	2009	NCT00835679
Colonic Neoplasms	D003110	dasatinib	Phase 2	2007	2015	NCT00504153;NCT02465060
Liver Neoplasms	D008113	dasatinib	Phase 1	2008	2009	NCT00835679;NCT00608361
Liver Neoplasms	D008113	dasatinib	Phase 2	2007	2008	NCT00788125;NCT00459108
Leukemia, B-Cell	D015448	dasatinib	Phase 3	2016	2016	NCT03564470
Lymphoma, B-Cell	D016393	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, B-Cell	D016393	dasatinib	Phase 2	2009	2009	NCT00918463
Lymphoma, Large B-Cell, Diffuse	D016403	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, Large B-Cell, Diffuse	D016403	dasatinib	Phase 2	2009	2009	NCT00918463
Neoplasms, Germ Cell and Embryonal	D009373	dasatinib	Phase 2	2008	2008	NCT00788125
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	D054218	dasatinib	Phase 1	2008	2008	NCT00608361
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	D054218	dasatinib	Phase 2	2009	2009	NCT00792948
Carcinoma, Squamous Cell	D002294	dasatinib	Phase 2	2007	2011	NCT00563290;NCT01488318;NCT00507767
Skin Neoplasms	D012878	dasatinib	Phase 2	2007	2015	NCT00563290;NCT02465060
Hodgkin Disease	D006689	dasatinib	Phase 1	2008	2020	NCT01643603;NCT00608361;NCT01609816;NCT03878524
Brain Stem Neoplasms	D020295	dasatinib	Phase 2	2017	2017	NCT03352427
Squamous Cell Carcinoma of Head and Neck	D000077195	dasatinib	Phase 2	2011	2011	NCT01488318
Ovarian Neoplasms	D010051	dasatinib	Phase 1	2007	2007	NCT00672295
Ovarian Neoplasms	D010051	dasatinib	Phase 2	2015	2015	NCT02465060
Fallopian Tube Neoplasms	D005185	dasatinib	Phase 1	2007	2007	NCT00672295
Carcinoma, Ovarian Epithelial	D000077216	dasatinib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	dasatinib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	dasatinib	Phase 2	2015	2015	NCT02465060
Thyroid Neoplasms	D013964	dasatinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	dasatinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	dasatinib	Phase 1	2008	2008	NCT00608361
Carcinoma, Hepatocellular	D006528	dasatinib	Phase 2	2007	2015	NCT02465060;NCT00459108
Carcinoma, Renal Cell	D002292	dasatinib	Phase 2	2015	2015	NCT02465060
Kidney Neoplasms	D007680	dasatinib	Phase 2	2015	2015	NCT02465060
Leukemia, Myelomonocytic, Chronic	D015477	dasatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	dasatinib	Phase 2	2005	2012	NCT00255346;NCT01620216
Head and Neck Neoplasms	D006258	dasatinib	Phase 1	2009	2009	NCT00882583;NCT00779389
Head and Neck Neoplasms	D006258	dasatinib	Phase 2	2007	2014	NCT02558387;NCT00507767
Leukemia, Myelomonocytic, Juvenile	D054429	dasatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	dasatinib	Phase 2	2012	2012	NCT01620216
Burkitt Lymphoma	D002051	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, Follicular	D008224	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, Mantle-Cell	D020522	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, B-Cell, Marginal Zone	D018442	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, T-Cell	D016399	dasatinib	Phase 1	2008	2008	NCT00608361
Mycosis Fungoides	D009182	dasatinib	Phase 1	2008	2015	NCT00608361;NCT01609816
Sezary Syndrome	D012751	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, T-Cell, Cutaneous	D016410	dasatinib	Phase 1	2008	2008	NCT00608361
Leukemia, T-Cell	D015458	dasatinib	Phase 1	2008	2008	NCT00608361
Leukemia-Lymphoma, Adult T-Cell	D015459	dasatinib	Phase 1	2008	2008	NCT00608361
Waldenstrom Macroglobulinemia	D008258	dasatinib	Phase 1	2008	2019	NCT00608361;NCT04115059
Lymphoma, Large-Cell, Anaplastic	D017728	dasatinib	Phase 1	2008	2008	NCT00608361
Leukemia, Hairy Cell	D007943	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphomatoid Granulomatosis	D008230	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, Extranodal NK-T-Cell	D054391	dasatinib	Phase 1	2008	2008	NCT00608361
Intraocular Lymphoma	D064090	dasatinib	Phase 1	2008	2008	NCT00608361
Leukemia, Large Granular Lymphocytic	D054066	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, T-Cell, Peripheral	D016411	dasatinib	Phase 1	2008	2008	NCT00608361
Plasmablastic Lymphoma	D000069293	dasatinib	Phase 1	2008	2008	NCT00608361
Lymphoma, Large-Cell, Immunoblastic	D016400	dasatinib	Phase 1	2008	2008	NCT00608361
Laryngeal Neoplasms	D007822	dasatinib	Phase 2	2007	2007	NCT00507767
Oropharyngeal Neoplasms	D009959	dasatinib	Phase 2	2007	2007	NCT00507767
Carcinoma, Verrucous	D018289	dasatinib	Phase 2	2007	2007	NCT00507767
Nasopharyngeal Carcinoma	D000077274	dasatinib	Phase 2	2007	2007	NCT00507767
Paranasal Sinus Neoplasms	D010255	dasatinib	Phase 2	2007	2007	NCT00507767
Neoplasms, Unknown Primary	D009382	dasatinib	Phase 2	2007	2007	NCT00507767
Tongue Neoplasms	D014062	dasatinib	Phase 2	2007	2007	NCT00507767
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	dasatinib	Phase 1	2020	2020	NCT03878524
Cholangiocarcinoma	D018281	dasatinib	Phase 2	2015	2015	NCT02428855
Hematologic Neoplasms	D019337	duvelisib	Phase 1	2011	2017	NCT01476657;NCT03757000
Hematologic Neoplasms	D019337	duvelisib	Phase 2	2016	2016	NCT02711852
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	duvelisib	Phase 1	2013	2019	NCT02292225;NCT03892044;NCT01871675;NCT03757000;NCT02640833
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	duvelisib	Phase 2	2014	2020	NCT03534323;NCT02158091;NCT03370185;NCT03961672;NCT04209621
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	duvelisib	Phase 3	2013	2015	NCT02576275;NCT02049515;NCT02004522
Lymphoma	D008223	duvelisib	Phase 1	2013	2021	NCT03892044;NCT02783625;NCT01871675;NCT04639843;NCT02598570;NCT02640833
Lymphoma	D008223	duvelisib	Phase 2	2013	2020	NCT02605694;NCT04038359;NCT04707079;NCT02391545;NCT04331119;NCT03372057;NCT04379167;NCT01882803;NCT03370185;NCT03961672
Lymphoma	D008223	duvelisib	Phase 3	2013	2015	NCT02576275;NCT02049515;NCT02004522;NCT02204982
Leukemia	D007938	duvelisib	Phase 1	2013	2019	NCT03892044;NCT01871675;NCT02640833
Leukemia	D007938	duvelisib	Phase 2	2013	2020	NCT02028039;NCT03534323;NCT02158091;NCT03370185;NCT03961672;NCT04209621
Leukemia	D007938	duvelisib	Phase 3	2013	2013	NCT02049515;NCT02004522
Lymphoma, Follicular	D008224	duvelisib	Phase 1	2019	2019	NCT03892044
Lymphoma, Follicular	D008224	duvelisib	Phase 2	2014	2020	NCT02605694;NCT04707079;NCT02391545;NCT04379167
Lymphoma, Follicular	D008224	duvelisib	Phase 3	2014	2015	NCT02576275;NCT02204982
Leukemia, Lymphoid	D007945	duvelisib	Phase 1	2013	2019	NCT03892044;NCT01871675;NCT02640833
Leukemia, Lymphoid	D007945	duvelisib	Phase 2	2013	2020	NCT02028039;NCT03534323;NCT02158091;NCT03370185;NCT03961672;NCT04209621
Leukemia, Lymphoid	D007945	duvelisib	Phase 3	2013	2013	NCT02049515;NCT02004522
Lymphoma, B-Cell	D016393	duvelisib	Phase 1	2017	2019	NCT03892044;NCT03757000
Lymphoma, B-Cell	D016393	duvelisib	Phase 2	2020	2020	NCT04331119
Lymphoma, Large B-Cell, Diffuse	D016403	duvelisib	Phase 1	2019	2019	NCT03892044
Lymphoma, Non-Hodgkin	D008228	duvelisib	Phase 1	2013	2016	NCT01871675;NCT02640833
Lymphoma, Non-Hodgkin	D008228	duvelisib	Phase 2	2013	2019	NCT04038359;NCT01882803
Lymphoma, Non-Hodgkin	D008228	duvelisib	Phase 3	2015	2015	NCT02576275
Lymphoma, B-Cell, Marginal Zone	D018442	duvelisib	Phase 3	2015	2015	NCT02576275
Mycosis Fungoides	D009182	duvelisib	Phase 1	2021	2021	NCT04652960
Sezary Syndrome	D012751	duvelisib	Phase 1	2021	2021	NCT04652960
Melanoma	D008545	duvelisib	Phase 2	2021	2021	NCT04688658
Lymphoma, T-Cell	D016399	duvelisib	Phase 1	2013	2021	NCT02783625;NCT01871675;NCT04639843
Lymphoma, T-Cell	D016399	duvelisib	Phase 2	2018	2018	NCT03372057
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	duvelisib	Phase 2	2013	2013	NCT02028039
Carcinoma, Squamous Cell	D002294	duvelisib	Phase 2	2020	2020	NCT04193293
Squamous Cell Carcinoma of Head and Neck	D000077195	duvelisib	Phase 2	2020	2020	NCT04193293
Lymphoma, T-Cell, Peripheral	D016411	duvelisib	Phase 2	2018	2018	NCT03372057
Leukemia, T-Cell	D015458	duvelisib	Phase 1	2021	2021	NCT04639843
Leukemia-Lymphoma, Adult T-Cell	D015459	duvelisib	Phase 1	2021	2021	NCT04639843
Lymphoma, Extranodal NK-T-Cell	D054391	duvelisib	Phase 1	2021	2021	NCT04639843
Enteropathy-Associated T-Cell Lymphoma	D058527	duvelisib	Phase 1	2021	2021	NCT04639843
Colorectal Neoplasms	D015179	encorafenib	Phase 1	2016	2016	NCT02857270
Colorectal Neoplasms	D015179	encorafenib	Phase 2	2012	2020	NCT04017650;NCT04044430;NCT02278133;NCT03693170;NCT01719380
Colorectal Neoplasms	D015179	encorafenib	Phase 3	2016	2020	NCT04607421;NCT02928224;NCT03803553
Melanoma	D008545	encorafenib	Phase 1	2011	2021	NCT04759846;NCT04741997;NCT03026517;NCT01436656;NCT03864042;NCT03878719
Melanoma	D008545	encorafenib	Phase 2	2012	2021	NCT04511013;NCT02159066;NCT04221438;NCT01894672;NCT04074096;NCT02631447;NCT01820364;NCT02902042;NCT03911869;NCT01519427;NCT02263898;NCT03235245;NCT03563729;NCT04720768;NCT03898908;NCT01777776;NCT04655157
Melanoma	D008545	encorafenib	Phase 3	2013	2021	NCT04657991;NCT01909453
Skin Neoplasms	D012878	encorafenib	Phase 2	2020	2020	NCT04511013;NCT04221438
Lung Neoplasms	D008175	encorafenib	Phase 2	2015	2021	NCT02109653;NCT04526782;NCT03915951
Carcinoma, Non-Small-Cell Lung	D002289	encorafenib	Phase 1	2016	2016	NCT02857270
Carcinoma, Non-Small-Cell Lung	D002289	encorafenib	Phase 2	2015	2021	NCT02109653;NCT04526782;NCT03915951;NCT04585815
Carcinoma	D002277	encorafenib	Phase 2	2019	2021	NCT04017650;NCT04390243;NCT04061980
Adenocarcinoma	D000230	encorafenib	Phase 2	2019	2020	NCT04017650;NCT04044430
Rectal Neoplasms	D012004	encorafenib	Phase 2	2019	2020	NCT04017650;NCT04044430
Colonic Neoplasms	D003110	encorafenib	Phase 2	2020	2020	NCT04044430
Hematologic Neoplasms	D019337	encorafenib	Phase 2	2014	2014	NCT01981187
Neoplasm Metastasis	D009362	encorafenib	Phase 2	2019	2019	NCT03911869;NCT03898908
Neoplasms, Second Primary	D016609	encorafenib	Phase 2	2019	2019	NCT03911869
Brain Neoplasms	D001932	encorafenib	Phase 2	2019	2019	NCT03911869
Pancreatic Neoplasms	D010190	encorafenib	Phase 2	2021	2021	NCT04390243
Thyroid Neoplasms	D013964	encorafenib	Phase 2	2020	2020	NCT04061980
Leukemia, Hairy Cell	D007943	encorafenib	Phase 2	2020	2020	NCT04324112
Glioblastoma	D005909	encorafenib	Phase 2	2019	2019	NCT03973918
Astrocytoma	D001254	encorafenib	Phase 2	2019	2019	NCT03973918
Gliosarcoma	D018316	encorafenib	Phase 2	2019	2019	NCT03973918
Multiple Myeloma	D009101	encorafenib	Phase 2	2016	2016	NCT02834364
Neoplasms, Plasma Cell	D054219	encorafenib	Phase 2	2016	2016	NCT02834364
Carcinoma, Non-Small-Cell Lung	D002289	entrectinib	Phase 2	2015	2021	NCT02568267;NCT04302025;NCT04621188
Carcinoma, Non-Small-Cell Lung	D002289	entrectinib	Phase 3	2017	2021	NCT03178552;NCT04603807
Colorectal Neoplasms	D015179	entrectinib	Phase 2	2015	2015	NCT02568267
Melanoma	D008545	entrectinib	Phase 2	2015	2021	NCT02568267;NCT04589832;NCT02587650
Pancreatic Neoplasms	D010190	entrectinib	Phase 2	2015	2015	NCT02568267
Sarcoma	D012509	entrectinib	Phase 1	2016	2016	NCT03056599
Sarcoma	D012509	entrectinib	Phase 2	2015	2015	NCT02568267
Ovarian Neoplasms	D010051	entrectinib	Phase 2	2015	2015	NCT02568267
Brain Neoplasms	D001932	entrectinib	Phase 2	2015	2015	NCT02568267
Thyroid Neoplasms	D013964	entrectinib	Phase 2	2015	2015	NCT02568267
Neuroendocrine Tumors	D018358	entrectinib	Phase 2	2015	2015	NCT02568267
Cholangiocarcinoma	D018281	entrectinib	Phase 2	2015	2015	NCT02568267
Salivary Gland Neoplasms	D012468	entrectinib	Phase 2	2015	2015	NCT02568267
Head and Neck Neoplasms	D006258	entrectinib	Phase 2	2015	2015	NCT02568267
Thyroid Cancer, Papillary	D000077273	entrectinib	Phase 2	2015	2015	NCT02568267
Lymphoma, Large-Cell, Anaplastic	D017728	entrectinib	Phase 2	2015	2015	NCT02568267
Lung Neoplasms	D008175	entrectinib	Phase 2	2020	2021	NCT04302025;NCT04621188
Lung Neoplasms	D008175	entrectinib	Phase 3	2017	2017	NCT03178552
Neoplasms, Unknown Primary	D009382	entrectinib	Phase 2	2018	2018	NCT03498521
Carcinoma	D002277	entrectinib	Phase 2	2021	2021	NCT04551495
Breast Neoplasms	D001943	entrectinib	Phase 2	2021	2021	NCT04551495
Carcinoma, Lobular	D018275	entrectinib	Phase 2	2021	2021	NCT04551495
Neoplasm Metastasis	D009362	entrectinib	Phase 1	2014	2014	NCT02097810
Uveal Neoplasms	D014604	entrectinib	Phase 2	2021	2021	NCT04589832
Gastrointestinal Neoplasms	D005770	entrectinib	Phase 2	2020	2020	NCT04591431
Skin Neoplasms	D012878	entrectinib	Phase 2	2015	2015	NCT02587650
Central Nervous System Neoplasms	D016543	entrectinib	Phase 2	2016	2016	NCT02650401
Multiple Myeloma	D009101	erdafitinib	Phase 2	2015	2019	NCT02952573;NCT03732703;NCT02465060
Neoplasms, Plasma Cell	D054219	erdafitinib	Phase 2	2015	2019	NCT02952573;NCT03732703;NCT02465060
Carcinoma	D002277	erdafitinib	Phase 2	2015	2021	NCT03999515;NCT04754425;NCT02465060;NCT02421185
Prostatic Neoplasms	D011471	erdafitinib	Phase 2	2015	2021	NCT03999515;NCT04754425;NCT02465060
Carcinoma, Transitional Cell	D002295	erdafitinib	Phase 2	2018	2018	NCT03473743
Lung Neoplasms	D008175	erdafitinib	Phase 2	2015	2019	NCT03827850;NCT02465060;NCT02699606
Carcinoma, Neuroendocrine	D018278	erdafitinib	Phase 2	2021	2021	NCT04754425
Carcinoma, Small Cell	D018288	erdafitinib	Phase 2	2021	2021	NCT04754425
Breast Neoplasms	D001943	erdafitinib	Phase 1	2017	2017	NCT03238196
Breast Neoplasms	D001943	erdafitinib	Phase 2	2015	2015	NCT02465060
Urinary Bladder Neoplasms	D001749	erdafitinib	Phase 2	2015	2020	NCT04172675;NCT02465060
Lymphoma	D008223	erdafitinib	Phase 2	2015	2017	NCT02465060;NCT03210714;NCT03155620
Melanoma	D008545	erdafitinib	Phase 2	2015	2015	NCT02465060
Glioma	D005910	erdafitinib	Phase 2	2015	2017	NCT02465060;NCT03210714;NCT03155620
Colorectal Neoplasms	D015179	erdafitinib	Phase 2	2015	2015	NCT02465060
Endometrial Neoplasms	D016889	erdafitinib	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	erdafitinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	erdafitinib	Phase 2	2015	2015	NCT02465060
Pancreatic Neoplasms	D010190	erdafitinib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	erdafitinib	Phase 2	2015	2016	NCT02465060;NCT02699606
Stomach Neoplasms	D013274	erdafitinib	Phase 2	2015	2015	NCT02465060
Rectal Neoplasms	D012004	erdafitinib	Phase 2	2015	2015	NCT02465060
Thyroid Neoplasms	D013964	erdafitinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	erdafitinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	erdafitinib	Phase 2	2015	2015	NCT02465060;NCT02421185
Colonic Neoplasms	D003110	erdafitinib	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	erdafitinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Renal Cell	D002292	erdafitinib	Phase 2	2015	2015	NCT02465060
Kidney Neoplasms	D007680	erdafitinib	Phase 2	2015	2015	NCT02465060
Sarcoma	D012509	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Lymphoma, Non-Hodgkin	D008228	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Neuroblastoma	D009447	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Osteosarcoma	D012516	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Rhabdomyosarcoma	D012208	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Ependymoma	D004806	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Sarcoma, Ewing	D012512	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Medulloblastoma	D008527	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Neuroectodermal Tumors	D017599	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Neuroectodermal Tumors, Primitive	D018242	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Wilms Tumor	D009396	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Neuroectodermal Tumors, Primitive, Peripheral	D018241	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Rhabdoid Tumor	D018335	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Nervous System Neoplasms	D009423	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Central Nervous System Neoplasms	D016543	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Hepatoblastoma	D018197	erdafitinib	Phase 2	2017	2017	NCT03210714;NCT03155620
Neoplasms, Germ Cell and Embryonal	D009373	erdafitinib	Phase 2	2017	2017	NCT03155620
Histiocytic Sarcoma	D054747	erdafitinib	Phase 2	2017	2017	NCT03155620
Carcinoma, Non-Small-Cell Lung	D002289	erdafitinib	Phase 2	2016	2016	NCT02699606
Cholangiocarcinoma	D018281	erdafitinib	Phase 2	2016	2016	NCT02699606
Carcinoma	D002277	erlotinib	Phase 1	2001	2020	NCT00047346;NCT00079053;NCT00254384;NCT01515137;NCT00954226;NCT00823290;NCT00049283;NCT00397384;NCT01660971;NCT01288430;NCT00113347;NCT01115803;NCT00878163;NCT01332279;NCT00049166;NCT00966472;NCT00030498;NCT03878524
Carcinoma	D002277	erlotinib	Phase 2	2002	2021	NCT00391586;NCT00910676;NCT00031993;NCT00942734;NCT01294306;NCT01454180;NCT00392665;NCT04172779;NCT03486509;NCT00410826;NCT00193258;NCT00522249;NCT01009203;NCT02788201;NCT00055913;NCT04644432;NCT01192815;NCT00602030;NCT00353301;NCT00047333;NCT00369512;NCT01608022;NCT00081614;NCT00287222;NCT01927744;NCT01180959;NCT00033462;NCT01688973;NCT00101348;NCT02169284;NCT00950365;NCT00737243;NCT00476476;NCT01316757;NCT02039674;NCT00063895;NCT00830245;NCT00832637;NCT00242502;NCT01198028;NCT00749892;NCT01093222;NCT02353936;NCT00791544;NCT00532441;NCT02748707;NCT00055770;NCT01064479;NCT02273362;NCT01465815;NCT01306045
Carcinoma	D002277	erlotinib	Phase 3	2006	2016	NCT01149122;NCT00448240;NCT01752205;NCT02193282;NCT02775006;NCT00901901;NCT01523587;NCT00442455;NCT00673049;NCT02926638
Carcinoma, Non-Small-Cell Lung	D002289	erlotinib	Phase 1	2001	2020	NCT00692640;NCT00633529;NCT00042835;NCT02013219;NCT02157883;NCT01069757;NCT02468661;NCT04449874;NCT00254384;NCT01594398;NCT00569114;NCT02134886;NCT00072072;NCT00738335;NCT02277457;NCT00934076;NCT01302808;NCT00975767;NCT00088959;NCT01193881;NCT00397384;NCT00702182;NCT02507375;NCT01121575;NCT01545947;NCT01570296;NCT00444015;NCT01251796;NCT01288430;NCT00777699;NCT00294736;NCT00619424;NCT01090011;NCT00993499;NCT01115803;NCT00456833;NCT00581789;NCT02206763;NCT01515969;NCT01454102;NCT01839955;NCT00536861;NCT01602289;NCT03050411;NCT01199068;NCT02342353;NCT02040064;NCT02991651;NCT01998126;NCT02364609;NCT01026844;NCT00030498;NCT02080078;NCT01911507;NCT00975182;NCT01859026;NCT00729742;NCT00707252
Carcinoma, Non-Small-Cell Lung	D002289	erlotinib	Phase 2	2002	2020	NCT00391586;NCT00910676;NCT00087412;NCT00826449;NCT01204307;NCT01728181;NCT02716311;NCT01211483;NCT02098954;NCT00370383;NCT01248247;NCT00732810;NCT00701558;NCT00940875;NCT00294762;NCT00997334;NCT00251589;NCT01998919;NCT02355431;NCT00553462;NCT03126799;NCT01027598;NCT00408499;NCT00871923;NCT01104155;NCT00596648;NCT01928160;NCT01294306;NCT00855894;NCT00351039;NCT00973310;NCT01378962;NCT01217619;NCT00531960;NCT00592007;NCT02738983;NCT01350817;NCT00642473;NCT00339586;NCT00283634;NCT00548093;NCT00281021;NCT00387322;NCT01130779;NCT02064491;NCT01091376;NCT01573702;NCT00801385;NCT00312728;NCT03497767;NCT03799094;NCT00840125;NCT00062101;NCT02747953;NCT00266877;NCT00750698;NCT00621049;NCT03461185;NCT00778167;NCT01131429;NCT02146118;NCT00547105;NCT01854034;NCT02250846;NCT00615758;NCT00147537;NCT00125359;NCT01532089;NCT01410214;NCT04148898;NCT00518011;NCT00777309;NCT02318368;NCT00854308;NCT00888511;NCT00278187;NCT00411632;NCT01259089;NCT00265317;NCT00783471;NCT00977470;NCT02036359;NCT00673569;NCT00600587;NCT00743938;NCT01250119;NCT01372384;NCT00602030;NCT01683175;NCT00800202;NCT02774278;NCT01857271;NCT03151161;NCT01186861;NCT00661193;NCT03382795;NCT03119519;NCT04455594;NCT01174563;NCT00550537;NCT00124280;NCT00702975;NCT00809237;NCT01167244;NCT00816868;NCT00567359;NCT01229150;NCT01932229;NCT02353741;NCT01260181;NCT03123484;NCT02535338;NCT01610336;NCT00503971;NCT01233687;NCT00287989;NCT02117024;NCT00620269;NCT00466284;NCT02095782;NCT00321815;NCT00773383;NCT00499655;NCT00101348;NCT01897480;NCT00453362;NCT00522145;NCT00652340;NCT01900652;NCT00200395;NCT03595644;NCT00950365;NCT02770014;NCT00391248;NCT00072631;NCT00600015;NCT01471964;NCT00466089;NCT00087269;NCT00678964;NCT00609804;NCT01470716;NCT02424617;NCT01755923;NCT02191059;NCT00536640;NCT00385996;NCT00280150;NCT02906163;NCT02006043;NCT00835471;NCT00230126;NCT01557959;NCT02655536;NCT02039674;NCT00100854;NCT00462995;NCT01101334;NCT00447057;NCT01188707;NCT00908336;NCT00994123;NCT00137800;NCT02117167;NCT00760929;NCT01514877;NCT00590902;NCT00983307;NCT01221077;NCT00749567;NCT00606502;NCT03137771;NCT00063895;NCT02495233;NCT00568841;NCT00531934;NCT00553800;NCT00278148;NCT02066038;NCT00452075;NCT02314364;NCT01708954;NCT00769067;NCT00830245;NCT01796288;NCT04193007;NCT02556593;NCT01153984;NCT00722969;NCT02045446;NCT02034097;NCT01047059;NCT00522938;NCT03399669;NCT00711594;NCT01518621;NCT02013206;NCT00085839;NCT01714908;NCT00343187;NCT01204697;NCT02069418;NCT01801111;NCT01822496;NCT02705820;NCT00660816;NCT01310036;NCT01504542;NCT01955421;NCT00563784;NCT02037997;NCT01866410;NCT01487265;NCT00663689;NCT01996332;NCT02954523;NCT01395758;NCT00452413;NCT02574078;NCT00553254;NCT04165031;NCT02507518;NCT00976677;NCT03424759;NCT01306045;NCT01580735;NCT00095225;NCT00550173;NCT03399487;NCT00654420
Carcinoma, Non-Small-Cell Lung	D002289	erlotinib	Phase 3	2001	2018	NCT00775385;NCT01342965;NCT00298415;NCT01887795;NCT00883779;NCT01158170;NCT00091663;NCT00556322;NCT00989690;NCT00268684;NCT02296125;NCT01328951;NCT02759614;NCT02193282;NCT02134015;NCT00312377;NCT01244191;NCT01404260;NCT02186301;NCT01377376;NCT01360554;NCT02178397;NCT02775006;NCT00446225;NCT01351415;NCT02411448;NCT00036647;NCT02031744;NCT03074864;NCT00364351;NCT01523587;NCT00874419;NCT02714010;NCT01456325;NCT00153803;NCT00718315;NCT02795884;NCT01383148;NCT01487174;NCT02416739;NCT00300586;NCT01887886;NCT00349219;NCT01667562;NCT01183858;NCT00257608;NCT00637910;NCT02588261;NCT00373425;NCT02001896;NCT00656136;NCT01407822;NCT01652469;NCT03529084;NCT00096265;NCT00130728;NCT00556712;NCT00440414;NCT00738881;NCT01802021;NCT01085136;NCT00673049;NCT00457392;NCT00955695;NCT02633189
Carcinoma, Non-Small-Cell Lung	D002289	erlotinib	Phase 4	2004	2020	NCT01287754;NCT01320501;NCT01230710;NCT01066884;NCT01196078;NCT04401059;NCT02031601;NCT03264794;NCT03460678;NCT00949910;NCT02000531;NCT04356118
Lung Neoplasms	D008175	erlotinib	Phase 1	2001	2018	NCT00633529;NCT00042835;NCT02013219;NCT02157883;NCT01069757;NCT02468661;NCT01594398;NCT00569114;NCT02134886;NCT00072072;NCT00738335;NCT02277457;NCT01302808;NCT00975767;NCT00088959;NCT01193881;NCT00397384;NCT00702182;NCT02507375;NCT01121575;NCT01545947;NCT01570296;NCT00738751;NCT02321293;NCT01251796;NCT00965731;NCT01288430;NCT00294736;NCT00708448;NCT00456833;NCT00581789;NCT01515969;NCT01454102;NCT01839955;NCT00536861;NCT03050411;NCT02342353;NCT02991651;NCT01998126;NCT02364609;NCT01026844;NCT00030498;NCT01967095;NCT03628521;NCT01911507;NCT00779389;NCT01859026;NCT00707252
Lung Neoplasms	D008175	erlotinib	Phase 2	2002	2019	NCT00391586;NCT00910676;NCT00087412;NCT00826449;NCT01204307;NCT01728181;NCT02716311;NCT01211483;NCT00370383;NCT01248247;NCT00701558;NCT00940875;NCT00997334;NCT00367601;NCT00251589;NCT01998919;NCT00553462;NCT03126799;NCT01027598;NCT00408499;NCT00871923;NCT01104155;NCT00596648;NCT01928160;NCT02759835;NCT01294306;NCT00855894;NCT00351039;NCT00973310;NCT01556191;NCT01378962;NCT00531960;NCT02738983;NCT01350817;NCT00339586;NCT00577707;NCT01130753;NCT00281021;NCT00387322;NCT01130779;NCT01091376;NCT01116219;NCT00801385;NCT00312728;NCT03497767;NCT00840125;NCT00062101;NCT02747953;NCT00266877;NCT00750698;NCT00621049;NCT03461185;NCT00778167;NCT01131429;NCT00547105;NCT02250846;NCT00615758;NCT00147537;NCT00125359;NCT01410214;NCT04148898;NCT00518011;NCT00777309;NCT02318368;NCT00854308;NCT00888511;NCT02625168;NCT00278187;NCT00411632;NCT01259089;NCT00265317;NCT00783471;NCT00673569;NCT01250119;NCT01372384;NCT00800202;NCT02774278;NCT01857271;NCT00661193;NCT01455389;NCT03119519;NCT01174563;NCT00550537;NCT00702975;NCT00809237;NCT00816868;NCT00567359;NCT01229150;NCT00390429;NCT02353741;NCT01260181;NCT03123484;NCT01610336;NCT00503971;NCT00585533;NCT00287989;NCT02117024;NCT00466284;NCT02095782;NCT00283244;NCT00773383;NCT00499655;NCT00410059;NCT00101348;NCT00453362;NCT00473083;NCT00043823;NCT00652340;NCT00445848;NCT00570401;NCT00436332;NCT00200395;NCT03595644;NCT00950365;NCT01480141;NCT02770014;NCT00063258;NCT00391248;NCT00072631;NCT00600015;NCT03865511;NCT01471964;NCT01189435;NCT00554775;NCT00466089;NCT00087269;NCT00678964;NCT00609804;NCT01344824;NCT02424617;NCT02191059;NCT00280150;NCT00039182;NCT02906163;NCT01557959;NCT02039674;NCT00100854;NCT00462995;NCT01101334;NCT00385398;NCT01188707;NCT00908336;NCT00994123;NCT00137800;NCT02117167;NCT00760929;NCT01068587;NCT01514877;NCT00590902;NCT01221077;NCT00749567;NCT00606502;NCT03137771;NCT00063895;NCT02495233;NCT00531934;NCT00278148;NCT00452075;NCT02314364;NCT00769067;NCT00830245;NCT00416650;NCT00284141;NCT01796288;NCT02556593;NCT02352948;NCT00722969;NCT02045446;NCT03076164;NCT02034097;NCT00988169;NCT00522938;NCT03399669;NCT00711594;NCT02013206;NCT00085839;NCT01714908;NCT00343187;NCT01204697;NCT02069418;NCT01822496;NCT02705820;NCT00660816;NCT00354549;NCT01310036;NCT01504542;NCT01955421;NCT00563784;NCT01866410;NCT01487265;NCT01562028;NCT00663689;NCT01996332;NCT02954523;NCT01395758;NCT00452413;NCT02574078;NCT02507518;NCT00976677;NCT03424759;NCT02044601;NCT01306045;NCT01580735;NCT00095225;NCT00550173;NCT03399487
Lung Neoplasms	D008175	erlotinib	Phase 3	2001	2017	NCT01342965;NCT01887795;NCT00883779;NCT01158170;NCT00091663;NCT00556322;NCT00989690;NCT02296125;NCT01328951;NCT02134015;NCT00312377;NCT01244191;NCT01404260;NCT01377376;NCT01360554;NCT00047736;NCT00446225;NCT01351415;NCT02152631;NCT02411448;NCT00036647;NCT02031744;NCT03074864;NCT00364351;NCT00874419;NCT02714010;NCT01456325;NCT00153803;NCT00718315;NCT02416739;NCT00300586;NCT01887886;NCT00349219;NCT01667562;NCT01183858;NCT00257608;NCT00275132;NCT00637910;NCT02588261;NCT00373425;NCT01407822;NCT00096265;NCT00130728;NCT00556712;NCT00440414;NCT00738881;NCT01802021;NCT00673049;NCT00457392;NCT00955695;NCT02633189;NCT02926638
Lung Neoplasms	D008175	erlotinib	Phase 4	2004	2020	NCT01287754;NCT01320501;NCT01230710;NCT03890055;NCT01066884;NCT01196078;NCT04401059;NCT02031601;NCT03264794;NCT00949910;NCT04356118;NCT01336192
Glioblastoma	D005909	erlotinib	Phase 1	2001	2010	NCT01103375;NCT00227032;NCT00609999;NCT00030498
Glioblastoma	D005909	erlotinib	Phase 2	2002	2011	NCT01110876;NCT00301418;NCT00525525;NCT00720356;NCT00445588;NCT00112736;NCT00671970;NCT00337883;NCT00187486;NCT00274833;NCT00672243;NCT00045110;NCT00054496;NCT00387894;NCT00086879;NCT00039494;NCT00335764
Glioma	D005910	erlotinib	Phase 1	2001	2011	NCT01103375;NCT00509431;NCT00901849;NCT00360854;NCT01257594;NCT00418327;NCT00030498
Glioma	D005910	erlotinib	Phase 2	2002	2014	NCT01182350;NCT00112736;NCT00124657;NCT02233049;NCT00671970;NCT00337883;NCT00672243;NCT00045110;NCT00602667
Astrocytoma	D001254	erlotinib	Phase 1	2001	2010	NCT01103375;NCT00077454;NCT00030498
Astrocytoma	D001254	erlotinib	Phase 2	2002	2006	NCT00301418;NCT00112736;NCT00045110
Gliosarcoma	D018316	erlotinib	Phase 1	2001	2010	NCT01103375;NCT00609999;NCT00030498
Gliosarcoma	D018316	erlotinib	Phase 2	2002	2009	NCT00525525;NCT00720356;NCT00445588;NCT00112736;NCT00671970;NCT00187486;NCT00672243;NCT00045110;NCT00387894;NCT00039494;NCT00335764
Oligodendroglioma	D009837	erlotinib	Phase 1	2001	2010	NCT01103375;NCT00030498
Oligodendroglioma	D009837	erlotinib	Phase 2	2002	2005	NCT00112736;NCT00045110
Colorectal Neoplasms	D015179	erlotinib	Phase 1	2002	2020	NCT04449874;NCT00047762;NCT00118261
Colorectal Neoplasms	D015179	erlotinib	Phase 2	2002	2019	NCT00910676;NCT02723578;NCT03086538;NCT01135498;NCT00123851;NCT00784667;NCT00049101;NCT00642746;NCT00459901;NCT01187901;NCT00940316;NCT01703910;NCT00116506;NCT01243047;NCT04165031;NCT02961374
Colorectal Neoplasms	D015179	erlotinib	Phase 3	2005	2010	NCT00265824;NCT01229813;NCT00598156
Adenocarcinoma of Lung	D000077192	erlotinib	Phase 1	2002	2013	NCT00042835;NCT01851096
Adenocarcinoma of Lung	D000077192	erlotinib	Phase 2	2004	2020	NCT00087412;NCT02759835;NCT01294306;NCT02155465;NCT01578668;NCT00126581;NCT02788058;NCT01131429;NCT02146118;NCT00198380;NCT00716456;NCT01259089;NCT01565538;NCT02704767;NCT02787447;NCT04201756;NCT00950365;NCT00137839;NCT01557959;NCT00284141;NCT03076164
Adenocarcinoma of Lung	D000077192	erlotinib	Phase 3	2013	2016	NCT02889692;NCT02893332
Adenocarcinoma of Lung	D000077192	erlotinib	Phase 4	2012	2015	NCT02399566;NCT01609543
Carcinoma, Squamous Cell	D002294	erlotinib	Phase 1	2001	2011	NCT00079053;NCT01515137;NCT00049283;NCT00397384;NCT00113347;NCT01332279;NCT00049166;NCT00966472;NCT00030498
Carcinoma, Squamous Cell	D002294	erlotinib	Phase 2	2002	2018	NCT00031993;NCT00942734;NCT00392665;NCT03486509;NCT00410826;NCT01009203;NCT00055913;NCT00076310;NCT01192815;NCT00369512;NCT01608022;NCT01927744;NCT00101348;NCT00720304;NCT00304278;NCT00476476;NCT01316757;NCT00063895;NCT01198028;NCT01059305;NCT02353936;NCT02748707;NCT00055770;NCT01064479;NCT01465815
Carcinoma, Squamous Cell	D002294	erlotinib	Phase 3	2006	2012	NCT00448240;NCT01752205;NCT00442455;NCT00673049
Pancreatic Neoplasms	D010190	erlotinib	Phase 1	2001	2020	NCT03403049;NCT00266097;NCT00925769;NCT00761345;NCT02154737;NCT00614653;NCT00954525;NCT00397384;NCT00243854;NCT01660971;NCT00033241;NCT00047307;NCT01010945;NCT01181245;NCT00878163;NCT00987766;NCT00480584;NCT00063947;NCT00565487;NCT00030498;NCT00885066;NCT03878524
Pancreatic Neoplasms	D010190	erlotinib	Phase 2	2003	2016	NCT01505530;NCT00366457;NCT01555489;NCT00497224;NCT00470535;NCT01454180;NCT00336700;NCT01222689;NCT00536770;NCT00837876;NCT00709826;NCT00376948;NCT02004262;NCT00564720;NCT00276744;NCT00922896;NCT00769483;NCT00640978;NCT00696696;NCT00652366;NCT00101348;NCT00674973;NCT01505413;NCT01210911;NCT00766636;NCT02737228;NCT00091026;NCT00461708;NCT01693419;NCT00733746;NCT01303029;NCT00125021;NCT01683422;NCT00550836;NCT00260364;NCT00636883;NCT00841035;NCT00617708;NCT00365144;NCT00810719;NCT01608841;NCT00482625;NCT00313560;NCT01531712
Pancreatic Neoplasms	D010190	erlotinib	Phase 3	2001	2009	NCT00634725;NCT01013649;NCT00026338;NCT00440167;NCT02694536;NCT01214720;NCT00040183
Pancreatic Neoplasms	D010190	erlotinib	Phase 4	2007	2007	NCT00642733
Carcinoma, Hepatocellular	D006528	erlotinib	Phase 1	2002	2009	NCT00047346;NCT00823290
Carcinoma, Hepatocellular	D006528	erlotinib	Phase 2	2002	2021	NCT04172779;NCT00047333;NCT00287222;NCT01180959;NCT00832637;NCT00242502;NCT00791544;NCT00365391;NCT00532441;NCT02273362
Carcinoma, Hepatocellular	D006528	erlotinib	Phase 3	2009	2009	NCT00901901
Liver Neoplasms	D008113	erlotinib	Phase 1	2001	2009	NCT00047346;NCT00397384;NCT00987766;NCT00030498
Liver Neoplasms	D008113	erlotinib	Phase 2	2002	2011	NCT00293436;NCT00881751;NCT00047333;NCT01180959;NCT00033462;NCT00242502;NCT00605722;NCT00365391
Brain Neoplasms	D001932	erlotinib	Phase 1	2004	2011	NCT00077454;NCT00360854;NCT00536861;NCT01257594;NCT00418327
Brain Neoplasms	D001932	erlotinib	Phase 2	2006	2019	NCT01110876;NCT00871923;NCT01578668;NCT01763385;NCT00312728;NCT02250846;NCT02655536;NCT04193007;NCT00387894;NCT00663689
Sarcoma	D012509	erlotinib	Phase 1	2004	2004	NCT00077454
Sarcoma	D012509	erlotinib	Phase 2	2003	2003	NCT00068367
Neuroblastoma	D009447	erlotinib	Phase 1	2004	2004	NCT00077454
Neuroblastoma	D009447	erlotinib	Phase 2	2009	2009	NCT00947167
Osteosarcoma	D012516	erlotinib	Phase 1	2004	2004	NCT00077454
Osteosarcoma	D012516	erlotinib	Phase 2	2016	2016	NCT02689336
Rhabdomyosarcoma	D012208	erlotinib	Phase 1	2004	2004	NCT00077454
Rhabdomyosarcoma	D012208	erlotinib	Phase 2	2016	2016	NCT02689336
Ependymoma	D004806	erlotinib	Phase 1	2001	2004	NCT00077454;NCT00030498
Ependymoma	D004806	erlotinib	Phase 2	2007	2016	NCT01247922;NCT02689336;NCT01032070;NCT00602667
Medulloblastoma	D008527	erlotinib	Phase 1	2004	2004	NCT00077454
Medulloblastoma	D008527	erlotinib	Phase 2	2016	2016	NCT02689336
Neuroectodermal Tumors	D017599	erlotinib	Phase 1	2004	2004	NCT00077454
Neuroectodermal Tumors	D017599	erlotinib	Phase 2	2016	2016	NCT02689336
Neuroectodermal Tumors, Primitive	D018242	erlotinib	Phase 1	2001	2004	NCT00077454;NCT00030498
Neuroectodermal Tumors, Primitive	D018242	erlotinib	Phase 2	2016	2016	NCT02689336
Rhabdomyosarcoma, Embryonal	D018233	erlotinib	Phase 1	2004	2004	NCT00077454
Nervous System Neoplasms	D009423	erlotinib	Phase 1	2005	2006	NCT00227032;NCT00509431;NCT00360854
Nervous System Neoplasms	D009423	erlotinib	Phase 2	2002	2009	NCT00720356;NCT00124657;NCT00054496;NCT00086879;NCT00602667
Central Nervous System Neoplasms	D016543	erlotinib	Phase 1	2005	2006	NCT00227032;NCT00509431;NCT00360854
Central Nervous System Neoplasms	D016543	erlotinib	Phase 2	2002	2009	NCT00720356;NCT00124657;NCT00274833;NCT00054496;NCT00086879;NCT00602667
Breast Neoplasms	D001943	erlotinib	Phase 1	2001	2020	NCT01594398;NCT00600496;NCT01650506;NCT00574366;NCT00030498;NCT03878524
Breast Neoplasms	D001943	erlotinib	Phase 2	2001	2019	NCT00732810;NCT00597597;NCT00030537;NCT00054275;NCT04034589;NCT00611715;NCT01205685;NCT00033514;NCT01013506;NCT00109265;NCT00739063;NCT00491816;NCT00059852;NCT00733408;NCT00633750;NCT00570258;NCT00054132;NCT00834678
Adenocarcinoma, Bronchiolo-Alveolar	D002282	erlotinib	Phase 1	2002	2002	NCT00042835
Adenocarcinoma, Bronchiolo-Alveolar	D002282	erlotinib	Phase 2	2005	2011	NCT01294306;NCT00339586;NCT00126581;NCT00384826;NCT00436332;NCT00950365;NCT01557959
Neoplasm Metastasis	D009362	erlotinib	Phase 1	2006	2010	NCT01115803;NCT00536861
Neoplasm Metastasis	D009362	erlotinib	Phase 2	2003	2019	NCT01578668;NCT01763385;NCT00312728;NCT02250846;NCT04148898;NCT02142036;NCT00123851;NCT00461708;NCT00125021;NCT04193007;NCT01703910;NCT00116506;NCT00663689
Neoplasm Metastasis	D009362	erlotinib	Phase 3	2005	2018	NCT01887795;NCT00268684;NCT02714010;NCT01456325;NCT03653546;NCT02882984
Neoplasm Metastasis	D009362	erlotinib	Phase 4	2020	2020	NCT04356118
Ovarian Neoplasms	D010051	erlotinib	Phase 2	2002	2009	NCT00130520;NCT00030446;NCT01003938;NCT00217529
Ovarian Neoplasms	D010051	erlotinib	Phase 3	2005	2005	NCT00263822
Carcinoma, Ovarian Epithelial	D000077216	erlotinib	Phase 1	2001	2001	NCT00030498
Carcinoma, Ovarian Epithelial	D000077216	erlotinib	Phase 2	2002	2009	NCT00130520;NCT00059787;NCT00126542;NCT00030446;NCT00063895;NCT01003938;NCT00217529
Carcinoma, Ovarian Epithelial	D000077216	erlotinib	Phase 3	2005	2005	NCT00263822
Nerve Sheath Neoplasms	D018317	erlotinib	Phase 2	2003	2003	NCT00068367
Neurofibrosarcoma	D018319	erlotinib	Phase 2	2003	2003	NCT00068367
Head and Neck Neoplasms	D006258	erlotinib	Phase 1	2001	2011	NCT00400374;NCT00954226;NCT00049283;NCT01116336;NCT00397384;NCT00738751;NCT00113347;NCT00601913;NCT00405405;NCT01332279;NCT00140556;NCT00030498;NCT00779389
Head and Neck Neoplasms	D006258	erlotinib	Phase 2	2001	2013	NCT00392704;NCT00570232;NCT00281866;NCT00076310;NCT01192815;NCT01927744;NCT00101348;NCT00030576;NCT00720304;NCT00750555;NCT00304278;NCT01316757;NCT00970502;NCT00573989
Head and Neck Neoplasms	D006258	erlotinib	Phase 3	2006	2007	NCT00448240;NCT00412217
Hematologic Neoplasms	D019337	erlotinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	erlotinib	Phase 2	2014	2014	NCT02355431
Rectal Neoplasms	D012004	erlotinib	Phase 1	2001	2007	NCT00543842;NCT00060411;NCT00397384;NCT00030498
Rectal Neoplasms	D012004	erlotinib	Phase 2	2002	2008	NCT00307736;NCT00101348;NCT00754494;NCT00032110
Leukemia, Myeloid	D007951	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	erlotinib	Phase 2	2013	2015	NCT02638428;NCT01664897
Carcinoma, Renal Cell	D002292	erlotinib	Phase 1	2007	2014	NCT00600496;NCT01115803;NCT02071862
Carcinoma, Renal Cell	D002292	erlotinib	Phase 2	2002	2020	NCT00193258;NCT00060307;NCT00522249;NCT04644432;NCT00425386;NCT00045487;NCT00353301;NCT00081614;NCT01688973;NCT01130519;NCT00101348;NCT00193154
Carcinoma, Renal Cell	D002292	erlotinib	Phase 4	2012	2012	NCT01402089
Gastrointestinal Stromal Tumors	D046152	erlotinib	Phase 1	2007	2014	NCT00397384;NCT02071862
Gastrointestinal Stromal Tumors	D046152	erlotinib	Phase 4	2012	2012	NCT01402089
Small Cell Lung Carcinoma	D055752	erlotinib	Phase 2	2011	2017	NCT02876081;NCT02352948;NCT01306045
Small Cell Lung Carcinoma	D055752	erlotinib	Phase 4	2019	2019	NCT03890055
Stomach Neoplasms	D013274	erlotinib	Phase 1	2007	2007	NCT01561014;NCT00397384
Stomach Neoplasms	D013274	erlotinib	Phase 2	2002	2002	NCT00032123
Esophageal Neoplasms	D004938	erlotinib	Phase 1	2001	2007	NCT00566800;NCT01561014;NCT00397384;NCT00030498
Esophageal Neoplasms	D004938	erlotinib	Phase 2	2002	2015	NCT00032123;NCT00591123;NCT00045526;NCT00393068;NCT00442507;NCT00524121;NCT00539617;NCT02353936
Esophageal Neoplasms	D004938	erlotinib	Phase 3	2008	2008	NCT00686114
Barrett Esophagus	D001471	erlotinib	Phase 1	2007	2007	NCT00566800
Precancerous Conditions	D011230	erlotinib	Phase 1	2007	2010	NCT00566800;NCT01013831;NCT01116336
Precancerous Conditions	D011230	erlotinib	Phase 2	2006	2006	NCT00314262
Adenocarcinoma	D000230	erlotinib	Phase 1	2003	2020	NCT00266097;NCT00735306;NCT00060411;NCT01561014;NCT00397384;NCT00987766;NCT01851096;NCT03878524
Adenocarcinoma	D000230	erlotinib	Phase 2	2002	2020	NCT02155465;NCT01578668;NCT00059787;NCT00591123;NCT00126581;NCT00384826;NCT01222689;NCT02788058;NCT01131429;NCT02146118;NCT00045526;NCT00198380;NCT00716456;NCT01259089;NCT01204372;NCT01565538;NCT00769483;NCT00816868;NCT02704767;NCT01389440;NCT02787447;NCT04201756;NCT01108458;NCT00728000;NCT00873353;NCT02876081;NCT00137839;NCT00284141;NCT00832637;NCT01093222;NCT03076164;NCT03213626;NCT01703910;NCT00032110
Adenocarcinoma	D000230	erlotinib	Phase 3	2009	2016	NCT01013649;NCT02889692;NCT02893332
Adenocarcinoma	D000230	erlotinib	Phase 4	2012	2015	NCT02399566;NCT01609543
Squamous Cell Carcinoma of Head and Neck	D000077195	erlotinib	Phase 1	2003	2005	NCT00079053;NCT01515137
Squamous Cell Carcinoma of Head and Neck	D000077195	erlotinib	Phase 2	2006	2013	NCT00392665;NCT01927744;NCT00304278;NCT01064479
Squamous Cell Carcinoma of Head and Neck	D000077195	erlotinib	Phase 3	2006	2006	NCT00442455
Neoplasms, Second Primary	D016609	erlotinib	Phase 2	2012	2019	NCT01578668;NCT01763385;NCT02250846;NCT04148898;NCT02142036;NCT04193007
Neoplasms, Second Primary	D016609	erlotinib	Phase 3	2018	2018	NCT03653546
Neoplasms, Second Primary	D016609	erlotinib	Phase 4	2020	2020	NCT04356118
Fallopian Tube Neoplasms	D005185	erlotinib	Phase 2	2002	2007	NCT00059787;NCT00126542;NCT00030446;NCT00520013;NCT00217529
Fallopian Tube Neoplasms	D005185	erlotinib	Phase 3	2005	2005	NCT00263822
Carcinoma, Endometrioid	D018269	erlotinib	Phase 2	2003	2003	NCT00059787
Cystadenocarcinoma	D003536	erlotinib	Phase 1	2003	2003	NCT00060411
Cystadenocarcinoma	D003536	erlotinib	Phase 2	2003	2003	NCT00059787
Cystadenocarcinoma, Serous	D018284	erlotinib	Phase 2	2003	2003	NCT00059787
Cystadenocarcinoma, Mucinous	D018282	erlotinib	Phase 2	2003	2003	NCT00059787
Brenner Tumor	D001948	erlotinib	Phase 2	2003	2003	NCT00059787
Gallbladder Neoplasms	D005706	erlotinib	Phase 1	2004	2009	NCT00266097;NCT00397384;NCT00987766
Gallbladder Neoplasms	D005706	erlotinib	Phase 2	2002	2010	NCT00356889;NCT00033462;NCT00350753;NCT00832637;NCT01093222
Bile Duct Neoplasms	D001650	erlotinib	Phase 1	2004	2009	NCT00266097;NCT00397384;NCT00987766
Bile Duct Neoplasms	D001650	erlotinib	Phase 2	2002	2010	NCT00356889;NCT00033462;NCT00832637;NCT01093222
Cholangiocarcinoma	D018281	erlotinib	Phase 1	2004	2009	NCT00266097;NCT00955149;NCT00397384;NCT00987766
Cholangiocarcinoma	D018281	erlotinib	Phase 2	2002	2010	NCT00356889;NCT00033462;NCT00350753;NCT00832637;NCT01093222
Prostatic Neoplasms	D011471	erlotinib	Phase 1	2001	2020	NCT00030498;NCT03878524
Prostatic Neoplasms	D011471	erlotinib	Phase 2	2004	2006	NCT00203424;NCT00148772;NCT00996502;NCT00272038;NCT00087035
Peritoneal Neoplasms	D010534	erlotinib	Phase 2	2005	2007	NCT00126542;NCT00520013
Lymphoma	D008223	erlotinib	Phase 1	2006	2020	NCT00725634;NCT03878524;NCT00705874
Lymphoma	D008223	erlotinib	Phase 2	2019	2019	NCT04004572
Lymphoma, T-Cell	D016399	erlotinib	Phase 2	2019	2019	NCT04004572
Pleural Effusion, Malignant	D016066	erlotinib	Phase 2	2005	2005	NCT00126581
Carcinoma, Adenosquamous	D018196	erlotinib	Phase 2	2005	2005	NCT00126581
Carcinoma, Adenosquamous	D018196	erlotinib	Phase 3	2008	2008	NCT00673049
Endometrial Neoplasms	D016889	erlotinib	Phase 2	2002	2002	NCT00030485
Neoplasms, Unknown Primary	D009382	erlotinib	Phase 1	2001	2007	NCT00049283;NCT00397384;NCT00030498
Neoplasms, Unknown Primary	D009382	erlotinib	Phase 2	2004	2018	NCT03498521;NCT00101348;NCT01316757;NCT00193622;NCT00360360
Laryngeal Neoplasms	D007822	erlotinib	Phase 1	2001	2011	NCT00049283;NCT00397384;NCT01332279;NCT00030498
Laryngeal Neoplasms	D007822	erlotinib	Phase 2	2002	2011	NCT00410826;NCT00055913;NCT01192815;NCT00101348;NCT01316757;NCT00970502;NCT00063895;NCT00055770
Oropharyngeal Neoplasms	D009959	erlotinib	Phase 1	2001	2007	NCT00049283;NCT00397384;NCT00049166;NCT00030498
Oropharyngeal Neoplasms	D009959	erlotinib	Phase 2	2002	2011	NCT00410826;NCT00055913;NCT01192815;NCT00101348;NCT01316757;NCT00063895;NCT00055770
Nasopharyngeal Carcinoma	D000077274	erlotinib	Phase 1	2001	2007	NCT00049283;NCT00397384;NCT00030498
Nasopharyngeal Carcinoma	D000077274	erlotinib	Phase 2	2002	2011	NCT00410826;NCT00055913;NCT01192815;NCT00101348;NCT01316757;NCT00603915;NCT00063895;NCT00055770
Melanoma	D008545	erlotinib	Phase 1	2006	2007	NCT00600496;NCT00405405
Melanoma	D008545	erlotinib	Phase 2	2004	2004	NCT00466687
Colonic Neoplasms	D003110	erlotinib	Phase 1	2001	2007	NCT00600496;NCT00060411;NCT00397384;NCT00030498
Colonic Neoplasms	D003110	erlotinib	Phase 2	2002	2008	NCT00101348;NCT00754494;NCT00032110
Kidney Neoplasms	D007680	erlotinib	Phase 1	2007	2007	NCT00600496
Kidney Neoplasms	D007680	erlotinib	Phase 2	2002	2020	NCT04644432;NCT00425386;NCT00045487;NCT00193154;NCT00749892
Preleukemia	D011289	erlotinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	erlotinib	Phase 2	2007	2013	NCT00977548;NCT01664897;NCT01085838;NCT00570375
Leukemia	D007938	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	erlotinib	Phase 2	2010	2013	NCT01664897;NCT01174043
Leukemia, Myeloid, Acute	D015470	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	erlotinib	Phase 2	2010	2013	NCT01664897;NCT01174043
Leukemia, Myelomonocytic, Chronic	D015477	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	erlotinib	Phase 2	2013	2013	NCT01664897
Leukemia, Myelomonocytic, Juvenile	D054429	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	erlotinib	Phase 2	2013	2013	NCT01664897
Leukemia, Promyelocytic, Acute	D015473	erlotinib	Phase 2	2013	2013	NCT01664897
Mesothelioma	D008654	erlotinib	Phase 1	2001	2014	NCT00030498;NCT02071862
Mesothelioma	D008654	erlotinib	Phase 2	2002	2012	NCT00137826;NCT01592383;NCT00039182
Esophageal Squamous Cell Carcinoma	D000077277	erlotinib	Phase 1	2007	2007	NCT01561014
Esophageal Squamous Cell Carcinoma	D000077277	erlotinib	Phase 2	2002	2015	NCT00045526;NCT01608022;NCT02353936
Carcinoma, Verrucous	D018289	erlotinib	Phase 1	2001	2011	NCT00049283;NCT00397384;NCT01332279;NCT00030498
Carcinoma, Verrucous	D018289	erlotinib	Phase 2	2005	2011	NCT01192815;NCT00101348;NCT01316757
Tongue Neoplasms	D014062	erlotinib	Phase 1	2002	2011	NCT00049283;NCT00397384;NCT01332279
Tongue Neoplasms	D014062	erlotinib	Phase 2	2011	2015	NCT01316757;NCT02748707
Meningeal Carcinomatosis	D055756	erlotinib	Phase 2	2009	2019	NCT04148898;NCT00830245
Meningeal Carcinomatosis	D055756	erlotinib	Phase 4	2020	2020	NCT04356118
Urinary Bladder Neoplasms	D001749	erlotinib	Phase 1	2001	2001	NCT00030498
Urinary Bladder Neoplasms	D001749	erlotinib	Phase 2	2004	2017	NCT02788201;NCT00380029;NCT02169284;NCT00088946;NCT00749892
Carcinoma, Transitional Cell	D002295	erlotinib	Phase 2	2008	2017	NCT02788201;NCT00749892
Paranasal Sinus Neoplasms	D010255	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Paranasal Sinus Neoplasms	D010255	erlotinib	Phase 2	2002	2011	NCT00055913;NCT00101348;NCT01316757;NCT00970502;NCT00055770
Urogenital Neoplasms	D014565	erlotinib	Phase 2	2020	2020	NCT04644432
Urologic Neoplasms	D014571	erlotinib	Phase 2	2020	2020	NCT04644432
Neoplasms, Squamous Cell	D018307	erlotinib	Phase 2	2004	2011	NCT00076310;NCT01192815;NCT01059305
Multiple Myeloma	D009101	erlotinib	Phase 1	2008	2020	NCT00725634;NCT03878524
Multiple Myeloma	D009101	erlotinib	Phase 2	2017	2017	NCT03297606
Lymphoma, Non-Hodgkin	D008228	erlotinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	erlotinib	Phase 2	2017	2017	NCT03297606
Adenocarcinoma, Mucinous	D002288	erlotinib	Phase 1	2003	2003	NCT00060411
Neurofibromatoses	D017253	erlotinib	Phase 1	2007	2007	NCT00901849
Neurofibromatosis 1	D009456	erlotinib	Phase 1	2007	2007	NCT00901849
Neurofibroma	D009455	erlotinib	Phase 1	2007	2007	NCT00901849
Sarcoma, Ewing	D012512	erlotinib	Phase 2	2016	2016	NCT02689336
Wilms Tumor	D009396	erlotinib	Phase 2	2016	2016	NCT02689336
Carcinoma, Acinar Cell	D018267	erlotinib	Phase 1	2009	2009	NCT00878163
Carcinoma, Acinar Cell	D018267	erlotinib	Phase 3	2009	2009	NCT01013649
Pancreatic Intraductal Neoplasms	D000077779	erlotinib	Phase 2	2007	2007	NCT00482625
Pancreatic Intraductal Neoplasms	D000077779	erlotinib	Phase 3	2009	2009	NCT01013649
Carcinoma, Basal Cell	D002280	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Carcinoma, Basal Cell	D002280	erlotinib	Phase 2	2005	2005	NCT00101348
Papilloma	D010212	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Papilloma	D010212	erlotinib	Phase 2	2005	2005	NCT00101348
Salivary Gland Neoplasms	D012468	erlotinib	Phase 1	2001	2011	NCT00397384;NCT01332279;NCT00030498
Salivary Gland Neoplasms	D012468	erlotinib	Phase 2	2002	2011	NCT00101348;NCT01316757;NCT00055770
Carcinoid Tumor	D002276	erlotinib	Phase 1	2007	2007	NCT00397384
Carcinoid Tumor	D002276	erlotinib	Phase 2	2009	2009	NCT00947167
Anus Neoplasms	D001005	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Carcinoma, Adenoid Cystic	D003528	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Carcinoma, Adenoid Cystic	D003528	erlotinib	Phase 2	2005	2005	NCT00101348
Leiomyosarcoma	D007890	erlotinib	Phase 1	2007	2007	NCT00397384
Carcinoma, Mucoepidermoid	D018277	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Carcinoma, Mucoepidermoid	D018277	erlotinib	Phase 2	2005	2005	NCT00101348
Esthesioneuroblastoma, Olfactory	D018304	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Esthesioneuroblastoma, Olfactory	D018304	erlotinib	Phase 2	2005	2005	NCT00101348
Papilloma, Inverted	D018308	erlotinib	Phase 1	2001	2007	NCT00397384;NCT00030498
Papilloma, Inverted	D018308	erlotinib	Phase 2	2005	2005	NCT00101348
Malignant Carcinoid Syndrome	D008303	erlotinib	Phase 1	2007	2007	NCT00397384
Gastrointestinal Neoplasms	D005770	erlotinib	Phase 1	2007	2007	NCT00397384
Gastrointestinal Neoplasms	D005770	erlotinib	Phase 2	2006	2020	NCT00356889;NCT04591431
Intestinal Neoplasms	D007414	erlotinib	Phase 1	2007	2009	NCT00397384;NCT00987766
Mixed Tumor, Mullerian	D018200	erlotinib	Phase 2	2007	2007	NCT00520013
Triple Negative Breast Neoplasms	D064726	erlotinib	Phase 1	2009	2014	NCT01650506;NCT00998036;NCT02071862
Triple Negative Breast Neoplasms	D064726	erlotinib	Phase 2	2008	2008	NCT00733408
Neuroendocrine Tumors	D018358	erlotinib	Phase 1	2010	2010	NCT01115803
Neuroendocrine Tumors	D018358	erlotinib	Phase 2	2009	2009	NCT00947167;NCT00843531
Endocrine Gland Neoplasms	D004701	erlotinib	Phase 2	2009	2009	NCT00947167
Multiple Endocrine Neoplasia	D009377	erlotinib	Phase 2	2009	2009	NCT00947167
Leiomyomatosis	D018231	erlotinib	Phase 2	2010	2010	NCT01130519
Neoplastic Syndromes, Hereditary	D009386	erlotinib	Phase 2	2010	2010	NCT01130519
Skin Neoplasms	D012878	erlotinib	Phase 2	2010	2011	NCT01130519;NCT01059305;NCT01465815
Uterine Neoplasms	D014594	erlotinib	Phase 2	2010	2010	NCT01130519
Biliary Tract Neoplasms	D001661	erlotinib	Phase 1	2009	2009	NCT00987766
Biliary Tract Neoplasms	D001661	erlotinib	Phase 2	2021	2021	NCT03110484
Thymoma	D013945	erlotinib	Phase 2	2006	2011	NCT00369889;NCT01306045
Thymus Neoplasms	D013953	erlotinib	Phase 2	2006	2006	NCT00369889
Thoracic Neoplasms	D013899	erlotinib	Phase 2	2018	2018	NCT03389256
Thoracic Neoplasms	D013899	erlotinib	Phase 3	2009	2009	NCT01024413
Meningioma	D008579	erlotinib	Phase 2	2002	2002	NCT00045110
Nasopharyngeal Neoplasms	D009303	erlotinib	Phase 2	2006	2017	NCT00603915;NCT01187901;NCT02961374
Pharyngeal Neoplasms	D010610	erlotinib	Phase 1	2005	2005	NCT00140556
Pharyngeal Neoplasms	D010610	erlotinib	Phase 2	2007	2007	NCT00970502
Adenomatous Polyps	D018256	erlotinib	Phase 2	2008	2008	NCT00754494
Adenomatous Polyposis Coli	D011125	erlotinib	Phase 2	2010	2017	NCT01187901;NCT02961374
Polycythemia Vera	D011087	erlotinib	Phase 2	2009	2009	NCT01038856
Leukemia, Myelomonocytic, Acute	D015479	erlotinib	Phase 2	2010	2010	NCT01174043
Mouth Neoplasms	D009062	erlotinib	Phase 3	2006	2006	NCT00402779
Lip Neoplasms	D008048	erlotinib	Phase 3	2006	2006	NCT00402779
Urethral Neoplasms	D014523	erlotinib	Phase 2	2008	2008	NCT00749892
Ureteral Neoplasms	D014516	erlotinib	Phase 2	2008	2008	NCT00749892
Pelvic Neoplasms	D010386	erlotinib	Phase 2	2008	2008	NCT00749892
Klatskin Tumor	D018285	erlotinib	Phase 2	2010	2010	NCT01093222
Carcinoma, Ductal	D044584	erlotinib	Phase 2	2010	2010	NCT01093222
Neoplasms, Germ Cell and Embryonal	D009373	erlotinib	Phase 2	2014	2014	NCT01962896
Thyroid Neoplasms	D013964	erlotinib	Phase 1	2006	2006	NCT00405405
Neoplasms, Plasma Cell	D054219	erlotinib	Phase 1	2008	2020	NCT00725634;NCT03878524
Carcinoma, Pancreatic Ductal	D021441	erlotinib	Phase 2	2011	2011	NCT01394120
Uterine Cervical Neoplasms	D002583	erlotinib	Phase 1	2001	2007	NCT00030498;NCT00428194
Breast Neoplasms, Male	D018567	erlotinib	Phase 1	2001	2001	NCT00030498
Glioma, Subependymal	D018315	erlotinib	Phase 1	2001	2001	NCT00030498
Carcinoma, Large Cell	D018287	erlotinib	Phase 3	2008	2008	NCT00673049
Carcinoma, Small Cell	D018288	erlotinib	Phase 2	2011	2011	NCT01306045
Leukemia, Lymphoid	D007945	erlotinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	erlotinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	erlotinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	erlotinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	erlotinib	Phase 1	2020	2020	NCT03878524
Neoplasm Recurrence, Local	D009364	erlotinib	Phase 2	2004	2004	NCT00095225
Neuroendocrine Tumors	D018358	everolimus	Phase 1	2008	2017	NCT01204476;NCT00942682;NCT01469572;NCT02077933;NCT01590199;NCT02063958;NCT01324492;NCT01115803;NCT01218555;NCT00804336;NCT01864070;NCT03014297;NCT01263353
Neuroendocrine Tumors	D018358	everolimus	Phase 2	2006	2021	NCT02031536;NCT01784861;NCT01648465;NCT04665739;NCT00688623;NCT02113800;NCT02273752;NCT03670030;NCT00576680;NCT01175096;NCT01678664;NCT01628913;NCT01374451;NCT01229943;NCT03950609;NCT00843531;NCT03629847;NCT02713763;NCT02305810;NCT02315625;NCT00363051;NCT03070301
Neuroendocrine Tumors	D018358	everolimus	Phase 3	2007	2017	NCT03049189;NCT00510068;NCT01524783;NCT02246127
Neuroendocrine Tumors	D018358	everolimus	Phase 4	2011	2016	NCT02842749;NCT01595009;NCT01317615
Adenoma, Islet Cell	D007516	everolimus	Phase 2	2008	2017	NCT00576680;NCT01628913;NCT01374451;NCT01229943;NCT02713763;NCT02305810
Adenoma, Islet Cell	D007516	everolimus	Phase 4	2016	2016	NCT02842749
Breast Neoplasms	D001943	everolimus	Phase 1	2005	2020	NCT02058381;NCT04188548;NCT00473005;NCT03154281;NCT02077933;NCT02619669;NCT00426530;NCT00253318;NCT02152943;NCT00680758;NCT01482156;NCT02120469;NCT01857193;NCT00574366;NCT02616848;NCT03616587;NCT02057133;NCT03878524;NCT00426556
Breast Neoplasms	D001943	everolimus	Phase 2	2005	2020	NCT00317720;NCT01627067;NCT00855114;NCT02531932;NCT02871791;NCT00107016;NCT01163929;NCT00934895;NCT01298713;NCT01127763;NCT02273752;NCT02035813;NCT02742051;NCT04355858;NCT01520103;NCT03032406;NCT02456857;NCT02049957;NCT02387099;NCT00674414;NCT03805399;NCT02028364;NCT01272141;NCT00930475;NCT00930930;NCT03750396;NCT00255788;NCT02216786;NCT01939418;NCT00458237;NCT02520063;NCT02829008;NCT01499160;NCT00912340;NCT02069093;NCT00466102;NCT01088893;NCT01797120;NCT01783756;NCT00915603;NCT02344550;NCT01283789;NCT02015559;NCT02258451;NCT01698918;NCT01931163;NCT03312738;NCT01783444;NCT02269670;NCT04395989;NCT02236572;NCT02229136;NCT03659136;NCT02732119;NCT00570921;NCT00827567;NCT01031446;NCT02291913;NCT02313051;NCT00499603;NCT01305941
Breast Neoplasms	D001943	everolimus	Phase 3	2007	2015	NCT02511639;NCT01626222;NCT02376985;NCT00876395;NCT02404051;NCT01007942;NCT01773460;NCT01805271;NCT00567554;NCT03176238;NCT01674140;NCT00863655;NCT02137837
Breast Neoplasms	D001943	everolimus	Phase 4	2011	2014	NCT02248571;NCT01948960;NCT01743560;NCT01231659
Neoplasm Metastasis	D009362	everolimus	Phase 1	2007	2010	NCT00426530;NCT01115803;NCT01122199
Neoplasm Metastasis	D009362	everolimus	Phase 2	2006	2014	NCT00317720;NCT01298713;NCT02142036;NCT01678664;NCT01960829;NCT01499160;NCT00466102;NCT01783756;NCT01178151;NCT01305941
Melanoma	D008545	everolimus	Phase 1	2004	2004	NCT00655655
Melanoma	D008545	everolimus	Phase 2	2005	2013	NCT01014351;NCT00591734;NCT00098553;NCT00402662;NCT01252251;NCT01960829;NCT00976573;NCT00521001
Insulinoma	D007340	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Insulinoma	D007340	everolimus	Phase 2	2014	2014	NCT02031536;NCT02273752
Carcinoma, Islet Cell	D018273	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Carcinoma, Islet Cell	D018273	everolimus	Phase 2	2005	2014	NCT02031536;NCT02273752;NCT00113360;NCT00363051
Gastrinoma	D015408	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Gastrinoma	D015408	everolimus	Phase 2	2010	2014	NCT02031536;NCT02273752;NCT01229943
Glucagonoma	D005935	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Glucagonoma	D005935	everolimus	Phase 2	2014	2014	NCT02031536;NCT02273752
Somatostatinoma	D013005	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Somatostatinoma	D013005	everolimus	Phase 2	2014	2014	NCT02031536;NCT02273752
Carcinoma	D002277	everolimus	Phase 1	2004	2020	NCT00384969;NCT04339062;NCT01204476;NCT00655655;NCT01677390;NCT00788060;NCT01637194;NCT00422344;NCT02152943;NCT02454478;NCT01115803;NCT01218555;NCT02577458;NCT00828594;NCT03324373;NCT01332279;NCT03878524
Carcinoma	D002277	everolimus	Phase 2	2005	2020	NCT02283658;NCT02687958;NCT00688753;NCT01051791;NCT00942734;NCT01136733;NCT01442090;NCT00607113;NCT02113800;NCT01731158;NCT01152840;NCT00719264;NCT00936702;NCT02273752;NCT03173560;NCT00714025;NCT02248012;NCT01108445;NCT01215136;NCT01616186;NCT00830895;NCT02456857;NCT01715935;NCT01185366;NCT01034631;NCT01566747;NCT01239342;NCT03163667;NCT00516165;NCT00113360;NCT01545817;NCT00448149;NCT01399918;NCT00390195;NCT01217931;NCT04134390;NCT02695459;NCT03008408;NCT01491672;NCT01582009;NCT01488487;NCT01563354;NCT01797523;NCT00886691;NCT01133678;NCT02187302;NCT01379521;NCT02724020;NCT01453595;NCT00827359;NCT02315625;NCT04203901;NCT01642186;NCT00363051;NCT01510119;NCT00805129;NCT02915783;NCT02599324;NCT00903175;NCT02049047
Carcinoma	D002277	everolimus	Phase 3	2006	2020	NCT01035229;NCT01224288;NCT04195750;NCT01865747;NCT01265810;NCT00410124;NCT01668784;NCT02811861;NCT01198158
Carcinoma	D002277	everolimus	Phase 4	2009	2015	NCT02056587;NCT02081755;NCT01206764;NCT01514448;NCT01266837;NCT02338570
Carcinoma, Renal Cell	D002292	everolimus	Phase 1	2004	2019	NCT00384969;NCT00655655;NCT01334073;NCT02890069;NCT02077933;NCT01677390;NCT02133742;NCT00788060;NCT01714765;NCT00422344;NCT02454478;NCT01115803;NCT01482156;NCT02577458;NCT03324373;NCT01152801;NCT02071862
Carcinoma, Renal Cell	D002292	everolimus	Phase 2	2005	2020	NCT00688753;NCT00831480;NCT01136733;NCT02089334;NCT01442090;NCT02560012;NCT01731158;NCT00719264;NCT02273752;NCT03173560;NCT01408004;NCT02479490;NCT01108445;NCT01616186;NCT00830895;NCT01715935;NCT01185366;NCT00651482;NCT01034631;NCT01566747;NCT00529802;NCT01239342;NCT00392821;NCT03163667;NCT00446368;NCT00331409;NCT01545817;NCT00448149;NCT01399918;NCT01217931;NCT01793636;NCT04134390;NCT01784978;NCT02504892;NCT01491672;NCT01582009;NCT00323739;NCT02187302;NCT02724020;NCT01453595;NCT01888042;NCT00827359;NCT04203901;NCT01462214;NCT01510119;NCT02915783;NCT02599324;NCT00903175
Carcinoma, Renal Cell	D002292	everolimus	Phase 3	2006	2020	NCT03095040;NCT01224288;NCT04195750;NCT01865747;NCT01120249;NCT01265810;NCT00410124;NCT01668784;NCT02811861;NCT01198158
Carcinoma, Renal Cell	D002292	everolimus	Phase 4	2009	2015	NCT02056587;NCT01206764;NCT01514448;NCT01266837;NCT02338570
Adenocarcinoma	D000230	everolimus	Phase 1	2009	2020	NCT02138929;NCT03878524;NCT00981162
Adenocarcinoma	D000230	everolimus	Phase 2	2007	2017	NCT02283658;NCT00560963;NCT02397083;NCT02985125;NCT03008408;NCT00597506;NCT02599324;NCT01231399
Ovarian Neoplasms	D010051	everolimus	Phase 2	2010	2014	NCT02283658;NCT01149434;NCT02188550
Carcinoma, Ovarian Epithelial	D000077216	everolimus	Phase 1	2010	2010	NCT01281514
Carcinoma, Ovarian Epithelial	D000077216	everolimus	Phase 2	2010	2014	NCT02283658;NCT01149434;NCT02188550
Carcinoma, Endometrioid	D018269	everolimus	Phase 2	2014	2017	NCT02283658;NCT02397083;NCT03008408
Cystadenocarcinoma	D003536	everolimus	Phase 2	2014	2014	NCT02283658
Cystadenocarcinoma, Serous	D018284	everolimus	Phase 2	2014	2014	NCT02283658
Cystadenocarcinoma, Serous	D018284	everolimus	Phase 3	2017	2017	NCT03285802
Adenocarcinoma, Papillary	D000231	everolimus	Phase 2	2014	2014	NCT02283658
Neurofibromatoses	D017253	everolimus	Phase 1	2013	2013	NCT01880749
Neurofibromatoses	D017253	everolimus	Phase 2	2011	2015	NCT01412892;NCT01490476;NCT02332902;NCT01345136;NCT01419639;NCT01365468
Neurofibromatosis 1	D009456	everolimus	Phase 2	2011	2015	NCT01412892;NCT01490476;NCT02332902;NCT01345136;NCT01419639;NCT01365468
Neurofibroma	D009455	everolimus	Phase 2	2011	2015	NCT01412892;NCT01490476;NCT02332902;NCT01345136;NCT01419639;NCT01365468
Neurofibroma, Plexiform	D018318	everolimus	Phase 2	2011	2012	NCT01412892;NCT01365468
Squamous Cell Carcinoma of Head and Neck	D000077195	everolimus	Phase 2	2010	2011	NCT01283334;NCT01051791;NCT01133678
Head and Neck Neoplasms	D006258	everolimus	Phase 1	2008	2018	NCT00935961;NCT01637194;NCT00858663;NCT03578432;NCT01332279;NCT01057277;NCT01058408
Head and Neck Neoplasms	D006258	everolimus	Phase 2	2009	2011	NCT01283334;NCT01333085;NCT01313390;NCT01111058;NCT01118065;NCT01009346
Carcinoma, Squamous Cell	D002294	everolimus	Phase 1	2008	2020	NCT04339062;NCT01637194;NCT01332279
Carcinoma, Squamous Cell	D002294	everolimus	Phase 2	2009	2010	NCT01051791;NCT00942734;NCT01133678
Pancreatic Neoplasms	D010190	everolimus	Phase 1	2009	2020	NCT01204476;NCT01263353;NCT03878524;NCT00981162
Pancreatic Neoplasms	D010190	everolimus	Phase 2	2006	2014	NCT01784861;NCT01648465;NCT02273752;NCT01042028;NCT00640978;NCT00409292;NCT01077986;NCT00363051
Lymphoma	D008223	everolimus	Phase 1	2006	2020	NCT00352443;NCT01334502;NCT01341834;NCT01567475;NCT02254239;NCT02240719;NCT00962507;NCT01854606;NCT01088048;NCT02900716;NCT00622258;NCT03328104;NCT00671112;NCT03878524
Lymphoma	D008223	everolimus	Phase 2	2004	2020	NCT00727207;NCT00702052;NCT01164267;NCT00474929;NCT01075321;NCT00516412;NCT01665768;NCT01453504;NCT03697408;NCT00978432;NCT01198665;NCT04305444;NCT00967044;NCT00918333;NCT00081874;NCT00869999;NCT01022996;NCT00436618;NCT01637090
Lymphoma	D008223	everolimus	Phase 3	2009	2009	NCT00790036
Lymphoma, Mantle-Cell	D020522	everolimus	Phase 1	2010	2014	NCT02240719;NCT01088048
Lymphoma, Mantle-Cell	D020522	everolimus	Phase 2	2004	2012	NCT00727207;NCT00702052;NCT01075321;NCT00516412;NCT01665768;NCT00918333;NCT00081874
Neurilemmoma	D009442	everolimus	Phase 1	2013	2013	NCT01880749
Neurilemmoma	D009442	everolimus	Phase 2	2012	2015	NCT01490476;NCT01345136
Neuroma, Acoustic	D009464	everolimus	Phase 1	2013	2013	NCT01880749
Neuroma, Acoustic	D009464	everolimus	Phase 2	2012	2015	NCT01490476;NCT01345136
Neurofibromatosis 2	D016518	everolimus	Phase 1	2013	2013	NCT01880749
Neurofibromatosis 2	D016518	everolimus	Phase 2	2011	2015	NCT01490476;NCT01345136;NCT01419639
Carcinoma, Hepatocellular	D006528	everolimus	Phase 1	2008	2012	NCT01733004;NCT00828594
Carcinoma, Hepatocellular	D006528	everolimus	Phase 2	2006	2012	NCT00516165;NCT00775073;NCT00390195;NCT01488487;NCT01379521;NCT01642186
Carcinoma, Hepatocellular	D006528	everolimus	Phase 3	2010	2011	NCT01035229;NCT01265810
Carcinoma, Hepatocellular	D006528	everolimus	Phase 4	2014	2014	NCT02081755
Lymphangioleiomyomatosis	D018192	everolimus	Phase 1	2019	2019	NCT04388371
Lymphangioleiomyomatosis	D018192	everolimus	Phase 2	2005	2018	NCT01059318;NCT03131999;NCT02061397;NCT02484664;NCT00792766;NCT00457964
Lymphangioleiomyomatosis	D018192	everolimus	Phase 3	2009	2009	NCT00790400
Sarcoma, Kaposi	D012514	everolimus	Phase 2	2008	2008	NCT01412515
Sarcoma	D012509	everolimus	Phase 1	2004	2020	NCT00187174;NCT00927966;NCT04199026
Sarcoma	D012509	everolimus	Phase 2	2008	2017	NCT01412515;NCT01281865;NCT01661283;NCT01216839;NCT01830153;NCT01048723;NCT00767819;NCT03114527
Tuberous Sclerosis	D014402	everolimus	Phase 2	2005	2014	NCT01954693;NCT01929642;NCT00411619;NCT02201212;NCT01289912;NCT01070316;NCT02451696;NCT02061397;NCT00792766;NCT00457964
Tuberous Sclerosis	D014402	everolimus	Phase 3	2009	2020	NCT01730209;NCT01713946;NCT02962414;NCT00789828;NCT00790400;NCT02860494
Tuberous Sclerosis	D014402	everolimus	Phase 4	2018	2018	NCT03525834
Carcinoma, Transitional Cell	D002295	everolimus	Phase 2	2008	2011	NCT01801137;NCT00714025;NCT01215136;NCT00933374;NCT00805129
Carcinoma, Neuroendocrine	D018278	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Carcinoma, Neuroendocrine	D018278	everolimus	Phase 2	2005	2016	NCT02687958;NCT00607113;NCT02113800;NCT02248012;NCT02205515;NCT00113360;NCT02695459;NCT01563354;NCT02315625;NCT00363051;NCT01625520
Colorectal Neoplasms	D015179	everolimus	Phase 1	2007	2010	NCT00478634;NCT01154335
Colorectal Neoplasms	D015179	everolimus	Phase 2	2006	2010	NCT01047293;NCT00337545;NCT00522665;NCT01139138;NCT00390364;NCT01058655;NCT01387880;NCT00419159
Leukemia, Myeloid	D007951	everolimus	Phase 1	2007	2020	NCT01154439;NCT00544999;NCT00636922;NCT03878524
Leukemia, Myeloid	D007951	everolimus	Phase 2	2004	2015	NCT02638428;NCT00093639;NCT01188889;NCT00762632
Carcinoma, Merkel Cell	D015266	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Carcinoid Tumor	D002276	everolimus	Phase 1	2004	2010	NCT01204476;NCT00942682;NCT00655655;NCT00804336
Carcinoid Tumor	D002276	everolimus	Phase 2	2008	2021	NCT04665739;NCT00688623;NCT01175096;NCT01152827;NCT03950609
Carcinoid Tumor	D002276	everolimus	Phase 3	2006	2006	NCT00412061
Paraganglioma	D010235	everolimus	Phase 1	2010	2010	NCT01204476
Paraganglioma	D010235	everolimus	Phase 2	2008	2008	NCT01152827
Carcinoma, Medullary	D018276	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Intestinal Neoplasms	D007414	everolimus	Phase 1	2010	2010	NCT01204476;NCT01263353
Intestinal Neoplasms	D007414	everolimus	Phase 2	2012	2012	NCT01648465
Stomach Neoplasms	D013274	everolimus	Phase 1	2008	2010	NCT01204476;NCT01049620;NCT01042782;NCT01263353
Stomach Neoplasms	D013274	everolimus	Phase 2	2007	2012	NCT01482299;NCT01648465;NCT00519324;NCT01514110;NCT00985192;NCT00632268;NCT00729482;NCT01099527;NCT01231399
Stomach Neoplasms	D013274	everolimus	Phase 3	2009	2011	NCT01248403;NCT00879333
Malignant Carcinoid Syndrome	D008303	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Malignant Carcinoid Syndrome	D008303	everolimus	Phase 3	2006	2006	NCT00412061
Gastrointestinal Neoplasms	D005770	everolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Gastrointestinal Neoplasms	D005770	everolimus	Phase 2	2010	2020	NCT01648465;NCT01567488;NCT01058655;NCT04591431
Sarcoma, Synovial	D013584	everolimus	Phase 2	2011	2011	NCT01281865
Lung Neoplasms	D008175	everolimus	Phase 1	2004	2012	NCT00434174;NCT01063478;NCT00655655;NCT01470209;NCT01167530;NCT00401778;NCT01079481;NCT00807755;NCT00466466;NCT00456833;NCT00892801;NCT00457119;NCT01700400
Lung Neoplasms	D008175	everolimus	Phase 2	2004	2018	NCT00406276;NCT00096486;NCT03670030;NCT00374140;NCT00770120;NCT01563354;NCT01427946
Lung Neoplasms	D008175	everolimus	Phase 4	2011	2011	NCT01317615
Carcinoma, Non-Small-Cell Lung	D002289	everolimus	Phase 1	2004	2016	NCT00434174;NCT01063478;NCT00655655;NCT01167530;NCT02890069;NCT00933777;NCT01115803;NCT00456833;NCT00892801;NCT01061788;NCT00457119;NCT01700400
Carcinoma, Non-Small-Cell Lung	D002289	everolimus	Phase 2	2004	2011	NCT00096486;NCT00124280;NCT01427946
Kidney Neoplasms	D007680	everolimus	Phase 1	2004	2016	NCT02890069;NCT01184326;NCT02077933;NCT00303732;NCT01714765;NCT00422344
Kidney Neoplasms	D007680	everolimus	Phase 2	2006	2020	NCT00688753;NCT00831480;NCT01408004;NCT02479490;NCT01715935;NCT01185366;NCT00651482;NCT01239342;NCT00392821;NCT00331409;NCT01217931;NCT01793636;NCT04134390;NCT01784978;NCT02504892;NCT00323739;NCT01453595;NCT01888042;NCT00827359
Kidney Neoplasms	D007680	everolimus	Phase 3	2011	2011	NCT01120249
Multiple Myeloma	D009101	everolimus	Phase 1	2008	2020	NCT00729638;NCT01889420;NCT02240719;NCT00962507;NCT02407509;NCT03878524
Multiple Myeloma	D009101	everolimus	Phase 2	2005	2010	NCT00618345;NCT00474929;NCT00918333;NCT01234974
Neoplasms, Plasma Cell	D054219	everolimus	Phase 1	2008	2020	NCT00729638;NCT01889420;NCT00962507;NCT02407509;NCT03878524
Neoplasms, Plasma Cell	D054219	everolimus	Phase 2	2005	2010	NCT00618345;NCT00474929;NCT00918333;NCT01234974
Triple Negative Breast Neoplasms	D064726	everolimus	Phase 1	2014	2016	NCT02890069;NCT02616848;NCT02071862
Triple Negative Breast Neoplasms	D064726	everolimus	Phase 2	2013	2020	NCT02531932;NCT03805399;NCT01931163;NCT04395989
Meningioma	D008579	everolimus	Phase 1	2013	2013	NCT01880749
Meningioma	D008579	everolimus	Phase 2	2010	2015	NCT02333565;NCT00972335
Glioblastoma	D005909	everolimus	Phase 1	2005	2020	NCT04135807;NCT03834740;NCT03355794;NCT00387400;NCT00613132
Glioblastoma	D005909	everolimus	Phase 2	2003	2016	NCT01062399;NCT00085566;NCT00515086;NCT00805961;NCT01434602;NCT00553150;NCT00107237
Glioma	D005910	everolimus	Phase 1	2017	2020	NCT04135807;NCT03834740;NCT04485559;NCT03355794;NCT03387020
Glioma	D005910	everolimus	Phase 2	2009	2019	NCT02023905;NCT00782626;NCT02233049;NCT03632317;NCT01434602;NCT03352427;NCT01158651;NCT01734512;NCT00823459
Brain Neoplasms	D001932	everolimus	Phase 1	2004	2020	NCT04135807;NCT00187174;NCT03387020
Brain Neoplasms	D001932	everolimus	Phase 2	2009	2016	NCT01434602;NCT00823459
Astrocytoma	D001254	everolimus	Phase 1	2017	2020	NCT04135807;NCT03355794
Astrocytoma	D001254	everolimus	Phase 2	2007	2018	NCT02023905;NCT00782626;NCT00411619;NCT00823459
Astrocytoma	D001254	everolimus	Phase 3	2009	2009	NCT00789828
Oligodendroglioma	D009837	everolimus	Phase 1	2020	2020	NCT04135807
Oligodendroglioma	D009837	everolimus	Phase 2	2009	2018	NCT02023905;NCT00823459
Lymphoma, B-Cell	D016393	everolimus	Phase 1	2010	2016	NCT01334502;NCT01854606;NCT01088048;NCT02900716
Lymphoma, B-Cell	D016393	everolimus	Phase 2	2009	2020	NCT01164267;NCT01075321;NCT01665768;NCT00978432;NCT04305444;NCT00918333;NCT00869999
Lymphoma, B-Cell	D016393	everolimus	Phase 3	2009	2009	NCT00790036
Lymphoma, B-Cell, Marginal Zone	D018442	everolimus	Phase 2	2009	2011	NCT01164267;NCT01075321;NCT00918333
Nervous System Neoplasms	D009423	everolimus	Phase 1	2006	2006	NCT00387400
Nervous System Neoplasms	D009423	everolimus	Phase 2	2003	2010	NCT01062399;NCT00085566;NCT00553150;NCT00107237
Central Nervous System Neoplasms	D016543	everolimus	Phase 1	2006	2008	NCT00387400;NCT00756340
Central Nervous System Neoplasms	D016543	everolimus	Phase 2	2003	2017	NCT01062399;NCT00085566;NCT03245151;NCT00553150;NCT00107237
Rhabdomyosarcoma	D012208	everolimus	Phase 1	2004	2004	NCT00187174
Rhabdomyosarcoma	D012208	everolimus	Phase 2	2011	2011	NCT01216839
Liver Neoplasms	D008113	everolimus	Phase 1	2014	2014	NCT01864070
Liver Neoplasms	D008113	everolimus	Phase 2	2008	2010	NCT01423708;NCT01005199;NCT01009801;NCT00775073
Leukemia	D007938	everolimus	Phase 1	2007	2020	NCT03740334;NCT01154439;NCT00544999;NCT01523977;NCT01088048;NCT02900716;NCT00636922;NCT03328104;NCT00671112;NCT03878524
Leukemia	D007938	everolimus	Phase 2	2004	2020	NCT00935792;NCT00968253;NCT00093639;NCT01188889;NCT04305444;NCT00918333;NCT00762632;NCT00081874;NCT00436618
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	everolimus	Phase 1	2011	2020	NCT03740334;NCT01523977;NCT03328104;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	everolimus	Phase 2	2009	2009	NCT00968253;NCT00918333
Leukemia, Lymphoid	D007945	everolimus	Phase 1	2010	2020	NCT03740334;NCT01523977;NCT01088048;NCT02900716;NCT03328104;NCT03878524
Leukemia, Lymphoid	D007945	everolimus	Phase 2	2009	2020	NCT00935792;NCT00968253;NCT04305444;NCT00918333
Thyroid Neoplasms	D013964	everolimus	Phase 2	2009	2017	NCT01270321;NCT01263951;NCT03139747;NCT01141309;NCT01164176;NCT01118065;NCT02143726;NCT01625520;NCT00936858
Digestive System Neoplasms	D004067	everolimus	Phase 2	2011	2012	NCT01648465;NCT01567488
Prostatic Neoplasms	D011471	everolimus	Phase 1	2009	2020	NCT01548807;NCT00943956;NCT02125084;NCT02106507;NCT01642732;NCT03878524
Prostatic Neoplasms	D011471	everolimus	Phase 2	2004	2016	NCT00630344;NCT00085566;NCT00814788;NCT00574769;NCT00976755;NCT00629525;NCT01313559;NCT00657982;NCT00526591;NCT01051570;NCT00459186;NCT02913131
Prostatic Neoplasms	D011471	everolimus	Phase 3	2019	2019	NCT03580239
Plasmacytoma	D010954	everolimus	Phase 1	2009	2009	NCT00962507
Plasmacytoma	D010954	everolimus	Phase 2	2005	2007	NCT00618345;NCT00474929
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	everolimus	Phase 1	2010	2020	NCT02240719;NCT01088048;NCT02900716;NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	everolimus	Phase 2	2009	2020	NCT00935792;NCT04305444;NCT00918333
Ependymoma	D004806	everolimus	Phase 1	2018	2018	NCT03387020
Ependymoma	D004806	everolimus	Phase 2	2015	2015	NCT02155920
Leukemia, Myeloid, Acute	D015470	everolimus	Phase 1	2007	2020	NCT01154439;NCT00544999;NCT00636922;NCT03878524
Leukemia, Myeloid, Acute	D015470	everolimus	Phase 2	2007	2007	NCT00762632
Pheochromocytoma	D010673	everolimus	Phase 1	2004	2004	NCT00655655
Pheochromocytoma	D010673	everolimus	Phase 2	2008	2008	NCT01152827
Skin Neoplasms	D012878	everolimus	Phase 1	2004	2004	NCT00655655
Skin Neoplasms	D012878	everolimus	Phase 3	2008	2008	NCT00799188
Endocrine Gland Neoplasms	D004701	everolimus	Phase 2	2009	2019	NCT00688623;NCT01678664;NCT01149434;NCT03950609;NCT02294006
Testicular Neoplasms	D013736	everolimus	Phase 2	2010	2011	NCT01242631;NCT01466231
Neoplasms, Germ Cell and Embryonal	D009373	everolimus	Phase 2	2010	2011	NCT01242631;NCT01466231
Endometrial Neoplasms	D016889	everolimus	Phase 1	2008	2019	NCT04188548;NCT00703807
Endometrial Neoplasms	D016889	everolimus	Phase 2	2004	2017	NCT01068249;NCT00870337;NCT02228681;NCT00087685;NCT02397083;NCT03008408;NCT01797523;NCT02188550
Peutz-Jeghers Syndrome	D010580	everolimus	Phase 2	2008	2010	NCT00811590;NCT01178151
Carcinoma, Adenoid Cystic	D003528	everolimus	Phase 1	2008	2010	NCT01637194;NCT01218555
Carcinoma, Adenoid Cystic	D003528	everolimus	Phase 2	2008	2008	NCT01152840
Mastocytosis	D008415	everolimus	Phase 2	2007	2007	NCT00449748
Mastocytosis, Systemic	D034721	everolimus	Phase 2	2007	2007	NCT00449748
Cholangiocarcinoma	D018281	everolimus	Phase 1	2009	2009	NCT00949949
Cholangiocarcinoma	D018281	everolimus	Phase 2	2009	2016	NCT00973713;NCT01525719;NCT03768375;NCT02836847
Neoplasms, Unknown Primary	D009382	everolimus	Phase 2	2009	2009	NCT00936702
Neoplastic Cells, Circulating	D009360	everolimus	Phase 2	2014	2014	NCT02035813
Lymphoma, Large B-Cell, Diffuse	D016403	everolimus	Phase 1	2012	2014	NCT01334502;NCT02240719;NCT01854606
Lymphoma, Large B-Cell, Diffuse	D016403	everolimus	Phase 2	2009	2020	NCT01075321;NCT00978432;NCT04305444;NCT00918333;NCT00869999
Lymphoma, Large B-Cell, Diffuse	D016403	everolimus	Phase 3	2009	2009	NCT00790036
Carcinoma in Situ	D002278	everolimus	Phase 2	2010	2010	NCT01259063
Preleukemia	D011289	everolimus	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	everolimus	Phase 2	2005	2005	NCT00809185
Sturge-Weber Syndrome	D013341	everolimus	Phase 2	2014	2014	NCT01997255
Osteosarcoma	D012516	everolimus	Phase 2	2010	2011	NCT01216826;NCT01804374;NCT01830153
Urinary Bladder Neoplasms	D001749	everolimus	Phase 2	2009	2010	NCT01215136;NCT00933374
Nasopharyngeal Carcinoma	D000077274	everolimus	Phase 1	2008	2010	NCT01341834;NCT01637194
Esophageal Neoplasms	D004938	everolimus	Phase 1	2012	2014	NCT01490749;NCT02138929
Esophageal Neoplasms	D004938	everolimus	Phase 2	2009	2012	NCT00985192;NCT01231399
Carotid Body Tumor	D002345	everolimus	Phase 2	2008	2008	NCT01152827
Paraganglioma, Extra-Adrenal	D010236	everolimus	Phase 2	2008	2008	NCT01152827
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	everolimus	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	everolimus	Phase 2	2004	2013	NCT00093639;NCT01188889
Leukemia, Myeloid, Chronic-Phase	D015466	everolimus	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	everolimus	Phase 2	2004	2013	NCT00093639;NCT01188889
Burkitt Lymphoma	D002051	everolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Lymphoma, Follicular	D008224	everolimus	Phase 1	2014	2014	NCT02240719
Lymphoma, Follicular	D008224	everolimus	Phase 2	2009	2020	NCT01075321;NCT04305444;NCT00918333
Lymphoma, Non-Hodgkin	D008228	everolimus	Phase 1	2008	2020	NCT01567475;NCT01088048;NCT00622258;NCT03878524
Lymphoma, Non-Hodgkin	D008228	everolimus	Phase 2	2009	2020	NCT01075321;NCT04305444;NCT00918333
Hodgkin Disease	D006689	everolimus	Phase 1	2014	2020	NCT02254239;NCT02240719;NCT03878524
Hodgkin Disease	D006689	everolimus	Phase 2	2009	2019	NCT01075321;NCT01665768;NCT01453504;NCT03697408;NCT00918333;NCT01022996
Lymphoma, T-Cell	D016399	everolimus	Phase 2	2009	2012	NCT01075321;NCT01198665;NCT00918333;NCT01637090
Mycosis Fungoides	D009182	everolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Sezary Syndrome	D012751	everolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Leukemia, T-Cell	D015458	everolimus	Phase 2	2004	2011	NCT01075321;NCT00918333;NCT00081874
Leukemia-Lymphoma, Adult T-Cell	D015459	everolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Waldenstrom Macroglobulinemia	D008258	everolimus	Phase 2	2009	2011	NCT01075321;NCT01125293;NCT00918333;NCT00976248
Lymphoma, Large-Cell, Anaplastic	D017728	everolimus	Phase 2	2009	2011	NCT01075321;NCT01198665;NCT00918333
Lymphoma, T-Cell, Peripheral	D016411	everolimus	Phase 2	2010	2011	NCT01075321;NCT01198665
Lymphoma, Extranodal NK-T-Cell	D054391	everolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Neoplasms, Second Primary	D016609	everolimus	Phase 2	2012	2014	NCT02142036;NCT01678664
Angiomyolipoma	D018207	everolimus	Phase 2	2005	2015	NCT02539459;NCT00792766;NCT00457964
Angiomyolipoma	D018207	everolimus	Phase 3	2009	2009	NCT00790400
Angiomyolipoma	D018207	everolimus	Phase 4	2018	2018	NCT03525834
Ureteral Neoplasms	D014516	everolimus	Phase 1	2010	2010	NCT01182168
Pelvic Neoplasms	D010386	everolimus	Phase 1	2010	2010	NCT01182168
Nerve Sheath Neoplasms	D018317	everolimus	Phase 2	2012	2012	NCT01661283
Neurofibrosarcoma	D018319	everolimus	Phase 2	2012	2012	NCT01661283
Small Cell Lung Carcinoma	D055752	everolimus	Phase 1	2007	2009	NCT01079481;NCT00807755;NCT00466466
Small Cell Lung Carcinoma	D055752	everolimus	Phase 2	2006	2006	NCT00374140
Uveal Neoplasms	D014604	everolimus	Phase 2	2010	2010	NCT01252251
Colonic Neoplasms	D003110	everolimus	Phase 1	2008	2008	NCT01637194
Colonic Neoplasms	D003110	everolimus	Phase 2	2010	2010	NCT01149434
Lymphoma, T-Cell, Cutaneous	D016410	everolimus	Phase 2	2009	2012	NCT01198665;NCT00918333;NCT01637090
Gallbladder Neoplasms	D005706	everolimus	Phase 1	2009	2009	NCT00949949
Gallbladder Neoplasms	D005706	everolimus	Phase 2	2016	2016	NCT03768375;NCT02836847
Vipoma	D003969	everolimus	Phase 2	2010	2010	NCT01229943
Uterine Neoplasms	D014594	everolimus	Phase 3	2017	2017	NCT03285802
Multiple Endocrine Neoplasia	D009377	everolimus	Phase 2	2019	2019	NCT03950609
Multiple Endocrine Neoplasia Type 1	D018761	everolimus	Phase 2	2019	2019	NCT03950609
Laryngeal Neoplasms	D007822	everolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Oropharyngeal Neoplasms	D009959	everolimus	Phase 1	2008	2008	NCT01637194
Carcinoma, Verrucous	D018289	everolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Carcinoma, Basal Cell	D002280	everolimus	Phase 1	2008	2008	NCT01637194
Papilloma	D010212	everolimus	Phase 1	2008	2008	NCT01637194
Salivary Gland Neoplasms	D012468	everolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Paranasal Sinus Neoplasms	D010255	everolimus	Phase 1	2008	2008	NCT01637194
Carcinoma, Mucoepidermoid	D018277	everolimus	Phase 1	2008	2008	NCT01637194
Esthesioneuroblastoma, Olfactory	D018304	everolimus	Phase 1	2008	2008	NCT01637194
Papilloma, Inverted	D018308	everolimus	Phase 1	2008	2008	NCT01637194
Tongue Neoplasms	D014062	everolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Brain Stem Neoplasms	D020295	everolimus	Phase 2	2017	2017	NCT03352427
Mesothelioma	D008654	everolimus	Phase 1	2014	2014	NCT02071862
Mesothelioma	D008654	everolimus	Phase 2	2008	2009	NCT00770120;NCT01024946
Breast Neoplasms, Male	D018567	everolimus	Phase 2	2013	2013	NCT01783756
Birt-Hogg-Dube Syndrome	D058249	everolimus	Phase 2	2015	2015	NCT02504892
Uterine Cervical Neoplasms	D002583	everolimus	Phase 1	2009	2011	NCT00967928;NCT01217177
Medulloblastoma	D008527	everolimus	Phase 1	2018	2018	NCT03387020
Rhabdoid Tumor	D018335	everolimus	Phase 1	2018	2018	NCT03387020
Gastrointestinal Stromal Tumors	D046152	everolimus	Phase 1	2014	2014	NCT02071862
Gastrointestinal Stromal Tumors	D046152	everolimus	Phase 2	2002	2002	NCT01275222
Gastrointestinal Stromal Tumors	D046152	everolimus	Phase 3	2011	2011	NCT01265810
Gastrointestinal Stromal Tumors	D046152	everolimus	Phase 4	2006	2006	NCT00510354
Neuroma	D009463	everolimus	Phase 2	2015	2015	NCT01345136
Hamartoma	D006222	everolimus	Phase 2	2017	2017	NCT02991807
Hamartoma Syndrome, Multiple	D006223	everolimus	Phase 2	2017	2017	NCT02991807
Neoplastic Processes	D009385	everolimus	Phase 2	2010	2010	NCT01178151
Gliosarcoma	D018316	everolimus	Phase 1	2005	2005	NCT00613132
Angiolipoma	D018206	everolimus	Phase 2	2008	2008	NCT00792766
Fallopian Tube Neoplasms	D005185	everolimus	Phase 1	2010	2010	NCT01281514
Fallopian Tube Neoplasms	D005185	everolimus	Phase 2	2010	2010	NCT01031381
Angiofibroma	D018322	everolimus	Phase 3	2020	2020	NCT02860494
Carcinoma, Large Cell	D018287	everolimus	Phase 4	2011	2011	NCT01317615
Blast Crisis	D001752	everolimus	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	everolimus	Phase 2	2004	2004	NCT00081874
Chondrosarcoma	D002813	everolimus	Phase 2	2014	2014	NCT02008019
Leiomyosarcoma	D007890	everolimus	Phase 2	2017	2017	NCT03114527
Liposarcoma	D008080	everolimus	Phase 2	2017	2017	NCT03114527
Hematologic Neoplasms	D019337	everolimus	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	everolimus	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	everolimus	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	everolimus	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	everolimus	Phase 1	2020	2020	NCT03878524
Carcinoma, Acinar Cell	D018267	everolimus	Phase 1	2009	2009	NCT00981162
Thymoma	D013945	everolimus	Phase 2	2011	2011	NCT02049047
Thymus Neoplasms	D013953	everolimus	Phase 2	2011	2011	NCT02049047
Polycythemia Vera	D011087	fedratinib	Phase 1	2008	2008	NCT00631462
Polycythemia Vera	D011087	fedratinib	Phase 2	2020	2021	NCT04282187;NCT04629508;NCT04446650
Polycythemia Vera	D011087	fedratinib	Phase 3	2019	2019	NCT03952039;NCT03755518
Blast Crisis	D001752	fedratinib	Phase 2	2020	2020	NCT04282187
Neoplasm Metastasis	D009362	fedratinib	Phase 2	2021	2021	NCT04370301
Carcinoma	D002277	fostamatinib	Phase 2	2009	2009	NCT00923481
Carcinoma, Renal Cell	D002292	fostamatinib	Phase 2	2009	2009	NCT00923481
Carcinoma, Non-Small-Cell Lung	D002289	fostamatinib	Phase 2	2009	2009	NCT00923481
Colorectal Neoplasms	D015179	fostamatinib	Phase 2	2009	2009	NCT00923481
Head and Neck Neoplasms	D006258	fostamatinib	Phase 2	2009	2009	NCT00923481
Pheochromocytoma	D010673	fostamatinib	Phase 2	2009	2009	NCT00923481
Lymphoma	D008223	fostamatinib	Phase 2	2007	2011	NCT00446095;NCT00798096;NCT01499303
Lymphoma, B-Cell	D016393	fostamatinib	Phase 2	2007	2011	NCT00446095;NCT01499303
Ovarian Neoplasms	D010051	fostamatinib	Phase 1	2018	2018	NCT03246074
Carcinoma, Ovarian Epithelial	D000077216	fostamatinib	Phase 1	2018	2018	NCT03246074
Lymphoma, T-Cell	D016399	fostamatinib	Phase 2	2009	2009	NCT00798096
Lymphoma, Large B-Cell, Diffuse	D016403	fostamatinib	Phase 2	2011	2011	NCT01499303
Hematologic Neoplasms	D019337	fostamatinib	Phase 1	2016	2016	NCT02611063
Carcinoma	D002277	gefitinib	Phase 1	2002	2011	NCT00033449;NCT01288430;NCT00083057
Carcinoma	D002277	gefitinib	Phase 2	2002	2018	NCT00113529;NCT00181688;NCT03486509;NCT00228488;NCT00126555;NCT00233636;NCT01449201;NCT02788201;NCT01608022;NCT01027676;NCT00229723;NCT00215202;NCT02039674;NCT00519077;NCT00082667;NCT00027690;NCT02353936;NCT00212108;NCT01039948;NCT00071994;NCT00054691
Carcinoma	D002277	gefitinib	Phase 3	2003	2003	NCT00234429;NCT00206219
Carcinoma, Renal Cell	D002292	gefitinib	Phase 2	2001	2004	NCT00113529;NCT00467077;NCT00014183;NCT00012337
Kidney Neoplasms	D007680	gefitinib	Phase 2	2001	2004	NCT00467077;NCT00014144;NCT00014183;NCT00012337;NCT00041106
Lung Neoplasms	D008175	gefitinib	Phase 1	1999	2018	NCT02157883;NCT00255489;NCT00328562;NCT01121575;NCT01570296;NCT00372515;NCT02321293;NCT00252798;NCT01288430;NCT03599518;NCT01147211;NCT00310154;NCT02374645;NCT03050411;NCT00005806;NCT01967095
Lung Neoplasms	D008175	gefitinib	Phase 2	2001	2019	NCT03122717;NCT02716311;NCT01192243;NCT02025218;NCT01982955;NCT03292133;NCT00891579;NCT00062270;NCT01928160;NCT02759835;NCT01556191;NCT01196234;NCT00333294;NCT00096486;NCT00062062;NCT02319577;NCT03944772;NCT00411047;NCT01498562;NCT02347839;NCT02747953;NCT00266877;NCT03461185;NCT00615758;NCT04148898;NCT00319800;NCT00173875;NCT00298688;NCT00238628;NCT01783834;NCT00025207;NCT00452244;NCT02179671;NCT03119519;NCT00809237;NCT03123484;NCT01610336;NCT01192230;NCT00029003;NCT01510990;NCT02804776;NCT00570401;NCT00188617;NCT03595644;NCT00986284;NCT01480141;NCT01749072;NCT03865511;NCT01189435;NCT01312337;NCT02191059;NCT02906163;NCT01784549;NCT02039674;NCT01871480;NCT00068653;NCT02025114;NCT01514877;NCT01530334;NCT00616499;NCT01037998;NCT00238251;NCT00614809;NCT00040794;NCT01391260;NCT00234442;NCT03399669;NCT00711594;NCT01951469;NCT00231465;NCT01039948;NCT00193336;NCT01024712;NCT01997775;NCT00344773;NCT00217698;NCT01466660;NCT01955421;NCT01513174;NCT02954523;NCT00098462;NCT00588445;NCT03424759;NCT00048087;NCT01580735;NCT00409006;NCT03399487;NCT00103051
Lung Neoplasms	D008175	gefitinib	Phase 3	2000	2020	NCT01158170;NCT02296125;NCT00049543;NCT02518802;NCT02350361;NCT00020709;NCT00144066;NCT01405079;NCT01544179;NCT01404260;NCT02326285;NCT02411448;NCT04239833;NCT02714010;NCT04028778;NCT04248829;NCT03787992;NCT01040780;NCT03856697;NCT02416739;NCT01066195;NCT00091156;NCT02588261;NCT02338011;NCT00357734;NCT00252707;NCT01017874;NCT00955695;NCT00006048;NCT00006049
Lung Neoplasms	D008175	gefitinib	Phase 4	2008	2020	NCT01720901;NCT00770588;NCT01000740;NCT04401059;NCT02031601;NCT03264794
Carcinoma, Non-Small-Cell Lung	D002289	gefitinib	Phase 1	1999	2018	NCT02157883;NCT00255489;NCT00497250;NCT02088112;NCT00328562;NCT01121575;NCT01570296;NCT00372515;NCT00252798;NCT01288430;NCT03599518;NCT01090011;NCT01147211;NCT02151721;NCT00993499;NCT00310154;NCT02374645;NCT01602289;NCT03333343;NCT03050411;NCT02040064;NCT00162318;NCT00005806
Carcinoma, Non-Small-Cell Lung	D002289	gefitinib	Phase 2	2001	2020	NCT03122717;NCT02716311;NCT01192243;NCT01982955;NCT02139579;NCT01746277;NCT00891579;NCT02856893;NCT00062270;NCT01928160;NCT01933347;NCT01196234;NCT00333294;NCT00096486;NCT00062062;NCT02319577;NCT03944772;NCT01469000;NCT00411047;NCT01498562;NCT03799094;NCT02747953;NCT00266877;NCT03461185;NCT01854034;NCT00615758;NCT04148898;NCT00319800;NCT00173875;NCT00059722;NCT03267654;NCT01783834;NCT03151161;NCT02976116;NCT02179671;NCT04358562;NCT03382795;NCT03119519;NCT03002844;NCT00124280;NCT00198393;NCT00809237;NCT01167244;NCT01932229;NCT03123484;NCT01610336;NCT01027676;NCT01192230;NCT00029003;NCT01510990;NCT01864681;NCT03758287;NCT00522145;NCT03595644;NCT00986284;NCT02930954;NCT01749072;NCT01312337;NCT01755923;NCT02191059;NCT00824746;NCT02906163;NCT01784549;NCT02039674;NCT01871480;NCT00256711;NCT02025114;NCT01514877;NCT00280787;NCT00616499;NCT02066038;NCT01037998;NCT01017679;NCT00614809;NCT04193007;NCT00040794;NCT01391260;NCT00264498;NCT00234442;NCT03399669;NCT00711594;NCT01951469;NCT00231465;NCT01039948;NCT00193336;NCT01024712;NCT03374280;NCT01997775;NCT00217698;NCT01955421;NCT01513174;NCT02954523;NCT00098462;NCT00588445;NCT00553254;NCT01833572;NCT03424759;NCT00048087;NCT01580735;NCT00409006;NCT03399487
Carcinoma, Non-Small-Cell Lung	D002289	gefitinib	Phase 3	2000	2020	NCT01158170;NCT02296125;NCT00049543;NCT00020709;NCT03866499;NCT00259064;NCT00076388;NCT01405079;NCT01544179;NCT03849768;NCT01404260;NCT03381066;NCT02326285;NCT02411448;NCT04239833;NCT02714010;NCT04028778;NCT04248829;NCT03787992;NCT01040780;NCT03856697;NCT02387086;NCT02824458;NCT02416739;NCT00090675;NCT01774721;NCT01066195;NCT00322452;NCT02859077;NCT00091156;NCT02588261;NCT00656136;NCT03529084;NCT02338011;NCT00234468;NCT00252707;NCT01017874;NCT00807066;NCT01085136;NCT00955695;NCT00006048;NCT00006049
Carcinoma, Non-Small-Cell Lung	D002289	gefitinib	Phase 4	2007	2020	NCT01203917;NCT00770588;NCT02299765;NCT01000740;NCT00536107;NCT04401059;NCT02778893;NCT02031601;NCT00608868;NCT03264794
Thyroid Neoplasms	D013964	gefitinib	Phase 2	2003	2003	NCT00095836
Carcinoma, Hepatocellular	D006528	gefitinib	Phase 2	2004	2005	NCT00282100;NCT00071994
Adenoma	D000236	gefitinib	Phase 2	2015	2015	NCT02484755
ACTH-Secreting Pituitary Adenoma	D049913	gefitinib	Phase 2	2015	2015	NCT02484755
Urinary Bladder Neoplasms	D001749	gefitinib	Phase 2	2001	2017	NCT00479089;NCT00246974;NCT02788201;NCT00014144
Urinary Bladder Neoplasms	D001749	gefitinib	Phase 3	2006	2006	NCT00352079
Head and Neck Neoplasms	D006258	gefitinib	Phase 1	2002	2004	NCT00820417;NCT00185835;NCT00681967
Head and Neck Neoplasms	D006258	gefitinib	Phase 2	2001	2011	NCT00255476;NCT01449201;NCT01185171;NCT00169221;NCT00242762;NCT00242749;NCT00239304;NCT00519077;NCT00024089;NCT00195078;NCT00015964;NCT01405846;NCT00352105;NCT00193284
Head and Neck Neoplasms	D006258	gefitinib	Phase 3	2004	2004	NCT00088907
Colorectal Neoplasms	D015179	gefitinib	Phase 1	2001	2018	NCT03491709;NCT00026364
Colorectal Neoplasms	D015179	gefitinib	Phase 2	2001	2015	NCT02723578;NCT00030524;NCT00233623;NCT00242788;NCT00025350;NCT00087334;NCT00026299;NCT00025142
Colorectal Neoplasms	D015179	gefitinib	Phase 3	2003	2003	NCT00234429
Glioblastoma	D005909	gefitinib	Phase 1	2005	2005	NCT00132158
Glioblastoma	D005909	gefitinib	Phase 2	2001	2011	NCT00025675;NCT00042991;NCT00085566;NCT01310855;NCT00014170;NCT00238797;NCT00016991;NCT00250887;NCT00052208
Astrocytoma	D001254	gefitinib	Phase 2	2001	2002	NCT00025675;NCT00042991
Meningioma	D008579	gefitinib	Phase 2	2001	2001	NCT00025675
Nervous System Neoplasms	D009423	gefitinib	Phase 1	2002	2002	NCT00027625
Nervous System Neoplasms	D009423	gefitinib	Phase 2	2001	2004	NCT00025675;NCT00085566;NCT00016991
Central Nervous System Neoplasms	D016543	gefitinib	Phase 1	2002	2002	NCT00027625
Central Nervous System Neoplasms	D016543	gefitinib	Phase 2	2001	2004	NCT00025675;NCT00085566;NCT00016991
Adenocarcinoma of Lung	D000077192	gefitinib	Phase 2	2002	2018	NCT02759835;NCT03486496;NCT02788058;NCT00198380;NCT02951637;NCT00716456;NCT01502202;NCT02787447;NCT00040794;NCT01466660
Adenocarcinoma of Lung	D000077192	gefitinib	Phase 3	2001	2016	NCT00049543;NCT02518802;NCT00020709;NCT02889692;NCT02929693;NCT02893332
Small Cell Lung Carcinoma	D055752	gefitinib	Phase 2	2004	2017	NCT00298688;NCT02876081
Small Cell Lung Carcinoma	D055752	gefitinib	Phase 4	2013	2013	NCT01720901
Squamous Cell Carcinoma of Head and Neck	D000077195	gefitinib	Phase 1	2004	2004	NCT00083057
Squamous Cell Carcinoma of Head and Neck	D000077195	gefitinib	Phase 2	2004	2014	NCT02216916;NCT01449201;NCT00229723;NCT00519077
Squamous Cell Carcinoma of Head and Neck	D000077195	gefitinib	Phase 3	2003	2003	NCT00206219
Adenocarcinoma, Bronchiolo-Alveolar	D002282	gefitinib	Phase 2	2001	2002	NCT00029003;NCT00040794
Adenocarcinoma, Bronchiolo-Alveolar	D002282	gefitinib	Phase 3	2001	2002	NCT00049543;NCT00020709
Breast Neoplasms	D001943	gefitinib	Phase 2	2001	2013	NCT00080743;NCT00206414;NCT00239343;NCT00051051;NCT00255463;NCT00024154;NCT00999804;NCT00632723;NCT00319618;NCT00234403;NCT00077025;NCT00229697;NCT00066339;NCT00252811;NCT00428896;NCT00206492;NCT00049062;NCT00086957;NCT00057941;NCT00066378;NCT00637026;NCT01732276;NCT00052169;NCT00247481
Adenocarcinoma	D000230	gefitinib	Phase 2	2002	2018	NCT03486496;NCT02788058;NCT00198380;NCT02951637;NCT00716456;NCT01502202;NCT02787447;NCT02876081;NCT01871480;NCT00052585;NCT00344773;NCT01466660
Adenocarcinoma	D000230	gefitinib	Phase 3	2005	2016	NCT02518802;NCT01243398;NCT00455936;NCT02889692;NCT01066195;NCT02929693;NCT02893332
Prostatic Neoplasms	D011471	gefitinib	Phase 2	2001	2004	NCT00025116;NCT00085566;NCT00239291;NCT00319787;NCT00241475;NCT00635856;NCT00265070;NCT00483561;NCT00242918;NCT00418080
Ovarian Neoplasms	D010051	gefitinib	Phase 2	2002	2004	NCT00181688;NCT00049556;NCT00317772
Carcinoma, Ovarian Epithelial	D000077216	gefitinib	Phase 2	2002	2003	NCT00181688;NCT00049556
Neoplasms, Squamous Cell	D018307	gefitinib	Phase 1	2002	2002	NCT00185835
Neoplasms, Squamous Cell	D018307	gefitinib	Phase 2	2004	2011	NCT00255476;NCT01449201;NCT00229723
Carcinoma, Squamous Cell	D002294	gefitinib	Phase 1	2002	2004	NCT00185835;NCT00033449;NCT00083057
Carcinoma, Squamous Cell	D002294	gefitinib	Phase 2	2002	2018	NCT03486509;NCT00255476;NCT00126555;NCT00233636;NCT01449201;NCT01185158;NCT01608022;NCT00229723;NCT00519077;NCT02353936;NCT00054691
Carcinoma, Squamous Cell	D002294	gefitinib	Phase 3	2003	2003	NCT00206219
Uterine Cervical Neoplasms	D002583	gefitinib	Phase 2	2002	2002	NCT00049556
Fallopian Tube Neoplasms	D005185	gefitinib	Phase 2	2002	2004	NCT00049556;NCT00317772
Glioma	D005910	gefitinib	Phase 1	2002	2002	NCT00027625
Glioma	D005910	gefitinib	Phase 2	2002	2002	NCT00042991
Gliosarcoma	D018316	gefitinib	Phase 2	2001	2002	NCT00042991;NCT00014170;NCT00052208
Oligodendroglioma	D009837	gefitinib	Phase 2	2002	2002	NCT00042991
Neoplasms, Neuroepithelial	D018302	gefitinib	Phase 2	2002	2002	NCT00042991
Skin Neoplasms	D012878	gefitinib	Phase 2	2004	2006	NCT00423397;NCT00126555;NCT00054691
Breast Neoplasms, Male	D018567	gefitinib	Phase 2	2002	2002	NCT00024154
Pancreatic Neoplasms	D010190	gefitinib	Phase 2	2002	2004	NCT00177242;NCT00137761;NCT00234416
Neoplasm Metastasis	D009362	gefitinib	Phase 2	2004	2019	NCT04148898;NCT02142036;NCT00614809;NCT04193007;NCT00234442;NCT01951469
Neoplasm Metastasis	D009362	gefitinib	Phase 3	2000	2018	NCT02714010;NCT00034879;NCT02338011;NCT03653546;NCT02882984
Neoplasms, Second Primary	D016609	gefitinib	Phase 2	2007	2019	NCT04148898;NCT02142036;NCT00614809;NCT04193007
Neoplasms, Second Primary	D016609	gefitinib	Phase 3	2018	2018	NCT03653546
Meningeal Carcinomatosis	D055756	gefitinib	Phase 1	2006	2006	NCT00372515
Meningeal Carcinomatosis	D055756	gefitinib	Phase 2	2019	2019	NCT04148898
Carcinoma, Transitional Cell	D002295	gefitinib	Phase 2	2001	2017	NCT02788201;NCT00014144;NCT00041106
Stomach Neoplasms	D013274	gefitinib	Phase 2	2003	2017	NCT00237900;NCT03170180;NCT00215995
Esophageal Neoplasms	D004938	gefitinib	Phase 1	2005	2005	NCT00290719
Esophageal Neoplasms	D004938	gefitinib	Phase 2	2003	2015	NCT00258323;NCT00258297;NCT00493025;NCT00268346;NCT00215995;NCT01291823;NCT00100945;NCT02353936;NCT00093652
Esophageal Neoplasms	D004938	gefitinib	Phase 3	2009	2009	NCT01243398
Urethral Neoplasms	D014523	gefitinib	Phase 2	2001	2001	NCT00014144
Ureteral Neoplasms	D014516	gefitinib	Phase 2	2001	2002	NCT00014144;NCT00041106
Mesothelioma	D008654	gefitinib	Phase 2	2001	2003	NCT00025207;NCT00787410
Esophageal Squamous Cell Carcinoma	D000077277	gefitinib	Phase 2	2012	2015	NCT01608022;NCT02353936
Laryngeal Neoplasms	D007822	gefitinib	Phase 1	2002	2002	NCT00033449
Oropharyngeal Neoplasms	D009959	gefitinib	Phase 1	2002	2002	NCT00033449
Cholangiocarcinoma	D018281	gefitinib	Phase 2	2016	2016	NCT03768375;NCT02836847
Gallbladder Neoplasms	D005706	gefitinib	Phase 2	2016	2016	NCT03768375;NCT02836847
Adrenocortical Carcinoma	D018268	gefitinib	Phase 2	2004	2004	NCT00215202
Neuroendocrine Tumors	D018358	gefitinib	Phase 2	2003	2003	NCT00075439
Carcinoid Tumor	D002276	gefitinib	Phase 2	2003	2003	NCT00075439
Malignant Carcinoid Syndrome	D008303	gefitinib	Phase 2	2003	2003	NCT00075439
Gastrointestinal Neoplasms	D005770	gefitinib	Phase 2	2003	2003	NCT00075439
Insulinoma	D007340	gefitinib	Phase 2	2003	2003	NCT00075439
Carcinoma, Islet Cell	D018273	gefitinib	Phase 2	2003	2003	NCT00075439
Gastrinoma	D015408	gefitinib	Phase 2	2003	2003	NCT00075439
Glucagonoma	D005935	gefitinib	Phase 2	2003	2003	NCT00075439
Somatostatinoma	D013005	gefitinib	Phase 2	2003	2003	NCT00075439
Vipoma	D003969	gefitinib	Phase 2	2003	2003	NCT00075439
Thoracic Neoplasms	D013899	gefitinib	Phase 2	2018	2018	NCT03389256
Thoracic Neoplasms	D013899	gefitinib	Phase 3	2009	2009	NCT01024413
Neuroblastoma	D009447	gefitinib	Phase 1	2005	2005	NCT00132158
Neuroblastoma	D009447	gefitinib	Phase 2	2005	2005	NCT00135135
Osteosarcoma	D012516	gefitinib	Phase 1	2005	2005	NCT00132158
Rhabdomyosarcoma	D012208	gefitinib	Phase 1	2005	2005	NCT00132158
Neoplasms, Germ Cell and Embryonal	D009373	gefitinib	Phase 2	2002	2002	NCT00198159
Carcinoma in Situ	D002278	gefitinib	Phase 2	2002	2002	NCT00082667
Carcinoma, Ductal	D044584	gefitinib	Phase 2	2002	2002	NCT00082667
Carcinoma, Intraductal, Noninfiltrating	D002285	gefitinib	Phase 2	2002	2002	NCT00082667
Breast Carcinoma In Situ	D000071960	gefitinib	Phase 2	2002	2002	NCT00082667
Neoplasms, Unknown Primary	D009382	gefitinib	Phase 3	2003	2003	NCT00193596
Carcinoma, Bronchogenic	D002283	gefitinib	Phase 2	2011	2011	NCT01485809
Peritoneal Neoplasms	D010534	gefitinib	Phase 2	2004	2004	NCT00317772
Salivary Gland Neoplasms	D012468	gefitinib	Phase 2	2004	2004	NCT00509002
Leukemia	D007938	gefitinib	Phase 2	2005	2005	NCT00130702
Leukemia, Myeloid	D007951	gefitinib	Phase 2	2005	2005	NCT00130702
Leukemia, Myeloid, Acute	D015470	gefitinib	Phase 2	2005	2005	NCT00130702
Brain Neoplasms	D001932	gefitinib	Phase 2	2004	2019	NCT00614809;NCT04193007;NCT00234442;NCT01951469
Brain Neoplasms	D001932	gefitinib	Phase 3	2014	2014	NCT02338011
Nasopharyngeal Carcinoma	D000077274	gefitinib	Phase 2	2003	2003	NCT00212108
Sarcoma	D012509	gefitinib	Phase 2	2002	2002	NCT00052754
Sarcoma, Synovial	D013584	gefitinib	Phase 2	2002	2002	NCT00052754
Respiratory Tract Neoplasms	D012142	gefitinib	Phase 2	2009	2009	NCT01039948
Rectal Neoplasms	D012004	gefitinib	Phase 2	2002	2002	NCT00052585
Colonic Neoplasms	D003110	gefitinib	Phase 2	2002	2002	NCT00052585
Adenocarcinoma, Mucinous	D002288	gefitinib	Phase 2	2002	2002	NCT00052585
Cystadenocarcinoma	D003536	gefitinib	Phase 2	2002	2002	NCT00052585
Liver Neoplasms	D008113	gefitinib	Phase 2	2004	2004	NCT00071994
Leukemia	D007938	gilteritinib	Phase 1	2014	2021	NCT03625505;NCT02181660;NCT04655391;NCT02236013
Leukemia	D007938	gilteritinib	Phase 2	2013	2020	NCT04140487;NCT03730012;NCT02927262;NCT02014558;NCT02115295;NCT04240002;NCT03013998;NCT03836209;NCT04477291;NCT02310321;NCT04336982
Leukemia	D007938	gilteritinib	Phase 3	2015	2019	NCT02997202;NCT02752035;NCT04027309;NCT03182244;NCT02421939
Leukemia, Myeloid	D007951	gilteritinib	Phase 1	2014	2021	NCT03625505;NCT02181660;NCT04655391;NCT02236013
Leukemia, Myeloid	D007951	gilteritinib	Phase 2	2013	2020	NCT04140487;NCT03730012;NCT02927262;NCT02014558;NCT02115295;NCT02561455;NCT04240002;NCT03013998;NCT03836209;NCT04477291;NCT02310321;NCT04336982
Leukemia, Myeloid	D007951	gilteritinib	Phase 3	2015	2019	NCT02997202;NCT02752035;NCT04027309;NCT03182244;NCT02421939
Leukemia, Myeloid, Acute	D015470	gilteritinib	Phase 1	2014	2021	NCT03625505;NCT02181660;NCT04655391;NCT02236013
Leukemia, Myeloid, Acute	D015470	gilteritinib	Phase 2	2013	2020	NCT04140487;NCT03730012;NCT02927262;NCT02014558;NCT02115295;NCT02561455;NCT04240002;NCT03013998;NCT03836209;NCT04477291;NCT02310321;NCT04336982
Leukemia, Myeloid, Acute	D015470	gilteritinib	Phase 3	2015	2019	NCT02997202;NCT02752035;NCT04027309;NCT03182244;NCT02421939
Preleukemia	D011289	gilteritinib	Phase 2	2014	2019	NCT04140487;NCT02115295
Preleukemia	D011289	gilteritinib	Phase 3	2019	2019	NCT04027309
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	gilteritinib	Phase 2	2014	2014	NCT02115295
Blast Crisis	D001752	gilteritinib	Phase 2	2014	2014	NCT02115295
Leukemia, Biphenotypic, Acute	D015456	gilteritinib	Phase 2	2014	2014	NCT02115295
Lung Neoplasms	D008175	gilteritinib	Phase 2	2015	2015	NCT02495233
Carcinoma, Non-Small-Cell Lung	D002289	gilteritinib	Phase 2	2015	2015	NCT02495233
Leukemia	D007938	ibrutinib	Phase 1	2009	2021	NCT02759016;NCT02640209;NCT03479268;NCT02787369;NCT02537613;NCT02200848;NCT03422393;NCT02109224;NCT02556892;NCT02815059;NCT02303392;NCT01292135;NCT01886859;NCT01644253;NCT02160015;NCT04781855;NCT00849654;NCT03447808;NCT02611908;NCT02635074;NCT02614508;NCT02381080;NCT03400176
Leukemia	D007938	ibrutinib	Phase 2	2010	2021	NCT02662296;NCT02518555;NCT02689141;NCT02406742;NCT02910583;NCT02007044;NCT03162536;NCT03267186;NCT04155710;NCT02639910;NCT03708003;NCT02997761;NCT02912754;NCT03943342;NCT03873493;NCT04665115;NCT03734198;NCT02232386;NCT03045328;NCT04419389;NCT02869633;NCT03128879;NCT02666898;NCT02742090;NCT03513562;NCT04758975;NCT04010968;NCT03331198;NCT02514083;NCT03153202;NCT04754035;NCT02733042;NCT04685915;NCT04477291;NCT02420912;NCT02351037;NCT04771507;NCT03755947;NCT02629809;NCT02677948;NCT02427451;NCT02251548;NCT01520519;NCT03572634;NCT03280160;NCT02141282;NCT03514017;NCT02129062;NCT03980002;NCT03265717;NCT02332980;NCT03207555;NCT01752426;NCT04016805;NCT02758665;NCT02649387;NCT04230304;NCT02005289;NCT01217749;NCT02388048;NCT01109069;NCT01841723;NCT01105247;NCT01744691;NCT01589302;NCT02557516;NCT02756897;NCT02315768;NCT03370185;NCT04209621;NCT01500733;NCT03740529;NCT03226301
Leukemia	D007938	ibrutinib	Phase 3	2012	2021	NCT01722487;NCT01724346;NCT02264574;NCT02048813;NCT02991638;NCT03701282;NCT02477696;NCT02863718;NCT03642236;NCT03734016;NCT02950051;NCT02801578;NCT02301156;NCT01578707;NCT01611090;NCT01973387;NCT03737981;NCT01886872;NCT04608318;NCT03462719;NCT04666038
Leukemia	D007938	ibrutinib	Phase 4	2019	2019	NCT03190330
Leukemia, Lymphoid	D007945	ibrutinib	Phase 1	2011	2021	NCT02759016;NCT02640209;NCT03479268;NCT03301207;NCT02787369;NCT02537613;NCT04043845;NCT02200848;NCT03422393;NCT02268851;NCT02109224;NCT02556892;NCT02815059;NCT02303392;NCT02743546;NCT01292135;NCT01886859;NCT01644253;NCT02160015;NCT04781855;NCT03447808;NCT02611908;NCT02614508;NCT02381080;NCT03400176
Leukemia, Lymphoid	D007945	ibrutinib	Phase 2	2010	2021	NCT02662296;NCT02518555;NCT02689141;NCT02406742;NCT02910583;NCT02007044;NCT03162536;NCT03088878;NCT04155710;NCT02639910;NCT03708003;NCT02997761;NCT02912754;NCT03943342;NCT04665115;NCT03685708;NCT03734198;NCT02232386;NCT03045328;NCT04419389;NCT02869633;NCT03128879;NCT02666898;NCT02742090;NCT03513562;NCT04758975;NCT04010968;NCT03331198;NCT02514083;NCT03153202;NCT04754035;NCT02733042;NCT04685915;NCT02420912;NCT04771507;NCT03755947;NCT02629809;NCT03702231;NCT04494503;NCT02677948;NCT02427451;NCT02251548;NCT01520519;NCT03572634;NCT03280160;NCT02141282;NCT03514017;NCT02129062;NCT03980002;NCT04560322;NCT03265717;NCT02332980;NCT03207555;NCT04016805;NCT02758665;NCT02649387;NCT04230304;NCT02005289;NCT01217749;NCT02388048;NCT01109069;NCT01105247;NCT01744691;NCT01589302;NCT02557516;NCT02756897;NCT02315768;NCT02717611;NCT03370185;NCT04209621;NCT01500733;NCT03204188;NCT03740529;NCT03226301
Leukemia, Lymphoid	D007945	ibrutinib	Phase 3	2012	2021	NCT01722487;NCT01724346;NCT02264574;NCT02048813;NCT02991638;NCT03701282;NCT02477696;NCT02863718;NCT03734016;NCT02950051;NCT02801578;NCT02301156;NCT02757040;NCT01578707;NCT01611090;NCT01973387;NCT03737981;NCT01886872;NCT04608318;NCT03462719;NCT04666038;NCT01804686
Leukemia, Lymphoid	D007945	ibrutinib	Phase 4	2019	2019	NCT03190330
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	ibrutinib	Phase 1	2009	2021	NCT02759016;NCT02640209;NCT03479268;NCT03301207;NCT02787369;NCT02537613;NCT03454165;NCT04043845;NCT02200848;NCT03422393;NCT03960840;NCT02268851;NCT02109224;NCT02556892;NCT04688385;NCT02303392;NCT02743546;NCT02006485;NCT01292135;NCT01886859;NCT01644253;NCT02160015;NCT04781855;NCT00849654;NCT03447808;NCT02611908;NCT02614508;NCT02381080;NCT03400176
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	ibrutinib	Phase 2	2010	2021	NCT02662296;NCT02518555;NCT02689141;NCT02406742;NCT02910583;NCT02007044;NCT03162536;NCT03088878;NCT04155710;NCT02639910;NCT03708003;NCT02912754;NCT03943342;NCT04665115;NCT03685708;NCT03734198;NCT02232386;NCT03045328;NCT04419389;NCT02869633;NCT03128879;NCT02666898;NCT02742090;NCT03513562;NCT04758975;NCT04010968;NCT03331198;NCT02514083;NCT03153202;NCT04754035;NCT02733042;NCT04685915;NCT02420912;NCT04771507;NCT03755947;NCT02629809;NCT03702231;NCT04494503;NCT02677948;NCT04659044;NCT02427451;NCT02251548;NCT01520519;NCT03572634;NCT03280160;NCT02141282;NCT03514017;NCT03980002;NCT04560322;NCT03265717;NCT02332980;NCT03207555;NCT02013128;NCT04016805;NCT02758665;NCT02649387;NCT04230304;NCT02005289;NCT04116437;NCT01217749;NCT02388048;NCT01109069;NCT01105247;NCT01744691;NCT01589302;NCT02557516;NCT02756897;NCT02315768;NCT02717611;NCT03370185;NCT04209621;NCT01500733;NCT03204188;NCT03740529;NCT03226301
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	ibrutinib	Phase 3	2012	2021	NCT01722487;NCT01724346;NCT02264574;NCT02048813;NCT02991638;NCT03701282;NCT02477696;NCT02863718;NCT03734016;NCT02950051;NCT02801578;NCT02301156;NCT02757040;NCT01578707;NCT01611090;NCT01973387;NCT03737981;NCT01886872;NCT04608318;NCT03462719;NCT04666038;NCT01804686
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	ibrutinib	Phase 4	2019	2019	NCT03190330
Lymphoma	D008223	ibrutinib	Phase 1	2009	2021	NCT02640209;NCT02780830;NCT03479268;NCT02756247;NCT02055924;NCT02269085;NCT03220022;NCT03440567;NCT01479842;NCT04043845;NCT03223610;NCT03876028;NCT02419560;NCT01955499;NCT02954406;NCT02268851;NCT02109224;NCT03424122;NCT04739813;NCT01829568;NCT02303392;NCT03136497;NCT02159755;NCT02743546;NCT02966730;NCT02219737;NCT01292135;NCT01886859;NCT01644253;NCT02160015;NCT03703167;NCT02309580;NCT04781855;NCT00849654;NCT03295240;NCT01569750;NCT02203526;NCT02614508;NCT03219047;NCT02950220;NCT02446236
Lymphoma	D008223	ibrutinib	Phase 2	2010	2021	NCT02662296;NCT02518555;NCT02406742;NCT02077166;NCT02910583;NCT03162536;NCT03088878;NCT04155710;NCT01980628;NCT03399513;NCT02874404;NCT03617484;NCT01880567;NCT02455297;NCT02736617;NCT02356458;NCT02542514;NCT04514393;NCT02760485;NCT04665115;NCT01599949;NCT04477486;NCT03045328;NCT02207062;NCT04419389;NCT02869633;NCT03282396;NCT04421560;NCT03581942;NCT02532257;NCT02471391;NCT03128879;NCT03877055;NCT02460276;NCT04548648;NCT04450173;NCT02940301;NCT02626884;NCT03710772;NCT03129828;NCT03331198;NCT02514083;NCT03153202;NCT03310619;NCT02733042;NCT02401048;NCT02420912;NCT04189757;NCT01779791;NCT01849263;NCT03478514;NCT02692248;NCT01980654;NCT02636322;NCT02747732;NCT04129710;NCT03232307;NCT02927964;NCT04234061;NCT02677948;NCT04659044;NCT02689869;NCT01520519;NCT03198026;NCT02451111;NCT02315326;NCT02242097;NCT02956382;NCT02682641;NCT03323151;NCT03684694;NCT03093831;NCT02670616;NCT02744612;NCT02332980;NCT04446962;NCT03697512;NCT04230304;NCT02670317;NCT02005289;NCT04116437;NCT01217749;NCT02824029;NCT02142049;NCT01109069;NCT03144674;NCT02623010;NCT03949062;NCT03964090;NCT01325701;NCT01744691;NCT02272686;NCT01589302;NCT03770416;NCT02427620;NCT03235544;NCT02558816;NCT02756897;NCT01236391;NCT02169180;NCT02436707;NCT03370185;NCT04066920;NCT03939182;NCT01500733;NCT03740529;NCT02955628;NCT04607772
Lymphoma	D008223	ibrutinib	Phase 3	2012	2021	NCT01722487;NCT03570892;NCT02947347;NCT01724346;NCT04662255;NCT03112174;NCT02858258;NCT02264574;NCT02048813;NCT02735876;NCT02991638;NCT01776840;NCT01974440;NCT03734016;NCT02443077;NCT01646021;NCT01855750;NCT01578707;NCT01611090;NCT01973387;NCT04212013;NCT02703272;NCT04666038;NCT01804686
Lymphoma	D008223	ibrutinib	Phase 4	2017	2019	NCT03229200;NCT03190330
Lymphoma, Large B-Cell, Diffuse	D016403	ibrutinib	Phase 1	2011	2021	NCT02780830;NCT03479268;NCT02756247;NCT03220022;NCT03440567;NCT01479842;NCT03223610;NCT03876028;NCT01955499;NCT03960840;NCT02109224;NCT04739813;NCT02303392;NCT03136497;NCT02743546;NCT02219737;NCT02950220
Lymphoma, Large B-Cell, Diffuse	D016403	ibrutinib	Phase 2	2011	2020	NCT04025593;NCT02077166;NCT03162536;NCT03399513;NCT02874404;NCT02760485;NCT03731234;NCT03129828;NCT03310619;NCT02401048;NCT02692248;NCT02636322;NCT02747732;NCT03684694;NCT02670616;NCT04446962;NCT02142049;NCT03949062;NCT01325701;NCT03939182;NCT02955628;NCT04607772
Lymphoma, Large B-Cell, Diffuse	D016403	ibrutinib	Phase 3	2013	2016	NCT02443077;NCT01855750;NCT01804686
Lymphoma, Non-Hodgkin	D008228	ibrutinib	Phase 1	2011	2018	NCT03479268;NCT01479842;NCT01955499;NCT02954406;NCT02109224;NCT02303392;NCT01569750;NCT02950220
Lymphoma, Non-Hodgkin	D008228	ibrutinib	Phase 2	2010	2021	NCT02662296;NCT02207062;NCT04419389;NCT03310619;NCT01980654;NCT04659044;NCT03198026;NCT02332980;NCT01109069
Lymphoma, Non-Hodgkin	D008228	ibrutinib	Phase 3	2014	2019	NCT03570892;NCT01974440;NCT02703272
Lymphoma, Non-Hodgkin	D008228	ibrutinib	Phase 4	2017	2017	NCT03229200
Leukemia, Prolymphocytic	D015463	ibrutinib	Phase 1	2013	2018	NCT03479268;NCT02303392;NCT01886859
Leukemia, Prolymphocytic	D015463	ibrutinib	Phase 2	2012	2020	NCT02662296;NCT02007044;NCT03873493;NCT02005289;NCT01589302
Lymphoma, B-Cell	D016393	ibrutinib	Phase 1	2009	2021	NCT02780830;NCT03479268;NCT02756247;NCT02055924;NCT03220022;NCT03440567;NCT01479842;NCT03223610;NCT03876028;NCT01955499;NCT01704963;NCT02109224;NCT03424122;NCT04739813;NCT03136497;NCT02219737;NCT00849654;NCT01569750;NCT02950220
Lymphoma, B-Cell	D016393	ibrutinib	Phase 2	2010	2021	NCT02077166;NCT03162536;NCT03399513;NCT02874404;NCT02760485;NCT02207062;NCT03129828;NCT03478514;NCT02692248;NCT01980654;NCT02636322;NCT02747732;NCT04659044;NCT03684694;NCT03093831;NCT02670616;NCT02332980;NCT02670317;NCT02142049;NCT01109069;NCT03949062;NCT03964090;NCT01325701;NCT02272686;NCT03770416;NCT02436707;NCT03939182;NCT03740529;NCT02955628;NCT04607772
Lymphoma, B-Cell	D016393	ibrutinib	Phase 3	2013	2019	NCT03570892;NCT02991638;NCT02443077;NCT01855750;NCT02703272;NCT01804686
Lymphoma, B-Cell	D016393	ibrutinib	Phase 4	2017	2017	NCT03229200
Hematologic Neoplasms	D019337	ibrutinib	Phase 1	2015	2017	NCT02352558;NCT03328078
Hematologic Neoplasms	D019337	ibrutinib	Phase 2	2015	2017	NCT03162536;NCT02329847
Leukemia, B-Cell	D015448	ibrutinib	Phase 1	2009	2009	NCT00849654
Leukemia, B-Cell	D015448	ibrutinib	Phase 4	2017	2017	NCT03229200
Lymphoma, Follicular	D008224	ibrutinib	Phase 1	2011	2018	NCT03479268;NCT02756247;NCT01479842;NCT01955499;NCT02109224;NCT01829568;NCT02743546;NCT02966730;NCT02950220
Lymphoma, Follicular	D008224	ibrutinib	Phase 2	2013	2021	NCT03162536;NCT02869633;NCT02532257;NCT04450173;NCT03310619;NCT01779791;NCT01849263;NCT01980654;NCT02927964;NCT04659044;NCT02689869;NCT02451111;NCT02956382;NCT02332980
Lymphoma, Follicular	D008224	ibrutinib	Phase 3	2013	2017	NCT02947347;NCT01804686
Lymphoma, Mantle-Cell	D020522	ibrutinib	Phase 1	2011	2020	NCT03479268;NCT02756247;NCT02269085;NCT03440567;NCT01479842;NCT04043845;NCT02419560;NCT01955499;NCT02268851;NCT02109224;NCT02303392;NCT02159755;NCT02743546;NCT03295240;NCT03219047;NCT02950220;NCT02446236
Lymphoma, Mantle-Cell	D020522	ibrutinib	Phase 2	2010	2021	NCT03162536;NCT03088878;NCT03617484;NCT01880567;NCT02455297;NCT02736617;NCT02356458;NCT04665115;NCT01599949;NCT04477486;NCT04419389;NCT02869633;NCT03282396;NCT02471391;NCT03877055;NCT02460276;NCT03710772;NCT03153202;NCT04189757;NCT03478514;NCT03232307;NCT02927964;NCT04234061;NCT04659044;NCT02242097;NCT02682641;NCT03323151;NCT03684694;NCT02013128;NCT04116437;NCT01109069;NCT02427620;NCT03235544;NCT02558816;NCT01236391;NCT02169180;NCT03939182;NCT03740529
Lymphoma, Mantle-Cell	D020522	ibrutinib	Phase 3	2012	2021	NCT04662255;NCT03112174;NCT02858258;NCT02735876;NCT02991638;NCT01776840;NCT01646021;NCT01804686
Lymphoma, Mantle-Cell	D020522	ibrutinib	Phase 4	2019	2019	NCT03190330
Lymphoma, B-Cell, Marginal Zone	D018442	ibrutinib	Phase 1	2011	2020	NCT03479268;NCT01479842;NCT04043845;NCT02109224
Lymphoma, B-Cell, Marginal Zone	D018442	ibrutinib	Phase 2	2013	2021	NCT03162536;NCT01980628;NCT02532257;NCT02927964;NCT04659044;NCT03093831;NCT02332980;NCT03697512;NCT03144674;NCT03740529
Lymphoma, B-Cell, Marginal Zone	D018442	ibrutinib	Phase 3	2019	2019	NCT04212013
Waldenstrom Macroglobulinemia	D008258	ibrutinib	Phase 1	2011	2020	NCT03479268;NCT01479842;NCT04260217;NCT04043845;NCT04274738;NCT01955499;NCT02109224;NCT02950220;NCT04115059
Waldenstrom Macroglobulinemia	D008258	ibrutinib	Phase 2	2010	2021	NCT03162536;NCT02604511;NCT04665115;NCT03225716;NCT01614821;NCT03506373;NCT04062448;NCT03620903;NCT04273139;NCT02332980;NCT04116437;NCT01109069;NCT03679624;NCT03740529
Waldenstrom Macroglobulinemia	D008258	ibrutinib	Phase 3	2013	2021	NCT04061512;NCT02991638;NCT04263480;NCT03053440;NCT02165397;NCT01804686
Waldenstrom Macroglobulinemia	D008258	ibrutinib	Phase 4	2019	2019	NCT04042376
Leukemia, Prolymphocytic, B-Cell	D054403	ibrutinib	Phase 1	2013	2018	NCT03479268;NCT01886859
Leukemia, Prolymphocytic, B-Cell	D054403	ibrutinib	Phase 2	2012	2012	NCT01589302
Carcinoma	D002277	ibrutinib	Phase 2	2015	2018	NCT02884453;NCT03646461;NCT02599324
Adenocarcinoma	D000230	ibrutinib	Phase 2	2015	2015	NCT02562898;NCT02599324
Adenocarcinoma	D000230	ibrutinib	Phase 3	2015	2015	NCT02436668
Lung Neoplasms	D008175	ibrutinib	Phase 2	2015	2016	NCT02950038;NCT02403271;NCT02321540
Carcinoma, Non-Small-Cell Lung	D002289	ibrutinib	Phase 2	2015	2016	NCT02950038;NCT02403271;NCT02321540
Multiple Myeloma	D009101	ibrutinib	Phase 1	2014	2019	NCT02109224;NCT03702725
Multiple Myeloma	D009101	ibrutinib	Phase 2	2012	2017	NCT02902965;NCT03015792;NCT01962792;NCT01478581;NCT02548962;NCT02943473
Neoplasms, Plasma Cell	D054219	ibrutinib	Phase 1	2019	2019	NCT03702725
Neoplasms, Plasma Cell	D054219	ibrutinib	Phase 2	2012	2017	NCT02902965;NCT03015792;NCT01962792;NCT01478581;NCT02548962;NCT02943473
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ibrutinib	Phase 1	2014	2019	NCT03960840;NCT02109224;NCT02815059
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ibrutinib	Phase 2	2014	2017	NCT03267186;NCT02997761;NCT02129062;NCT02388048
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	ibrutinib	Phase 2	2017	2017	NCT03267186
Leukemia, Biphenotypic, Acute	D015456	ibrutinib	Phase 2	2017	2017	NCT03267186
Prostatic Neoplasms	D011471	ibrutinib	Phase 2	2016	2016	NCT02643667
Lymphoma, AIDS-Related	D016483	ibrutinib	Phase 1	2017	2017	NCT03220022
Intraocular Lymphoma	D064090	ibrutinib	Phase 1	2014	2014	NCT02109224
Intraocular Lymphoma	D064090	ibrutinib	Phase 2	2015	2015	NCT02542514
Leukemia, Prolymphocytic, T-Cell	D015461	ibrutinib	Phase 2	2020	2020	NCT03873493
Hodgkin Disease	D006689	ibrutinib	Phase 2	2016	2016	NCT02869633;NCT02940301;NCT02626884;NCT02744612;NCT02824029
Burkitt Lymphoma	D002051	ibrutinib	Phase 1	2014	2021	NCT03223610;NCT02109224;NCT04739813;NCT02950220
Burkitt Lymphoma	D002051	ibrutinib	Phase 2	2010	2010	NCT01109069
Neoplasm, Residual	D018365	ibrutinib	Phase 2	2016	2021	NCT04758975;NCT02649387
Leukemia, Myeloid	D007951	ibrutinib	Phase 1	2016	2016	NCT02635074
Leukemia, Myeloid	D007951	ibrutinib	Phase 2	2015	2020	NCT04477291;NCT02351037
Leukemia, Myeloid	D007951	ibrutinib	Phase 3	2018	2018	NCT03642236
Leukemia, Myeloid, Acute	D015470	ibrutinib	Phase 1	2016	2016	NCT02635074
Leukemia, Myeloid, Acute	D015470	ibrutinib	Phase 2	2015	2020	NCT04477291;NCT02351037
Leukemia, Myeloid, Acute	D015470	ibrutinib	Phase 3	2018	2018	NCT03642236
Leukemia, Hairy Cell	D007943	ibrutinib	Phase 1	2014	2014	NCT02109224
Leukemia, Hairy Cell	D007943	ibrutinib	Phase 2	2013	2013	NCT01841723
Lymphomatoid Granulomatosis	D008230	ibrutinib	Phase 1	2014	2014	NCT02109224
Plasmablastic Lymphoma	D000069293	ibrutinib	Phase 1	2014	2014	NCT02109224
Lymphoma, Large-Cell, Immunoblastic	D016400	ibrutinib	Phase 1	2014	2014	NCT02109224
Breast Neoplasms	D001943	ibrutinib	Phase 2	2015	2017	NCT02403271;NCT03379428
Pancreatic Neoplasms	D010190	ibrutinib	Phase 2	2015	2015	NCT02403271
Melanoma	D008545	ibrutinib	Phase 1	2017	2017	NCT03021460
Melanoma	D008545	ibrutinib	Phase 2	2016	2016	NCT02581930
Skin Neoplasms	D012878	ibrutinib	Phase 1	2017	2017	NCT03021460
Skin Neoplasms	D012878	ibrutinib	Phase 2	2016	2016	NCT02581930
Immunoglobulin Light-chain Amyloidosis	D000075363	ibrutinib	Phase 2	2018	2018	NCT03130348
Neuroendocrine Tumors	D018358	ibrutinib	Phase 2	2015	2015	NCT02575300
Carcinoid Tumor	D002276	ibrutinib	Phase 2	2015	2015	NCT02575300
Mastocytosis	D008415	ibrutinib	Phase 2	2015	2015	NCT02415608
Mastocytosis, Systemic	D034721	ibrutinib	Phase 2	2015	2015	NCT02415608
Leukemia, Mast-Cell	D007946	ibrutinib	Phase 2	2015	2015	NCT02415608
Carcinoma, Renal Cell	D002292	ibrutinib	Phase 2	2015	2016	NCT02899078;NCT02599324
Neoplasm Metastasis	D009362	ibrutinib	Phase 1	2019	2019	NCT03703167
Neoplasm Metastasis	D009362	ibrutinib	Phase 2	2014	2019	NCT02315326;NCT03964090
Colorectal Neoplasms	D015179	ibrutinib	Phase 2	2018	2018	NCT03332498
Carcinoma, Squamous Cell	D002294	ibrutinib	Phase 2	2018	2018	NCT03646461
Squamous Cell Carcinoma of Head and Neck	D000077195	ibrutinib	Phase 2	2018	2018	NCT03646461
Glioblastoma	D005909	ibrutinib	Phase 1	2018	2018	NCT03535350
Nervous System Neoplasms	D009423	ibrutinib	Phase 2	2020	2020	NCT04446962
Central Nervous System Neoplasms	D016543	ibrutinib	Phase 2	2020	2020	NCT04446962
Lymphoma, T-Cell	D016399	ibrutinib	Phase 1	2012	2015	NCT01644253;NCT02309580
Lymphoma, T-Cell, Peripheral	D016411	ibrutinib	Phase 1	2012	2012	NCT01644253
Preleukemia	D011289	ibrutinib	Phase 1	2016	2017	NCT03359460;NCT02553941
Smoldering Multiple Myeloma	D000075122	ibrutinib	Phase 2	2017	2017	NCT02943473
Leukemia, Myelomonocytic, Chronic	D015477	ibrutinib	Phase 1	2016	2016	NCT02553941
Leukemia, Myelomonocytic, Juvenile	D054429	ibrutinib	Phase 1	2016	2016	NCT02553941
Neoplasm Metastasis	D009362	icotinib	Phase 2	2011	2018	NCT01516983;NCT03754530;NCT01688713;NCT02726568
Neoplasm Metastasis	D009362	icotinib	Phase 3	2012	2018	NCT01724801;NCT02714010;NCT04058704;NCT02882984
Brain Neoplasms	D001932	icotinib	Phase 2	2011	2018	NCT01516983;NCT03754530;NCT02726568
Brain Neoplasms	D001932	icotinib	Phase 3	2018	2018	NCT04058704
Carcinoma, Non-Small-Cell Lung	D002289	icotinib	Phase 1	2014	2014	NCT02066870
Carcinoma, Non-Small-Cell Lung	D002289	icotinib	Phase 2	2011	2019	NCT01744925;NCT04029350;NCT02264210;NCT02738983;NCT03396185;NCT02430974;NCT01690390;NCT03736837;NCT03749213;NCT03151161;NCT02407366;NCT01707329;NCT02027090;NCT03123484;NCT02960607;NCT03595644;NCT02062515;NCT02961270;NCT01929200;NCT02191059;NCT01514877;NCT03349203;NCT01688713;NCT02215356;NCT02272127;NCT01843647;NCT02820116
Carcinoma, Non-Small-Cell Lung	D002289	icotinib	Phase 3	2009	2019	NCT02486354;NCT01724801;NCT02714010;NCT01040780;NCT02883543;NCT04206072;NCT03008109;NCT03992885;NCT02448797
Carcinoma, Non-Small-Cell Lung	D002289	icotinib	Phase 4	2011	2020	NCT01926171;NCT04401059;NCT02778893;NCT02031601;NCT01465243;NCT02404675;NCT01646450;NCT02194556
Lung Neoplasms	D008175	icotinib	Phase 1	2014	2014	NCT02066870
Lung Neoplasms	D008175	icotinib	Phase 2	2012	2018	NCT01744925;NCT02264210;NCT02738983;NCT03396185;NCT03153358;NCT03749213;NCT02407366;NCT02027090;NCT03123484;NCT02375022;NCT03595644;NCT02062515;NCT02009605;NCT02961270;NCT01929200;NCT02191059;NCT01514877;NCT03349203;NCT01688713;NCT02215356;NCT03346811
Lung Neoplasms	D008175	icotinib	Phase 3	2009	2019	NCT01724801;NCT01996098;NCT02714010;NCT01040780;NCT03008109;NCT03992885;NCT02448797
Lung Neoplasms	D008175	icotinib	Phase 4	2013	2020	NCT01720901;NCT04401059;NCT02031601;NCT02194556;NCT02744664
Small Cell Lung Carcinoma	D055752	icotinib	Phase 4	2013	2013	NCT01720901
Adenocarcinoma of Lung	D000077192	icotinib	Phase 2	2015	2018	NCT02264210;NCT02788058;NCT02787447;NCT03402464;NCT03544814;NCT02737774
Adenocarcinoma of Lung	D000077192	icotinib	Phase 3	2012	2013	NCT02889692;NCT01719536
Adenocarcinoma of Lung	D000077192	icotinib	Phase 4	2012	2014	NCT02103257;NCT02283424;NCT01665417
Bronchial Neoplasms	D001984	icotinib	Phase 2	2015	2015	NCT02264210
Adenocarcinoma	D000230	icotinib	Phase 2	2014	2016	NCT02788058;NCT02787447;NCT02044328
Adenocarcinoma	D000230	icotinib	Phase 3	2012	2014	NCT02125240;NCT02889692;NCT01719536
Adenocarcinoma	D000230	icotinib	Phase 4	2012	2014	NCT02103257;NCT02283424;NCT01665417
Esophageal Neoplasms	D004938	icotinib	Phase 2	2013	2015	NCT02375581;NCT01855854
Carcinoma	D002277	icotinib	Phase 2	2012	2014	NCT01855854;NCT01534585;NCT02328261;NCT01973725
Neoplasms, Second Primary	D016609	icotinib	Phase 2	2018	2018	NCT03754530
Neoplasms, Second Primary	D016609	icotinib	Phase 4	2014	2014	NCT02283424
Pancreatic Neoplasms	D010190	icotinib	Phase 1	2013	2014	NCT02278458;NCT02024633
Neurofibromatoses	D017253	icotinib	Phase 2	2016	2016	NCT02934256
Neurofibromatosis 1	D009456	icotinib	Phase 2	2016	2016	NCT02934256
Neurofibroma	D009455	icotinib	Phase 2	2016	2016	NCT02934256
Neurilemmoma	D009442	icotinib	Phase 2	2016	2016	NCT02934256
Neuroma, Acoustic	D009464	icotinib	Phase 2	2016	2016	NCT02934256
Neurofibromatosis 2	D016518	icotinib	Phase 2	2016	2016	NCT02934256
Nasopharyngeal Carcinoma	D000077274	icotinib	Phase 2	2012	2014	NCT01534585;NCT02328261
Esophageal Squamous Cell Carcinoma	D000077277	icotinib	Phase 2	2013	2013	NCT01973725
Breast Neoplasms	D001943	icotinib	Phase 2	2015	2015	NCT02362230
Breast Neoplasms	D001943	imatinib	Phase 1	2003	2020	NCT00080665;NCT03878524
Breast Neoplasms	D001943	imatinib	Phase 2	2002	2006	NCT00338728;NCT00193180;NCT00323063;NCT00045188;NCT00087152
Breast Neoplasms	D001943	imatinib	Phase 4	2006	2006	NCT00372476
Leukemia	D007938	imatinib	Phase 1	2001	2020	NCT00316953;NCT00324077;NCT00686218;NCT00306202;NCT00346632;NCT02081378;NCT00852709;NCT00101088;NCT01077544;NCT00103701;NCT00040105;NCT01933906;NCT01795716;NCT00860535;NCT00025415;NCT01397734;NCT00428909;NCT00301093;NCT00233961;NCT01751425;NCT01460498;NCT00047502;NCT01130688;NCT00827138;NCT00268229;NCT00064285;NCT00258271;NCT00066326;NCT00064233;NCT01426334;NCT03228303;NCT01214655;NCT00352677;NCT01066468;NCT00004932;NCT00100997;NCT03878524
Leukemia	D007938	imatinib	Phase 2	2000	2021	NCT00261846;NCT00298987;NCT01698905;NCT01383447;NCT00136409;NCT00048672;NCT00990249;NCT04578847;NCT00866736;NCT01872442;NCT00042003;NCT00101660;NCT00219726;NCT00511121;NCT01392170;NCT00777036;NCT00815321;NCT00006053;NCT00511069;NCT00006052;NCT00384228;NCT00042016;NCT03578367;NCT00750659;NCT01279473;NCT00244829;NCT00022490;NCT00045422;NCT00070499;NCT00458848;NCT00858806;NCT00416884;NCT00015834;NCT00982488;NCT02687425;NCT00363649;NCT00103844;NCT02767063;NCT00171223;NCT03516279;NCT00895297;NCT01312818;NCT01227135;NCT00049192;NCT01126814;NCT00149136;NCT00493181;NCT00219752;NCT00451997;NCT00499889;NCT04709731;NCT00466726;NCT00427791;NCT03023046;NCT00388895;NCT00167180;NCT00171912;NCT00015847;NCT01005758;NCT01593254;NCT00039377;NCT04043676;NCT00093639;NCT00109707;NCT00088231;NCT00114959;NCT01746836;NCT01804985;NCT00482703;NCT00510926;NCT01227356;NCT00769327;NCT01725204;NCT01030718;NCT00030394;NCT00469014;NCT00514969;NCT01004497;NCT04006847;NCT00661180;NCT00558961;NCT00882206;NCT04070443;NCT01883219;NCT02709083;NCT01092741;NCT00130195;NCT01188889;NCT00154349;NCT04688983;NCT00337454;NCT00509093;NCT02398825;NCT00702403;NCT00028847;NCT02852486;NCT00852566;NCT00101595;NCT00529763;NCT01003054;NCT00041990;NCT01616238;NCT03610971;NCT00905398;NCT00267085;NCT00811070;NCT00219765;NCT00110058;NCT00415857;NCT00618501;NCT00973752;NCT01844765;NCT00594555;NCT00763763;NCT00054431;NCT00015860;NCT01690065;NCT00058747;NCT01802450;NCT01503502;NCT00335868;NCT01916785;NCT00038649;NCT00171249;NCT01724879;NCT00415909;NCT00101816;NCT00036738;NCT02888990;NCT00006475;NCT01602952;NCT00375219;NCT04126681;NCT01914484;NCT00287105;NCT00320190;NCT00376467;NCT00112775;NCT00210119;NCT04147533;NCT00038610;NCT02001818;NCT00955916;NCT01319981;NCT02896842;NCT00511303;NCT01005914;NCT00199186;NCT00053248;NCT02538926;NCT01429610;NCT02115672;NCT00101647;NCT04626024;NCT01641107;NCT01221376;NCT00573378;NCT00276926;NCT00079313;NCT03241199;NCT00081133;NCT00061945;NCT01011998
Leukemia	D007938	imatinib	Phase 3	1993	2021	NCT00022737;NCT00514488;NCT00137111;NCT04307576;NCT02174445;NCT03007147;NCT02108951;NCT00802841;NCT04375683;NCT00481247;NCT02103322;NCT00237120;NCT01460693;NCT03459534;NCT02115386;NCT03746054;NCT00519090;NCT00123474;NCT02272777;NCT01085617;NCT01755325;NCT00006343;NCT00055874;NCT00574873;NCT00327678;NCT02326311;NCT00264160;NCT01254188;NCT00471497;NCT00795756;NCT01511289;NCT03589326;NCT00050531;NCT00362466;NCT01275196;NCT00002514;NCT00123487;NCT00760877;NCT00327262;NCT02881086;NCT02130557;NCT03624530;NCT00219739;NCT02627677;NCT00124748;NCT01650805;NCT03515018;NCT01819389;NCT00349518;NCT01126892;NCT00333840;NCT03722420;NCT04722848
Leukemia	D007938	imatinib	Phase 4	2003	2016	NCT02317159;NCT00390897;NCT00786812;NCT02204722;NCT01243489;NCT02894645;NCT00081926;NCT01043874;NCT00171899;NCT00644878;NCT02602314;NCT01368523;NCT00461929;NCT00980018;NCT00845221;NCT01131325;NCT01660906;NCT01901666;NCT01491763
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	imatinib	Phase 1	2001	2020	NCT00316953;NCT00346632;NCT02081378;NCT00852709;NCT01077544;NCT00103701;NCT00860535;NCT00025415;NCT00352677;NCT01066468;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	imatinib	Phase 2	2001	2021	NCT00298987;NCT01383447;NCT00990249;NCT00476190;NCT00384228;NCT00750659;NCT01279473;NCT00458848;NCT00171223;NCT01312818;NCT00149136;NCT00427791;NCT03023046;NCT00388895;NCT00167180;NCT01005758;NCT00039377;NCT00109707;NCT01030718;NCT01004497;NCT00882206;NCT01883219;NCT00130195;NCT00154349;NCT04688983;NCT00702403;NCT00101595;NCT01616238;NCT00905398;NCT00618501;NCT00973752;NCT00763763;NCT00171249;NCT01724879;NCT00036738;NCT02888990;NCT01914484;NCT00287105;NCT00376467;NCT00038610;NCT01319981;NCT01005914;NCT00199186;NCT02538926;NCT01429610;NCT01641107;NCT00081133;NCT00061945
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	imatinib	Phase 3	1993	2021	NCT00022737;NCT00137111;NCT04307576;NCT03007147;NCT02611492;NCT04375683;NCT01085617;NCT00327678;NCT00795756;NCT03589326;NCT00002514;NCT00123487;NCT02881086;NCT03624530;NCT00349518;NCT04722848
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	imatinib	Phase 4	2008	2008	NCT02894645;NCT01491763
Leukemia, Lymphoid	D007945	imatinib	Phase 1	2001	2020	NCT00316953;NCT02081378;NCT00852709;NCT01077544;NCT00860535;NCT00025415;NCT00352677;NCT01066468;NCT03878524
Leukemia, Lymphoid	D007945	imatinib	Phase 2	2001	2021	NCT00298987;NCT01383447;NCT00990249;NCT00384228;NCT00750659;NCT01279473;NCT00458848;NCT00171223;NCT01312818;NCT00149136;NCT00427791;NCT03023046;NCT00388895;NCT00167180;NCT00039377;NCT00109707;NCT01030718;NCT01004497;NCT00558961;NCT00882206;NCT01883219;NCT00130195;NCT00154349;NCT04688983;NCT00702403;NCT00101595;NCT01616238;NCT00905398;NCT00618501;NCT00973752;NCT00763763;NCT00171249;NCT01724879;NCT00036738;NCT02888990;NCT01914484;NCT00287105;NCT00376467;NCT00038610;NCT01319981;NCT01005914;NCT00199186;NCT02538926;NCT01429610;NCT01641107;NCT00081133;NCT00061945
Leukemia, Lymphoid	D007945	imatinib	Phase 3	1993	2021	NCT00022737;NCT00137111;NCT04307576;NCT03007147;NCT01085617;NCT00327678;NCT00795756;NCT03589326;NCT00002514;NCT02881086;NCT00349518;NCT04722848
Leukemia, Lymphoid	D007945	imatinib	Phase 4	2008	2008	NCT02894645;NCT01491763
Leukemia, Myeloid	D007951	imatinib	Phase 1	2001	2020	NCT00316953;NCT00324077;NCT00346632;NCT02081378;NCT00852709;NCT00101088;NCT01077544;NCT00103701;NCT00040105;NCT01933906;NCT01795716;NCT00860535;NCT00025415;NCT01397734;NCT00428909;NCT01751425;NCT01460498;NCT00047502;NCT01130688;NCT00066326;NCT00064233;NCT01426334;NCT03228303;NCT00352677;NCT01066468;NCT00100997;NCT03878524;NCT00455221
Leukemia, Myeloid	D007951	imatinib	Phase 2	2000	2021	NCT00298987;NCT01698905;NCT00048672;NCT04578847;NCT00866736;NCT01872442;NCT00042003;NCT00101660;NCT02638428;NCT00511121;NCT01392170;NCT00815321;NCT03205267;NCT00006053;NCT00006052;NCT00384228;NCT00042016;NCT03578367;NCT00750659;NCT01279473;NCT00022490;NCT00045422;NCT00070499;NCT00481052;NCT00858806;NCT00015834;NCT00982488;NCT02687425;NCT00103844;NCT02767063;NCT00171223;NCT03516279;NCT00895297;NCT00049192;NCT00493181;NCT00451997;NCT04709731;NCT00466726;NCT00167180;NCT00015847;NCT01593254;NCT04043676;NCT00093639;NCT00109707;NCT00088231;NCT00114959;NCT01746836;NCT01804985;NCT00482703;NCT02888964;NCT00510926;NCT01227356;NCT02480608;NCT01725204;NCT01030718;NCT00030394;NCT00469014;NCT00514969;NCT04006847;NCT00661180;NCT04070443;NCT02709083;NCT01092741;NCT01188889;NCT00337454;NCT00509093;NCT02398825;NCT00702403;NCT00852566;NCT00101595;NCT01003054;NCT00041990;NCT03610971;NCT00267085;NCT00811070;NCT00110058;NCT01844765;NCT00594555;NCT00763763;NCT00054431;NCT01690065;NCT00058747;NCT01802450;NCT01503502;NCT00335868;NCT01916785;NCT00038649;NCT00171249;NCT00415909;NCT00101816;NCT00036738;NCT00006475;NCT01602952;NCT00375219;NCT04126681;NCT01914484;NCT00320190;NCT00146913;NCT00112775;NCT00210119;NCT04147533;NCT02001818;NCT02896842;NCT00511303;NCT00053248;NCT02115672;NCT00101647;NCT04626024;NCT01221376;NCT00573378;NCT00079313;NCT03241199;NCT00081133;NCT01774630;NCT01011998
Leukemia, Myeloid	D007951	imatinib	Phase 3	2000	2019	NCT00514488;NCT02174445;NCT02108951;NCT00802841;NCT00481247;NCT02103322;NCT00237120;NCT01460693;NCT03459534;NCT02115386;NCT03746054;NCT00519090;NCT00123474;NCT02272777;NCT01755325;NCT01743989;NCT00006343;NCT00055874;NCT00264160;NCT01254188;NCT00471497;NCT01511289;NCT00050531;NCT00297570;NCT00362466;NCT01275196;NCT00123487;NCT00760877;NCT00327262;NCT02130557;NCT02627677;NCT00124748;NCT01650805;NCT01819389;NCT01827930;NCT01126892;NCT00333840;NCT03722420
Leukemia, Myeloid	D007951	imatinib	Phase 4	2003	2016	NCT02317159;NCT00390897;NCT00786812;NCT02204722;NCT01243489;NCT00081926;NCT01043874;NCT00171899;NCT00644878;NCT02602314;NCT01368523;NCT00461929;NCT00980018;NCT00845221;NCT01131325;NCT01660906;NCT01901666
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	imatinib	Phase 1	2001	2020	NCT00316953;NCT00324077;NCT00346632;NCT02081378;NCT00852709;NCT00101088;NCT01077544;NCT00103701;NCT00040105;NCT01933906;NCT01795716;NCT00860535;NCT00025415;NCT01397734;NCT00428909;NCT00301093;NCT00233961;NCT01751425;NCT01460498;NCT00047502;NCT01130688;NCT00827138;NCT00258271;NCT00066326;NCT01270984;NCT00064233;NCT01426334;NCT03228303;NCT01751919;NCT00352677;NCT01066468;NCT00100997;NCT03878524;NCT00455221
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	imatinib	Phase 2	2000	2021	NCT00261846;NCT00298987;NCT01698905;NCT00048672;NCT04578847;NCT00866736;NCT01872442;NCT00042003;NCT00101660;NCT00219726;NCT00511121;NCT01392170;NCT00815321;NCT03205267;NCT03193281;NCT00006053;NCT00006052;NCT00384228;NCT00042016;NCT03578367;NCT00750659;NCT01279473;NCT02268370;NCT00022490;NCT00045422;NCT00070499;NCT00481052;NCT00858806;NCT00015834;NCT00982488;NCT02687425;NCT00103844;NCT01866553;NCT02767063;NCT00171223;NCT03516279;NCT00895297;NCT01227135;NCT00049192;NCT00493181;NCT00219752;NCT04709731;NCT00466726;NCT00167180;NCT00015847;NCT01593254;NCT04043676;NCT00093639;NCT00109707;NCT00088231;NCT00114959;NCT01746836;NCT01804985;NCT00482703;NCT02888964;NCT00510926;NCT01227356;NCT02480608;NCT00769327;NCT01725204;NCT01030718;NCT00030394;NCT00469014;NCT00514969;NCT04006847;NCT00661180;NCT04070443;NCT02709083;NCT01092741;NCT01188889;NCT03906292;NCT00337454;NCT02398825;NCT00702403;NCT00028847;NCT02852486;NCT00852566;NCT00101595;NCT01003054;NCT00041990;NCT03610971;NCT00267085;NCT00811070;NCT00219765;NCT00110058;NCT01844765;NCT00594555;NCT00763763;NCT00054431;NCT00015860;NCT01690065;NCT00058747;NCT01802450;NCT01503502;NCT00335868;NCT01916785;NCT00038649;NCT00171249;NCT00415909;NCT00101816;NCT00036738;NCT00006475;NCT00171158;NCT01602952;NCT00375219;NCT04126681;NCT01914484;NCT00320190;NCT00146913;NCT00112775;NCT00210119;NCT04147533;NCT02001818;NCT02896842;NCT00511303;NCT00199186;NCT00053248;NCT02115672;NCT02949570;NCT00101647;NCT04626024;NCT01221376;NCT00573378;NCT00079313;NCT03241199;NCT00081133;NCT01774630;NCT01011998
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	imatinib	Phase 3	2000	2019	NCT00514488;NCT02174445;NCT02108951;NCT00802841;NCT01400074;NCT00481247;NCT02103322;NCT00237120;NCT01460693;NCT03459534;NCT02115386;NCT03746054;NCT00519090;NCT00123474;NCT02272777;NCT01755325;NCT01743989;NCT00006343;NCT00055874;NCT00574873;NCT02326311;NCT00264160;NCT01254188;NCT00471497;NCT01511289;NCT00050531;NCT00297570;NCT00362466;NCT01275196;NCT00123487;NCT00760877;NCT00327262;NCT02130557;NCT00219739;NCT02627677;NCT00124748;NCT01650805;NCT03515018;NCT01819389;NCT01827930;NCT00349518;NCT01126892;NCT00333840;NCT03722420
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	imatinib	Phase 4	2003	2021	NCT02317159;NCT00390897;NCT00786812;NCT02204722;NCT01243489;NCT00081926;NCT01043874;NCT00171899;NCT00644878;NCT02602314;NCT04677439;NCT01368523;NCT00461929;NCT00980018;NCT02086487;NCT01578213;NCT00845221;NCT01131325;NCT01660906;NCT01901666
Gastrointestinal Stromal Tumors	D046152	imatinib	Phase 1	2001	2020	NCT00573404;NCT04276415;NCT02164240;NCT02508532;NCT00025415;NCT00135005;NCT01735968;NCT01738139;NCT01270984;NCT00441155;NCT01468688;NCT01751919;NCT04006769;NCT02185937;NCT02268435
Gastrointestinal Stromal Tumors	D046152	imatinib	Phase 2	2000	2020	NCT02257541;NCT01091207;NCT00137449;NCT00265798;NCT02342600;NCT00769782;NCT00585221;NCT00455559;NCT01389583;NCT01172548;NCT00112632;NCT03171389;NCT01110668;NCT00278876;NCT00237185;NCT02365441;NCT00500188;NCT04193553;NCT04633122;NCT03944304;NCT02336724;NCT03440515;NCT00867113;NCT02889328;NCT01440959;NCT00570635;NCT02216578;NCT00006357;NCT00117299;NCT02712112;NCT03609424;NCT04258956;NCT00618319;NCT02607332;NCT01294202;NCT01991379;NCT00782834;NCT01541709;NCT01039519;NCT03291054;NCT00385203;NCT01391611;NCT01068769;NCT04138381;NCT01478373;NCT01506336;NCT01275222;NCT00764595;NCT00254267;NCT03556384;NCT00940563;NCT01267695;NCT00025246;NCT00091078;NCT01907607;NCT03165721;NCT00290485;NCT01483014;NCT00718562;NCT00457743;NCT00089960;NCT00028002;NCT00359333;NCT00030667;NCT02401815;NCT01524848;NCT04106024;NCT00633295;NCT01323400;NCT00237172
Gastrointestinal Stromal Tumors	D046152	imatinib	Phase 3	2000	2020	NCT03673501;NCT03353753;NCT03465722;NCT00751036;NCT02260505;NCT02103322;NCT00293124;NCT01031628;NCT01271712;NCT00471328;NCT00041197;NCT00324987;NCT00075218;NCT03426722;NCT00785785;NCT00685828;NCT00956072;NCT00103168;NCT01151852;NCT00367861;NCT00009906;NCT04409223;NCT00116935;NCT00688766;NCT00812240;NCT01289028;NCT02576080;NCT00372567;NCT01694277
Gastrointestinal Stromal Tumors	D046152	imatinib	Phase 4	2004	2008	NCT00171977;NCT00793871;NCT00510354
Leukemia, Myeloid, Chronic-Phase	D015466	imatinib	Phase 1	2001	2020	NCT00324077;NCT00686218;NCT00101088;NCT00103701;NCT00040105;NCT01933906;NCT00025415;NCT00301093;NCT00064233;NCT01426334;NCT00100997;NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	imatinib	Phase 2	2001	2021	NCT00048672;NCT00777036;NCT03205267;NCT00045422;NCT02767063;NCT03516279;NCT00049192;NCT04709731;NCT01593254;NCT00093639;NCT00114959;NCT01746836;NCT02888964;NCT00510926;NCT00769327;NCT01725204;NCT00030394;NCT02709083;NCT01092741;NCT01188889;NCT03906292;NCT00702403;NCT03610971;NCT00038649;NCT01914484;NCT00320190;NCT00146913;NCT00112775;NCT02949570
Leukemia, Myeloid, Chronic-Phase	D015466	imatinib	Phase 3	2002	2018	NCT01460693;NCT03459534;NCT00123474;NCT00055874;NCT02130557;NCT02627677;NCT00124748;NCT01827930
Leukemia, Myeloid, Chronic-Phase	D015466	imatinib	Phase 4	2003	2012	NCT00390897;NCT00644878;NCT01660906
Blast Crisis	D001752	imatinib	Phase 1	2001	2020	NCT00316953;NCT00101088;NCT00103701;NCT00860535;NCT00025415;NCT00258271;NCT03878524
Blast Crisis	D001752	imatinib	Phase 2	2000	2013	NCT00042003;NCT00015834;NCT00114959;NCT00514969;NCT00702403;NCT00101595;NCT00594555;NCT00763763;NCT00054431;NCT01690065;NCT00101816;NCT00006475;NCT00171158;NCT01914484;NCT00199186;NCT00081133
Blast Crisis	D001752	imatinib	Phase 3	2009	2009	NCT01126892
Blast Crisis	D001752	imatinib	Phase 4	2008	2008	NCT00786812;NCT01368523
Leukemia, Myeloid, Accelerated Phase	D015465	imatinib	Phase 1	2001	2020	NCT00316953;NCT00101088;NCT00025415;NCT01426334;NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	imatinib	Phase 2	2000	2013	NCT00006052;NCT00114959;NCT00702403;NCT00110058;NCT00054431;NCT01914484;NCT00101647
Leukemia, Myeloid, Accelerated Phase	D015465	imatinib	Phase 3	2005	2005	NCT00123487
Hematologic Neoplasms	D019337	imatinib	Phase 1	2015	2020	NCT02352558;NCT03878524
Hematologic Neoplasms	D019337	imatinib	Phase 4	2016	2016	NCT03844360
Polycythemia Vera	D011087	imatinib	Phase 1	2001	2001	NCT00025415
Polycythemia Vera	D011087	imatinib	Phase 2	2002	2007	NCT00430066;NCT00039416;NCT01120821
Leukemia, Myelomonocytic, Acute	D015479	imatinib	Phase 1	2007	2007	NCT00852709
Leukemia, Myelomonocytic, Acute	D015479	imatinib	Phase 2	2002	2004	NCT00136409;NCT00079313
Leukemia, Myelomonocytic, Chronic	D015477	imatinib	Phase 1	2001	2020	NCT00852709;NCT00025415;NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	imatinib	Phase 2	2002	2004	NCT00136409;NCT00171912;NCT00039416;NCT00079313
Leukemia, Myelomonocytic, Juvenile	D054429	imatinib	Phase 1	2001	2020	NCT00852709;NCT00025415;NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	imatinib	Phase 2	2002	2004	NCT00136409;NCT00171912;NCT00039416;NCT00079313
Neoplasm Metastasis	D009362	imatinib	Phase 1	2001	2001	NCT00025415
Neoplasm Metastasis	D009362	imatinib	Phase 2	2003	2014	NCT02461849;NCT00769782;NCT02142036;NCT00080678;NCT01089595;NCT00084825;NCT00764595
Ovarian Neoplasms	D010051	imatinib	Phase 2	2002	2009	NCT00840450;NCT00042952;NCT00216112;NCT00039585;NCT00510653;NCT00928642
Glioblastoma	D005909	imatinib	Phase 1	2005	2007	NCT00613054;NCT00613132
Glioblastoma	D005909	imatinib	Phase 2	2004	2007	NCT00606008;NCT00615927;NCT00290771;NCT00171938;NCT00354913
Glioblastoma	D005909	imatinib	Phase 3	2004	2018	NCT00154375;NCT03632135
Astrocytoma	D001254	imatinib	Phase 2	2007	2007	NCT00606008
Astrocytoma	D001254	imatinib	Phase 3	2004	2004	NCT00154375
Lymphoma	D008223	imatinib	Phase 1	2001	2020	NCT00025415;NCT03878524
Lymphoma	D008223	imatinib	Phase 2	2008	2018	NCT00990249;NCT02431403;NCT03023046;NCT02462538;NCT00882206;NCT01665001;NCT00684411;NCT02538926
Lymphoma	D008223	imatinib	Phase 3	2016	2016	NCT02881086
Neurofibromatoses	D017253	imatinib	Phase 2	2006	2018	NCT02177825;NCT01673009;NCT01140360;NCT03688568
Neurofibromatosis 1	D009456	imatinib	Phase 2	2006	2018	NCT02177825;NCT01673009;NCT01140360;NCT03688568
Neurofibroma	D009455	imatinib	Phase 2	2006	2018	NCT02177825;NCT01673009;NCT01140360;NCT03688568
Neurofibroma, Plexiform	D018318	imatinib	Phase 2	2006	2018	NCT02177825;NCT01673009;NCT01140360;NCT03688568
Glioma	D005910	imatinib	Phase 1	2004	2007	NCT00401024;NCT00354068;NCT00613054
Glioma	D005910	imatinib	Phase 2	2001	2003	NCT00021229;NCT00049127;NCT00039364;NCT00010049
Nervous System Neoplasms	D009423	imatinib	Phase 1	2004	2006	NCT00401024;NCT00354068;NCT00387933
Nervous System Neoplasms	D009423	imatinib	Phase 2	2001	2009	NCT00021229;NCT00039364;NCT00904735;NCT00010049
Central Nervous System Neoplasms	D016543	imatinib	Phase 1	2004	2006	NCT00401024;NCT00354068;NCT00387933
Central Nervous System Neoplasms	D016543	imatinib	Phase 2	2001	2009	NCT00021229;NCT00039364;NCT00904735;NCT00010049
Lung Neoplasms	D008175	imatinib	Phase 1	2002	2003	NCT00052494;NCT00045604
Lung Neoplasms	D008175	imatinib	Phase 2	2002	2016	NCT01083589;NCT00425646;NCT00408460;NCT00248482;NCT01011075;NCT00193349;NCT01019798;NCT00323362;NCT00222144;NCT02127372;NCT00156286;NCT02954523;NCT00052949
Lung Neoplasms	D008175	imatinib	Phase 4	2017	2017	NCT03264794
Carcinoma, Non-Small-Cell Lung	D002289	imatinib	Phase 2	2004	2016	NCT01083589;NCT00425646;NCT00408460;NCT01011075;NCT01019798;NCT00323362;NCT02127372;NCT02954523
Carcinoma, Non-Small-Cell Lung	D002289	imatinib	Phase 4	2017	2017	NCT03264794
Fibromatosis, Aggressive	D018222	imatinib	Phase 2	2004	2019	NCT03802084;NCT01137916;NCT00928525;NCT00287846;NCT02495519
Sarcoma	D012509	imatinib	Phase 2	2000	2019	NCT01281865;NCT00062205;NCT00085475;NCT00084630;NCT00006357;NCT00117299;NCT00385203;NCT04138381;NCT00031915;NCT00767819;NCT00400569;NCT00090987;NCT00359333;NCT00030667;NCT02048371
Sarcoma	D012509	imatinib	Phase 3	2004	2015	NCT02413736;NCT00116935
Sarcoma, Synovial	D013584	imatinib	Phase 2	2002	2011	NCT01281865;NCT00030667
Adenocarcinoma	D000230	imatinib	Phase 1	2007	2020	NCT00598091;NCT03878524
Adenocarcinoma	D000230	imatinib	Phase 2	2004	2004	NCT00209079
Preleukemia	D011289	imatinib	Phase 1	2001	2020	NCT00346632;NCT00852709;NCT00025415;NCT03878524
Preleukemia	D011289	imatinib	Phase 2	2004	2006	NCT00451997;NCT00469014
Leukemia, Myeloid, Acute	D015470	imatinib	Phase 1	2001	2020	NCT00346632;NCT00025415;NCT03878524
Leukemia, Myeloid, Acute	D015470	imatinib	Phase 2	2004	2012	NCT00171223;NCT01126814;NCT00088231;NCT00469014;NCT00509093;NCT00594555;NCT01690065;NCT00171249;NCT00744081;NCT00955916
Dermatofibrosarcoma	D018223	imatinib	Phase 2	2004	2010	NCT01059656;NCT00085475;NCT00171912;NCT00084630;NCT00243191;NCT00122473
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	D054218	imatinib	Phase 2	2018	2018	NCT02538926
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	D054218	imatinib	Phase 3	2017	2017	NCT03007147
Mesothelioma	D008654	imatinib	Phase 1	2006	2006	NCT00402766
Mesothelioma	D008654	imatinib	Phase 2	2008	2014	NCT02303899;NCT00551252
Prostatic Neoplasms	D011471	imatinib	Phase 1	2001	2020	NCT00038194;NCT00424385;NCT03878524
Prostatic Neoplasms	D011471	imatinib	Phase 2	2003	2007	NCT01316458;NCT00861471;NCT00500110;NCT00080678;NCT00427999;NCT00084825;NCT00251225
Lymphangioleiomyomatosis	D018192	imatinib	Phase 2	2018	2018	NCT03131999
Leukemia, Promyelocytic, Acute	D015473	imatinib	Phase 1	2007	2007	NCT00852709
Colorectal Neoplasms	D015179	imatinib	Phase 1	2002	2009	NCT01271166;NCT00183833;NCT00920868
Colorectal Neoplasms	D015179	imatinib	Phase 2	2008	2009	NCT00784446;NCT00867334
Gliosarcoma	D018316	imatinib	Phase 1	2005	2007	NCT00613054;NCT00613132
Gliosarcoma	D018316	imatinib	Phase 2	2005	2006	NCT00615927;NCT00354913
Carcinoma, Ovarian Epithelial	D000077216	imatinib	Phase 2	2002	2009	NCT00036751;NCT00041041;NCT00216112;NCT00039585;NCT00510653;NCT00928642
Pleural Effusion, Malignant	D016066	imatinib	Phase 2	2006	2006	NCT00408460
Neoplasms, Germ Cell and Embryonal	D009373	imatinib	Phase 2	2002	2002	NCT00042952
Germinoma	D018237	imatinib	Phase 2	2002	2002	NCT00042952
Testicular Neoplasms	D013736	imatinib	Phase 2	2002	2002	NCT00042952
Seminoma	D018239	imatinib	Phase 2	2002	2002	NCT00042952
Dysgerminoma	D004407	imatinib	Phase 2	2002	2002	NCT00042952
Melanoma	D008545	imatinib	Phase 1	2013	2013	NCT01738139
Melanoma	D008545	imatinib	Phase 2	2001	2020	NCT01099514;NCT04598009;NCT00424515;NCT04546074;NCT02812693;NCT01782508;NCT00402662;NCT00074308;NCT00421317;NCT00027586;NCT00881049;NCT00667953;NCT00470470;NCT00788775
Desmoplastic Small Round Cell Tumor	D058405	imatinib	Phase 2	2002	2005	NCT00417807;NCT00062205;NCT00030667
Urogenital Neoplasms	D014565	imatinib	Phase 2	2003	2020	NCT01316458;NCT04644432
Genital Neoplasms, Male	D005834	imatinib	Phase 2	2003	2003	NCT01316458
Abdominal Neoplasms	D000008	imatinib	Phase 2	2003	2003	NCT01316458
Carcinoma	D002277	imatinib	Phase 1	2006	2020	NCT00314873;NCT03878524
Carcinoma	D002277	imatinib	Phase 2	2003	2020	NCT00193258;NCT01153750;NCT02788201;NCT04644432;NCT00354523;NCT00180921;NCT00506779;NCT00068783
Carcinoma, Renal Cell	D002292	imatinib	Phase 2	2004	2020	NCT00193258;NCT00323791;NCT04644432;NCT00331409;NCT03165721
Neoplasm, Residual	D018365	imatinib	Phase 1	2012	2013	NCT01751425;NCT01460498
Neoplasm, Residual	D018365	imatinib	Phase 2	2005	2018	NCT03516279;NCT01883219;NCT00267085
Neoplasm, Residual	D018365	imatinib	Phase 3	2018	2018	NCT03624530
Cholangiocarcinoma	D018281	imatinib	Phase 2	2007	2007	NCT01153750
Lymphoma, Non-Hodgkin	D008228	imatinib	Phase 1	2001	2020	NCT00025415;NCT03878524
Lymphoma, Non-Hodgkin	D008228	imatinib	Phase 2	2008	2018	NCT02431403;NCT03023046;NCT00684411;NCT02538926
Lymphoma, Non-Hodgkin	D008228	imatinib	Phase 3	2016	2016	NCT02881086
Chordoma	D002817	imatinib	Phase 1	2011	2011	NCT01175109
Chordoma	D002817	imatinib	Phase 2	2004	2019	NCT04042597;NCT00150072
Small Cell Lung Carcinoma	D055752	imatinib	Phase 1	2002	2003	NCT00052494;NCT00045604
Small Cell Lung Carcinoma	D055752	imatinib	Phase 2	2002	2003	NCT00248482;NCT00156286;NCT00052949
Sarcoma, Ewing	D012512	imatinib	Phase 2	2002	2002	NCT00062205;NCT00030667
Neuroectodermal Tumors, Primitive, Peripheral	D018241	imatinib	Phase 2	2002	2002	NCT00062205;NCT00030667
Urinary Bladder Neoplasms	D001749	imatinib	Phase 2	2017	2017	NCT02788201
Carcinoma, Transitional Cell	D002295	imatinib	Phase 2	2017	2017	NCT02788201
Kidney Neoplasms	D007680	imatinib	Phase 2	2006	2020	NCT00323791;NCT04644432;NCT00331409;NCT03165721
Multiple Myeloma	D009101	imatinib	Phase 1	2001	2020	NCT00025415;NCT03878524
Multiple Myeloma	D009101	imatinib	Phase 2	2004	2004	NCT00167180
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	imatinib	Phase 1	2001	2020	NCT00025415;NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	imatinib	Phase 2	2004	2005	NCT00167180;NCT00558961
Mastocytosis	D008415	imatinib	Phase 2	2004	2004	NCT00171912;NCT00109707
Mastocytosis	D008415	imatinib	Phase 4	2011	2011	NCT01297777
Mastocytosis, Systemic	D034721	imatinib	Phase 2	2004	2004	NCT00171912;NCT00109707
Mastocytosis, Systemic	D034721	imatinib	Phase 4	2011	2011	NCT01297777
Urologic Neoplasms	D014571	imatinib	Phase 2	2020	2020	NCT04644432
Skin Neoplasms	D012878	imatinib	Phase 1	2013	2013	NCT01738139
Skin Neoplasms	D012878	imatinib	Phase 2	2001	2016	NCT02812693;NCT00027586;NCT00068783
Colonic Neoplasms	D003110	imatinib	Phase 1	2002	2002	NCT00183833
Colonic Neoplasms	D003110	imatinib	Phase 2	2002	2016	NCT00041340;NCT02685046
Gastrointestinal Neoplasms	D005770	imatinib	Phase 2	2004	2007	NCT00570635;NCT00089960
Gastrointestinal Neoplasms	D005770	imatinib	Phase 4	2008	2008	NCT00793871
Digestive System Neoplasms	D004067	imatinib	Phase 2	2007	2007	NCT00570635
Digestive System Neoplasms	D004067	imatinib	Phase 4	2008	2008	NCT00793871
Stomach Neoplasms	D013274	imatinib	Phase 1	2007	2007	NCT00601510
Stomach Neoplasms	D013274	imatinib	Phase 2	2004	2017	NCT03170180;NCT00068380
Neoplasms, Second Primary	D016609	imatinib	Phase 2	2014	2014	NCT02142036
Burkitt Lymphoma	D002051	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, Follicular	D008224	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, B-Cell	D016393	imatinib	Phase 1	2001	2001	NCT00025415
Hodgkin Disease	D006689	imatinib	Phase 1	2001	2020	NCT00025415;NCT03878524
Lymphoma, Mantle-Cell	D020522	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, B-Cell, Marginal Zone	D018442	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, T-Cell	D016399	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, T-Cell	D016399	imatinib	Phase 2	2008	2008	NCT00684411
Lymphoma, Large B-Cell, Diffuse	D016403	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, Large-Cell, Immunoblastic	D016400	imatinib	Phase 1	2001	2001	NCT00025415
Plasmablastic Lymphoma	D000069293	imatinib	Phase 1	2001	2001	NCT00025415
Mycosis Fungoides	D009182	imatinib	Phase 1	2001	2001	NCT00025415
Sezary Syndrome	D012751	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, T-Cell, Cutaneous	D016410	imatinib	Phase 1	2001	2001	NCT00025415
Leukemia, T-Cell	D015458	imatinib	Phase 1	2001	2001	NCT00025415
Leukemia-Lymphoma, Adult T-Cell	D015459	imatinib	Phase 1	2001	2001	NCT00025415
Waldenstrom Macroglobulinemia	D008258	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, Large-Cell, Anaplastic	D017728	imatinib	Phase 1	2001	2001	NCT00025415
Lymphoma, Large-Cell, Anaplastic	D017728	imatinib	Phase 2	2015	2015	NCT02462538
Leukemia, Hairy Cell	D007943	imatinib	Phase 1	2001	2001	NCT00025415
Leukemia, Prolymphocytic	D015463	imatinib	Phase 1	2001	2001	NCT00025415
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	imatinib	Phase 1	2001	2020	NCT00025415;NCT03878524
Plasmacytoma	D010954	imatinib	Phase 1	2001	2001	NCT00025415
Intraocular Lymphoma	D064090	imatinib	Phase 1	2001	2001	NCT00025415
Leukemia, Large Granular Lymphocytic	D054066	imatinib	Phase 1	2001	2001	NCT00025415
Immunoglobulin Light-chain Amyloidosis	D000075363	imatinib	Phase 1	2001	2001	NCT00025415
Fibrosarcoma	D005354	imatinib	Phase 2	2004	2006	NCT00084630;NCT00400569
Endometrial Neoplasms	D016889	imatinib	Phase 2	2000	2000	NCT00006357
Intestinal Neoplasms	D007414	imatinib	Phase 2	2000	2000	NCT00006357
Meningioma	D008579	imatinib	Phase 2	2001	2009	NCT00354913;NCT00045734;NCT00904735;NCT00010049
Thyroid Neoplasms	D013964	imatinib	Phase 1	2018	2018	NCT03469011
Thyroid Neoplasms	D013964	imatinib	Phase 2	2004	2004	NCT00354523;NCT00115739
Oligodendroglioma	D009837	imatinib	Phase 2	2003	2003	NCT00049127
Brain Neoplasms	D001932	imatinib	Phase 2	2003	2003	NCT00049127
Salivary Gland Neoplasms	D012468	imatinib	Phase 2	2002	2002	NCT00045669
Nerve Sheath Neoplasms	D018317	imatinib	Phase 3	2006	2006	NCT00427583
Neurofibrosarcoma	D018319	imatinib	Phase 3	2006	2006	NCT00427583
Rectal Neoplasms	D012004	imatinib	Phase 2	2002	2002	NCT00041340
Head and Neck Neoplasms	D006258	imatinib	Phase 2	2004	2007	NCT00485485;NCT00180921
Neoplasms, Squamous Cell	D018307	imatinib	Phase 2	2007	2007	NCT00485485
Carcinoma, Squamous Cell	D002294	imatinib	Phase 2	2007	2007	NCT00485485
Hemangiopericytoma	D006393	imatinib	Phase 2	2003	2003	NCT00045734
Fallopian Tube Neoplasms	D005185	imatinib	Phase 2	2002	2002	NCT00039585
Carcinoma, Adenoid Cystic	D003528	imatinib	Phase 2	2004	2004	NCT00180921
Thyroid Cancer, Papillary	D000077273	imatinib	Phase 1	2018	2018	NCT03469011
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	D015452	imatinib	Phase 2	2009	2009	NCT00905398
Pancreatic Neoplasms	D010190	imatinib	Phase 1	2005	2020	NCT01048320;NCT00281996;NCT03878524
Pancreatic Neoplasms	D010190	imatinib	Phase 2	2005	2005	NCT00161213
Fibroma	D005350	imatinib	Phase 2	2004	2014	NCT01137916;NCT00287846;NCT02495519
Uterine Neoplasms	D014594	imatinib	Phase 2	2003	2003	NCT00506779
Cystadenocarcinoma, Serous	D018284	imatinib	Phase 2	2003	2003	NCT00506779
Thymoma	D013945	imatinib	Phase 1	2006	2006	NCT00314873
Carcinosarcoma	D002296	imatinib	Phase 2	2004	2004	NCT00075400
Mixed Tumor, Mullerian	D018200	imatinib	Phase 2	2004	2004	NCT00075400
Osteosarcoma	D012516	imatinib	Phase 2	2002	2014	NCT00031915;NCT00030667;NCT02048371
Histiocytoma	D051642	imatinib	Phase 2	2002	2006	NCT00031915;NCT00400569
Histiocytoma, Benign Fibrous	D018219	imatinib	Phase 2	2002	2006	NCT00031915;NCT00400569
Histiocytoma, Malignant Fibrous	D051677	imatinib	Phase 2	2002	2006	NCT00031915;NCT00400569
Chondrosarcoma	D002813	imatinib	Phase 2	2007	2014	NCT00928525;NCT02048371
Thoracic Neoplasms	D013899	imatinib	Phase 2	2018	2018	NCT03389256
Leiomyosarcoma	D007890	imatinib	Phase 2	2006	2006	NCT00400569
Liposarcoma	D008080	imatinib	Phase 2	2006	2014	NCT00400569;NCT02048371
Carcinoma, Merkel Cell	D015266	imatinib	Phase 2	2003	2003	NCT00068783
Carcinoma, Neuroendocrine	D018278	imatinib	Phase 2	2003	2003	NCT00068783
Breast Neoplasms, Male	D018567	imatinib	Phase 2	2002	2002	NCT00045188
Pheochromocytoma	D010673	imatinib	Phase 2	2017	2017	NCT03165721
Paraganglioma	D010235	imatinib	Phase 2	2017	2017	NCT03165721
Carotid Body Tumor	D002345	imatinib	Phase 2	2017	2017	NCT03165721
Sarcoma, Kaposi	D012514	imatinib	Phase 2	2005	2005	NCT00090987
Neuroblastoma	D009447	imatinib	Phase 2	2002	2002	NCT00030667
Neuroectodermal Tumors	D017599	imatinib	Phase 2	2002	2002	NCT00030667
Neuroectodermal Tumors, Primitive	D018242	imatinib	Phase 2	2002	2002	NCT00030667
Neoplasms, Plasma Cell	D054219	imatinib	Phase 1	2020	2020	NCT03878524
Rhabdomyosarcoma	D012208	imatinib	Phase 2	2014	2014	NCT02048371
Chondrosarcoma, Mesenchymal	D018211	imatinib	Phase 2	2014	2014	NCT02048371
Pancreatic Neoplasms	D010190	lapatinib	Phase 1	2006	2006	NCT00439179
Pancreatic Neoplasms	D010190	lapatinib	Phase 2	2007	2009	NCT00881621;NCT00447122;NCT00962312
Stomach Neoplasms	D013274	lapatinib	Phase 1	2006	2012	NCT00313599;NCT01705340
Stomach Neoplasms	D013274	lapatinib	Phase 2	2004	2012	NCT01152853;NCT01123473;NCT02015169;NCT00526669;NCT00103324
Stomach Neoplasms	D013274	lapatinib	Phase 3	2007	2007	NCT00486954
Lung Neoplasms	D008175	lapatinib	Phase 1	2006	2007	NCT00528281;NCT00313599
Lung Neoplasms	D008175	lapatinib	Phase 2	2003	2019	NCT00073008;NCT03845270;NCT01306045
Carcinoma, Non-Small-Cell Lung	D002289	lapatinib	Phase 1	2007	2007	NCT00528281
Carcinoma, Non-Small-Cell Lung	D002289	lapatinib	Phase 2	2003	2019	NCT00073008;NCT03845270;NCT01306045
Breast Neoplasms	D001943	lapatinib	Phase 1	2003	2016	NCT01434303;NCT01245205;NCT01471847;NCT00424164;NCT02650752;NCT01875666;NCT00849329;NCT00996762;NCT00169533;NCT00371488;NCT00821054;NCT01238029;NCT00807859;NCT00388076;NCT00790816;NCT00331630;NCT01199367;NCT00544804;NCT00367471;NCT00258050;NCT00632489;NCT00379509;NCT00359190;NCT01281163;NCT00462956;NCT00316875;NCT00470847;NCT00650910;NCT02073916;NCT00313599;NCT00148902;NCT01300962;NCT00513058;NCT00085020;NCT00634088;NCT00614978;NCT01133912;NCT02131506;NCT00251433;NCT00753207;NCT01705340
Breast Neoplasms	D001943	lapatinib	Phase 2	2002	2020	NCT01361945;NCT00479856;NCT01594177;NCT00826267;NCT01873833;NCT00455039;NCT02396108;NCT00356811;NCT00299286;NCT00952692;NCT00912275;NCT01273610;NCT00320411;NCT01589861;NCT00444535;NCT00477464;NCT03500380;NCT00347919;NCT01118975;NCT00657137;NCT01565200;NCT00759642;NCT00316407;NCT01137994;NCT00404066;NCT01068704;NCT01218529;NCT00706030;NCT01138046;NCT00105950;NCT00343759;NCT01262469;NCT00436566;NCT00709761;NCT00694252;NCT00999804;NCT00842998;NCT01557764;NCT00903656;NCT02238509;NCT01973660;NCT01161368;NCT00496366;NCT03273595;NCT00820924;NCT01431196;NCT00263588;NCT00754702;NCT01272141;NCT01477060;NCT00548184;NCT00756470;NCT01934894;NCT00499681;NCT01658358;NCT04334330;NCT01688609;NCT01494662;NCT00524303;NCT00118157;NCT01138384;NCT00741260;NCT00111787;NCT01499160;NCT00820872;NCT00098605;NCT00769470;NCT01044485;NCT00777101;NCT03755141;NCT01783756;NCT02362958;NCT01868503;NCT01985893;NCT01827163;NCT00721630;NCT00709618;NCT01283789;NCT00450892;NCT00225758;NCT01485926;NCT01275859;NCT01441596;NCT00437073;NCT01912963;NCT00967031;NCT00482391;NCT00089999;NCT00206427;NCT00841828;NCT01622868;NCT01172223;NCT02422199;NCT00429299;NCT00051103;NCT02213042;NCT03913234;NCT00684983;NCT02073487;NCT02768415;NCT01730677;NCT00062686;NCT01309607;NCT01205217;NCT02139358;NCT01005641;NCT00558103;NCT01534455;NCT00422903;NCT00470704;NCT01495884;NCT01479179
Breast Neoplasms	D001943	lapatinib	Phase 3	2003	2018	NCT00770809;NCT00508274;NCT00688194;NCT02394496;NCT00078572;NCT01426880;NCT00374322;NCT03085368;NCT01160211;NCT00667251;NCT03262935;NCT00490139;NCT00553358;NCT01419197;NCT01808573;NCT01619111;NCT01526369;NCT00073528;NCT00567554;NCT00281658;NCT00272987;NCT01104571;NCT03084939;NCT00320385;NCT03080805;NCT00075270;NCT00829166;NCT00486668;NCT00820222;NCT00390455;NCT04185649;NCT03523585
Breast Neoplasms, Male	D018567	lapatinib	Phase 1	2010	2012	NCT01245205;NCT01705340
Breast Neoplasms, Male	D018567	lapatinib	Phase 2	2004	2013	NCT00118157;NCT00098605;NCT01783756;NCT01868503
Breast Neoplasms, Male	D018567	lapatinib	Phase 3	2008	2008	NCT00770809
Carcinoma	D002277	lapatinib	Phase 1	2011	2013	NCT01434303;NCT01245660;NCT01454479;NCT01947023
Carcinoma	D002277	lapatinib	Phase 2	2004	2017	NCT00114283;NCT00095563;NCT00096447;NCT01612351;NCT01382706;NCT02788201;NCT00371566;NCT00098631;NCT00118157;NCT00107536;NCT01044433;NCT01622868;NCT00684983;NCT01666431;NCT00239200;NCT01306045
Carcinoma	D002277	lapatinib	Phase 3	2006	2006	NCT00390455
Glioblastoma	D005909	lapatinib	Phase 1	2014	2020	NCT04135807;NCT02101905
Glioblastoma	D005909	lapatinib	Phase 2	2004	2012	NCT00095940;NCT00107003;NCT01591577
Glioma	D005910	lapatinib	Phase 1	2014	2020	NCT04135807;NCT02101905
Glioma	D005910	lapatinib	Phase 2	2004	2006	NCT00095940;NCT00350727;NCT00107003
Astrocytoma	D001254	lapatinib	Phase 1	2014	2020	NCT04135807;NCT02101905
Astrocytoma	D001254	lapatinib	Phase 2	2004	2004	NCT00095940
Ependymoma	D004806	lapatinib	Phase 1	2014	2014	NCT02101905
Ependymoma	D004806	lapatinib	Phase 2	2004	2009	NCT00095940;NCT00883688;NCT00826241
Gliosarcoma	D018316	lapatinib	Phase 1	2014	2014	NCT02101905
Gliosarcoma	D018316	lapatinib	Phase 2	2004	2005	NCT00095940;NCT00107003
Medulloblastoma	D008527	lapatinib	Phase 2	2004	2004	NCT00095940
Oligodendroglioma	D009837	lapatinib	Phase 1	2014	2020	NCT04135807;NCT02101905
Oligodendroglioma	D009837	lapatinib	Phase 2	2004	2004	NCT00095940
Carcinoma, Renal Cell	D002292	lapatinib	Phase 1	2004	2007	NCT00516672;NCT00387205;NCT00158782;NCT00363194
Brain Neoplasms	D001932	lapatinib	Phase 1	2007	2020	NCT04135807;NCT02101905;NCT00470847
Brain Neoplasms	D001932	lapatinib	Phase 2	2005	2020	NCT00107003;NCT01218529;NCT04334330;NCT00883688;NCT00826241
Sarcoma	D012509	lapatinib	Phase 3	2019	2019	NCT03784014
Prostatic Neoplasms	D011471	lapatinib	Phase 1	2006	2006	NCT00313599
Prostatic Neoplasms	D011471	lapatinib	Phase 2	2004	2009	NCT00246753;NCT00953576;NCT00095667;NCT00103194
Head and Neck Neoplasms	D006258	lapatinib	Phase 1	2010	2010	NCT01184482
Head and Neck Neoplasms	D006258	lapatinib	Phase 2	2004	2013	NCT00387127;NCT01711658;NCT01612351;NCT00098631;NCT00490061;NCT00498953;NCT01044433
Head and Neck Neoplasms	D006258	lapatinib	Phase 3	2006	2006	NCT00424255
Inflammatory Breast Neoplasms	D058922	lapatinib	Phase 2	2005	2008	NCT00105950;NCT00756470;NCT00111787;NCT00558103
Inflammatory Breast Neoplasms	D058922	lapatinib	Phase 3	2011	2011	NCT01426880
Carcinoma, Ductal, Breast	D018270	lapatinib	Phase 2	2013	2013	NCT01891357
Carcinoma, Ductal, Breast	D018270	lapatinib	Phase 3	2011	2011	NCT01426880
Neoplasm Metastasis	D009362	lapatinib	Phase 1	2007	2016	NCT02650752;NCT01427322;NCT00470847;NCT00614978
Neoplasm Metastasis	D009362	lapatinib	Phase 2	2004	2020	NCT01118975;NCT01218529;NCT02142036;NCT00263588;NCT01934894;NCT04334330;NCT02015169;NCT01499160;NCT00098605;NCT01783756;NCT01441596;NCT00437073
Neoplasm Metastasis	D009362	lapatinib	Phase 3	2009	2009	NCT00820222
Carcinoma, Squamous Cell	D002294	lapatinib	Phase 2	2004	2012	NCT00114283;NCT01612351;NCT00371566;NCT00098631;NCT00490061;NCT01044433;NCT01666431;NCT00239200
Laryngeal Neoplasms	D007822	lapatinib	Phase 2	2004	2009	NCT00114283;NCT00098631;NCT01044433
Oropharyngeal Neoplasms	D009959	lapatinib	Phase 2	2004	2009	NCT00114283;NCT00098631;NCT01044433
Carcinoma, Verrucous	D018289	lapatinib	Phase 2	2005	2009	NCT00114283;NCT01044433
Salivary Gland Neoplasms	D012468	lapatinib	Phase 2	2004	2009	NCT00114283;NCT00095563;NCT01044433
Nasopharyngeal Carcinoma	D000077274	lapatinib	Phase 2	2004	2005	NCT00114283;NCT00098631
Paranasal Sinus Neoplasms	D010255	lapatinib	Phase 2	2004	2009	NCT00114283;NCT00098631;NCT01044433
Tongue Neoplasms	D014062	lapatinib	Phase 2	2005	2005	NCT00114283
Colorectal Neoplasms	D015179	lapatinib	Phase 1	2007	2010	NCT00536809;NCT01184482
Colorectal Neoplasms	D015179	lapatinib	Phase 2	2002	2015	NCT02230553;NCT03225937;NCT00044343;NCT03418558
Gastrointestinal Neoplasms	D005770	lapatinib	Phase 2	2008	2020	NCT00526669;NCT04591431
Gastrointestinal Neoplasms	D005770	lapatinib	Phase 3	2007	2008	NCT00680901;NCT00486954
Digestive System Neoplasms	D004067	lapatinib	Phase 2	2008	2008	NCT00526669
Digestive System Neoplasms	D004067	lapatinib	Phase 3	2007	2008	NCT00680901;NCT00486954
Neurofibromatoses	D017253	lapatinib	Phase 1	2009	2009	NCT00863122
Neurofibromatoses	D017253	lapatinib	Phase 2	2009	2009	NCT00973739
Neurofibromatosis 1	D009456	lapatinib	Phase 2	2009	2009	NCT00973739
Neurofibroma	D009455	lapatinib	Phase 2	2009	2009	NCT00973739
Neurilemmoma	D009442	lapatinib	Phase 1	2009	2009	NCT00863122
Neurilemmoma	D009442	lapatinib	Phase 2	2009	2009	NCT00973739
Neuroma, Acoustic	D009464	lapatinib	Phase 1	2009	2009	NCT00863122
Neuroma, Acoustic	D009464	lapatinib	Phase 2	2009	2009	NCT00973739
Neurofibromatosis 2	D016518	lapatinib	Phase 1	2009	2009	NCT00863122
Neurofibromatosis 2	D016518	lapatinib	Phase 2	2009	2009	NCT00973739
Carcinoma, Ovarian Epithelial	D000077216	lapatinib	Phase 1	2005	2020	NCT00317434;NCT04608409
Carcinoma, Ovarian Epithelial	D000077216	lapatinib	Phase 2	2005	2005	NCT00316407;NCT00113373
Carcinoma, Adenoid Cystic	D003528	lapatinib	Phase 2	2004	2004	NCT00095563
Carcinoma, Mucoepidermoid	D018277	lapatinib	Phase 2	2004	2004	NCT00095563
Carcinoma, Acinar Cell	D018267	lapatinib	Phase 2	2004	2004	NCT00095563
Neoplasms, Second Primary	D016609	lapatinib	Phase 2	2010	2014	NCT01218529;NCT02142036;NCT01934894
Adenocarcinoma	D000230	lapatinib	Phase 2	2004	2011	NCT01123473;NCT01395537;NCT00259987;NCT00574171;NCT00103324
Adenocarcinoma	D000230	lapatinib	Phase 3	2007	2007	NCT00450203
Esophageal Neoplasms	D004938	lapatinib	Phase 1	2006	2012	NCT00313599;NCT01705340
Esophageal Neoplasms	D004938	lapatinib	Phase 2	2005	2011	NCT01123473;NCT01395537;NCT01145404;NCT00239200
Lymphoma	D008223	lapatinib	Phase 1	2006	2006	NCT00352443
Urinary Bladder Neoplasms	D001749	lapatinib	Phase 1	2006	2011	NCT00623064;NCT01245660;NCT00313599
Urinary Bladder Neoplasms	D001749	lapatinib	Phase 2	2011	2017	NCT01382706;NCT02788201;NCT01700010
Urinary Bladder Neoplasms	D001749	lapatinib	Phase 3	2009	2009	NCT00949455
Carcinoma, Transitional Cell	D002295	lapatinib	Phase 1	2007	2007	NCT00623064
Carcinoma, Transitional Cell	D002295	lapatinib	Phase 2	2011	2017	NCT01382706;NCT02788201
Kidney Neoplasms	D007680	lapatinib	Phase 1	2007	2007	NCT00623064
Ureteral Neoplasms	D014516	lapatinib	Phase 1	2007	2007	NCT00623064
Endometrial Neoplasms	D016889	lapatinib	Phase 1	2011	2011	NCT01454479
Endometrial Neoplasms	D016889	lapatinib	Phase 2	2004	2004	NCT00096447
Squamous Cell Carcinoma of Head and Neck	D000077195	lapatinib	Phase 2	2006	2012	NCT01612351;NCT00371566
Nervous System Neoplasms	D009423	lapatinib	Phase 1	2006	2006	NCT00313599
Nervous System Neoplasms	D009423	lapatinib	Phase 2	2004	2004	NCT00099060
Central Nervous System Neoplasms	D016543	lapatinib	Phase 1	2006	2006	NCT00313599
Central Nervous System Neoplasms	D016543	lapatinib	Phase 2	2004	2004	NCT00099060
Ovarian Neoplasms	D010051	lapatinib	Phase 1	2005	2020	NCT00317434;NCT04608409
Melanoma	D008545	lapatinib	Phase 2	2011	2011	NCT01264081
Adenoma	D000236	lapatinib	Phase 2	2009	2009	NCT00939523
Pituitary Neoplasms	D010911	lapatinib	Phase 2	2009	2009	NCT00939523
Prolactinoma	D015175	lapatinib	Phase 2	2009	2009	NCT00939523
Carcinoma, Ductal	D044584	lapatinib	Phase 2	2013	2013	NCT01891357
Neoplasms, Unknown Primary	D009382	lapatinib	Phase 2	2004	2009	NCT00098631;NCT01044433
Neoplastic Cells, Circulating	D009360	lapatinib	Phase 2	2008	2008	NCT00820924
Neoplastic Cells, Circulating	D009360	lapatinib	Phase 3	2012	2012	NCT01619111
Carcinosarcoma	D002296	lapatinib	Phase 1	2011	2011	NCT01454479
Mixed Tumor, Mullerian	D018200	lapatinib	Phase 1	2011	2011	NCT01454479
Liver Neoplasms	D008113	lapatinib	Phase 2	2004	2012	NCT02015169;NCT00107536;NCT00101036
Gallbladder Neoplasms	D005706	lapatinib	Phase 2	2004	2016	NCT00107536;NCT03768375;NCT02836847;NCT00101036
Bile Duct Neoplasms	D001650	lapatinib	Phase 2	2004	2005	NCT00107536;NCT00101036
Cholangiocarcinoma	D018281	lapatinib	Phase 2	2004	2016	NCT00107536;NCT03768375;NCT02836847;NCT00101036
Uterine Cervical Neoplasms	D002583	lapatinib	Phase 2	2006	2006	NCT00430781
Uterine Neoplasms	D014594	lapatinib	Phase 2	2006	2006	NCT00430781
Carcinoma, Hepatocellular	D006528	lapatinib	Phase 2	2004	2004	NCT00101036
Thyroid Neoplasms	D013964	lapatinib	Phase 1	2013	2013	NCT01947023
Neoplasms, Germ Cell and Embryonal	D009373	lapatinib	Phase 1	2006	2006	NCT00313599
Neuroma	D009463	lapatinib	Phase 1	2009	2009	NCT00863122
Spinal Cord Neoplasms	D013120	lapatinib	Phase 2	2009	2009	NCT00826241
Esophageal Squamous Cell Carcinoma	D000077277	lapatinib	Phase 2	2005	2005	NCT00239200
Small Cell Lung Carcinoma	D055752	lapatinib	Phase 2	2011	2011	NCT01306045
Carcinoma, Small Cell	D018288	lapatinib	Phase 2	2011	2011	NCT01306045
Thymoma	D013945	lapatinib	Phase 2	2011	2011	NCT01306045
Glioma	D005910	larotrectinib	Phase 1	2021	2021	NCT04655404
Glioma	D005910	larotrectinib	Phase 2	2015	2017	NCT03213704;NCT02465060;NCT03155620
Lymphoma	D008223	larotrectinib	Phase 2	2015	2017	NCT03213704;NCT02465060;NCT03155620
Sarcoma	D012509	larotrectinib	Phase 1	2016	2016	NCT03056599
Sarcoma	D012509	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Lymphoma, Non-Hodgkin	D008228	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Neuroblastoma	D009447	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Neoplasms, Germ Cell and Embryonal	D009373	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Osteosarcoma	D012516	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Rhabdomyosarcoma	D012208	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Ependymoma	D004806	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Sarcoma, Ewing	D012512	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Medulloblastoma	D008527	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Neuroectodermal Tumors	D017599	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Neuroectodermal Tumors, Primitive	D018242	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Wilms Tumor	D009396	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Neuroectodermal Tumors, Primitive, Peripheral	D018241	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Rhabdoid Tumor	D018335	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Nervous System Neoplasms	D009423	larotrectinib	Phase 2	2017	2019	NCT03213704;NCT03834961;NCT03155620
Central Nervous System Neoplasms	D016543	larotrectinib	Phase 2	2017	2019	NCT03213704;NCT03834961;NCT03155620
Hepatoblastoma	D018197	larotrectinib	Phase 2	2017	2017	NCT03213704;NCT03155620
Leukemia	D007938	larotrectinib	Phase 2	2019	2019	NCT03834961
Fibrosarcoma	D005354	larotrectinib	Phase 2	2019	2019	NCT03834961
Carcinoma	D002277	larotrectinib	Phase 2	2015	2015	NCT02465060
Melanoma	D008545	larotrectinib	Phase 2	2015	2015	NCT02465060
Multiple Myeloma	D009101	larotrectinib	Phase 2	2015	2015	NCT02465060
Neoplasms, Plasma Cell	D054219	larotrectinib	Phase 2	2015	2015	NCT02465060
Breast Neoplasms	D001943	larotrectinib	Phase 2	2015	2015	NCT02465060
Lung Neoplasms	D008175	larotrectinib	Phase 2	2015	2015	NCT02465060
Colorectal Neoplasms	D015179	larotrectinib	Phase 2	2015	2015	NCT02465060
Endometrial Neoplasms	D016889	larotrectinib	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	larotrectinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	larotrectinib	Phase 2	2015	2015	NCT02465060
Prostatic Neoplasms	D011471	larotrectinib	Phase 2	2015	2015	NCT02465060
Pancreatic Neoplasms	D010190	larotrectinib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	larotrectinib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	larotrectinib	Phase 2	2015	2015	NCT02465060
Urinary Bladder Neoplasms	D001749	larotrectinib	Phase 2	2015	2015	NCT02465060
Rectal Neoplasms	D012004	larotrectinib	Phase 2	2015	2015	NCT02465060
Thyroid Neoplasms	D013964	larotrectinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	larotrectinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	larotrectinib	Phase 2	2015	2015	NCT02465060
Colonic Neoplasms	D003110	larotrectinib	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	larotrectinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Renal Cell	D002292	larotrectinib	Phase 2	2015	2015	NCT02465060
Kidney Neoplasms	D007680	larotrectinib	Phase 2	2015	2015	NCT02465060
Histiocytic Sarcoma	D054747	larotrectinib	Phase 2	2017	2017	NCT03155620
Carcinoma	D002277	lenvatinib	Phase 1	2015	2020	NCT03006926;NCT03524326;NCT02953743;NCT02454478;NCT03324373;NCT02788708;NCT03418922;NCT03878524
Carcinoma	D002277	lenvatinib	Phase 2	2009	2021	NCT04444167;NCT04241523;NCT04267120;NCT04731740;NCT01136733;NCT04710628;NCT04605796;NCT00946153;NCT04490694;NCT04327700;NCT04170179;NCT03173560;NCT02860936;NCT04227808;NCT02780310;NCT03899428;NCT04317248;NCT04193696;NCT04042805;NCT04741165;NCT04443309;NCT03775707;NCT04209660;NCT03433703;NCT04428151;NCT03746249;NCT03919383;NCT03914300;NCT04273100;NCT04368078;NCT04511455;NCT04740307;NCT04626479;NCT04044313;NCT04626518;NCT04599790;NCT04171622;NCT04080154;NCT04704219;NCT04728321;NCT03803254;NCT04781088;NCT03499626;NCT04401800;NCT03841201;NCT04203901;NCT03506048;NCT02973997;NCT02657369;NCT02915783
Carcinoma	D002277	lenvatinib	Phase 3	2013	2021	NCT03713593;NCT04194775;NCT04586231;NCT04053985;NCT03898180;NCT03744247;NCT04736706;NCT04246177;NCT04044651;NCT01761266;NCT03905967;NCT04237740;NCT04229355;NCT04319484;NCT04168944;NCT03791918;NCT04687163;NCT04199104;NCT02811861;NCT04053972;NCT04039607;NCT03775395;NCT04770896
Carcinoma	D002277	lenvatinib	Phase 4	2019	2021	NCT04127396;NCT04297254
Carcinoma, Hepatocellular	D006528	lenvatinib	Phase 1	2016	2019	NCT03006926;NCT02953743;NCT04008797;NCT03418922
Carcinoma, Hepatocellular	D006528	lenvatinib	Phase 2	2009	2021	NCT04444167;NCT04241523;NCT04605796;NCT00946153;NCT04490694;NCT04327700;NCT04170179;NCT04227808;NCT03899428;NCT04317248;NCT04193696;NCT04042805;NCT04741165;NCT04443309;NCT03775707;NCT04542837;NCT03433703;NCT03746249;NCT03919383;NCT04273100;NCT04368078;NCT04511455;NCT04627363;NCT04740307;NCT04044313;NCT04599790;NCT04080154;NCT04728321;NCT03803254;NCT03499626;NCT04401800;NCT03841201
Carcinoma, Hepatocellular	D006528	lenvatinib	Phase 3	2013	2021	NCT03713593;NCT04194775;NCT04053985;NCT03744247;NCT04246177;NCT04044651;NCT01761266;NCT03905967;NCT04237740;NCT04229355;NCT04319484;NCT04168944;NCT03791918;NCT04687163;NCT04523493;NCT04053972;NCT04039607;NCT03775395;NCT04770896
Carcinoma, Hepatocellular	D006528	lenvatinib	Phase 4	2019	2021	NCT04127396;NCT04297254
Lung Neoplasms	D008175	lenvatinib	Phase 1	2009	2009	NCT00832819
Lung Neoplasms	D008175	lenvatinib	Phase 2	2011	2018	NCT01529112;NCT03516981
Lung Neoplasms	D008175	lenvatinib	Phase 3	2019	2019	NCT04716933;NCT03976375;NCT03829332;NCT03829319;NCT04676412
Carcinoma, Non-Small-Cell Lung	D002289	lenvatinib	Phase 1	2009	2009	NCT00832819
Carcinoma, Non-Small-Cell Lung	D002289	lenvatinib	Phase 2	2011	2021	NCT01529112;NCT03516981;NCT04777084
Carcinoma, Non-Small-Cell Lung	D002289	lenvatinib	Phase 3	2019	2019	NCT04716933;NCT03976375;NCT03829332;NCT03829319;NCT04676412
Lymphoma	D008223	lenvatinib	Phase 1	2005	2020	NCT02578316;NCT01525394;NCT00121719;NCT03878524
Thyroid Neoplasms	D013964	lenvatinib	Phase 1	2016	2016	NCT02915172
Thyroid Neoplasms	D013964	lenvatinib	Phase 2	2008	2021	NCT04321954;NCT04731740;NCT02702388;NCT01728623;NCT02726503;NCT03139747;NCT03914300;NCT03732495;NCT02432274;NCT00784303;NCT03630120;NCT04171622;NCT03506048;NCT02973997;NCT02657369
Thyroid Neoplasms	D013964	lenvatinib	Phase 3	2011	2017	NCT01321554;NCT03048877;NCT02966093
Thyroid Neoplasms	D013964	lenvatinib	Phase 4	2018	2018	NCT03573960
Cholangiocarcinoma	D018281	lenvatinib	Phase 2	2018	2021	NCT03951597;NCT03801499;NCT04506281;NCT03779100;NCT04361331;NCT03895970;NCT04527679;NCT04550624;NCT04656249
Cholangiocarcinoma	D018281	lenvatinib	Phase 3	2020	2020	NCT04669496
Carcinoma, Renal Cell	D002292	lenvatinib	Phase 1	2015	2019	NCT02454478;NCT03324373
Carcinoma, Renal Cell	D002292	lenvatinib	Phase 2	2010	2021	NCT04267120;NCT01136733;NCT03173560;NCT04626479;NCT04626518;NCT04704219;NCT04393350;NCT04714697;NCT04203901;NCT02915783
Carcinoma, Renal Cell	D002292	lenvatinib	Phase 3	2016	2021	NCT04586231;NCT04736706;NCT02811861
Melanoma	D008545	lenvatinib	Phase 1	2005	2005	NCT00121680
Melanoma	D008545	lenvatinib	Phase 2	2010	2021	NCT03776136;NCT04700072;NCT01136967;NCT04622566;NCT04207086;NCT04305054;NCT04305041;NCT01133977
Melanoma	D008545	lenvatinib	Phase 3	2019	2019	NCT03820986
Neuroendocrine Tumors	D018358	lenvatinib	Phase 2	2015	2019	NCT02678780;NCT03290079;NCT03950609
Thyroid Carcinoma, Anaplastic	D065646	lenvatinib	Phase 2	2016	2021	NCT04731740;NCT02726503;NCT04171622;NCT02657369
Glioblastoma	D005909	lenvatinib	Phase 2	2011	2019	NCT03797326;NCT01433991
Triple Negative Breast Neoplasms	D064726	lenvatinib	Phase 1	2020	2020	NCT04427293
Triple Negative Breast Neoplasms	D064726	lenvatinib	Phase 2	2019	2019	NCT03797326
Biliary Tract Neoplasms	D001661	lenvatinib	Phase 2	2015	2020	NCT03797326;NCT04211168;NCT04656249;NCT02579616
Thymoma	D013945	lenvatinib	Phase 2	2021	2021	NCT04710628
Breast Neoplasms	D001943	lenvatinib	Phase 1	2016	2020	NCT02915172;NCT04427293;NCT03878524
Breast Neoplasms	D001943	lenvatinib	Phase 2	2015	2017	NCT02562118;NCT03168074
Genital Neoplasms, Female	D005833	lenvatinib	Phase 1	2016	2016	NCT02915172
Genital Neoplasms, Female	D005833	lenvatinib	Phase 2	2020	2020	NCT04519151
Genital Neoplasms, Male	D005834	lenvatinib	Phase 1	2016	2016	NCT02915172
Urologic Neoplasms	D014571	lenvatinib	Phase 1	2016	2016	NCT02915172
Lip Neoplasms	D008048	lenvatinib	Phase 1	2016	2016	NCT02915172
Bone Neoplasms	D001859	lenvatinib	Phase 1	2016	2016	NCT02915172
Eye Neoplasms	D005134	lenvatinib	Phase 1	2016	2016	NCT02915172
Soft Tissue Neoplasms	D012983	lenvatinib	Phase 1	2016	2016	NCT02915172
Neoplasms, Fibrous Tissue	D018218	lenvatinib	Phase 1	2016	2016	NCT02915172
Carcinoma, Transitional Cell	D002295	lenvatinib	Phase 3	2019	2019	NCT03898180
Glioma	D005910	lenvatinib	Phase 2	2010	2010	NCT01137604
Papilloma	D010212	lenvatinib	Phase 2	2021	2021	NCT04645602
Carcinoma, Neuroendocrine	D018278	lenvatinib	Phase 2	2017	2017	NCT03290079
Gastrointestinal Stromal Tumors	D046152	lenvatinib	Phase 2	2020	2020	NCT04193553
Neoplasm Metastasis	D009362	lenvatinib	Phase 2	2019	2021	NCT04170179;NCT04769908;NCT04729348
Carcinoma, Adenoid Cystic	D003528	lenvatinib	Phase 2	2015	2020	NCT02860936;NCT02780310;NCT04209660
Salivary Gland Neoplasms	D012468	lenvatinib	Phase 2	2015	2020	NCT02860936;NCT04209660
Central Nervous System Neoplasms	D016543	lenvatinib	Phase 2	2017	2017	NCT03245151
Carcinoma, Squamous Cell	D002294	lenvatinib	Phase 1	2018	2018	NCT03524326
Carcinoma, Squamous Cell	D002294	lenvatinib	Phase 2	2020	2020	NCT04428151
Carcinoma, Squamous Cell	D002294	lenvatinib	Phase 3	2020	2020	NCT04199104
Squamous Cell Carcinoma of Head and Neck	D000077195	lenvatinib	Phase 1	2018	2018	NCT03524326
Squamous Cell Carcinoma of Head and Neck	D000077195	lenvatinib	Phase 2	2020	2020	NCT04428151
Squamous Cell Carcinoma of Head and Neck	D000077195	lenvatinib	Phase 3	2020	2020	NCT04199104
Sarcoma	D012509	lenvatinib	Phase 2	2018	2021	NCT03526679;NCT04784247
Leiomyosarcoma	D007890	lenvatinib	Phase 2	2018	2018	NCT03526679
Liposarcoma	D008080	lenvatinib	Phase 2	2018	2018	NCT03526679
Endometrial Neoplasms	D016889	lenvatinib	Phase 1	2016	2016	NCT02788708
Endometrial Neoplasms	D016889	lenvatinib	Phase 2	2010	2021	NCT01111461;NCT04781088;NCT03005015
Endometrial Neoplasms	D016889	lenvatinib	Phase 3	2018	2019	NCT03517449;NCT03884101
Pheochromocytoma	D010673	lenvatinib	Phase 2	2017	2017	NCT03008369
Paraganglioma	D010235	lenvatinib	Phase 2	2017	2017	NCT03008369
Carotid Body Tumor	D002345	lenvatinib	Phase 2	2017	2017	NCT03008369
Carcinoma, Papillary	D002291	lenvatinib	Phase 2	2018	2019	NCT03914300;NCT03506048;NCT02973997
Thyroid Cancer, Papillary	D000077273	lenvatinib	Phase 2	2018	2019	NCT03914300;NCT03630120;NCT03506048;NCT02973997
Adenocarcinoma, Follicular	D018263	lenvatinib	Phase 2	2018	2019	NCT03914300;NCT03630120;NCT03506048;NCT02973997
Carcinoid Tumor	D002276	lenvatinib	Phase 2	2019	2019	NCT03950609
Endocrine Gland Neoplasms	D004701	lenvatinib	Phase 2	2019	2019	NCT03950609
Multiple Endocrine Neoplasia	D009377	lenvatinib	Phase 2	2019	2019	NCT03950609
Multiple Endocrine Neoplasia Type 1	D018761	lenvatinib	Phase 2	2019	2019	NCT03950609
Stomach Neoplasms	D013274	lenvatinib	Phase 2	2017	2021	NCT03609359;NCT03321630;NCT04519151;NCT04745988
Liver Neoplasms	D008113	lenvatinib	Phase 1	2019	2019	NCT04008797
Liver Neoplasms	D008113	lenvatinib	Phase 2	2019	2021	NCT03895970;NCT04627363
Osteosarcoma	D012516	lenvatinib	Phase 2	2014	2020	NCT02432274;NCT04154189
Neoplasms, Second Primary	D016609	lenvatinib	Phase 2	2021	2021	NCT04729348
Meningeal Carcinomatosis	D055756	lenvatinib	Phase 2	2021	2021	NCT04729348
Ovarian Neoplasms	D010051	lenvatinib	Phase 1	2016	2016	NCT02788708
Ovarian Neoplasms	D010051	lenvatinib	Phase 2	2010	2021	NCT01133756;NCT04519151;NCT04781088
Carcinoma, Ovarian Epithelial	D000077216	lenvatinib	Phase 1	2016	2016	NCT02788708
Carcinoma, Ovarian Epithelial	D000077216	lenvatinib	Phase 2	2010	2021	NCT01133756;NCT04519151;NCT04781088
Urogenital Neoplasms	D014565	lenvatinib	Phase 2	2020	2020	NCT04519151
Neoplasms, Glandular and Epithelial	D009375	lenvatinib	Phase 2	2020	2020	NCT04519151
Adenocarcinoma	D000230	lenvatinib	Phase 1	2016	2020	NCT02935309;NCT03878524
Adenocarcinoma	D000230	lenvatinib	Phase 2	2013	2021	NCT04699071;NCT01877083
Adenocarcinoma	D000230	lenvatinib	Phase 3	2020	2020	NCT04662710
Adenocarcinoma, Clear Cell	D018262	lenvatinib	Phase 2	2021	2021	NCT04699071
Kidney Neoplasms	D007680	lenvatinib	Phase 2	2020	2020	NCT04393350
Fallopian Tube Neoplasms	D005185	lenvatinib	Phase 2	2021	2021	NCT04781088
Mesothelioma	D008654	lenvatinib	Phase 2	2021	2021	NCT04287829
Adenocarcinoma of Lung	D000077192	lenvatinib	Phase 2	2013	2013	NCT01877083
Prostatic Neoplasms	D011471	lenvatinib	Phase 1	2016	2020	NCT02861573;NCT03878524
Rectal Neoplasms	D012004	lenvatinib	Phase 1	2016	2016	NCT02935309
Leukemia	D007938	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	lenvatinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	lenvatinib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	lenvatinib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	lenvatinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	lenvatinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	lenvatinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	lenvatinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	lenvatinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	lenvatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	lenvatinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	lenvatinib	Phase 1	2020	2020	NCT03878524
Colorectal Neoplasms	D015179	lenvatinib	Phase 3	2021	2021	NCT04776148
Lung Neoplasms	D008175	lorlatinib	Phase 2	2014	2021	NCT02584634;NCT01970865;NCT04292119;NCT04634110;NCT02927340;NCT04111705;NCT04621188;NCT03737994
Lung Neoplasms	D008175	lorlatinib	Phase 4	2020	2020	NCT04541706
Carcinoma, Non-Small-Cell Lung	D002289	lorlatinib	Phase 2	2014	2021	NCT02584634;NCT01970865;NCT03439215;NCT04127110;NCT03909971;NCT03612154;NCT02927340;NCT04111705;NCT04621188
Carcinoma, Non-Small-Cell Lung	D002289	lorlatinib	Phase 3	2017	2017	NCT03052608
Carcinoma, Non-Small-Cell Lung	D002289	lorlatinib	Phase 4	2020	2020	NCT04541706
Lymphoma	D008223	lorlatinib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	lorlatinib	Phase 2	2017	2020	NCT04292119;NCT03505554
Lymphoma	D008223	lorlatinib	Phase 4	2020	2020	NCT04362072
Neuroblastoma	D009447	lorlatinib	Phase 1	2017	2017	NCT03107988
Neoplasm Metastasis	D009362	lorlatinib	Phase 2	2021	2021	NCT04634110
Lymphoma, Large-Cell, Anaplastic	D017728	lorlatinib	Phase 2	2017	2017	NCT03505554
Carcinoma	D002277	lorlatinib	Phase 1	2020	2020	NCT03878524
Breast Neoplasms	D001943	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	lorlatinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	lorlatinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	lorlatinib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	lorlatinib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	lorlatinib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	lorlatinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	lorlatinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	lorlatinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	lorlatinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	lorlatinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	lorlatinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	lorlatinib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	midostaurin	Phase 1	2004	2019	NCT03900949;NCT00093600;NCT02078609;NCT01130662;NCT01174888;NCT04075747
Leukemia	D007938	midostaurin	Phase 2	2002	2020	NCT02634827;NCT01093573;NCT00233454;NCT02115295;NCT01477606;NCT00866281;NCT03951961;NCT03836209;NCT03280030;NCT01846624;NCT03760445;NCT04477291;NCT03226418;NCT01883362;NCT04385290;NCT01202877;NCT03207334;NCT03686345;NCT00045942;NCT00782067;NCT03609060
Leukemia	D007938	midostaurin	Phase 3	2008	2019	NCT02665065;NCT03512197;NCT03092674;NCT04027309;NCT03379727;NCT00651261
Leukemia, Myeloid	D007951	midostaurin	Phase 1	2004	2019	NCT01161550;NCT03900949;NCT00093600;NCT01130662;NCT01174888;NCT04075747
Leukemia, Myeloid	D007951	midostaurin	Phase 2	2002	2020	NCT02634827;NCT01093573;NCT02115295;NCT01477606;NCT00866281;NCT03951961;NCT03591510;NCT03836209;NCT03280030;NCT01846624;NCT01830361;NCT03760445;NCT04477291;NCT03226418;NCT01883362;NCT04385290;NCT03207334;NCT00045942;NCT03609060
Leukemia, Myeloid	D007951	midostaurin	Phase 3	2008	2019	NCT02665065;NCT03512197;NCT03092674;NCT04027309;NCT03379727;NCT00651261
Leukemia, Myeloid, Acute	D015470	midostaurin	Phase 1	2004	2019	NCT01161550;NCT03900949;NCT00093600;NCT02078609;NCT01130662;NCT01174888;NCT04075747
Leukemia, Myeloid, Acute	D015470	midostaurin	Phase 2	2002	2020	NCT02634827;NCT01093573;NCT02115295;NCT01477606;NCT00866281;NCT03951961;NCT03591510;NCT03836209;NCT03280030;NCT01846624;NCT01830361;NCT03760445;NCT04477291;NCT03226418;NCT01883362;NCT04385290;NCT03207334;NCT00045942;NCT03609060
Leukemia, Myeloid, Acute	D015470	midostaurin	Phase 3	2008	2019	NCT02665065;NCT03512197;NCT03092674;NCT04027309;NCT03379727;NCT00651261
Mastocytosis	D008415	midostaurin	Phase 2	2005	2013	NCT00233454;NCT01920204;NCT00782067
Mastocytosis, Systemic	D034721	midostaurin	Phase 2	2005	2013	NCT00233454;NCT01920204;NCT00782067
Leukemia, Mast-Cell	D007946	midostaurin	Phase 2	2005	2008	NCT00233454;NCT00782067
Preleukemia	D011289	midostaurin	Phase 1	2014	2014	NCT02078609
Preleukemia	D011289	midostaurin	Phase 2	2002	2014	NCT02115295;NCT00045942
Preleukemia	D011289	midostaurin	Phase 3	2017	2019	NCT03092674;NCT04027309
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	midostaurin	Phase 2	2014	2014	NCT02115295
Blast Crisis	D001752	midostaurin	Phase 2	2014	2014	NCT02115295
Leukemia, Biphenotypic, Acute	D015456	midostaurin	Phase 2	2014	2014	NCT02115295
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	midostaurin	Phase 2	2009	2009	NCT00866281
Leukemia, Lymphoid	D007945	midostaurin	Phase 2	2009	2009	NCT00866281
Neoplasm, Residual	D018365	midostaurin	Phase 2	2020	2020	NCT03951961
Rectal Neoplasms	D012004	midostaurin	Phase 1	2011	2011	NCT01282502
Carcinoma	D002277	necitumumab	Phase 1	2016	2016	NCT02496663
Carcinoma	D002277	necitumumab	Phase 2	2018	2021	NCT03387111;NCT04285671
Carcinoma, Squamous Cell	D002294	necitumumab	Phase 2	2018	2018	NCT03387111
Colorectal Neoplasms	D015179	necitumumab	Phase 2	2007	2007	NCT00835185
Lung Neoplasms	D008175	necitumumab	Phase 1	2015	2016	NCT02789345;NCT02451930
Lung Neoplasms	D008175	necitumumab	Phase 2	2013	2021	NCT03574818;NCT03944772;NCT02443337;NCT01769391;NCT04285671;NCT01788566;NCT02392507;NCT02941601;NCT01763788
Lung Neoplasms	D008175	necitumumab	Phase 3	2009	2010	NCT00982111;NCT00981058
Carcinoma, Non-Small-Cell Lung	D002289	necitumumab	Phase 1	2015	2017	NCT02789345;NCT02496663;NCT03054038;NCT02451930;NCT02411591
Carcinoma, Non-Small-Cell Lung	D002289	necitumumab	Phase 2	2013	2021	NCT03944772;NCT01769391;NCT04285671;NCT01788566;NCT02392507;NCT02941601;NCT01763788
Carcinoma, Non-Small-Cell Lung	D002289	necitumumab	Phase 3	2009	2010	NCT00982111;NCT00981058
Neoplasm Metastasis	D009362	necitumumab	Phase 1	2015	2015	NCT02411591
Breast Neoplasms	D001943	neratinib	Phase 1	2003	2020	NCT01423123;NCT00146172;NCT03878524
Breast Neoplasms	D001943	neratinib	Phase 2	2006	2021	NCT02673398;NCT02396108;NCT00398567;NCT01008150;NCT01111825;NCT00706030;NCT03377387;NCT04366713;NCT00445458;NCT04760431;NCT03289039;NCT00915018;NCT03812393;NCT01494662;NCT00741260;NCT03101748;NCT00777101;NCT01042379;NCT00300781;NCT01670877;NCT02236000;NCT03182634;NCT02400476;NCT04460430;NCT03094052
Breast Neoplasms	D001943	neratinib	Phase 3	2009	2013	NCT00878709;NCT01808573
Nervous System Neoplasms	D009423	neratinib	Phase 2	2016	2016	NCT02932280
Central Nervous System Neoplasms	D016543	neratinib	Phase 2	2016	2016	NCT02932280
Triple Negative Breast Neoplasms	D064726	neratinib	Phase 2	2010	2019	NCT01111825;NCT03812393
Lung Neoplasms	D008175	neratinib	Phase 2	2005	2013	NCT00266877;NCT01827267
Carcinoma, Non-Small-Cell Lung	D002289	neratinib	Phase 2	2005	2013	NCT00266877;NCT01827267
Neoplasm Metastasis	D009362	neratinib	Phase 2	2021	2021	NCT04760431
Neoplasms, Second Primary	D016609	neratinib	Phase 2	2021	2021	NCT04760431
Brain Neoplasms	D001932	neratinib	Phase 2	2021	2021	NCT04760431
Colorectal Neoplasms	D015179	neratinib	Phase 2	2013	2018	NCT01960023;NCT03457896
Glioblastoma	D005909	neratinib	Phase 2	2017	2017	NCT02977780
Ovarian Neoplasms	D010051	neratinib	Phase 1	2020	2020	NCT04502602
Carcinoma, Ovarian Epithelial	D000077216	neratinib	Phase 1	2020	2020	NCT04502602
Carcinoma	D002277	neratinib	Phase 1	2020	2020	NCT03878524
Carcinoma	D002277	neratinib	Phase 2	2018	2018	NCT03101748
Inflammatory Breast Neoplasms	D058922	neratinib	Phase 2	2018	2018	NCT03101748
Prostatic Neoplasms	D011471	neratinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	neratinib	Phase 2	2021	2021	NCT04781374
Adenocarcinoma	D000230	neratinib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	neratinib	Phase 2	2021	2021	NCT04781374
Hemangiosarcoma	D006394	neratinib	Phase 2	2010	2010	NCT01042379
Lymphoma	D008223	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	neratinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	neratinib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	neratinib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	neratinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	neratinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	neratinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	neratinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	neratinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	neratinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	neratinib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	nilotinib	Phase 1	2009	2017	NCT01220648;NCT02081378;NCT01077544;NCT00860535;NCT01397734;NCT02225574;NCT01751425;NCT01460498;NCT01702064;NCT00827138;NCT01456676;NCT03228303
Leukemia	D007938	nilotinib	Phase 2	2001	2020	NCT01667133;NCT01698905;NCT04578847;NCT01784068;NCT01392170;NCT00384228;NCT01274351;NCT03578367;NCT00750659;NCT01279473;NCT03654768;NCT01218477;NCT02767063;NCT03516279;NCT01806571;NCT00109707;NCT01746836;NCT01804985;NCT00769327;NCT01207440;NCT04006847;NCT01883219;NCT02709083;NCT01222143;NCT00702403;NCT00809211;NCT00129740;NCT03610971;NCT00905398;NCT00844298;NCT02917720;NCT01294618;NCT01844765;NCT04216563;NCT01690065;NCT00036738;NCT01602952;NCT04126681;NCT01914484;NCT00762632;NCT03874858;NCT04147533;NCT02001818;NCT01528085;NCT04233346;NCT02353728;NCT04626024;NCT00573378;NCT01670084
Leukemia	D007938	nilotinib	Phase 3	2007	2020	NCT03079505;NCT02201459;NCT02174445;NCT02108951;NCT00802841;NCT04375683;NCT01535391;NCT02115386;NCT03746054;NCT00519090;NCT02272777;NCT02326311;NCT01254188;NCT00471497;NCT01275196;NCT00760877;NCT02627677;NCT01819389;NCT03942094;NCT01126892;NCT01657604
Leukemia	D007938	nilotinib	Phase 4	2008	2016	NCT00786812;NCT01043874;NCT02389920;NCT00644878;NCT02602314;NCT01368523;NCT01227577;NCT00980018;NCT03332511;NCT01131325;NCT01901666
Leukemia, Myeloid	D007951	nilotinib	Phase 1	2009	2017	NCT01220648;NCT02081378;NCT01077544;NCT00860535;NCT01397734;NCT02225574;NCT01751425;NCT01460498;NCT01702064;NCT01456676;NCT03228303
Leukemia, Myeloid	D007951	nilotinib	Phase 2	2001	2020	NCT01667133;NCT01698905;NCT04578847;NCT01784068;NCT01392170;NCT03205267;NCT00384228;NCT01274351;NCT03578367;NCT00750659;NCT01279473;NCT03654768;NCT00481052;NCT02767063;NCT03516279;NCT01856283;NCT01806571;NCT00109707;NCT01746836;NCT01804985;NCT01207440;NCT04006847;NCT02709083;NCT01222143;NCT00702403;NCT00809211;NCT00129740;NCT03610971;NCT02917720;NCT01294618;NCT01844765;NCT04216563;NCT01690065;NCT00036738;NCT01602952;NCT04126681;NCT01914484;NCT00762632;NCT03874858;NCT04147533;NCT02001818;NCT04233346;NCT02353728;NCT04626024;NCT00573378;NCT01670084;NCT01774630
Leukemia, Myeloid	D007951	nilotinib	Phase 3	2007	2019	NCT03079505;NCT02174445;NCT02108951;NCT00802841;NCT01535391;NCT02115386;NCT03746054;NCT00519090;NCT02272777;NCT01743989;NCT01254188;NCT00471497;NCT01275196;NCT00760877;NCT02627677;NCT01819389;NCT03942094;NCT01126892;NCT01657604
Leukemia, Myeloid	D007951	nilotinib	Phase 4	2008	2016	NCT00786812;NCT02546674;NCT01043874;NCT00644878;NCT02602314;NCT01368523;NCT01227577;NCT00980018;NCT03332511;NCT01131325;NCT01901666
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	nilotinib	Phase 1	2009	2017	NCT01220648;NCT02081378;NCT01077544;NCT00860535;NCT01397734;NCT02225574;NCT01223898;NCT01751425;NCT01460498;NCT01702064;NCT00827138;NCT01456676;NCT02253277;NCT03228303
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	nilotinib	Phase 2	2001	2020	NCT01667133;NCT01698905;NCT04578847;NCT01784068;NCT01392170;NCT03205267;NCT00384228;NCT01274351;NCT03578367;NCT00750659;NCT01279473;NCT03654768;NCT00481052;NCT01866553;NCT02767063;NCT03516279;NCT01856283;NCT00109707;NCT01746836;NCT01804985;NCT00769327;NCT01207440;NCT04006847;NCT02709083;NCT03906292;NCT00702403;NCT00809211;NCT00129740;NCT03610971;NCT02917720;NCT02973711;NCT01294618;NCT01844765;NCT04216563;NCT01690065;NCT00036738;NCT01602952;NCT04126681;NCT01914484;NCT03874858;NCT04147533;NCT02001818;NCT04233346;NCT02353728;NCT04626024;NCT00573378;NCT01670084;NCT01774630
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	nilotinib	Phase 3	2007	2019	NCT03079505;NCT02201459;NCT02174445;NCT02108951;NCT00802841;NCT01400074;NCT01535391;NCT02115386;NCT03746054;NCT00519090;NCT02272777;NCT01743989;NCT02326311;NCT01254188;NCT00471497;NCT01275196;NCT00760877;NCT02627677;NCT01819389;NCT03942094;NCT01126892;NCT01657604
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	nilotinib	Phase 4	2008	2016	NCT00786812;NCT01605981;NCT02546674;NCT01043874;NCT02389920;NCT00644878;NCT02602314;NCT01368523;NCT01227577;NCT00980018;NCT02086487;NCT03332511;NCT01131325;NCT01901666
Leukemia, Myeloid, Chronic-Phase	D015466	nilotinib	Phase 1	2013	2013	NCT01702064
Leukemia, Myeloid, Chronic-Phase	D015466	nilotinib	Phase 2	2005	2019	NCT03205267;NCT03654768;NCT02767063;NCT03516279;NCT01856283;NCT01746836;NCT00769327;NCT02709083;NCT03906292;NCT00702403;NCT00809211;NCT00129740;NCT03610971;NCT02973711;NCT01294618;NCT01914484
Leukemia, Myeloid, Chronic-Phase	D015466	nilotinib	Phase 3	2015	2017	NCT03079505;NCT02627677
Leukemia, Myeloid, Chronic-Phase	D015466	nilotinib	Phase 4	2008	2008	NCT00644878
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	nilotinib	Phase 1	2009	2014	NCT02081378;NCT01077544;NCT00860535
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	nilotinib	Phase 2	2001	2020	NCT01667133;NCT00384228;NCT00750659;NCT01279473;NCT00109707;NCT01207440;NCT01883219;NCT00702403;NCT00905398;NCT00844298;NCT00036738;NCT01914484;NCT01528085;NCT04233346;NCT01670084
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	nilotinib	Phase 3	2016	2020	NCT02611492;NCT04375683
Leukemia, Lymphoid	D007945	nilotinib	Phase 1	2009	2014	NCT02081378;NCT01077544;NCT00860535
Leukemia, Lymphoid	D007945	nilotinib	Phase 2	2001	2013	NCT01667133;NCT00384228;NCT00750659;NCT01279473;NCT00109707;NCT01207440;NCT01883219;NCT00702403;NCT00905398;NCT00844298;NCT00036738;NCT01914484;NCT01528085;NCT01670084
Blast Crisis	D001752	nilotinib	Phase 1	2009	2009	NCT00860535
Blast Crisis	D001752	nilotinib	Phase 2	2008	2013	NCT00702403;NCT01690065;NCT01914484;NCT01670084
Blast Crisis	D001752	nilotinib	Phase 3	2009	2009	NCT01126892
Blast Crisis	D001752	nilotinib	Phase 4	2008	2008	NCT00786812;NCT01368523
Giant Cell Tumors	D005870	nilotinib	Phase 2	2010	2010	NCT01261429;NCT01207492
Giant Cell Tumor of Tendon Sheath	D000070779	nilotinib	Phase 2	2010	2010	NCT01261429;NCT01207492
Synovitis, Pigmented Villonodular	D013586	nilotinib	Phase 2	2010	2010	NCT01261429;NCT01207492
Glioma	D005910	nilotinib	Phase 1	2013	2013	NCT01884922
Glioma	D005910	nilotinib	Phase 2	2010	2013	NCT01887522;NCT01140568
Sarcoma	D012509	nilotinib	Phase 3	2019	2019	NCT03784014
Gastrointestinal Stromal Tumors	D046152	nilotinib	Phase 1	2006	2006	NCT00441155
Gastrointestinal Stromal Tumors	D046152	nilotinib	Phase 2	2008	2013	NCT01110668;NCT00782834;NCT01863745;NCT00718562;NCT01270893;NCT00633295
Gastrointestinal Stromal Tumors	D046152	nilotinib	Phase 3	2007	2009	NCT00751036;NCT00471328;NCT00785785;NCT00688766;NCT01289028
Gastrointestinal Stromal Tumors	D046152	nilotinib	Phase 4	2008	2008	NCT00756509
Melanoma	D008545	nilotinib	Phase 2	2009	2010	NCT01099514;NCT01028222;NCT01395121;NCT01168050;NCT00788775
Neoplasm, Residual	D018365	nilotinib	Phase 1	2012	2013	NCT01751425;NCT01460498
Neoplasm, Residual	D018365	nilotinib	Phase 2	2013	2018	NCT03516279;NCT01883219
Carcinoma	D002277	nilotinib	Phase 2	2017	2017	NCT02788201
Urinary Bladder Neoplasms	D001749	nilotinib	Phase 2	2017	2017	NCT02788201
Carcinoma, Transitional Cell	D002295	nilotinib	Phase 2	2017	2017	NCT02788201
Leukemia, Myeloid, Acute	D015470	nilotinib	Phase 2	2007	2015	NCT01806571;NCT01222143;NCT01690065;NCT00762632
Mastocytosis	D008415	nilotinib	Phase 2	2004	2004	NCT00109707
Mastocytosis, Systemic	D034721	nilotinib	Phase 2	2004	2004	NCT00109707
Neoplasm Metastasis	D009362	nilotinib	Phase 2	2009	2014	NCT02142036;NCT01089595
Neoplasms, Second Primary	D016609	nilotinib	Phase 2	2014	2014	NCT02142036
Lymphoma	D008223	nilotinib	Phase 1	2010	2010	NCT01155817
Lymphoma, Non-Hodgkin	D008228	nilotinib	Phase 1	2010	2010	NCT01155817
Lymphoma, T-Cell	D016399	nilotinib	Phase 1	2010	2010	NCT01155817
Lymphoma, T-Cell, Peripheral	D016411	nilotinib	Phase 1	2010	2010	NCT01155817
Head and Neck Neoplasms	D006258	nilotinib	Phase 1	2014	2014	NCT01871311
Chordoma	D002817	nilotinib	Phase 1	2011	2011	NCT01407198
Leukemia, Myeloid, Accelerated Phase	D015465	nilotinib	Phase 2	2008	2013	NCT00702403;NCT01914484
Leiomyosarcoma	D007890	nilotinib	Phase 2	2012	2012	NCT02587169
Liposarcoma	D008080	nilotinib	Phase 2	2012	2012	NCT02587169
Chondrosarcoma	D002813	nilotinib	Phase 2	2012	2012	NCT02587169
Breast Neoplasms	D001943	nilotinib	Phase 1	2020	2020	NCT04205903
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	D015452	nilotinib	Phase 2	2009	2009	NCT00905398
Neurofibromatoses	D017253	nilotinib	Phase 1	2011	2011	NCT01275586
Neurofibromatosis 1	D009456	nilotinib	Phase 1	2011	2011	NCT01275586
Neurofibroma	D009455	nilotinib	Phase 1	2011	2011	NCT01275586
Neurofibroma, Plexiform	D018318	nilotinib	Phase 1	2011	2011	NCT01275586
Colonic Neoplasms	D003110	nilotinib	Phase 1	2016	2016	NCT02774512
Neurilemmoma	D009442	nilotinib	Phase 2	2010	2010	NCT01201538
Neuroma, Acoustic	D009464	nilotinib	Phase 2	2010	2010	NCT01201538
Gastrointestinal Neoplasms	D005770	nilotinib	Phase 2	2011	2011	NCT01270893
Adenocarcinoma	D000230	nintedanib	Phase 1	2014	2016	NCT02668393;NCT02300298
Adenocarcinoma	D000230	nintedanib	Phase 2	2011	2020	NCT03361319;NCT02234596;NCT02393755;NCT02856867;NCT04046614;NCT01225887
Adenocarcinoma of Lung	D000077192	nintedanib	Phase 1	2016	2016	NCT02668393
Adenocarcinoma of Lung	D000077192	nintedanib	Phase 2	2018	2020	NCT03361319;NCT04046614
Lung Neoplasms	D008175	nintedanib	Phase 1	2013	2015	NCT02225405;NCT01683682
Lung Neoplasms	D008175	nintedanib	Phase 2	2011	2018	NCT03377023;NCT01948141;NCT01441297;NCT02531737;NCT02152059;NCT02299141
Carcinoma, Non-Small-Cell Lung	D002289	nintedanib	Phase 1	2005	2016	NCT00979576;NCT02182102;NCT02668393;NCT02225405;NCT01346540;NCT02751385;NCT02182232;NCT02300298;NCT01683682;NCT01684111;NCT00876460
Carcinoma, Non-Small-Cell Lung	D002289	nintedanib	Phase 2	2005	2018	NCT03377023;NCT02452463;NCT01948141;NCT02182050;NCT02299141
Carcinoma, Non-Small-Cell Lung	D002289	nintedanib	Phase 3	2008	2014	NCT02231164;NCT00806819;NCT00805194
Carcinoma	D002277	nintedanib	Phase 1	2012	2016	NCT02835833;NCT02225405;NCT01594125
Carcinoma	D002277	nintedanib	Phase 2	2009	2015	NCT02866370;NCT02278978;NCT02452463;NCT02393755;NCT01004003;NCT00987935;NCT01225887
Adenomyoepithelioma	D055331	nintedanib	Phase 2	2015	2015	NCT02866370
Adenocarcinoma, Clear Cell	D018262	nintedanib	Phase 2	2011	2015	NCT02866370;NCT01225887
Carcinoma, Ovarian Epithelial	D000077216	nintedanib	Phase 1	2011	2011	NCT01485874
Carcinoma, Ovarian Epithelial	D000077216	nintedanib	Phase 2	2012	2015	NCT02866370;NCT01583322;NCT01669798;NCT01610869
Carcinoma, Transitional Cell	D002295	nintedanib	Phase 2	2011	2014	NCT02278978;NCT01225887
Mesothelioma	D008654	nintedanib	Phase 2	2015	2018	NCT02568449;NCT02863055
Mesothelioma	D008654	nintedanib	Phase 3	2013	2013	NCT01907100
Glioblastoma	D005909	nintedanib	Phase 2	2011	2012	NCT01666600;NCT01380782;NCT01251484
Breast Neoplasms	D001943	nintedanib	Phase 1	2015	2015	NCT02619162
Breast Neoplasms	D001943	nintedanib	Phase 2	2011	2015	NCT02389764;NCT01658462;NCT01484080
Inflammatory Breast Neoplasms	D058922	nintedanib	Phase 2	2015	2015	NCT02389764
Sarcoma	D012509	nintedanib	Phase 2	2017	2017	NCT02808247
Head and Neck Neoplasms	D006258	nintedanib	Phase 2	2014	2017	NCT03292250;NCT02558387
Prostatic Neoplasms	D011471	nintedanib	Phase 1	2005	2005	NCT02182219
Prostatic Neoplasms	D011471	nintedanib	Phase 2	2005	2006	NCT02182063;NCT00706628
Ovarian Neoplasms	D010051	nintedanib	Phase 1	2011	2011	NCT01485874;NCT01314105;NCT01329549
Ovarian Neoplasms	D010051	nintedanib	Phase 2	2006	2014	NCT01583322;NCT01669798;NCT00710762;NCT01610869
Ovarian Neoplasms	D010051	nintedanib	Phase 3	2009	2009	NCT01015118
Fallopian Tube Neoplasms	D005185	nintedanib	Phase 1	2011	2011	NCT01314105
Fallopian Tube Neoplasms	D005185	nintedanib	Phase 2	2013	2014	NCT01669798;NCT01610869
Peritoneal Neoplasms	D010534	nintedanib	Phase 1	2011	2011	NCT01314105
Peritoneal Neoplasms	D010534	nintedanib	Phase 3	2009	2009	NCT01015118
Carcinoid Tumor	D002276	nintedanib	Phase 2	2015	2015	NCT02399215
Neuroendocrine Tumors	D018358	nintedanib	Phase 2	2015	2015	NCT02399215
Colorectal Neoplasms	D015179	nintedanib	Phase 2	2006	2016	NCT02780700;NCT00801294;NCT01362361;NCT00904839
Colorectal Neoplasms	D015179	nintedanib	Phase 3	2014	2014	NCT02149108
Uterine Cervical Neoplasms	D002583	nintedanib	Phase 2	2014	2014	NCT02009579
Appendiceal Neoplasms	D001063	nintedanib	Phase 2	2017	2017	NCT03287947
Carcinoma, Renal Cell	D002292	nintedanib	Phase 1	2016	2016	NCT02835833
Carcinoma, Renal Cell	D002292	nintedanib	Phase 2	2009	2009	NCT01024920
Endometrial Neoplasms	D016889	nintedanib	Phase 2	2016	2016	NCT02730416
Pancreatic Neoplasms	D010190	nintedanib	Phase 2	2017	2017	NCT02902484
Melanoma	D008545	nintedanib	Phase 2	2015	2015	NCT02308553
Liver Neoplasms	D008113	nintedanib	Phase 3	2006	2006	NCT00363584
Biliary Tract Neoplasms	D001661	nintedanib	Phase 3	2006	2006	NCT00363584
Gallbladder Neoplasms	D005706	nintedanib	Phase 3	2006	2006	NCT00363584
Bile Duct Neoplasms	D001650	nintedanib	Phase 3	2006	2006	NCT00363584
Cholangiocarcinoma	D018281	nintedanib	Phase 3	2006	2006	NCT00363584
Thyroid Neoplasms	D013964	nintedanib	Phase 2	2014	2014	NCT01788982
Carcinoma, Neuroendocrine	D018278	nintedanib	Phase 2	2014	2014	NCT01788982
Leukemia	D007938	nintedanib	Phase 1	2018	2018	NCT03513484
Leukemia	D007938	nintedanib	Phase 2	2012	2016	NCT02665143;NCT01488344
Leukemia, Myeloid	D007951	nintedanib	Phase 1	2018	2018	NCT03513484
Leukemia, Myeloid	D007951	nintedanib	Phase 2	2012	2016	NCT02665143;NCT01488344
Leukemia, Myeloid, Acute	D015470	nintedanib	Phase 1	2018	2018	NCT03513484
Leukemia, Myeloid, Acute	D015470	nintedanib	Phase 2	2012	2016	NCT02665143;NCT01488344
Rectal Neoplasms	D012004	nintedanib	Phase 2	2015	2015	NCT02393755
Colonic Neoplasms	D003110	nintedanib	Phase 2	2015	2015	NCT02393755
Multiple Myeloma	D009101	nintedanib	Phase 1	2003	2003	NCT02182141
Neoplasms, Plasma Cell	D054219	nintedanib	Phase 1	2003	2003	NCT02182141
Lymphangioleiomyomatosis	D018192	nintedanib	Phase 2	2016	2016	NCT03062943
Small Cell Lung Carcinoma	D055752	nintedanib	Phase 2	2011	2014	NCT01441297;NCT02152059
Carcinoma, Hepatocellular	D006528	nintedanib	Phase 1	2012	2012	NCT01594125
Carcinoma, Hepatocellular	D006528	nintedanib	Phase 2	2009	2009	NCT01004003;NCT00987935
Neoplasm Metastasis	D009362	nintedanib	Phase 2	2016	2016	NCT02856867
Astrocytoma	D001254	nintedanib	Phase 2	2012	2012	NCT01380782
Gliosarcoma	D018316	nintedanib	Phase 2	2012	2012	NCT01380782
Oligodendroglioma	D009837	nintedanib	Phase 2	2012	2012	NCT01380782
Genital Neoplasms, Female	D005833	nintedanib	Phase 1	2005	2005	NCT02182245
Salivary Gland Neoplasms	D012468	nintedanib	Phase 2	2014	2014	NCT02558387
Cystadenocarcinoma, Serous	D018284	nintedanib	Phase 2	2011	2011	NCT01225887
Adenocarcinoma, Mucinous	D002288	nintedanib	Phase 2	2011	2011	NCT01225887
Cystadenocarcinoma	D003536	nintedanib	Phase 2	2011	2011	NCT01225887
Neoplasm Metastasis	D009362	olaratumab	Phase 1	2016	2016	NCT02677116
Sarcoma	D012509	olaratumab	Phase 1	2015	2018	NCT02326025;NCT02783599;NCT03056599;NCT03283696;NCT03126591;NCT03985722
Sarcoma	D012509	olaratumab	Phase 2	2010	2018	NCT02584309;NCT01185964;NCT03698227;NCT02659020
Sarcoma	D012509	olaratumab	Phase 3	2015	2015	NCT02451943
Lung Neoplasms	D008175	olaratumab	Phase 2	2010	2010	NCT00918203
Carcinoma, Non-Small-Cell Lung	D002289	olaratumab	Phase 2	2010	2010	NCT00918203
Leiomyosarcoma	D007890	olaratumab	Phase 1	2019	2019	NCT03437070
Leiomyosarcoma	D007890	olaratumab	Phase 2	2016	2016	NCT02584309
Prostatic Neoplasms	D011471	olaratumab	Phase 2	2010	2010	NCT01204710
Gastrointestinal Stromal Tumors	D046152	olaratumab	Phase 2	2011	2011	NCT01316263
Glioblastoma	D005909	olaratumab	Phase 2	2010	2010	NCT00895180
Liposarcoma	D008080	olaratumab	Phase 2	2016	2016	NCT02584309
Sarcoma, Synovial	D013584	olaratumab	Phase 2	2016	2016	NCT02584309
Hemangiosarcoma	D006394	olaratumab	Phase 2	2016	2016	NCT02584309
Nerve Sheath Neoplasms	D018317	olaratumab	Phase 2	2016	2016	NCT02584309
Neurofibrosarcoma	D018319	olaratumab	Phase 2	2016	2016	NCT02584309
Fibrosarcoma	D005354	olaratumab	Phase 2	2016	2016	NCT02584309
Histiocytoma, Malignant Fibrous	D051677	olaratumab	Phase 2	2016	2016	NCT02584309
Pancreatic Neoplasms	D010190	olaratumab	Phase 2	2017	2017	NCT03086369
Ovarian Neoplasms	D010051	olaratumab	Phase 2	2009	2009	NCT00913835
Carcinoma, Non-Small-Cell Lung	D002289	olmutinib	Phase 1	2018	2018	NCT04510415
Carcinoma, Non-Small-Cell Lung	D002289	olmutinib	Phase 2	2012	2017	NCT02444819;NCT03228277;NCT01588145;NCT02485652
Lung Neoplasms	D008175	olmutinib	Phase 2	2015	2015	NCT02485652
Lung Neoplasms	D008175	osimertinib	Phase 1	2014	2021	NCT02228369;NCT03255083;NCT03755102;NCT02157883;NCT02789345;NCT02317016;NCT03567642;NCT03891615;NCT03535363;NCT03810807;NCT04676477;NCT03858491;NCT04762199;NCT04141644;NCT04479306;NCT03050411;NCT04448379;NCT04085315;NCT02163733;NCT04780568
Lung Neoplasms	D008175	osimertinib	Phase 2	2013	2021	NCT03392246;NCT03122717;NCT04743505;NCT03460275;NCT02917993;NCT03434418;NCT03586453;NCT03804580;NCT02759835;NCT03257124;NCT03831932;NCT03455829;NCT04563871;NCT03944772;NCT03667820;NCT03497767;NCT02504346;NCT02841579;NCT04519983;NCT04148898;NCT03769103;NCT02442349;NCT02179671;NCT03410043;NCT04410796;NCT02803203;NCT04606771;NCT04285671;NCT02664935;NCT03865511;NCT03450330;NCT04099836;NCT02465060;NCT03433469;NCT04425681;NCT03810066;NCT04233021;NCT01802632;NCT03909334;NCT03239340;NCT02954523;NCT02769286;NCT03424759;NCT04335292;NCT04517526;NCT04545710
Lung Neoplasms	D008175	osimertinib	Phase 3	2014	2021	NCT04765059;NCT02151981;NCT02296125;NCT03515837;NCT02411448;NCT04035486;NCT04351555;NCT02511106;NCT02474355;NCT04181060;NCT03521154
Lung Neoplasms	D008175	osimertinib	Phase 4	2019	2020	NCT03853551;NCT04356118
Carcinoma, Non-Small-Cell Lung	D002289	osimertinib	Phase 1	2014	2021	NCT02197247;NCT02228369;NCT03255083;NCT02520778;NCT02157883;NCT02529995;NCT02789345;NCT02317016;NCT03535363;NCT04772235;NCT02143466;NCT02908750;NCT03463525;NCT02197234;NCT04077463;NCT04676477;NCT03858491;NCT04762199;NCT04141644;NCT04479306;NCT02496663;NCT02503722;NCT03050411;NCT04448379;NCT02163733;NCT04780568;NCT04001777
Carcinoma, Non-Small-Cell Lung	D002289	osimertinib	Phase 2	2013	2021	NCT03392246;NCT03122717;NCT03784599;NCT04743505;NCT03460275;NCT02917993;NCT03434418;NCT03586453;NCT02856893;NCT03133546;NCT03257124;NCT04029350;NCT03831932;NCT03455829;NCT04563871;NCT03944772;NCT03667820;NCT03497767;NCT03799094;NCT03418532;NCT03940703;NCT04438902;NCT02841579;NCT04338243;NCT04148898;NCT03769103;NCT02442349;NCT02094261;NCT03446417;NCT02771314;NCT02179671;NCT03410043;NCT04316351;NCT04769388;NCT03381274;NCT04606771;NCT04285671;NCT03318939;NCT03414814;NCT02664935;NCT03450330;NCT03758677;NCT04099836;NCT02811354;NCT03433469;NCT03191149;NCT02971501;NCT04425681;NCT04233021;NCT04486833;NCT01802632;NCT03909334;NCT04764214;NCT03239340;NCT02824952;NCT02954523;NCT03424759;NCT04335292
Carcinoma, Non-Small-Cell Lung	D002289	osimertinib	Phase 3	2014	2021	NCT04765059;NCT02151981;NCT02296125;NCT03515837;NCT02454933;NCT02411448;NCT04035486;NCT04351555;NCT02511106;NCT04695925;NCT04181060;NCT02972333;NCT03521154;NCT04487080;NCT02959749
Carcinoma, Non-Small-Cell Lung	D002289	osimertinib	Phase 4	2019	2020	NCT03853551;NCT04413201;NCT04356118
Carcinoma	D002277	osimertinib	Phase 1	2016	2021	NCT02520778;NCT04762199;NCT04479306;NCT02496663;NCT02503722
Carcinoma	D002277	osimertinib	Phase 2	2015	2021	NCT03831932;NCT04644432;NCT03410043;NCT04285671;NCT02465060;NCT03191149
Carcinoma	D002277	osimertinib	Phase 3	2015	2020	NCT02511106;NCT04181060
Glioblastoma	D005909	osimertinib	Phase 1	2020	2020	NCT04135807
Glioblastoma	D005909	osimertinib	Phase 2	2018	2018	NCT03732352
Glioma	D005910	osimertinib	Phase 1	2020	2020	NCT04135807
Glioma	D005910	osimertinib	Phase 2	2015	2015	NCT02465060
Brain Neoplasms	D001932	osimertinib	Phase 1	2020	2020	NCT04135807
Brain Neoplasms	D001932	osimertinib	Phase 2	2019	2019	NCT03769103
Astrocytoma	D001254	osimertinib	Phase 1	2020	2020	NCT04135807
Oligodendroglioma	D009837	osimertinib	Phase 1	2020	2020	NCT04135807
Adenocarcinoma of Lung	D000077192	osimertinib	Phase 2	2016	2020	NCT02759835;NCT04770688
Neoplasm Metastasis	D009362	osimertinib	Phase 2	2017	2020	NCT03257124;NCT04148898;NCT03769103;NCT04425681;NCT04233021
Neoplasm Metastasis	D009362	osimertinib	Phase 3	2016	2016	NCT02972333
Neoplasm Metastasis	D009362	osimertinib	Phase 4	2020	2020	NCT04356118
Meningeal Carcinomatosis	D055756	osimertinib	Phase 2	2017	2020	NCT03257124;NCT04148898;NCT04425681;NCT04233021
Meningeal Carcinomatosis	D055756	osimertinib	Phase 4	2020	2020	NCT04356118
Neoplasms, Second Primary	D016609	osimertinib	Phase 2	2017	2020	NCT04148898;NCT04425681;NCT04233021
Neoplasms, Second Primary	D016609	osimertinib	Phase 4	2020	2020	NCT04356118
Carcinoma, Renal Cell	D002292	osimertinib	Phase 2	2015	2020	NCT04644432;NCT02465060
Kidney Neoplasms	D007680	osimertinib	Phase 2	2015	2020	NCT04644432;NCT02465060
Urogenital Neoplasms	D014565	osimertinib	Phase 2	2020	2020	NCT04644432
Urologic Neoplasms	D014571	osimertinib	Phase 2	2020	2020	NCT04644432
Adenocarcinoma	D000230	osimertinib	Phase 2	2015	2015	NCT02664935
Carcinoma, Squamous Cell	D002294	osimertinib	Phase 2	2015	2015	NCT02664935
Bronchial Neoplasms	D001984	osimertinib	Phase 1	2018	2018	NCT03516214
Lymphoma	D008223	osimertinib	Phase 2	2015	2015	NCT02465060
Melanoma	D008545	osimertinib	Phase 2	2015	2015	NCT02465060
Multiple Myeloma	D009101	osimertinib	Phase 2	2015	2015	NCT02465060
Neoplasms, Plasma Cell	D054219	osimertinib	Phase 2	2015	2015	NCT02465060
Breast Neoplasms	D001943	osimertinib	Phase 2	2015	2015	NCT02465060
Colorectal Neoplasms	D015179	osimertinib	Phase 2	2015	2015	NCT02465060
Endometrial Neoplasms	D016889	osimertinib	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	osimertinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	osimertinib	Phase 2	2015	2015	NCT02465060
Prostatic Neoplasms	D011471	osimertinib	Phase 2	2015	2015	NCT02465060
Pancreatic Neoplasms	D010190	osimertinib	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	osimertinib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	osimertinib	Phase 2	2015	2015	NCT02465060
Urinary Bladder Neoplasms	D001749	osimertinib	Phase 2	2015	2015	NCT02465060
Rectal Neoplasms	D012004	osimertinib	Phase 2	2015	2015	NCT02465060
Thyroid Neoplasms	D013964	osimertinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	osimertinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Hepatocellular	D006528	osimertinib	Phase 2	2015	2015	NCT02465060
Colonic Neoplasms	D003110	osimertinib	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	osimertinib	Phase 2	2015	2015	NCT02465060
Multiple Myeloma	D009101	palbociclib	Phase 1	2014	2020	NCT02030483;NCT03878524
Multiple Myeloma	D009101	palbociclib	Phase 2	2008	2017	NCT02693535;NCT03297606;NCT00555906;NCT02465060
Lymphoma, Non-Hodgkin	D008228	palbociclib	Phase 1	2004	2020	NCT00141297;NCT03792256;NCT03878524
Lymphoma, Non-Hodgkin	D008228	palbociclib	Phase 2	2016	2018	NCT02693535;NCT03297606;NCT03526250;NCT03155620
Breast Neoplasms	D001943	palbociclib	Phase 1	2011	2021	NCT03332797;NCT02897375;NCT01976169;NCT02599714;NCT03685331;NCT04360941;NCT03006172;NCT04498520;NCT04504331;NCT02389842;NCT04483505;NCT03284723;NCT02626507;NCT03238196;NCT03471663;NCT03854903;NCT02913430;NCT03455270;NCT02499146;NCT01320592;NCT02684032;NCT04585724;NCT03900884;NCT03959891;NCT04288089;NCT03616587;NCT03878524
Breast Neoplasms	D001943	palbociclib	Phase 2	2008	2021	NCT03530696;NCT03560856;NCT04494958;NCT03644186;NCT01709370;NCT02917005;NCT03609047;NCT02448771;NCT04567420;NCT02871791;NCT02592083;NCT03633331;NCT04247633;NCT02491983;NCT02764541;NCT03628066;NCT04075604;NCT02603679;NCT01723774;NCT03709082;NCT04012918;NCT02530424;NCT02774681;NCT02296801;NCT03691493;NCT02760030;NCT02592746;NCT04256941;NCT04436744;NCT02549430;NCT02536742;NCT03304080;NCT03819010;NCT04334330;NCT03227328;NCT02907918;NCT04318223;NCT02605486;NCT02778685;NCT01684215;NCT03377101;NCT02668666;NCT03147287;NCT03280563;NCT04224272;NCT03065621;NCT00721409;NCT02738866;NCT02894398;NCT02008734;NCT02384239;NCT03573648;NCT04669587;NCT02465060;NCT03054363;NCT02400567;NCT03809988;NCT02690480;NCT03322215;NCT02630693;NCT03184090;NCT04563507;NCT03007979;NCT01823835;NCT03284957;NCT02632045;NCT04072952;NCT03913234;NCT03560531;NCT03128619;NCT03774472;NCT01037790;NCT02624973;NCT02448420;NCT02942355;NCT03439735;NCT02040857;NCT04220476
Breast Neoplasms	D001943	palbociclib	Phase 3	2013	2021	NCT03423199;NCT01864746;NCT02297438;NCT04478266;NCT04711252;NCT02028507;NCT02947685;NCT04047758;NCT03447132;NCT02600923;NCT03969121;NCT03079011;NCT01942135;NCT04060862;NCT03425838;NCT04191499;NCT03820830;NCT01740427;NCT02692755;NCT04546009;NCT02513394
Breast Neoplasms	D001943	palbociclib	Phase 4	2016	2019	NCT03220178;NCT03355157;NCT04137640;NCT02679755
Lymphoma	D008223	palbociclib	Phase 1	2007	2020	NCT01111188;NCT02159755;NCT00420056;NCT03792256;NCT03878524
Lymphoma	D008223	palbociclib	Phase 2	2014	2018	NCT02264613;NCT04439201;NCT03526250;NCT03478514;NCT02465060;NCT03155620
Lymphoma, Mantle-Cell	D020522	palbociclib	Phase 1	2007	2014	NCT01111188;NCT02159755;NCT00420056
Lymphoma, Mantle-Cell	D020522	palbociclib	Phase 2	2018	2018	NCT03478514
Neuroblastoma	D009447	palbociclib	Phase 1	2019	2019	NCT03709680
Neuroblastoma	D009447	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Rhabdomyosarcoma	D012208	palbociclib	Phase 1	2019	2019	NCT03709680
Rhabdomyosarcoma	D012208	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Sarcoma, Ewing	D012512	palbociclib	Phase 1	2019	2019	NCT03709680
Sarcoma, Ewing	D012512	palbociclib	Phase 2	2017	2019	NCT04129151;NCT03526250;NCT03155620
Medulloblastoma	D008527	palbociclib	Phase 1	2014	2019	NCT03709680;NCT02255461
Medulloblastoma	D008527	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Rhabdoid Tumor	D018335	palbociclib	Phase 1	2019	2019	NCT03709680
Rhabdoid Tumor	D018335	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Triple Negative Breast Neoplasms	D064726	palbociclib	Phase 1	2020	2020	NCT04360941
Triple Negative Breast Neoplasms	D064726	palbociclib	Phase 2	2020	2020	NCT04494958;NCT04553133
Carcinoma	D002277	palbociclib	Phase 1	2018	2021	NCT04498520;NCT03498378;NCT03878524
Carcinoma	D002277	palbociclib	Phase 2	2011	2021	NCT03981614;NCT03088059;NCT03389477;NCT02774681;NCT04644432;NCT03194373;NCT01356628;NCT01536743;NCT03531645;NCT02465060;NCT02499120;NCT03128619;NCT04605562
Carcinoma	D002277	palbociclib	Phase 3	2014	2014	NCT02785939
Colorectal Neoplasms	D015179	palbociclib	Phase 2	2015	2019	NCT03981614;NCT02465060
Neuroendocrine Tumors	D018358	palbociclib	Phase 2	2015	2019	NCT03981614;NCT02806648
Carcinoma, Intraductal, Noninfiltrating	D002285	palbociclib	Phase 2	2018	2018	NCT03535506
Lymphoma, T-Cell, Peripheral	D016411	palbociclib	Phase 2	2014	2014	NCT02264613
Lung Neoplasms	D008175	palbociclib	Phase 1	2016	2016	NCT02897375
Lung Neoplasms	D008175	palbociclib	Phase 2	2011	2020	NCT02022982;NCT02349633;NCT03386929;NCT04553133;NCT02664935;NCT03170206;NCT01291017;NCT02465060
Lung Neoplasms	D008175	palbociclib	Phase 3	2014	2014	NCT02785939
Carcinoma, Non-Small-Cell Lung	D002289	palbociclib	Phase 1	2016	2020	NCT02897375;NCT04606446
Carcinoma, Non-Small-Cell Lung	D002289	palbociclib	Phase 2	2011	2020	NCT02022982;NCT02349633;NCT03386929;NCT04553133;NCT02664935;NCT01291017
Pancreatic Neoplasms	D010190	palbociclib	Phase 1	2016	2020	NCT02897375;NCT03454035;NCT03878524
Pancreatic Neoplasms	D010190	palbociclib	Phase 2	2015	2015	NCT02465060
Neoplasm Metastasis	D009362	palbociclib	Phase 2	2016	2020	NCT02896335;NCT04334330
Sarcoma	D012509	palbociclib	Phase 2	2017	2019	NCT04129151;NCT03526250;NCT03242382;NCT03155620
Sarcoma	D012509	palbociclib	Phase 3	2019	2019	NCT03784014
Melanoma	D008545	palbociclib	Phase 2	2009	2020	NCT03454919;NCT02465060;NCT04720768;NCT02202200;NCT01037790
Carcinoma, Squamous Cell	D002294	palbociclib	Phase 1	2018	2018	NCT03498378
Carcinoma, Squamous Cell	D002294	palbociclib	Phase 2	2014	2018	NCT03088059;NCT02101034;NCT03389477;NCT03024489;NCT03194373;NCT02664935;NCT02499120
Squamous Cell Carcinoma of Head and Neck	D000077195	palbociclib	Phase 1	2018	2018	NCT03498378
Squamous Cell Carcinoma of Head and Neck	D000077195	palbociclib	Phase 2	2014	2018	NCT03088059;NCT02101034;NCT03389477;NCT03194373;NCT02499120
Head and Neck Neoplasms	D006258	palbociclib	Phase 1	2017	2017	NCT03065062
Leukemia	D007938	palbociclib	Phase 1	2012	2020	NCT03515200;NCT01701375;NCT03472573;NCT03792256;NCT03132454;NCT03878524
Leukemia	D007938	palbociclib	Phase 2	2015	2019	NCT03844997;NCT02310243
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	palbociclib	Phase 1	2017	2020	NCT03515200;NCT03472573;NCT03792256;NCT03132454;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	palbociclib	Phase 2	2015	2015	NCT02310243
Leukemia, Lymphoid	D007945	palbociclib	Phase 1	2017	2020	NCT03515200;NCT03472573;NCT03792256;NCT03132454;NCT03878524
Leukemia, Lymphoid	D007945	palbociclib	Phase 2	2015	2015	NCT02310243
Leukemia, Myeloid	D007951	palbociclib	Phase 1	2017	2020	NCT03132454;NCT03878524
Leukemia, Myeloid	D007951	palbociclib	Phase 2	2019	2019	NCT03844997
Leukemia, Myeloid, Acute	D015470	palbociclib	Phase 1	2017	2020	NCT03132454;NCT03878524
Leukemia, Myeloid, Acute	D015470	palbociclib	Phase 2	2015	2019	NCT03844997;NCT02310243
Carcinoma, Renal Cell	D002292	palbociclib	Phase 2	2015	2020	NCT04644432;NCT02465060
Kidney Neoplasms	D007680	palbociclib	Phase 2	2015	2020	NCT04644432;NCT02465060
Urogenital Neoplasms	D014565	palbociclib	Phase 2	2020	2020	NCT04644432
Urologic Neoplasms	D014571	palbociclib	Phase 2	2020	2020	NCT04644432
Prostatic Neoplasms	D011471	palbociclib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	palbociclib	Phase 2	2014	2017	NCT02059213;NCT02905318;NCT02465060
Ovarian Neoplasms	D010051	palbociclib	Phase 1	2021	2021	NCT04498520
Ovarian Neoplasms	D010051	palbociclib	Phase 2	2009	2020	NCT04553133;NCT02465060;NCT03936270;NCT01037790
Carcinoma, Ovarian Epithelial	D000077216	palbociclib	Phase 1	2021	2021	NCT04498520
Carcinoma, Ovarian Epithelial	D000077216	palbociclib	Phase 2	2011	2020	NCT01536743;NCT02465060;NCT03936270
Fallopian Tube Neoplasms	D005185	palbociclib	Phase 1	2021	2021	NCT04498520
Peritoneal Neoplasms	D010534	palbociclib	Phase 1	2021	2021	NCT04498520
Carcinoma, Endometrioid	D018269	palbociclib	Phase 1	2021	2021	NCT04498520
Preleukemia	D011289	palbociclib	Phase 1	2012	2020	NCT01701375;NCT03878524
Glioblastoma	D005909	palbociclib	Phase 1	2014	2014	NCT02255461
Glioblastoma	D005909	palbociclib	Phase 2	2010	2018	NCT01227434;NCT03158389
Astrocytoma	D001254	palbociclib	Phase 1	2014	2014	NCT02255461
Astrocytoma	D001254	palbociclib	Phase 2	2010	2010	NCT01227434
Gliosarcoma	D018316	palbociclib	Phase 1	2014	2014	NCT02255461
Gliosarcoma	D018316	palbociclib	Phase 2	2010	2010	NCT01227434
Glioma	D005910	palbociclib	Phase 2	2015	2018	NCT03526250;NCT02465060;NCT03155620
Neoplasms, Germ Cell and Embryonal	D009373	palbociclib	Phase 2	2009	2018	NCT03526250;NCT03155620;NCT01037790
Osteosarcoma	D012516	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Ependymoma	D004806	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Neuroectodermal Tumors	D017599	palbociclib	Phase 1	2014	2014	NCT02255461
Neuroectodermal Tumors	D017599	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Neuroectodermal Tumors, Primitive	D018242	palbociclib	Phase 1	2014	2014	NCT02255461
Neuroectodermal Tumors, Primitive	D018242	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Wilms Tumor	D009396	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Neuroectodermal Tumors, Primitive, Peripheral	D018241	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Hepatoblastoma	D018197	palbociclib	Phase 2	2017	2018	NCT03526250;NCT03155620
Brain Neoplasms	D001932	palbociclib	Phase 2	2020	2020	NCT04334330
Small Cell Lung Carcinoma	D055752	palbociclib	Phase 2	2020	2020	NCT04553133
Carcinoma, Transitional Cell	D002295	palbociclib	Phase 2	2015	2015	NCT02334527
Oligodendroglioma	D009837	palbociclib	Phase 1	2014	2014	NCT02255461
Oligodendroglioma	D009837	palbociclib	Phase 2	2015	2015	NCT02530320
Endometrial Neoplasms	D016889	palbociclib	Phase 2	2015	2017	NCT02730429;NCT02465060
Lymphoma, B-Cell	D016393	palbociclib	Phase 2	2018	2018	NCT03478514
Adenocarcinoma	D000230	palbociclib	Phase 1	2015	2020	NCT02501902;NCT03878524
Adenocarcinoma	D000230	palbociclib	Phase 2	2009	2015	NCT02664935;NCT01037790
Liposarcoma	D008080	palbociclib	Phase 2	2010	2020	NCT04438824;NCT01209598
Neoplasms, Plasma Cell	D054219	palbociclib	Phase 1	2014	2020	NCT02030483;NCT03878524
Neoplasms, Plasma Cell	D054219	palbociclib	Phase 2	2008	2015	NCT00555906;NCT02465060
Carcinoma, Hepatocellular	D006528	palbociclib	Phase 2	2011	2015	NCT01356628;NCT02465060
Liver Neoplasms	D008113	palbociclib	Phase 2	2011	2011	NCT01356628
Carcinoma, Ductal	D044584	palbociclib	Phase 1	2018	2018	NCT03455270
Carcinoma, Ductal, Breast	D018270	palbociclib	Phase 1	2018	2018	NCT03455270
Cystadenocarcinoma, Serous	D018284	palbociclib	Phase 2	2019	2019	NCT03531645
Genital Neoplasms, Female	D005833	palbociclib	Phase 2	2019	2019	NCT03531645
Colonic Neoplasms	D003110	palbociclib	Phase 2	2009	2018	NCT03446157;NCT02465060;NCT01037790
Meningioma	D008579	palbociclib	Phase 1	2014	2014	NCT02255461
Nervous System Neoplasms	D009423	palbociclib	Phase 1	2014	2014	NCT02255461
Nervous System Neoplasms	D009423	palbociclib	Phase 2	2017	2017	NCT03155620
Central Nervous System Neoplasms	D016543	palbociclib	Phase 1	2014	2014	NCT02255461
Central Nervous System Neoplasms	D016543	palbociclib	Phase 2	2017	2017	NCT03155620
Choroid Plexus Neoplasms	D016545	palbociclib	Phase 1	2014	2014	NCT02255461
Pinealoma	D010871	palbociclib	Phase 1	2014	2014	NCT02255461
Neoplasms, Neuroepithelial	D018302	palbociclib	Phase 1	2014	2014	NCT02255461
Esophageal Neoplasms	D004938	palbociclib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	palbociclib	Phase 2	2015	2015	NCT02465060
Urinary Bladder Neoplasms	D001749	palbociclib	Phase 2	2015	2015	NCT02465060
Rectal Neoplasms	D012004	palbociclib	Phase 2	2009	2015	NCT02465060;NCT01037790
Thyroid Neoplasms	D013964	palbociclib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	palbociclib	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	palbociclib	Phase 2	2015	2015	NCT02465060
Thymus Neoplasms	D013953	palbociclib	Phase 2	2017	2017	NCT03219554
Gastrointestinal Neoplasms	D005770	palbociclib	Phase 2	2020	2020	NCT04591431
Chordoma	D002817	palbociclib	Phase 2	2017	2017	NCT03110744
Histiocytic Sarcoma	D054747	palbociclib	Phase 2	2017	2017	NCT03155620
Gastrointestinal Stromal Tumors	D046152	palbociclib	Phase 2	2014	2014	NCT01907607
Neoplasm, Residual	D018365	palbociclib	Phase 1	2019	2019	NCT04130152
Nasopharyngeal Carcinoma	D000077274	palbociclib	Phase 2	2021	2021	NCT04605562
Leukemia, T-Cell	D015458	palbociclib	Phase 1	2019	2019	NCT03792256
Germinoma	D018237	palbociclib	Phase 2	2009	2009	NCT01037790
Teratoma	D013724	palbociclib	Phase 2	2009	2009	NCT01037790
Testicular Neoplasms	D013736	palbociclib	Phase 2	2009	2009	NCT01037790
Breast Neoplasms, Male	D018567	palbociclib	Phase 2	2009	2009	NCT01037790
Seminoma	D018239	palbociclib	Phase 2	2009	2009	NCT01037790
Dermoid Cyst	D003884	palbociclib	Phase 2	2009	2009	NCT01037790
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	palbociclib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	palbociclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	palbociclib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	palbociclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	palbociclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	palbociclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	palbociclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	palbociclib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	palbociclib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	palbociclib	Phase 1	2020	2020	NCT03878524
Carcinoma, Neuroendocrine	D018278	palbociclib	Phase 2	2015	2015	NCT02806648
Carcinoma, Islet Cell	D018273	palbociclib	Phase 2	2015	2015	NCT02806648
Colorectal Neoplasms	D015179	panitumumab	Phase 1	2004	2018	NCT02205398;NCT03428958;NCT00101894;NCT02199223;NCT00563316;NCT02630420;NCT00879385;NCT02008383;NCT01791309
Colorectal Neoplasms	D015179	panitumumab	Phase 2	2002	2021	NCT01508000;NCT04787341;NCT03693807;NCT03992456;NCT00630786;NCT03764137;NCT00411450;NCT01591421;NCT04031872;NCT04668976;NCT01991873;NCT03751176;NCT01801904;NCT00958386;NCT03983993;NCT01328171;NCT04425239;NCT00842257;NCT00039273;NCT00332163;NCT04587128;NCT01288339;NCT02399943;NCT02904031;NCT00327119;NCT00508404;NCT01750918;NCT01312857;NCT03164655;NCT01110785;NCT00083616;NCT02613221;NCT03227926;NCT01668498;NCT01384994;NCT03069950;NCT01927341;NCT00819780;NCT01413295;NCT01139138;NCT01776307;NCT00111761;NCT02337946;NCT01504477;NCT01358812;NCT04515394;NCT02508077;NCT01057017;NCT01215539;NCT01260415;NCT04117945;NCT01152437;NCT03470350;NCT02980510;NCT00950820;NCT01892527;NCT00867334;NCT03366155;NCT00891930;NCT00792363;NCT03263429;NCT03087071;NCT01226719;NCT03142516;NCT01418742;NCT00940316;NCT00326495;NCT01144195;NCT00788957;NCT00089635;NCT02476045;NCT03803436;NCT01704703;NCT00418938;NCT00655499;NCT03167268;NCT04775862;NCT03251612;NCT03186326;NCT01126112;NCT00885885;NCT03940131;NCT03311750;NCT00475293;NCT04169347;NCT02448810
Colorectal Neoplasms	D015179	panitumumab	Phase 3	2004	2018	NCT00339183;NCT01001377;NCT00115765;NCT00389870;NCT03635021;NCT01910610;NCT02394795;NCT00113763;NCT03300609;NCT01895257;NCT01412957;NCT02934529;NCT00364013;NCT02394834;NCT02162563;NCT02885753;NCT03231722
Colorectal Neoplasms	D015179	panitumumab	Phase 4	2015	2015	NCT02301962
Neoplasm Metastasis	D009362	panitumumab	Phase 2	2002	2019	NCT01508000;NCT00034346;NCT00101920;NCT03164655;NCT00083616;NCT02142036;NCT01384994;NCT01260415;NCT00346099;NCT03366155;NCT03142516;NCT03803436
Neoplasm Metastasis	D009362	panitumumab	Phase 3	2014	2014	NCT02162563
Neoplasm Metastasis	D009362	panitumumab	Phase 4	2013	2013	NCT02015923
Neoplasms, Second Primary	D016609	panitumumab	Phase 2	2010	2019	NCT01508000;NCT04034173;NCT02142036;NCT01260415;NCT03803436
Neoplasms, Second Primary	D016609	panitumumab	Phase 3	2014	2014	NCT02162563
Neoplasms, Second Primary	D016609	panitumumab	Phase 4	2013	2013	NCT02015923
Liver Neoplasms	D008113	panitumumab	Phase 2	2010	2019	NCT01508000;NCT01384994;NCT01260415;NCT03803436
Cholangiocarcinoma	D018281	panitumumab	Phase 2	2008	2020	NCT03693807;NCT01206049;NCT04668976;NCT00779454;NCT00948935;NCT01320254
Glioma	D005910	panitumumab	Phase 2	2010	2018	NCT03510208;NCT01017653
Brain Neoplasms	D001932	panitumumab	Phase 2	2018	2018	NCT03510208
Carcinoma	D002277	panitumumab	Phase 1	2006	2020	NCT00513383;NCT04163952;NCT03733210;NCT02192541
Carcinoma	D002277	panitumumab	Phase 2	2002	2020	NCT01285778;NCT00500760;NCT03992456;NCT03983993;NCT01221753;NCT00446446;NCT02876107;NCT00111774;NCT02337946;NCT00425035;NCT01581840;NCT00756444;NCT01418742;NCT01129154;NCT00547157;NCT01843452
Carcinoma	D002277	panitumumab	Phase 3	2010	2010	NCT02818725
Carcinoma, Transitional Cell	D002295	panitumumab	Phase 1	2014	2014	NCT02192541
Carcinoma, Transitional Cell	D002295	panitumumab	Phase 3	2010	2010	NCT02818725
Adenocarcinoma	D000230	panitumumab	Phase 2	2007	2020	NCT00667420;NCT01077999;NCT03992456;NCT01814501;NCT01262183;NCT03069950;NCT01443065;NCT00613730;NCT00757172;NCT01379807;NCT04117945;NCT00948935;NCT01182610;NCT03087071;NCT01202409;NCT01307956;NCT01389414;NCT03584711;NCT03384238
Carcinoma, Squamous Cell	D002294	panitumumab	Phase 1	2006	2020	NCT02205398;NCT00513383;NCT04163952
Carcinoma, Squamous Cell	D002294	panitumumab	Phase 2	2007	2012	NCT01077999;NCT01285778;NCT00500760;NCT01221753;NCT00446446;NCT01262183;NCT01581840;NCT00756444;NCT01129154;NCT00547157;NCT01843452
Carcinoma, Squamous Cell	D002294	panitumumab	Phase 3	2012	2012	NCT01627379
Esophageal Neoplasms	D004938	panitumumab	Phase 1	2000	2000	NCT00004879
Esophageal Neoplasms	D004938	panitumumab	Phase 2	2007	2011	NCT01077999;NCT01262183;NCT01128387;NCT01443065;NCT00757172;NCT01379807;NCT00578071;NCT01307956
Squamous Cell Carcinoma of Head and Neck	D000077195	panitumumab	Phase 1	2006	2019	NCT02205398;NCT00513383;NCT03733210
Squamous Cell Carcinoma of Head and Neck	D000077195	panitumumab	Phase 2	2007	2019	NCT01221753;NCT00446446;NCT00454779;NCT00756444;NCT03405142;NCT00547157;NCT01305772
Rectal Neoplasms	D012004	panitumumab	Phase 2	2006	2020	NCT01443377;NCT03992456;NCT01814501;NCT01257360;NCT03000374;NCT00819780;NCT00967655;NCT00973193;NCT00346099;NCT00788957;NCT00814619
Anus Neoplasms	D001005	panitumumab	Phase 2	2010	2012	NCT01285778;NCT01581840
Colonic Neoplasms	D003110	panitumumab	Phase 2	2006	2021	NCT03992456;NCT01814501;NCT00332163;NCT00819780;NCT01108107;NCT00788957;NCT04775862;NCT03442569
Colonic Neoplasms	D003110	panitumumab	Phase 3	2008	2017	NCT00647530;NCT04342676
Colonic Neoplasms	D003110	panitumumab	Phase 4	2013	2013	NCT02015923
Lung Neoplasms	D008175	panitumumab	Phase 1	2006	2020	NCT04667975;NCT02192541;NCT00352950
Lung Neoplasms	D008175	panitumumab	Phase 2	2002	2018	NCT00979212;NCT01042288;NCT00034346;NCT00101920;NCT03582124;NCT01038037;NCT00094835
Carcinoma, Non-Small-Cell Lung	D002289	panitumumab	Phase 1	2006	2020	NCT04667975;NCT02192541;NCT00352950;NCT01061788
Carcinoma, Non-Small-Cell Lung	D002289	panitumumab	Phase 2	2002	2011	NCT00979212;NCT01042288;NCT01088620;NCT00034346;NCT00101920;NCT01038037;NCT00094835
Head and Neck Neoplasms	D006258	panitumumab	Phase 1	2006	2019	NCT02415881;NCT00513383;NCT03733210
Head and Neck Neoplasms	D006258	panitumumab	Phase 2	2007	2020	NCT00500760;NCT00446446;NCT00798655;NCT00454779;NCT01264328;NCT04511078;NCT01312493;NCT00547157
Head and Neck Neoplasms	D006258	panitumumab	Phase 3	2007	2008	NCT00820248;NCT00460265
Breast Neoplasms	D001943	panitumumab	Phase 2	2009	2016	NCT01036087;NCT02593175;NCT01009983;NCT02876107;NCT00894504;NCT00933517
Inflammatory Breast Neoplasms	D058922	panitumumab	Phase 2	2010	2016	NCT01036087;NCT02876107
Adenoma	D000236	panitumumab	Phase 2	2011	2011	NCT00984217
Salivary Gland Neoplasms	D012468	panitumumab	Phase 2	2011	2011	NCT00984217
Adenoma, Pleomorphic	D008949	panitumumab	Phase 2	2011	2011	NCT00984217
Syringoma	D018252	panitumumab	Phase 2	2011	2011	NCT00984217
Adenocarcinoma, Mucinous	D002288	panitumumab	Phase 2	2013	2013	NCT01814501
Cystadenocarcinoma	D003536	panitumumab	Phase 2	2013	2013	NCT01814501
Papilloma	D010212	panitumumab	Phase 2	2011	2011	NCT01221753
Biliary Tract Neoplasms	D001661	panitumumab	Phase 2	2010	2010	NCT01308840
Gallbladder Neoplasms	D005706	panitumumab	Phase 2	2010	2010	NCT01308840
Pancreatic Neoplasms	D010190	panitumumab	Phase 1	2000	2000	NCT00004879
Pancreatic Neoplasms	D010190	panitumumab	Phase 2	2007	2010	NCT01175733;NCT00613730;NCT01130701;NCT00550836;NCT00601627
Prostatic Neoplasms	D011471	panitumumab	Phase 1	2000	2000	NCT00004879
Prostatic Neoplasms	D011471	panitumumab	Phase 2	2002	2003	NCT00054574;NCT00061126
Stomach Neoplasms	D013274	panitumumab	Phase 2	2010	2011	NCT01716546;NCT01443065;NCT01234324
Stomach Neoplasms	D013274	panitumumab	Phase 3	2008	2008	NCT00824785
Uterine Cervical Neoplasms	D002583	panitumumab	Phase 2	2010	2010	NCT01158248
Carcinoid Tumor	D002276	panitumumab	Phase 2	2013	2013	NCT01172717
Malignant Carcinoid Syndrome	D008303	panitumumab	Phase 2	2013	2013	NCT01172717
Carcinoma, Renal Cell	D002292	panitumumab	Phase 2	2003	2004	NCT00425035;NCT00425204
Ovarian Neoplasms	D010051	panitumumab	Phase 2	2009	2011	NCT01296035;NCT01388621;NCT00861120
Carcinoma, Ovarian Epithelial	D000077216	panitumumab	Phase 2	2009	2011	NCT01296035;NCT01388621;NCT00861120
Fallopian Tube Neoplasms	D005185	panitumumab	Phase 2	2011	2011	NCT01296035
Neoplasms, Squamous Cell	D018307	panitumumab	Phase 3	2012	2012	NCT01627379
Esophageal Squamous Cell Carcinoma	D000077277	panitumumab	Phase 3	2012	2012	NCT01627379
Sarcoma	D012509	panitumumab	Phase 1	2014	2014	NCT02192541
Glioblastoma	D005909	panitumumab	Phase 1	2016	2016	NCT02766699
Astrocytoma	D001254	panitumumab	Phase 1	2016	2016	NCT02766699
Gastrointestinal Neoplasms	D005770	panitumumab	Phase 2	2008	2010	NCT01202409;NCT00788957
Urinary Bladder Neoplasms	D001749	panitumumab	Phase 2	2010	2013	NCT01374789;NCT01916109
Leukemia, Myeloid	D007951	panitumumab	Phase 2	2019	2019	NCT03761914
Small Cell Lung Carcinoma	D055752	panitumumab	Phase 2	2019	2019	NCT03761914
Triple Negative Breast Neoplasms	D064726	panitumumab	Phase 2	2019	2019	NCT03761914
Leukemia, Myeloid, Acute	D015470	panitumumab	Phase 2	2019	2019	NCT03761914
Kidney Neoplasms	D007680	panitumumab	Phase 1	2000	2000	NCT00004879
Carcinoma	D002277	pazopanib	Phase 1	2007	2016	NCT01472081;NCT02406521;NCT02729194;NCT01716416;NCT01221506;NCT00450879;NCT02795819;NCT01202032;NCT02014636;NCT02009449;NCT00992121
Carcinoma	D002277	pazopanib	Phase 2	2005	2020	NCT01513187;NCT01813136;NCT02324803;NCT02959554;NCT01731158;NCT02122003;NCT01377298;NCT01649180;NCT01157091;NCT03334409;NCT01767636;NCT01361113;NCT01684397;NCT02788201;NCT01566747;NCT00454142;NCT01465659;NCT00625846;NCT02393820;NCT02089802;NCT00731211;NCT02956798;NCT01545817;NCT04462445;NCT02279576;NCT01855724;NCT01217931;NCT01147822;NCT00454363;NCT02187302;NCT03379012;NCT00782275;NCT01236547;NCT01664182;NCT04534855;NCT03200717;NCT01392183;NCT02700568;NCT00244764;NCT01577784;NCT01468909
Carcinoma	D002277	pazopanib	Phase 3	2006	2018	NCT01064310;NCT01613846;NCT01575548;NCT01224288;NCT03260894;NCT01235962;NCT03592472;NCT01265810;NCT00387764;NCT02535351;NCT00334282;NCT00720941
Carcinoma	D002277	pazopanib	Phase 4	2012	2015	NCT02570789;NCT01514448;NCT01521715;NCT02338570
Carcinoma, Renal Cell	D002292	pazopanib	Phase 1	2004	2016	NCT00516672;NCT01472081;NCT00401583;NCT02406521;NCT00478725;NCT02729194;NCT00861029;NCT00387205;NCT00158782;NCT00363194;NCT01012362;NCT01221506;NCT02795819;NCT01202032;NCT02014636;NCT02009449;NCT00992121
Carcinoma, Renal Cell	D002292	pazopanib	Phase 2	2005	2018	NCT01513187;NCT03387514;NCT02324803;NCT02959554;NCT02560012;NCT01731158;NCT02122003;NCT01649180;NCT01408004;NCT01157091;NCT03334409;NCT01767636;NCT01361113;NCT01684397;NCT01566747;NCT01538238;NCT02089802;NCT00731211;NCT02956798;NCT01545817;NCT04462445;NCT01158521;NCT01217931;NCT01793636;NCT02599779;NCT01147822;NCT00256880;NCT02187302;NCT03379012;NCT00782275;NCT02960906;NCT01664182;NCT03200717;NCT01392183;NCT02700568;NCT00244764;NCT01577784
Carcinoma, Renal Cell	D002292	pazopanib	Phase 3	2006	2018	NCT01064310;NCT01613846;NCT01575548;NCT01224288;NCT03260894;NCT01235962;NCT03592472;NCT01265810;NCT00387764;NCT02535351;NCT00334282;NCT00720941
Carcinoma, Renal Cell	D002292	pazopanib	Phase 4	2012	2015	NCT02570789;NCT01514448;NCT02555748;NCT01521715;NCT02338570
Adenocarcinoma	D000230	pazopanib	Phase 2	2010	2013	NCT01832259;NCT01035658
Sarcoma	D012509	pazopanib	Phase 1	2009	2020	NCT01130623;NCT03139331;NCT00929903;NCT01985295;NCT04199026;NCT01438554;NCT01012362;NCT02795819;NCT01468922
Sarcoma	D012509	pazopanib	Phase 2	2005	2020	NCT01755195;NCT02357810;NCT02300545;NCT01861951;NCT02367651;NCT01462630;NCT01418001;NCT01719302;NCT02601209;NCT01391962;NCT03798106;NCT01532687;NCT02207309;NCT03149120;NCT03660930;NCT02575066;NCT02113826;NCT01543802;NCT04605770;NCT01392352;NCT01900743;NCT01975519;NCT00297258;NCT01593748;NCT02048371
Sarcoma	D012509	pazopanib	Phase 3	2008	2021	NCT04741438;NCT00753688;NCT02180867;NCT02049905
Sarcoma	D012509	pazopanib	Phase 4	2018	2018	NCT03735758
Osteosarcoma	D012516	pazopanib	Phase 1	2010	2010	NCT01130623
Osteosarcoma	D012516	pazopanib	Phase 2	2012	2018	NCT02357810;NCT03359018;NCT01759303;NCT01532687;NCT02048371
Osteosarcoma	D012516	pazopanib	Phase 3	2014	2014	NCT02180867
Liposarcoma	D008080	pazopanib	Phase 2	2012	2015	NCT02357810;NCT01692496;NCT01532687;NCT01506596;NCT02048371
Liposarcoma	D008080	pazopanib	Phase 3	2014	2014	NCT02180867
Thyroid Neoplasms	D013964	pazopanib	Phase 1	2011	2011	NCT01413113;NCT01438554
Thyroid Neoplasms	D013964	pazopanib	Phase 2	2008	2013	NCT01813136;NCT00625846;NCT01236547
Prostatic Neoplasms	D011471	pazopanib	Phase 1	2011	2011	NCT01385228
Prostatic Neoplasms	D011471	pazopanib	Phase 2	2006	2009	NCT00945477;NCT00454571;NCT00486642
Prostatic Neoplasms	D011471	pazopanib	Phase 3	2014	2014	NCT02044354
Hemangiosarcoma	D006394	pazopanib	Phase 2	2011	2014	NCT01462630;NCT01532687;NCT02212015
Hemangiosarcoma	D006394	pazopanib	Phase 3	2017	2017	NCT02979899
Lung Neoplasms	D008175	pazopanib	Phase 1	2009	2010	NCT01060514;NCT00866528
Lung Neoplasms	D008175	pazopanib	Phase 2	2006	2015	NCT01027598;NCT02193152;NCT01179269;NCT00549328;NCT00871403;NCT01253369;NCT01262820;NCT00367679;NCT00459862;NCT01049776;NCT01392352;NCT01313663
Lung Neoplasms	D008175	pazopanib	Phase 3	2011	2011	NCT01208064
Carcinosarcoma	D002296	pazopanib	Phase 2	2011	2019	NCT01247571;NCT02203760
Mixed Tumor, Mullerian	D018200	pazopanib	Phase 2	2011	2019	NCT01247571;NCT02203760
Carcinoma, Non-Small-Cell Lung	D002289	pazopanib	Phase 1	2007	2013	NCT01060514;NCT00619424;NCT00678977;NCT00866528;NCT02009449
Carcinoma, Non-Small-Cell Lung	D002289	pazopanib	Phase 2	2006	2015	NCT01027598;NCT02193152;NCT01179269;NCT00549328;NCT00871403;NCT00367679;NCT01049776;NCT01313663
Carcinoma, Non-Small-Cell Lung	D002289	pazopanib	Phase 3	2008	2008	NCT00775307
Leukemia, Myeloid	D007951	pazopanib	Phase 2	2011	2015	NCT02638428;NCT01361334
Breast Neoplasms	D001943	pazopanib	Phase 1	2006	2013	NCT01498458;NCT00388076;NCT00722293;NCT01060514;NCT00450879;NCT01639911
Breast Neoplasms	D001943	pazopanib	Phase 2	2006	2012	NCT00509587;NCT00347919;NCT00849472;NCT01394211;NCT01466972;NCT00615524;NCT00558103
Neoplasm Metastasis	D009362	pazopanib	Phase 1	2010	2016	NCT01165385;NCT01642017;NCT02795819
Dermatofibrosarcoma	D018223	pazopanib	Phase 2	2010	2010	NCT01059656
Ovarian Neoplasms	D010051	pazopanib	Phase 1	2012	2012	NCT01608009
Ovarian Neoplasms	D010051	pazopanib	Phase 2	2006	2015	NCT01238770;NCT00281632;NCT01227928;NCT01644825;NCT01262014;NCT01600573;NCT01610206;NCT00561795;NCT02055690;NCT02383251
Ovarian Neoplasms	D010051	pazopanib	Phase 3	2009	2009	NCT00866697
Neoplasms, Germ Cell and Embryonal	D009373	pazopanib	Phase 1	2009	2009	NCT00929903
Neoplasms, Germ Cell and Embryonal	D009373	pazopanib	Phase 2	2013	2013	NCT01743482
Brain Neoplasms	D001932	pazopanib	Phase 1	2010	2010	NCT01130623
Brain Neoplasms	D001932	pazopanib	Phase 2	2015	2015	NCT01931098
Neuroblastoma	D009447	pazopanib	Phase 1	2010	2010	NCT01130623
Wilms Tumor	D009396	pazopanib	Phase 1	2010	2010	NCT01130623
Stomach Neoplasms	D013274	pazopanib	Phase 1	2012	2012	NCT01468922
Stomach Neoplasms	D013274	pazopanib	Phase 2	2007	2013	NCT01130805;NCT01716546;NCT00454363;NCT01841736;NCT01503372
Gastrointestinal Stromal Tumors	D046152	pazopanib	Phase 2	2011	2017	NCT02342600;NCT01391611;NCT01524848;NCT01323400
Gastrointestinal Stromal Tumors	D046152	pazopanib	Phase 3	2011	2011	NCT01265810
Fallopian Tube Neoplasms	D005185	pazopanib	Phase 2	2006	2012	NCT01402271;NCT00281632;NCT01035658;NCT01610206
Chondrosarcoma	D002813	pazopanib	Phase 2	2011	2014	NCT02066285;NCT01532687;NCT01330966;NCT02048371
Chondrosarcoma	D002813	pazopanib	Phase 3	2014	2014	NCT02180867
Solitary Fibrous Tumors	D054364	pazopanib	Phase 2	2014	2014	NCT02066285
Neoplasms, Fibrous Tissue	D018218	pazopanib	Phase 2	2014	2014	NCT02066285
Melanoma	D008545	pazopanib	Phase 2	2009	2021	NCT02645149;NCT01107665;NCT00861913;NCT01666418
Glioma	D005910	pazopanib	Phase 1	2009	2018	NCT00929903;NCT03275558
Glioma	D005910	pazopanib	Phase 2	2006	2006	NCT00350727
Carcinoma, Ovarian Epithelial	D000077216	pazopanib	Phase 1	2012	2012	NCT01608009
Carcinoma, Ovarian Epithelial	D000077216	pazopanib	Phase 2	2006	2015	NCT01238770;NCT00281632;NCT01644825;NCT01262014;NCT01600573;NCT01610206;NCT00561795;NCT02055690;NCT02383251
Carcinoma, Squamous Cell	D002294	pazopanib	Phase 1	2013	2013	NCT01716416
Carcinoma, Squamous Cell	D002294	pazopanib	Phase 2	2007	2015	NCT01377298;NCT00454142;NCT02279576
Squamous Cell Carcinoma of Head and Neck	D000077195	pazopanib	Phase 1	2013	2013	NCT01716416
Squamous Cell Carcinoma of Head and Neck	D000077195	pazopanib	Phase 2	2011	2011	NCT01377298
Neuroendocrine Tumors	D018358	pazopanib	Phase 2	2007	2013	NCT01280201;NCT01465659;NCT01099540;NCT00454363;NCT01841736
Leiomyosarcoma	D007890	pazopanib	Phase 2	2011	2019	NCT01418001;NCT02203760;NCT02601209;NCT01532687;NCT02378142;NCT01442662
Leiomyosarcoma	D007890	pazopanib	Phase 3	2014	2014	NCT02180867
Nerve Sheath Neoplasms	D018317	pazopanib	Phase 2	2011	2015	NCT01418001;NCT02601209;NCT01532687
Nerve Sheath Neoplasms	D018317	pazopanib	Phase 3	2014	2014	NCT02180867
Neurofibrosarcoma	D018319	pazopanib	Phase 2	2011	2015	NCT01418001;NCT02601209;NCT01532687
Neurofibrosarcoma	D018319	pazopanib	Phase 3	2014	2014	NCT02180867
Histiocytoma	D051642	pazopanib	Phase 2	2011	2011	NCT01418001
Histiocytoma	D051642	pazopanib	Phase 3	2014	2014	NCT02180867
Histiocytoma, Malignant Fibrous	D051677	pazopanib	Phase 2	2011	2015	NCT01418001;NCT02601209;NCT01532687
Histiocytoma, Malignant Fibrous	D051677	pazopanib	Phase 3	2014	2014	NCT02180867
Pheochromocytoma	D010673	pazopanib	Phase 2	2011	2011	NCT01340794
Paraganglioma	D010235	pazopanib	Phase 2	2011	2011	NCT01340794
Carotid Body Tumor	D002345	pazopanib	Phase 2	2011	2011	NCT01340794
Paraganglioma, Extra-Adrenal	D010236	pazopanib	Phase 2	2011	2011	NCT01340794
Kidney Neoplasms	D007680	pazopanib	Phase 1	2009	2011	NCT01184326;NCT01012362
Kidney Neoplasms	D007680	pazopanib	Phase 2	2009	2017	NCT01408004;NCT03456401;NCT01217931;NCT01793636;NCT00782275;NCT02960906;NCT01961583;NCT01392183;NCT01031875
Colorectal Neoplasms	D015179	pazopanib	Phase 1	2006	2013	NCT00387387;NCT02009449;NCT00540943
Carcinoma, Transitional Cell	D002295	pazopanib	Phase 2	2008	2017	NCT01620970;NCT02788201;NCT00471536;NCT01031875;NCT01622660
Urinary Bladder Neoplasms	D001749	pazopanib	Phase 2	2008	2017	NCT01620970;NCT01108055;NCT02788201;NCT01265940;NCT00471536;NCT01031875
Carcinoma, Medullary	D018276	pazopanib	Phase 2	2008	2013	NCT01767636;NCT00625846
Fibromatosis, Aggressive	D018222	pazopanib	Phase 2	2012	2012	NCT01876082
Glioblastoma	D005909	pazopanib	Phase 1	2018	2018	NCT03275558
Glioblastoma	D005909	pazopanib	Phase 2	2007	2015	NCT02331498;NCT01931098;NCT01392352;NCT00459381
Teratoma	D013724	pazopanib	Phase 1	2009	2009	NCT00929903
Endodermal Sinus Tumor	D018240	pazopanib	Phase 1	2009	2009	NCT00929903
Choriocarcinoma	D002822	pazopanib	Phase 1	2009	2009	NCT00929903
Germinoma	D018237	pazopanib	Phase 1	2009	2009	NCT00929903
Uterine Cervical Neoplasms	D002583	pazopanib	Phase 2	2006	2016	NCT02348398;NCT00430781
Sarcoma, Synovial	D013584	pazopanib	Phase 2	2012	2015	NCT02601209;NCT01532687
Sarcoma, Synovial	D013584	pazopanib	Phase 3	2014	2014	NCT02180867
Sarcoma, Alveolar Soft Part	D018234	pazopanib	Phase 2	2011	2014	NCT01391962;NCT01532687;NCT02113826
Sarcoma, Alveolar Soft Part	D018234	pazopanib	Phase 3	2014	2014	NCT02180867
Breast Neoplasms, Male	D018567	pazopanib	Phase 1	2007	2007	NCT00450879
Breast Neoplasms, Male	D018567	pazopanib	Phase 2	2011	2011	NCT01394211
Nasopharyngeal Carcinoma	D000077274	pazopanib	Phase 2	2007	2020	NCT00454142;NCT04534855
Carcinoma, Islet Cell	D018273	pazopanib	Phase 2	2007	2011	NCT01465659;NCT00454363
Carcinoma, Neuroendocrine	D018278	pazopanib	Phase 2	2007	2008	NCT00625846;NCT00454363
Thyroid Carcinoma, Anaplastic	D065646	pazopanib	Phase 2	2008	2010	NCT00625846;NCT01236547
Salivary Gland Neoplasms	D012468	pazopanib	Phase 2	2013	2013	NCT02393820
Small Cell Lung Carcinoma	D055752	pazopanib	Phase 2	2010	2013	NCT01253369;NCT01797874;NCT01713296;NCT01392352;NCT01313663
Uterine Neoplasms	D014594	pazopanib	Phase 2	2006	2006	NCT00430781
Rhabdomyosarcoma	D012208	pazopanib	Phase 2	2012	2014	NCT01532687;NCT02048371
Desmoplastic Small Round Cell Tumor	D058405	pazopanib	Phase 2	2012	2012	NCT01532687
Fibrosarcoma	D005354	pazopanib	Phase 2	2012	2012	NCT01532687
Fibrosarcoma	D005354	pazopanib	Phase 3	2014	2014	NCT02180867
Hemangiopericytoma	D006393	pazopanib	Phase 2	2012	2012	NCT01532687
Hemangioendothelioma	D006390	pazopanib	Phase 2	2012	2012	NCT01532687
Hemangioendothelioma, Epithelioid	D018323	pazopanib	Phase 2	2012	2012	NCT01532687
Thyroid Cancer, Papillary	D000077273	pazopanib	Phase 1	2011	2011	NCT01413113
Adenocarcinoma, Follicular	D018263	pazopanib	Phase 1	2011	2011	NCT01413113
Cholangiocarcinoma	D018281	pazopanib	Phase 1	2011	2011	NCT01438554
Cholangiocarcinoma	D018281	pazopanib	Phase 2	2013	2013	NCT01855724
Gallbladder Neoplasms	D005706	pazopanib	Phase 2	2013	2013	NCT01855724
Carcinoma, Hepatocellular	D006528	pazopanib	Phase 1	2006	2009	NCT00370513;NCT01012362
Carcinoma, Hepatocellular	D006528	pazopanib	Phase 3	2011	2011	NCT01265810
Urethral Neoplasms	D014523	pazopanib	Phase 2	2008	2009	NCT00471536;NCT01031875
Lymphoma	D008223	pazopanib	Phase 1	2008	2008	NCT00674024
Multiple Myeloma	D009101	pazopanib	Phase 2	2005	2005	NCT00256880
Gliosarcoma	D018316	pazopanib	Phase 1	2018	2018	NCT03275558
Gliosarcoma	D018316	pazopanib	Phase 2	2007	2015	NCT01931098;NCT00459381
Nervous System Neoplasms	D009423	pazopanib	Phase 2	2015	2015	NCT01931098
Central Nervous System Neoplasms	D016543	pazopanib	Phase 2	2015	2015	NCT01931098
Mesothelioma	D008654	pazopanib	Phase 2	2007	2007	NCT00459862
Carcinoid Tumor	D002276	pazopanib	Phase 2	2007	2013	NCT00454363;NCT01841736
Insulinoma	D007340	pazopanib	Phase 2	2007	2007	NCT00454363
Endocrine Gland Neoplasms	D004701	pazopanib	Phase 2	2007	2007	NCT00454363
Multiple Endocrine Neoplasia	D009377	pazopanib	Phase 2	2007	2007	NCT00454363
Glucagonoma	D005935	pazopanib	Phase 2	2007	2007	NCT00454363
Intestinal Neoplasms	D007414	pazopanib	Phase 2	2007	2013	NCT00454363;NCT01841736
Pancreatic Neoplasms	D010190	pazopanib	Phase 1	2009	2013	NCT01012362;NCT02009449
Pancreatic Neoplasms	D010190	pazopanib	Phase 2	2007	2013	NCT00454363;NCT01080248;NCT01841736
Malignant Carcinoid Syndrome	D008303	pazopanib	Phase 2	2007	2013	NCT00454363;NCT01841736
Gastrointestinal Neoplasms	D005770	pazopanib	Phase 1	2013	2013	NCT01639911
Gastrointestinal Neoplasms	D005770	pazopanib	Phase 2	2007	2013	NCT00454363;NCT01392352;NCT01841736
Multiple Endocrine Neoplasia Type 1	D018761	pazopanib	Phase 2	2007	2007	NCT00454363
Somatostatinoma	D013005	pazopanib	Phase 2	2007	2007	NCT00454363
Gastrinoma	D015408	pazopanib	Phase 2	2007	2007	NCT00454363
Head and Neck Neoplasms	D006258	pazopanib	Phase 1	2009	2013	NCT01012362;NCT01639911
Colonic Neoplasms	D003110	pazopanib	Phase 1	2009	2009	NCT01012362
Liver Neoplasms	D008113	pazopanib	Phase 1	2009	2009	NCT01012362
Leukemia	D007938	pazopanib	Phase 2	2011	2011	NCT01361334
Leukemia, Myeloid, Acute	D015470	pazopanib	Phase 2	2011	2011	NCT01361334
Genital Neoplasms, Female	D005833	pazopanib	Phase 1	2009	2009	NCT00800345
Urogenital Neoplasms	D014565	pazopanib	Phase 1	2013	2013	NCT01639911
Digestive System Neoplasms	D004067	pazopanib	Phase 1	2013	2013	NCT01639911
Thoracic Neoplasms	D013899	pazopanib	Phase 1	2013	2013	NCT01639911
Histiocytoma, Benign Fibrous	D018219	pazopanib	Phase 3	2014	2014	NCT02180867
Sarcoma, Clear Cell	D018227	pazopanib	Phase 3	2014	2014	NCT02180867
Chondrosarcoma, Mesenchymal	D018211	pazopanib	Phase 2	2014	2014	NCT02048371
Chondrosarcoma, Mesenchymal	D018211	pazopanib	Phase 3	2014	2014	NCT02180867
Glomus Tumor	D005918	pazopanib	Phase 3	2014	2014	NCT02180867
Granular Cell Tumor	D016586	pazopanib	Phase 3	2014	2014	NCT02180867
Hematologic Neoplasms	D019337	pazopanib	Phase 1	2008	2008	NCT00666081
Ureteral Neoplasms	D014516	pazopanib	Phase 2	2009	2009	NCT01031875
Inflammatory Breast Neoplasms	D058922	pazopanib	Phase 2	2007	2007	NCT00558103
Cholangiocarcinoma	D018281	pemigatinib	Phase 1	2021	2021	NCT04088188
Cholangiocarcinoma	D018281	pemigatinib	Phase 2	2015	2020	NCT02393248;NCT04256980;NCT02924376
Cholangiocarcinoma	D018281	pemigatinib	Phase 3	2019	2019	NCT03656536
Carcinoma	D002277	pemigatinib	Phase 2	2017	2021	NCT02872714;NCT04096417;NCT04586244;NCT04003610
Carcinoma, Transitional Cell	D002295	pemigatinib	Phase 2	2017	2021	NCT02872714;NCT03914794;NCT04586244;NCT04003610
Leukemia	D007938	pemigatinib	Phase 1	2021	2021	NCT04659616
Leukemia, Myeloid	D007951	pemigatinib	Phase 1	2021	2021	NCT04659616
Leukemia, Myeloid, Acute	D015470	pemigatinib	Phase 1	2021	2021	NCT04659616
Multiple Myeloma	D009101	pemigatinib	Phase 2	2015	2015	NCT02393248
Stomach Neoplasms	D013274	pemigatinib	Phase 2	2015	2015	NCT02393248
Endometrial Neoplasms	D016889	pemigatinib	Phase 2	2015	2021	NCT02393248;NCT04463771
Urinary Bladder Neoplasms	D001749	pemigatinib	Phase 2	2020	2020	NCT03914794
Colorectal Neoplasms	D015179	pemigatinib	Phase 2	2020	2020	NCT04096417
Gastrointestinal Neoplasms	D005770	pemigatinib	Phase 2	2020	2020	NCT04591431
Breast Neoplasms	D001943	pertuzumab	Phase 1	2013	2020	NCT02598427;NCT02390427;NCT01875666;NCT04692831;NCT03006172;NCT02060253;NCT02605915;NCT04253561;NCT03135171;NCT01805908;NCT03387553;NCT01918254;NCT02738970;NCT03716180;NCT02057133;NCT03878524
Breast Neoplasms	D001943	pertuzumab	Phase 2	2003	2021	NCT04398914;NCT02910219;NCT03058939;NCT01594177;NCT03238495;NCT03988036;NCT03644186;NCT04578106;NCT04197687;NCT04001829;NCT04246502;NCT00875979;NCT04569747;NCT04721977;NCT04329065;NCT01847001;NCT01922921;NCT04249622;NCT00934856;NCT03125928;NCT03820141;NCT02326974;NCT04215003;NCT02530424;NCT04538742;NCT02491892;NCT02993198;NCT04750122;NCT00976989;NCT00999804;NCT01491737;NCT03881878;NCT03412643;NCT03272477;NCT04760431;NCT04266249;NCT02229149;NCT01796197;NCT04717531;NCT01276041;NCT04733118;NCT04301375;NCT04255056;NCT04351230;NCT00301899;NCT03304080;NCT01674062;NCT02789657;NCT01817452;NCT02252887;NCT04094896;NCT04675827;NCT01835236;NCT00943670;NCT00545688;NCT02379585;NCT00951665;NCT02682693;NCT01597414;NCT02000596;NCT03101748;NCT03742986;NCT02689921;NCT04419181;NCT02436993;NCT01959490;NCT04108858;NCT01042379;NCT01669239;NCT01730833;NCT01565083;NCT02465060;NCT03820063;NCT03144947;NCT03747120;NCT03894007;NCT01912963;NCT01937117;NCT02536339;NCT03674112;NCT01855828;NCT02132949;NCT03913234;NCT03417544;NCT02073487;NCT02339532;NCT02411344;NCT03112590;NCT04425018;NCT02624973;NCT02827877;NCT01904903;NCT03414658;NCT02139358;NCT02345772;NCT02909751;NCT03161353;NCT03329378
Breast Neoplasms	D001943	pertuzumab	Phase 3	2008	2021	NCT03493854;NCT03726879;NCT02003209;NCT04784715;NCT02125344;NCT04514419;NCT01358877;NCT04024462;NCT02586025;NCT04254263;NCT02344472;NCT02625441;NCT04337658;NCT01996267;NCT01583426;NCT01120184;NCT02947685;NCT01026142;NCT04665986;NCT02514681;NCT04208178;NCT04193059;NCT02213744;NCT02568839;NCT04740918;NCT00567190;NCT03199885;NCT01966471;NCT02402712;NCT03595592;NCT02896855;NCT04629846;NCT02131064;NCT02019277;NCT03811418;NCT01572038
Breast Neoplasms	D001943	pertuzumab	Phase 4	2011	2015	NCT02445586;NCT01501487
Multiple Myeloma	D009101	pertuzumab	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	pertuzumab	Phase 2	2015	2017	NCT02693535;NCT03297606;NCT02465060
Lymphoma, Non-Hodgkin	D008228	pertuzumab	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	pertuzumab	Phase 2	2016	2017	NCT02693535;NCT03297606
Meningeal Neoplasms	D008577	pertuzumab	Phase 2	2020	2020	NCT04588545
Neoplasm Metastasis	D009362	pertuzumab	Phase 1	2017	2017	NCT02598427
Neoplasm Metastasis	D009362	pertuzumab	Phase 2	2008	2021	NCT00781612;NCT04760431;NCT03323424;NCT03417544
Neoplasm Metastasis	D009362	pertuzumab	Phase 3	2020	2020	NCT04337658
Neoplasms, Second Primary	D016609	pertuzumab	Phase 1	2017	2017	NCT02598427
Neoplasms, Second Primary	D016609	pertuzumab	Phase 2	2021	2021	NCT04760431
Brain Neoplasms	D001932	pertuzumab	Phase 1	2017	2017	NCT02598427
Brain Neoplasms	D001932	pertuzumab	Phase 2	2021	2021	NCT04760431
Inflammatory Breast Neoplasms	D058922	pertuzumab	Phase 2	2013	2019	NCT02682693;NCT03101748;NCT03742986;NCT01730833
Inflammatory Breast Neoplasms	D058922	pertuzumab	Phase 3	2012	2014	NCT02125344;NCT01583426
Carcinoma, Ductal, Breast	D018270	pertuzumab	Phase 2	2017	2017	NCT02682693
Carcinoma, Ductal, Breast	D018270	pertuzumab	Phase 3	2012	2014	NCT02125344;NCT01583426
Neoplasm Micrometastasis	D061206	pertuzumab	Phase 2	2021	2021	NCT04569747
Colorectal Neoplasms	D015179	pertuzumab	Phase 2	2012	2015	NCT02291289;NCT03225937;NCT02465060
Lung Neoplasms	D008175	pertuzumab	Phase 1	2006	2006	NCT02507375
Lung Neoplasms	D008175	pertuzumab	Phase 2	2003	2020	NCT00855894;NCT00063154;NCT04246671;NCT02465060;NCT03845270
Carcinoma, Non-Small-Cell Lung	D002289	pertuzumab	Phase 1	2006	2006	NCT02507375
Carcinoma, Non-Small-Cell Lung	D002289	pertuzumab	Phase 2	2003	2019	NCT00855894;NCT00063154;NCT03845270
Neoplasms, Unknown Primary	D009382	pertuzumab	Phase 2	2018	2018	NCT03498521
Prostatic Neoplasms	D011471	pertuzumab	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	pertuzumab	Phase 2	2003	2015	NCT00058539;NCT02465060;NCT02480010
Carcinoma, Merkel Cell	D015266	pertuzumab	Phase 2	2020	2020	NCT04246671
Small Cell Lung Carcinoma	D055752	pertuzumab	Phase 2	2020	2020	NCT04246671
Liver Neoplasms	D008113	pertuzumab	Phase 2	2020	2020	NCT04246671
Carcinoma, Hepatocellular	D006528	pertuzumab	Phase 2	2015	2020	NCT04246671;NCT02465060
Chordoma	D002817	pertuzumab	Phase 2	2020	2020	NCT04246671
Carcinoma	D002277	pertuzumab	Phase 1	2020	2020	NCT03878524
Carcinoma	D002277	pertuzumab	Phase 2	2014	2020	NCT04351230;NCT03101748;NCT03365882;NCT04108858;NCT02465060;NCT02120911
Carcinoma	D002277	pertuzumab	Phase 3	2019	2019	NCT03199885
Stomach Neoplasms	D013274	pertuzumab	Phase 2	2011	2015	NCT02205047;NCT02465060;NCT01461057
Stomach Neoplasms	D013274	pertuzumab	Phase 3	2013	2016	NCT02581462;NCT01774786
Breast Neoplasms, Male	D018567	pertuzumab	Phase 1	2014	2018	NCT02060253;NCT03387553
Breast Neoplasms, Male	D018567	pertuzumab	Phase 2	2017	2017	NCT03112590
Neuroblastoma	D009447	pertuzumab	Phase 2	2009	2009	NCT00947167
Neuroendocrine Tumors	D018358	pertuzumab	Phase 2	2009	2009	NCT00947167
Carcinoid Tumor	D002276	pertuzumab	Phase 2	2009	2009	NCT00947167
Endocrine Gland Neoplasms	D004701	pertuzumab	Phase 2	2009	2009	NCT00947167
Multiple Endocrine Neoplasia	D009377	pertuzumab	Phase 2	2009	2009	NCT00947167
Fallopian Tube Neoplasms	D005185	pertuzumab	Phase 2	2005	2005	NCT00096993
Adenocarcinoma	D000230	pertuzumab	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	pertuzumab	Phase 2	2007	2017	NCT01108458;NCT03365882;NCT00551421
Adenocarcinoma	D000230	pertuzumab	Phase 3	2019	2019	NCT03199885
Rectal Neoplasms	D012004	pertuzumab	Phase 2	2007	2017	NCT03365882;NCT02465060;NCT00551421
Colonic Neoplasms	D003110	pertuzumab	Phase 2	2007	2017	NCT03365882;NCT02465060;NCT00551421
Hemangiosarcoma	D006394	pertuzumab	Phase 2	2010	2010	NCT01042379
Lymphoma	D008223	pertuzumab	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	pertuzumab	Phase 2	2015	2015	NCT02465060
Melanoma	D008545	pertuzumab	Phase 2	2015	2015	NCT02465060
Neoplasms, Plasma Cell	D054219	pertuzumab	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	pertuzumab	Phase 2	2015	2015	NCT02465060
Glioma	D005910	pertuzumab	Phase 2	2015	2015	NCT02465060
Endometrial Neoplasms	D016889	pertuzumab	Phase 2	2015	2015	NCT02465060
Ovarian Neoplasms	D010051	pertuzumab	Phase 2	2003	2015	NCT02465060;NCT02004093;NCT00058552
Ovarian Neoplasms	D010051	pertuzumab	Phase 3	2012	2012	NCT01684878
Carcinoma, Ovarian Epithelial	D000077216	pertuzumab	Phase 2	2003	2015	NCT02465060;NCT02004093;NCT00058552
Carcinoma, Ovarian Epithelial	D000077216	pertuzumab	Phase 3	2012	2012	NCT01684878
Pancreatic Neoplasms	D010190	pertuzumab	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	pertuzumab	Phase 2	2015	2015	NCT02465060
Esophageal Neoplasms	D004938	pertuzumab	Phase 2	2014	2015	NCT02465060;NCT02120911
Urinary Bladder Neoplasms	D001749	pertuzumab	Phase 2	2015	2015	NCT02465060
Thyroid Neoplasms	D013964	pertuzumab	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	pertuzumab	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	pertuzumab	Phase 2	2015	2015	NCT02465060
Carcinoma, Renal Cell	D002292	pertuzumab	Phase 2	2015	2015	NCT02465060
Kidney Neoplasms	D007680	pertuzumab	Phase 2	2015	2015	NCT02465060
Gastrointestinal Neoplasms	D005770	pertuzumab	Phase 2	2020	2020	NCT04591431
Carcinoma, Neuroendocrine	D018278	pertuzumab	Phase 2	2010	2010	NCT01121939
Leukemia	D007938	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	pertuzumab	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	pertuzumab	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	pertuzumab	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	pertuzumab	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	pertuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	pertuzumab	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	pertuzumab	Phase 1	2020	2020	NCT03878524
Colorectal Neoplasms	D015179	pexidartinib	Phase 1	2016	2016	NCT02777710
Giant Cell Tumors	D005870	pexidartinib	Phase 2	2021	2021	NCT04703322
Giant Cell Tumors	D005870	pexidartinib	Phase 3	2015	2020	NCT02371369;NCT04488822
Giant Cell Tumors	D005870	pexidartinib	Phase 4	2020	2020	NCT04526704
Giant Cell Tumor of Tendon Sheath	D000070779	pexidartinib	Phase 2	2021	2021	NCT04703322
Giant Cell Tumor of Tendon Sheath	D000070779	pexidartinib	Phase 3	2015	2020	NCT02371369;NCT04488822
Giant Cell Tumor of Tendon Sheath	D000070779	pexidartinib	Phase 4	2020	2020	NCT04526704
Synovitis, Pigmented Villonodular	D013586	pexidartinib	Phase 3	2015	2015	NCT02371369
Melanoma	D008545	pexidartinib	Phase 2	2015	2015	NCT02452424
Squamous Cell Carcinoma of Head and Neck	D000077195	pexidartinib	Phase 2	2015	2015	NCT02452424
Gastrointestinal Stromal Tumors	D046152	pexidartinib	Phase 1	2017	2017	NCT03158103
Gastrointestinal Stromal Tumors	D046152	pexidartinib	Phase 2	2015	2015	NCT02452424
Glioblastoma	D005909	pexidartinib	Phase 2	2011	2013	NCT01790503;NCT01349036
Leukemia	D007938	ponatinib	Phase 1	2008	2020	NCT00660920;NCT02779283;NCT03878524
Leukemia	D007938	ponatinib	Phase 2	2010	2021	NCT01667133;NCT02629692;NCT04188405;NCT02829840;NCT04501614;NCT03895671;NCT02767063;NCT03147612;NCT04554459;NCT04709731;NCT04043676;NCT01746836;NCT01424982;NCT04475731;NCT01207440;NCT04070443;NCT01883219;NCT04688983;NCT02398825;NCT04747912;NCT03934372;NCT03263572;NCT01570868;NCT02467270;NCT01620216;NCT03807479;NCT04233346;NCT01641107;NCT03576547
Leukemia	D007938	ponatinib	Phase 3	2012	2021	NCT03746054;NCT03589326;NCT03624530;NCT02627677;NCT01650805;NCT04530565;NCT04722848
Leukemia, Myeloid	D007951	ponatinib	Phase 1	2008	2020	NCT00660920;NCT02779283;NCT03878524
Leukemia, Myeloid	D007951	ponatinib	Phase 2	2010	2021	NCT01667133;NCT02629692;NCT04188405;NCT03690115;NCT02829840;NCT04160546;NCT03895671;NCT02767063;NCT03147612;NCT04709731;NCT04043676;NCT01746836;NCT01424982;NCT01207440;NCT04070443;NCT02398825;NCT03934372;NCT03263572;NCT01570868;NCT02467270;NCT01620216;NCT03807479;NCT04233346;NCT03576547
Leukemia, Myeloid	D007951	ponatinib	Phase 3	2012	2019	NCT03746054;NCT02627677;NCT01650805
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ponatinib	Phase 1	2016	2020	NCT02779283;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ponatinib	Phase 2	2010	2021	NCT01667133;NCT04501614;NCT03147612;NCT04554459;NCT01424982;NCT04475731;NCT01207440;NCT01883219;NCT04688983;NCT04747912;NCT03934372;NCT03263572;NCT01620216;NCT02776605;NCT04233346;NCT01641107;NCT03576547
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ponatinib	Phase 3	2018	2021	NCT03589326;NCT03624530;NCT04530565;NCT04722848
Leukemia, Lymphoid	D007945	ponatinib	Phase 1	2016	2020	NCT02779283;NCT03878524
Leukemia, Lymphoid	D007945	ponatinib	Phase 2	2010	2021	NCT01667133;NCT04501614;NCT03147612;NCT04554459;NCT01424982;NCT04475731;NCT01207440;NCT01883219;NCT04688983;NCT04747912;NCT03263572;NCT01620216;NCT02776605;NCT01641107;NCT03576547
Leukemia, Lymphoid	D007945	ponatinib	Phase 3	2018	2021	NCT03589326;NCT04530565;NCT04722848
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	ponatinib	Phase 1	2008	2020	NCT00660920;NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	ponatinib	Phase 2	2010	2021	NCT01667133;NCT02629692;NCT04188405;NCT04160546;NCT03895671;NCT02767063;NCT03147612;NCT04709731;NCT04043676;NCT01746836;NCT01424982;NCT01207440;NCT04070443;NCT02398825;NCT03934372;NCT03263572;NCT01570868;NCT02467270;NCT03807479;NCT04233346;NCT03576547
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	ponatinib	Phase 3	2012	2019	NCT03746054;NCT02627677;NCT01650805
Leukemia, Myeloid, Acute	D015470	ponatinib	Phase 1	2016	2020	NCT02779283;NCT03878524
Leukemia, Myeloid, Acute	D015470	ponatinib	Phase 2	2012	2020	NCT04188405;NCT03690115;NCT02829840;NCT01620216
Blast Crisis	D001752	ponatinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	ponatinib	Phase 2	2011	2020	NCT04188405;NCT03895671;NCT03147612;NCT01424982;NCT03934372;NCT03263572;NCT03576547
Preleukemia	D011289	ponatinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	ponatinib	Phase 2	2016	2016	NCT02829840
Thyroid Neoplasms	D013964	ponatinib	Phase 2	2013	2019	NCT03838692;NCT01838642
Carcinoma, Neuroendocrine	D018278	ponatinib	Phase 2	2019	2019	NCT03838692
Lung Neoplasms	D008175	ponatinib	Phase 2	2013	2018	NCT01935336;NCT01813734;NCT03704688
Carcinoma, Non-Small-Cell Lung	D002289	ponatinib	Phase 2	2013	2018	NCT01935336;NCT01813734;NCT03704688
Small Cell Lung Carcinoma	D055752	ponatinib	Phase 2	2014	2014	NCT01935336
Adenocarcinoma of Lung	D000077192	ponatinib	Phase 2	2014	2014	NCT01935336
Head and Neck Neoplasms	D006258	ponatinib	Phase 3	2013	2013	NCT01761747
Gastrointestinal Stromal Tumors	D046152	ponatinib	Phase 2	2013	2017	NCT03171389;NCT01874665
Leukemia, Myeloid, Chronic-Phase	D015466	ponatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	ponatinib	Phase 2	2013	2021	NCT02767063;NCT04709731;NCT01746836;NCT03934372;NCT02467270;NCT03807479
Leukemia, Myeloid, Chronic-Phase	D015466	ponatinib	Phase 3	2015	2015	NCT02627677
Leukemia, Myeloid, Accelerated Phase	D015465	ponatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	ponatinib	Phase 2	2011	2020	NCT03147612;NCT01424982;NCT03934372;NCT03263572
Glioblastoma	D005909	ponatinib	Phase 2	2015	2015	NCT02478164
Hematologic Neoplasms	D019337	ponatinib	Phase 1	2008	2020	NCT00660920;NCT03878524
Neoplasm, Residual	D018365	ponatinib	Phase 2	2013	2013	NCT01883219
Neoplasm, Residual	D018365	ponatinib	Phase 3	2018	2018	NCT03624530
Leukemia, Myelomonocytic, Chronic	D015477	ponatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	ponatinib	Phase 2	2012	2012	NCT01620216
Leukemia, Myelomonocytic, Juvenile	D054429	ponatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	ponatinib	Phase 2	2012	2012	NCT01620216
Gastrointestinal Neoplasms	D005770	ponatinib	Phase 2	2020	2020	NCT04591431
Lymphoma	D008223	ponatinib	Phase 1	2020	2020	NCT03878524
Carcinoma	D002277	ponatinib	Phase 1	2020	2020	NCT03878524
Breast Neoplasms	D001943	ponatinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	ponatinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	ponatinib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	ponatinib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	ponatinib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	ponatinib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	ponatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	ponatinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	ponatinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	ponatinib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	quizartinib	Phase 1	2007	2018	NCT02834390;NCT03552029;NCT03723681;NCT01390337;NCT00462761;NCT01411267;NCT01468467
Leukemia	D007938	quizartinib	Phase 2	2009	2020	NCT03661307;NCT04107727;NCT01892371;NCT02829840;NCT04493138;NCT03735875;NCT03793478;NCT04128748;NCT04477291;NCT04112589;NCT02984995;NCT01565668;NCT04209725;NCT00989261;NCT04047641;NCT04687761
Leukemia	D007938	quizartinib	Phase 3	2014	2016	NCT02668653;NCT02039726
Leukemia, Myeloid	D007951	quizartinib	Phase 1	2007	2018	NCT02834390;NCT03552029;NCT03723681;NCT01390337;NCT00462761;NCT01468467
Leukemia, Myeloid	D007951	quizartinib	Phase 2	2009	2020	NCT03661307;NCT04107727;NCT01892371;NCT02829840;NCT03735875;NCT03793478;NCT04128748;NCT04477291;NCT04112589;NCT02984995;NCT01565668;NCT04209725;NCT00989261;NCT04047641;NCT04687761
Leukemia, Myeloid	D007951	quizartinib	Phase 3	2014	2016	NCT02668653;NCT02039726
Leukemia, Myeloid, Acute	D015470	quizartinib	Phase 1	2007	2018	NCT02834390;NCT03552029;NCT03723681;NCT01390337;NCT00462761;NCT01411267;NCT01468467
Leukemia, Myeloid, Acute	D015470	quizartinib	Phase 2	2009	2020	NCT03661307;NCT04107727;NCT01892371;NCT02829840;NCT03735875;NCT03793478;NCT04128748;NCT04477291;NCT04112589;NCT02984995;NCT01565668;NCT04209725;NCT00989261;NCT04047641;NCT04687761
Leukemia, Myeloid, Acute	D015470	quizartinib	Phase 3	2014	2016	NCT02668653;NCT02039726
Preleukemia	D011289	quizartinib	Phase 2	2013	2020	NCT03661307;NCT01892371;NCT02829840;NCT04493138;NCT04128748;NCT04047641
Leukemia, Myelomonocytic, Acute	D015479	quizartinib	Phase 2	2013	2020	NCT01892371;NCT04493138
Leukemia, Myelomonocytic, Chronic	D015477	quizartinib	Phase 2	2013	2020	NCT01892371;NCT04493138
Leukemia, Myelomonocytic, Juvenile	D054429	quizartinib	Phase 2	2013	2020	NCT01892371;NCT04493138
Leukemia, Promyelocytic, Acute	D015473	quizartinib	Phase 2	2020	2020	NCT03989713
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	quizartinib	Phase 1	2011	2011	NCT01411267
Leukemia, Biphenotypic, Acute	D015456	quizartinib	Phase 2	2019	2019	NCT04047641
Colorectal Neoplasms	D015179	ramucirumab	Phase 1	2011	2019	NCT03428958;NCT01286818;NCT03798626
Colorectal Neoplasms	D015179	ramucirumab	Phase 2	2009	2018	NCT00862784;NCT01111604;NCT03271255;NCT01079780;NCT03251612
Colorectal Neoplasms	D015179	ramucirumab	Phase 3	2010	2019	NCT03520946;NCT01183780
Carcinoma	D002277	ramucirumab	Phase 1	2011	2019	NCT01286818;NCT02443324;NCT02069041;NCT03652467;NCT03798626
Carcinoma	D002277	ramucirumab	Phase 2	2007	2020	NCT02520141;NCT03921671;NCT03694002;NCT04267913;NCT04316182;NCT00515697;NCT04179110;NCT01282463;NCT00721162;NCT04120454;NCT01246986;NCT03650764;NCT03762564;NCT03008278;NCT04310007
Carcinoma	D002277	ramucirumab	Phase 3	2010	2015	NCT02426125;NCT01140347;NCT02435433
Cholangiocarcinoma	D018281	ramucirumab	Phase 1	2019	2019	NCT03872947
Cholangiocarcinoma	D018281	ramucirumab	Phase 2	2015	2015	NCT02520141
Gallbladder Neoplasms	D005706	ramucirumab	Phase 2	2015	2015	NCT02520141
Carcinoma, Ductal	D044584	ramucirumab	Phase 2	2015	2015	NCT02520141
Stomach Neoplasms	D013274	ramucirumab	Phase 1	2015	2015	NCT02359058
Stomach Neoplasms	D013274	ramucirumab	Phase 2	2011	2021	NCT04632459;NCT02726399;NCT01246960;NCT03995017;NCT03704077;NCT04592211;NCT04739202;NCT02999295;NCT03766607;NCT04660760;NCT03008278;NCT03760822;NCT01983878;NCT03694977
Stomach Neoplasms	D013274	ramucirumab	Phase 3	2009	2021	NCT04704934;NCT00917384;NCT02934464;NCT02661971
Adenocarcinoma	D000230	ramucirumab	Phase 1	2010	2017	NCT02443324;NCT02572687;NCT01253525;NCT03193918
Adenocarcinoma	D000230	ramucirumab	Phase 2	2014	2021	NCT02213289;NCT04205968;NCT02678182;NCT02628951;NCT02514551;NCT03739801;NCT02082210;NCT03686488;NCT04069273;NCT03995017;NCT03704077;NCT04656002;NCT02443883;NCT04739202;NCT03745430;NCT03141034;NCT04660760;NCT03966118;NCT02539225;NCT03008278;NCT03281369;NCT04604132
Adenocarcinoma	D000230	ramucirumab	Phase 3	2009	2021	NCT04499924;NCT04704934;NCT01170663;NCT00917384;NCT04675983;NCT02314117;NCT02898077
Esophageal Neoplasms	D004938	ramucirumab	Phase 1	2016	2016	NCT02970539
Esophageal Neoplasms	D004938	ramucirumab	Phase 2	2015	2021	NCT02628951;NCT02514551;NCT03739801;NCT03995017;NCT02443883;NCT03141034;NCT04660760;NCT03762564;NCT02539225;NCT03008278;NCT03281369
Esophageal Neoplasms	D004938	ramucirumab	Phase 3	2015	2021	NCT04499924;NCT04704934;NCT02314117;NCT02898077
Pancreatic Neoplasms	D010190	ramucirumab	Phase 2	2016	2016	NCT02581215
Gastrointestinal Neoplasms	D005770	ramucirumab	Phase 2	2018	2018	NCT03271255
Digestive System Neoplasms	D004067	ramucirumab	Phase 2	2018	2018	NCT03271255
Intestinal Neoplasms	D007414	ramucirumab	Phase 2	2018	2018	NCT03271255
Lung Neoplasms	D008175	ramucirumab	Phase 1	2015	2016	NCT02789345;NCT02443324
Lung Neoplasms	D008175	ramucirumab	Phase 2	2009	2021	NCT04151563;NCT04267913;NCT04394624;NCT04340882;NCT04040361;NCT00735696;NCT02831491;NCT04120454;NCT04332367;NCT01160744;NCT01703091;NCT03689855;NCT03909334;NCT02730247;NCT04310007;NCT03971474
Lung Neoplasms	D008175	ramucirumab	Phase 3	2010	2015	NCT02411448;NCT01168973
Carcinoma, Non-Small-Cell Lung	D002289	ramucirumab	Phase 1	2014	2016	NCT02789345;NCT02443324;NCT02079636
Carcinoma, Non-Small-Cell Lung	D002289	ramucirumab	Phase 2	2009	2021	NCT04151563;NCT04394624;NCT03904108;NCT04040361;NCT00735696;NCT02831491;NCT04120454;NCT04332367;NCT01160744;NCT01703091;NCT03689855;NCT03527108;NCT03909334;NCT02730247;NCT04310007;NCT03971474
Carcinoma, Non-Small-Cell Lung	D002289	ramucirumab	Phase 3	2010	2015	NCT02411448;NCT01168973
Sarcoma	D012509	ramucirumab	Phase 1	2006	2006	NCT00428272
Sarcoma	D012509	ramucirumab	Phase 2	2020	2020	NCT04145700
Sarcoma, Synovial	D013584	ramucirumab	Phase 2	2020	2020	NCT04145700
Breast Neoplasms	D001943	ramucirumab	Phase 1	2010	2010	NCT01256567
Breast Neoplasms	D001943	ramucirumab	Phase 2	2011	2011	NCT01234402;NCT01427933
Breast Neoplasms	D001943	ramucirumab	Phase 3	2008	2008	NCT00703326
Mesothelioma	D008654	ramucirumab	Phase 2	2016	2018	NCT03502746;NCT03560973
Carcinoma, Renal Cell	D002292	ramucirumab	Phase 1	2019	2019	NCT03872947;NCT03798626
Carcinoma, Renal Cell	D002292	ramucirumab	Phase 2	2007	2014	NCT02082210;NCT00515697
Thymoma	D013945	ramucirumab	Phase 2	2018	2018	NCT03921671;NCT03694002
Thymus Neoplasms	D013953	ramucirumab	Phase 2	2018	2018	NCT03921671
Carcinoma, Transitional Cell	D002295	ramucirumab	Phase 1	2015	2015	NCT02443324
Carcinoma, Transitional Cell	D002295	ramucirumab	Phase 2	2020	2020	NCT04179110
Carcinoma, Transitional Cell	D002295	ramucirumab	Phase 3	2015	2015	NCT02426125
Carcinoma, Hepatocellular	D006528	ramucirumab	Phase 1	2014	2018	NCT02572687;NCT02069041;NCT03652467
Carcinoma, Hepatocellular	D006528	ramucirumab	Phase 2	2008	2020	NCT04316182;NCT02082210;NCT01246986;NCT00627042
Carcinoma, Hepatocellular	D006528	ramucirumab	Phase 3	2010	2015	NCT01140347;NCT02435433
Lymphoma	D008223	ramucirumab	Phase 1	2017	2017	NCT03013218
Lymphoma, Non-Hodgkin	D008228	ramucirumab	Phase 1	2017	2017	NCT03013218
Liver Neoplasms	D008113	ramucirumab	Phase 2	2014	2014	NCT02082210
Neuroblastoma	D009447	ramucirumab	Phase 1	2006	2006	NCT00428272
Osteosarcoma	D012516	ramucirumab	Phase 1	2006	2006	NCT00428272
Rhabdomyosarcoma	D012208	ramucirumab	Phase 1	2006	2006	NCT00428272
Sarcoma, Ewing	D012512	ramucirumab	Phase 1	2006	2006	NCT00428272
Carcinoid Tumor	D002276	ramucirumab	Phase 2	2016	2016	NCT02795858
Glioblastoma	D005909	ramucirumab	Phase 2	2010	2010	NCT00895180
Biliary Tract Neoplasms	D001661	ramucirumab	Phase 1	2015	2015	NCT02443324
Biliary Tract Neoplasms	D001661	ramucirumab	Phase 2	2016	2016	NCT02711553
Prostatic Neoplasms	D011471	ramucirumab	Phase 2	2008	2008	NCT00683475
Desmoplastic Small Round Cell Tumor	D058405	ramucirumab	Phase 2	2020	2020	NCT04145349
Ovarian Neoplasms	D010051	ramucirumab	Phase 2	2008	2008	NCT00721162
Carcinoma, Ovarian Epithelial	D000077216	ramucirumab	Phase 2	2008	2008	NCT00721162
Fallopian Tube Neoplasms	D005185	ramucirumab	Phase 2	2008	2008	NCT00721162
Carcinoma, Squamous Cell	D002294	ramucirumab	Phase 2	2019	2019	NCT03650764;NCT03762564
Squamous Cell Carcinoma of Head and Neck	D000077195	ramucirumab	Phase 2	2019	2019	NCT03650764
Melanoma	D008545	ramucirumab	Phase 2	2007	2007	NCT00533702
Esophageal Squamous Cell Carcinoma	D000077277	ramucirumab	Phase 2	2019	2019	NCT03762564
Lymphoma, Mantle-Cell	D020522	ramucirumab	Phase 1	2016	2016	NCT02745769
Colorectal Neoplasms	D015179	regorafenib	Phase 1	2009	2020	NCT00934882;NCT03081494;NCT03712943;NCT02199223;NCT02116894;NCT04362839;NCT03305913
Colorectal Neoplasms	D015179	regorafenib	Phase 2	2011	2021	NCT04787341;NCT03992456;NCT02835924;NCT01896856;NCT03190616;NCT02619435;NCT03880877;NCT03215264;NCT03563157;NCT02651415;NCT03099486;NCT02402036;NCT04030260;NCT04683965;NCT04534218;NCT04450836;NCT04008511;NCT02368886;NCT01298570;NCT04660812;NCT02316340;NCT02581059;NCT03946917;NCT03843853;NCT02425683;NCT02465502;NCT02699073;NCT04117945;NCT02466009;NCT03828799;NCT03898102;NCT02195011;NCT04745130;NCT02175654;NCT03475953;NCT01875380;NCT03377361;NCT04110093;NCT03844620;NCT01289821;NCT03657641;NCT04775862;NCT02119676;NCT03555149;NCT03251612;NCT02096354;NCT04126733;NCT01949194
Colorectal Neoplasms	D015179	regorafenib	Phase 3	2010	2021	NCT01584830;NCT03829462;NCT01939223;NCT01103323;NCT02934529;NCT01189903;NCT01786538;NCT04776148;NCT01853319
Colorectal Neoplasms	D015179	regorafenib	Phase 4	2014	2018	NCT02800330;NCT03564938;NCT02287025
Multiple Myeloma	D009101	regorafenib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	regorafenib	Phase 2	2016	2016	NCT02693535
Lymphoma, Non-Hodgkin	D008228	regorafenib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	regorafenib	Phase 2	2016	2016	NCT02693535
Pelvic Neoplasms	D010386	regorafenib	Phase 2	2015	2015	NCT02459119
Breast Neoplasms	D001943	regorafenib	Phase 1	2017	2020	NCT03251378;NCT03878524
Triple Negative Breast Neoplasms	D064726	regorafenib	Phase 1	2017	2017	NCT03251378
Triple Negative Breast Neoplasms	D064726	regorafenib	Phase 2	2019	2019	NCT03761914
Carcinoma	D002277	regorafenib	Phase 1	2018	2020	NCT03347292;NCT03878524
Carcinoma	D002277	regorafenib	Phase 2	2009	2021	NCT03992456;NCT01003015;NCT02795156;NCT02053376;NCT04170556;NCT04718909;NCT04327700;NCT04316182;NCT03899428;NCT02098538;NCT04310709;NCT04183088;NCT03475953;NCT02584465;NCT04696055;NCT03732547
Carcinoma	D002277	regorafenib	Phase 3	2013	2021	NCT04777851;NCT01774344
Carcinoma, Hepatocellular	D006528	regorafenib	Phase 1	2018	2018	NCT03347292
Carcinoma, Hepatocellular	D006528	regorafenib	Phase 2	2009	2021	NCT04476329;NCT01003015;NCT04170556;NCT04718909;NCT04327700;NCT04316182;NCT03899428;NCT04310709;NCT04183088;NCT03475953;NCT04696055;NCT03732547
Carcinoma, Hepatocellular	D006528	regorafenib	Phase 3	2013	2021	NCT04777851;NCT01774344
Adenocarcinoma	D000230	regorafenib	Phase 1	2020	2020	NCT04362839;NCT03878524
Adenocarcinoma	D000230	regorafenib	Phase 2	2013	2020	NCT03992456;NCT02023333;NCT02234180;NCT02368886;NCT02788006;NCT02425683;NCT04117945;NCT03722108;NCT04446091;NCT01929616;NCT04483219
Adenocarcinoma	D000230	regorafenib	Phase 3	2016	2016	NCT02788279
Rectal Neoplasms	D012004	regorafenib	Phase 1	2017	2020	NCT04362839;NCT02910843
Rectal Neoplasms	D012004	regorafenib	Phase 2	2015	2021	NCT03992456;NCT04503694;NCT02287727
Colonic Neoplasms	D003110	regorafenib	Phase 1	2018	2020	NCT03712943;NCT04362839
Colonic Neoplasms	D003110	regorafenib	Phase 2	2020	2021	NCT03992456;NCT04775862
Colonic Neoplasms	D003110	regorafenib	Phase 3	2016	2016	NCT02664077
Gastrointestinal Stromal Tumors	D046152	regorafenib	Phase 1	2014	2014	NCT02164240
Gastrointestinal Stromal Tumors	D046152	regorafenib	Phase 2	2010	2019	NCT02638766;NCT03171389;NCT02365441;NCT03944304;NCT02889328;NCT03609424;NCT01068769;NCT02606097
Gastrointestinal Stromal Tumors	D046152	regorafenib	Phase 3	2011	2018	NCT03353753;NCT03465722;NCT01271712
Gastrointestinal Stromal Tumors	D046152	regorafenib	Phase 4	2016	2016	NCT02800330
Pancreatic Neoplasms	D010190	regorafenib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	regorafenib	Phase 2	2014	2014	NCT02080260;NCT02307500
Glioblastoma	D005909	regorafenib	Phase 2	2015	2019	NCT02926222;NCT04051606
Glioblastoma	D005909	regorafenib	Phase 3	2019	2019	NCT03970447
Carcinoma, Non-Small-Cell Lung	D002289	regorafenib	Phase 1	2010	2010	NCT01187615
Carcinoma, Non-Small-Cell Lung	D002289	regorafenib	Phase 2	2016	2018	NCT02795156;NCT03475953;NCT03520842
Cholangiocarcinoma	D018281	regorafenib	Phase 2	2014	2014	NCT02053376;NCT02162914
Esophageal Neoplasms	D004938	regorafenib	Phase 2	2014	2015	NCT02234180;NCT02406170
Esophageal Neoplasms	D004938	regorafenib	Phase 3	2016	2016	NCT02773524
Gastrointestinal Neoplasms	D005770	regorafenib	Phase 2	2014	2016	NCT02241720;NCT02259725;NCT02024607
Neuroendocrine Tumors	D018358	regorafenib	Phase 2	2016	2018	NCT02259725;NCT03475953
Carcinoid Tumor	D002276	regorafenib	Phase 2	2016	2016	NCT02259725
Malignant Carcinoid Syndrome	D008303	regorafenib	Phase 2	2016	2016	NCT02259725
Insulinoma	D007340	regorafenib	Phase 2	2016	2016	NCT02259725
Carcinoma, Islet Cell	D018273	regorafenib	Phase 2	2016	2016	NCT02259725
Gastrinoma	D015408	regorafenib	Phase 2	2016	2016	NCT02259725
Glucagonoma	D005935	regorafenib	Phase 2	2016	2016	NCT02259725
Somatostatinoma	D013005	regorafenib	Phase 2	2016	2016	NCT02259725
Carcinoma, Adenoid Cystic	D003528	regorafenib	Phase 2	2014	2014	NCT02098538
Neoplasm Metastasis	D009362	regorafenib	Phase 1	2014	2014	NCT02168777
Neoplasm Metastasis	D009362	regorafenib	Phase 2	2013	2020	NCT04534218;NCT02195011;NCT02175654;NCT01875380;NCT02406170
Neoplasm Metastasis	D009362	regorafenib	Phase 3	2013	2013	NCT01939223
Bile Duct Neoplasms	D001650	regorafenib	Phase 2	2014	2014	NCT02115542
Ovarian Neoplasms	D010051	regorafenib	Phase 2	2015	2016	NCT02736305;NCT02584465
Carcinoma, Ovarian Epithelial	D000077216	regorafenib	Phase 2	2015	2016	NCT02736305;NCT02584465
Thymoma	D013945	regorafenib	Phase 2	2014	2014	NCT02307500
Thymus Neoplasms	D013953	regorafenib	Phase 2	2014	2014	NCT02307500
Biliary Tract Neoplasms	D001661	regorafenib	Phase 2	2014	2021	NCT02386397;NCT04781192;NCT03475953
Sarcoma	D012509	regorafenib	Phase 2	2013	2021	NCT02048722;NCT04698785;NCT03475953;NCT02389244;NCT01900743;NCT03793361;NCT02048371
Hemangiosarcoma	D006394	regorafenib	Phase 2	2014	2014	NCT02048722
Lung Neoplasms	D008175	regorafenib	Phase 1	2010	2010	NCT01187615
Lung Neoplasms	D008175	regorafenib	Phase 2	2018	2018	NCT03520842
Small Cell Lung Carcinoma	D055752	regorafenib	Phase 1	2010	2010	NCT01187615
Small Cell Lung Carcinoma	D055752	regorafenib	Phase 2	2019	2019	NCT03761914
Stomach Neoplasms	D013274	regorafenib	Phase 2	2015	2018	NCT03627728;NCT03475953;NCT02406170
Osteosarcoma	D012516	regorafenib	Phase 2	2014	2021	NCT04698785;NCT02389244;NCT02048371
Adenocarcinoma, Mucinous	D002288	regorafenib	Phase 2	2020	2020	NCT04446091
Cystadenocarcinoma	D003536	regorafenib	Phase 2	2020	2020	NCT04446091
Thyroid Neoplasms	D013964	regorafenib	Phase 2	2016	2018	NCT03475953;NCT02657551
Sarcoma, Ewing	D012512	regorafenib	Phase 2	2014	2014	NCT02389244
Chondrosarcoma	D002813	regorafenib	Phase 2	2014	2014	NCT02389244;NCT02048371
Chondroma	D002812	regorafenib	Phase 2	2014	2014	NCT02389244
Melanoma	D008545	regorafenib	Phase 2	2015	2015	NCT02587650;NCT02501551
Skin Neoplasms	D012878	regorafenib	Phase 2	2015	2015	NCT02587650
Fallopian Tube Neoplasms	D005185	regorafenib	Phase 2	2015	2015	NCT02278783
Leukemia, Myeloid	D007951	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	regorafenib	Phase 2	2019	2019	NCT03761914
Leukemia, Myeloid, Acute	D015470	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	regorafenib	Phase 2	2019	2019	NCT03761914
Carcinoma, Renal Cell	D002292	regorafenib	Phase 2	2008	2008	NCT00664326
Lymphoma	D008223	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	regorafenib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	regorafenib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	regorafenib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	regorafenib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	regorafenib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	regorafenib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	regorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	regorafenib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	regorafenib	Phase 1	2020	2020	NCT03878524
Rhabdomyosarcoma	D012208	regorafenib	Phase 2	2014	2014	NCT02048371
Liposarcoma	D008080	regorafenib	Phase 2	2014	2014	NCT02048371
Chondrosarcoma, Mesenchymal	D018211	regorafenib	Phase 2	2014	2014	NCT02048371
Breast Neoplasms	D001943	ribociclib	Phase 1	2013	2020	NCT02734615;NCT02333370;NCT02599363;NCT03294694;NCT04483505;NCT02608216;NCT02586675;NCT02088684;NCT02754011;NCT01857193;NCT04315233;NCT04585724;NCT02154776
Breast Neoplasms	D001943	ribociclib	Phase 2	2013	2019	NCT03090165;NCT03078751;NCT03613220;NCT03839823;NCT02035813;NCT03285412;NCT04256941;NCT03822468;NCT03477396;NCT03555877;NCT03227328;NCT03280563;NCT02712723;NCT03944434;NCT01919229;NCT02632045;NCT03913234;NCT02732119;NCT02657343;NCT03671330;NCT03283384;NCT01872260;NCT03248427
Breast Neoplasms	D001943	ribociclib	Phase 3	2013	2019	NCT03096847;NCT02344472;NCT01958021;NCT03701334;NCT03081234;NCT03425838;NCT03905343;NCT02278120;NCT03462251;NCT04055493;NCT02422615;NCT03439046;NCT02941926;NCT03050398
Carcinoma	D002277	ribociclib	Phase 1	2015	2020	NCT04000529;NCT04213404;NCT02429089
Carcinoma	D002277	ribociclib	Phase 2	2015	2018	NCT02524119;NCT03008408;NCT02555189;NCT02657928;NCT03673124
Carcinoma, Hepatocellular	D006528	ribociclib	Phase 2	2016	2016	NCT02524119
Melanoma	D008545	ribociclib	Phase 1	2017	2017	NCT02974725
Melanoma	D008545	ribociclib	Phase 2	2013	2021	NCT02159066;NCT02645149;NCT01820364;NCT01781572;NCT04417621;NCT01777776;NCT03484923
Triple Negative Breast Neoplasms	D064726	ribociclib	Phase 2	2017	2017	NCT03090165
Leukemia	D007938	ribociclib	Phase 1	2019	2019	NCT03740334
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ribociclib	Phase 1	2019	2019	NCT03740334
Leukemia, Lymphoid	D007945	ribociclib	Phase 1	2019	2019	NCT03740334
Lung Neoplasms	D008175	ribociclib	Phase 1	2015	2017	NCT02292550;NCT02974725
Carcinoma, Non-Small-Cell Lung	D002289	ribociclib	Phase 1	2010	2019	NCT02292550;NCT04000529;NCT02974725;NCT03333343
Squamous Cell Carcinoma of Head and Neck	D000077195	ribociclib	Phase 1	2015	2020	NCT04000529;NCT03179956;NCT04213404;NCT02429089
Gastrointestinal Stromal Tumors	D046152	ribociclib	Phase 1	2019	2019	NCT04000529
Esophageal Squamous Cell Carcinoma	D000077277	ribociclib	Phase 1	2019	2019	NCT04000529
Neoplastic Cells, Circulating	D009360	ribociclib	Phase 2	2014	2014	NCT02035813
Glioblastoma	D005909	ribociclib	Phase 1	2016	2018	NCT03834740;NCT03355794;NCT02933736;NCT03434262;NCT02345824
Glioma	D005910	ribociclib	Phase 1	2016	2018	NCT03834740;NCT03355794;NCT03434262;NCT03387020;NCT02345824
Glioma	D005910	ribociclib	Phase 2	2016	2016	NCT02607124
Carcinoma, Squamous Cell	D002294	ribociclib	Phase 1	2015	2020	NCT03179956;NCT04213404;NCT02429089
Neoplasms, Squamous Cell	D018307	ribociclib	Phase 1	2018	2018	NCT03179956
Ovarian Neoplasms	D010051	ribociclib	Phase 1	2017	2017	NCT03294694;NCT03056833
Carcinoma, Ovarian Epithelial	D000077216	ribociclib	Phase 1	2017	2017	NCT03294694;NCT03056833
Lymphoma	D008223	ribociclib	Phase 1	2010	2015	NCT01237236;NCT02414724
Neuroblastoma	D009447	ribociclib	Phase 1	2013	2018	NCT01747876;NCT02780128;NCT03434262
Rhabdoid Tumor	D018335	ribociclib	Phase 1	2013	2018	NCT01747876;NCT03434262;NCT03387020
Neuroendocrine Tumors	D018358	ribociclib	Phase 2	2015	2017	NCT02420691;NCT03070301
Adenoma, Islet Cell	D007516	ribociclib	Phase 2	2015	2015	NCT02420691
Thymus Neoplasms	D013953	ribociclib	Phase 2	2015	2015	NCT02420691
Thymoma	D013945	ribociclib	Phase 2	2015	2015	NCT02420691
Sarcoma	D012509	ribociclib	Phase 1	2017	2017	NCT03009201
Sarcoma	D012509	ribociclib	Phase 2	2016	2017	NCT02571829;NCT03096912;NCT03114527
Liposarcoma	D008080	ribociclib	Phase 1	2015	2017	NCT02343172;NCT03009201
Liposarcoma	D008080	ribociclib	Phase 2	2016	2017	NCT02571829;NCT03096912;NCT03114527
Astrocytoma	D001254	ribociclib	Phase 1	2017	2018	NCT03355794;NCT03434262
Meningioma	D008579	ribociclib	Phase 1	2016	2018	NCT02933736;NCT03434262
Brain Neoplasms	D001932	ribociclib	Phase 1	2018	2018	NCT03434262;NCT03387020
Ependymoma	D004806	ribociclib	Phase 1	2018	2018	NCT03434262;NCT03387020
Medulloblastoma	D008527	ribociclib	Phase 1	2018	2018	NCT03434262;NCT03387020
Oligodendroglioma	D009837	ribociclib	Phase 1	2018	2018	NCT03434262
Neuroectodermal Tumors	D017599	ribociclib	Phase 1	2018	2018	NCT03434262
Neuroectodermal Tumors, Primitive	D018242	ribociclib	Phase 1	2018	2018	NCT03434262
Central Nervous System Neoplasms	D016543	ribociclib	Phase 1	2018	2018	NCT03434262
Nervous System Neoplasms	D009423	ribociclib	Phase 1	2018	2018	NCT03434262
Pinealoma	D010871	ribociclib	Phase 1	2018	2018	NCT03434262
Neoplasms, Germ Cell and Embryonal	D009373	ribociclib	Phase 1	2018	2018	NCT03434262
Ganglioglioma	D018303	ribociclib	Phase 1	2018	2018	NCT03434262
Ganglioneuroblastoma	D018305	ribociclib	Phase 1	2018	2018	NCT03434262
Neoplasms, Neuroepithelial	D018302	ribociclib	Phase 1	2018	2018	NCT03434262
Prostatic Neoplasms	D011471	ribociclib	Phase 2	2015	2015	NCT02494921;NCT02555189
Adenocarcinoma	D000230	ribociclib	Phase 2	2017	2017	NCT02985125;NCT03008408
Endometrial Neoplasms	D016889	ribociclib	Phase 2	2016	2017	NCT03008408;NCT02657928
Carcinoma, Endometrioid	D018269	ribociclib	Phase 2	2017	2017	NCT03008408
Fallopian Tube Neoplasms	D005185	ribociclib	Phase 1	2017	2017	NCT03056833
Colorectal Neoplasms	D015179	ribociclib	Phase 1	2016	2016	NCT02703571
Pancreatic Neoplasms	D010190	ribociclib	Phase 1	2016	2016	NCT02703571
Cystadenocarcinoma, Serous	D018284	ribociclib	Phase 2	2018	2018	NCT03673124
Neoplasm Metastasis	D009362	ribociclib	Phase 2	2020	2020	NCT04116541
Rhabdomyosarcoma	D012208	ribociclib	Phase 1	2017	2017	NCT03009201
Leiomyosarcoma	D007890	ribociclib	Phase 1	2017	2017	NCT03009201
Leiomyosarcoma	D007890	ribociclib	Phase 2	2017	2017	NCT03114527
Sarcoma, Synovial	D013584	ribociclib	Phase 1	2017	2017	NCT03009201
Hemangiosarcoma	D006394	ribociclib	Phase 1	2017	2017	NCT03009201
Nerve Sheath Neoplasms	D018317	ribociclib	Phase 1	2017	2017	NCT03009201
Neurofibrosarcoma	D018319	ribociclib	Phase 1	2017	2017	NCT03009201
Fibrosarcoma	D005354	ribociclib	Phase 1	2017	2017	NCT03009201
Histiocytoma, Malignant Fibrous	D051677	ribociclib	Phase 1	2017	2017	NCT03009201
Teratoma	D013724	ribociclib	Phase 2	2015	2015	NCT02300987
Breast Neoplasms	D001943	ruxolitinib	Phase 1	2017	2020	NCT03012230;NCT03878524
Breast Neoplasms	D001943	ruxolitinib	Phase 2	2012	2017	NCT02066532;NCT02041429;NCT01594216;NCT02120417;NCT02876302;NCT01562873
Polycythemia Vera	D011087	ruxolitinib	Phase 1	2011	2019	NCT01433445;NCT03373877;NCT02436135;NCT02493530;NCT03935555
Polycythemia Vera	D011087	ruxolitinib	Phase 2	2007	2021	NCT04282187;NCT04629508;NCT04485260;NCT01369498;NCT01348490;NCT03878199;NCT01790295;NCT00726232;NCT00509899;NCT02577926;NCT01392443;NCT01787487;NCT04644211;NCT01445769;NCT01981850;NCT04455841;NCT03287245;NCT02966353;NCT03627403;NCT02226172;NCT01787552;NCT03669965
Polycythemia Vera	D011087	ruxolitinib	Phase 3	2009	2021	NCT01632904;NCT04603495;NCT04116502;NCT04551053;NCT01243944;NCT02292446;NCT03952039;NCT02101268;NCT02055781;NCT02038036;NCT04551066;NCT00934544;NCT01969838;NCT03755518;NCT00952289;NCT03165734;NCT02087059
Polycythemia Vera	D011087	ruxolitinib	Phase 4	2010	2010	NCT02386800
Blast Crisis	D001752	ruxolitinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	ruxolitinib	Phase 2	2013	2021	NCT04282187;NCT04281498;NCT01914484
Leukemia, Myeloid	D007951	ruxolitinib	Phase 1	2013	2020	NCT02528877;NCT01751425;NCT01702064;NCT03017820;NCT03874052;NCT02779283;NCT03878524
Leukemia, Myeloid	D007951	ruxolitinib	Phase 2	2008	2019	NCT02638428;NCT03654768;NCT02158858;NCT03286530;NCT03558607;NCT03610971;NCT02257138;NCT01620216;NCT01914484;NCT02092324;NCT00674479
Pancreatic Neoplasms	D010190	ruxolitinib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	ruxolitinib	Phase 2	2011	2011	NCT01423604
Pancreatic Neoplasms	D010190	ruxolitinib	Phase 3	2014	2014	NCT02117479;NCT02119663
Neoplasm Metastasis	D009362	ruxolitinib	Phase 1	2015	2015	NCT02528877
Neoplasm Metastasis	D009362	ruxolitinib	Phase 2	2013	2021	NCT01644110;NCT04384692;NCT04370301;NCT02142036;NCT03558607;NCT02251821
Multiple Myeloma	D009101	ruxolitinib	Phase 1	2017	2020	NCT03110822;NCT03017820;NCT03878524
Multiple Myeloma	D009101	ruxolitinib	Phase 2	2008	2019	NCT03773107;NCT00639002
Neoplasms, Plasma Cell	D054219	ruxolitinib	Phase 1	2017	2020	NCT03110822;NCT03017820;NCT03878524
Neoplasms, Plasma Cell	D054219	ruxolitinib	Phase 2	2008	2019	NCT03773107;NCT00639002
Leukemia	D007938	ruxolitinib	Phase 1	2010	2020	NCT02528877;NCT03515200;NCT01164163;NCT03571321;NCT01751425;NCT01702064;NCT02494882;NCT03017820;NCT03874052;NCT02779283;NCT03878524
Leukemia	D007938	ruxolitinib	Phase 2	2008	2020	NCT03722407;NCT03654768;NCT04055844;NCT02912754;NCT04669210;NCT03286530;NCT02015208;NCT02131584;NCT03558607;NCT03610971;NCT02257138;NCT03041636;NCT01712659;NCT01251965;NCT02420717;NCT01776723;NCT01620216;NCT02723994;NCT01914484;NCT01319981;NCT02092324;NCT03613428;NCT00674479
Leukemia	D007938	ruxolitinib	Phase 3	2017	2017	NCT03117751
Leukemia, Myelomonocytic, Acute	D015479	ruxolitinib	Phase 2	2013	2019	NCT03722407;NCT01776723
Leukemia, Myelomonocytic, Chronic	D015477	ruxolitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	ruxolitinib	Phase 2	2012	2019	NCT03722407;NCT01776723;NCT01620216
Leukemia, Myelomonocytic, Juvenile	D054429	ruxolitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	ruxolitinib	Phase 2	2012	2019	NCT03722407;NCT01776723;NCT01620216
Lymphoma	D008223	ruxolitinib	Phase 1	2016	2020	NCT02613598;NCT03017820;NCT03878524
Lymphoma	D008223	ruxolitinib	Phase 2	2011	2019	NCT03922724;NCT01877005;NCT01431209;NCT03041636;NCT02974647;NCT02164500;NCT03681561;NCT01965119
Lymphoma	D008223	ruxolitinib	Phase 3	2017	2017	NCT03117751
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ruxolitinib	Phase 1	2015	2020	NCT03515200;NCT03571321;NCT02494882;NCT02779283;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ruxolitinib	Phase 2	2008	2020	NCT04669210;NCT02420717;NCT01620216;NCT02723994;NCT01914484;NCT01319981;NCT00674479
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	ruxolitinib	Phase 3	2017	2017	NCT03117751
Leukemia, Lymphoid	D007945	ruxolitinib	Phase 1	2015	2020	NCT03515200;NCT03571321;NCT02494882;NCT02779283;NCT03878524
Leukemia, Lymphoid	D007945	ruxolitinib	Phase 2	2008	2020	NCT02912754;NCT04669210;NCT02015208;NCT02131584;NCT03041636;NCT02420717;NCT01620216;NCT02723994;NCT01914484;NCT01319981;NCT00674479
Leukemia, Lymphoid	D007945	ruxolitinib	Phase 3	2017	2017	NCT03117751
Adenocarcinoma	D000230	ruxolitinib	Phase 1	2017	2020	NCT04303403;NCT03120624;NCT03878524
Adenocarcinoma	D000230	ruxolitinib	Phase 2	2014	2016	NCT02155465;NCT02713386
Adenocarcinoma of Lung	D000077192	ruxolitinib	Phase 2	2014	2014	NCT02155465
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	ruxolitinib	Phase 1	2013	2020	NCT01751425;NCT01702064;NCT02253277;NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	ruxolitinib	Phase 2	2008	2019	NCT03654768;NCT03610971;NCT02973711;NCT01914484;NCT02092324;NCT00674479
Leukemia, Myeloid, Chronic-Phase	D015466	ruxolitinib	Phase 1	2013	2020	NCT01702064;NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	ruxolitinib	Phase 2	2013	2019	NCT03654768;NCT03610971;NCT02973711;NCT01914484
Glioblastoma	D005909	ruxolitinib	Phase 1	2018	2018	NCT03514069
Glioma	D005910	ruxolitinib	Phase 1	2018	2018	NCT03514069
Leukemia, Myeloid, Acute	D015470	ruxolitinib	Phase 1	2015	2020	NCT02528877;NCT03017820;NCT03874052;NCT02779283;NCT03878524
Leukemia, Myeloid, Acute	D015470	ruxolitinib	Phase 2	2008	2018	NCT02158858;NCT03286530;NCT03558607;NCT02257138;NCT01620216;NCT00674479
Lung Neoplasms	D008175	ruxolitinib	Phase 2	2014	2014	NCT02119650
Carcinoma, Non-Small-Cell Lung	D002289	ruxolitinib	Phase 2	2014	2014	NCT02119650
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	ruxolitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	ruxolitinib	Phase 2	2014	2017	NCT02912754;NCT02015208;NCT02131584;NCT03041636
Inflammatory Breast Neoplasms	D058922	ruxolitinib	Phase 2	2017	2017	NCT02876302
Lymphoma, T-Cell	D016399	ruxolitinib	Phase 1	2017	2017	NCT03017820
Lymphoma, T-Cell	D016399	ruxolitinib	Phase 2	2011	2019	NCT03922724;NCT01431209
Lymphoma, T-Cell, Peripheral	D016411	ruxolitinib	Phase 1	2017	2017	NCT03017820
Lymphoma, T-Cell, Peripheral	D016411	ruxolitinib	Phase 2	2011	2019	NCT03922724;NCT01431209
Prostatic Neoplasms	D011471	ruxolitinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	ruxolitinib	Phase 2	2008	2008	NCT00638378
Carcinoma	D002277	ruxolitinib	Phase 1	2017	2020	NCT03120624;NCT03878524
Carcinoma	D002277	ruxolitinib	Phase 2	2017	2018	NCT02788201;NCT02928978
Urinary Bladder Neoplasms	D001749	ruxolitinib	Phase 2	2017	2017	NCT02788201
Carcinoma, Transitional Cell	D002295	ruxolitinib	Phase 2	2017	2017	NCT02788201
Preleukemia	D011289	ruxolitinib	Phase 1	2010	2020	NCT01164163;NCT01895842;NCT03017820;NCT03878524
Preleukemia	D011289	ruxolitinib	Phase 2	2008	2014	NCT02158858;NCT00674479
Neoplasms, Second Primary	D016609	ruxolitinib	Phase 2	2014	2014	NCT02142036
Head and Neck Neoplasms	D006258	ruxolitinib	Phase 1	2017	2017	NCT02593929
Head and Neck Neoplasms	D006258	ruxolitinib	Phase 2	2018	2018	NCT03153982
Squamous Cell Carcinoma of Head and Neck	D000077195	ruxolitinib	Phase 1	2017	2017	NCT02593929
Squamous Cell Carcinoma of Head and Neck	D000077195	ruxolitinib	Phase 2	2018	2018	NCT03153982
Colorectal Neoplasms	D015179	ruxolitinib	Phase 1	2018	2018	NCT04303403
Colorectal Neoplasms	D015179	ruxolitinib	Phase 2	2014	2014	NCT02119676
Ovarian Neoplasms	D010051	ruxolitinib	Phase 2	2016	2016	NCT02713386
Carcinoma, Ovarian Epithelial	D000077216	ruxolitinib	Phase 2	2016	2016	NCT02713386
Fallopian Tube Neoplasms	D005185	ruxolitinib	Phase 2	2016	2016	NCT02713386
Peritoneal Neoplasms	D010534	ruxolitinib	Phase 2	2016	2016	NCT02713386
Cystadenocarcinoma, Serous	D018284	ruxolitinib	Phase 1	2017	2017	NCT03120624
Cystadenocarcinoma, Serous	D018284	ruxolitinib	Phase 2	2016	2016	NCT02713386
Carcinoma, Endometrioid	D018269	ruxolitinib	Phase 1	2017	2017	NCT03120624
Carcinoma, Endometrioid	D018269	ruxolitinib	Phase 2	2016	2016	NCT02713386
Adenocarcinoma, Clear Cell	D018262	ruxolitinib	Phase 1	2017	2017	NCT03120624
Adenocarcinoma, Clear Cell	D018262	ruxolitinib	Phase 2	2016	2016	NCT02713386
Hodgkin Disease	D006689	ruxolitinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	ruxolitinib	Phase 2	2013	2018	NCT01877005;NCT02164500;NCT03681561;NCT01965119
Lymphoma, Non-Hodgkin	D008228	ruxolitinib	Phase 1	2016	2020	NCT02613598;NCT03017820;NCT03878524
Lymphoma, Non-Hodgkin	D008228	ruxolitinib	Phase 2	2011	2011	NCT01431209
Lymphoma, B-Cell	D016393	ruxolitinib	Phase 2	2011	2013	NCT01431209;NCT01965119
Lymphoma, Large B-Cell, Diffuse	D016403	ruxolitinib	Phase 2	2011	2011	NCT01431209
Neoplasm, Residual	D018365	ruxolitinib	Phase 1	2013	2013	NCT01751425
Hematologic Neoplasms	D019337	ruxolitinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	ruxolitinib	Phase 2	2008	2020	NCT04016116;NCT04582604;NCT01523171;NCT01594723;NCT00674479
Carcinoma, Squamous Cell	D002294	ruxolitinib	Phase 1	2017	2017	NCT02593929
Endometrial Neoplasms	D016889	ruxolitinib	Phase 1	2017	2017	NCT03120624
Carcinosarcoma	D002296	ruxolitinib	Phase 1	2017	2017	NCT03120624
Leukemia, T-Cell	D015458	ruxolitinib	Phase 2	2012	2018	NCT01712659;NCT03613428
Leukemia-Lymphoma, Adult T-Cell	D015459	ruxolitinib	Phase 2	2012	2012	NCT01712659
Mycosis Fungoides	D009182	ruxolitinib	Phase 1	2017	2017	NCT03017820
Lymphoma, T-Cell, Cutaneous	D016410	ruxolitinib	Phase 1	2017	2017	NCT03017820
Lymphoma, Large-Cell, Anaplastic	D017728	ruxolitinib	Phase 1	2017	2017	NCT03017820
Leukemia, Myeloid, Accelerated Phase	D015465	ruxolitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	ruxolitinib	Phase 2	2013	2013	NCT01914484
Triple Negative Breast Neoplasms	D064726	ruxolitinib	Phase 1	2017	2017	NCT03012230
Carcinoma in Situ	D002278	ruxolitinib	Phase 2	2018	2018	NCT02928978
Carcinoma, Ductal	D044584	ruxolitinib	Phase 2	2018	2018	NCT02928978
Carcinoma, Intraductal, Noninfiltrating	D002285	ruxolitinib	Phase 2	2018	2018	NCT02928978
Precancerous Conditions	D011230	ruxolitinib	Phase 2	2018	2018	NCT02928978
Carcinoma, Lobular	D018275	ruxolitinib	Phase 2	2018	2018	NCT02928978
Breast Carcinoma In Situ	D000071960	ruxolitinib	Phase 2	2018	2018	NCT02928978
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	ruxolitinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	ruxolitinib	Phase 2	2014	2014	NCT02092324
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	D054218	ruxolitinib	Phase 2	2018	2018	NCT03613428
Leukemia, Promyelocytic, Acute	D015473	ruxolitinib	Phase 4	2019	2019	NCT04446806
Lung Neoplasms	D008175	selumetinib	Phase 1	2010	2016	NCT02503358;NCT01605916;NCT01586624;NCT01809210;NCT01146756
Lung Neoplasms	D008175	selumetinib	Phase 2	2006	2019	NCT03392246;NCT01248247;NCT03586453;NCT01610544;NCT03004105;NCT02179671;NCT01229150;NCT02664935;NCT02117167;NCT02025114;NCT01750281;NCT02583542;NCT03581487;NCT02337530;NCT00372788;NCT01306045
Lung Neoplasms	D008175	selumetinib	Phase 3	2013	2013	NCT01933932
Carcinoma, Non-Small-Cell Lung	D002289	selumetinib	Phase 1	2010	2016	NCT02503358;NCT02143466;NCT01783197;NCT01605916;NCT01586624;NCT01809210;NCT01146756
Carcinoma, Non-Small-Cell Lung	D002289	selumetinib	Phase 2	2006	2019	NCT03392246;NCT01248247;NCT03586453;NCT01610544;NCT03004105;NCT02179671;NCT01229150;NCT00890825;NCT02664935;NCT02117167;NCT02025114;NCT01750281;NCT03581487;NCT02337530;NCT00372788;NCT02450656;NCT01306045
Carcinoma, Non-Small-Cell Lung	D002289	selumetinib	Phase 3	2013	2013	NCT01933932
Glioma	D005910	selumetinib	Phase 2	2010	2019	NCT01089101;NCT03326388;NCT03155620
Glioma	D005910	selumetinib	Phase 3	2019	2021	NCT03871257;NCT04576117;NCT04166409
Neurofibromatoses	D017253	selumetinib	Phase 1	2018	2020	NCT04590235;NCT03649165;NCT04495127
Neurofibromatoses	D017253	selumetinib	Phase 2	2010	2019	NCT01089101;NCT01362803;NCT02407405;NCT03109301;NCT03095248;NCT03326388;NCT02839720;NCT03433183
Neurofibromatoses	D017253	selumetinib	Phase 3	2019	2019	NCT03871257
Neurofibromatosis 1	D009456	selumetinib	Phase 1	2018	2020	NCT04590235;NCT03649165;NCT04495127
Neurofibromatosis 1	D009456	selumetinib	Phase 2	2010	2019	NCT01089101;NCT01362803;NCT02407405;NCT03109301;NCT03095248;NCT03326388;NCT02839720;NCT03433183
Neurofibromatosis 1	D009456	selumetinib	Phase 3	2019	2019	NCT03871257
Neurofibroma	D009455	selumetinib	Phase 1	2018	2020	NCT04590235;NCT03649165;NCT04495127
Neurofibroma	D009455	selumetinib	Phase 2	2010	2019	NCT01089101;NCT01362803;NCT02407405;NCT03109301;NCT03095248;NCT03326388;NCT02839720
Neurofibroma	D009455	selumetinib	Phase 3	2019	2019	NCT03871257
Astrocytoma	D001254	selumetinib	Phase 2	2010	2010	NCT01089101
Astrocytoma	D001254	selumetinib	Phase 3	2020	2021	NCT04576117;NCT04166409
Melanoma	D008545	selumetinib	Phase 1	2007	2017	NCT00600496;NCT01364051;NCT00710515;NCT02768766
Melanoma	D008545	selumetinib	Phase 2	2006	2012	NCT01519427;NCT01256359;NCT00936221;NCT00866177;NCT00338130;NCT01166126;NCT01143402
Melanoma	D008545	selumetinib	Phase 3	2014	2014	NCT01974752
Uveal Neoplasms	D014604	selumetinib	Phase 1	2017	2017	NCT02768766
Uveal Neoplasms	D014604	selumetinib	Phase 2	2010	2010	NCT01143402
Uveal Neoplasms	D014604	selumetinib	Phase 3	2014	2014	NCT01974752
Carcinoma	D002277	selumetinib	Phase 2	2007	2015	NCT00551070;NCT00604721;NCT01658943;NCT01011933;NCT02151084;NCT01029418;NCT00559949;NCT02393690;NCT01306045
Adenocarcinoma	D000230	selumetinib	Phase 1	2010	2010	NCT01134601
Adenocarcinoma	D000230	selumetinib	Phase 2	2007	2020	NCT00551070;NCT01222689;NCT01011933;NCT02664935;NCT02448290;NCT01859182;NCT04348045
Cystadenocarcinoma, Serous	D018284	selumetinib	Phase 2	2007	2007	NCT00551070
Brenner Tumor	D001948	selumetinib	Phase 2	2007	2007	NCT00551070
Thymoma	D013945	selumetinib	Phase 2	2011	2012	NCT01610544;NCT01306045
Thymus Neoplasms	D013953	selumetinib	Phase 2	2012	2012	NCT01610544
Pancreatic Neoplasms	D010190	selumetinib	Phase 2	2006	2017	NCT01222689;NCT01658943;NCT03040986;NCT00372944;NCT02450656
Breast Neoplasms	D001943	selumetinib	Phase 1	2007	2017	NCT00600496;NCT03162627;NCT01313039
Breast Neoplasms	D001943	selumetinib	Phase 2	2009	2016	NCT02685657;NCT01160718;NCT02299999;NCT00780676
Colonic Neoplasms	D003110	selumetinib	Phase 1	2007	2012	NCT00600496;NCT01287130;NCT01217450
Kidney Neoplasms	D007680	selumetinib	Phase 1	2007	2007	NCT00600496
Carcinoma, Renal Cell	D002292	selumetinib	Phase 1	2007	2007	NCT00600496
Thyroid Neoplasms	D013964	selumetinib	Phase 1	2017	2017	NCT03162627
Thyroid Neoplasms	D013964	selumetinib	Phase 2	2007	2015	NCT00559949;NCT02393690
Thyroid Neoplasms	D013964	selumetinib	Phase 3	2013	2013	NCT01843062
Optic Nerve Glioma	D020339	selumetinib	Phase 2	2010	2019	NCT01089101;NCT03326388;NCT02839720
Carcinoma, Hepatocellular	D006528	selumetinib	Phase 2	2007	2009	NCT00604721;NCT01029418
Liver Neoplasms	D008113	selumetinib	Phase 2	2007	2013	NCT00604721;NCT01859182
Neurofibroma, Plexiform	D018318	selumetinib	Phase 1	2018	2020	NCT04590235;NCT03649165
Neurofibroma, Plexiform	D018318	selumetinib	Phase 2	2011	2019	NCT01362803;NCT02407405;NCT03326388
Colorectal Neoplasms	D015179	selumetinib	Phase 1	2014	2014	NCT02188264
Colorectal Neoplasms	D015179	selumetinib	Phase 2	2006	2015	NCT00514761;NCT01333475;NCT01116271;NCT02450656
Urinary Bladder Neoplasms	D001749	selumetinib	Phase 1	2016	2016	NCT02546661
Carcinoma, Acinar Cell	D018267	selumetinib	Phase 2	2012	2012	NCT01658943
Adenocarcinoma, Clear Cell	D018262	selumetinib	Phase 2	2009	2009	NCT01011933
Carcinoma, Adenosquamous	D018196	selumetinib	Phase 2	2009	2009	NCT01011933
Rectal Neoplasms	D012004	selumetinib	Phase 1	2010	2012	NCT01217450;NCT01160926;NCT01134601
Leukemia	D007938	selumetinib	Phase 2	2007	2018	NCT00588809;NCT03705507
Leukemia, Myeloid	D007951	selumetinib	Phase 1	2018	2018	NCT03326310
Leukemia, Myeloid	D007951	selumetinib	Phase 2	2007	2007	NCT00588809
Leukemia, Myeloid, Acute	D015470	selumetinib	Phase 2	2007	2007	NCT00588809
Leukemia, Promyelocytic, Acute	D015473	selumetinib	Phase 2	2007	2007	NCT00588809
Genital Neoplasms, Female	D005833	selumetinib	Phase 1	2017	2017	NCT03162627
Genital Neoplasms, Male	D005834	selumetinib	Phase 1	2017	2017	NCT03162627
Triple Negative Breast Neoplasms	D064726	selumetinib	Phase 2	2015	2016	NCT02685657;NCT02583542
Multiple Myeloma	D009101	selumetinib	Phase 2	2010	2010	NCT01085214
Neoplasms, Plasma Cell	D054219	selumetinib	Phase 2	2010	2010	NCT01085214
Gastrointestinal Stromal Tumors	D046152	selumetinib	Phase 2	2017	2017	NCT03109301
Neoplasms, Nerve Tissue	D009380	selumetinib	Phase 2	2017	2017	NCT03109301
Carcinoma, Squamous Cell	D002294	selumetinib	Phase 2	2015	2015	NCT02664935
Lymphoma	D008223	selumetinib	Phase 2	2010	2017	NCT03213691;NCT03155620;NCT01278615
Lymphoma, Non-Hodgkin	D008228	selumetinib	Phase 2	2017	2017	NCT03213691;NCT03155620
Neuroblastoma	D009447	selumetinib	Phase 2	2017	2017	NCT03213691;NCT03155620
Nervous System Neoplasms	D009423	selumetinib	Phase 2	2017	2017	NCT03213691;NCT03155620
Central Nervous System Neoplasms	D016543	selumetinib	Phase 2	2017	2017	NCT03213691;NCT03155620
Biliary Tract Neoplasms	D001661	selumetinib	Phase 1	2012	2015	NCT01949870;NCT01242605;NCT02586987
Biliary Tract Neoplasms	D001661	selumetinib	Phase 2	2007	2007	NCT00553332
Sarcoma	D012509	selumetinib	Phase 2	2010	2017	NCT01206140;NCT03155620;NCT01752569
Ependymoma	D004806	selumetinib	Phase 2	2017	2017	NCT03095248;NCT03155620
Meningioma	D008579	selumetinib	Phase 2	2017	2017	NCT03095248
Neurilemmoma	D009442	selumetinib	Phase 2	2017	2017	NCT03095248
Neuroma, Acoustic	D009464	selumetinib	Phase 2	2017	2017	NCT03095248
Neurofibromatosis 2	D016518	selumetinib	Phase 2	2017	2017	NCT03095248
Skin Neoplasms	D012878	selumetinib	Phase 2	2009	2009	NCT00866177
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	selumetinib	Phase 1	2018	2018	NCT03326310
Cholangiocarcinoma	D018281	selumetinib	Phase 1	2012	2012	NCT01242605
Cholangiocarcinoma	D018281	selumetinib	Phase 2	2007	2013	NCT01859182;NCT00553332
Gallbladder Neoplasms	D005706	selumetinib	Phase 1	2012	2012	NCT01242605
Gallbladder Neoplasms	D005706	selumetinib	Phase 2	2013	2013	NCT01859182
Bile Duct Neoplasms	D001650	selumetinib	Phase 2	2007	2013	NCT01859182;NCT00553332
Nerve Sheath Neoplasms	D018317	selumetinib	Phase 2	2019	2019	NCT03433183
Neurofibrosarcoma	D018319	selumetinib	Phase 2	2019	2019	NCT03433183
Neoplasms, Germ Cell and Embryonal	D009373	selumetinib	Phase 2	2017	2017	NCT03155620
Osteosarcoma	D012516	selumetinib	Phase 2	2017	2017	NCT03155620
Rhabdomyosarcoma	D012208	selumetinib	Phase 2	2017	2017	NCT03155620
Sarcoma, Ewing	D012512	selumetinib	Phase 2	2017	2017	NCT03155620
Medulloblastoma	D008527	selumetinib	Phase 2	2017	2017	NCT03155620
Neuroectodermal Tumors	D017599	selumetinib	Phase 2	2017	2017	NCT03155620
Neuroectodermal Tumors, Primitive	D018242	selumetinib	Phase 2	2017	2017	NCT03155620
Wilms Tumor	D009396	selumetinib	Phase 2	2017	2017	NCT03155620
Neuroectodermal Tumors, Primitive, Peripheral	D018241	selumetinib	Phase 2	2017	2017	NCT03155620
Rhabdoid Tumor	D018335	selumetinib	Phase 2	2017	2017	NCT03155620
Hepatoblastoma	D018197	selumetinib	Phase 2	2017	2017	NCT03155620
Histiocytic Sarcoma	D054747	selumetinib	Phase 2	2017	2017	NCT03155620
Lymphoma, B-Cell	D016393	selumetinib	Phase 2	2010	2010	NCT01278615
Lymphoma, Large B-Cell, Diffuse	D016403	selumetinib	Phase 2	2010	2010	NCT01278615
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	selumetinib	Phase 2	2018	2018	NCT03705507
Leukemia, Lymphoid	D007945	selumetinib	Phase 2	2018	2018	NCT03705507
Carcinoma, Papillary	D002291	selumetinib	Phase 2	2007	2015	NCT00559949;NCT02393690
Thyroid Cancer, Papillary	D000077273	selumetinib	Phase 2	2007	2015	NCT00559949;NCT02393690
Sarcoma, Kaposi	D012514	selumetinib	Phase 2	2012	2012	NCT01752569
Adenocarcinoma, Follicular	D018263	selumetinib	Phase 2	2015	2015	NCT02393690
Gastrointestinal Neoplasms	D005770	selumetinib	Phase 2	2015	2015	NCT02450656
Digestive System Neoplasms	D004067	selumetinib	Phase 2	2015	2015	NCT02450656
Small Cell Lung Carcinoma	D055752	selumetinib	Phase 2	2011	2011	NCT01306045
Carcinoma, Small Cell	D018288	selumetinib	Phase 2	2011	2011	NCT01306045
Urinary Bladder Neoplasms	D001749	sirolimus	Phase 1	2012	2016	NCT01522820;NCT02646319;NCT01827618;NCT02753309
Urinary Bladder Neoplasms	D001749	sirolimus	Phase 2	2008	2021	NCT03047213;NCT02009332;NCT01938573;NCT02788201;NCT04375813;NCT01827943;NCT01090466
Urinary Bladder Neoplasms	D001749	sirolimus	Phase 3	2018	2018	NCT03298958
Nervous System Neoplasms	D009423	sirolimus	Phase 1	2001	2018	NCT00003712;NCT00509431;NCT01135563;NCT00784914;NCT03696355;NCT02975882;NCT01204450
Nervous System Neoplasms	D009423	sirolimus	Phase 2	2001	2017	NCT00022724;NCT00047073;NCT01019434;NCT03213678;NCT03155620
Central Nervous System Neoplasms	D016543	sirolimus	Phase 1	2001	2018	NCT00003712;NCT00509431;NCT01135563;NCT00784914;NCT03696355;NCT02975882;NCT01204450
Central Nervous System Neoplasms	D016543	sirolimus	Phase 2	2001	2017	NCT02574728;NCT00022724;NCT00047073;NCT01019434;NCT03213678;NCT03155620
Carcinoma	D002277	sirolimus	Phase 1	2004	2020	NCT04339062;NCT01204476;NCT01198184;NCT00655655;NCT01522820;NCT02646319;NCT01552434;NCT01008917;NCT02142803;NCT01548482;NCT02833506;NCT01637194;NCT02152943;NCT01625351;NCT01218555;NCT03324373;NCT01155258;NCT00563147;NCT03333694;NCT01332279;NCT00999882;NCT00408655;NCT03878524
Carcinoma	D002277	sirolimus	Phase 2	2003	2020	NCT02283658;NCT03047213;NCT01517243;NCT02687958;NCT02730923;NCT01764607;NCT01195922;NCT01798446;NCT03190174;NCT01374750;NCT01010126;NCT01015664;NCT02273752;NCT01737502;NCT01009203;NCT02788201;NCT01372813;NCT02456857;NCT00072176;NCT01026792;NCT00353301;NCT01566747;NCT01256385;NCT02565901;NCT01687673;NCT01239342;NCT01567930;NCT02330783;NCT00390195;NCT00112840;NCT01762033;NCT00093782;NCT03008408;NCT01582009;NCT00417677;NCT00886691;NCT00729586;NCT00782275;NCT02514824;NCT01453595;NCT00723255;NCT00378703;NCT04203901;NCT02093598;NCT00619268;NCT01392183;NCT01856101;NCT00494091;NCT03685448;NCT01510119;NCT00805129;NCT01335074;NCT01460979;NCT00923845;NCT00699491;NCT02049047
Carcinoma	D002277	sirolimus	Phase 3	1996	2019	NCT00474786;NCT00065468;NCT01223027;NCT00328770;NCT00631371;NCT01265810;NCT04168944;NCT00355862;NCT01198158
Carcinoma	D002277	sirolimus	Phase 4	2009	2012	NCT01206764;NCT01521715
Carcinoma, Renal Cell	D002292	sirolimus	Phase 1	2002	2019	NCT01198184;NCT00655655;NCT01522820;NCT02646319;NCT00600496;NCT02145559;NCT01548482;NCT01079286;NCT02133742;NCT00112476;NCT03324373;NCT01122615;NCT01155258;NCT00563147;NCT00045370
Carcinoma, Renal Cell	D002292	sirolimus	Phase 2	2005	2020	NCT01517243;NCT01798446;NCT02560012;NCT02019693;NCT02273752;NCT01372813;NCT01246817;NCT00353301;NCT01566747;NCT02423954;NCT01239342;NCT00331409;NCT02330783;NCT00112840;NCT01762033;NCT01582009;NCT00417677;NCT00782275;NCT01453595;NCT00979966;NCT00378703;NCT04203901;NCT00619268;NCT01392183;NCT00494091;NCT03685448;NCT01510119;NCT00923845
Carcinoma, Renal Cell	D002292	sirolimus	Phase 3	2003	2011	NCT00474786;NCT00065468;NCT01223027;NCT00631371;NCT01265810;NCT01198158
Carcinoma, Renal Cell	D002292	sirolimus	Phase 4	2009	2012	NCT01206764;NCT01521715
Sarcoma	D012509	sirolimus	Phase 1	2006	2020	NCT01552434;NCT01331135;NCT00450320;NCT04199026;NCT01548482;NCT01155258;NCT00288431;NCT04185883;NCT00996346;NCT01204450
Sarcoma	D012509	sirolimus	Phase 2	2002	2020	NCT01842594;NCT01412515;NCT01281865;NCT03190174;NCT01222715;NCT00087074;NCT00743509;NCT01661283;NCT01614795;NCT02584647;NCT03213678;NCT02008877;NCT01206140;NCT03660930;NCT00043979;NCT03778996;NCT00357396;NCT02987959;NCT00093080;NCT00949325;NCT03155620;NCT01010672;NCT01016015;NCT03114527;NCT01946529;NCT01684449
Sarcoma	D012509	sirolimus	Phase 3	2007	2007	NCT00538239
Kidney Neoplasms	D007680	sirolimus	Phase 1	2002	2014	NCT00600496;NCT02145559;NCT00659568;NCT01122615;NCT00045370
Kidney Neoplasms	D007680	sirolimus	Phase 2	2006	2014	NCT01264341;NCT02019693;NCT01372813;NCT01239342;NCT00331409;NCT00498966;NCT00782275;NCT01453595;NCT00979966;NCT01392183;NCT01090466
Kidney Neoplasms	D007680	sirolimus	Phase 3	2003	2003	NCT00065468
Pancreatic Neoplasms	D010190	sirolimus	Phase 1	2007	2020	NCT01204476;NCT00593008;NCT01537107;NCT03878524;NCT00981162
Pancreatic Neoplasms	D010190	sirolimus	Phase 2	2003	2018	NCT00075647;NCT01010126;NCT02273752;NCT00276744;NCT00499486;NCT01210911;NCT03662412
Pancreatic Neoplasms	D010190	sirolimus	Phase 3	2018	2020	NCT03512756;NCT04229004
Multiple Myeloma	D009101	sirolimus	Phase 1	2003	2020	NCT00602693;NCT01689987;NCT00398515;NCT01396200;NCT03963024;NCT01163357;NCT02240719;NCT00962507;NCT00973804;NCT00060632;NCT03657420;NCT03018223;NCT00317798;NCT00513474;NCT00060645;NCT01634217;NCT03878524;NCT00693433
Multiple Myeloma	D009101	sirolimus	Phase 2	2001	2020	NCT02693535;NCT00105001;NCT00691015;NCT01116232;NCT00079456;NCT01460420;NCT01177397;NCT00133367;NCT03225417;NCT00474929;NCT02356159;NCT03297606;NCT01303965;NCT01251575;NCT04176380;NCT01239368;NCT01534143;NCT03246906;NCT00918333;NCT03192397;NCT00544115;NCT00589563;NCT02991898;NCT00520130;NCT00089037;NCT00483262;NCT02722668
Multiple Myeloma	D009101	sirolimus	Phase 3	2010	2010	NCT01231412
Lymphoma, Non-Hodgkin	D008228	sirolimus	Phase 1	2003	2020	NCT04473911;NCT01614197;NCT01658007;NCT02728700;NCT00068302;NCT00973804;NCT01088048;NCT03018223;NCT00622258;NCT01403415;NCT03878524
Lymphoma, Non-Hodgkin	D008228	sirolimus	Phase 2	2002	2017	NCT02693535;NCT00105001;NCT00290472;NCT01177397;NCT01281917;NCT01381692;NCT03297606;NCT01251575;NCT01075321;NCT02790515;NCT00350181;NCT00033267;NCT01181271;NCT03213678;NCT01170052;NCT01076543;NCT00918333;NCT00577278;NCT03155620;NCT01220297
Lymphoma, Non-Hodgkin	D008228	sirolimus	Phase 3	2010	2010	NCT01231412
Lymphoma, Non-Hodgkin	D008228	sirolimus	Phase 4	2011	2011	NCT01180049
Melanoma	D008545	sirolimus	Phase 1	2004	2012	NCT00655655;NCT01522820;NCT00600496;NCT00349206;NCT00112476
Melanoma	D008545	sirolimus	Phase 2	2001	2012	NCT01014351;NCT01851408;NCT00397982;NCT01614301;NCT00281957;NCT01166126;NCT00022464
Prostatic Neoplasms	D011471	sirolimus	Phase 1	2007	2020	NCT01548807;NCT01522820;NCT02646319;NCT02064608;NCT01174199;NCT01353625;NCT00512668;NCT01155258;NCT03618355;NCT03878524
Prostatic Neoplasms	D011471	sirolimus	Phase 2	2000	2016	NCT00887640;NCT00311623;NCT00012142;NCT00777959;NCT00919035;NCT02565901;NCT02091531;NCT01026623;NCT01206036;NCT01313559;NCT00657982;NCT01020305;NCT00110188;NCT02796898;NCT01083368;NCT00071968;NCT02407054
Prostatic Neoplasms	D011471	sirolimus	Phase 3	2009	2009	NCT00922129
Neoplastic Cells, Circulating	D009360	sirolimus	Phase 2	2009	2009	NCT00887640
Burkitt Lymphoma	D002051	sirolimus	Phase 1	2010	2010	NCT01184885
Burkitt Lymphoma	D002051	sirolimus	Phase 2	2004	2017	NCT00105001;NCT00290472;NCT01075321;NCT00776373;NCT00918333;NCT02991898;NCT02722668
Lymphoma	D008223	sirolimus	Phase 1	2003	2020	NCT01535989;NCT04473911;NCT02343718;NCT00602693;NCT01902160;NCT01991938;NCT01614197;NCT01341834;NCT00659568;NCT01658007;NCT02728700;NCT00068302;NCT00787969;NCT02254239;NCT02240719;NCT00962507;NCT00275093;NCT01184885;NCT01854606;NCT00973804;NCT01588678;NCT01088048;NCT03018223;NCT01625351;NCT00622258;NCT03730142;NCT00513474;NCT01473095;NCT01634217;NCT01403415;NCT03878524
Lymphoma	D008223	sirolimus	Phase 2	2001	2019	NCT00105001;NCT01389427;NCT00727207;NCT00290472;NCT02669511;NCT01027000;NCT00691015;NCT01116232;NCT01177397;NCT01281917;NCT01381692;NCT00474929;NCT03922724;NCT02356159;NCT03120000;NCT01251575;NCT01075321;NCT02793544;NCT00033267;NCT00942747;NCT00838955;NCT00776373;NCT00317785;NCT03697408;NCT01181271;NCT01198665;NCT00074490;NCT02061800;NCT01843998;NCT03213678;NCT01078142;NCT01170052;NCT01076543;NCT03246906;NCT00918333;NCT03192397;NCT00577278;NCT00544115;NCT00589563;NCT03155620;NCT00086840;NCT00109967;NCT01162551;NCT02991898;NCT00869999;NCT00520130;NCT01220297;NCT01653067;NCT00089037;NCT02722668;NCT01637090
Lymphoma	D008223	sirolimus	Phase 3	2005	2012	NCT00117598;NCT01646021;NCT00928018;NCT01231412
Lymphoma	D008223	sirolimus	Phase 4	2011	2011	NCT01180049
Leukemia	D007938	sirolimus	Phase 1	2003	2020	NCT04473911;NCT00101088;NCT02528877;NCT00602693;NCT01822015;NCT01614197;NCT02226861;NCT01658007;NCT02728700;NCT00068302;NCT01523977;NCT02861040;NCT00874562;NCT01184885;NCT00973804;NCT01088048;NCT03018223;NCT00780104;NCT00513474;NCT00473551;NCT01756118;NCT00957320;NCT01634217;NCT01403415;NCT00861874;NCT03878524
Leukemia	D007938	sirolimus	Phase 2	1996	2020	NCT00105001;NCT00002790;NCT04339101;NCT00290472;NCT00795886;NCT01869114;NCT00634244;NCT01027000;NCT00691015;NCT01116232;NCT00935792;NCT03670966;NCT00133367;NCT00084916;NCT00775593;NCT00144703;NCT01611116;NCT00144677;NCT02583893;NCT01251575;NCT02790515;NCT02793544;NCT00776373;NCT00317785;NCT00792948;NCT01188889;NCT00074490;NCT02061800;NCT01363297;NCT01488253;NCT03434704;NCT03970096;NCT03246906;NCT01885689;NCT02756572;NCT00918333;NCT00544466;NCT03192397;NCT00577278;NCT00235560;NCT00544115;NCT00589563;NCT00086840;NCT01162551;NCT02991898;NCT00520130;NCT03128034;NCT00089037;NCT02722668
Leukemia	D007938	sirolimus	Phase 3	2006	2012	NCT01539291;NCT00406393;NCT00382109;NCT01231412;NCT01188798
Leukemia, Myeloid	D007951	sirolimus	Phase 1	2005	2020	NCT00101088;NCT02528877;NCT01822015;NCT02226861;NCT02728700;NCT00780104;NCT01756118;NCT01634217;NCT00861874;NCT03878524
Leukemia, Myeloid	D007951	sirolimus	Phase 2	2003	2019	NCT00105001;NCT01869114;NCT00634244;NCT03670966;NCT00133367;NCT00084916;NCT00775593;NCT01611116;NCT00144677;NCT02583893;NCT02109744;NCT01251575;NCT02790515;NCT01188889;NCT01488253;NCT01885689;NCT02756572;NCT00235560;NCT02991898;NCT03128034
Leukemia, Myeloid	D007951	sirolimus	Phase 3	2006	2010	NCT00406393;NCT01188798
Leukemia, Myeloid, Acute	D015470	sirolimus	Phase 1	2010	2020	NCT04473911;NCT02528877;NCT01822015;NCT02226861;NCT02728700;NCT01756118;NCT01634217;NCT00861874;NCT03878524
Leukemia, Myeloid, Acute	D015470	sirolimus	Phase 2	2003	2019	NCT00105001;NCT01869114;NCT00634244;NCT03670966;NCT00084916;NCT00775593;NCT01611116;NCT00144677;NCT02583893;NCT02109744;NCT01251575;NCT02790515;NCT02793544;NCT02061800;NCT01885689;NCT02756572;NCT00235560;NCT02991898;NCT03128034
Leukemia, Myeloid, Acute	D015470	sirolimus	Phase 3	2006	2010	NCT00406393;NCT01188798
Lymphoma, Follicular	D008224	sirolimus	Phase 1	2014	2014	NCT02240719
Lymphoma, Follicular	D008224	sirolimus	Phase 2	2004	2011	NCT00105001;NCT00290472;NCT01381692;NCT01075321;NCT01078142;NCT00918333
Preleukemia	D011289	sirolimus	Phase 1	2008	2020	NCT04473911;NCT02728700;NCT00513474;NCT03878524
Preleukemia	D011289	sirolimus	Phase 2	1996	2020	NCT00105001;NCT00002790;NCT04339101;NCT01869114;NCT00691015;NCT01116232;NCT03670966;NCT00084916;NCT01251575;NCT02790515;NCT02793544;NCT00317785;NCT01111448;NCT00074490;NCT02061800;NCT03434704;NCT01885689;NCT02756572;NCT00506948;NCT00544466;NCT00544115;NCT00589563;NCT00520130;NCT03128034;NCT00089037
Leukemia, Lymphoid	D007945	sirolimus	Phase 1	2007	2020	NCT04473911;NCT01614197;NCT02226861;NCT01658007;NCT02728700;NCT01523977;NCT02861040;NCT00874562;NCT01184885;NCT01088048;NCT00957320;NCT01634217;NCT01403415;NCT03878524
Leukemia, Lymphoid	D007945	sirolimus	Phase 2	2004	2019	NCT00105001;NCT00290472;NCT00795886;NCT01027000;NCT00935792;NCT03670966;NCT00084916;NCT01251575;NCT00776373;NCT00792948;NCT01363297;NCT03246906;NCT00918333;NCT00086840;NCT01162551;NCT03128034
Leukemia, Lymphoid	D007945	sirolimus	Phase 3	2006	2012	NCT01539291;NCT00406393;NCT00382109;NCT01231412
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	sirolimus	Phase 1	2007	2020	NCT04473911;NCT01614197;NCT02226861;NCT01658007;NCT02728700;NCT01523977;NCT02861040;NCT00874562;NCT01184885;NCT01756118;NCT00957320;NCT01634217;NCT01403415;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	sirolimus	Phase 2	2002	2019	NCT00105001;NCT00290472;NCT00795886;NCT03670966;NCT00084916;NCT00144703;NCT00144677;NCT01251575;NCT02790515;NCT02793544;NCT00776373;NCT00792948;NCT02061800;NCT01363297;NCT03970096;NCT03246906;NCT01885689;NCT00918333;NCT03192397;NCT01162551;NCT02991898;NCT03128034;NCT02722668
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	sirolimus	Phase 3	2006	2010	NCT00406393;NCT00382109;NCT01231412;NCT01188798
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	sirolimus	Phase 1	2010	2020	NCT02226861;NCT02240719;NCT01353625;NCT01088048;NCT01634217;NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	sirolimus	Phase 2	2004	2017	NCT00105001;NCT00290472;NCT01027000;NCT00935792;NCT01381692;NCT01251575;NCT02793544;NCT01181271;NCT03246906;NCT00918333;NCT00086840;NCT02991898;NCT02722668
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	sirolimus	Phase 3	2010	2012	NCT01539291;NCT01231412
Hodgkin Disease	D006689	sirolimus	Phase 1	2009	2020	NCT04473911;NCT01902160;NCT02728700;NCT02254239;NCT02240719;NCT00973804;NCT03878524
Hodgkin Disease	D006689	sirolimus	Phase 2	2002	2019	NCT00105001;NCT00133367;NCT00144703;NCT00144677;NCT01075321;NCT00838955;NCT03697408;NCT01181271;NCT01076543;NCT00918333;NCT00086840
Hodgkin Disease	D006689	sirolimus	Phase 3	2010	2010	NCT01188798
Lymphoma, Mantle-Cell	D020522	sirolimus	Phase 1	2009	2014	NCT00787969;NCT02240719;NCT01184885;NCT01088048
Lymphoma, Mantle-Cell	D020522	sirolimus	Phase 2	2002	2017	NCT00105001;NCT01389427;NCT00727207;NCT01381692;NCT01251575;NCT01075321;NCT00033267;NCT01181271;NCT01078142;NCT01170052;NCT03246906;NCT00918333;NCT00109967;NCT02991898;NCT02722668
Lymphoma, Mantle-Cell	D020522	sirolimus	Phase 3	2005	2012	NCT00117598;NCT01646021;NCT01231412
Lymphoma, Mantle-Cell	D020522	sirolimus	Phase 4	2011	2011	NCT01180049
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	sirolimus	Phase 1	2005	2020	NCT00101088;NCT02226861;NCT02728700;NCT03018223;NCT01756118;NCT01634217;NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	sirolimus	Phase 2	2003	2017	NCT00105001;NCT00084916;NCT00144677;NCT01251575;NCT02790515;NCT01188889;NCT02061800;NCT01488253;NCT03246906;NCT03192397;NCT02991898;NCT02722668
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	sirolimus	Phase 3	2006	2010	NCT00406393;NCT01231412;NCT01188798
Lymphoma, B-Cell, Marginal Zone	D018442	sirolimus	Phase 2	2004	2017	NCT00105001;NCT00290472;NCT01381692;NCT01075321;NCT00918333;NCT02991898;NCT02722668
Lymphoma, Large B-Cell, Diffuse	D016403	sirolimus	Phase 1	2013	2014	NCT02240719;NCT01854606
Lymphoma, Large B-Cell, Diffuse	D016403	sirolimus	Phase 2	2004	2017	NCT00105001;NCT00290472;NCT01177397;NCT01251575;NCT01075321;NCT01181271;NCT03246906;NCT00918333;NCT00086840;NCT00869999;NCT01653067
Lymphoma, Large B-Cell, Diffuse	D016403	sirolimus	Phase 3	2010	2010	NCT01231412
Waldenstrom Macroglobulinemia	D008258	sirolimus	Phase 2	2004	2017	NCT00105001;NCT00290472;NCT01381692;NCT01251575;NCT01075321;NCT01076543;NCT03246906;NCT00918333;NCT03192397;NCT02991898;NCT02722668
Waldenstrom Macroglobulinemia	D008258	sirolimus	Phase 3	2010	2010	NCT01231412
Lymphoma, Large-Cell, Anaplastic	D017728	sirolimus	Phase 2	2004	2011	NCT00105001;NCT01075321;NCT01198665;NCT00918333
Leukemia, Myeloid, Accelerated Phase	D015465	sirolimus	Phase 1	2005	2020	NCT00101088;NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	sirolimus	Phase 2	2004	2012	NCT00105001;NCT01488253
Leukemia, Promyelocytic, Acute	D015473	sirolimus	Phase 2	2004	2004	NCT00105001
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	sirolimus	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	sirolimus	Phase 2	2004	2004	NCT00105001
Blast Crisis	D001752	sirolimus	Phase 1	2005	2020	NCT00101088;NCT02728700;NCT03878524
Blast Crisis	D001752	sirolimus	Phase 2	2004	2004	NCT00105001;NCT00084916
Plasmablastic Lymphoma	D000069293	sirolimus	Phase 2	2004	2004	NCT00105001;NCT00290472
Lymphoma, Large-Cell, Immunoblastic	D016400	sirolimus	Phase 2	2004	2004	NCT00105001;NCT00290472
Tuberous Sclerosis	D014402	sirolimus	Phase 1	2009	2013	NCT01853423;NCT01031901
Tuberous Sclerosis	D014402	sirolimus	Phase 2	2002	2020	NCT00490789;NCT00457808;NCT02104011;NCT01929642;NCT04595513;NCT00411619;NCT01070316;NCT02061397;NCT01526356;NCT03363763;NCT03356769;NCT00457964
Tuberous Sclerosis	D014402	sirolimus	Phase 3	2009	2019	NCT02634931;NCT01730209;NCT01713946;NCT02635789;NCT00789828;NCT03826628;NCT03140449;NCT00790400
Tuberous Sclerosis	D014402	sirolimus	Phase 4	2008	2008	NCT01217125
Lymphangioleiomyomatosis	D018192	sirolimus	Phase 1	2012	2019	NCT01552434;NCT04388371;NCT01687179
Lymphangioleiomyomatosis	D018192	sirolimus	Phase 2	2002	2018	NCT00490789;NCT01059318;NCT03131999;NCT00457808;NCT03253913;NCT02061397;NCT02484664;NCT00457964
Lymphangioleiomyomatosis	D018192	sirolimus	Phase 3	2006	2018	NCT00414648;NCT03150914;NCT00790400
Neuroendocrine Tumors	D018358	sirolimus	Phase 1	2010	2012	NCT01204476;NCT01548482;NCT01218555
Neuroendocrine Tumors	D018358	sirolimus	Phase 2	2009	2021	NCT02031536;NCT04665739;NCT01177397;NCT01010126;NCT02273752;NCT03670030;NCT01229943;NCT03950609;NCT01658436;NCT02279758;NCT02305810
Neuroendocrine Tumors	D018358	sirolimus	Phase 3	2014	2014	NCT02246127
Insulinoma	D007340	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Insulinoma	D007340	sirolimus	Phase 2	2009	2014	NCT02031536;NCT01010126;NCT02273752
Carcinoma, Islet Cell	D018273	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655;NCT01155258
Carcinoma, Islet Cell	D018273	sirolimus	Phase 2	2003	2014	NCT02031536;NCT01010126;NCT02273752;NCT00093782
Gastrinoma	D015408	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Gastrinoma	D015408	sirolimus	Phase 2	2009	2014	NCT02031536;NCT01010126;NCT02273752;NCT01229943
Glucagonoma	D005935	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Glucagonoma	D005935	sirolimus	Phase 2	2009	2014	NCT02031536;NCT01010126;NCT02273752
Somatostatinoma	D013005	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655
Somatostatinoma	D013005	sirolimus	Phase 2	2009	2014	NCT02031536;NCT01010126;NCT02273752
Hematologic Neoplasms	D019337	sirolimus	Phase 1	2011	2021	NCT00890500;NCT04177004;NCT03963024;NCT02728700;NCT01353625;NCT03531281;NCT03878524
Hematologic Neoplasms	D019337	sirolimus	Phase 2	2002	2019	NCT01203722;NCT01244906;NCT00086125;NCT01460420;NCT00144703;NCT00146614;NCT02790515;NCT03983850;NCT01428973;NCT03434704;NCT00506948
Hematologic Neoplasms	D019337	sirolimus	Phase 3	2010	2010	NCT01231412;NCT01188798
Cholangiocarcinoma	D018281	sirolimus	Phase 1	2009	2013	NCT01888302;NCT00949949
Adenocarcinoma	D000230	sirolimus	Phase 1	2009	2020	NCT02048384;NCT02142803;NCT01537107;NCT03878524;NCT00981162
Adenocarcinoma	D000230	sirolimus	Phase 2	2005	2017	NCT02283658;NCT01010126;NCT00977574;NCT00560963;NCT01026792;NCT00106353;NCT02397083;NCT03008408;NCT01231399
Ovarian Neoplasms	D010051	sirolimus	Phase 1	2007	2017	NCT01522820;NCT02646319;NCT02142803;NCT02833506;NCT00982631;NCT02312661;NCT01155258;NCT00408655
Ovarian Neoplasms	D010051	sirolimus	Phase 2	2009	2014	NCT02283658;NCT00926107;NCT01010126;NCT01149434;NCT01196429;NCT01460979
Carcinoma, Ovarian Epithelial	D000077216	sirolimus	Phase 1	2007	2017	NCT01522820;NCT02646319;NCT02142803;NCT02833506;NCT00982631;NCT02312661;NCT01155258;NCT01281514;NCT00408655;NCT01536054
Carcinoma, Ovarian Epithelial	D000077216	sirolimus	Phase 2	2007	2014	NCT02283658;NCT00926107;NCT01010126;NCT00429793;NCT01149434;NCT01196429
Carcinoma, Endometrioid	D018269	sirolimus	Phase 1	2014	2014	NCT02142803
Carcinoma, Endometrioid	D018269	sirolimus	Phase 2	2009	2017	NCT02283658;NCT01010126;NCT02397083;NCT03008408;NCT02093598
Cystadenocarcinoma	D003536	sirolimus	Phase 1	2014	2014	NCT02142803
Cystadenocarcinoma	D003536	sirolimus	Phase 2	2010	2014	NCT02283658;NCT01196429
Cystadenocarcinoma, Serous	D018284	sirolimus	Phase 1	2010	2014	NCT01198184;NCT02142803
Cystadenocarcinoma, Serous	D018284	sirolimus	Phase 2	2004	2014	NCT02283658;NCT01010126;NCT00977574;NCT00072176
Adenocarcinoma, Papillary	D000231	sirolimus	Phase 2	2009	2014	NCT02283658;NCT01010126
Neurofibromatoses	D017253	sirolimus	Phase 1	2007	2012	NCT01552434;NCT00901849;NCT01031901
Neurofibromatoses	D017253	sirolimus	Phase 2	2008	2019	NCT01412892;NCT01490476;NCT02332902;NCT03433183;NCT00634270
Neurofibromatoses	D017253	sirolimus	Phase 3	2020	2020	NCT04461886
Neurofibromatosis 1	D009456	sirolimus	Phase 1	2007	2009	NCT00901849;NCT01031901
Neurofibromatosis 1	D009456	sirolimus	Phase 2	2008	2019	NCT01412892;NCT01490476;NCT02332902;NCT03433183;NCT00634270
Neurofibromatosis 1	D009456	sirolimus	Phase 3	2020	2020	NCT04461886
Neurofibroma	D009455	sirolimus	Phase 1	2007	2009	NCT00901849;NCT01031901
Neurofibroma	D009455	sirolimus	Phase 2	2008	2015	NCT01412892;NCT01490476;NCT02332902;NCT00634270
Neurofibroma	D009455	sirolimus	Phase 3	2020	2020	NCT04461886
Neurofibroma, Plexiform	D018318	sirolimus	Phase 2	2008	2011	NCT01412892;NCT00634270
Stomach Neoplasms	D013274	sirolimus	Phase 1	2010	2012	NCT01204476;NCT01522820
Stomach Neoplasms	D013274	sirolimus	Phase 2	2008	2017	NCT03082833;NCT01010126;NCT00985192;NCT00632268;NCT03061708;NCT01231399
Carcinoma, Squamous Cell	D002294	sirolimus	Phase 1	2008	2020	NCT04339062;NCT01637194;NCT03333694;NCT01332279
Carcinoma, Squamous Cell	D002294	sirolimus	Phase 2	2009	2010	NCT01195922;NCT01016769;NCT01015664;NCT01009203;NCT01256385
Carcinoma, Transitional Cell	D002295	sirolimus	Phase 2	2008	2017	NCT03047213;NCT02788201;NCT01856101;NCT01090466;NCT00805129
Hemangioendothelioma	D006390	sirolimus	Phase 1	2020	2020	NCT04409691
Hemangioendothelioma	D006390	sirolimus	Phase 2	2009	2017	NCT00975819;NCT02110069;NCT03188068
Hemangioendothelioma	D006390	sirolimus	Phase 3	2021	2021	NCT04775173
Hemangioendothelioma	D006390	sirolimus	Phase 4	2019	2020	NCT04077515;NCT04406870;NCT04448873
Lymphangioma	D008202	sirolimus	Phase 2	2009	2020	NCT00975819;NCT03243019;NCT04128722;NCT03972592
Neurilemmoma	D009442	sirolimus	Phase 2	2012	2012	NCT01490476
Neuroma, Acoustic	D009464	sirolimus	Phase 2	2012	2012	NCT01490476
Neurofibromatosis 2	D016518	sirolimus	Phase 1	2012	2012	NCT01552434
Neurofibromatosis 2	D016518	sirolimus	Phase 2	2012	2012	NCT01490476
Sarcoma, Kaposi	D012514	sirolimus	Phase 1	2007	2020	NCT00450320;NCT04409691
Sarcoma, Kaposi	D012514	sirolimus	Phase 2	2008	2017	NCT01412515;NCT02110069;NCT03188068
Sarcoma, Kaposi	D012514	sirolimus	Phase 3	2021	2021	NCT04775173
Sarcoma, Kaposi	D012514	sirolimus	Phase 4	2019	2020	NCT04077515;NCT04448873
Carcinoma, Neuroendocrine	D018278	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655;NCT01155258
Carcinoma, Neuroendocrine	D018278	sirolimus	Phase 2	2003	2016	NCT02687958;NCT01010126;NCT02205515;NCT00093782
Colorectal Neoplasms	D015179	sirolimus	Phase 1	2007	2020	NCT01522820;NCT01154335;NCT03203525;NCT00593060
Colorectal Neoplasms	D015179	sirolimus	Phase 2	2007	2021	NCT01047293;NCT03439462;NCT00522665;NCT04094675;NCT02423954;NCT00827684;NCT03095703;NCT01925274;NCT04230499
Endometrial Neoplasms	D016889	sirolimus	Phase 1	2007	2016	NCT01198184;NCT02646319;NCT00659568;NCT01065662;NCT00982631;NCT01205672;NCT01364844;NCT01155258;NCT00703807;NCT00408655
Endometrial Neoplasms	D016889	sirolimus	Phase 2	2004	2017	NCT02730923;NCT00739830;NCT00977574;NCT00072176;NCT00122343;NCT02755844;NCT00087685;NCT01420081;NCT02397083;NCT03099499;NCT03008408;NCT00729586;NCT00723255;NCT02093598;NCT01460979
Breast Neoplasms	D001943	sirolimus	Phase 1	2007	2020	NCT01248494;NCT00473005;NCT01522820;NCT02646319;NCT00600496;NCT02145559;NCT01552434;NCT02619669;NCT00659568;NCT01220570;NCT02152943;NCT02684032;NCT02120469;NCT01155258;NCT02616848;NCT03878524
Breast Neoplasms	D001943	sirolimus	Phase 2	2002	2021	NCT04720664;NCT01495247;NCT01298713;NCT01111825;NCT02273752;NCT04355858;NCT01520103;NCT02456857;NCT01658176;NCT02723877;NCT03805399;NCT01272141;NCT02642094;NCT00736970;NCT02216786;NCT01234857;NCT01797120;NCT01783756;NCT00411788;NCT00062751;NCT02269670;NCT00376688;NCT01430585;NCT02313051;NCT00499603;NCT00699491
Breast Neoplasms	D001943	sirolimus	Phase 3	2004	2021	NCT04736589;NCT01626222;NCT00083993;NCT01633060;NCT01805271;NCT03176238
Skin Neoplasms	D012878	sirolimus	Phase 1	2004	2012	NCT00655655;NCT01522820;NCT01155258
Skin Neoplasms	D012878	sirolimus	Phase 2	2008	2013	NCT01764607;NCT00397982
Skin Neoplasms	D012878	sirolimus	Phase 3	2004	2008	NCT00133887;NCT00799188
Skin Neoplasms	D012878	sirolimus	Phase 4	2005	2018	NCT00866684;NCT03767660;NCT01797315;NCT00129961
Carcinoma, Merkel Cell	D015266	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655;NCT01155258
Carcinoma, Merkel Cell	D015266	sirolimus	Phase 2	2015	2015	NCT02514824
Carcinoid Tumor	D002276	sirolimus	Phase 1	2004	2012	NCT01204476;NCT00655655;NCT01548482;NCT01155258
Carcinoid Tumor	D002276	sirolimus	Phase 2	2003	2021	NCT04665739;NCT01010126;NCT03950609;NCT00093782
Paraganglioma	D010235	sirolimus	Phase 1	2010	2010	NCT01204476;NCT01155258
Carcinoma, Medullary	D018276	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655;NCT01155258
Intestinal Neoplasms	D007414	sirolimus	Phase 1	2010	2010	NCT01204476
Intestinal Neoplasms	D007414	sirolimus	Phase 2	2007	2009	NCT01010126;NCT00589563
Malignant Carcinoid Syndrome	D008303	sirolimus	Phase 1	2004	2010	NCT01204476;NCT00655655;NCT01155258
Malignant Carcinoid Syndrome	D008303	sirolimus	Phase 2	2003	2009	NCT01010126;NCT00093782
Gastrointestinal Neoplasms	D005770	sirolimus	Phase 1	2004	2012	NCT01204476;NCT00655655;NCT01625351;NCT01155258
Gastrointestinal Neoplasms	D005770	sirolimus	Phase 2	2003	2011	NCT01010126;NCT01567488;NCT00093782
Gastrointestinal Neoplasms	D005770	sirolimus	Phase 4	2018	2018	NCT03767660
Sarcoma, Synovial	D013584	sirolimus	Phase 2	2011	2012	NCT01281865;NCT01614795
Carcinoma, Hepatocellular	D006528	sirolimus	Phase 1	2009	2012	NCT01522820;NCT01008917;NCT02724332;NCT00999882
Carcinoma, Hepatocellular	D006528	sirolimus	Phase 2	2006	2012	NCT01374750;NCT01010126;NCT01251458;NCT01687673;NCT01567930;NCT00390195;NCT01281943;NCT01335074
Carcinoma, Hepatocellular	D006528	sirolimus	Phase 3	1996	2019	NCT00554125;NCT00328770;NCT01265810;NCT04168944;NCT00355862
Lymphoma, B-Cell	D016393	sirolimus	Phase 1	2010	2013	NCT01854606;NCT01088048
Lymphoma, B-Cell	D016393	sirolimus	Phase 2	2004	2012	NCT00290472;NCT01251575;NCT01075321;NCT00918333;NCT00577278;NCT00869999;NCT01653067
Hepatoblastoma	D018197	sirolimus	Phase 1	2011	2011	NCT01331135
Hepatoblastoma	D018197	sirolimus	Phase 2	2017	2017	NCT03213678;NCT03155620
Hepatoblastoma	D018197	sirolimus	Phase 3	2009	2009	NCT00980460
Leukemia, Monocytic, Acute	D007948	sirolimus	Phase 1	2013	2013	NCT01822015
Leukemia, Monocytic, Acute	D007948	sirolimus	Phase 2	2008	2008	NCT00634244
Leukemia, Myelomonocytic, Acute	D015479	sirolimus	Phase 1	2013	2013	NCT01822015
Leukemia, Myelomonocytic, Acute	D015479	sirolimus	Phase 2	2008	2014	NCT00634244;NCT01885689
Leukemia, Megakaryoblastic, Acute	D007947	sirolimus	Phase 1	2013	2013	NCT01822015
Leukemia, Megakaryoblastic, Acute	D007947	sirolimus	Phase 2	2008	2008	NCT00634244
Leukemia, Erythroblastic, Acute	D004915	sirolimus	Phase 1	2013	2013	NCT01822015
Leukemia, Erythroblastic, Acute	D004915	sirolimus	Phase 2	2008	2008	NCT00634244
Squamous Cell Carcinoma of Head and Neck	D000077195	sirolimus	Phase 1	2011	2011	NCT01353625
Squamous Cell Carcinoma of Head and Neck	D000077195	sirolimus	Phase 2	2010	2019	NCT01195922;NCT01015664;NCT03740100;NCT01172769
Head and Neck Neoplasms	D006258	sirolimus	Phase 1	2008	2018	NCT03065062;NCT01637194;NCT03578432;NCT01332279
Head and Neck Neoplasms	D006258	sirolimus	Phase 2	2010	2010	NCT01195922;NCT01256385
Mouth Neoplasms	D009062	sirolimus	Phase 2	2010	2010	NCT01195922
Tongue Neoplasms	D014062	sirolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Tongue Neoplasms	D014062	sirolimus	Phase 2	2010	2010	NCT01195922
Glioma	D005910	sirolimus	Phase 1	2004	2020	NCT00509431;NCT04485559;NCT02238496;NCT00901849;NCT01316809;NCT00087451;NCT03387020;NCT03696355;NCT02420613
Glioma	D005910	sirolimus	Phase 2	2001	2018	NCT00022724;NCT01051557;NCT00112736;NCT03213678;NCT03463265;NCT00672243;NCT00823459;NCT03155620
Leukemia, Myelomonocytic, Chronic	D015477	sirolimus	Phase 1	2017	2020	NCT04473911;NCT03018223;NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	sirolimus	Phase 2	2004	2019	NCT03670966;NCT00084916;NCT01885689;NCT02756572;NCT03192397;NCT03128034
Leukemia, Myelomonocytic, Juvenile	D054429	sirolimus	Phase 1	2017	2020	NCT04473911;NCT03018223;NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	sirolimus	Phase 2	2004	2019	NCT03670966;NCT00084916;NCT02790515;NCT02061800;NCT01885689;NCT02756572;NCT03192397;NCT03128034
Thyroid Neoplasms	D013964	sirolimus	Phase 1	2012	2012	NCT01552434
Thyroid Neoplasms	D013964	sirolimus	Phase 2	2009	2017	NCT03099356;NCT03139747;NCT01141309;NCT01025453
Neoplasms, Plasma Cell	D054219	sirolimus	Phase 1	2006	2020	NCT00602693;NCT01689987;NCT00398515;NCT01396200;NCT01163357;NCT00962507;NCT03657420;NCT00317798;NCT00513474;NCT03878524;NCT00693433
Neoplasms, Plasma Cell	D054219	sirolimus	Phase 2	2001	2020	NCT00691015;NCT01116232;NCT00079456;NCT01460420;NCT01177397;NCT00474929;NCT01303965;NCT04176380;NCT01239368;NCT01534143;NCT00918333;NCT00544115;NCT00589563;NCT00089037;NCT00483262;NCT02722668
Sarcoma, Ewing	D012512	sirolimus	Phase 1	2011	2012	NCT01331135;NCT01625351
Sarcoma, Ewing	D012512	sirolimus	Phase 2	2012	2020	NCT03190174;NCT01614795;NCT03213678;NCT03778996;NCT03155620;NCT01946529
Chordoma	D002817	sirolimus	Phase 2	2017	2017	NCT03190174
Rhabdomyosarcoma	D012208	sirolimus	Phase 1	2011	2012	NCT01331135;NCT01625351
Rhabdomyosarcoma	D012208	sirolimus	Phase 2	2010	2017	NCT01222715;NCT01614795;NCT03213678;NCT03155620
Rhabdomyosarcoma	D012208	sirolimus	Phase 3	2016	2016	NCT02567435
Rhabdomyosarcoma, Embryonal	D018233	sirolimus	Phase 2	2010	2012	NCT01222715;NCT01614795
Rhabdomyosarcoma, Embryonal	D018233	sirolimus	Phase 3	2016	2016	NCT02567435
Rhabdomyosarcoma, Alveolar	D018232	sirolimus	Phase 2	2010	2010	NCT01222715
Rhabdomyosarcoma, Alveolar	D018232	sirolimus	Phase 3	2016	2016	NCT02567435
Sturge-Weber Syndrome	D013341	sirolimus	Phase 2	2011	2011	NCT02080624
Sturge-Weber Syndrome	D013341	sirolimus	Phase 3	2017	2017	NCT03047980
Ependymoma	D004806	sirolimus	Phase 1	2011	2018	NCT01331135;NCT03387020
Ependymoma	D004806	sirolimus	Phase 2	2015	2017	NCT02155920;NCT03213678;NCT03155620
Triple Negative Breast Neoplasms	D064726	sirolimus	Phase 1	2009	2015	NCT01920061;NCT02616848;NCT00998036
Triple Negative Breast Neoplasms	D064726	sirolimus	Phase 2	2010	2018	NCT01111825;NCT02723877;NCT03805399;NCT02583542
Lung Neoplasms	D008175	sirolimus	Phase 1	2004	2019	NCT00655655;NCT00796796;NCT01522820;NCT01383668;NCT02145559;NCT00659568;NCT00401778;NCT01545947;NCT02372227;NCT00352950;NCT00555256;NCT01155258;NCT02126527;NCT04348292
Lung Neoplasms	D008175	sirolimus	Phase 2	2002	2018	NCT03670030;NCT01737502;NCT00079235;NCT00818675;NCT00770120;NCT02583542;NCT03664115;NCT01827267;NCT00028028;NCT00098462
Carcinoma, Non-Small-Cell Lung	D002289	sirolimus	Phase 1	2004	2019	NCT00655655;NCT00796796;NCT01383668;NCT01545947;NCT00993499;NCT00352950;NCT00555256;NCT01155258;NCT03217669;NCT02126527;NCT04348292
Carcinoma, Non-Small-Cell Lung	D002289	sirolimus	Phase 2	2004	2018	NCT02920450;NCT01737502;NCT00079235;NCT00124280;NCT00818675;NCT03664115;NCT00921310;NCT01827267;NCT00923273;NCT00098462
Pheochromocytoma	D010673	sirolimus	Phase 1	2004	2010	NCT00655655;NCT01155258
Leukemia, Myeloid, Chronic-Phase	D015466	sirolimus	Phase 1	2005	2020	NCT00101088;NCT02728700;NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	sirolimus	Phase 2	2010	2013	NCT01251575;NCT01188889;NCT01488253
Neoplasm Metastasis	D009362	sirolimus	Phase 1	2006	2020	NCT02528877;NCT02517918;NCT00667485;NCT01353625;NCT00375245;NCT03203525;NCT01122199
Neoplasm Metastasis	D009362	sirolimus	Phase 2	2007	2014	NCT01298713;NCT02142036;NCT01783756;NCT01020305;NCT00589563
Neoplasm Metastasis	D009362	sirolimus	Phase 3	2004	2004	NCT00083993
Angiomyolipoma	D018207	sirolimus	Phase 2	2005	2015	NCT02104011;NCT00126672;NCT00457964
Angiomyolipoma	D018207	sirolimus	Phase 3	2009	2009	NCT00790400
Angiomyolipoma	D018207	sirolimus	Phase 4	2008	2008	NCT01217125
Glioblastoma	D005909	sirolimus	Phase 1	2004	2014	NCT00821080;NCT01522820;NCT02238496;NCT02142803;NCT01316809;NCT01353625;NCT00087451;NCT01240460;NCT00316849
Glioblastoma	D005909	sirolimus	Phase 2	2001	2018	NCT01177397;NCT01051557;NCT00515086;NCT00329719;NCT00112736;NCT00047073;NCT01019434;NCT03463265;NCT00672243;NCT03158389;NCT03522298;NCT00800917;NCT00016328;NCT00335764;NCT02850744;NCT02430363
Glioblastoma	D005909	sirolimus	Phase 3	2018	2018	NCT03008148
Hemangioma	D006391	sirolimus	Phase 2	2014	2017	NCT02042326;NCT02110069
Hemangioma	D006391	sirolimus	Phase 4	2019	2019	NCT04077515
Peutz-Jeghers Syndrome	D010580	sirolimus	Phase 2	2008	2008	NCT00811590
Peutz-Jeghers Syndrome	D010580	sirolimus	Phase 4	2018	2018	NCT03781050
Plasmacytoma	D010954	sirolimus	Phase 1	2006	2009	NCT00602693;NCT00962507;NCT00317798
Plasmacytoma	D010954	sirolimus	Phase 2	2007	2007	NCT00474929
Pinealoma	D010871	sirolimus	Phase 1	2010	2010	NCT01182883
Pinealoma	D010871	sirolimus	Phase 2	2016	2016	NCT02596828
Neoplasms, Squamous Cell	D018307	sirolimus	Phase 2	2009	2009	NCT01016769
Esophageal Neoplasms	D004938	sirolimus	Phase 1	2012	2012	NCT01522820
Esophageal Neoplasms	D004938	sirolimus	Phase 2	2009	2012	NCT00985192;NCT01231399
Astrocytoma	D001254	sirolimus	Phase 1	2011	2014	NCT01522820;NCT01331135;NCT02238496;NCT01316809;NCT01240460
Astrocytoma	D001254	sirolimus	Phase 2	2005	2010	NCT01051557;NCT00112736;NCT00411619;NCT00823459
Astrocytoma	D001254	sirolimus	Phase 3	2009	2009	NCT00789828
Oligodendroglioma	D009837	sirolimus	Phase 1	2011	2014	NCT01522820;NCT02238496;NCT01316809
Oligodendroglioma	D009837	sirolimus	Phase 2	2005	2010	NCT01051557;NCT00112736;NCT00823459
Brain Neoplasms	D001932	sirolimus	Phase 1	2008	2018	NCT01522820;NCT00784914;NCT02238496;NCT00949026;NCT02389309;NCT03387020
Brain Neoplasms	D001932	sirolimus	Phase 2	2006	2010	NCT01051557;NCT00329719;NCT00823459
Genital Neoplasms, Female	D005833	sirolimus	Phase 1	2007	2012	NCT00523432;NCT01552434
Uterine Cervical Neoplasms	D002583	sirolimus	Phase 1	2010	2016	NCT02646319;NCT01155258;NCT01217177
Uterine Cervical Neoplasms	D002583	sirolimus	Phase 2	2009	2009	NCT01026792
Uterine Neoplasms	D014594	sirolimus	Phase 1	2016	2016	NCT02646319
Fallopian Tube Neoplasms	D005185	sirolimus	Phase 1	2010	2017	NCT02142803;NCT02833506;NCT01065662;NCT01281514;NCT01536054
Fallopian Tube Neoplasms	D005185	sirolimus	Phase 2	2007	2010	NCT01010126;NCT00429793;NCT01031381
Adenoma	D000236	sirolimus	Phase 2	2009	2009	NCT01010126
Peritoneal Neoplasms	D010534	sirolimus	Phase 1	2012	2017	NCT02142803;NCT02833506;NCT01536054
Peritoneal Neoplasms	D010534	sirolimus	Phase 2	2009	2009	NCT01010126
Carcinosarcoma	D002296	sirolimus	Phase 2	2009	2010	NCT01010126;NCT01061606
Mixed Tumor, Mullerian	D018200	sirolimus	Phase 2	2009	2010	NCT01010126;NCT01061606
Liver Neoplasms	D008113	sirolimus	Phase 1	2006	2014	NCT02145559;NCT00467194
Liver Neoplasms	D008113	sirolimus	Phase 2	2009	2011	NCT01010126;NCT01281943;NCT01079767
Osteosarcoma	D012516	sirolimus	Phase 1	2011	2015	NCT02517918;NCT01331135;NCT01353625
Osteosarcoma	D012516	sirolimus	Phase 2	2004	2017	NCT00743509;NCT01614795;NCT03213678;NCT00093080;NCT03155620;NCT02429973;NCT01016015
Osteosarcoma	D012516	sirolimus	Phase 3	2007	2007	NCT00538239
Colonic Neoplasms	D003110	sirolimus	Phase 1	2007	2008	NCT00600496;NCT01637194
Colonic Neoplasms	D003110	sirolimus	Phase 2	2010	2010	NCT01149434
Gliosarcoma	D018316	sirolimus	Phase 1	2004	2006	NCT00087451;NCT00316849
Gliosarcoma	D018316	sirolimus	Phase 2	2001	2013	NCT01051557;NCT00329719;NCT00112736;NCT01614795;NCT00672243;NCT00016328;NCT00335764;NCT02430363
Adenocarcinoma, Clear Cell	D018262	sirolimus	Phase 1	2012	2014	NCT02142803;NCT01625351
Adenocarcinoma, Clear Cell	D018262	sirolimus	Phase 2	2004	2009	NCT00977574;NCT00072176
Carcinoma, Adenosquamous	D018196	sirolimus	Phase 2	2004	2009	NCT00977574;NCT00072176;NCT01026792
Neuroblastoma	D009447	sirolimus	Phase 1	2009	2012	NCT01331135;NCT01625351;NCT01204450
Neuroblastoma	D009447	sirolimus	Phase 2	2008	2017	NCT01467986;NCT01767194;NCT00808899;NCT03213678;NCT03155620
Adenocarcinoma of Lung	D000077192	sirolimus	Phase 2	2012	2012	NCT01737502
Small Cell Lung Carcinoma	D055752	sirolimus	Phase 1	2010	2010	NCT01155258
Small Cell Lung Carcinoma	D055752	sirolimus	Phase 2	2002	2012	NCT01737502;NCT00028028
Carcinoma in Situ	D002278	sirolimus	Phase 1	2017	2017	NCT03333694
Carcinoma in Situ	D002278	sirolimus	Phase 2	2010	2010	NCT01259063
Angiofibroma	D018322	sirolimus	Phase 1	2009	2013	NCT01853423;NCT01031901
Angiofibroma	D018322	sirolimus	Phase 2	2012	2017	NCT01526356;NCT03363763
Angiofibroma	D018322	sirolimus	Phase 3	2013	2019	NCT02634931;NCT02635789;NCT03826628;NCT03140449
Lymphoma, T-Cell	D016399	sirolimus	Phase 1	2011	2011	NCT01403415
Lymphoma, T-Cell	D016399	sirolimus	Phase 2	2009	2019	NCT03922724;NCT01075321;NCT01198665;NCT01843998;NCT01076543;NCT00918333;NCT01637090
Lymphoma, T-Cell, Peripheral	D016411	sirolimus	Phase 1	2011	2015	NCT01614197;NCT01403415
Lymphoma, T-Cell, Peripheral	D016411	sirolimus	Phase 2	2010	2019	NCT03922724;NCT01075321;NCT01198665
Hemangioma, Capillary	D018324	sirolimus	Phase 1	2008	2008	NCT00830466;NCT00800722
Nevus, Blue	D018329	sirolimus	Phase 4	2018	2018	NCT03767660
Gastrointestinal Stromal Tumors	D046152	sirolimus	Phase 2	2004	2004	NCT00087074
Gastrointestinal Stromal Tumors	D046152	sirolimus	Phase 3	2011	2011	NCT01265810
Adenomyoepithelioma	D055331	sirolimus	Phase 1	2012	2012	NCT01625351
Adenomyoepithelioma	D055331	sirolimus	Phase 2	2004	2004	NCT00072176
Nasopharyngeal Carcinoma	D000077274	sirolimus	Phase 1	2008	2010	NCT01341834;NCT01637194
Thoracic Neoplasms	D013899	sirolimus	Phase 1	2012	2012	NCT01552434
Respiratory Tract Neoplasms	D012142	sirolimus	Phase 1	2012	2012	NCT01552434
Soft Tissue Neoplasms	D012983	sirolimus	Phase 1	2012	2012	NCT01552434
Pharyngeal Neoplasms	D010610	sirolimus	Phase 1	2012	2012	NCT01552434
Endocrine Gland Neoplasms	D004701	sirolimus	Phase 1	2012	2012	NCT01552434
Endocrine Gland Neoplasms	D004701	sirolimus	Phase 2	2010	2019	NCT01149434;NCT03950609;NCT02294006
Urologic Neoplasms	D014571	sirolimus	Phase 1	2012	2012	NCT01552434
Genital Neoplasms, Male	D005834	sirolimus	Phase 1	2012	2012	NCT01552434
Neoplasms, Mesothelial	D018301	sirolimus	Phase 1	2012	2012	NCT01552434
Medulloblastoma	D008527	sirolimus	Phase 1	2011	2018	NCT01331135;NCT03387020
Medulloblastoma	D008527	sirolimus	Phase 2	2017	2017	NCT03213678;NCT03155620
Wilms Tumor	D009396	sirolimus	Phase 1	2011	2012	NCT01331135;NCT01625351
Wilms Tumor	D009396	sirolimus	Phase 2	2017	2017	NCT03213678;NCT03155620
Retinoblastoma	D012175	sirolimus	Phase 1	2011	2011	NCT01331135
Rhabdoid Tumor	D018335	sirolimus	Phase 1	2011	2018	NCT01331135;NCT03387020;NCT01625351
Rhabdoid Tumor	D018335	sirolimus	Phase 2	2017	2017	NCT03213678;NCT03155620
Sarcoma, Clear Cell	D018227	sirolimus	Phase 1	2011	2011	NCT01331135
Leukemia, Prolymphocytic	D015463	sirolimus	Phase 2	2010	2017	NCT01251575;NCT03246906;NCT02991898;NCT02722668
Leukemia, Prolymphocytic	D015463	sirolimus	Phase 3	2010	2010	NCT01231412
Leukemia, Prolymphocytic, T-Cell	D015461	sirolimus	Phase 2	2010	2010	NCT01251575
Mycosis Fungoides	D009182	sirolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Sezary Syndrome	D012751	sirolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Leukemia, T-Cell	D015458	sirolimus	Phase 1	2010	2010	NCT01184885
Leukemia, T-Cell	D015458	sirolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Leukemia-Lymphoma, Adult T-Cell	D015459	sirolimus	Phase 1	2010	2010	NCT01184885
Leukemia-Lymphoma, Adult T-Cell	D015459	sirolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Lymphoma, Extranodal NK-T-Cell	D054391	sirolimus	Phase 2	2009	2011	NCT01075321;NCT00918333
Neoplasms, Second Primary	D016609	sirolimus	Phase 2	2014	2014	NCT02142036
Birt-Hogg-Dube Syndrome	D058249	sirolimus	Phase 3	2010	2010	NCT00928798
Nasopharyngeal Neoplasms	D009303	sirolimus	Phase 2	2017	2021	NCT04094675;NCT03095703;NCT04230499
Hamartoma	D006222	sirolimus	Phase 2	2008	2019	NCT04094675;NCT00971789
Hamartoma Syndrome, Multiple	D006223	sirolimus	Phase 2	2008	2019	NCT04094675;NCT00971789
Cystadenocarcinoma, Mucinous	D018282	sirolimus	Phase 1	2014	2014	NCT02142803
Carcinoma, Verrucous	D018289	sirolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Carcinoma, Verrucous	D018289	sirolimus	Phase 2	2010	2010	NCT01256385
Salivary Gland Neoplasms	D012468	sirolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Salivary Gland Neoplasms	D012468	sirolimus	Phase 2	2010	2010	NCT01256385
Kasabach-Merritt Syndrome	D059885	sirolimus	Phase 1	2020	2020	NCT04409691
Kasabach-Merritt Syndrome	D059885	sirolimus	Phase 2	2017	2017	NCT02110069;NCT03188068
Kasabach-Merritt Syndrome	D059885	sirolimus	Phase 3	2021	2021	NCT04775173
Kasabach-Merritt Syndrome	D059885	sirolimus	Phase 4	2019	2020	NCT04077515;NCT04448873
Sarcoma, Myeloid	D023981	sirolimus	Phase 2	2016	2016	NCT02790515
Leukemia, Biphenotypic, Acute	D015456	sirolimus	Phase 2	2016	2019	NCT02793544;NCT03970096
Perivascular Epithelioid Cell Neoplasms	D054973	sirolimus	Phase 2	2012	2015	NCT01690871;NCT02494570
Ganglioneuroblastoma	D018305	sirolimus	Phase 2	2013	2013	NCT01767194
Nerve Sheath Neoplasms	D018317	sirolimus	Phase 2	2012	2019	NCT01661283;NCT01614795;NCT02584647;NCT02008877;NCT03433183
Neurofibrosarcoma	D018319	sirolimus	Phase 2	2012	2019	NCT01661283;NCT01614795;NCT02584647;NCT02008877;NCT03433183
Liposarcoma	D008080	sirolimus	Phase 2	2004	2017	NCT02821507;NCT01614795;NCT00093080;NCT03114527
Chondrosarcoma	D002813	sirolimus	Phase 2	2014	2014	NCT02821507
Liposarcoma, Myxoid	D018208	sirolimus	Phase 2	2014	2014	NCT02821507
Chondrosarcoma, Mesenchymal	D018211	sirolimus	Phase 2	2014	2014	NCT02821507
Mesothelioma	D008654	sirolimus	Phase 1	2015	2018	NCT03436732;NCT02372227
Mesothelioma	D008654	sirolimus	Phase 2	2008	2008	NCT00770120
Neuroectodermal Tumors	D017599	sirolimus	Phase 2	2012	2017	NCT01614795;NCT03213678;NCT03155620;NCT01946529
Neuroectodermal Tumors, Primitive	D018242	sirolimus	Phase 2	2012	2017	NCT01614795;NCT03213678;NCT03155620;NCT01946529
Leiomyosarcoma	D007890	sirolimus	Phase 2	2004	2017	NCT01614795;NCT00093080;NCT03114527
Neuroectodermal Tumors, Primitive, Peripheral	D018241	sirolimus	Phase 2	2012	2020	NCT01614795;NCT03213678;NCT03778996;NCT03155620;NCT01946529
Hemangiosarcoma	D006394	sirolimus	Phase 2	2012	2012	NCT01614795
Fibrosarcoma	D005354	sirolimus	Phase 2	2012	2012	NCT01614795
Sarcoma, Alveolar Soft Part	D018234	sirolimus	Phase 2	2012	2012	NCT01614795
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	D054218	sirolimus	Phase 1	2011	2011	NCT01403415
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	D054218	sirolimus	Phase 2	2009	2009	NCT00792948
Leukemia, Plasma Cell	D007952	sirolimus	Phase 1	2011	2011	NCT01163357
Leukemia, Plasma Cell	D007952	sirolimus	Phase 2	2017	2017	NCT02722668
Digestive System Neoplasms	D004067	sirolimus	Phase 1	2012	2012	NCT01625351
Digestive System Neoplasms	D004067	sirolimus	Phase 2	2011	2011	NCT01567488
Lymphoma, T-Cell, Cutaneous	D016410	sirolimus	Phase 2	2009	2014	NCT01198665;NCT01843998;NCT00918333;NCT01637090
Adenoma, Islet Cell	D007516	sirolimus	Phase 2	2010	2013	NCT01229943;NCT01658436;NCT02305810
Vipoma	D003969	sirolimus	Phase 2	2010	2010	NCT01229943
Carcinoma, Acinar Cell	D018267	sirolimus	Phase 1	2009	2012	NCT01537107;NCT00981162
Multiple Endocrine Neoplasia	D009377	sirolimus	Phase 2	2019	2019	NCT03950609
Multiple Endocrine Neoplasia Type 1	D018761	sirolimus	Phase 2	2019	2019	NCT03950609
Laryngeal Neoplasms	D007822	sirolimus	Phase 1	2008	2011	NCT01637194;NCT01332279
Oropharyngeal Neoplasms	D009959	sirolimus	Phase 1	2008	2008	NCT01637194
Carcinoma, Basal Cell	D002280	sirolimus	Phase 1	2008	2008	NCT01637194
Papilloma	D010212	sirolimus	Phase 1	2008	2008	NCT01637194
Paranasal Sinus Neoplasms	D010255	sirolimus	Phase 1	2008	2008	NCT01637194
Carcinoma, Adenoid Cystic	D003528	sirolimus	Phase 1	2008	2010	NCT01637194;NCT01218555
Carcinoma, Mucoepidermoid	D018277	sirolimus	Phase 1	2008	2008	NCT01637194
Esthesioneuroblastoma, Olfactory	D018304	sirolimus	Phase 1	2008	2008	NCT01637194
Papilloma, Inverted	D018308	sirolimus	Phase 1	2008	2008	NCT01637194
Neoplasms, Germ Cell and Embryonal	D009373	sirolimus	Phase 1	2007	2010	NCT01155258;NCT00408655
Neoplasms, Germ Cell and Embryonal	D009373	sirolimus	Phase 2	2014	2017	NCT03213678;NCT01962896;NCT03155620
Fibromatosis, Aggressive	D018222	sirolimus	Phase 2	2014	2014	NCT01265030
Fibroma	D005350	sirolimus	Phase 2	2014	2014	NCT01265030
Breast Neoplasms, Male	D018567	sirolimus	Phase 1	2010	2010	NCT01155258
Breast Neoplasms, Male	D018567	sirolimus	Phase 2	2008	2013	NCT01783756;NCT00699491
Gallbladder Neoplasms	D005706	sirolimus	Phase 1	2009	2009	NCT00949949
Adenomatous Polyposis Coli	D011125	sirolimus	Phase 2	2017	2021	NCT03095703;NCT04230499
Meningioma	D008579	sirolimus	Phase 1	2019	2019	NCT03631953
Rectal Neoplasms	D012004	sirolimus	Phase 2	2006	2006	NCT00409994
Germinoma	D018237	sirolimus	Phase 1	2007	2010	NCT01155258;NCT00408655
Carotid Body Tumor	D002345	sirolimus	Phase 1	2010	2010	NCT01155258
Neoplasm, Residual	D018365	sirolimus	Phase 2	2017	2017	NCT03192397
Precancerous Conditions	D011230	sirolimus	Phase 2	2001	2007	NCT00544115;NCT00589563
Histiocytic Sarcoma	D054747	sirolimus	Phase 2	2017	2017	NCT03155620
Leiomyoma	D007889	sirolimus	Phase 4	2018	2018	NCT03500367
Myofibroma	D047708	sirolimus	Phase 4	2018	2018	NCT03500367
Leiomyomatosis	D018231	sirolimus	Phase 4	2018	2018	NCT03500367
Urethral Neoplasms	D014523	sirolimus	Phase 2	2008	2008	NCT01090466
Ureteral Neoplasms	D014516	sirolimus	Phase 2	2008	2008	NCT01090466
Desmoplastic Small Round Cell Tumor	D058405	sirolimus	Phase 2	2013	2013	NCT01946529
Brain Stem Neoplasms	D020295	sirolimus	Phase 1	2010	2010	NCT01182883
Thymoma	D013945	sirolimus	Phase 2	2011	2011	NCT02049047
Thymus Neoplasms	D013953	sirolimus	Phase 2	2011	2011	NCT02049047
Carcinoma	D002277	sorafenib	Phase 1	2006	2020	NCT00384969;NCT01337492;NCT00956436;NCT01131689;NCT02101593;NCT02143401;NCT01618253;NCT01441388;NCT00892658;NCT00844168;NCT02988440;NCT01498952;NCT00823290;NCT01383343;NCT02406521;NCT01008917;NCT02642913;NCT02035527;NCT00622479;NCT00846131;NCT01628640;NCT01801163;NCT01844947;NCT02358395;NCT00976170;NCT02989870;NCT00828594;NCT02323906;NCT03966209;NCT00478374;NCT01308723;NCT00712855;NCT01008566;NCT01042041;NCT02240433;NCT01348503;NCT00960167;NCT01666756;NCT02354898;NCT00635791;NCT01897038;NCT03878524
Carcinoma	D002277	sorafenib	Phase 2	2002	2021	NCT01900002;NCT01556815;NCT02290977;NCT01964235;NCT03211416;NCT03163992;NCT00480389;NCT01126645;NCT00752063;NCT01387555;NCT03520257;NCT01171482;NCT00768937;NCT00044512;NCT03008512;NCT01840592;NCT00703365;NCT02702414;NCT00882869;NCT02452853;NCT01798446;NCT00126594;NCT00557830;NCT02425605;NCT01100242;NCT00110344;NCT01444807;NCT03582618;NCT00496301;NCT02279719;NCT00854620;NCT02981498;NCT03511703;NCT01731158;NCT01658878;NCT04170556;NCT00609934;NCT01342627;NCT00906373;NCT00678288;NCT01217034;NCT00923130;NCT02122003;NCT01171651;NCT01649180;NCT01205828;NCT00389285;NCT04327700;NCT00939627;NCT00618384;NCT01306058;NCT03439891;NCT00448721;NCT03535259;NCT01272557;NCT04316182;NCT02311205;NCT00848640;NCT01041482;NCT03722498;NCT02788201;NCT03899428;NCT01372813;NCT01616186;NCT01170104;NCT00238212;NCT04317248;NCT01953406;NCT04193696;NCT00862082;NCT00098618;NCT00112905;NCT01502410;NCT00943449;NCT00919009;NCT04599777;NCT00712790;NCT00609401;NCT01271504;NCT02406508;NCT03316872;NCT02114658;NCT01687673;NCT01777594;NCT01752933;NCT01567930;NCT04135690;NCT00576056;NCT02942329;NCT04479527;NCT01180959;NCT03586973;NCT03645980;NCT01624285;NCT00101413;NCT01204177;NCT00461851;NCT01258608;NCT00634751;NCT02129322;NCT02330783;NCT03812783;NCT02716766;NCT01754987;NCT03914300;NCT03578874;NCT00464919;NCT02115373;NCT00687596;NCT00126659;NCT00448149;NCT00786110;NCT01264705;NCT00093626;NCT03812770;NCT03648073;NCT00494182;NCT01605734;NCT02089763;NCT01101906;NCT00445042;NCT02400788;NCT01381211;NCT00844688;NCT01480817;NCT03780634;NCT02939807;NCT01375569;NCT00619541;NCT00490685;NCT04611165;NCT01357486;NCT03009461;NCT00844883;NCT02178358;NCT01246986;NCT04518852;NCT00096200;NCT01545804;NCT00532025;NCT01736878;NCT00121251;NCT02772029;NCT01762150;NCT01911000;NCT02575339;NCT00108953;NCT04710641;NCT00855218;NCT01582009;NCT00661375;NCT00126503;NCT01032850;NCT00467025;NCT01033240;NCT01004003;NCT01507064;NCT02187302;NCT02672488;NCT00618982;NCT01988493;NCT00808145;NCT00782275;NCT01093222;NCT01935700;NCT03499626;NCT01897610;NCT01911273;NCT03606590;NCT02560779;NCT00990860;NCT03563170;NCT00378703;NCT02024087;NCT00791544;NCT01664182;NCT01915602;NCT01232296;NCT00971126;NCT01029418;NCT00586495;NCT03516071;NCT00390325;NCT00987935;NCT01934829;NCT03732547;NCT03389126;NCT00872014;NCT04000737;NCT02227914;NCT00117637;NCT00999843;NCT01335074;NCT03318562;NCT00096512;NCT04162158
Carcinoma	D002277	sorafenib	Phase 3	2004	2021	NCT01030783;NCT00474786;NCT04709380;NCT01035229;NCT01901692;NCT01903694;NCT01223027;NCT02436902;NCT02460991;NCT03164382;NCT02867280;NCT00492986;NCT00586105;NCT04720716;NCT00494299;NCT01613846;NCT03434379;NCT01076010;NCT01906216;NCT01829035;NCT01655693;NCT01015833;NCT00901901;NCT00699374;NCT02627963;NCT03298451;NCT04465734;NCT04560894;NCT00858871;NCT00732914;NCT04344158;NCT00606866;NCT01747642;NCT01481870;NCT01761266;NCT01009593;NCT01140347;NCT01833299;NCT01932385;NCT04167293;NCT01405573;NCT00478114;NCT03794440;NCT01108705;NCT03755791;NCT01214343;NCT01387503;NCT01135056;NCT01887717;NCT00111020;NCT01908426;NCT04229355;NCT00692770;NCT01265810;NCT04387695;NCT04667351;NCT00410124;NCT00105443;NCT01774344;NCT01482442;NCT01730937;NCT00492752;NCT03468231;NCT04103398;NCT02856126;NCT00326898;NCT04723004;NCT04687163;NCT02576509;NCT04143191;NCT02435433;NCT02562755;NCT01004978;NCT03533582;NCT03412773;NCT04039607;NCT03775395;NCT03236649;NCT04770896
Carcinoma	D002277	sorafenib	Phase 4	2006	2019	NCT02056587;NCT04127396;NCT00352859;NCT03212625;NCT01203787;NCT03963206;NCT02504983;NCT03518502;NCT01409499;NCT01098760;NCT02733809;NCT02338570
Carcinoma, Hepatocellular	D006528	sorafenib	Phase 1	2007	2019	NCT01337492;NCT00956436;NCT03965546;NCT01131689;NCT02101593;NCT02143401;NCT01618253;NCT01441388;NCT00892658;NCT00844168;NCT02988440;NCT01498952;NCT00823290;NCT02423239;NCT01008917;NCT02642913;NCT02716012;NCT00997022;NCT00846131;NCT01628640;NCT01801163;NCT02358395;NCT00976170;NCT02989870;NCT00828594;NCT02323906;NCT03966209;NCT00478374;NCT02288507;NCT01308723;NCT00712855;NCT02292173;NCT01008566;NCT02069145;NCT01042041;NCT02240433;NCT01348503;NCT00960167;NCT01666756;NCT02354898;NCT01897038
Carcinoma, Hepatocellular	D006528	sorafenib	Phase 2	2002	2021	NCT01900002;NCT01556815;NCT02290977;NCT01964235;NCT02426450;NCT03211416;NCT03163992;NCT01126645;NCT04476329;NCT00752063;NCT01387555;NCT03520257;NCT01171482;NCT00768937;NCT00044512;NCT03008512;NCT01840592;NCT00703365;NCT02702414;NCT00882869;NCT02452853;NCT02425605;NCT03582618;NCT02279719;NCT02981498;NCT03511703;NCT01658878;NCT04170556;NCT00906373;NCT01217034;NCT01171651;NCT01205828;NCT04327700;NCT00618384;NCT01306058;NCT01539018;NCT03439891;NCT03535259;NCT01272557;NCT04316182;NCT02311205;NCT03037437;NCT03722498;NCT03899428;NCT01170104;NCT01418729;NCT04317248;NCT01953406;NCT04193696;NCT00862082;NCT01502410;NCT00943449;NCT00919009;NCT04599777;NCT00712790;NCT01271504;NCT02406508;NCT03316872;NCT01687673;NCT01777594;NCT01752933;NCT01567930;NCT04135690;NCT00576056;NCT02942329;NCT04479527;NCT01180959;NCT04588051;NCT03586973;NCT03645980;NCT01624285;NCT01265576;NCT01204177;NCT01258608;NCT00813293;NCT00933816;NCT02129322;NCT03812783;NCT01334710;NCT02716766;NCT01754987;NCT03971201;NCT03578874;NCT00464919;NCT02115373;NCT00687596;NCT01264705;NCT03812770;NCT03648073;NCT02908165;NCT01605734;NCT02089763;NCT01101906;NCT02400788;NCT01381211;NCT00844688;NCT01480817;NCT03780634;NCT02939807;NCT00717756;NCT01375569;NCT00619541;NCT00490685;NCT04611165;NCT01357486;NCT03009461;NCT00844883;NCT02178358;NCT01246986;NCT04518852;NCT01545804;NCT02772029;NCT01911000;NCT02575339;NCT00108953;NCT04710641;NCT00855218;NCT03630640;NCT01032850;NCT01033240;NCT01004003;NCT01507064;NCT02672488;NCT01988493;NCT00808145;NCT01935700;NCT04069949;NCT03499626;NCT01897610;NCT01775501;NCT01911273;NCT03606590;NCT02560779;NCT00990860;NCT03563170;NCT02024087;NCT00791544;NCT01915602;NCT01232296;NCT00971126;NCT01029418;NCT03516071;NCT00987935;NCT01934829;NCT03732547;NCT03389126;NCT03275376;NCT00872014;NCT04000737;NCT02227914;NCT01259193;NCT00999843;NCT01335074;NCT03318562;NCT04162158
Carcinoma, Hepatocellular	D006528	sorafenib	Phase 3	2005	2021	NCT04709380;NCT01035229;NCT01901692;NCT02774187;NCT01903694;NCT02436902;NCT02460991;NCT03164382;NCT02867280;NCT04720716;NCT02029157;NCT02645981;NCT00494299;NCT03434379;NCT01906216;NCT01829035;NCT01655693;NCT01015833;NCT00901901;NCT00699374;NCT02971696;NCT03017326;NCT03298451;NCT04465734;NCT04560894;NCT00858871;NCT04344158;NCT01747642;NCT01761266;NCT01009593;NCT01140347;NCT01833299;NCT01932385;NCT04167293;NCT01405573;NCT03794440;NCT01108705;NCT02738697;NCT03755791;NCT01214343;NCT01387503;NCT01135056;NCT01887717;NCT01908426;NCT04229355;NCT00692770;NCT01265810;NCT04387695;NCT04667351;NCT00105443;NCT01774344;NCT01482442;NCT01730937;NCT00492752;NCT03468231;NCT04103398;NCT01245582;NCT02856126;NCT04723004;NCT04687163;NCT02576509;NCT04143191;NCT02435433;NCT02562755;NCT02220088;NCT01004978;NCT03533582;NCT03412773;NCT04039607;NCT03775395;NCT03236649;NCT04770896;NCT02794337
Carcinoma, Hepatocellular	D006528	sorafenib	Phase 4	2010	2019	NCT01849588;NCT02961998;NCT04127396;NCT03212625;NCT01203787;NCT03963206;NCT01806740;NCT02504983;NCT03518502;NCT01409499;NCT01098760;NCT02733809
Liver Neoplasms	D008113	sorafenib	Phase 1	2008	2019	NCT03965546;NCT01497444;NCT01011010;NCT01618253;NCT00844168;NCT00767468;NCT02716012;NCT00997022;NCT00873002;NCT01075113;NCT02288507;NCT02292173;NCT01008566;NCT02069145;NCT01042041;NCT01666756
Liver Neoplasms	D008113	sorafenib	Phase 2	2008	2020	NCT01556815;NCT01387555;NCT00875615;NCT01217034;NCT00881751;NCT01306058;NCT03037437;NCT01502410;NCT01005199;NCT01180959;NCT01624285;NCT00813293;NCT01334710;NCT01754987;NCT01009801;NCT03971201;NCT01264705;NCT00717756;NCT01375569;NCT00949182;NCT04518852;NCT00892424;NCT00867321;NCT01033240;NCT01182272;NCT04069949;NCT01775501;NCT02632864;NCT00941967
Liver Neoplasms	D008113	sorafenib	Phase 3	2009	2019	NCT03164382;NCT01075555;NCT01324076;NCT01009593;NCT01214343;NCT04163237;NCT01730937;NCT00825955;NCT01245582;NCT03533582;NCT02794337
Liver Neoplasms	D008113	sorafenib	Phase 4	2013	2013	NCT01849588
Neoplasms by Site	D009371	sorafenib	Phase 2	2012	2012	NCT01556815
Neoplasms by Site	D009371	sorafenib	Phase 3	2010	2010	NCT01009593
Digestive System Neoplasms	D004067	sorafenib	Phase 1	2012	2012	NCT01640665
Digestive System Neoplasms	D004067	sorafenib	Phase 2	2012	2020	NCT01556815;NCT04518852
Digestive System Neoplasms	D004067	sorafenib	Phase 3	2010	2010	NCT01009593
Gastrointestinal Neoplasms	D005770	sorafenib	Phase 1	2012	2012	NCT01640665
Gastrointestinal Neoplasms	D005770	sorafenib	Phase 2	2005	2020	NCT01556815;NCT00131911;NCT04518852
Gastrointestinal Neoplasms	D005770	sorafenib	Phase 3	2010	2010	NCT01009593
Neoplasms by Histologic Type	D009370	sorafenib	Phase 2	2012	2012	NCT01556815
Neoplasms by Histologic Type	D009370	sorafenib	Phase 3	2010	2010	NCT01009593
Neoplasms, Glandular and Epithelial	D009375	sorafenib	Phase 2	2012	2012	NCT01556815
Neoplasms, Glandular and Epithelial	D009375	sorafenib	Phase 3	2010	2010	NCT01009593
Carcinoma, Renal Cell	D002292	sorafenib	Phase 1	2006	2015	NCT00384969;NCT01497444;NCT01441388;NCT00589550;NCT02406521;NCT00622479;NCT00715182;NCT01005797;NCT00418496;NCT00405366;NCT00635791;NCT00398814
Carcinoma, Renal Cell	D002292	sorafenib	Phase 2	2002	2016	NCT00282048;NCT00480389;NCT01798446;NCT00126594;NCT00557830;NCT01100242;NCT00110344;NCT01444807;NCT00496301;NCT00854620;NCT02560012;NCT00866320;NCT01731158;NCT00101114;NCT00609934;NCT01342627;NCT00678288;NCT00923130;NCT02122003;NCT01649180;NCT00389285;NCT00448721;NCT00848640;NCT01041482;NCT01372813;NCT01616186;NCT01189370;NCT01246817;NCT00098618;NCT00609401;NCT00392821;NCT01538238;NCT02330783;NCT00126659;NCT00448149;NCT00496756;NCT00445042;NCT00079612;NCT00301847;NCT00121251;NCT01762150;NCT01582009;NCT00661375;NCT00126503;NCT00467025;NCT00672178;NCT02187302;NCT00618982;NCT00782275;NCT00378703;NCT01664182;NCT00586495;NCT00117637
Carcinoma, Renal Cell	D002292	sorafenib	Phase 3	2003	2016	NCT01030783;NCT00474786;NCT01223027;NCT00492986;NCT00586105;NCT01613846;NCT01076010;NCT02627963;NCT00732914;NCT00606866;NCT00492258;NCT01481870;NCT00678392;NCT00478114;NCT00111020;NCT01265810;NCT00073307;NCT00410124;NCT00326898;NCT00920816
Carcinoma, Renal Cell	D002292	sorafenib	Phase 4	2006	2015	NCT02056587;NCT00352859;NCT02338570
Leukemia	D007938	sorafenib	Phase 1	2005	2020	NCT00303797;NCT00908167;NCT00943943;NCT00217646;NCT01861314;NCT00665990;NCT00875745;NCT00131989;NCT01159301;NCT03132454;NCT02779283;NCT03878524
Leukemia	D007938	sorafenib	Phase 2	2004	2021	NCT00303966;NCT01534260;NCT02829840;NCT00542971;NCT01253070;NCT02135874;NCT00661180;NCT02196857;NCT03164057;NCT04752527;NCT00516828;NCT02530476;NCT01510756;NCT02728050;NCT01620216;NCT03247088;NCT00893373;NCT01445080;NCT04326439;NCT01254890
Leukemia	D007938	sorafenib	Phase 3	2011	2020	NCT01371981;NCT04674345;NCT02665065;NCT03642236;NCT02474290
Leukemia, Lymphoid	D007945	sorafenib	Phase 1	2005	2020	NCT00303797;NCT00131989;NCT03132454;NCT02779283;NCT03878524
Leukemia, Lymphoid	D007945	sorafenib	Phase 2	2005	2012	NCT00303966;NCT01510756;NCT01620216
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	sorafenib	Phase 1	2004	2020	NCT00303797;NCT00118170;NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	sorafenib	Phase 2	2005	2011	NCT00303966;NCT01510756
Lung Neoplasms	D008175	sorafenib	Phase 1	2006	2009	NCT00533585;NCT00466232;NCT00870532;NCT00954278;NCT01005797;NCT01069328;NCT00543335;NCT00635791
Lung Neoplasms	D008175	sorafenib	Phase 2	2004	2011	NCT00098254;NCT01248247;NCT00801801;NCT01159327;NCT00801385;NCT00647426;NCT00754923;NCT00454194;NCT00098540;NCT00101413;NCT00182689;NCT00600015;NCT00417248;NCT00547443;NCT00609804;NCT00726986;NCT00532025;NCT00411671;NCT00722969;NCT00922584;NCT00064350;NCT00107432
Lung Neoplasms	D008175	sorafenib	Phase 3	2006	2009	NCT00300885;NCT00863746;NCT00449033
Carcinoma, Non-Small-Cell Lung	D002289	sorafenib	Phase 1	2006	2009	NCT00533585;NCT00870532;NCT00954278;NCT00933777;NCT01005797;NCT01069328;NCT00543335;NCT00635791
Carcinoma, Non-Small-Cell Lung	D002289	sorafenib	Phase 2	2004	2011	NCT00098254;NCT01248247;NCT00801801;NCT00801385;NCT00647426;NCT00754923;NCT00454194;NCT00098540;NCT00101413;NCT00473486;NCT00600015;NCT00417248;NCT00547443;NCT00609804;NCT00532025;NCT00722969;NCT00922584;NCT00064350
Carcinoma, Non-Small-Cell Lung	D002289	sorafenib	Phase 3	2006	2009	NCT00300885;NCT00558636;NCT00863746;NCT00449033
Carcinoma, Transitional Cell	D002295	sorafenib	Phase 1	2012	2012	NCT01844947
Carcinoma, Transitional Cell	D002295	sorafenib	Phase 2	2005	2017	NCT00714948;NCT02788201;NCT00112905;NCT00112671
Osteosarcoma	D012516	sorafenib	Phase 1	2011	2011	NCT01518413
Osteosarcoma	D012516	sorafenib	Phase 2	2006	2018	NCT00889057;NCT01804374;NCT03359018;NCT00330421;NCT02048371
Osteosarcoma	D012516	sorafenib	Phase 3	2016	2016	NCT02711007
Neoplasms, Squamous Cell	D018307	sorafenib	Phase 2	2007	2008	NCT00815295;NCT00494182
Carcinoma, Squamous Cell	D002294	sorafenib	Phase 1	2014	2014	NCT02035527
Carcinoma, Squamous Cell	D002294	sorafenib	Phase 2	2004	2009	NCT00815295;NCT00939627;NCT00494182;NCT00096512
Breast Neoplasms	D001943	sorafenib	Phase 1	2010	2020	NCT01498458;NCT01724606;NCT03878524
Breast Neoplasms	D001943	sorafenib	Phase 2	2004	2017	NCT00632541;NCT00828074;NCT01320111;NCT00548899;NCT00096434;NCT00634634;NCT00499525;NCT00954135;NCT00607438;NCT00101400;NCT00493636;NCT02624700;NCT00825734;NCT00217399;NCT00622466;NCT01194869;NCT00525161;NCT00722072;NCT00764972;NCT03318562;NCT00573755
Breast Neoplasms	D001943	sorafenib	Phase 3	2011	2011	NCT01234337
Gastrointestinal Stromal Tumors	D046152	sorafenib	Phase 2	2005	2009	NCT01091207;NCT00265798
Gastrointestinal Stromal Tumors	D046152	sorafenib	Phase 3	2011	2011	NCT01265810
Thyroid Neoplasms	D013964	sorafenib	Phase 2	2004	2019	NCT03565536;NCT00654238;NCT00126568;NCT01263951;NCT01502410;NCT01141309;NCT02114658;NCT03914300;NCT02143726;NCT00095693;NCT03630120;NCT02084732;NCT01025453;NCT01736878;NCT00887107;NCT00390325;NCT00936858
Thyroid Neoplasms	D013964	sorafenib	Phase 3	2009	2016	NCT03048877;NCT00984282
Thyroid Carcinoma, Anaplastic	D065646	sorafenib	Phase 2	2004	2018	NCT03565536;NCT00654238;NCT00126568;NCT00095693
Rectal Neoplasms	D012004	sorafenib	Phase 1	2005	2017	NCT01376453;NCT01383343;NCT00134069;NCT02910843
Rectal Neoplasms	D012004	sorafenib	Phase 2	2009	2009	NCT00869570;NCT00826540
Prostatic Neoplasms	D011471	sorafenib	Phase 1	2006	2020	NCT00424385;NCT00405210;NCT03878524
Prostatic Neoplasms	D011471	sorafenib	Phase 2	2004	2008	NCT00452387;NCT00589420;NCT00466752;NCT00090545;NCT00694291;NCT00619996;NCT00414388;NCT00924807;NCT00093457
Kidney Neoplasms	D007680	sorafenib	Phase 1	2006	2012	NCT01497444;NCT00589550;NCT01005797;NCT00418496;NCT00405366;NCT00398814
Kidney Neoplasms	D007680	sorafenib	Phase 2	2005	2014	NCT00282048;NCT00854620;NCT00866320;NCT01372813;NCT00112905;NCT00392821;NCT03456401;NCT00496756;NCT00301847;NCT00498966;NCT00112671;NCT00782275
Kidney Neoplasms	D007680	sorafenib	Phase 3	2007	2009	NCT00492258;NCT00678392;NCT00920816
Neoplasm Metastasis	D009362	sorafenib	Phase 1	2005	2012	NCT00217646;NCT00639262;NCT01724606;NCT01276210
Neoplasm Metastasis	D009362	sorafenib	Phase 2	2002	2015	NCT00480389;NCT00657254;NCT02311205;NCT01953406;NCT00609401;NCT00892424;NCT01935700;NCT01703910
Neoplasm Metastasis	D009362	sorafenib	Phase 3	2016	2016	NCT02711007
Neoplasm Metastasis	D009362	sorafenib	Phase 4	2012	2012	NCT03518502
Multiple Myeloma	D009101	sorafenib	Phase 1	2004	2020	NCT00303797;NCT00687674;NCT00118170;NCT03878524
Multiple Myeloma	D009101	sorafenib	Phase 2	2006	2007	NCT00536575;NCT00474929;NCT00253578
Neoplasms, Plasma Cell	D054219	sorafenib	Phase 1	2004	2020	NCT00303797;NCT00687674;NCT00118170;NCT03878524
Neoplasms, Plasma Cell	D054219	sorafenib	Phase 2	2006	2007	NCT00536575;NCT00474929;NCT00253578
Plasmacytoma	D010954	sorafenib	Phase 1	2008	2008	NCT00687674
Plasmacytoma	D010954	sorafenib	Phase 2	2007	2007	NCT00474929
Sarcoma, Kaposi	D012514	sorafenib	Phase 1	2006	2006	NCT00287495
Sarcoma	D012509	sorafenib	Phase 1	2006	2011	NCT00287495;NCT01518413;NCT00822848;NCT01005797
Sarcoma	D012509	sorafenib	Phase 2	2005	2014	NCT00541840;NCT00245102;NCT00874874;NCT00217620;NCT01391962;NCT00406601;NCT00864032;NCT00880542;NCT00837148;NCT00330421;NCT02050919;NCT00238121;NCT01946529;NCT02048371
Leukemia, Myeloid	D007951	sorafenib	Phase 1	2005	2020	NCT00943943;NCT00217646;NCT01861314;NCT00875745;NCT00131989;NCT01159301;NCT03132454;NCT02779283;NCT03878524
Leukemia, Myeloid	D007951	sorafenib	Phase 2	2004	2021	NCT02638428;NCT01534260;NCT02829840;NCT00542971;NCT01253070;NCT00373373;NCT00661180;NCT02196857;NCT03164057;NCT04752527;NCT02530476;NCT02728050;NCT01620216;NCT03247088;NCT00893373;NCT01445080;NCT04326439
Leukemia, Myeloid	D007951	sorafenib	Phase 3	2011	2018	NCT01371981;NCT02665065;NCT03642236;NCT02474290
Ovarian Neoplasms	D010051	sorafenib	Phase 2	2006	2010	NCT00526799;NCT00436215;NCT00390611;NCT00791778;NCT01047891
Carcinoma, Ovarian Epithelial	D000077216	sorafenib	Phase 2	2004	2010	NCT00526799;NCT00522301;NCT00390611;NCT00096395;NCT01047891
Neuroendocrine Tumors	D018358	sorafenib	Phase 1	2009	2009	NCT00942682
Neuroendocrine Tumors	D018358	sorafenib	Phase 2	2005	2008	NCT00605566;NCT00131911
Carcinoid Tumor	D002276	sorafenib	Phase 1	2009	2009	NCT00942682
Carcinoid Tumor	D002276	sorafenib	Phase 2	2005	2005	NCT00131911
Rhabdomyosarcoma	D012208	sorafenib	Phase 1	2011	2011	NCT01518413
Rhabdomyosarcoma	D012208	sorafenib	Phase 2	2012	2014	NCT01871766;NCT01502410;NCT02050919;NCT02048371
Leukemia, Myeloid, Acute	D015470	sorafenib	Phase 1	2005	2020	NCT00908167;NCT00943943;NCT00217646;NCT01861314;NCT02412475;NCT00875745;NCT00131989;NCT01159301;NCT03132454;NCT02779283;NCT03878524
Leukemia, Myeloid, Acute	D015470	sorafenib	Phase 2	2006	2021	NCT01534260;NCT02829840;NCT00542971;NCT01253070;NCT00373373;NCT02196857;NCT03164057;NCT04752527;NCT02530476;NCT02728050;NCT01620216;NCT03247088;NCT00893373;NCT04326439;NCT03622541
Leukemia, Myeloid, Acute	D015470	sorafenib	Phase 3	2011	2018	NCT01371981;NCT02665065;NCT03642236;NCT02474290
Hematologic Neoplasms	D019337	sorafenib	Phase 1	2009	2020	NCT00908167;NCT02270788;NCT03878524
Small Cell Lung Carcinoma	D055752	sorafenib	Phase 1	2007	2007	NCT00466232
Small Cell Lung Carcinoma	D055752	sorafenib	Phase 2	2005	2010	NCT01159327;NCT00182689;NCT00726986
Preleukemia	D011289	sorafenib	Phase 1	2005	2020	NCT00217646;NCT00875745;NCT03878524
Preleukemia	D011289	sorafenib	Phase 2	2006	2016	NCT02829840;NCT00510289;NCT02196857;NCT00516828;NCT02728050;NCT01254890
Sarcoma, Myeloid	D023981	sorafenib	Phase 3	2011	2011	NCT01371981
Head and Neck Neoplasms	D006258	sorafenib	Phase 1	2014	2014	NCT02035527
Head and Neck Neoplasms	D006258	sorafenib	Phase 2	2004	2014	NCT00199160;NCT00939627;NCT02558387;NCT00096512
Pancreatic Neoplasms	D010190	sorafenib	Phase 1	2006	2020	NCT02349867;NCT00375310;NCT00789763;NCT03878524;NCT00981162
Pancreatic Neoplasms	D010190	sorafenib	Phase 2	2004	2008	NCT00114244;NCT00837876;NCT00696696;NCT00634751;NCT00758381;NCT00095966
Pancreatic Neoplasms	D010190	sorafenib	Phase 3	2006	2006	NCT00541021
Melanoma	D008545	sorafenib	Phase 1	2006	2013	NCT00349206;NCT00565968;NCT01303341;NCT01078961;NCT01893099;NCT00418496
Melanoma	D008545	sorafenib	Phase 2	2005	2012	NCT00538005;NCT00794235;NCT00498836;NCT00492505;NCT00329641;NCT00623402;NCT00387751;NCT00119249;NCT01851408;NCT00602576;NCT00492297;NCT01377025;NCT00673361;NCT00110994;NCT00483301;NCT00811759;NCT00281957;NCT02517736
Melanoma	D008545	sorafenib	Phase 3	2005	2005	NCT00110019;NCT00111007
Colorectal Neoplasms	D015179	sorafenib	Phase 1	2008	2008	NCT00780169;NCT00779311
Colorectal Neoplasms	D015179	sorafenib	Phase 2	2006	2017	NCT00989469;NCT00889343;NCT01290926;NCT01471353;NCT00839111;NCT00865709;NCT01715441;NCT00326495;NCT01703910;NCT03251612;NCT01949194
Glioblastoma	D005909	sorafenib	Phase 1	2004	2011	NCT00734526;NCT01441388;NCT00884416;NCT00093613
Glioblastoma	D005909	sorafenib	Phase 2	2006	2016	NCT01817751;NCT00445588;NCT00329719;NCT00544817;NCT00597493;NCT01434602;NCT00621686;NCT02599090;NCT00335764
Gliosarcoma	D018316	sorafenib	Phase 1	2004	2009	NCT00734526;NCT00884416;NCT00093613
Gliosarcoma	D018316	sorafenib	Phase 2	2006	2008	NCT00445588;NCT00329719;NCT02599090;NCT00335764
Neuroblastoma	D009447	sorafenib	Phase 1	2011	2015	NCT01518413;NCT02298348
Neuroblastoma	D009447	sorafenib	Phase 2	2015	2015	NCT02559778
Sarcoma, Ewing	D012512	sorafenib	Phase 1	2011	2011	NCT01518413
Sarcoma, Ewing	D012512	sorafenib	Phase 2	2006	2013	NCT00330421;NCT01946529
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	sorafenib	Phase 1	2004	2020	NCT00217646;NCT00118170;NCT00131989;NCT03132454;NCT02779283;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	sorafenib	Phase 2	2006	2012	NCT01620216;NCT01445080
Blast Crisis	D001752	sorafenib	Phase 1	2005	2020	NCT00217646;NCT01159301;NCT03878524
Leukemia, Promyelocytic, Acute	D015473	sorafenib	Phase 1	2005	2009	NCT00217646;NCT00875745
Leukemia, Promyelocytic, Acute	D015473	sorafenib	Phase 2	2006	2011	NCT01253070;NCT01445080
Leukemia, Monocytic, Acute	D007948	sorafenib	Phase 1	2005	2010	NCT00217646;NCT00131989;NCT01159301
Leukemia, Myelomonocytic, Acute	D015479	sorafenib	Phase 1	2005	2010	NCT00217646;NCT00131989;NCT01159301
Leukemia, Megakaryoblastic, Acute	D007947	sorafenib	Phase 1	2005	2010	NCT00217646;NCT00131989;NCT01159301
Leukemia, Erythroblastic, Acute	D004915	sorafenib	Phase 1	2005	2010	NCT00217646;NCT00131989;NCT01159301
Leukemia, Basophilic, Acute	D015471	sorafenib	Phase 1	2005	2010	NCT00217646;NCT00131989;NCT01159301
Leukemia, Eosinophilic, Acute	D015472	sorafenib	Phase 1	2005	2010	NCT00217646;NCT00131989;NCT01159301
Carcinoma, Small Cell	D018288	sorafenib	Phase 1	2007	2007	NCT00466232
Mesothelioma	D008654	sorafenib	Phase 1	2008	2008	NCT00703638
Mesothelioma	D008654	sorafenib	Phase 2	2004	2008	NCT00794859;NCT00107432
Skin Neoplasms	D012878	sorafenib	Phase 1	2011	2011	NCT01303341
Skin Neoplasms	D012878	sorafenib	Phase 2	2006	2006	NCT00387751
Skin Neoplasms	D012878	sorafenib	Phase 3	2005	2005	NCT00110019
Fallopian Tube Neoplasms	D005185	sorafenib	Phase 2	2004	2007	NCT00436215;NCT00522301;NCT00096200
Peritoneal Neoplasms	D010534	sorafenib	Phase 2	2006	2006	NCT00436215
Glioma	D005910	sorafenib	Phase 1	2004	2009	NCT00884416;NCT00093613
Glioma	D005910	sorafenib	Phase 2	2011	2016	NCT01817751;NCT01434602;NCT01338857
Brain Neoplasms	D001932	sorafenib	Phase 1	2008	2012	NCT00639262;NCT01724606
Brain Neoplasms	D001932	sorafenib	Phase 2	2006	2016	NCT01817751;NCT00329719;NCT01434602
Urinary Bladder Neoplasms	D001749	sorafenib	Phase 1	2007	2007	NCT00544609
Urinary Bladder Neoplasms	D001749	sorafenib	Phase 2	2005	2017	NCT01222676;NCT02788201;NCT00112905;NCT00461851;NCT01215266;NCT00112671
Astrocytoma	D001254	sorafenib	Phase 1	2004	2009	NCT00884416;NCT00093613
Astrocytoma	D001254	sorafenib	Phase 2	2011	2011	NCT01338857
Oligodendroglioma	D009837	sorafenib	Phase 1	2004	2009	NCT00884416;NCT00093613
Leiomyosarcoma	D007890	sorafenib	Phase 2	2005	2009	NCT00245102;NCT00837148
Sarcoma, Synovial	D013584	sorafenib	Phase 2	2005	2009	NCT00245102;NCT00837148
Carcinosarcoma	D002296	sorafenib	Phase 2	2005	2005	NCT00245102;NCT00238121
Hemangiosarcoma	D006394	sorafenib	Phase 2	2005	2008	NCT00245102;NCT00874874
Histiocytoma	D051642	sorafenib	Phase 2	2005	2005	NCT00245102
Histiocytoma, Benign Fibrous	D018219	sorafenib	Phase 2	2005	2005	NCT00245102
Histiocytoma, Malignant Fibrous	D051677	sorafenib	Phase 2	2005	2005	NCT00245102
Neurofibrosarcoma	D018319	sorafenib	Phase 2	2005	2009	NCT00245102;NCT00837148
Adenocarcinoma	D000230	sorafenib	Phase 1	2006	2020	NCT00375310;NCT03878524;NCT00981162
Adenocarcinoma	D000230	sorafenib	Phase 2	2005	2012	NCT01262482;NCT00253370;NCT00238212;NCT00661830;NCT00430235;NCT01093222;NCT01703910;NCT00456716
Esophageal Neoplasms	D004938	sorafenib	Phase 2	2008	2015	NCT01262482;NCT01158287;NCT02544737
Laryngeal Neoplasms	D007822	sorafenib	Phase 1	2014	2014	NCT02035527
Laryngeal Neoplasms	D007822	sorafenib	Phase 2	2004	2009	NCT00939627;NCT00096512
Oropharyngeal Neoplasms	D009959	sorafenib	Phase 1	2014	2014	NCT02035527
Oropharyngeal Neoplasms	D009959	sorafenib	Phase 2	2004	2009	NCT00939627;NCT00096512
Carcinoma, Verrucous	D018289	sorafenib	Phase 1	2014	2014	NCT02035527
Carcinoma, Verrucous	D018289	sorafenib	Phase 2	2004	2009	NCT00939627;NCT00096512
Salivary Gland Neoplasms	D012468	sorafenib	Phase 1	2014	2014	NCT02035527
Salivary Gland Neoplasms	D012468	sorafenib	Phase 2	2004	2014	NCT00939627;NCT02857712;NCT01703455;NCT02558387;NCT00096512
Nasopharyngeal Carcinoma	D000077274	sorafenib	Phase 1	2014	2014	NCT02035527
Nasopharyngeal Carcinoma	D000077274	sorafenib	Phase 2	2004	2009	NCT00939627;NCT00747799;NCT00096512
Paranasal Sinus Neoplasms	D010255	sorafenib	Phase 1	2014	2014	NCT02035527
Paranasal Sinus Neoplasms	D010255	sorafenib	Phase 2	2004	2009	NCT00939627;NCT00096512
Neoplasms, Unknown Primary	D009382	sorafenib	Phase 1	2014	2014	NCT02035527
Neoplasms, Unknown Primary	D009382	sorafenib	Phase 2	2004	2009	NCT00939627;NCT00096512
Tongue Neoplasms	D014062	sorafenib	Phase 1	2014	2014	NCT02035527
Tongue Neoplasms	D014062	sorafenib	Phase 2	2004	2009	NCT00939627;NCT00096512
Stomach Neoplasms	D013274	sorafenib	Phase 1	2008	2008	NCT00663741
Stomach Neoplasms	D013274	sorafenib	Phase 2	2005	2016	NCT00253370;NCT00565370;NCT01187212;NCT02942329;NCT01158287;NCT00595985
Adenoma	D000236	sorafenib	Phase 2	2011	2011	NCT01306058
Neoplasms, Experimental	D009374	sorafenib	Phase 2	2011	2011	NCT01306058
Adenoma, Liver Cell	D018248	sorafenib	Phase 2	2011	2011	NCT01306058
Liver Neoplasms, Experimental	D008114	sorafenib	Phase 2	2011	2011	NCT01306058
Lymphoma	D008223	sorafenib	Phase 1	2004	2020	NCT01561833;NCT00118170;NCT00788099;NCT03878524
Lymphoma	D008223	sorafenib	Phase 2	2005	2007	NCT00474929;NCT00278382;NCT00131937
Neoplasms, Second Primary	D016609	sorafenib	Phase 1	2008	2008	NCT00639262
Neoplasms, Second Primary	D016609	sorafenib	Phase 2	2008	2015	NCT02311205;NCT01953406;NCT00892424
Leukemia, Biphenotypic, Acute	D015456	sorafenib	Phase 2	2014	2016	NCT02135874;NCT02728050
Breast Neoplasms, Male	D018567	sorafenib	Phase 2	2004	2004	NCT00096434
Colonic Neoplasms	D003110	sorafenib	Phase 1	2005	2011	NCT01383343;NCT00134069
Colonic Neoplasms	D003110	sorafenib	Phase 2	2009	2009	NCT00826540
Cholangiocarcinoma	D018281	sorafenib	Phase 2	2005	2016	NCT00238212;NCT03768375;NCT02836847;NCT00919061;NCT01093222;NCT00955721
Gallbladder Neoplasms	D005706	sorafenib	Phase 2	2005	2016	NCT00238212;NCT03768375;NCT02836847;NCT00919061;NCT01093222;NCT00955721
Bile Duct Neoplasms	D001650	sorafenib	Phase 2	2005	2010	NCT00238212;NCT00634751;NCT00919061;NCT01093222
Leukemia, Myelomonocytic, Chronic	D015477	sorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	sorafenib	Phase 2	2006	2012	NCT00510289;NCT01620216
Fibromatosis, Aggressive	D018222	sorafenib	Phase 3	2014	2014	NCT02066181
Fibroma	D005350	sorafenib	Phase 3	2014	2014	NCT02066181
Urethral Neoplasms	D014523	sorafenib	Phase 1	2012	2012	NCT01844947
Urethral Neoplasms	D014523	sorafenib	Phase 2	2005	2005	NCT00112905
Ureteral Neoplasms	D014516	sorafenib	Phase 1	2012	2012	NCT01844947
Ureteral Neoplasms	D014516	sorafenib	Phase 2	2005	2005	NCT00112905;NCT00112671
Wilms Tumor	D009396	sorafenib	Phase 2	2012	2012	NCT01502410
Rhabdomyosarcoma, Embryonal	D018233	sorafenib	Phase 2	2012	2012	NCT01502410
Thyroid Cancer, Papillary	D000077273	sorafenib	Phase 2	2004	2019	NCT01502410;NCT03914300;NCT00095693;NCT03630120;NCT00887107
Squamous Cell Carcinoma of Head and Neck	D000077195	sorafenib	Phase 1	2014	2014	NCT02035527
Squamous Cell Carcinoma of Head and Neck	D000077195	sorafenib	Phase 2	2007	2007	NCT00494182
Sarcoma, Alveolar Soft Part	D018234	sorafenib	Phase 2	2011	2011	NCT01391962
Lymphoma, Non-Hodgkin	D008228	sorafenib	Phase 1	2004	2020	NCT00118170;NCT03878524
Lymphoma, Non-Hodgkin	D008228	sorafenib	Phase 2	2005	2005	NCT00278382;NCT00131937
Lymphoma, Mantle-Cell	D020522	sorafenib	Phase 1	2004	2004	NCT00118170
Lymphoma, Mantle-Cell	D020522	sorafenib	Phase 2	2005	2005	NCT00278382
Lymphoma, Large B-Cell, Diffuse	D016403	sorafenib	Phase 1	2004	2004	NCT00118170
Lymphoma, Large B-Cell, Diffuse	D016403	sorafenib	Phase 2	2005	2005	NCT00278382;NCT00131937
Lymphoma, Large-Cell, Anaplastic	D017728	sorafenib	Phase 2	2005	2005	NCT00278382;NCT00131937
Hepatoblastoma	D018197	sorafenib	Phase 3	2017	2018	NCT03017326;NCT03533582
Triple Negative Breast Neoplasms	D064726	sorafenib	Phase 2	2016	2017	NCT02624700;NCT03318562
Uveal Neoplasms	D014604	sorafenib	Phase 2	2011	2011	NCT00329641;NCT01377025
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	sorafenib	Phase 1	2010	2020	NCT01159301;NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	sorafenib	Phase 2	2004	2006	NCT00661180;NCT01445080
Lymphoma, T-Cell	D016399	sorafenib	Phase 1	2009	2009	NCT01561833
Lymphoma, T-Cell	D016399	sorafenib	Phase 2	2005	2005	NCT00131937
Neurofibromatoses	D017253	sorafenib	Phase 1	2008	2008	NCT00727233
Neurofibromatoses	D017253	sorafenib	Phase 2	2011	2011	NCT01338857
Neurofibromatosis 1	D009456	sorafenib	Phase 1	2008	2008	NCT00727233
Neurofibromatosis 1	D009456	sorafenib	Phase 2	2011	2011	NCT01338857
Neurofibroma	D009455	sorafenib	Phase 1	2008	2008	NCT00727233
Neurofibroma	D009455	sorafenib	Phase 2	2011	2011	NCT01338857
Lymphoma, Large-Cell, Immunoblastic	D016400	sorafenib	Phase 1	2004	2004	NCT00118170
Lymphoma, Large-Cell, Immunoblastic	D016400	sorafenib	Phase 2	2005	2005	NCT00131937
Plasmablastic Lymphoma	D000069293	sorafenib	Phase 1	2004	2004	NCT00118170
Plasmablastic Lymphoma	D000069293	sorafenib	Phase 2	2005	2005	NCT00131937
Lymphoma, T-Cell, Cutaneous	D016410	sorafenib	Phase 2	2005	2005	NCT00131937
Leukemia, T-Cell	D015458	sorafenib	Phase 2	2005	2005	NCT00131937
Leukemia-Lymphoma, Adult T-Cell	D015459	sorafenib	Phase 2	2005	2005	NCT00131937
Lymphoma, T-Cell, Peripheral	D016411	sorafenib	Phase 2	2005	2005	NCT00131937
Carcinoma, Papillary	D002291	sorafenib	Phase 2	2019	2019	NCT03914300
Adenocarcinoma, Follicular	D018263	sorafenib	Phase 2	2004	2019	NCT03914300;NCT00095693;NCT03630120
Adrenocortical Carcinoma	D018268	sorafenib	Phase 2	2008	2008	NCT00786110
Malignant Carcinoid Syndrome	D008303	sorafenib	Phase 2	2005	2005	NCT00131911
Insulinoma	D007340	sorafenib	Phase 2	2005	2005	NCT00131911
Carcinoma, Islet Cell	D018273	sorafenib	Phase 2	2005	2005	NCT00131911
Gastrinoma	D015408	sorafenib	Phase 2	2005	2005	NCT00131911
Glucagonoma	D005935	sorafenib	Phase 2	2005	2005	NCT00131911
Somatostatinoma	D013005	sorafenib	Phase 2	2005	2005	NCT00131911
Vipoma	D003969	sorafenib	Phase 2	2005	2005	NCT00131911
Nasopharyngeal Neoplasms	D009303	sorafenib	Phase 2	2009	2009	NCT00747799
Pelvic Neoplasms	D010386	sorafenib	Phase 1	2012	2012	NCT01844947
Burkitt Lymphoma	D002051	sorafenib	Phase 1	2004	2004	NCT00118170
Lymphoma, Follicular	D008224	sorafenib	Phase 1	2004	2004	NCT00118170
Lymphoma, B-Cell	D016393	sorafenib	Phase 1	2004	2004	NCT00118170
Lymphoma, B-Cell, Marginal Zone	D018442	sorafenib	Phase 1	2004	2004	NCT00118170
Waldenstrom Macroglobulinemia	D008258	sorafenib	Phase 1	2004	2004	NCT00118170
Lymphomatoid Granulomatosis	D008230	sorafenib	Phase 1	2004	2004	NCT00118170
Testicular Neoplasms	D013736	sorafenib	Phase 2	2008	2008	NCT00772694
Uterine Cervical Neoplasms	D002583	sorafenib	Phase 2	2007	2007	NCT00510250
Carcinoma, Neuroendocrine	D018278	sorafenib	Phase 2	2006	2012	NCT01736878;NCT00390325
Carcinoma, Ductal	D044584	sorafenib	Phase 2	2010	2011	NCT01762150;NCT01093222
Leukemia, Myelomonocytic, Juvenile	D054429	sorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	sorafenib	Phase 2	2006	2012	NCT01620216;NCT01445080
Neurofibroma, Plexiform	D018318	sorafenib	Phase 1	2008	2008	NCT00727233
Nerve Sheath Neoplasms	D018317	sorafenib	Phase 2	2009	2009	NCT00837148
Klatskin Tumor	D018285	sorafenib	Phase 2	2010	2010	NCT01093222
Neuroectodermal Tumors	D017599	sorafenib	Phase 2	2006	2013	NCT00330421;NCT01946529
Neuroectodermal Tumors, Primitive	D018242	sorafenib	Phase 2	2006	2013	NCT00330421;NCT01946529
Neuroectodermal Tumors, Primitive, Peripheral	D018241	sorafenib	Phase 2	2006	2013	NCT00330421;NCT01946529
Adenocarcinoma of Lung	D000077192	sorafenib	Phase 2	2007	2007	NCT00456716
Biliary Tract Neoplasms	D001661	sorafenib	Phase 2	2009	2009	NCT00955721
Mixed Tumor, Mullerian	D018200	sorafenib	Phase 2	2005	2005	NCT00238121
Nervous System Neoplasms	D009423	sorafenib	Phase 2	2008	2008	NCT00621686
Central Nervous System Neoplasms	D016543	sorafenib	Phase 2	2008	2008	NCT00621686
Carcinoma, Medullary	D018276	sorafenib	Phase 2	2006	2006	NCT00390325
Endocrine Gland Neoplasms	D004701	sorafenib	Phase 2	2006	2006	NCT00390325
Multiple Endocrine Neoplasia	D009377	sorafenib	Phase 2	2006	2006	NCT00390325
Multiple Endocrine Neoplasia Type 2a	D018813	sorafenib	Phase 2	2006	2006	NCT00390325
Multiple Endocrine Neoplasia Type 2b	D018814	sorafenib	Phase 2	2006	2006	NCT00390325
Desmoplastic Small Round Cell Tumor	D058405	sorafenib	Phase 2	2013	2013	NCT01946529
Hodgkin Disease	D006689	sorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	sorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	sorafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	sorafenib	Phase 1	2020	2020	NCT03878524
Carcinoma, Acinar Cell	D018267	sorafenib	Phase 1	2009	2009	NCT00981162
Liposarcoma	D008080	sorafenib	Phase 2	2014	2014	NCT02048371
Chondrosarcoma	D002813	sorafenib	Phase 2	2014	2014	NCT02048371
Chondrosarcoma, Mesenchymal	D018211	sorafenib	Phase 2	2014	2014	NCT02048371
Lung Neoplasms	D008175	sunitinib	Phase 1	2007	2007	NCT00581789;NCT00555256
Lung Neoplasms	D008175	sunitinib	Phase 2	2005	2015	NCT01850147;NCT00620347;NCT00113516;NCT00864721;NCT00698815;NCT00748163;NCT00430261;NCT01216371;NCT00265317;NCT00953459;NCT00616109;NCT01019798;NCT01210053;NCT02465060;NCT00372775;NCT00695292;NCT00092001;NCT00434226;NCT00392444;NCT01306045
Lung Neoplasms	D008175	sunitinib	Phase 3	2007	2008	NCT00693992;NCT00457392
Carcinoma	D002277	sunitinib	Phase 1	2006	2020	NCT00906360;NCT01441388;NCT01472081;NCT01243359;NCT00499135;NCT00788060;NCT01061411;NCT00372853;NCT00422344;NCT00421512;NCT01381822;NCT02386111;NCT03905889;NCT03878524
Carcinoma	D002277	sunitinib	Phase 2	2004	2021	NCT00113529;NCT00486538;NCT01118351;NCT03323710;NCT00979992;NCT01517243;NCT00478426;NCT01673386;NCT01219751;NCT02324803;NCT03066427;NCT01798446;NCT02072031;NCT01391130;NCT00387335;NCT04710628;NCT00859339;NCT02959554;NCT00254540;NCT00247676;NCT01731158;NCT01089088;NCT01342627;NCT00678288;NCT00853372;NCT00923130;NCT01377298;NCT01649180;NCT02919371;NCT00453895;NCT03541902;NCT01824615;NCT01309633;NCT00448721;NCT00522249;NCT03598816;NCT01108445;NCT00381641;NCT03035630;NCT02788201;NCT01372813;NCT01216371;NCT01616186;NCT04644432;NCT01185366;NCT00480935;NCT00389974;NCT00089648;NCT01566747;NCT00077974;NCT02623127;NCT02398552;NCT00731211;NCT00709995;NCT01835158;NCT03463460;NCT00137423;NCT00663559;NCT00886132;NCT00556205;NCT01147822;NCT00787787;NCT02761057;NCT01082809;NCT02465060;NCT00891475;NCT00453154;NCT01491672;NCT01482949;NCT01042795;NCT01582009;NCT00519896;NCT00417677;NCT02432846;NCT03075423;NCT00617253;NCT01215565;NCT00678119;NCT00444314;NCT02071641;NCT02187302;NCT02626754;NCT01984242;NCT03379012;NCT00782275;NCT03109015;NCT00556049;NCT00975806;NCT00794950;NCT02315625;NCT01070186;NCT01664182;NCT00619268;NCT00715442;NCT02700568;NCT00570882;NCT03592199;NCT01158222;NCT00408252;NCT02689167;NCT03449173;NCT00361309;NCT01069770;NCT01306045;NCT02060370;NCT00903175
Carcinoma	D002277	sunitinib	Phase 3	2004	2020	NCT00474786;NCT01064310;NCT02231749;NCT01582672;NCT02853331;NCT00869011;NCT03091192;NCT04394975;NCT00699374;NCT03260894;NCT00732914;NCT03729245;NCT03141177;NCT01481870;NCT03013946;NCT01265810;NCT00410124;NCT02420821;NCT00326898;NCT01265901;NCT00428597;NCT02535351;NCT02811861;NCT00930033;NCT00720941;NCT00083889
Carcinoma	D002277	sunitinib	Phase 4	2008	2015	NCT02570789;NCT02056587;NCT01514448;NCT00706706;NCT00930345;NCT02338570
Carcinoma, Renal Cell	D002292	sunitinib	Phase 1	2006	2019	NCT01441388;NCT01472081;NCT00399152;NCT01243359;NCT00499135;NCT00694096;NCT01258348;NCT00788060;NCT01061411;NCT00890747;NCT00372853;NCT01714765;NCT00422344;NCT00715182;NCT00421512;NCT01381822;NCT01122615;NCT02386111;NCT03905889;NCT00747305
Carcinoma, Renal Cell	D002292	sunitinib	Phase 2	2004	2020	NCT00113529;NCT00486538;NCT00267748;NCT03323710;NCT00338884;NCT03387514;NCT01517243;NCT00626509;NCT01673386;NCT01219751;NCT01499121;NCT00330564;NCT00459979;NCT02324803;NCT03066427;NCT01798446;NCT02072031;NCT01391130;NCT00890110;NCT02959554;NCT02560012;NCT00254540;NCT00866320;NCT01731158;NCT01342627;NCT00678288;NCT00853372;NCT00923130;NCT01649180;NCT02919371;NCT03541902;NCT00448721;NCT00522249;NCT03598816;NCT01108445;NCT03035630;NCT01372813;NCT01216371;NCT01616186;NCT04644432;NCT01246817;NCT01185366;NCT00425386;NCT00480935;NCT00089648;NCT01566747;NCT00077974;NCT01164228;NCT02398552;NCT01538238;NCT00731211;NCT00709995;NCT01835158;NCT00137423;NCT00465179;NCT00663559;NCT01793636;NCT02019576;NCT01024205;NCT02599779;NCT01784978;NCT00556205;NCT00717587;NCT01147822;NCT00853125;NCT02761057;NCT02465060;NCT00891475;NCT00541008;NCT01491672;NCT01482949;NCT00462982;NCT01582009;NCT00417677;NCT02432846;NCT03075423;NCT00459875;NCT00617253;NCT00678119;NCT00444314;NCT00814021;NCT02071641;NCT02187302;NCT02446795;NCT02626754;NCT01984242;NCT03379012;NCT00782275;NCT02960906;NCT03109015;NCT00556049;NCT00979966;NCT00975806;NCT03024437;NCT01829841;NCT01070186;NCT01664182;NCT00619268;NCT00715442;NCT00982657;NCT01034878;NCT02700568;NCT00570882;NCT03592199;NCT01158222;NCT02689167;NCT00491738;NCT01024920;NCT01069770;NCT02060370;NCT00903175
Carcinoma, Renal Cell	D002292	sunitinib	Phase 3	2004	2020	NCT00474786;NCT01064310;NCT02231749;NCT04523272;NCT01582672;NCT02853331;NCT00869011;NCT03091192;NCT04394975;NCT03260894;NCT00732914;NCT03729245;NCT03141177;NCT00397345;NCT02684006;NCT01481870;NCT03013946;NCT01265810;NCT01099423;NCT00410124;NCT02420821;NCT00326898;NCT01265901;NCT02535351;NCT02811861;NCT00930033;NCT00720941;NCT00083889
Carcinoma, Renal Cell	D002292	sunitinib	Phase 4	2008	2015	NCT02570789;NCT01402089;NCT02056587;NCT01514448;NCT02555748;NCT00706706;NCT00930345;NCT02338570
Kidney Neoplasms	D007680	sunitinib	Phase 1	2006	2015	NCT00399152;NCT01714765;NCT00422344;NCT00421512;NCT01122615;NCT02386111;NCT00747305
Kidney Neoplasms	D007680	sunitinib	Phase 2	2003	2020	NCT00054886;NCT00626509;NCT00459979;NCT03066427;NCT00866320;NCT01089088;NCT00792025;NCT03035630;NCT01372813;NCT04644432;NCT01185366;NCT00425386;NCT01164228;NCT03456401;NCT01835158;NCT00465179;NCT01793636;NCT01024205;NCT01784978;NCT00717587;NCT00853125;NCT02465060;NCT00498966;NCT00541008;NCT00462982;NCT00459875;NCT00814021;NCT02446795;NCT00782275;NCT02960906;NCT01118039;NCT00979966;NCT03024437;NCT00397488;NCT01034878;NCT02689167;NCT02060370
Kidney Neoplasms	D007680	sunitinib	Phase 3	2006	2020	NCT04523272;NCT03091192;NCT00375674;NCT00397345;NCT01099423
Neuroendocrine Tumors	D018358	sunitinib	Phase 1	2011	2011	NCT01381822
Neuroendocrine Tumors	D018358	sunitinib	Phase 2	2003	2017	NCT01215578;NCT01121562;NCT00434109;NCT02713763;NCT02315625;NCT00056693;NCT02402062
Neuroendocrine Tumors	D018358	sunitinib	Phase 4	2012	2012	NCT01525550
Pancreatic Neoplasms	D010190	sunitinib	Phase 1	2007	2020	NCT00462553;NCT03878524
Pancreatic Neoplasms	D010190	sunitinib	Phase 2	2006	2015	NCT01215578;NCT00967603;NCT00397787;NCT02230176;NCT02465060;NCT02402062;NCT00673504
Endocrine Gland Neoplasms	D004701	sunitinib	Phase 2	2008	2008	NCT01215578
Breast Neoplasms	D001943	sunitinib	Phase 1	2005	2020	NCT00372424;NCT01498458;NCT02074878;NCT00291577;NCT00174434;NCT03878524
Breast Neoplasms	D001943	sunitinib	Phase 2	2004	2016	NCT00824538;NCT00078000;NCT00931450;NCT00513695;NCT00243503;NCT00905021;NCT00616122;NCT01070706;NCT00471276;NCT01176799;NCT00887575;NCT00417885;NCT02465060;NCT00270413;NCT00246571;NCT00482755;NCT00434356;NCT02790580;NCT00570908;NCT00662025
Breast Neoplasms	D001943	sunitinib	Phase 3	2006	2007	NCT00373113;NCT00393939;NCT00435409;NCT00373256
Gastrointestinal Stromal Tumors	D046152	sunitinib	Phase 1	2007	2019	NCT00573404;NCT02164240;NCT01735968;NCT01381822;NCT01468688;NCT04006769;NCT02268435
Gastrointestinal Stromal Tumors	D046152	sunitinib	Phase 2	2005	2020	NCT01091207;NCT00137449;NCT00265798;NCT02342600;NCT01389583;NCT03171389;NCT04193553;NCT04633122;NCT01396148;NCT03944304;NCT02889328;NCT01440959;NCT00570635;NCT02216578;NCT02712112;NCT03609424;NCT04258956;NCT00618319;NCT02607332;NCT00782834;NCT01039519;NCT01068769;NCT01506336;NCT03556384;NCT01907607;NCT00718562;NCT00457743;NCT02401815;NCT01524848;NCT04106024;NCT00633295;NCT01323400
Gastrointestinal Stromal Tumors	D046152	sunitinib	Phase 3	2003	2020	NCT03673501;NCT03353753;NCT01271712;NCT00471328;NCT00075218;NCT01151852;NCT01265810;NCT04409223;NCT00688766;NCT01289028;NCT00372567;NCT01694277
Gastrointestinal Stromal Tumors	D046152	sunitinib	Phase 4	2008	2012	NCT01402089;NCT00793871
Small Cell Lung Carcinoma	D055752	sunitinib	Phase 2	2007	2011	NCT00620347;NCT00953459;NCT00616109;NCT00453154;NCT00695292;NCT01306045
Multiple Myeloma	D009101	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Multiple Myeloma	D009101	sunitinib	Phase 2	2007	2017	NCT02693535;NCT03297606;NCT02465060;NCT00514137
Lymphoma, Non-Hodgkin	D008228	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Lymphoma, Non-Hodgkin	D008228	sunitinib	Phase 2	2007	2017	NCT02693535;NCT03297606;NCT00392496
Melanoma	D008545	sunitinib	Phase 1	2008	2008	NCT01005472
Melanoma	D008545	sunitinib	Phase 2	2006	2015	NCT00304200;NCT02400385;NCT01551459;NCT02068586;NCT00631618;NCT00482911;NCT00496223;NCT00577382;NCT02465060;NCT00462982;NCT01216657;NCT00489944
Urinary Bladder Neoplasms	D001749	sunitinib	Phase 2	2006	2017	NCT01118351;NCT00859339;NCT01089088;NCT00792025;NCT02788201;NCT00578526;NCT00847015;NCT02465060;NCT00526656;NCT01118039;NCT00397488;NCT00818350
Carcinoma, Transitional Cell	D002295	sunitinib	Phase 2	2006	2017	NCT01118351;NCT00393796;NCT00859339;NCT01089088;NCT00792025;NCT02788201;NCT01042795;NCT01118039;NCT00794950;NCT00397488
Prostatic Neoplasms	D011471	sunitinib	Phase 1	2006	2020	NCT00790595;NCT00631527;NCT03878524
Prostatic Neoplasms	D011471	sunitinib	Phase 2	2005	2015	NCT00748358;NCT00550810;NCT01254864;NCT00299741;NCT00795171;NCT00329043;NCT00137436;NCT00599313;NCT02465060;NCT00734851;NCT00672594;NCT00879619
Prostatic Neoplasms	D011471	sunitinib	Phase 3	2008	2014	NCT02044354;NCT00676650
Ovarian Neoplasms	D010051	sunitinib	Phase 2	2007	2015	NCT00979992;NCT00543049;NCT01824615;NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	sunitinib	Phase 2	2007	2015	NCT00979992;NCT00543049;NCT02465060;NCT00388037
Adenocarcinoma, Clear Cell	D018262	sunitinib	Phase 2	2010	2013	NCT00979992;NCT01824615
Adenocarcinoma	D000230	sunitinib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	sunitinib	Phase 2	2006	2013	NCT01020630;NCT00478426;NCT00430261;NCT00397787;NCT00389974;NCT00411151;NCT01829217;NCT00891878
Glioblastoma	D005909	sunitinib	Phase 1	2007	2018	NCT01441388;NCT00864864;NCT00611728;NCT01122888;NCT03275558
Glioblastoma	D005909	sunitinib	Phase 2	2007	2012	NCT00606008;NCT00535379;NCT00499473;NCT01100177;NCT00923117;NCT02928575
Glioblastoma	D005909	sunitinib	Phase 3	2018	2018	NCT03025893
Astrocytoma	D001254	sunitinib	Phase 2	2007	2012	NCT00606008;NCT01462695;NCT00499473
Cystadenocarcinoma, Serous	D018284	sunitinib	Phase 2	2007	2007	NCT00478426
Carcinoma, Endometrioid	D018269	sunitinib	Phase 2	2007	2007	NCT00478426
Carcinosarcoma	D002296	sunitinib	Phase 2	2007	2007	NCT00478426
Mixed Tumor, Mullerian	D018200	sunitinib	Phase 2	2007	2007	NCT00478426
Neoplasms, Germ Cell and Embryonal	D009373	sunitinib	Phase 1	2006	2006	NCT00387920
Neoplasms, Germ Cell and Embryonal	D009373	sunitinib	Phase 2	2006	2009	NCT00453310;NCT00371553;NCT00912912
Teratoma	D013724	sunitinib	Phase 1	2006	2006	NCT00387920
Teratoma	D013724	sunitinib	Phase 2	2007	2007	NCT00453310
Testicular Neoplasms	D013736	sunitinib	Phase 2	2007	2007	NCT00453310
Carcinoma, Non-Small-Cell Lung	D002289	sunitinib	Phase 1	2004	2007	NCT00581789;NCT00555256;NCT00712504
Carcinoma, Non-Small-Cell Lung	D002289	sunitinib	Phase 2	2005	2013	NCT00113516;NCT00864721;NCT00698815;NCT00748163;NCT00265317;NCT01019798;NCT01210053;NCT00372775;NCT01803503;NCT00092001;NCT00434226;NCT01306045
Carcinoma, Non-Small-Cell Lung	D002289	sunitinib	Phase 3	2007	2008	NCT00693992;NCT00457392
Sarcoma	D012509	sunitinib	Phase 1	2011	2012	NCT01498835;NCT01308034
Sarcoma	D012509	sunitinib	Phase 2	2006	2019	NCT01391962;NCT00753727;NCT00521092;NCT03641326;NCT03277924;NCT00474994;NCT02113826;NCT00767819;NCT00400569;NCT00859456;NCT02048371
Liver Neoplasms	D008113	sunitinib	Phase 2	2006	2008	NCT00495625;NCT00247676;NCT00514228;NCT00524316;NCT00787787;NCT00361309
Liver Neoplasms	D008113	sunitinib	Phase 3	2010	2010	NCT01164202
Carcinoma, Hepatocellular	D006528	sunitinib	Phase 1	2011	2011	NCT01441388
Carcinoma, Hepatocellular	D006528	sunitinib	Phase 2	2006	2015	NCT00495625;NCT00247676;NCT00787787;NCT02465060;NCT01215565;NCT00361309
Carcinoma, Hepatocellular	D006528	sunitinib	Phase 3	2008	2011	NCT00699374;NCT01265810
Breast Neoplasms, Male	D018567	sunitinib	Phase 2	2007	2007	NCT00513695
Inflammatory Breast Neoplasms	D058922	sunitinib	Phase 2	2007	2007	NCT00513695
Fallopian Tube Neoplasms	D005185	sunitinib	Phase 2	2007	2008	NCT00543049;NCT00768144;NCT00388037
Hemangioblastoma	D018325	sunitinib	Phase 2	2006	2007	NCT00330564;NCT00589784
Leiomyosarcoma	D007890	sunitinib	Phase 2	2006	2006	NCT00378911;NCT00400569
Neoplasms, Hormone-Dependent	D009376	sunitinib	Phase 2	2008	2008	NCT00748358
Carcinoma, Squamous Cell	D002294	sunitinib	Phase 1	2008	2008	NCT00906360
Carcinoma, Squamous Cell	D002294	sunitinib	Phase 2	2006	2011	NCT00387335;NCT01377298
Head and Neck Neoplasms	D006258	sunitinib	Phase 1	2008	2008	NCT00906360
Head and Neck Neoplasms	D006258	sunitinib	Phase 2	2006	2014	NCT00387335;NCT02558387
Laryngeal Neoplasms	D007822	sunitinib	Phase 1	2008	2008	NCT00906360
Laryngeal Neoplasms	D007822	sunitinib	Phase 2	2006	2006	NCT00387335
Oropharyngeal Neoplasms	D009959	sunitinib	Phase 1	2008	2008	NCT00906360
Oropharyngeal Neoplasms	D009959	sunitinib	Phase 2	2006	2006	NCT00387335
Carcinoma, Verrucous	D018289	sunitinib	Phase 1	2008	2008	NCT00906360
Salivary Gland Neoplasms	D012468	sunitinib	Phase 1	2008	2008	NCT00906360
Salivary Gland Neoplasms	D012468	sunitinib	Phase 2	2007	2014	NCT00886132;NCT02558387
Nasopharyngeal Carcinoma	D000077274	sunitinib	Phase 1	2008	2008	NCT00906360
Nasopharyngeal Carcinoma	D000077274	sunitinib	Phase 2	2006	2011	NCT00387335;NCT01309633
Paranasal Sinus Neoplasms	D010255	sunitinib	Phase 1	2008	2008	NCT00906360
Paranasal Sinus Neoplasms	D010255	sunitinib	Phase 2	2006	2006	NCT00387335
Neoplasms, Unknown Primary	D009382	sunitinib	Phase 1	2008	2008	NCT00906360
Neoplasms, Unknown Primary	D009382	sunitinib	Phase 2	2006	2006	NCT00387335
Tongue Neoplasms	D014062	sunitinib	Phase 1	2008	2008	NCT00906360
Leukemia	D007938	sunitinib	Phase 1	2009	2020	NCT00890747;NCT02779283;NCT03878524
Leukemia	D007938	sunitinib	Phase 2	2006	2012	NCT00451048;NCT00398112;NCT00387426;NCT01620216
Preleukemia	D011289	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Preleukemia	D011289	sunitinib	Phase 2	2007	2007	NCT00451048
Leukemia, Myelomonocytic, Acute	D015479	sunitinib	Phase 2	2007	2007	NCT00451048
Leukemia, Myelomonocytic, Chronic	D015477	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	sunitinib	Phase 2	2006	2012	NCT00451048;NCT00387426;NCT01620216
Leukemia, Myelomonocytic, Juvenile	D054429	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	sunitinib	Phase 2	2006	2012	NCT00451048;NCT00387426;NCT01620216
Pheochromocytoma	D010673	sunitinib	Phase 2	2009	2011	NCT01371201;NCT00843037
Paraganglioma	D010235	sunitinib	Phase 2	2009	2011	NCT01371201;NCT00843037
Carotid Body Tumor	D002345	sunitinib	Phase 2	2009	2011	NCT01371201;NCT00843037
Thymoma	D013945	sunitinib	Phase 2	2011	2021	NCT04710628;NCT02623127;NCT03463460;NCT01621568;NCT03449173;NCT01306045
Cholangiocarcinoma	D018281	sunitinib	Phase 2	2011	2011	NCT01718327
Urethral Neoplasms	D014523	sunitinib	Phase 2	2006	2009	NCT01089088;NCT01118039;NCT00397488
Ureteral Neoplasms	D014516	sunitinib	Phase 2	2006	2009	NCT01089088;NCT00792025;NCT01118039;NCT00397488
Esophageal Neoplasms	D004938	sunitinib	Phase 1	2007	2007	NCT00524186
Esophageal Neoplasms	D004938	sunitinib	Phase 2	2006	2015	NCT00730353;NCT00400114;NCT02465060;NCT00891878;NCT00702884
Adenoma, Islet Cell	D007516	sunitinib	Phase 1	2011	2011	NCT01381822
Adenoma, Islet Cell	D007516	sunitinib	Phase 2	2006	2017	NCT01121562;NCT00434109;NCT02713763
Adenoma, Islet Cell	D007516	sunitinib	Phase 3	2007	2007	NCT00428597
Adenoma, Islet Cell	D007516	sunitinib	Phase 4	2012	2012	NCT01525550
Squamous Cell Carcinoma of Head and Neck	D000077195	sunitinib	Phase 2	2011	2011	NCT01377298
Meningioma	D008579	sunitinib	Phase 2	2007	2007	NCT00589784
Neurofibromatoses	D017253	sunitinib	Phase 2	2007	2012	NCT00589784;NCT01402817
Neurofibromatosis 1	D009456	sunitinib	Phase 2	2007	2012	NCT00589784;NCT01402817
Neurofibroma	D009455	sunitinib	Phase 2	2007	2012	NCT00589784;NCT01402817
Hemangiopericytoma	D006393	sunitinib	Phase 2	2007	2007	NCT00589784
Central Nervous System Neoplasms	D016543	sunitinib	Phase 2	2007	2007	NCT00589784
Adenocarcinoma of Lung	D000077192	sunitinib	Phase 2	2007	2013	NCT00430261;NCT01829217
Adrenocortical Carcinoma	D018268	sunitinib	Phase 2	2007	2007	NCT00453895
Urologic Neoplasms	D014571	sunitinib	Phase 1	2015	2015	NCT02386111
Urologic Neoplasms	D014571	sunitinib	Phase 2	2018	2020	NCT03541902;NCT04644432
Urologic Neoplasms	D014571	sunitinib	Phase 3	2017	2017	NCT03091192
Adenomyoepithelioma	D055331	sunitinib	Phase 2	2013	2013	NCT01824615
Lymphoma	D008223	sunitinib	Phase 1	2006	2020	NCT00890747;NCT03878524;NCT00705874
Lymphoma	D008223	sunitinib	Phase 2	2007	2015	NCT00398112;NCT02465060;NCT00392496
Leukemia, Lymphoid	D007945	sunitinib	Phase 1	2009	2020	NCT00890747;NCT02779283;NCT03878524
Leukemia, Lymphoid	D007945	sunitinib	Phase 2	2006	2012	NCT00398112;NCT00387426;NCT01620216
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	sunitinib	Phase 2	2006	2007	NCT00398112;NCT00387426
Thyroid Neoplasms	D013964	sunitinib	Phase 2	2006	2015	NCT00381641;NCT00510640;NCT00668811;NCT02465060;NCT00519896
Carcinoma, Medullary	D018276	sunitinib	Phase 2	2006	2007	NCT00381641;NCT00519896
Carcinoma, Neuroendocrine	D018278	sunitinib	Phase 2	2006	2015	NCT00381641;NCT02230176;NCT02315625
Carcinoma, Papillary	D002291	sunitinib	Phase 2	2006	2006	NCT00381641
Thyroid Cancer, Papillary	D000077273	sunitinib	Phase 2	2006	2008	NCT00381641;NCT00668811;NCT00519896
Adenocarcinoma, Follicular	D018263	sunitinib	Phase 2	2006	2008	NCT00381641;NCT00668811;NCT00519896
Osteosarcoma	D012516	sunitinib	Phase 1	2019	2019	NCT03900793
Osteosarcoma	D012516	sunitinib	Phase 2	2014	2017	NCT03277924;NCT02048371
Neoplasms by Site	D009371	sunitinib	Phase 3	2017	2017	NCT03091192
Carcinoma, Acinar Cell	D018267	sunitinib	Phase 2	2006	2006	NCT00397787
Neoplasm Metastasis	D009362	sunitinib	Phase 1	2009	2009	NCT00981890
Neoplasm Metastasis	D009362	sunitinib	Phase 2	2007	2014	NCT01216371;NCT02142036;NCT00910039;NCT00806663;NCT00372775;NCT00556049;NCT01069770
Urogenital Neoplasms	D014565	sunitinib	Phase 1	2015	2015	NCT02386111
Urogenital Neoplasms	D014565	sunitinib	Phase 2	2014	2020	NCT04644432;NCT02060370
Uveal Neoplasms	D014604	sunitinib	Phase 2	2010	2014	NCT01551459;NCT02068586
Gastrointestinal Neoplasms	D005770	sunitinib	Phase 2	2007	2007	NCT00570635
Gastrointestinal Neoplasms	D005770	sunitinib	Phase 4	2008	2008	NCT00793871
Digestive System Neoplasms	D004067	sunitinib	Phase 2	2007	2007	NCT00570635
Digestive System Neoplasms	D004067	sunitinib	Phase 4	2008	2008	NCT00793871
Glioma	D005910	sunitinib	Phase 1	2018	2018	NCT03275558
Glioma	D005910	sunitinib	Phase 2	2007	2015	NCT01462695;NCT00499473;NCT01200134;NCT02465060;NCT00923117
Ependymoma	D004806	sunitinib	Phase 2	2012	2012	NCT01462695
Oligodendroglioma	D009837	sunitinib	Phase 2	2007	2012	NCT01462695;NCT00499473
Colorectal Neoplasms	D015179	sunitinib	Phase 1	2005	2008	NCT00631410;NCT00777478;NCT00599924
Colorectal Neoplasms	D015179	sunitinib	Phase 2	2003	2015	NCT00961571;NCT00806663;NCT00077987;NCT00609622;NCT02465060;NCT00361244;NCT00668863
Colorectal Neoplasms	D015179	sunitinib	Phase 3	2007	2019	NCT00457691;NCT03909724
Neoplasms, Second Primary	D016609	sunitinib	Phase 1	2009	2009	NCT00981890
Neoplasms, Second Primary	D016609	sunitinib	Phase 2	2014	2014	NCT02142036
Sarcoma, Alveolar Soft Part	D018234	sunitinib	Phase 2	2011	2014	NCT01391962;NCT02113826
Uterine Cervical Neoplasms	D002583	sunitinib	Phase 2	2007	2007	NCT00389974
Carcinoma, Adenosquamous	D018196	sunitinib	Phase 2	2007	2007	NCT00389974
Gliosarcoma	D018316	sunitinib	Phase 1	2009	2018	NCT01122888;NCT03275558
Gliosarcoma	D018316	sunitinib	Phase 2	2007	2019	NCT00499473;NCT03641326
Brain Neoplasms	D001932	sunitinib	Phase 1	2009	2009	NCT01122888;NCT00981890
Brain Neoplasms	D001932	sunitinib	Phase 3	2018	2018	NCT03025893
Stomach Neoplasms	D013274	sunitinib	Phase 1	2007	2008	NCT00555672;NCT00555620;NCT00553696;NCT00524186
Stomach Neoplasms	D013274	sunitinib	Phase 2	2006	2017	NCT03170180;NCT00226811;NCT01238055;NCT02465060;NCT01803503
Carcinoid Tumor	D002276	sunitinib	Phase 2	2013	2013	NCT01731925
Leukemia, Myeloid	D007951	sunitinib	Phase 1	2009	2020	NCT00890747;NCT02779283;NCT03878524
Leukemia, Myeloid	D007951	sunitinib	Phase 2	2006	2012	NCT00387426;NCT00783653;NCT01620216
Leukemia, Myeloid, Acute	D015470	sunitinib	Phase 1	2009	2020	NCT00890747;NCT02779283;NCT03878524
Leukemia, Myeloid, Acute	D015470	sunitinib	Phase 2	2006	2012	NCT00387426;NCT00783653;NCT01620216
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	sunitinib	Phase 1	2009	2020	NCT00890747;NCT02779283;NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	sunitinib	Phase 2	2006	2012	NCT00387426;NCT01620216
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	sunitinib	Phase 2	2006	2006	NCT00387426
Leukemia, Hairy Cell	D007943	sunitinib	Phase 1	2009	2009	NCT00890747
Leukemia, Hairy Cell	D007943	sunitinib	Phase 2	2006	2006	NCT00387426
Leukemia, Myeloid, Chronic-Phase	D015466	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	sunitinib	Phase 2	2006	2006	NCT00387426
Blast Crisis	D001752	sunitinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	sunitinib	Phase 2	2006	2006	NCT00387426
Leukemia, Myeloid, Accelerated Phase	D015465	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	sunitinib	Phase 2	2006	2006	NCT00387426
Leukemia, Prolymphocytic	D015463	sunitinib	Phase 1	2009	2009	NCT00890747
Leukemia, Prolymphocytic	D015463	sunitinib	Phase 2	2006	2006	NCT00387426
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	sunitinib	Phase 2	2006	2006	NCT00387426
Leukemia, Large Granular Lymphocytic	D054066	sunitinib	Phase 1	2009	2009	NCT00890747
Leukemia, Large Granular Lymphocytic	D054066	sunitinib	Phase 2	2006	2006	NCT00387426
Leukemia, Mast-Cell	D007946	sunitinib	Phase 1	2009	2009	NCT00890747
Leukemia, Mast-Cell	D007946	sunitinib	Phase 2	2006	2006	NCT00387426
Sarcoma, Kaposi	D012514	sunitinib	Phase 2	2009	2009	NCT00521092
Barrett Esophagus	D001471	sunitinib	Phase 2	2006	2006	NCT00411151
Rectal Neoplasms	D012004	sunitinib	Phase 2	2009	2015	NCT00936832;NCT02465060
Nervous System Neoplasms	D009423	sunitinib	Phase 1	2007	2007	NCT00437372
Thoracic Neoplasms	D013899	sunitinib	Phase 1	2007	2007	NCT00437372
Pelvic Neoplasms	D010386	sunitinib	Phase 1	2007	2007	NCT00437372
Sarcoma, Clear Cell	D018227	sunitinib	Phase 1	2010	2010	NCT01061411
Neurofibroma, Plexiform	D018318	sunitinib	Phase 2	2012	2012	NCT01402817
Carcinoma, Islet Cell	D018273	sunitinib	Phase 2	2015	2015	NCT02230176
Carcinoma, Islet Cell	D018273	sunitinib	Phase 3	2007	2007	NCT00428597
Burkitt Lymphoma	D002051	sunitinib	Phase 1	2009	2009	NCT00890747
Neoplasms, Plasma Cell	D054219	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Neoplasms, Plasma Cell	D054219	sunitinib	Phase 2	2007	2015	NCT02465060;NCT00514137
Lymphoma, Follicular	D008224	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, B-Cell	D016393	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, B-Cell	D016393	sunitinib	Phase 2	2007	2007	NCT00392496
Hodgkin Disease	D006689	sunitinib	Phase 1	2009	2020	NCT00890747;NCT03878524
Lymphoma, Mantle-Cell	D020522	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, B-Cell, Marginal Zone	D018442	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, T-Cell	D016399	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, Large B-Cell, Diffuse	D016403	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, Large B-Cell, Diffuse	D016403	sunitinib	Phase 2	2007	2007	NCT00392496
Lymphoma, Large-Cell, Immunoblastic	D016400	sunitinib	Phase 1	2009	2009	NCT00890747
Plasmablastic Lymphoma	D000069293	sunitinib	Phase 1	2009	2009	NCT00890747
Mycosis Fungoides	D009182	sunitinib	Phase 1	2009	2009	NCT00890747
Sezary Syndrome	D012751	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, T-Cell, Cutaneous	D016410	sunitinib	Phase 1	2009	2009	NCT00890747
Leukemia, T-Cell	D015458	sunitinib	Phase 1	2009	2009	NCT00890747
Leukemia-Lymphoma, Adult T-Cell	D015459	sunitinib	Phase 1	2009	2009	NCT00890747
Waldenstrom Macroglobulinemia	D008258	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, Large-Cell, Anaplastic	D017728	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, T-Cell, Peripheral	D016411	sunitinib	Phase 1	2009	2009	NCT00890747
Polycythemia Vera	D011087	sunitinib	Phase 1	2009	2009	NCT00890747
Plasmacytoma	D010954	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphomatoid Granulomatosis	D008230	sunitinib	Phase 1	2009	2009	NCT00890747
Lymphoma, Extranodal NK-T-Cell	D054391	sunitinib	Phase 1	2009	2009	NCT00890747
Intraocular Lymphoma	D064090	sunitinib	Phase 1	2009	2009	NCT00890747
Immunoglobulin Light-chain Amyloidosis	D000075363	sunitinib	Phase 1	2009	2009	NCT00890747
Triple Negative Breast Neoplasms	D064726	sunitinib	Phase 2	2009	2009	NCT00887575
Conjunctival Neoplasms	D003230	sunitinib	Phase 2	2007	2007	NCT00482911
Carcinoma, Adenoid Cystic	D003528	sunitinib	Phase 2	2007	2007	NCT00886132
Endometrial Neoplasms	D016889	sunitinib	Phase 2	2007	2015	NCT02465060;NCT00474994
Uterine Neoplasms	D014594	sunitinib	Phase 2	2015	2015	NCT02465060
Colonic Neoplasms	D003110	sunitinib	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	sunitinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Small Cell	D018288	sunitinib	Phase 2	2007	2011	NCT00453154;NCT01306045
Intestinal Neoplasms	D007414	sunitinib	Phase 2	2007	2007	NCT00474994
Fibromatosis, Aggressive	D018222	sunitinib	Phase 2	2007	2007	NCT00474994
Histiocytoma	D051642	sunitinib	Phase 2	2006	2007	NCT00474994;NCT00400569
Histiocytoma, Benign Fibrous	D018219	sunitinib	Phase 2	2006	2007	NCT00474994;NCT00400569
Histiocytoma, Malignant Fibrous	D051677	sunitinib	Phase 2	2006	2007	NCT00474994;NCT00400569
Liposarcoma	D008080	sunitinib	Phase 2	2006	2014	NCT00400569;NCT02048371
Fibrosarcoma	D005354	sunitinib	Phase 2	2006	2006	NCT00400569
Thymus Neoplasms	D013953	sunitinib	Phase 2	2012	2017	NCT01621568;NCT03449173
Peritoneal Neoplasms	D010534	sunitinib	Phase 2	2007	2007	NCT00388037
Neoplasms by Histologic Type	D009370	sunitinib	Phase 1	2015	2015	NCT02386111
Endodermal Sinus Tumor	D018240	sunitinib	Phase 1	2006	2006	NCT00387920
Choriocarcinoma	D002822	sunitinib	Phase 1	2006	2006	NCT00387920
Germinoma	D018237	sunitinib	Phase 1	2006	2006	NCT00387920
Mesothelioma	D008654	sunitinib	Phase 2	2007	2007	NCT00392444
Hematologic Neoplasms	D019337	sunitinib	Phase 1	2020	2020	NCT03878524
Rhabdomyosarcoma	D012208	sunitinib	Phase 2	2014	2014	NCT02048371
Chondrosarcoma	D002813	sunitinib	Phase 2	2014	2014	NCT02048371
Chondrosarcoma, Mesenchymal	D018211	sunitinib	Phase 2	2014	2014	NCT02048371
Carcinoma	D002277	tivozanib	Phase 1	2007	2007	NCT00563147
Carcinoma	D002277	tivozanib	Phase 2	2007	2019	NCT01673386;NCT03970616;NCT01297244;NCT00502307;NCT01835223;NCT01834183;NCT03136627
Carcinoma	D002277	tivozanib	Phase 3	2009	2016	NCT01030783;NCT01076010;NCT02627963
Carcinoma, Renal Cell	D002292	tivozanib	Phase 1	2007	2007	NCT00563147
Carcinoma, Renal Cell	D002292	tivozanib	Phase 2	2007	2017	NCT01673386;NCT01297244;NCT00502307;NCT01834183;NCT03136627
Carcinoma, Renal Cell	D002292	tivozanib	Phase 3	2009	2016	NCT01030783;NCT01076010;NCT02627963
Prostatic Neoplasms	D011471	tivozanib	Phase 2	2013	2013	NCT01885949
Carcinoma, Non-Small-Cell Lung	D002289	tivozanib	Phase 1	2009	2009	NCT00826878
Carcinoma, Non-Small-Cell Lung	D002289	tivozanib	Phase 2	2013	2013	NCT01728181
Lung Neoplasms	D008175	tivozanib	Phase 2	2013	2013	NCT01728181
Cholangiocarcinoma	D018281	tivozanib	Phase 2	2021	2021	NCT04645160
Bile Duct Neoplasms	D001650	tivozanib	Phase 2	2021	2021	NCT04645160
Liver Neoplasms	D008113	tivozanib	Phase 2	2013	2013	NCT01807156
Carcinoma, Hepatocellular	D006528	tivozanib	Phase 2	2013	2019	NCT01807156;NCT03970616;NCT01835223
Glioblastoma	D005909	tivozanib	Phase 2	2013	2013	NCT01846871
Colorectal Neoplasms	D015179	tivozanib	Phase 1	2008	2010	NCT01306630;NCT00660153
Colorectal Neoplasms	D015179	tivozanib	Phase 2	2010	2011	NCT01478594;NCT01058655
Gastrointestinal Neoplasms	D005770	tivozanib	Phase 1	2008	2008	NCT00660153
Gastrointestinal Neoplasms	D005770	tivozanib	Phase 2	2010	2010	NCT01058655
Sarcoma	D012509	tivozanib	Phase 2	2013	2013	NCT01782313
Breast Neoplasms	D001943	tivozanib	Phase 1	2009	2009	NCT00717340
Breast Neoplasms	D001943	tivozanib	Phase 2	2012	2012	NCT01745367
Ovarian Neoplasms	D010051	tivozanib	Phase 2	2013	2013	NCT01972516
Fallopian Tube Neoplasms	D005185	tivozanib	Phase 2	2013	2013	NCT01972516;NCT01853644
Peritoneal Neoplasms	D010534	tivozanib	Phase 2	2013	2013	NCT01853644
Carcinoma, Ovarian Epithelial	D000077216	tivozanib	Phase 2	2013	2013	NCT01853644
Triple Negative Breast Neoplasms	D064726	tivozanib	Phase 2	2012	2012	NCT01745367
Myasthenia Gravis	D009157	tofacitinib	Phase 1	2020	2020	NCT04431895
Adenocarcinoma	D000230	tofacitinib	Phase 1	2019	2019	NCT04034238
Mesothelioma	D008654	tofacitinib	Phase 1	2019	2019	NCT04034238
Cholangiocarcinoma	D018281	tofacitinib	Phase 1	2019	2019	NCT04034238
Lymphoma	D008223	tofacitinib	Phase 2	2019	2019	NCT03598959
Lymphoma, T-Cell	D016399	tofacitinib	Phase 2	2019	2019	NCT03598959
Lymphoma, Extranodal NK-T-Cell	D054391	tofacitinib	Phase 2	2019	2019	NCT03598959
Melanoma	D008545	trametinib	Phase 1	2013	2019	NCT02447939;NCT01767454;NCT02027961;NCT02915666;NCT02097225;NCT03932253;NCT02357732;NCT03088176;NCT03026517;NCT03272464;NCT02300935;NCT02974725;NCT03501368;NCT01940809;NCT02382549;NCT02138292
Melanoma	D008545	trametinib	Phase 2	2009	2021	NCT01902173;NCT03149029;NCT02872259;NCT04310397;NCT02858921;NCT02625337;NCT02410863;NCT01721603;NCT04527549;NCT01989585;NCT03580382;NCT01928940;NCT02645149;NCT01978236;NCT02231775;NCT02083354;NCT02977052;NCT02257424;NCT01619774;NCT01941927;NCT03754179;NCT02392871;NCT02314143;NCT03949153;NCT02968303;NCT01972347;NCT03808441;NCT02130466;NCT03352947;NCT01328106;NCT03972046;NCT02296996;NCT02910700;NCT01037127;NCT04417621;NCT02110355;NCT01701037;NCT03563729;NCT04557956;NCT01726738;NCT03391050;NCT02465060;NCT02143050;NCT04059224;NCT01979523;NCT02196181;NCT02039947;NCT03455764;NCT02974803;NCT02296112
Melanoma	D008545	trametinib	Phase 3	2010	2018	NCT02967692;NCT02224781;NCT03551626;NCT01682083;NCT01584648;NCT01245062;NCT01597908
Melanoma	D008545	trametinib	Phase 4	2017	2017	NCT03340506
Skin Neoplasms	D012878	trametinib	Phase 1	2013	2014	NCT02097225;NCT01940809
Skin Neoplasms	D012878	trametinib	Phase 2	2013	2021	NCT01902173;NCT04310397;NCT04527549;NCT01989585;NCT02231775;NCT02910700;NCT04557956;NCT02465060;NCT02196181
Skin Neoplasms	D012878	trametinib	Phase 3	2015	2015	NCT02224781
Thyroid Neoplasms	D013964	trametinib	Phase 1	2011	2020	NCT03975231;NCT03085056;NCT01438554
Thyroid Neoplasms	D013964	trametinib	Phase 2	2012	2021	NCT04238624;NCT01723202;NCT04675710;NCT03244956;NCT04544111;NCT04739566;NCT04619316;NCT02152995;NCT02465060;NCT04554680
Thyroid Carcinoma, Anaplastic	D065646	trametinib	Phase 1	2017	2020	NCT03975231;NCT03085056
Thyroid Carcinoma, Anaplastic	D065646	trametinib	Phase 2	2020	2021	NCT04238624;NCT04675710;NCT04739566
Lung Neoplasms	D008175	trametinib	Phase 1	2013	2018	NCT03299088;NCT02258607;NCT01938456;NCT02974725
Lung Neoplasms	D008175	trametinib	Phase 2	2011	2018	NCT01362296;NCT02580708;NCT03704688;NCT03225664;NCT03232892;NCT02672358;NCT02465060;NCT03087448;NCT03076164;NCT01336634;NCT03543306
Lung Neoplasms	D008175	trametinib	Phase 4	2017	2017	NCT03340506
Carcinoma, Non-Small-Cell Lung	D002289	trametinib	Phase 1	2010	2018	NCT03299088;NCT02258607;NCT01938456;NCT02974725;NCT03333343;NCT01912625
Carcinoma, Non-Small-Cell Lung	D002289	trametinib	Phase 2	2011	2020	NCT01362296;NCT02580708;NCT03704688;NCT03225664;NCT02642042;NCT03232892;NCT02672358;NCT03087448;NCT04452877;NCT01336634
Carcinoma, Non-Small-Cell Lung	D002289	trametinib	Phase 4	2017	2017	NCT03340506
Glioma	D005910	trametinib	Phase 1	2018	2020	NCT04485559;NCT03434262
Glioma	D005910	trametinib	Phase 2	2015	2019	NCT02684058;NCT03919071;NCT03363217;NCT02465060;NCT04201457
Glioma	D005910	trametinib	Phase 4	2017	2019	NCT03340506;NCT03975829
Ameloblastoma	D000564	trametinib	Phase 2	2017	2017	NCT02367859
Adamantinoma	D050398	trametinib	Phase 2	2017	2017	NCT02367859
Thyroid Cancer, Papillary	D000077273	trametinib	Phase 2	2012	2020	NCT01723202;NCT04544111;NCT02152995
Adenocarcinoma, Follicular	D018263	trametinib	Phase 2	2012	2020	NCT01723202;NCT04544111;NCT02152995
Leukemia	D007938	trametinib	Phase 1	2014	2020	NCT02016729;NCT03878524
Leukemia	D007938	trametinib	Phase 2	2011	2020	NCT01907815;NCT04487106;NCT03190915;NCT00920140
Leukemia, Myeloid	D007951	trametinib	Phase 1	2009	2020	NCT02016729;NCT01428427;NCT03878524
Leukemia, Myeloid	D007951	trametinib	Phase 2	2013	2020	NCT01907815;NCT04487106
Leukemia, Myeloid, Acute	D015470	trametinib	Phase 1	2009	2020	NCT02016729;NCT01428427;NCT03878524
Leukemia, Myeloid, Acute	D015470	trametinib	Phase 2	2013	2020	NCT01907815;NCT04487106
Sarcoma	D012509	trametinib	Phase 1	2011	2011	NCT01438554
Sarcoma	D012509	trametinib	Phase 3	2019	2019	NCT03784014
Carcinoma	D002277	trametinib	Phase 1	2013	2020	NCT03975231;NCT03299088;NCT01935973;NCT03825289;NCT03317119;NCT03878524
Carcinoma	D002277	trametinib	Phase 2	2013	2021	NCT04675710;NCT02042443;NCT04644432;NCT03225664;NCT04739566;NCT02152995;NCT02465060;NCT04554680;NCT01964924;NCT02881242
Preleukemia	D011289	trametinib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	trametinib	Phase 2	2020	2020	NCT04487106
Leukemia, Myelomonocytic, Acute	D015479	trametinib	Phase 2	2017	2020	NCT04487106;NCT03190915
Leukemia, Myelomonocytic, Chronic	D015477	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	trametinib	Phase 2	2017	2020	NCT04487106;NCT03190915
Leukemia, Myelomonocytic, Juvenile	D054429	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	trametinib	Phase 2	2017	2020	NCT04487106;NCT03190915
Gastrointestinal Stromal Tumors	D046152	trametinib	Phase 2	2017	2017	NCT02342600
Multiple Myeloma	D009101	trametinib	Phase 1	2011	2020	NCT01476137;NCT03091257;NCT03878524
Multiple Myeloma	D009101	trametinib	Phase 2	2013	2016	NCT04439318;NCT04439279;NCT04439292;NCT02465060;NCT01989598;NCT02140840;NCT04439357
Neoplasms, Plasma Cell	D054219	trametinib	Phase 1	2011	2020	NCT01476137;NCT03091257;NCT03878524
Neoplasms, Plasma Cell	D054219	trametinib	Phase 2	2013	2016	NCT04439318;NCT04439279;NCT04439292;NCT02465060;NCT01989598;NCT02140840;NCT04439357
Neoplasm Metastasis	D009362	trametinib	Phase 2	2014	2019	NCT01978236;NCT03972046;NCT02039947;NCT02974803
Glioblastoma	D005909	trametinib	Phase 1	2018	2018	NCT03434262
Glioblastoma	D005909	trametinib	Phase 2	2017	2019	NCT02684058;NCT03919071
Glioblastoma	D005909	trametinib	Phase 4	2019	2019	NCT03975829
Astrocytoma	D001254	trametinib	Phase 1	2018	2018	NCT03434262
Astrocytoma	D001254	trametinib	Phase 2	2017	2019	NCT02684058;NCT03919071
Astrocytoma	D001254	trametinib	Phase 4	2019	2019	NCT03975829
Oligodendroglioma	D009837	trametinib	Phase 1	2018	2018	NCT03434262
Oligodendroglioma	D009837	trametinib	Phase 2	2017	2017	NCT02684058
Oligodendroglioma	D009837	trametinib	Phase 4	2019	2019	NCT03975829
Ganglioglioma	D018303	trametinib	Phase 1	2018	2018	NCT03434262
Ganglioglioma	D018303	trametinib	Phase 2	2017	2019	NCT02684058;NCT03919071
Ganglioglioma	D018303	trametinib	Phase 4	2019	2019	NCT03975829
Neurocytoma	D018306	trametinib	Phase 2	2017	2017	NCT02684058
Neurocytoma	D018306	trametinib	Phase 4	2019	2019	NCT03975829
Ganglioneuroma	D005729	trametinib	Phase 2	2017	2017	NCT02684058
Ganglioneuroma	D005729	trametinib	Phase 4	2019	2019	NCT03975829
Neurofibromatoses	D017253	trametinib	Phase 2	2015	2019	NCT03741101;NCT02124772;NCT03363217;NCT03190915;NCT04201457
Neurofibromatoses	D017253	trametinib	Phase 4	2019	2019	NCT03975829
Neurofibromatosis 1	D009456	trametinib	Phase 2	2017	2019	NCT03741101;NCT03190915;NCT04201457
Neurofibromatosis 1	D009456	trametinib	Phase 4	2019	2019	NCT03975829
Carcinoma, Hepatocellular	D006528	trametinib	Phase 1	2015	2015	NCT02292173
Carcinoma, Hepatocellular	D006528	trametinib	Phase 2	2014	2015	NCT02042443;NCT02465060
Liver Neoplasms	D008113	trametinib	Phase 1	2015	2015	NCT02292173
Liver Neoplasms	D008113	trametinib	Phase 2	2014	2014	NCT02042443
Cholangiocarcinoma	D018281	trametinib	Phase 1	2011	2011	NCT01438554
Cholangiocarcinoma	D018281	trametinib	Phase 2	2014	2021	NCT02042443;NCT04566133
Gallbladder Neoplasms	D005706	trametinib	Phase 2	2014	2014	NCT02042443
Bile Duct Neoplasms	D001650	trametinib	Phase 2	2014	2021	NCT02042443;NCT04566133
Klatskin Tumor	D018285	trametinib	Phase 2	2014	2014	NCT02042443
Carcinoma, Ductal	D044584	trametinib	Phase 2	2014	2014	NCT02042443
Colorectal Neoplasms	D015179	trametinib	Phase 1	2016	2020	NCT04303403;NCT04294160;NCT02703571;NCT03317119;NCT03714958
Colorectal Neoplasms	D015179	trametinib	Phase 2	2012	2018	NCT02399943;NCT01750918;NCT02230553;NCT03668431;NCT03428126;NCT02465060;NCT03087071;NCT03377361
Sarcoma, Clear Cell	D018227	trametinib	Phase 2	2017	2017	NCT02968303
Adenoma, Oxyphilic	D018249	trametinib	Phase 2	2020	2020	NCT04544111
Carcinoma, Renal Cell	D002292	trametinib	Phase 2	2015	2020	NCT04644432;NCT02465060
Kidney Neoplasms	D007680	trametinib	Phase 2	2015	2020	NCT04644432;NCT02465060
Urogenital Neoplasms	D014565	trametinib	Phase 2	2020	2020	NCT04644432
Urologic Neoplasms	D014571	trametinib	Phase 2	2020	2020	NCT04644432
Adenocarcinoma	D000230	trametinib	Phase 1	2013	2020	NCT01935973;NCT04303403;NCT02900664;NCT03878524
Adenocarcinoma	D000230	trametinib	Phase 2	2017	2017	NCT03087071;NCT03076164
Adenocarcinoma	D000230	trametinib	Phase 3	2014	2014	NCT02101788
Endometrial Neoplasms	D016889	trametinib	Phase 1	2013	2013	NCT01935973
Endometrial Neoplasms	D016889	trametinib	Phase 2	2015	2015	NCT02465060
Cystadenocarcinoma, Serous	D018284	trametinib	Phase 1	2013	2013	NCT01935973
Cystadenocarcinoma, Serous	D018284	trametinib	Phase 3	2014	2014	NCT02101788
Adenocarcinoma, Clear Cell	D018262	trametinib	Phase 1	2013	2013	NCT01935973
Colonic Neoplasms	D003110	trametinib	Phase 1	2018	2018	NCT03317119
Colonic Neoplasms	D003110	trametinib	Phase 2	2015	2018	NCT03428126;NCT02465060
Neoplasms, Squamous Cell	D018307	trametinib	Phase 2	2013	2013	NCT01553851
Carcinoma, Squamous Cell	D002294	trametinib	Phase 2	2013	2013	NCT01553851
Mouth Neoplasms	D009062	trametinib	Phase 2	2013	2013	NCT01553851
Pancreatic Neoplasms	D010190	trametinib	Phase 1	2016	2020	NCT03825289;NCT02703571;NCT03878524
Pancreatic Neoplasms	D010190	trametinib	Phase 2	2015	2016	NCT02704156;NCT02465060;NCT02428270
Neurofibroma	D009455	trametinib	Phase 2	2015	2019	NCT03741101;NCT02124772;NCT03363217;NCT04201457
Neurofibroma, Plexiform	D018318	trametinib	Phase 2	2015	2019	NCT03741101;NCT02124772;NCT03363217
Squamous Cell Carcinoma of Head and Neck	D000077195	trametinib	Phase 1	2015	2015	NCT02538627
Rectal Neoplasms	D012004	trametinib	Phase 1	2012	2018	NCT01740648;NCT03317119
Rectal Neoplasms	D012004	trametinib	Phase 2	2015	2015	NCT02465060
Stomach Neoplasms	D013274	trametinib	Phase 1	2021	2021	NCT04454476
Stomach Neoplasms	D013274	trametinib	Phase 2	2015	2015	NCT02465060
Uveal Neoplasms	D014604	trametinib	Phase 2	2010	2013	NCT01328106;NCT01979523
Breast Neoplasms	D001943	trametinib	Phase 1	2012	2020	NCT01467310;NCT03878524
Breast Neoplasms	D001943	trametinib	Phase 2	2013	2015	NCT02465060;NCT01964924
Triple Negative Breast Neoplasms	D064726	trametinib	Phase 1	2012	2016	NCT01467310;NCT02900664
Triple Negative Breast Neoplasms	D064726	trametinib	Phase 2	2013	2013	NCT01964924
Brain Neoplasms	D001932	trametinib	Phase 1	2018	2018	NCT03434262
Brain Neoplasms	D001932	trametinib	Phase 2	2016	2016	NCT02974803
Neuroblastoma	D009447	trametinib	Phase 1	2018	2018	NCT03434262
Ependymoma	D004806	trametinib	Phase 1	2018	2018	NCT03434262
Meningioma	D008579	trametinib	Phase 1	2018	2019	NCT03434262;NCT03631953
Medulloblastoma	D008527	trametinib	Phase 1	2018	2018	NCT03434262
Neuroectodermal Tumors	D017599	trametinib	Phase 1	2018	2018	NCT03434262
Neuroectodermal Tumors, Primitive	D018242	trametinib	Phase 1	2018	2018	NCT03434262
Rhabdoid Tumor	D018335	trametinib	Phase 1	2018	2018	NCT03434262
Central Nervous System Neoplasms	D016543	trametinib	Phase 1	2018	2018	NCT03434262
Nervous System Neoplasms	D009423	trametinib	Phase 1	2018	2018	NCT03434262
Pinealoma	D010871	trametinib	Phase 1	2018	2018	NCT03434262
Neoplasms, Germ Cell and Embryonal	D009373	trametinib	Phase 1	2018	2018	NCT03434262
Ganglioneuroblastoma	D018305	trametinib	Phase 1	2018	2018	NCT03434262
Neoplasms, Neuroepithelial	D018302	trametinib	Phase 1	2018	2018	NCT03434262
Lymphoma	D008223	trametinib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	trametinib	Phase 2	2015	2016	NCT04439318;NCT04439279;NCT04439292;NCT02465060;NCT04439357
Bronchial Neoplasms	D001984	trametinib	Phase 1	2018	2018	NCT03516214
Carcinoma, Papillary	D002291	trametinib	Phase 2	2014	2014	NCT02152995
Ovarian Neoplasms	D010051	trametinib	Phase 2	2015	2015	NCT02465060
Carcinoma, Ovarian Epithelial	D000077216	trametinib	Phase 2	2015	2015	NCT02465060
Prostatic Neoplasms	D011471	trametinib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	trametinib	Phase 2	2014	2018	NCT02465060;NCT01990196;NCT02881242
Esophageal Neoplasms	D004938	trametinib	Phase 2	2015	2015	NCT02465060
Urinary Bladder Neoplasms	D001749	trametinib	Phase 2	2015	2015	NCT02465060
Uterine Neoplasms	D014594	trametinib	Phase 2	2015	2015	NCT02465060
Adenocarcinoma of Lung	D000077192	trametinib	Phase 2	2017	2017	NCT03076164
Biliary Tract Neoplasms	D001661	trametinib	Phase 2	2013	2021	NCT04566133;NCT01943864
Hemangioendothelioma	D006390	trametinib	Phase 2	2017	2017	NCT03148275
Hemangioendothelioma, Epithelioid	D018323	trametinib	Phase 2	2017	2017	NCT03148275
Uterine Cervical Neoplasms	D002583	trametinib	Phase 2	2013	2013	NCT01958112
Lymphoma, Non-Hodgkin	D008228	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	trametinib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	trametinib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	trametinib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	trametinib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	trametinib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	trametinib	Phase 1	2020	2020	NCT03878524
Breast Neoplasms	D001943	trastuzumab	Phase 1	1999	2021	NCT00009997;NCT02598427;NCT01097460;NCT04398108;NCT02390427;NCT04382352;NCT03281824;NCT01434303;NCT04042051;NCT00932373;NCT01245205;NCT00620594;NCT01471847;NCT00393783;NCT00803556;NCT01976169;NCT02025192;NCT04556773;NCT03014076;NCT01265927;NCT01875666;NCT00199212;NCT03032107;NCT04704661;NCT01730118;NCT01423123;NCT00372424;NCT04188548;NCT03429101;NCT04367090;NCT00371488;NCT00412412;NCT00960960;NCT01238029;NCT00807859;NCT02167854;NCT02705859;NCT03006172;NCT00950742;NCT00790816;NCT00301730;NCT03364348;NCT00028535;NCT01432886;NCT03432741;NCT00014430;NCT01921335;NCT01513083;NCT03153163;NCT02060253;NCT02038010;NCT00367471;NCT03944499;NCT02605915;NCT01148849;NCT04509596;NCT03062007;NCT04253561;NCT01304797;NCT02569489;NCT00426530;NCT04120246;NCT01649271;NCT00367250;NCT00674791;NCT04332588;NCT02152943;NCT02649686;NCT03135171;NCT00462956;NCT04294628;NCT04296942;NCT01816035;NCT01805908;NCT03767335;NCT01596530;NCT03387553;NCT00605397;NCT00788931;NCT04102618;NCT00004074;NCT00470847;NCT00068757;NCT01445054;NCT02073916;NCT01880385;NCT00949247;NCT02738970;NCT02562378;NCT01300962;NCT00085020;NCT03716180;NCT02135159;NCT03953833;NCT01420146;NCT01969643;NCT03013881;NCT01384253;NCT00928330;NCT00039455;NCT03846583;NCT00251433;NCT01983501;NCT01602406;NCT02063724;NCT01705340;NCT02057133;NCT03878524;NCT00426556;NCT04023110
Breast Neoplasms	D001943	trastuzumab	Phase 2	1998	2021	NCT01401959;NCT00317720;NCT04398914;NCT02910219;NCT00670982;NCT02066532;NCT03058939;NCT00193063;NCT01423695;NCT00479856;NCT03765983;NCT01594177;NCT03238495;NCT00532857;NCT00826267;NCT01340430;NCT01873833;NCT00193089;NCT00193076;NCT03988036;NCT03644186;NCT04578106;NCT02129556;NCT00475670;NCT04197687;NCT04001829;NCT02843126;NCT04246502;NCT00003539;NCT00875979;NCT00455039;NCT03735966;NCT04569747;NCT00574587;NCT04721977;NCT02396108;NCT00387907;NCT00118053;NCT03203616;NCT01206881;NCT00004888;NCT00429247;NCT01779050;NCT01745965;NCT04329065;NCT01254136;NCT01847001;NCT00254592;NCT00952692;NCT01922921;NCT04152057;NCT03997539;NCT00258960;NCT01273610;NCT04681911;NCT02177175;NCT00398567;NCT00320411;NCT03571633;NCT00955890;NCT02000882;NCT00250874;NCT04001621;NCT01163929;NCT04579380;NCT01589861;NCT01008150;NCT01329640;NCT01439191;NCT03095352;NCT01570036;NCT04383275;NCT03140553;NCT00934856;NCT03500380;NCT00679341;NCT00567879;NCT01009918;NCT01111825;NCT01472146;NCT01042925;NCT02654119;NCT04170595;NCT00657137;NCT00006123;NCT01565200;NCT00379015;NCT00051051;NCT01137994;NCT04508803;NCT03125928;NCT03709082;NCT00404066;NCT01363986;NCT02658084;NCT03820141;NCT00079326;NCT01928615;NCT00943410;NCT02091960;NCT02326974;NCT01262469;NCT03368729;NCT01220128;NCT02530424;NCT00024154;NCT00182793;NCT00054470;NCT04681287;NCT00509769;NCT00129896;NCT00436566;NCT00365365;NCT00006108;NCT00629499;NCT02774681;NCT04538742;NCT01306942;NCT02993198;NCT04750122;NCT00976989;NCT00444587;NCT00773344;NCT00398489;NCT03501979;NCT00191373;NCT04095390;NCT00542451;NCT00999804;NCT04034589;NCT01679743;NCT01196052;NCT01190345;NCT00842998;NCT01512199;NCT02297698;NCT01491737;NCT00093808;NCT03881878;NCT01557764;NCT00944047;NCT03412643;NCT04481932;NCT00446030;NCT00095706;NCT00903656;NCT03272477;NCT02041338;NCT00427427;NCT01271920;NCT00331552;NCT00503750;NCT00403988;NCT02238509;NCT00674414;NCT04760431;NCT00003612;NCT00243503;NCT01973660;NCT04266249;NCT02229149;NCT00216073;NCT00194779;NCT01106898;NCT02199418;NCT01796197;NCT04717531;NCT03273595;NCT01750073;NCT00043394;NCT01276041;NCT01428414;NCT04733118;NCT04301375;NCT04255056;NCT04351230;NCT02308020;NCT00428922;NCT00301899;NCT01431196;NCT03304080;NCT00263588;NCT02510781;NCT00811135;NCT00297596;NCT04469127;NCT01674062;NCT00847171;NCT00717405;NCT01367028;NCT00110695;NCT00407888;NCT00138125;NCT02789657;NCT00548184;NCT01817452;NCT04066790;NCT00033514;NCT00885755;NCT01853748;NCT04307329;NCT00006381;NCT02252887;NCT00736970;NCT00401427;NCT04334330;NCT00134680;NCT00003992;NCT00618657;NCT00915018;NCT03321981;NCT03213925;NCT01688609;NCT04094896;NCT04675827;NCT01387295;NCT02907918;NCT01835236;NCT00464646;NCT00943670;NCT00545688;NCT01084863;NCT00405938;NCT01373710;NCT03923166;NCT04759248;NCT00303108;NCT02725541;NCT00788333;NCT00726180;NCT00810017;NCT02379585;NCT01494662;NCT04088110;NCT01690325;NCT01625429;NCT00617942;NCT04034823;NCT00256243;NCT00524303;NCT01630226;NCT00458237;NCT00951665;NCT01436604;NCT02682693;NCT02154529;NCT00741260;NCT02924883;NCT04539938;NCT02748213;NCT00518583;NCT01597414;NCT03367676;NCT02000596;NCT04172259;NCT00820872;NCT00392392;NCT00912340;NCT03101748;NCT04158856;NCT04262804;NCT03742986;NCT01641406;NCT02689921;NCT01242449;NCT03907800;NCT00864175;NCT01132664;NCT04752059;NCT01142778;NCT01816594;NCT00533936;NCT00769470;NCT00216047;NCT03994107;NCT01763710;NCT04236310;NCT03931551;NCT04419181;NCT00364611;NCT00270894;NCT03755141;NCT02436993;NCT01290718;NCT00453635;NCT01959490;NCT00431067;NCT04108858;NCT00006825;NCT02675231;NCT01194908;NCT00086957;NCT00088985;NCT01783756;NCT04464967;NCT01042379;NCT01325428;NCT00337649;NCT01269346;NCT01975142;NCT02362958;NCT00490646;NCT00077376;NCT02214004;NCT01669239;NCT01985893;NCT00036868;NCT01325207;NCT00386685;NCT01730833;NCT02598310;NCT01548677;NCT01565083;NCT01827163;NCT00136539;NCT00817362;NCT00431704;NCT02465060;NCT03820063;NCT02048059;NCT03248492;NCT00411788;NCT03144947;NCT02614794;NCT00721630;NCT00232479;NCT00780000;NCT04296162;NCT00006228;NCT00242203;NCT00343109;NCT01283789;NCT00300781;NCT00093145;NCT03242551;NCT00450892;NCT00004013;NCT01480583;NCT03747120;NCT00485979;NCT03894007;NCT01670877;NCT00830544;NCT00824733;NCT01485926;NCT01185509;NCT02674204;NCT01441596;NCT04553770;NCT00550771;NCT00295893;NCT01432223;NCT01434134;NCT00522457;NCT02236000;NCT00591851;NCT00258349;NCT01912963;NCT03190967;NCT00399529;NCT00482391;NCT04512261;NCT00795899;NCT00821886;NCT00841828;NCT01937117;NCT00006110;NCT00006104;NCT03760588;NCT02536339;NCT00266110;NCT01832051;NCT01828021;NCT00429104;NCT00041067;NCT02422199;NCT02400476;NCT01388647;NCT03674112;NCT03379428;NCT01401166;NCT03879577;NCT00107393;NCT00964704;NCT00429299;NCT01855828;NCT03933319;NCT00019812;NCT01321775;NCT02015676;NCT01387373;NCT02213042;NCT02132949;NCT03913234;NCT00684983;NCT03417544;NCT00238290;NCT00687440;NCT00712881;NCT00679211;NCT00303992;NCT00284180;NCT02073487;NCT02339532;NCT00796978;NCT00068341;NCT00148668;NCT02411344;NCT00133796;NCT03742102;NCT00191451;NCT04639271;NCT02488564;NCT03112590;NCT00130507;NCT01730677;NCT03587740;NCT00434031;NCT02657343;NCT04158947;NCT00146042;NCT00005635;NCT00377780;NCT04425018;NCT04278144;NCT00493649;NCT01702558;NCT02624973;NCT02827877;NCT04298918;NCT03179904;NCT01004172;NCT04126525;NCT01904903;NCT01205217;NCT02448420;NCT00971737;NCT03910712;NCT00057993;NCT03414658;NCT01830244;NCT02059876;NCT03094052;NCT00201760;NCT02139358;NCT04605575;NCT03698383;NCT02345772;NCT02307227;NCT02260531;NCT00041470;NCT00397501;NCT00148681;NCT04420598;NCT01534455;NCT01170143;NCT02297230;NCT00768859;NCT02909751;NCT00470704;NCT00004925;NCT03161353;NCT01495884;NCT01479179;NCT03329378;NCT01305941;NCT00140140
Breast Neoplasms	D001943	trastuzumab	Phase 3	1998	2021	NCT03493854;NCT00513292;NCT00639366;NCT00770809;NCT03726879;NCT02003209;NCT01275677;NCT04784715;NCT02125344;NCT03588091;NCT04736589;NCT00440622;NCT04514419;NCT00512993;NCT00878709;NCT01358877;NCT01426880;NCT00288002;NCT03529110;NCT01917578;NCT01950182;NCT04024462;NCT02586025;NCT04254263;NCT02344472;NCT01964391;NCT04400695;NCT04290793;NCT02194166;NCT02625441;NCT02236806;NCT01566721;NCT00045032;NCT00593697;NCT03980054;NCT04494425;NCT04337658;NCT01996267;NCT01413828;NCT03085368;NCT01583426;NCT00294996;NCT01125566;NCT04547907;NCT03561740;NCT01772472;NCT01160211;NCT01120184;NCT00448279;NCT02947685;NCT01875367;NCT02187744;NCT00667251;NCT03949634;NCT04457596;NCT01926886;NCT03262935;NCT02973737;NCT03006614;NCT01026142;NCT00309556;NCT00712140;NCT00876395;NCT03863223;NCT04665986;NCT04109391;NCT00490139;NCT00553358;NCT00146549;NCT02514681;NCT01419197;NCT00615602;NCT03556358;NCT03734029;NCT01007942;NCT03975647;NCT00391092;NCT01901146;NCT00381901;NCT01940497;NCT04208178;NCT03418961;NCT00430001;NCT01084876;NCT00047255;NCT03433313;NCT01104935;NCT00520975;NCT04193059;NCT02213744;NCT00021255;NCT01526369;NCT00798070;NCT03705429;NCT02568839;NCT04740918;NCT03989037;NCT01989676;NCT00054587;NCT00567190;NCT03199885;NCT00103233;NCT01966471;NCT00567554;NCT02162667;NCT00625898;NCT00629278;NCT03084237;NCT04646759;NCT03168880;NCT00637325;NCT02402712;NCT00004935;NCT03595592;NCT02492711;NCT00016276;NCT01810393;NCT01764022;NCT02896855;NCT00169104;NCT01998906;NCT04629846;NCT02149524;NCT00148876;NCT00272987;NCT03425656;NCT02131064;NCT01104571;NCT03084939;NCT04622319;NCT00320385;NCT01702571;NCT03080805;NCT00038402;NCT00829166;NCT00950300;NCT00486668;NCT02019277;NCT02040935;NCT01613482;NCT00004067;NCT02144012;NCT00820222;NCT02472964;NCT03811418;NCT00003440;NCT00005970;NCT04185649;NCT00022672;NCT03523585;NCT03013504;NCT01572038;NCT01785420
Breast Neoplasms	D001943	trastuzumab	Phase 4	2003	2021	NCT02696707;NCT00127933;NCT02658734;NCT02445586;NCT01501487;NCT00171847;NCT02419742;NCT04739761;NCT01301729
Carcinoma	D002277	trastuzumab	Phase 1	1999	2021	NCT01434303;NCT03319459;NCT04704661;NCT03364348;NCT01454479;NCT04120246;NCT02152943;NCT00004074;NCT03878524
Carcinoma	D002277	trastuzumab	Phase 2	2000	2021	NCT01556815;NCT03185988;NCT00005831;NCT02774681;NCT04644432;NCT01750073;NCT04351230;NCT04285671;NCT03101748;NCT03365882;NCT01641406;NCT04430738;NCT04108858;NCT02465060;NCT02120911;NCT01828736;NCT00126607;NCT00004856;NCT00684983;NCT00006089
Carcinoma	D002277	trastuzumab	Phase 3	2007	2021	NCT00769379;NCT02158988;NCT04457596;NCT00520975;NCT03199885
Carcinoma, Hepatocellular	D006528	trastuzumab	Phase 2	2012	2020	NCT01556815;NCT04246671;NCT02465060
Liver Neoplasms	D008113	trastuzumab	Phase 1	1999	1999	NCT00004074
Liver Neoplasms	D008113	trastuzumab	Phase 2	2010	2020	NCT01556815;NCT04246671;NCT01387295;NCT01387373
Liver Neoplasms	D008113	trastuzumab	Phase 4	2013	2013	NCT02380131
Neoplasms by Site	D009371	trastuzumab	Phase 2	2011	2012	NCT01556815;NCT01472146
Digestive System Neoplasms	D004067	trastuzumab	Phase 2	2012	2017	NCT01556815;NCT03329690
Gastrointestinal Neoplasms	D005770	trastuzumab	Phase 1	1999	1999	NCT00004074
Gastrointestinal Neoplasms	D005770	trastuzumab	Phase 2	2012	2020	NCT01556815;NCT03329690;NCT04430738;NCT04591431
Neoplasms by Histologic Type	D009370	trastuzumab	Phase 2	2012	2012	NCT01556815
Neoplasms, Glandular and Epithelial	D009375	trastuzumab	Phase 2	2012	2012	NCT01556815
Stomach Neoplasms	D013274	trastuzumab	Phase 1	1999	2018	NCT03319459;NCT02205463;NCT01148849;NCT01649271;NCT00004074;NCT03219268;NCT01384253;NCT01602406;NCT01705340
Stomach Neoplasms	D013274	trastuzumab	Phase 2	2004	2021	NCT01152853;NCT02005484;NCT02901301;NCT02030561;NCT02726399;NCT01396707;NCT04510285;NCT03588533;NCT02393248;NCT01774851;NCT02725424;NCT01364493;NCT01746771;NCT01402401;NCT02689284;NCT01748773;NCT01130337;NCT04379596;NCT02205047;NCT03409848;NCT04464967;NCT03556345;NCT01228045;NCT03766607;NCT02465060;NCT01928290;NCT01503983;NCT01461057;NCT01736410;NCT01359397;NCT00515411;NCT02250209;NCT02805829;NCT04278144;NCT01702558;NCT04168931;NCT02004769;NCT03694977;NCT03701373;NCT04661150
Stomach Neoplasms	D013274	trastuzumab	Phase 3	2005	2021	NCT04704934;NCT01450696;NCT01641939;NCT03615326;NCT02158988;NCT04082364;NCT02581462;NCT04714190;NCT02578368;NCT01041404;NCT01774786
Stomach Neoplasms	D013274	trastuzumab	Phase 4	2011	2013	NCT02380131;NCT01260194
Neoplasm Metastasis	D009362	trastuzumab	Phase 1	1999	2020	NCT02598427;NCT02571530;NCT04602117;NCT01921335;NCT00426530;NCT02735798;NCT00004074;NCT03219268;NCT00470847
Neoplasm Metastasis	D009362	trastuzumab	Phase 2	2005	2021	NCT00317720;NCT03203616;NCT02000882;NCT00781612;NCT00679341;NCT04760431;NCT02142036;NCT02308020;NCT00263588;NCT04334330;NCT01387295;NCT03323424;NCT01386580;NCT01783756;NCT04464967;NCT02048059;NCT01480583;NCT01441596;NCT01503983;NCT03190967;NCT04512261;NCT01387373;NCT03417544;NCT04158947;NCT00377780;NCT02004769;NCT02260531;NCT04420598;NCT01305941
Neoplasm Metastasis	D009362	trastuzumab	Phase 3	2009	2020	NCT04337658;NCT02158988;NCT02492711;NCT00820222
Neoplasm Metastasis	D009362	trastuzumab	Phase 4	2013	2021	NCT02380131;NCT04739761
Multiple Myeloma	D009101	trastuzumab	Phase 1	2009	2020	NCT00991562;NCT03878524
Multiple Myeloma	D009101	trastuzumab	Phase 2	2015	2017	NCT02693535;NCT02393248;NCT04439110;NCT03297606;NCT02465060
Lymphoma, Non-Hodgkin	D008228	trastuzumab	Phase 1	2017	2020	NCT03013218;NCT03432741;NCT03878524
Lymphoma, Non-Hodgkin	D008228	trastuzumab	Phase 2	2016	2017	NCT02693535;NCT03297606
Meningeal Neoplasms	D008577	trastuzumab	Phase 2	2020	2020	NCT04588545
Neoplasms, Second Primary	D016609	trastuzumab	Phase 1	2017	2017	NCT02598427
Neoplasms, Second Primary	D016609	trastuzumab	Phase 2	2010	2021	NCT04760431;NCT02142036;NCT01387295;NCT01386580;NCT02048059;NCT01480583;NCT03190967;NCT01387373;NCT04158947;NCT04420598
Neoplasms, Second Primary	D016609	trastuzumab	Phase 3	2014	2014	NCT02158988
Brain Neoplasms	D001932	trastuzumab	Phase 1	2007	2017	NCT02598427;NCT00470847
Brain Neoplasms	D001932	trastuzumab	Phase 2	2011	2021	NCT03203616;NCT02000882;NCT04760431;NCT04334330;NCT01386580;NCT02048059;NCT01480583;NCT03190967;NCT04512261;NCT04158947;NCT04420598
Carcinoma, Non-Small-Cell Lung	D002289	trastuzumab	Phase 1	1999	2021	NCT03319459;NCT04686305;NCT00004074;NCT04042701
Carcinoma, Non-Small-Cell Lung	D002289	trastuzumab	Phase 2	1999	2021	NCT02226757;NCT03784599;NCT02314481;NCT04579380;NCT02289833;NCT04644237;NCT03505710;NCT02308020;NCT04285671;NCT03334617;NCT00758134;NCT04464967;NCT00016367;NCT00004883;NCT03845270
Breast Neoplasms, Male	D018567	trastuzumab	Phase 1	1999	2018	NCT01245205;NCT00028535;NCT02060253;NCT03387553;NCT00004074;NCT00039455;NCT01705340
Breast Neoplasms, Male	D018567	trastuzumab	Phase 2	2000	2017	NCT00024154;NCT00331552;NCT01783756;NCT00077376;NCT00006228;NCT00343109;NCT00258349;NCT03112590
Breast Neoplasms, Male	D018567	trastuzumab	Phase 3	2008	2008	NCT00770809
Cholangiocarcinoma	D018281	trastuzumab	Phase 1	1999	1999	NCT00004074
Cholangiocarcinoma	D018281	trastuzumab	Phase 2	2007	2020	NCT03613168;NCT00478140;NCT02393248;NCT02999672;NCT03768375;NCT04430738;NCT02836847
Biliary Tract Neoplasms	D001661	trastuzumab	Phase 2	2017	2021	NCT03613168;NCT04482309;NCT04579380;NCT03185988;NCT04329429;NCT04722133
Carcinoma, Transitional Cell	D002295	trastuzumab	Phase 1	1999	2018	NCT03523572;NCT00004074
Carcinoma, Transitional Cell	D002295	trastuzumab	Phase 2	2000	2019	NCT03507166;NCT00005831;NCT03809013;NCT04073602;NCT01828736;NCT00004856
Adenocarcinoma	D000230	trastuzumab	Phase 1	2020	2021	NCT04704661;NCT03878524
Adenocarcinoma	D000230	trastuzumab	Phase 2	2006	2021	NCT02213289;NCT00478140;NCT03950271;NCT04150640;NCT02678182;NCT01204372;NCT04014075;NCT03329690;NCT03409848;NCT03365882;NCT04430738;NCT03783936;NCT03966118;NCT01472029;NCT04309578;NCT01359397;NCT00515411;NCT03368131;NCT04661150
Adenocarcinoma	D000230	trastuzumab	Phase 3	2010	2021	NCT04499924;NCT01196390;NCT04704934;NCT03615326;NCT03691454;NCT02578368;NCT03199885
Esophageal Neoplasms	D004938	trastuzumab	Phase 1	1999	2021	NCT04704661;NCT00004074;NCT01705340
Esophageal Neoplasms	D004938	trastuzumab	Phase 2	2006	2021	NCT04510285;NCT01774851;NCT03783936;NCT04464967;NCT02465060;NCT02120911;NCT01928290;NCT01472029;NCT01359397;NCT00515411;NCT03368131
Esophageal Neoplasms	D004938	trastuzumab	Phase 3	2010	2021	NCT04499924;NCT01196390;NCT04704934;NCT03615326
Inflammatory Breast Neoplasms	D058922	trastuzumab	Phase 1	1999	2011	NCT00004074;NCT01880385
Inflammatory Breast Neoplasms	D058922	trastuzumab	Phase 2	2005	2019	NCT00118053;NCT02199418;NCT02682693;NCT03101748;NCT03742986;NCT01641406;NCT01325428;NCT01730833
Inflammatory Breast Neoplasms	D058922	trastuzumab	Phase 3	2001	2014	NCT02125344;NCT01426880;NCT01583426;NCT00016276
Carcinoma, Ductal, Breast	D018270	trastuzumab	Phase 2	2013	2017	NCT01891357;NCT02199418;NCT02682693
Carcinoma, Ductal, Breast	D018270	trastuzumab	Phase 3	2008	2014	NCT02125344;NCT01426880;NCT00769379;NCT01583426
Gallbladder Neoplasms	D005706	trastuzumab	Phase 1	1999	1999	NCT00004074
Gallbladder Neoplasms	D005706	trastuzumab	Phase 2	2007	2016	NCT00478140;NCT03768375;NCT02836847
Bile Duct Neoplasms	D001650	trastuzumab	Phase 1	1999	1999	NCT00004074
Bile Duct Neoplasms	D001650	trastuzumab	Phase 2	2007	2007	NCT00478140
Leukemia, Myeloid	D007951	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	trastuzumab	Phase 2	2015	2015	NCT02638428
Neoplasm Micrometastasis	D061206	trastuzumab	Phase 1	2009	2009	NCT00949247
Neoplasm Micrometastasis	D061206	trastuzumab	Phase 2	2021	2021	NCT04569747
Lung Neoplasms	D008175	trastuzumab	Phase 1	1999	2021	NCT04686305;NCT00028535;NCT00004074
Lung Neoplasms	D008175	trastuzumab	Phase 2	1999	2021	NCT00003881;NCT02289833;NCT04246671;NCT01679743;NCT04644237;NCT03505710;NCT02308020;NCT04285671;NCT03334617;NCT00758134;NCT04464967;NCT00016367;NCT02465060;NCT00004883;NCT03845270
Pancreatic Neoplasms	D010190	trastuzumab	Phase 1	1999	2020	NCT00004074;NCT01384253;NCT03878524
Pancreatic Neoplasms	D010190	trastuzumab	Phase 2	1999	2021	NCT04482309;NCT02999672;NCT00005926;NCT04464967;NCT02465060;NCT00003797;NCT00923299
Ovarian Neoplasms	D010051	trastuzumab	Phase 1	2011	2011	NCT01384253
Ovarian Neoplasms	D010051	trastuzumab	Phase 2	2015	2021	NCT04482309;NCT04464967;NCT02465060;NCT00194714
Endometrial Neoplasms	D016889	trastuzumab	Phase 1	1999	2019	NCT04188548;NCT00028535;NCT01454479;NCT00004074
Endometrial Neoplasms	D016889	trastuzumab	Phase 2	2011	2021	NCT04482309;NCT02393248;NCT01367002;NCT04464967;NCT02465060;NCT04205630
Colorectal Neoplasms	D015179	trastuzumab	Phase 1	2018	2021	NCT03319459;NCT04704661
Colorectal Neoplasms	D015179	trastuzumab	Phase 2	1999	2021	NCT02291289;NCT03185988;NCT03043313;NCT00003995;NCT03225937;NCT03457896;NCT04430738;NCT04464967;NCT04744831;NCT00006015;NCT02465060;NCT03418558;NCT03384940;NCT04380012
Colorectal Neoplasms	D015179	trastuzumab	Phase 3	2016	2016	NCT03288987
Carcinoma, Squamous Cell	D002294	trastuzumab	Phase 1	1999	2018	NCT03319459;NCT00004074
Carcinoma, Squamous Cell	D002294	trastuzumab	Phase 2	2017	2021	NCT03185988;NCT04464967
Squamous Cell Carcinoma of Head and Neck	D000077195	trastuzumab	Phase 1	2018	2018	NCT03319459
Squamous Cell Carcinoma of Head and Neck	D000077195	trastuzumab	Phase 2	2021	2021	NCT04464967
Hamartoma Syndrome, Multiple	D006223	trastuzumab	Phase 1	2006	2006	NCT00620594
Ependymoma	D004806	trastuzumab	Phase 1	2016	2016	NCT02774421
Uterine Cervical Neoplasms	D002583	trastuzumab	Phase 1	1999	1999	NCT00004074
Uterine Cervical Neoplasms	D002583	trastuzumab	Phase 2	2021	2021	NCT04579380;NCT04464967
Uterine Neoplasms	D014594	trastuzumab	Phase 2	2015	2021	NCT04579380;NCT02465060
Urologic Neoplasms	D014571	trastuzumab	Phase 2	2000	2021	NCT04579380;NCT04644432;NCT00151034;NCT02006667;NCT02675829;NCT02013765
Carcinoma in Situ	D002278	trastuzumab	Phase 2	2011	2011	NCT01641406
Carcinoma in Situ	D002278	trastuzumab	Phase 3	2008	2008	NCT00769379
Carcinoma, Ductal	D044584	trastuzumab	Phase 2	2013	2013	NCT01891357
Carcinoma, Ductal	D044584	trastuzumab	Phase 3	2008	2008	NCT00769379
Carcinoma, Intraductal, Noninfiltrating	D002285	trastuzumab	Phase 3	2008	2008	NCT00769379
Triple Negative Breast Neoplasms	D064726	trastuzumab	Phase 1	2021	2021	NCT04296942
Triple Negative Breast Neoplasms	D064726	trastuzumab	Phase 2	2010	2021	NCT01111825;NCT03907800;NCT04464967;NCT03742102
Triple Negative Breast Neoplasms	D064726	trastuzumab	Phase 3	2010	2010	NCT03168880
Esophageal Squamous Cell Carcinoma	D000077277	trastuzumab	Phase 2	2017	2017	NCT03185988
Neoplasms, Unknown Primary	D009382	trastuzumab	Phase 1	1999	1999	NCT00004074
Neoplasms, Unknown Primary	D009382	trastuzumab	Phase 2	2018	2018	NCT03498521
Urinary Bladder Neoplasms	D001749	trastuzumab	Phase 1	1999	1999	NCT00004074
Urinary Bladder Neoplasms	D001749	trastuzumab	Phase 2	2000	2021	NCT00005831;NCT00238420;NCT04464967;NCT02465060;NCT01828736;NCT00004856
Kidney Neoplasms	D007680	trastuzumab	Phase 1	1999	1999	NCT00004074
Kidney Neoplasms	D007680	trastuzumab	Phase 2	2000	2020	NCT00005831;NCT04644432;NCT02465060;NCT00004856
Ureteral Neoplasms	D014516	trastuzumab	Phase 1	1999	1999	NCT00004074
Ureteral Neoplasms	D014516	trastuzumab	Phase 2	2000	2002	NCT00005831;NCT00004856
Peritoneal Neoplasms	D010534	trastuzumab	Phase 1	2011	2011	NCT01384253
Peritoneal Neoplasms	D010534	trastuzumab	Phase 3	2014	2014	NCT02158988
Carcinoma, Merkel Cell	D015266	trastuzumab	Phase 2	2020	2020	NCT04246671
Small Cell Lung Carcinoma	D055752	trastuzumab	Phase 1	2001	2001	NCT00028535
Small Cell Lung Carcinoma	D055752	trastuzumab	Phase 2	2020	2020	NCT04246671
Chordoma	D002817	trastuzumab	Phase 2	2020	2020	NCT04246671
Neoplasm, Residual	D018365	trastuzumab	Phase 3	2013	2013	NCT01772472
Lymphoma	D008223	trastuzumab	Phase 1	2017	2020	NCT03013218;NCT03432741;NCT03878524
Lymphoma	D008223	trastuzumab	Phase 2	2015	2015	NCT04439110;NCT02465060
Neoplasms, Plasma Cell	D054219	trastuzumab	Phase 1	2009	2020	NCT00991562;NCT03878524
Neoplasms, Plasma Cell	D054219	trastuzumab	Phase 2	2015	2015	NCT04439110;NCT02465060
Prostatic Neoplasms	D011471	trastuzumab	Phase 1	1999	2020	NCT00004074;NCT03878524
Prostatic Neoplasms	D011471	trastuzumab	Phase 2	1998	2015	NCT00005857;NCT02465060;NCT00003740
Carcinoma, Renal Cell	D002292	trastuzumab	Phase 1	1999	1999	NCT00004074
Carcinoma, Renal Cell	D002292	trastuzumab	Phase 2	2015	2020	NCT04644432;NCT02465060
Urogenital Neoplasms	D014565	trastuzumab	Phase 2	2020	2020	NCT04644432
Carcinoma, Ovarian Epithelial	D000077216	trastuzumab	Phase 1	1999	2001	NCT00028535;NCT00004074
Carcinoma, Ovarian Epithelial	D000077216	trastuzumab	Phase 2	2015	2016	NCT02465060;NCT00194714
Sarcoma	D012509	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Sarcoma	D012509	trastuzumab	Phase 2	2005	2021	NCT00104949;NCT02452554;NCT04464967
Sarcoma, Synovial	D013584	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Sarcoma, Synovial	D013584	trastuzumab	Phase 2	2005	2015	NCT00104949;NCT02452554
Melanoma	D008545	trastuzumab	Phase 2	2015	2015	NCT02308020;NCT02465060
Hodgkin Disease	D006689	trastuzumab	Phase 1	2018	2020	NCT03432741;NCT03878524
Lymphoma, B-Cell, Marginal Zone	D018442	trastuzumab	Phase 1	2018	2018	NCT03432741
Mycosis Fungoides	D009182	trastuzumab	Phase 1	2018	2018	NCT03432741
Lymphoma, T-Cell	D016399	trastuzumab	Phase 1	2018	2018	NCT03432741
Lymphoma, T-Cell, Cutaneous	D016410	trastuzumab	Phase 1	2018	2018	NCT03432741
Osteosarcoma	D012516	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Osteosarcoma	D012516	trastuzumab	Phase 2	1999	2021	NCT04616560;NCT00023998;NCT00005033
Carcinosarcoma	D002296	trastuzumab	Phase 1	2011	2011	NCT01454479
Mixed Tumor, Mullerian	D018200	trastuzumab	Phase 1	2011	2011	NCT01454479
Meningeal Carcinomatosis	D055756	trastuzumab	Phase 2	2011	2011	NCT01373710
Hematologic Neoplasms	D019337	trastuzumab	Phase 1	2011	2020	NCT01351350;NCT03219268;NCT03878524
Salivary Gland Neoplasms	D012468	trastuzumab	Phase 1	1999	1999	NCT00004074
Salivary Gland Neoplasms	D012468	trastuzumab	Phase 2	1999	2020	NCT00004163;NCT04620187;NCT00126607
Leukemia	D007938	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	trastuzumab	Phase 2	2006	2006	NCT00724360
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	trastuzumab	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	trastuzumab	Phase 2	2006	2006	NCT00724360
Leukemia, Lymphoid	D007945	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	trastuzumab	Phase 2	2006	2006	NCT00724360
Rectal Neoplasms	D012004	trastuzumab	Phase 1	1999	1999	NCT00004074
Rectal Neoplasms	D012004	trastuzumab	Phase 2	2015	2017	NCT03365882;NCT02465060
Colonic Neoplasms	D003110	trastuzumab	Phase 1	1999	1999	NCT00004074
Colonic Neoplasms	D003110	trastuzumab	Phase 2	2015	2017	NCT03365882;NCT02465060
Carcinoma, Lobular	D018275	trastuzumab	Phase 2	2011	2011	NCT01641406
Breast Carcinoma In Situ	D000071960	trastuzumab	Phase 2	2011	2011	NCT01641406
Glioma	D005910	trastuzumab	Phase 2	2011	2015	NCT01386580;NCT02465060
Neuroblastoma	D009447	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Neuroblastoma	D009447	trastuzumab	Phase 2	2015	2015	NCT02452554
Rhabdomyosarcoma	D012208	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Rhabdomyosarcoma	D012208	trastuzumab	Phase 2	2015	2015	NCT02452554
Wilms Tumor	D009396	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Wilms Tumor	D009396	trastuzumab	Phase 2	2015	2015	NCT02452554
Nerve Sheath Neoplasms	D018317	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Nerve Sheath Neoplasms	D018317	trastuzumab	Phase 2	2015	2015	NCT02452554
Neurofibrosarcoma	D018319	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Neurofibrosarcoma	D018319	trastuzumab	Phase 2	2015	2015	NCT02452554
Pulmonary Blastoma	D018202	trastuzumab	Phase 2	2015	2015	NCT02452554
Hemangiosarcoma	D006394	trastuzumab	Phase 2	2010	2010	NCT01042379
Neoplastic Cells, Circulating	D009360	trastuzumab	Phase 2	2013	2013	NCT01975142;NCT01548677
Cystadenocarcinoma, Serous	D018284	trastuzumab	Phase 1	2021	2021	NCT04585958
Thyroid Neoplasms	D013964	trastuzumab	Phase 1	1999	1999	NCT00004074
Thyroid Neoplasms	D013964	trastuzumab	Phase 2	2015	2015	NCT02465060
Skin Neoplasms	D012878	trastuzumab	Phase 2	2015	2015	NCT02465060
Neoplasms, Germ Cell and Embryonal	D009373	trastuzumab	Phase 1	1999	1999	NCT00004074
Fallopian Tube Neoplasms	D005185	trastuzumab	Phase 1	1999	1999	NCT00004074
Laryngeal Neoplasms	D007822	trastuzumab	Phase 1	1999	1999	NCT00004074
Oropharyngeal Neoplasms	D009959	trastuzumab	Phase 1	1999	1999	NCT00004074
Nasopharyngeal Carcinoma	D000077274	trastuzumab	Phase 1	1999	1999	NCT00004074
Carcinoid Tumor	D002276	trastuzumab	Phase 1	1999	1999	NCT00004074
Anus Neoplasms	D001005	trastuzumab	Phase 1	1999	1999	NCT00004074
Carcinoma, Adenoid Cystic	D003528	trastuzumab	Phase 1	1999	1999	NCT00004074
Testicular Neoplasms	D013736	trastuzumab	Phase 1	1999	1999	NCT00004074
Vulvar Neoplasms	D014846	trastuzumab	Phase 1	1999	1999	NCT00004074
Carcinoma, Mucoepidermoid	D018277	trastuzumab	Phase 1	1999	1999	NCT00004074
Carcinoma, Mucoepidermoid	D018277	trastuzumab	Phase 2	2005	2005	NCT00126607
Vaginal Neoplasms	D014625	trastuzumab	Phase 1	1999	1999	NCT00004074
Urethral Neoplasms	D014523	trastuzumab	Phase 1	1999	1999	NCT00004074
Urethral Neoplasms	D014523	trastuzumab	Phase 2	2002	2002	NCT00004856
Pleural Effusion, Malignant	D016066	trastuzumab	Phase 1	1999	1999	NCT00004074
Adrenocortical Carcinoma	D018268	trastuzumab	Phase 1	1999	1999	NCT00004074
Malignant Carcinoid Syndrome	D008303	trastuzumab	Phase 1	1999	1999	NCT00004074
Thyroid Cancer, Papillary	D000077273	trastuzumab	Phase 1	1999	1999	NCT00004074
Intestinal Neoplasms	D007414	trastuzumab	Phase 1	1999	1999	NCT00004074
Thyroid Carcinoma, Anaplastic	D065646	trastuzumab	Phase 1	1999	1999	NCT00004074
Carcinoma, Medullary	D018276	trastuzumab	Phase 1	1999	1999	NCT00004074
Adenocarcinoma, Follicular	D018263	trastuzumab	Phase 1	1999	1999	NCT00004074
Insulinoma	D007340	trastuzumab	Phase 1	1999	1999	NCT00004074
Carcinoma, Islet Cell	D018273	trastuzumab	Phase 1	1999	1999	NCT00004074
Gastrinoma	D015408	trastuzumab	Phase 1	1999	1999	NCT00004074
Glucagonoma	D005935	trastuzumab	Phase 1	1999	1999	NCT00004074
Somatostatinoma	D013005	trastuzumab	Phase 1	1999	1999	NCT00004074
Vipoma	D003969	trastuzumab	Phase 1	1999	1999	NCT00004074
Parathyroid Neoplasms	D010282	trastuzumab	Phase 1	1999	1999	NCT00004074
Sarcoma, Ewing	D012512	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Retinoblastoma	D012175	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Rhabdoid Tumor	D018335	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Hepatoblastoma	D018197	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Desmoplastic Small Round Cell Tumor	D058405	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Sarcoma, Clear Cell	D018227	trastuzumab	Phase 1	2019	2020	NCT03618381;NCT04483778
Carcinoma, Acinar Cell	D018267	trastuzumab	Phase 2	2005	2005	NCT00126607
Nervous System Neoplasms	D009423	trastuzumab	Phase 2	2013	2013	NCT00397501
Central Nervous System Neoplasms	D016543	trastuzumab	Phase 2	2013	2013	NCT00397501
Leukemia, Myeloid, Acute	D015470	trastuzumab	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	trastuzumab	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	trastuzumab	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	trastuzumab	Phase 1	2020	2020	NCT03878524
Head and Neck Neoplasms	D006258	trastuzumab	Phase 1	2015	2015	NCT02627274
Adenocarcinoma	D000230	tucatinib	Phase 2	2020	2020	NCT04430738
Adenocarcinoma	D000230	tucatinib	Phase 3	2021	2021	NCT04499924
Esophageal Neoplasms	D004938	tucatinib	Phase 3	2021	2021	NCT04499924
Breast Neoplasms	D001943	tucatinib	Phase 1	2013	2020	NCT02025192;NCT03846583;NCT01983501
Breast Neoplasms	D001943	tucatinib	Phase 2	2010	2021	NCT04721977;NCT04579380;NCT04538742;NCT03501979;NCT04760431;NCT04539938;NCT01042379;NCT03054363;NCT02614794;NCT04512261
Breast Neoplasms	D001943	tucatinib	Phase 3	2019	2021	NCT04457596;NCT03975647
Carcinoma, Non-Small-Cell Lung	D002289	tucatinib	Phase 2	2021	2021	NCT04579380
Uterine Cervical Neoplasms	D002583	tucatinib	Phase 2	2021	2021	NCT04579380
Uterine Neoplasms	D014594	tucatinib	Phase 2	2021	2021	NCT04579380
Biliary Tract Neoplasms	D001661	tucatinib	Phase 2	2021	2021	NCT04579380
Urologic Neoplasms	D014571	tucatinib	Phase 2	2021	2021	NCT04579380
Colorectal Neoplasms	D015179	tucatinib	Phase 2	2017	2020	NCT03043313;NCT04430738
Carcinoma	D002277	tucatinib	Phase 2	2020	2020	NCT04430738
Carcinoma	D002277	tucatinib	Phase 3	2021	2021	NCT04457596
Neoplasm Metastasis	D009362	tucatinib	Phase 2	2021	2021	NCT04760431;NCT04512261
Neoplasms, Second Primary	D016609	tucatinib	Phase 2	2021	2021	NCT04760431
Brain Neoplasms	D001932	tucatinib	Phase 2	2021	2021	NCT04760431;NCT04512261
Cholangiocarcinoma	D018281	tucatinib	Phase 2	2020	2020	NCT04430738
Gastrointestinal Neoplasms	D005770	tucatinib	Phase 2	2020	2020	NCT04430738
Hemangiosarcoma	D006394	tucatinib	Phase 2	2010	2010	NCT01042379
Carcinoma	D002277	vandetanib	Phase 2	2007	2017	NCT02495103;NCT01661179;NCT02788201;NCT01372813;NCT00508001;NCT00753675;NCT00514046;NCT01414426
Carcinoma	D002277	vandetanib	Phase 3	2006	2006	NCT00404924
Carcinoma, Renal Cell	D002292	vandetanib	Phase 2	2007	2015	NCT02495103;NCT01372813;NCT00566995
Kidney Neoplasms	D007680	vandetanib	Phase 2	2007	2015	NCT02495103;NCT01372813;NCT01191892;NCT00566995
Leiomyomatosis	D018231	vandetanib	Phase 2	2015	2015	NCT02495103
Lung Neoplasms	D008175	vandetanib	Phase 1	2005	2011	NCT01004419;NCT00745732;NCT00807170;NCT01586624;NCT00734890;NCT00506051;NCT00937417
Lung Neoplasms	D008175	vandetanib	Phase 2	2003	2014	NCT00410189;NCT00777179;NCT01823068;NCT00066313;NCT02117167;NCT00459121;NCT00753714;NCT00290537;NCT00687297
Lung Neoplasms	D008175	vandetanib	Phase 3	2006	2007	NCT00418886;NCT00404924;NCT00312377;NCT00364351
Carcinoma, Non-Small-Cell Lung	D002289	vandetanib	Phase 1	2008	2011	NCT01004419;NCT00745732;NCT00807170;NCT01586624
Carcinoma, Non-Small-Cell Lung	D002289	vandetanib	Phase 2	2004	2014	NCT00777179;NCT01823068;NCT00252746;NCT02117167;NCT00459121;NCT00753714;NCT00687297
Carcinoma, Non-Small-Cell Lung	D002289	vandetanib	Phase 3	2006	2007	NCT00418886;NCT00404924;NCT00312377;NCT00364351
Leukemia, Myeloid	D007951	vandetanib	Phase 2	2015	2015	NCT02638428
Neuroblastoma	D009447	vandetanib	Phase 1	2007	2007	NCT00533169
Thyroid Neoplasms	D013964	vandetanib	Phase 1	2012	2012	NCT01539655
Thyroid Neoplasms	D013964	vandetanib	Phase 2	2004	2019	NCT01661179;NCT03838692;NCT00537095;NCT00923247;NCT00098345;NCT01838642;NCT03630120;NCT00514046;NCT00358956
Thyroid Neoplasms	D013964	vandetanib	Phase 3	2006	2021	NCT01876784;NCT00410761;NCT04760288;NCT04211337;NCT01298323
Thyroid Neoplasms	D013964	vandetanib	Phase 4	2012	2012	NCT01496313
Carcinoma, Neuroendocrine	D018278	vandetanib	Phase 2	2006	2019	NCT01661179;NCT03838692;NCT00514046;NCT00358956
Carcinoma, Neuroendocrine	D018278	vandetanib	Phase 3	2006	2020	NCT00410761;NCT04211337;NCT01298323
Colorectal Neoplasms	D015179	vandetanib	Phase 1	2005	2006	NCT00532909;NCT00499850;NCT00496509
Colorectal Neoplasms	D015179	vandetanib	Phase 2	2007	2007	NCT00500292;NCT00454116
Rectal Neoplasms	D012004	vandetanib	Phase 1	2006	2006	NCT00532909
Adenocarcinoma	D000230	vandetanib	Phase 1	2005	2008	NCT00732745;NCT00507091
Esophageal Neoplasms	D004938	vandetanib	Phase 1	2008	2008	NCT00732745;NCT01183559
Ovarian Neoplasms	D010051	vandetanib	Phase 2	2007	2009	NCT00445549;NCT00862836
Peritoneal Neoplasms	D010534	vandetanib	Phase 2	2007	2007	NCT00445549
Fallopian Tube Neoplasms	D005185	vandetanib	Phase 2	2007	2010	NCT00445549;NCT00872989
Breast Neoplasms	D001943	vandetanib	Phase 1	2007	2008	NCT00496665;NCT00937417
Breast Neoplasms	D001943	vandetanib	Phase 2	2006	2014	NCT00811369;NCT00752986;NCT01934335;NCT02299999;NCT00494481;NCT00481845
Glioblastoma	D005909	vandetanib	Phase 1	2007	2008	NCT00821080;NCT00613054;NCT00613223
Glioblastoma	D005909	vandetanib	Phase 2	2007	2009	NCT00995007;NCT00441142
Pancreatic Neoplasms	D010190	vandetanib	Phase 1	2006	2006	NCT00681798
Pancreatic Neoplasms	D010190	vandetanib	Phase 2	2011	2011	NCT01601808
Prostatic Neoplasms	D011471	vandetanib	Phase 1	2008	2008	NCT00937417
Prostatic Neoplasms	D011471	vandetanib	Phase 2	2005	2009	NCT00757692;NCT00686036;NCT00659438;NCT00498797
Stomach Neoplasms	D013274	vandetanib	Phase 1	2008	2008	NCT01183559
Stomach Neoplasms	D013274	vandetanib	Phase 2	2008	2008	NCT00683787
Urinary Bladder Neoplasms	D001749	vandetanib	Phase 2	2010	2017	NCT02788201;NCT01191892
Carcinoma, Transitional Cell	D002295	vandetanib	Phase 2	2006	2017	NCT02788201;NCT01191892;NCT00880334
Carcinoma, Hepatocellular	D006528	vandetanib	Phase 1	2017	2017	NCT03291379
Carcinoma, Hepatocellular	D006528	vandetanib	Phase 2	2007	2007	NCT00508001
Neoplasm Metastasis	D009362	vandetanib	Phase 1	2009	2009	NCT00807170
Neoplasm Metastasis	D009362	vandetanib	Phase 2	2014	2014	NCT02142036
Neoplasms, Second Primary	D016609	vandetanib	Phase 2	2014	2014	NCT02142036
Urethral Neoplasms	D014523	vandetanib	Phase 2	2010	2010	NCT01191892
Ureteral Neoplasms	D014516	vandetanib	Phase 2	2010	2010	NCT01191892
Head and Neck Neoplasms	D006258	vandetanib	Phase 1	2006	2008	NCT00450138;NCT00937417
Head and Neck Neoplasms	D006258	vandetanib	Phase 2	2008	2008	NCT00720083
Small Cell Lung Carcinoma	D055752	vandetanib	Phase 2	2003	2003	NCT00066313
Glioma	D005910	vandetanib	Phase 1	2007	2009	NCT00822887;NCT00472017;NCT00613054;NCT00996723;NCT00613223
Glioma	D005910	vandetanib	Phase 2	2009	2009	NCT00995007
Nervous System Neoplasms	D009423	vandetanib	Phase 1	2007	2007	NCT00472017
Central Nervous System Neoplasms	D016543	vandetanib	Phase 1	2007	2007	NCT00472017
Astrocytoma	D001254	vandetanib	Phase 2	2009	2009	NCT00995007
Gliosarcoma	D018316	vandetanib	Phase 1	2007	2008	NCT00613054;NCT00613223
Gliosarcoma	D018316	vandetanib	Phase 2	2007	2009	NCT00995007;NCT00441142
Oligodendroglioma	D009837	vandetanib	Phase 2	2009	2009	NCT00995007
Thyroid Cancer, Papillary	D000077273	vandetanib	Phase 2	2018	2018	NCT03630120
Adenocarcinoma, Follicular	D018263	vandetanib	Phase 2	2018	2018	NCT03630120
Cholangiocarcinoma	D018281	vandetanib	Phase 2	2008	2008	NCT00753675
Biliary Tract Neoplasms	D001661	vandetanib	Phase 2	2008	2008	NCT00753675
Gallbladder Neoplasms	D005706	vandetanib	Phase 2	2008	2008	NCT00753675
Mesothelioma	D008654	vandetanib	Phase 2	2007	2007	NCT00597116
Endocrine Gland Neoplasms	D004701	vandetanib	Phase 2	2007	2007	NCT00514046
Multiple Endocrine Neoplasia	D009377	vandetanib	Phase 2	2007	2007	NCT00514046
Multiple Endocrine Neoplasia Type 2a	D018813	vandetanib	Phase 2	2006	2007	NCT00514046;NCT00358956
Multiple Endocrine Neoplasia Type 2b	D018814	vandetanib	Phase 2	2007	2007	NCT00514046
Carcinoma, Medullary	D018276	vandetanib	Phase 2	2006	2006	NCT00358956
Gastrointestinal Stromal Tumors	D046152	vandetanib	Phase 2	2013	2013	NCT02015065
Lymphoma	D008223	vandetanib	Phase 1	2008	2008	NCT00734890
Intestinal Neoplasms	D007414	vandetanib	Phase 1	2008	2008	NCT00734890
Carcinoma, Ovarian Epithelial	D000077216	vandetanib	Phase 2	2009	2009	NCT00862836
Neuroendocrine Tumors	D018358	vandetanib	Phase 1	2014	2014	NCT01941849
Pheochromocytoma	D010673	vandetanib	Phase 1	2014	2014	NCT01941849
Paraganglioma	D010235	vandetanib	Phase 1	2014	2014	NCT01941849
Carotid Body Tumor	D002345	vandetanib	Phase 1	2014	2014	NCT01941849
Carcinoma, Verrucous	D018289	vandetanib	Phase 2	2012	2012	NCT01414426
Precancerous Conditions	D011230	vandetanib	Phase 2	2012	2012	NCT01414426
Multiple Myeloma	D009101	vemurafenib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	vemurafenib	Phase 2	2012	2017	NCT02693535;NCT03297606;NCT01524978;NCT02115035
Lymphoma, Non-Hodgkin	D008228	vemurafenib	Phase 1	2020	2020	NCT03878524
Lymphoma, Non-Hodgkin	D008228	vemurafenib	Phase 2	2016	2017	NCT02693535;NCT03220035;NCT03297606;NCT03155620
Melanoma	D008545	vemurafenib	Phase 1	2006	2018	NCT01164891;NCT01611675;NCT01264380;NCT00405587;NCT02068079;NCT01657591;NCT01841463;NCT01843738;NCT01519323;NCT01826448;NCT01851824;NCT01603212;NCT01001299;NCT02818023;NCT01835184;NCT01765543;NCT01876641;NCT01765556;NCT01849666;NCT03026517;NCT01765569;NCT02077114;NCT01897116;NCT03543969;NCT01585415;NCT01943422;NCT02441465;NCT01107418;NCT02608034;NCT02721459;NCT01844674;NCT01271803;NCT01656642;NCT01910181;NCT01400451
Melanoma	D008545	vemurafenib	Phase 2	2009	2020	NCT02050321;NCT03625141;NCT00949702;NCT02537600;NCT03514901;NCT02414750;NCT03101254;NCT01659151;NCT01378975;NCT01983124;NCT01754376;NCT02968303;NCT02052193;NCT02038348;NCT02303951;NCT01495988;NCT01474551;NCT03224208;NCT04722575;NCT02583516;NCT01519427;NCT01781026;NCT02296996;NCT01638676;NCT01616199;NCT03430947;NCT01813214;NCT01673854;NCT01973322;NCT01586195;NCT02354690;NCT01959633;NCT03005639;NCT01942993;NCT02036086;NCT01512251;NCT02768207;NCT03554083;NCT01248936;NCT02902029;NCT02202200;NCT02230306
Melanoma	D008545	vemurafenib	Phase 3	2010	2017	NCT01307397;NCT02427893;NCT01909453;NCT01667419;NCT01689519;NCT01597908;NCT02908672;NCT01006980
Melanoma	D008545	vemurafenib	Phase 4	2012	2013	NCT01683188;NCT01898585
Neoplasm Metastasis	D009362	vemurafenib	Phase 2	2014	2018	NCT03625141;NCT02537600;NCT02142036;NCT03430947;NCT02230306
Neoplasm Metastasis	D009362	vemurafenib	Phase 4	2020	2020	NCT04356118
Leukemia, Myeloid	D007951	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid	D007951	vemurafenib	Phase 2	2015	2015	NCT02638428
Colorectal Neoplasms	D015179	vemurafenib	Phase 1	2006	2013	NCT00405587;NCT01787500;NCT01791309
Colorectal Neoplasms	D015179	vemurafenib	Phase 2	2014	2018	NCT02291289;NCT02164916;NCT03727763
Lung Neoplasms	D008175	vemurafenib	Phase 2	2020	2020	NCT04302025
Lung Neoplasms	D008175	vemurafenib	Phase 3	2017	2017	NCT03178552
Lung Neoplasms	D008175	vemurafenib	Phase 4	2020	2020	NCT04356118
Carcinoma, Non-Small-Cell Lung	D002289	vemurafenib	Phase 2	2017	2020	NCT02314481;NCT04302025
Carcinoma, Non-Small-Cell Lung	D002289	vemurafenib	Phase 3	2017	2017	NCT03178552
Carcinoma, Non-Small-Cell Lung	D002289	vemurafenib	Phase 4	2020	2020	NCT04356118
Lymphoma	D008223	vemurafenib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03013491;NCT03155620
Sarcoma	D012509	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Neuroblastoma	D009447	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Osteosarcoma	D012516	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Glioma	D005910	vemurafenib	Phase 1	2014	2014	NCT01748149
Glioma	D005910	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Rhabdomyosarcoma	D012208	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Ependymoma	D004806	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Sarcoma, Ewing	D012512	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Neuroectodermal Tumors	D017599	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Neuroectodermal Tumors, Primitive	D018242	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Wilms Tumor	D009396	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Neuroectodermal Tumors, Primitive, Peripheral	D018241	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Rhabdoid Tumor	D018335	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Nervous System Neoplasms	D009423	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Central Nervous System Neoplasms	D016543	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Hepatoblastoma	D018197	vemurafenib	Phase 2	2017	2017	NCT03220035;NCT03155620
Neoplasms, Unknown Primary	D009382	vemurafenib	Phase 2	2018	2018	NCT03498521
Carcinoma	D002277	vemurafenib	Phase 1	2020	2020	NCT03878524
Carcinoma	D002277	vemurafenib	Phase 2	2017	2017	NCT02788201;NCT03181100
Urinary Bladder Neoplasms	D001749	vemurafenib	Phase 2	2017	2017	NCT02788201
Carcinoma, Transitional Cell	D002295	vemurafenib	Phase 2	2017	2017	NCT02788201
Leukemia	D007938	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia	D007938	vemurafenib	Phase 2	2012	2018	NCT03410875;NCT01711632
Leukemia, Hairy Cell	D007943	vemurafenib	Phase 2	2012	2020	NCT03410875;NCT04324112;NCT01711632
Sarcoma, Clear Cell	D018227	vemurafenib	Phase 2	2017	2017	NCT02968303
Thyroid Neoplasms	D013964	vemurafenib	Phase 1	2015	2020	NCT04462471;NCT02456701
Thyroid Neoplasms	D013964	vemurafenib	Phase 2	2011	2017	NCT01709292;NCT01286753;NCT03181100
Thyroid Cancer, Papillary	D000077273	vemurafenib	Phase 1	2020	2020	NCT04462471
Thyroid Cancer, Papillary	D000077273	vemurafenib	Phase 2	2011	2011	NCT01286753
Neoplasms, Second Primary	D016609	vemurafenib	Phase 2	2014	2014	NCT02142036
Neoplasms, Second Primary	D016609	vemurafenib	Phase 4	2020	2020	NCT04356118
Neoplasms, Plasma Cell	D054219	vemurafenib	Phase 1	2020	2020	NCT03878524
Neoplasms, Plasma Cell	D054219	vemurafenib	Phase 2	2014	2014	NCT02115035
Skin Neoplasms	D012878	vemurafenib	Phase 1	2016	2018	NCT03543969;NCT02721459
Skin Neoplasms	D012878	vemurafenib	Phase 2	2013	2018	NCT01973322;NCT03554083
Craniopharyngioma	D003397	vemurafenib	Phase 2	2017	2017	NCT03224767
Adamantinoma	D050398	vemurafenib	Phase 2	2017	2017	NCT03224767
Brain Neoplasms	D001932	vemurafenib	Phase 2	2015	2018	NCT03430947;NCT02230306
Hematologic Neoplasms	D019337	vemurafenib	Phase 1	2020	2020	NCT03878524
Hematologic Neoplasms	D019337	vemurafenib	Phase 2	2014	2014	NCT02304809
Gastrointestinal Neoplasms	D005770	vemurafenib	Phase 2	2020	2020	NCT04591431
Neoplasms, Germ Cell and Embryonal	D009373	vemurafenib	Phase 2	2017	2017	NCT03155620
Medulloblastoma	D008527	vemurafenib	Phase 2	2017	2017	NCT03155620
Histiocytic Sarcoma	D054747	vemurafenib	Phase 2	2017	2017	NCT03155620
Thyroid Carcinoma, Anaplastic	D065646	vemurafenib	Phase 2	2017	2017	NCT03181100
Meningeal Carcinomatosis	D055756	vemurafenib	Phase 4	2020	2020	NCT04356118
Breast Neoplasms	D001943	vemurafenib	Phase 1	2020	2020	NCT03878524
Prostatic Neoplasms	D011471	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Acute	D015470	vemurafenib	Phase 1	2020	2020	NCT03878524
Adenocarcinoma	D000230	vemurafenib	Phase 1	2020	2020	NCT03878524
Pancreatic Neoplasms	D010190	vemurafenib	Phase 1	2020	2020	NCT03878524
Preleukemia	D011289	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphoid	D007945	vemurafenib	Phase 1	2020	2020	NCT03878524
Precursor Cell Lymphoblastic Leukemia-Lymphoma	D054198	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	vemurafenib	Phase 1	2020	2020	NCT03878524
Hodgkin Disease	D006689	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	D015464	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Chronic	D015477	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myelomonocytic, Juvenile	D054429	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic-Phase	D015466	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Accelerated Phase	D015465	vemurafenib	Phase 1	2020	2020	NCT03878524
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative	D054438	vemurafenib	Phase 1	2020	2020	NCT03878524
Blast Crisis	D001752	vemurafenib	Phase 1	2020	2020	NCT03878524
Lymphoma	D008223	zanubrutinib	Phase 1	2016	2020	NCT02914938;NCT03189524;NCT04436107
Lymphoma	D008223	zanubrutinib	Phase 2	2017	2021	NCT04458610;NCT04282018;NCT03162536;NCT03206970;NCT03145064;NCT04460248;NCT04705129;NCT04736914;NCT03206918;NCT04624958;NCT04668365;NCT04116437;NCT03520920;NCT03846427;NCT03332017;NCT03740529
Lymphoma	D008223	zanubrutinib	Phase 3	2017	2021	NCT03336333;NCT04662255;NCT03734016;NCT04002297;NCT04666038
Leukemia	D007938	zanubrutinib	Phase 2	2017	2020	NCT04458610;NCT03162536;NCT03824483;NCT04477291;NCT03206918;NCT03740529
Leukemia	D007938	zanubrutinib	Phase 3	2017	2021	NCT03336333;NCT03734016;NCT04666038
Leukemia, Lymphoid	D007945	zanubrutinib	Phase 2	2017	2020	NCT04458610;NCT03162536;NCT03824483;NCT04515238;NCT03206918;NCT03740529
Leukemia, Lymphoid	D007945	zanubrutinib	Phase 3	2017	2021	NCT03336333;NCT03734016;NCT04666038
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	zanubrutinib	Phase 1	2016	2016	NCT02914938
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	zanubrutinib	Phase 2	2017	2020	NCT04458610;NCT04282018;NCT03162536;NCT03824483;NCT04515238;NCT03206918;NCT04116437;NCT03740529
Leukemia, Lymphocytic, Chronic, B-Cell	D015451	zanubrutinib	Phase 3	2017	2021	NCT03336333;NCT03734016;NCT04666038
Lymphoma, Mantle-Cell	D020522	zanubrutinib	Phase 1	2016	2016	NCT02914938
Lymphoma, Mantle-Cell	D020522	zanubrutinib	Phase 2	2017	2021	NCT04282018;NCT03162536;NCT03206970;NCT04736914;NCT04624958;NCT04116437;NCT03740529
Lymphoma, Mantle-Cell	D020522	zanubrutinib	Phase 3	2019	2021	NCT04662255;NCT04002297
Lymphoma, Large B-Cell, Diffuse	D016403	zanubrutinib	Phase 1	2016	2020	NCT02914938;NCT04436107
Lymphoma, Large B-Cell, Diffuse	D016403	zanubrutinib	Phase 2	2017	2020	NCT04282018;NCT03162536;NCT03145064;NCT04460248;NCT04668365;NCT03520920
Lymphoma, Follicular	D008224	zanubrutinib	Phase 2	2017	2017	NCT03162536;NCT03332017
Lymphoma, B-Cell	D016393	zanubrutinib	Phase 1	2016	2020	NCT02914938;NCT03189524;NCT04436107
Lymphoma, B-Cell	D016393	zanubrutinib	Phase 2	2017	2021	NCT03162536;NCT03145064;NCT04460248;NCT04705129;NCT04668365;NCT03520920;NCT03740529
Lymphoma, B-Cell, Marginal Zone	D018442	zanubrutinib	Phase 1	2016	2016	NCT02914938
Lymphoma, B-Cell, Marginal Zone	D018442	zanubrutinib	Phase 2	2017	2019	NCT03162536;NCT03520920;NCT03846427;NCT03740529
Hematologic Neoplasms	D019337	zanubrutinib	Phase 2	2017	2017	NCT03162536
Waldenstrom Macroglobulinemia	D008258	zanubrutinib	Phase 2	2017	2020	NCT03162536;NCT04463953;NCT03332173;NCT04116437;NCT03740529
Waldenstrom Macroglobulinemia	D008258	zanubrutinib	Phase 3	2017	2017	NCT03053440
Lymphoma, Non-Hodgkin	D008228	zanubrutinib	Phase 1	2016	2016	NCT02914938
Lymphoma, Non-Hodgkin	D008228	zanubrutinib	Phase 2	2017	2017	NCT03332017
Lymphoma, Non-Hodgkin	D008228	zanubrutinib	Phase 3	2019	2019	NCT04002297
Leukemia, Myeloid	D007951	zanubrutinib	Phase 2	2020	2020	NCT04477291
Leukemia, Myeloid, Acute	D015470	zanubrutinib	Phase 2	2020	2020	NCT04477291
Adenocarcinoma	D000230	zanubrutinib	Phase 3	2018	2018	NCT03777657
Esophageal Neoplasms	D004938	zanubrutinib	Phase 3	2018	2018	NCT03777657
